[{"documents": ["24325358", "23100277", "21765412", "17209061"], "answer": [["NBEAL2"], ["GFI1B"], ["GATA1"]], "id": "52f89f4f2059c6d71c00004e", "snippets": [{"text": "We detected a nonsense mutation in the gene encoding the transcription factor GFI1B (growth factor independent 1B) that causes autosomal dominant gray platelet syndrome. ", "begin": 145, "document": "24325358", "end": 315, "section": "abstract"}, {"text": "The genetic defect responsible for gray platelet syndrome was recently identified in biallelic mutations in the NBEAL2 gene.", "begin": 155, "document": "23100277", "end": 279, "section": "abstract"}, {"text": "Here we show that mutations in NBEAL2 (neurobeachin-like 2), which encodes a BEACH/ARM/WD40 domain protein, cause GPS and that megakaryocytes and platelets from individuals with GPS express a unique combination of NBEAL2 transcripts. ", "begin": 136, "document": "21765412", "end": 370, "section": "abstract"}, {"text": "Linkage analysis revealed a 63 cM region on the X chromosome between markers G10578 and DXS6797, which segregated with the platelet phenotype and included the GATA1 gene. Sequencing of GATA1 revealed a G-to-A mutation at position 759 corresponding to amino acid change Arg216Gln. ", "begin": 385, "document": "17209061", "end": 665, "section": "abstract"}, {"text": "We identified a family with gray platelet syndrome (GPS) segregating as a sex-linked trait. ", "begin": 0, "document": "17209061", "end": 92, "section": "abstract"}, {"text": "X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation", "begin": 0, "document": "17209061", "end": 65, "section": "title"}]}, {"documents": ["23889121", "23749642", "22989627", "22916248", "21902453", "21248284", "20646000", "19969073", "19812325", "19375361", "18479207", "18222042", "17522089", "17105810", "12943237"], "answer": ["antioxidant"], "id": "52bf1f1303868f1b06000014", "snippets": [{"text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.", "begin": 11, "document": "23889121", "end": 108, "section": "abstract"}, {"text": "We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells.", "begin": 215, "document": "23749642", "end": 349, "section": "abstract"}, {"text": "The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats. ", "begin": 51, "document": "22989627", "end": 248, "section": "abstract"}, {"text": "The mRNA profiler array showed more than 2-fold differential expression of 32 oxidative stress-related genes in unstimulated moDCs, including peroxiredoxin-2 (PRDX2), an enzyme reducing hydrogen peroxide and lipid peroxides. ", "begin": 1167, "document": "22916248", "end": 1392, "section": "abstract"}, {"text": "Peroxiredoxin-2 (Prx-2) is an abundant mammalian enzyme that protects against oxidative stress.", "begin": 159, "document": "21902453", "end": 254, "section": "abstract"}, {"text": "Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme whose main function is H(2)O(2) reduction in cells. ", "begin": 0, "document": "21248284", "end": 123, "section": "abstract"}, {"text": "These data indicate that Srx1 activity protects mice from the lethality of endotoxic shock, adding this enzyme to other host factors, as NRF2 and peroxiredoxin 2, which by regulating cellular reactive oxygen species levels act as important modifiers in the pathogenesis of sepsis.", "begin": 1067, "document": "21083423", "end": 1347, "section": "abstract"}, {"text": "One of the identified proteins was peroxiredoxin 2 (Prx2), an anti-oxidant enzyme. ", "begin": 639, "document": "20646000", "end": 722, "section": "abstract"}, {"text": "Peroxiredoxin-2 (Prdx2), a potent peroxide reductant, is the third most abundant protein in the erythrocyte and might be expected to play a major role in the cell's oxidative defenses. ", "begin": 0, "document": "19969073", "end": 185, "section": "abstract"}, {"text": "Importantly, we also demonstrate the antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk5. ", "begin": 819, "document": "19812325", "end": 940, "section": "abstract"}, {"text": "Human erythrocyte peroxiredoxin 2 (Prx2) is a typical 2-cys cytosolic peroxiredoxin with thiol-dependent hydrogen peroxide scavenger activity. ", "begin": 0, "document": "19375361", "end": 143, "section": "abstract"}, {"text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides.", "begin": 0, "document": "18479207", "end": 99, "section": "abstract"}, {"text": "Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated, implying a beneficial effect of lithium on neuronal cells.", "begin": 860, "document": "18222042", "end": 1077, "section": "abstract"}, {"text": "After 5 Gy irradiation, the relative abundance of peroxiredoxin 2, an antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased. ", "begin": 204, "document": "17522089", "end": 352, "section": "abstract"}, {"text": "Peroxiredoxin 2 (Prx2), a thiol-dependent peroxidase, is the third most abundant protein in the erythrocyte, and its absence in knock-out mice gives rise to hemolytic anemia. ", "begin": 0, "document": "17105810", "end": 175, "section": "abstract"}, {"text": "Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis. T", "begin": 0, "document": "12943237", "end": 340, "section": "abstract"}]}, {"documents": ["24030414", "24043612", "21161115", "16358146", "11865681", "2225986", "22457261", "22397493", "21866385", "20301510", "20232788", "15755703", "15554020", "11159287", "9587454", "9586150", "8322324", "7113187"], "answer": [["aortic root dilation"], ["mitral valve prolapse"], ["aortic regurgitation"], ["mitral valve regurgitation"]], "id": "530cf4e0c8a0b4a00c000005", "snippets": [{"text": "Cardiac manifestations of Marfan syndrome include aortic root dilation and mitral valve prolapse (MVP).", "begin": 12, "document": "24030414", "end": 115, "section": "abstract"}, {"text": "Marfan syndrome (MFS) is a genetic disorder of the connective tissue. Aortic root dilation is a main criterion of the Ghent Nosology. Dural ectasia and the presence of mitral valve prolapse (MVP) contribute to its systemic score.", "begin": 9, "document": "24043612", "end": 238, "section": "abstract"}, {"text": "The typical cardiac manifestations of Marfan syndrome are aortic regurgitation with progressive dilatation of the aortic root, which may cause dissection and rupture of the ascending aorta, mitral valve prolapse and mitral valve regurgitation.", "begin": 12, "document": "21161115", "end": 255, "section": "abstract"}, {"text": "To describe the clinical cardiac manifestations and temporal evolution of Marfan syndrome in children; to estimate the incidence of annuloaortic ectasia and mitral valve prolapse", "begin": 11, "document": "16358146", "end": 189, "section": "abstract"}, {"text": "the presence of mitral valve prolapse, aortic root diameter, mitral and aortic valves regurgitation, and aortic enlargement during beta-blocker therapy", "begin": 416, "document": "16358146", "end": 567, "section": "abstract"}, {"text": "Cardiovascular manifestations in Marfan syndrome.", "begin": 0, "document": "11865681", "end": 49, "section": "title"}, {"text": "The major cardiac diagnoses were aortic dilatation (1/3) and mitral valve prolapse with severe mitral regurgitation (2/3).", "begin": 1027, "document": "11865681", "end": 1149, "section": "abstract"}, {"text": "Marfan syndrome is a hereditable disorder of connective tissue that causes several distinct cardiovascular abnormalities, including aortic regurgitation, dissection, and aneurysm.", "begin": 0, "document": "2225986", "end": 179, "section": "abstract"}]}, {"documents": ["23107651", "21763255", "23015869", "11879111", "11555799", "20086611"], "answer": ["10-28%"], "id": "530cf4e0c8a0b4a00c000007", "snippets": [{"text": "At their commotio cordis event, 216 study patients were 0.2-51 years old (mean age 15\u00b19 years); 95% were males. Death occurred in 156 individuals (72%), while the other 60 (28%) survived.", "begin": 592, "document": "23107651", "end": 779, "section": "abstract"}, {"text": "In the 2 groups, events were largely similar demographically, including frequency of survival (26% in U.S. vs 25%; P = .84),", "begin": 740, "document": "21763255", "end": 864, "section": "abstract"}, {"text": "Survival of commotio cordis has risen from 10% to 15% since 2001.", "begin": 1443, "document": "23015869", "end": 1508, "section": "abstract"}, {"text": "Only 21 (16%) individuals survived their event, with particularly prompt cardiopulmonary resuscitation/defibrillation (most commonly reversing ventricular fibrillation) the only identifiable factor associated with a favorable outcome.", "begin": 1388, "document": "11879111", "end": 1622, "section": "abstract"}, {"text": "Survival rates for commotio cordis are low, even with prompt CPR and defibrillation.", "begin": 351, "document": "11555799", "end": 435, "section": "abstract"}, {"text": "Survival is low, even when resuscitation is performed. ", "begin": 481, "document": "20086611", "end": 536, "section": "abstract"}]}, {"documents": ["24268987", "24170966", "23592749", "23550058", "23419639", "23392090", "23235483", "23161551", "22890106", "22719050", "22543196", "21896621", "21835051", "21825978", "21303950", "21264952", "21098685", "20879691", "20713192", "20628049", "20435089", "20083155", "19936787", "19811520", "19641107", "19541799", "19018842", "18589880", "18398436", "17899191", "17574010", "15980113", "15889350", "24275187", "24027558"], "answer": ["Thyroid"], "id": "530f900ee3eabad021000003", "snippets": [{"text": "This syndrome is characterized by axial hypotonia, severe mental retardation, dysarthria, athetoid movements, spastic paraplegia, and a typical thyroid hormone profile. ", "begin": 144, "document": "24268987", "end": 313, "section": "abstract"}, {"text": "Our case and the review of the pertinent literature suggest that Allan-Herndon-Dudley syndrome should be suspected in males with the typical neurological and thyroid profile, even in cases with normal brain myelination.", "begin": 1226, "document": "24268987", "end": 1445, "section": "abstract"}, {"text": "Allan-Herndon-Dudley Syndrome (AHDS), an X linked condition, is characterized by congenital hypotonia that progresses to spasticity with severe psychomotor delays, in combination with altered thyroid hormone levels, in particular, high serum T3 levels. ", "begin": 0, "document": "24170966", "end": 253, "section": "abstract"}, {"text": "Mutations in the MCT8 gene are associated with Allan-Herndon-Dudley Syndrome (AHDS), consisting of severe psychomotor retardation and disturbed TH parameters.", "begin": 85, "document": "23550058", "end": 243, "section": "abstract"}, {"text": "Allan-Herndon-Dudley syndrome (AHDS), an X linked condition, is characterized by severe intellectual disability, dysarthria, athetoid movements, muscle hypoplasia and spastic paraplegia in combination with altered TH levels, in particular, high serum T3 levels. ", "begin": 0, "document": "23419639", "end": 262, "section": "abstract"}, {"text": "In two generations its presence was detected in the hemizygous state in two males with neurological abnormalities including mental retardation, axial hypotonia, hypertonia of arms and legs and athetoid movements. One of them presented normal thyroid hormone levels. ", "begin": 494, "document": "23419639", "end": 760, "section": "abstract"}, {"text": "Our results show the difficulty of distinguishing AHDS from patients with X-linked intellectual disability solely on the basis of clinical features and biochemical tests, and we advise screening for MCT8 mutations in either young or older patients with severe intellectual disability, axial hypotonia/dystonia, poor head control, spastic paraplegia, and athetoid movements even when they have normal thyroid hormone profiles.", "begin": 893, "document": "23419639", "end": 1318, "section": "abstract"}, {"text": "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels.", "begin": 489, "document": "23392090", "end": 642, "section": "abstract"}, {"text": "Allan-Herndon-Dudley syndrome (AHDS) is a severe psychomotor retardation characterized by neurological impairment and abnormal thyroid hormone (TH) levels. ", "begin": 0, "document": "23161551", "end": 156, "section": "abstract"}, {"text": "The hallmarks of Allan-Herndon-Dudley syndrome, caused by MCT8 mutations, are severe psychomotor retardation and elevated T(3) levels.", "begin": 263, "document": "22719050", "end": 397, "section": "abstract"}, {"text": "Inactivating mutations in the gene encoding MCT8 are associated with a severe form of psychomotor retardation and abnormal serum TH levels (Allan-Herndon-Dudley syndrome). ", "begin": 309, "document": "22543196", "end": 481, "section": "abstract"}, {"text": "Mutations of this transporter determine a distinct X-linked psychomotor retardation syndrome (Allan-Herndon-Dudley syndrome (AHDS)) that is attributed to disturbed thyroid hormone levels, especially elevated T(3) levels.", "begin": 124, "document": "21896621", "end": 344, "section": "abstract"}, {"text": "This syndrome is characterized by abnormally high T3, low/normal T4 serum levels and slightly elevated serum TSH.", "begin": 291, "document": "21835051", "end": 404, "section": "abstract"}, {"text": "High D1 activity in liver and kidney increases T4 and rT3 deiodination, and contributes to the increased serum T3.", "begin": 845, "document": "21825978", "end": 959, "section": "abstract"}, {"text": "One of these, monocarboxylate transporter 8 (MCT8) is mutated in Allan-Herndon-Dudley syndrome, a severe mental retardation associated with abnormal thyroid hormone constellations. ", "begin": 93, "document": "21264952", "end": 274, "section": "abstract"}, {"text": "The endocrine phenotype showed low serum total and free thyroxine (T4), very elevated total and free triiodothyronine (T3) and normal thyrotropin (TSH) with blunted response to thyrotropin-releasing hormone (TRH). ", "begin": 823, "document": "20713192", "end": 1037, "section": "abstract"}, {"text": "Monocarboxylate transporter 8 (MCT8, SLC16A2) is a thyroid hormone (TH) transmembrane transport protein mutated in Allan-Herndon-Dudley syndrome, a severe X-linked psychomotor retardation. ", "begin": 0, "document": "20628049", "end": 189, "section": "abstract"}, {"text": "The clinical importance of TH transporters is dramatically shown in patients with mutations in MCT8, suffering from severe X-linked psychomotor retardation in combination with disturbed TH levels, especially high serum T(3) levels, now referred as Allan-Herndon-Dudley Syndrome (AHDS). ", "begin": 312, "document": "20083155", "end": 598, "section": "abstract"}, {"text": "Therefore, the criterion for MCT8 mutation screening in these patients is the profile of increased T(3) and low-normal to low FT(4) serum levels.", "begin": 1000, "document": "20083155", "end": 1145, "section": "abstract"}, {"text": "However, T3 level was elevated.", "begin": 401, "document": "19936787", "end": 432, "section": "abstract"}, {"text": "AIM: Mutations in the SLC16A2 gene have been implicated in Allan-Herndon-Dudley syndrome (AHDS), an X-linked learning disability* syndrome associated with thyroid function test (TFT) abnormalities.", "begin": 0, "document": "19811520", "end": 197, "section": "abstract"}, {"text": "Dystonic cerebral palsy was the most common initial clinical diagnosis, and AHDS was suspected only retrospectively, considering the characteristically abnormal thyroid function tests, with high serum tri-iodothyronine (T(3)), as the most consistent finding.", "begin": 862, "document": "19811520", "end": 1120, "section": "abstract"}, {"text": "Although dysmorphic features suggestive of AHDS are not always present, T(3) measurement is a reliable screening test.", "begin": 1570, "document": "19811520", "end": 1688, "section": "abstract"}, {"text": "Mutations in one of these, monocarboxylate transporter 8 (MCT8), have been identified as underlying cause for the Allan-Herndon-Dudley syndrome, an X-linked mental retardation in which the patients also present with abnormally high 3',3,5-triiodothyronine (T(3)) plasma levels.", "begin": 82, "document": "19641107", "end": 359, "section": "abstract"}, {"text": "With the discovery of monocarboxylate transporter 8 (MCT8) as a specific thyroid hormone transporter and the finding that mutations in this transporter lead to a syndrome of severe psychomotor retardation and elevated serum 3,3',5-tri-iodothyronine levels known as the Allan-Herndon-Dudley syndrome, the interest in this area of research has greatly increased. ", "begin": 650, "document": "19541799", "end": 1011, "section": "abstract"}, {"text": "Elevated serum triiodothyronine and intellectual and motor disability with paroxysmal dyskinesia caused by a monocarboxylate transporter 8 gene mutation.", "begin": 0, "document": "19018842", "end": 153, "section": "title"}, {"text": "Additionally, the patient has a lesion in the left putamen region revealed by magnetic resonance imaging and elevated serum T3 levels.", "begin": 509, "document": "19018842", "end": 643, "section": "abstract"}, {"text": "The identified MCT8 gene mutation (R271H) is very likely to be the genetic cause for neuronal hypothyroidism despite elevated serum T3 levels.", "begin": 994, "document": "19018842", "end": 1136, "section": "abstract"}, {"text": "Abnormal transport function is reflected by elevated free T3 and decreased free T4 levels along with clinical features characterized by neurological abnormalities including global developmental delay, central hypotonia, rotatory nystagmus, impaired hearing, spasticity and contractures of joints. We report a child with classical clinical features along with confirmatory deranged thyroid levels in blood.", "begin": 140, "document": "18589880", "end": 545, "section": "abstract"}, {"text": "Consistent with previous reports on MCT8 missense changes, the patient with c.1673G>A showed elevated serum T3 level. ", "begin": 491, "document": "18398436", "end": 609, "section": "abstract"}, {"text": "Moreover, we characterized a de novo translocation t(X;9)(q13.2;p24) in a female patient with full blown AHDS clinical features including elevated serum T3 levels.", "begin": 970, "document": "18398436", "end": 1133, "section": "abstract"}, {"text": "Taken together, these data indicate that MCT8 mutations are not common in non-AHDS MR patients yet they support that elevated serum T3 levels can be indicative for AHDS and that AHDS clinical features can be present in female MCT8 mutation carriers whenever there is unfavorable nonrandom X-inactivation.", "begin": 1332, "document": "18398436", "end": 1636, "section": "abstract"}, {"text": "Endocrine functions other than thyroid hormone regulation and metabolism were intact, resulting in normal hypothalamic/pituitary function tests.", "begin": 746, "document": "17899191", "end": 890, "section": "abstract"}, {"text": "Conclusion: the characteristic thyroid hormone function tests and brain MRI findings may allow screening of high-risk populations for a better understanding of MCT8 pathophysiology.", "begin": 1041, "document": "17899191", "end": 1222, "section": "abstract"}, {"text": "Importantly, these patients have elevated serum levels of free T(3), low to below normal serum levels of free T(4), and levels of thyroid stimulating hormone that are within the normal range.", "begin": 651, "document": "17574010", "end": 842, "section": "abstract"}, {"text": "Pathogenic mutations in the MCT8 gene, which encodes a thyroid hormone transporter, results in elevated serum triiodothyronine (T3) levels, which were confirmed in four affected males of this family, while normal levels were found among obligate carriers.", "begin": 497, "document": "15980113", "end": 752, "section": "abstract"}, {"text": "In addition, the severe muscle hypoplasia observed in most AHDS patients may be a consequence of high serum T3 levels.", "begin": 1057, "document": "15980113", "end": 1175, "section": "abstract"}, {"text": "Abnormal transporter function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in the blood. ", "begin": 538, "document": "15889350", "end": 663, "section": "abstract"}, {"text": "Mct8 transports thyroid hormones (T4 and T3), and the Allan-Herndon-Dudley syndrome is likely caused by lack of T3 transport to neurons during critical periods of fetal brain development. ", "begin": 190, "document": "21303950", "end": 378, "section": "abstract"}]}, {"documents": ["23559085", "22529180", "19463607", "19114542", "17544610", "16542047", "16026106", "17636722"], "answer": ["effective in younger individuals"], "id": "52efbfccc8da898910000018", "snippets": [{"text": "sHT in older people should be not regarded as a unique condition, and moderately old patients (aged <70-75 y) could be considered clinically similar to the adult population, albeit with a higher optimal TSH target value. Conversely, the oldest old subjects should be carefully followed with a wait-and-see strategy, generally avoiding hormonal treatment. The decision to treat elderly people is still an unresolved clinical challenge--first, due to a lack of appropriately powered randomized controlled trials of L-T4 in sHT patients, examining cardiovascular hard endpoints in various classes of age; and second, because of the negative effects of possible overtreatment.", "begin": 1447, "document": "23559085", "end": 2119, "section": "abstract"}, {"text": "Treatment of SCH with levothyroxine was associated with fewer IHD events in younger individuals, but this was not evident in older people. An appropriately powered randomized controlled trial of levothyroxine in SCH examining vascular outcomes is now warranted.", "begin": 1535, "document": "22529180", "end": 1796, "section": "abstract"}, {"text": "SCH appears to influence the postoperative outcome for patients by increasing the development of postoperative atrial fibrillation. However, it is still unproven whether preoperative thyroxine replacement therapy for patients with SCH might prevent postoperative atrial fibrillation after CABG.", "begin": 1415, "document": "19463607", "end": 1709, "section": "abstract"}, {"text": "Sustained normalization of thyroid function during l-T(4) replacement therapy significantly decreases baPWV in female subclinical hypothyroid patients with autoimmune chronic thyroiditis, suggesting the improvement of arterial stiffening and, consequently, possible prevention of cardiovascular disease.", "begin": 1497, "document": "19114542", "end": 1800, "section": "abstract"}, {"text": "Our results suggest that L-T(4) replacement therapy may be especially beneficial in female subclinical hypothyroid patients with high baseline baPWV and pulse pressure. The beneficial effects of L-T(4) replacement therapy in decreasing arterial stiffening and thus preventing cardiovascular disease might be limited to this sub-population.", "begin": 1467, "document": "17544610", "end": 1806, "section": "abstract"}, {"text": "Although a consensus is still lacking, the strongest evidence for a beneficial effect of levothyroxine replacement on markers of cardiovascular risk is the substantial demonstration that restoration of euthyroidism can lower both total and low-density lipoprotein-cholesterol levels in most patients with subclinical hypothyroidism.", "begin": 1695, "document": "16542047", "end": 2027, "section": "abstract"}, {"text": "However, the actual effectiveness of thyroid hormone substitution in reducing the risk of cardiovascular events remains to be elucidated.", "begin": 2028, "document": "16542047", "end": 2165, "section": "abstract"}, {"text": "Restoration of euthyroidism by levothyroxine (LT4) treatment may correct the lipid profile and cardiac abnormalities, especially in patients with an initially higher deviation from normality and higher serum TSH levels. Importantly, a strong association between SH and atherosclerotic cardiovascular disease, independent of the traditional risk factors, has been recently reported in a large cross-sectional survey (the Rotterdam Study). However, whether SH confers a high risk for cardiovascular disease, and whether LT4 therapy has a long-term benefit that clearly outweighs the risks of overzealous treatment in these individuals, remain topics of controversy.", "begin": 970, "document": "16026106", "end": 1633, "section": "abstract"}]}, {"documents": ["22073124", "20880963", "19016324", "18954857", "18486124", "17579492", "17204552", "20739399"], "answer": [["negative inotropism"], ["negative chronotropy"]], "id": "532c12f2d6d3ac6a3400001d", "snippets": [{"text": "Intraperitoneal or central injection of 3-T(1)AM or T(0)AM into mice, rats, or Djungarian hamsters caused various prompt effects, such as metabolic depression, hypothermia, negative chronotropy, negative inotropy, hyperglycemia, reduction of the respiratory quotient, ketonuria, and reduction of fat mass. ", "begin": 641, "document": "20880963", "end": 947, "section": "abstract"}, {"text": "Functional effects have been observed after administration of exogenous T(1)AM: in the isolated heart, a negative inotropic and chronotropic action was produced, and the resistance to ischemic injury was increased, possibly as a consequence of an action on intracellular calcium homeostasis.", "begin": 329, "document": "19016324", "end": 620, "section": "abstract"}, {"text": "In conclusion, trace amines and thyronamines are negative inotropic agents. ", "begin": 1523, "document": "18486124", "end": 1599, "section": "abstract"}]}, {"documents": ["22421959", "22119737", "24025405", "22298808", "22422768", "22515980", "22650415", "22733215", "23595086"], "answer": [["CPVT", "catecholaminergic polymorphic ventricular tachycardia"], ["HCM", "hypertrophic cardiomyopathy"]], "id": "52e8e98298d0239505000020", "snippets": [{"text": " mutations in the gene encoding for cardiac calsequestrin, CASQ2, cause a rare but severe form of catecholaminergic polymorphic ventricular tachycardia (CPVT)", "begin": 316, "document": "22421959", "end": 474, "section": "abstract"}, {"text": "CPVT can be caused by mutations the cardiac ryanodine receptor gene (RYR2) or mutations in the cardiac calsequestrin gene CASQ2.", "begin": 193, "document": "22119737", "end": 321, "section": "abstract"}, {"text": "To date, about 189 variants in 5 genes (RYR2, CASQ2, CALM1, TRND, and KCNJ2) have been associated with CPVT pathogenesis. ", "begin": 219, "document": "24025405", "end": 341, "section": "abstract"}, {"text": "Catecholaminergic polymorphic ventricular tachycardia is an inherited disease that predisposes to cardiac arrest and sudden death. The disease is associated with mutations in the genes encoding for the cardiac ryanodine receptor (RyR2) and cardiac calsequestrin (CASQ2).", "begin": 12, "document": "22298808", "end": 282, "section": "abstract"}, {"text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease so far related to mutations in the cardiac ryanodine receptor (RYR2) or the cardiac calsequestrin (CASQ2) genes. ", "begin": 0, "document": "22422768", "end": 213, "section": "abstract"}, {"text": "mutations in RYR2-encoded ryanodine receptor 2, CASQ2-encoded calsequestrin 2, CALR3-encoded calreticulin 3, and SRI-encoded sorcin have been associated with HCM", "begin": 786, "document": "22515980", "end": 947, "section": "abstract"}, {"text": "The autosomal recessive form of CPVT is caused by mutations in the CASQ2 gene.", "begin": 176, "document": "22650415", "end": 254, "section": "abstract"}, {"text": "we discuss mutations in the genes encoding the ryanodine receptor 2 (RYR2) and calsequestrin 2 (CASQ2). These proteins are pivotal to the regulation of calcium release from the sarcoplasmic reticulum, and mutations can cause CPVT. ", "begin": 909, "document": "22733215", "end": 1140, "section": "abstract"}, {"text": "genetic testing was conducted in all exons on 3 CPVT-related genes: cardiac ryanodine receptor 2 (RYR2), calsequestrin 2 (CASQ2) and inward rectifier potassium channel 2 (KCNJ2),", "begin": 324, "document": "23595086", "end": 502, "section": "abstract"}]}, {"documents": ["24244333", "22427796", "24167038", "22166450", "22166400", "21626549", "20696312", "19297401", "19168133", "18787878", "18279377", "18175395", "17713120", "17713119", "17704838", "16003110", "15525661", "15917645", "14712351", "12446870", "11911988", "11487197", "11261251", "11128611", "10072423"], "answer": [["PARK2"], ["PARK7", "DJ-1"], ["PINK1"], ["PARK9", "ATP13A2"], ["PARK14", "PLA2G6"], ["PARK15", "FBX07"], [""]], "id": "5318367cb166e2b806000012", "snippets": [{"text": "Mutations in the Parkin gene (PARK2) are the major cause of autosomal recessive early-onset parkinsonism.", "begin": 295, "document": "24244333", "end": 400, "section": "abstract"}, {"text": "Early onset PD (EOPD) is particularly associated with autosomal recessive (AR) mutations, and three genes, PARK2, PARK7 and PINK1, have been found to carry mutations leading to AR disease. ", "begin": 138, "document": "22427796", "end": 327, "section": "abstract"}, {"text": "Homozygous or compound heterozygous mutations in the phosphatase and tensin homolog-induced putative kinase 1 (PINK1) gene are causative of autosomal recessive, early onset Parkinson's disease. ", "begin": 0, "document": "24167038", "end": 194, "section": "abstract"}, {"text": "Mutations in other genes, including ATP13A2 (PARK9), PLA2G6 (PARK14), and FBX07 (PARK15), cause more rare forms of recessive parkinsonism with very early-onset (<30 years)", "begin": 1122, "document": "22166450", "end": 1293, "section": "abstract"}, {"text": "In three forms, caused by mutations in parkin (PARK2), PINK1 (PARK6), or DJ-1 (PARK7),", "begin": 61, "document": "22166450", "end": 147, "section": "abstract"}, {"text": "oss-of-function mutations in Parkin, PINK1, DJ-1 and ATP13A2 cause autosomal recessive parkinsonism with early-onset.", "begin": 498, "document": "19297401", "end": 615, "section": "abstract"}, {"text": "mutations in the parkin gene, in DJ-1, PINK1 and ATP13A2 all cause autosomal-recessive parkinsonism of early onset.", "begin": 601, "document": "19168133", "end": 716, "section": "abstract"}, {"text": "mutations in the parkin gene, in DJ-1, PINK1 and ATP13A2 cause autosomal recessive parkinsonism of early onset", "begin": 551, "document": "18787878", "end": 661, "section": "abstract"}, {"text": "Mutations in the parkin gene, in DJ-1 and PINK1 all cause autosomal recessive parkinsonism of early onset.", "begin": 486, "document": "18175395", "end": 592, "section": "abstract"}, {"text": "PTEN-induced putative kinase 1 (PINK1) is a causative gene for autosomal recessive early onset parkinsonism.", "begin": 0, "document": "17713119", "end": 108, "section": "abstract"}, {"text": " we focus on PARK7, a gene relates to an autosomal recessive form of early-onset Parkinsonism and encodes a protein named DJ-1.", "begin": 288, "document": "17704838", "end": 415, "section": "abstract"}, {"text": "PINK-1 for an autosomal-recessive early-onset variant", "begin": 855, "document": "16003110", "end": 908, "section": "abstract"}, {"text": " Heritable mutations in alpha-synuclein, parkin, DJ-1 and PINK1 cause familial forms of PD. ", "begin": 152, "document": "15525661", "end": 244, "section": "abstract"}, {"text": "we focus on PARK7, an autosomal recessive form of early-onset parkinsonism caused by mutations in the DJ-1 gene", "begin": 173, "document": "14712351", "end": 284, "section": "abstract"}, {"text": "Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.", "begin": 0, "document": "12446870", "end": 88, "section": "title"}, {"text": "Autosomal recessive parkinsonism associated with mutations in the parkin gene represents a monogenic form of hereditary parkinsonism.", "begin": 0, "document": "11911988", "end": 133, "section": "abstract"}, {"text": "Mutations of the parkin gene on chromosome 6 cause autosomal recessive, early onset parkinsonism. ", "begin": 0, "document": "11487197", "end": 98, "section": "abstract"}, {"text": " A gene causing autosomal recessive parkinsonism of juvenile onset has been mapped to chromosome 6 (PARK 2), and the causative gene has been identified and named parkin. ", "begin": 1166, "document": "11128611", "end": 1336, "section": "abstract"}, {"text": "The gene responsible for AR-JP was recently identified and designated parkin.", "begin": 285, "document": "10072423", "end": 362, "section": "abstract"}]}, {"documents": ["24030101", "23704930", "23676277", "22918945", "22575891", "22496419", "22014515", "22252321", "21987634", "21944719"], "answer": [["MIB", "mitochondrial inter-membrane space bridging complex"], ["MINOS", "mitochondrial inner membrane organizing system"], ["MitOS"]], "id": "53215fca9b2d7acc7e000005", "snippets": [{"text": " and the mitochondrial structural proteins-components of mitochondrial inter-membrane space bridging (MIB) complex (Mitofilin, Sam50, and ChChd3), ", "begin": 915, "document": "24030101", "end": 1062, "section": "abstract"}, {"text": "APOOL is a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex", "begin": 0, "document": "23704930", "end": 81, "section": "title"}, {"text": "Mitofilin/MINOS protein complex ", "begin": 330, "document": "23704930", "end": 362, "section": "abstract"}, {"text": " APOOL physically interacts with several subunits of the MINOS complex, namely Mitofilin, MINOS1, and SAMM50. ", "begin": 879, "document": "23704930", "end": 989, "section": "abstract"}, {"text": "Mitofilin/MINOS protein complex ", "begin": 1054, "document": "23704930", "end": 1086, "section": "abstract"}, {"text": "MINOS subunits (mitofilin, MINOS1, and CHCHD3)", "begin": 616, "document": "23676277", "end": 662, "section": "abstract"}, {"text": "mitofilin, a core MINOS subunit,", "begin": 918, "document": "23676277", "end": 950, "section": "abstract"}, {"text": "The mitochondrial inner membrane organizing system (MINOS) is a large protein complex required for maintaining inner membrane architecture. ", "begin": 99, "document": "22918945", "end": 239, "section": "abstract"}, {"text": "Mitochondria lacking mitofilin, the large core subunit of MINOS,", "begin": 731, "document": "22918945", "end": 795, "section": "abstract"}, {"text": "The mitochondrial inner membrane contains a large protein complex crucial for membrane architecture, the mitochondrial inner membrane organizing system (MINOS).", "begin": 0, "document": "22575891", "end": 160, "section": "abstract"}, {"text": " To study if outer membrane interactions and maintenance of cristae morphology are directly coupled, we generated mutant forms of mitofilin/Fcj1 (formation of crista junction protein 1), a core component of MINOS. ", "begin": 343, "document": "22575891", "end": 557, "section": "abstract"}, {"text": "The C-terminal domain of Fcj1 is required for formation of crista junctions and interacts with the TOB/SAM complex in mitochondria.", "begin": 0, "document": "22496419", "end": 131, "section": "title"}, {"text": "Mitofilin/Fcj1, the central component of the MINOS complex,", "begin": 232, "document": "22014515", "end": 291, "section": "abstract"}, {"text": "We provide evidence that the SAM components exist in a large protein complex together with the IMM proteins mitofilin and CHCHD3, which we term the mitochondrial intermembrane space bridging (MIB) complex.", "begin": 443, "document": "22252321", "end": 648, "section": "abstract"}, {"text": "which we term MitOS for mitochondrial organizing structure, comprised of Fcj1/Mitofilin, a conserved inner membrane protein, and five additional components. ", "begin": 523, "document": "21987634", "end": 680, "section": "abstract"}, {"text": "Mitofilin is part of a large inner membrane complex, and we identify five partner proteins as constituents of the mitochondrial inner membrane organizing system (MINOS) that is required for keeping cristae membranes connected to the inner boundary membrane.", "begin": 342, "document": "21944719", "end": 599, "section": "abstract"}, {"text": " Our findings indicate that mitofilin is a central component\u00a0of MINOS", "begin": 744, "document": "21944719", "end": 813, "section": "abstract"}]}, {"documents": ["24200467", "23863084", "21170289", "21118133", "20713356", "7831320", "6649413", "956186"], "answer": [["RNA guanylyltransferase and 5'-phosphatase (RNGTT)"], ["RNA guanine-7 methyltransferase (RNMT or hMTr1)"], ["RNMT-activating mini-protein (RAM)"], ["RNA polymerase II"], ["S-adenosylhomocysteine hydrolase (SAHH)"], ["Myc"]], "id": "52f112bb2059c6d71c000002", "snippets": [{"text": "In mammals, cap synthesis is catalysed by the sequential action of RNGTT (RNA guanylyltransferase and 5'-phosphatase) and RNMT (RNA guanine-7 methyltransferase), enzymes recruited to RNA pol II (polymerase II) during the early stages of transcription. We recently discovered that the mammalian cap methyltransferase is a heterodimer consisting of RNMT and the RNMT-activating subunit RAM (RNMT-activating mini-protein). RAM activates and stabilizes RNMT and thus is critical for cellular cap methylation and cell viability.", "begin": 452, "document": "24200467", "end": 975, "section": "abstract"}, {"text": "Synthesis of the methyl cap initiates with the addition of 7-methylguanosine to the initiating nucleotide of RNA pol II (polymerase II) transcripts, which occurs predominantly during transcription and in mammals is catalysed by RNGTT (RNA guanylyltransferase and 5' phosphatase) and RNMT (RNA guanine-7 methyltransferase).", "begin": 125, "document": "23863084", "end": 447, "section": "abstract"}, {"text": "The RNMT-activating subunit, RAM (RNMT-activating miniprotein), is also recruited to transcription initiation sites via an interaction with RNMT.", "begin": 861, "document": "23863084", "end": 1006, "section": "abstract"}, {"text": "Phosphorylation of the CTD recruits RNGTT and RNMT, the enzymes involved in mRNA capping, to the nascent transcript.", "begin": 786, "document": "21170289", "end": 902, "section": "abstract"}, {"text": "Myc induces methyl cap formation by promoting RNA polymerase II phosphorylation which recruits the capping enzymes to RNA, and by up-regulating the enzyme SAHH (S-adenosylhomocysteine hydrolase), which neutralizes the inhibitory by-product of methylation reactions.", "begin": 666, "document": "21118133", "end": 931, "section": "abstract"}, {"text": "In the present study, we identify the methyltransferase responsible for cap1 formation in human cells, which we call hMTr1 (also known as FTSJD2 and ISG95).", "begin": 535, "document": "20713356", "end": 691, "section": "abstract"}, {"text": "The guanylyltransferase (GTP:mRNA guanylyltransferase, EC 2.7.7.50) reaction responsible for cap formation usually proceeds via a covalent enzyme-GMP intermediate.", "begin": 166, "document": "7831320", "end": 329, "section": "abstract"}, {"text": "The methylation of the 5' terminal guanosine residue of the cap structure of Semliki Forest virus (SFV) mRNAs has been shown to occur in vitro concomitantly with their synthesis (R. K. Cross and P. J. Gomatos, Virology, 114, 542-554, 1981). The enzyme responsible for this methylation, a guanine-7-methyltransferase, is associated with the SFV replication complex", "begin": 0, "document": "6649413", "end": 363, "section": "abstract"}, {"text": "An RNA (guanine-7-)-methyltransferase that specifically methylates the 5'-terminal guanosine residue of RNAs ending in the dinucleoside triphosphate G(5')pppN- has been purified from the cytoplasm of HeLa cells.", "begin": 92, "document": "956186", "end": 303, "section": "abstract"}]}, {"documents": ["23892221", "22739566", "21968872", "21159787", "18615229"], "answer": [["androgen replacement trials"], ["omega-3 fatty acid supplementation", "NCT00794079"]], "id": "52f893f92059c6d71c00003c", "snippets": [{"text": "several clinical trials with androgen replacement therapy have failed to show clinical benefit.", "begin": 154, "document": "23892221", "end": 249, "section": "abstract"}, {"text": "Clinical trials are needed to find better interventions for this syndrome.", "begin": 1146, "document": "22739566", "end": 1220, "section": "abstract"}, {"text": "emergence of many promising interventions towards this age-related condition (e.g., physical exercise [in particular, resistance training], testosterone, antioxidant supplementations), the need for Phase II trial designs is high. ", "begin": 705, "document": "21968872", "end": 935, "section": "abstract"}, {"text": "The objective of this study was to evaluate the effect of omega-3 fatty acid supplementation on the rate of muscle protein synthesis in older adults.", "begin": 299, "document": "21159787", "end": 448, "section": "abstract"}, {"text": "This trial was registered at clinical trials.gov as NCT00794079.", "begin": 1676, "document": "21159787", "end": 1740, "section": "abstract"}, {"text": "The extreme paucity of clinical trials on sarcopenia in literature is mainly due to difficulties in designing studies able to isolate the aging process from its multiple and interconnected consequences.", "begin": 487, "document": "18615229", "end": 689, "section": "abstract"}]}, {"documents": ["23713105", "21968521", "21631222", "21596366", "21048783", "20644152", "20635402", "19335127", "18576213", "18463369", "18174554", "17431895", "17138018", "16723886", "16475235", "16164190", "15675355", "15675354", "15362573", "15340753", "10754001", "11037190", "10757474", "9973290", "8898827", "8937199", "9128751", "22436252", "19918425", "23966756", "23077562", "22426657", "24167642"], "answer": [["3"], ["6"], ["8"], ["12"], ["15"], ["17"], ["21"], ["X"], ["Y"]], "id": "5312280ce3eabad02100000a", "snippets": [{"text": "Complex chromosome rearrangement of 6p25.3->p23 and 12q24.32->qter in a child with moyamoya.", "begin": 0, "document": "23713105", "end": 92, "section": "title"}, {"text": "Routine karyotype demonstrated extra chromosomal material on 6p. Single nucleotide polymorphism microarray revealed a previously unreported complex de novo genetic rearrangement involving subtelomeric segments on chromosomes 6p and 12q.", "begin": 298, "document": "23713105", "end": 534, "section": "abstract"}, {"text": "In terms of the genetics, recent literature suggests a low penetrance autosomal dominant or polygenic mode of transmission involving chromosomes 3, 6, 8, 12, and 17 for familial MMD. ", "begin": 573, "document": "21631222", "end": 756, "section": "abstract"}, {"text": "Furthermore, the current literature on familial MMD has pointed to a low penetrance autosomal dominant or polygenic mode of transmittance at loci on chromosomes 3, 6, 8, 12, and 17.", "begin": 1354, "document": "21631222", "end": 1535, "section": "abstract"}, {"text": "Here, we report on three unrelated families affected with an X-linked moyamoya syndrome characterized by the association of a moyamoya angiopathy, short stature, and a stereotyped facial dysmorphism. ", "begin": 767, "document": "21596366", "end": 967, "section": "abstract"}, {"text": "We show that this syndromic moyamoya is caused by Xq28 deletions removing MTCP1/MTCP1NB and BRCC3. ", "begin": 1160, "document": "21596366", "end": 1259, "section": "abstract"}, {"text": "A genome-wide association study of 785,720 single-nucleotide polymorphisms (SNPs) was performed, comparing 72 Japanese MMD patients with 45 Japanese controls and resulting in a strong association of chromosome 17q25-ter with MMD risk. This result was further confirmed by a locus-specific association study using 335 SNPs in the 17q25-ter region. ", "begin": 228, "document": "21048783", "end": 575, "section": "abstract"}, {"text": "Investigations included neuroimaging, cardiologic and ophthalmologic evaluation, hormonal testing, hemoglobin electrophoresis, chromosomal karyotyping, muscle biopsy for morphology, immunohistochemistry and enzyme assays, mtDNA mutation screening, and haplotype analysis of 2 loci previously linked to moyamoya, on chromosomes 10 (ACTA2) and 17.", "begin": 242, "document": "20644152", "end": 587, "section": "abstract"}, {"text": "These data strongly suggest that this family is affected by a hereditary moyamoya multisystem disorder with X-linked recessive pattern of inheritance.", "begin": 1554, "document": "20644152", "end": 1704, "section": "abstract"}, {"text": "Her features were consistent with TS and chromosome analysis revealed mosaicism in which 17% of the cells showed a pseudoisodicentric Y chromosome: 45,X (25)/46,X psu idic (Y)(11.2) (5). ", "begin": 345, "document": "20635402", "end": 532, "section": "abstract"}, {"text": "The small number of cases does not allow detailed analysis other than noting patient age (two older than 40 years), karyotype (two others associated with isochrome Xq), and associated cardiac risk factors (one with BAV).", "begin": 1011, "document": "20635402", "end": 1231, "section": "abstract"}, {"text": " Studies have shown a possible genetic association of MMD linked to chromosome 17 in Japanese cases as well as in cases found in other demographics. ", "begin": 667, "document": "19335127", "end": 816, "section": "abstract"}, {"text": "The gene responsible for NF1 is located on the chromosome region 17q11.2 and for familial moyamoya disease on chromosome 17q25. ", "begin": 308, "document": "18576213", "end": 436, "section": "abstract"}, {"text": "Autosomal dominant moyamoya disease maps to chromosome 17q25.3.", "begin": 0, "document": "18463369", "end": 63, "section": "title"}, {"text": "Under both classifications, significant evidence of linkage was only observed on chromosome 17q25.3, with maximum multipoint logarithm of odds (lod) scores of 6.57 (under the narrow classification) and 8.07 (under the broad classification) at D17S704. Haplotype analysis revealed segregation of a disease haplotype in all families but one, and informative crossovers enabled mapping of the MMD locus to a 3.5-Mb region between D17S1806 and the telomere of 17q, encompassing 94 annotated genes. CONCLUSIONS: Our data suggest that there is a major gene locus for autosomal dominant moyamoya disease on chromosome 17q25.3.", "begin": 619, "document": "18463369", "end": 1238, "section": "abstract"}, {"text": "However, the mitochondrial DNA and Y chromosomal genotype showed that affected members had the same sequence of the Mitochondrial 3 portion of D-loop with Japanese patients. ", "begin": 741, "document": "18174554", "end": 915, "section": "abstract"}, {"text": "Smith-Magenis syndrome and Moyamoya disease in a patient with del(17)(p11.2p13.1).", "begin": 0, "document": "17431895", "end": 82, "section": "title"}, {"text": "We have employed a combination of aCGH, FISH, and MLPA to characterize an approximately 6.3 Mb deletion spanning chromosome region 17p11.2-p13.1 in this patient, with the proximal breakpoint within the RAI1 gene. ", "begin": 936, "document": "17431895", "end": 1149, "section": "abstract"}, {"text": "Moyamoya syndrome in a child with trisomy 12p syndrome.", "begin": 0, "document": "17138018", "end": 55, "section": "title"}, {"text": "This report presents the first case of moyamoya syndrome with trisomy 12p with a familial pericentric inversion of chromosome 12.", "begin": 669, "document": "17138018", "end": 798, "section": "abstract"}, {"text": " She had been prenatally diagnosed with trisomy 12p with a familial pericentric inversion of chromosome 12 originating from her mother. She manifested developmental delay and some dysmorphic features of the face and limbs compatible with the clinical features of trisomy 12p.", "begin": 124, "document": "17138018", "end": 399, "section": "abstract"}, {"text": "The genes encoding tissue inhibitor of metalloproteinase (TIMP) 4 and TIMP2 span chromosomes 3p24.2-p26 and 17q25, respectively, which are the locations of familial moyamoya disease (FMMD) genes. ", "begin": 11, "document": "16723886", "end": 207, "section": "abstract"}, {"text": "We postulate that a protein encoded on chromosome 21 may be related to the pathogenesis of Down's syndrome with moyamoya syndrome.", "begin": 578, "document": "16164190", "end": 708, "section": "abstract"}, {"text": "[Molecular screening for moyamoya disease by use of expressed sequence tag on chromosome 3p].", "begin": 0, "document": "15675355", "end": 93, "section": "title"}, {"text": " To identify the expressed sequence tags (ESTs) with monoallelic expressions on chromosome 3, we used mouse A9 hybrid cells having human chromosome 3. Two ESTs showed only maternal expression in mouse A9 hybrid cells, and four showed non-expression in the lymphocytes derived from moyamoya patients. ", "begin": 307, "document": "15675355", "end": 607, "section": "abstract"}, {"text": "A novel susceptibility locus for moyamoya disease on chromosome 8q23.", "begin": 0, "document": "15362573", "end": 69, "section": "title"}, {"text": "Previous linkage studies have indicated that susceptibility loci for the disease are located on chromosomes 3p, 6q, and 17q. In the present study, we searched for loci linked to the disease in 12 Japanese families using 428 microsatellite markers and found significant evidence for linkage to 8q23 [maximum LOD score (MLS) of 3.6] and suggestive evidence for linkage to 12p12 (MLS=2.3). ", "begin": 335, "document": "15362573", "end": 722, "section": "abstract"}, {"text": "Considering the function, we selected nine genes as candidates from a total of 65 genes identified in the 9-cM region of D17S785-D17S836 in chromosome 17q25, and performed sequence analysis on the DNA samples obtained from a pedigree of familial moyamoya disease, which showed a complete linkage to the region by a haplotype analysis. ", "begin": 168, "document": "15340753", "end": 503, "section": "abstract"}, {"text": "Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25.", "begin": 0, "document": "10754001", "end": 105, "section": "title"}, {"text": "The characteristic lesions of moyamoya disease are occasionally seen in neurofibromatosis type 1, of which the causative gene (NF1) has been assigned to chromosome 17q11.2.", "begin": 189, "document": "10754001", "end": 361, "section": "abstract"}, {"text": "CONCLUSIONS: A gene for familial moyamoya disease is located on chromosome 17q25.", "begin": 1259, "document": "10754001", "end": 1340, "section": "abstract"}, {"text": "Recent genetic studies suggest some responsible genetic foci in chromosomes 3, 6 and 17.", "begin": 1104, "document": "11037190", "end": 1192, "section": "abstract"}, {"text": "To further specify the genetic component of moyamoya disease, a linkage study of moyamoya disease using markers on chromosome 6, where the HLA gene is located, was performed. ", "begin": 220, "document": "10757474", "end": 395, "section": "abstract"}, {"text": "Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26.", "begin": 0, "document": "9973290", "end": 69, "section": "title"}, {"text": "A linkage was found between the disease and markers located at 3p24.2-26.", "begin": 726, "document": "9973290", "end": 799, "section": "abstract"}, {"text": "We postulate that a protein encoded on chromosome 21 may be related to the pathogenesis of moyamoya disease. ", "begin": 1486, "document": "8898827", "end": 1595, "section": "abstract"}, {"text": "The diagnosis of PWS was confirmed genetically by the method of fluorescence in situ hybridization which showed the deletion of chromosome 15. ", "begin": 226, "document": "8937199", "end": 369, "section": "abstract"}]}, {"documents": ["24291220"], "answer": [["deafness"], ["onychodystrophy"], ["osteodystrophy"], ["mental retardation"], ["seizures"]], "id": "530e1c985937551c09000004", "snippets": [{"text": "Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a rare autosomal recessive disorder of unknown cause. ", "begin": 12, "document": "24291220", "end": 162, "section": "abstract"}, {"text": "Through a search of available case studies and communication with collaborators, we identified families that included at least one individual with at least three of the five main features of the DOORS syndrome: deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures. ", "begin": 284, "document": "24291220", "end": 577, "section": "abstract"}]}, {"documents": ["24240108", "24101146", "24043741", "23446853", "23153524", "22972611", "22863010", "22772063", "22767670", "22753585", "22488249", "22016509", "23723712", "23180582", "23847761", "24501545", "23037716", "23755375", "23431463", "23755370", "22350019", "22940834"], "answer": ["aurora kinase"], "id": "531dd4af267d7dd05300000d", "snippets": [{"text": "Inhibition of AURKA using an investigational small-molecule specific inhibitor, alisertib, decreased the HDM2 protein level and induced P53 transcriptional activity. ", "begin": 1197, "document": "24240108", "end": 1363, "section": "abstract"}, {"text": "Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.", "begin": 0, "document": "24101146", "end": 145, "section": "title"}, {"text": "Alisertib (MLN8237) is an investigational inhibitor of Aurora A kinase (AAK).", "begin": 9, "document": "24101146", "end": 86, "section": "abstract"}, {"text": "The spindle organization defects induced by alisertib have been used to develop a pharmacodynamic (PD) assay for Aurora A inhibition based on the percentage of mitotic cells with proper chromosomal alignment at the metaphase plate (% aligned spindles, abbreviated as AS). ", "begin": 408, "document": "24101146", "end": 680, "section": "abstract"}, {"text": "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.", "begin": 0, "document": "24043741", "end": 142, "section": "title"}, {"text": "We therefore designed a phase II study of alisertib, a selective AAK inhibitor, in patients with relapsed and refractory aggressive non-Hodgkin lymphomas.", "begin": 144, "document": "24043741", "end": 298, "section": "abstract"}, {"text": "In addition, we employed vMCF-7DRaf-1 cells that display high levels of endogenous cyclin-A and demonstrated that molecular targeting of Aurora-A by Alisertib reduces cyclin-A expression.", "begin": 1017, "document": "23446853", "end": 1204, "section": "abstract"}, {"text": "Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.", "begin": 0, "document": "23153524", "end": 219, "section": "title"}, {"text": "Alisertib (MLN8237) an investigational agent that inhibits Aurora A Ser/Thr kinase has shown activity in PTCL patients.", "begin": 159, "document": "23153524", "end": 278, "section": "abstract"}, {"text": "We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. ", "begin": 709, "document": "22863010", "end": 951, "section": "abstract"}, {"text": "Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.", "begin": 0, "document": "22772063", "end": 204, "section": "title"}, {"text": "This single-arm phase II study assessed single-agent efficacy and safety of the investigational AAK inhibitor MLN8237 (alisertib), in patients with platinum-refractory or -resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. ", "begin": 139, "document": "22772063", "end": 390, "section": "abstract"}, {"text": "This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral drug MLN8237 (alisertib), a small-molecule Aurora A kinase (AAK) inhibitor, in 87 adult patients with advanced solid tumors.", "begin": 9, "document": "22767670", "end": 251, "section": "abstract"}, {"text": "This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors. ", "begin": 107, "document": "22753585", "end": 306, "section": "abstract"}, {"text": "Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.", "begin": 0, "document": "22488249", "end": 148, "section": "title"}, {"text": "The investigational drug alisertib (MLN8237) is a novel Aurora A kinase inhibitor being studied in multiple Phase I and II studies.", "begin": 113, "document": "22488249", "end": 244, "section": "abstract"}, {"text": " Our collective data indicate that targeting Aurora A with alisertib represents a novel approach to increase the efficacy of ara-C that warrants further investigation.", "begin": 1215, "document": "22488249", "end": 1382, "section": "abstract"}, {"text": "Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.", "begin": 0, "document": "22016509", "end": 147, "section": "title"}, {"text": "Here, we describe preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, incorporating these novel pharmacodynamic assays.", "begin": 266, "document": "22016509", "end": 413, "section": "abstract"}, {"text": "We investigated the selectivity of alisertib for AAK and ABK and studied the antitumor and antiproliferative activity of alisertib in vitro and in vivo.", "begin": 435, "document": "22016509", "end": 587, "section": "abstract"}, {"text": "Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chromosomes in the HCT-116 xenograft model, a phenotype consistent with AAK inhibition.", "begin": 961, "document": "22016509", "end": 1193, "section": "abstract"}, {"text": "Alisertib is a selective and potent inhibitor of AAK. ", "begin": 1608, "document": "22016509", "end": 1662, "section": "abstract"}]}, {"documents": ["23074403", "16434186"], "answer": [["Codon 12"], ["Codon 13"], ["Codon 61"], ["Codon 146"], ["Codon 18"], ["Codon 31"], ["Codon 15"]], "id": "52e6c92598d0239505000019", "snippets": [{"text": "In this study we analyzed 15 sMTC for mutations in the hotspots codon 12, 13 and 61 of the H- and K-ras oncogene.", "begin": 613, "document": "10768832", "end": 726, "section": "abstract"}, {"text": "mutation in the codon 12, 13 and 61 of the H-ras and K-ras oncogene", "begin": 824, "document": "10768832", "end": 891, "section": "abstract"}, {"text": "the mutation hotspots of the K-ras proto-oncogene in human functional adrenocortical tumors are in codons 15, 16, 18, and 31", "begin": 31, "document": "11403720", "end": 155, "section": "abstract"}, {"text": "mutations C742T, G746T, G747T in the TP53 gene and G35T in the KRAS gene have been repeatedly found in sectors of human tumors", "begin": 4, "document": "16458330", "end": 130, "section": "abstract"}, {"text": "exons 1 and 2 of KRAS", "begin": 272, "document": "21266528", "end": 293, "section": "abstract"}, {"text": "KRAS (codon 12/13 hotspot)", "begin": 303, "document": "21199003", "end": 329, "section": "abstract"}, {"text": "three hotspots in KRAS (codons 12/13, 61 and 146)", "begin": 662, "document": "21199003", "end": 711, "section": "abstract"}, {"text": "analysis of KRAS (codon12/13)", "begin": 762, "document": "21199003", "end": 791, "section": "abstract"}, {"text": "mutations occurring in mutational hotspots (codons 12 and 13) of the KRAS protein", "begin": 2359, "document": "23074403", "end": 2440, "section": "abstract"}, {"text": "and N-, K-, and H-RAS (codons 12, 13, and 61)", "begin": 494, "document": "17638058", "end": 539, "section": "abstract"}]}, {"documents": ["22572731", "21803857", "20599948", "18987983", "17710556", "16705169", "15368356", "14506132", "12581305"], "answer": [["H3K9Me1", "H3K9Me2", "H3K9me3"], ["H3K27me1"], ["H3K27me2"], ["H4K20me3"], ["H3K79me3"], ["H3S10"]], "id": "52e0c9a298d0239505000010", "snippets": [{"text": "Remarkably, in mammalian somatic cells, H3S10P initiates in the pericentromeric heterochromatin during the late G2 phase, and phosphorylation spreads throughout the chromosomes arms in prophase, being maintained until the onset of anaphase when it gets dephosphorylated", "begin": 163, "document": "22572731", "end": 432, "section": "abstract"}, {"text": "Based on these findings, we believe that H3S10P is a good marker of pericentromeric heterochromatin, especially in the late 1- and 2-cell stages as it labels both parental genomes and that it can be used to further investigate epigenetic regulation and heterochromatin mechanisms in early preimplantation embryos", "begin": 1432, "document": "22572731", "end": 1744, "section": "abstract"}, {"text": "3S10 phosphorylation marks constitutive heterochromatin during interphase in early mouse embryos until the 4-cell stage", "begin": 1, "document": "22572731", "end": 120, "section": "title"}, {"text": "H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin", "begin": 8, "document": "21803857", "end": 102, "section": "title"}, {"text": "We show here that the maternally inherited Snurf-Snrpn 3-Mb region, which is silenced by a potent transcription repressive mechanism, is uniformly enriched in histone methylation marks usually found in constitutive heterochromatin, such as H4K20me3, H3K9me3, and H3K79me3", "begin": 393, "document": "21803857", "end": 664, "section": "abstract"}, {"text": "We show that H3K36me3 deposition within this large heterochromatin domain does not correlate with transcription events, suggesting the existence of an alternative pathway for the deposition of this histone modification", "begin": 899, "document": "21803857", "end": 1117, "section": "abstract"}, {"text": "In addition, we demonstrate that H3K36me3 is markedly enriched at the level of pericentromeric heterochromatin in mouse embryonic stem cells and fibroblasts", "begin": 1119, "document": "21803857", "end": 1275, "section": "abstract"}, {"text": "This result indicates that H3K36me3 is associated with both facultative and constitutive heterochromatin", "begin": 1277, "document": "21803857", "end": 1381, "section": "abstract"}, {"text": "Our data suggest that H3K36me3 function is not restricted to actively transcribed regions only and may contribute to the composition of heterochromatin, in combination with other histone modifications.", "begin": 1383, "document": "21803857", "end": 1584, "section": "abstract"}, {"text": "accumulation of histone H3.3 and euchromatic histone modifications in pericentromeric heterochromatin in response to a decrease in DNA methylation levels", "begin": 21, "document": "20599948", "end": 174, "section": "title"}, {"text": "In this study, we show that inhibition of DNA methylation in mouse fibroblast cells affects histone modification and the subnuclear localization of histone H3.3 in a cell cycle-dependent manner", "begin": 247, "document": "20599948", "end": 440, "section": "abstract"}, {"text": "Moreover, we found that histone H3.3 was deposited on the pericentromeric heterochromatin prior to the accumulation of the euchromatic histone modifications", "begin": 1169, "document": "20599948", "end": 1325, "section": "abstract"}, {"text": "Classical histone modifications associated with heterochromatin, including H3K9me2, H3K27me1 and H3K27me2, were distributed throughout both A and B chromosomes", "begin": 464, "document": "18987983", "end": 623, "section": "abstract"}, {"text": "However, H3K27me2 showed a reduced level on the B chromosome compared with the A chromosomes and was not associated with some classes of constitutive heterochromatin", "begin": 625, "document": "18987983", "end": 790, "section": "abstract"}, {"text": "Recently analyzed H3K9 methyltransferases (HMTases) as SUV39H1, Clr4p, DIM-5, Su(var)3-9 or SUVH2 are responsible for the establishment of histone H3 lysine 9 methylation (H3K9me), which is intimately connected with heterochromatinization", "begin": 150, "document": "17710556", "end": 388, "section": "abstract"}, {"text": "heterochromatic histone H3K9 methyltransferases left its marks behind", "begin": 23, "document": "17710556", "end": 92, "section": "title"}, {"text": "Compilation and parsimony analysis reveal that histone H3K9 methylation is, next to histone deacetylation, the evolutionary most stable heterochromatic mark, which is established by at least two subfamilies of specialized heterochromatic HMTases in almost all studied eukaryote", "begin": 815, "document": "17710556", "end": 1092, "section": "abstract"}, {"text": "Trimethylated H3(K9) marks pericentromeric constitutive heterochromatin and the male Y chromosome, while H2A.Z is dramatically reduced at these chromosomal locations", "begin": 280, "document": "16705169", "end": 445, "section": "abstract"}, {"text": "Of eight tested antibodies, the one for histone H4 acetylated at lysine 4, 8, 12, or 16 was best for distinguishing constitutive heterochromatin from unexpressed euchromatin, but differences in the extent of immunoprecipitation of these two types of chromatin were only modest, although highly reproducible", "begin": 448, "document": "15368356", "end": 754, "section": "abstract"}, {"text": "In addition, immunocytochemical analysis was done with an antibody to heterochromatin protein 1alpha (HP1alpha), whose preferential binding to heterochromatin has been linked to trimethylation of H3 at lysine 9", "begin": 1255, "document": "15368356", "end": 1465, "section": "abstract"}, {"text": "Our combined ChIP and immunocytochemical results suggest that factors other than hypoacetylation of the N-terminal tails of H4 and hypermethylation of H3 at lysine 9 can play an important role in determining whether a chromatin sequence in mammalian cells is constitutively heterochromatic", "begin": 1467, "document": "15368356", "end": 1756, "section": "abstract"}, {"text": "To test for the putative heterochromatinization, we quantitated chromatin immunoprecipitation with an antibody for acetylated histone H4 that discriminates between constitutive heterochromatin and unexpressed euchromatin", "begin": 599, "document": "14506132", "end": 819, "section": "abstract"}, {"text": "high methylation of H3 lysine 9 is dispensable for constitutive heterochromatin", "begin": 38, "document": "12581305", "end": 117, "section": "title"}, {"text": "Strong methylation at H3 lysine 4 was restricted to euchromatin, while strong methylation at H3 lysine 9 occurred preferentially in heterochromatic chromocenters of Arabidopsis nuclei", "begin": 546, "document": "12581305", "end": 729, "section": "abstract"}]}, {"documents": ["23042908", "22650415", "22557844", "21618644", "20302875", "19568611", "18684293", "18543230", "17607358", "15913575", "14571276", "12732448", "17655857"], "answer": [["catecholaminergic polymorphic ventricular tachycardia (CPVT)"], ["familial hypertrophic cardiomyopathy"]], "id": "52bf1af803868f1b06000008", "snippets": [{"text": "Recessively inherited CPVT is caused by either missense or null-allele mutations in the cardiac calsequestrin (CASQ2) gene. It was suggested that defects in CASQ2 cause protein deficiency and impair Ca(2+) uptake to the sarcoplasmic reticulum and Ca(2+)-dependent inhibition of ryanodine channels, leading to diastolic Ca(2+) leak, after-depolarizations, and arrhythmia. ", "begin": 136, "document": "23042908", "end": 507, "section": "abstract"}, {"text": "The autosomal recessive form of CPVT is caused by mutations in the CASQ2 gene. In a consanguineous family, a novel homozygous CASQ2 mutation (p.L77P) was identified in a child with CPVT who required implantation of a cardioverter defibrillator due to episodes of syncope while on medical therapy. ", "begin": 176, "document": "22650415", "end": 473, "section": "abstract"}, {"text": "Catecholaminergic polymorphic ventricular tachycardia is a familial cardiac arrhythmia that is related to RYR2 or CASQ2 gene mutation.", "begin": 0, "document": "22557844", "end": 134, "section": "abstract"}, {"text": "Thirteen mutations in the CASQ2 gene have been reported so far in association with CPVT. ", "begin": 209, "document": "21618644", "end": 298, "section": "abstract"}, {"text": "These data increased significantly the number of CASQ2 mutations described in association with CPVT, revealed the high prevalence of splicing and truncating mutations in this gene and brought new insight regarding the dominant inheritance of the disease. Moreover, our report of the first splicing abnormalities in CASQ2 caused by intronic mutation or synonymous change underlines the absolute necessity to perform extensive molecular analysis for genetic diagnosis and counseling of CPVT.", "begin": 715, "document": "21618644", "end": 1204, "section": "abstract"}, {"text": "Mutations in the human cardiac calsequestrin gene (CASQ2) are linked to catecholaminergic polymorphic ventricular tachycardia (CPVT-2).", "begin": 0, "document": "20302875", "end": 135, "section": "abstract"}, {"text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial cardiac arrhythmia that is related to RYR2 or CASQ2 gene mutation. ", "begin": 0, "document": "19568611", "end": 142, "section": "abstract"}, {"text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an uncommon heritable disease presenting with syncope or sudden cardiac death. Two genes involved in calcium homeostasis, the ryanodine receptor gene and the calsequestrin 2 (CASQ2) gene, have been implicated in this disease. We describe a young man presenting with exercise-induced syncope, clinically diagnosed as CPVT. Genetic analysis revealed two mutations, p.Y55C (c.164A>G) and p.P308L (c.923C>T), in the CASQ2 gene. ", "begin": 0, "document": "18684293", "end": 488, "section": "abstract"}, {"text": "A novel heterozygous mutation, F189L, in CASQ2 gene was identified in one family with CPVT.", "begin": 278, "document": "18543230", "end": 369, "section": "abstract"}, {"text": "Catecholamine-induced polymorphic ventricular tachycardia (CPVT) is a familial disorder caused by cardiac ryanodine receptor type 2 (RyR2) or calsequestrin 2 (CASQ2) gene mutations. ", "begin": 0, "document": "17607358", "end": 182, "section": "abstract"}, {"text": "We conclude that CPVT-causing CASQ2 missense mutations function as null alleles. ", "begin": 1144, "document": "17607358", "end": 1225, "section": "abstract"}, {"text": "The central role of RyR2 dysfunction in CASQ2 deficiency unifies the pathophysiologic mechanism underlying CPVT due to RyR2 or CASQ2 mutations and suggests a therapeutic approach for these inherited cardiac arrhythmias.", "begin": 1594, "document": "17607358", "end": 1813, "section": "abstract"}, {"text": "Mutations of the RyR2 gene cause autosomal dominant CPVT, while mutations of the CASQ2 gene may cause an autosomal recessive or dominant form of CPVT. ", "begin": 1021, "document": "15913575", "end": 1172, "section": "abstract"}, {"text": "Mutations of two myocardial calcium signaling molecules, ryanodine receptor 2 (RYR2) and calsequestrin 2 (CASQ2), may cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a severe inherited arrhythmic disease manifesting with salvoes of exercise-induced bidirectional and polymorphic tachycardias. ", "begin": 0, "document": "14571276", "end": 313, "section": "abstract"}, {"text": "These data, combined with our previous findings, show that RYR2 mutations are present in at least 6/16 (38%) of the catecholaminergic polymorphic ventricular tachycardia families, while CASQ2 mutations must be a rare cause of CPVT.", "begin": 823, "document": "14571276", "end": 1054, "section": "abstract"}, {"text": "This report reviews evidence that a missense mutation in the CASQ2 gene is associated with autosomal-recessive CPVT.", "begin": 259, "document": "12732448", "end": 375, "section": "abstract"}, {"text": "An Australian cohort of 252 unrelated familial hypertrophic cardiomyopathy patients were screened for mutations in the Ca(2+) regulatory genes, sorcin (SRI), calstabin (FKBP1B), calsequestrin (CASQ2), phospholamban (PLN), sarcolipin (SLN), calreticulin (CALR3) and calmodulin (CALM). A total of 17 exonic DNA variants were identified in the 7 Ca(2+) regulatory genes studied, of which 4 were considered of pathogenic significance. Two novel mutations in the CALR3 gene were identified (Lys82Arg, Arg73Gln) and one truncation mutation in the PLN gene (Leu39Ter). A variant was also identified in the CASQ2 gene (Asp63Glu). These four variants were all novel, resulted in changes in conserved amino acids and were not identified in a normal population.", "begin": 463, "document": "17655857", "end": 1213, "section": "abstract"}]}, {"documents": ["20020146"], "answer": ["LKB1 plays a physiological role in controlling the Wnt-signaling."], "id": "53175e9fb166e2b80600000a", "snippets": [{"text": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps.", "begin": 155, "document": "20020146", "end": 423, "section": "abstract"}, {"text": "PJS polyps from all patients showed generalized membrane and cytoplasmic localizations of beta-catenin along the mucosal endothelium.", "begin": 945, "document": "20020146", "end": 1078, "section": "abstract"}]}, {"documents": ["23580068", "22878818", "22392042", "21761402", "20805372"], "answer": ["Her2 status is positive"], "id": "5318929fb166e2b80600001b", "snippets": [{"text": "Prevalence of germline TP53 mutations in HER2+ breast cancer patients", "begin": 0, "document": "23580068", "end": 69, "section": "title"}, {"text": "Recent data show that breast cancer in germline TP53 mutation carriers is commonly HER2+ (63-83 %).", "begin": 158, "document": "23580068", "end": 257, "section": "abstract"}, {"text": "As seen in this case, most breast cancers in patients with LFS exhibit a triple-positive phenotype (estrogen receptor-positive/progesterone receptor-positive/HER2-positive). ", "begin": 644, "document": "22878818", "end": 818, "section": "abstract"}, {"text": "Breast cancers in TP53 mutation carriers recently have more often been reported to be hormone receptor and HER-2 positive by immunohistochemistry and FISH in small series.", "begin": 232, "document": "22392042", "end": 403, "section": "abstract"}, {"text": "The 43 tumors from 39 women comprise 32 invasive ductal carcinomas and 11 ductal carcinomas in situ (DCIS).", "begin": 997, "document": "22392042", "end": 1104, "section": "abstract"}, {"text": "Sixty three percent of invasive and 73% of in situ carcinomas were positive for Her2/neu (IHC 3+ or FISH amplified).", "begin": 1283, "document": "22392042", "end": 1399, "section": "abstract"}, {"text": "Most DCIS and invasive ductal carcinomas in LFS are hormone receptor positive and/or HER-2 positive.", "begin": 1682, "document": "22392042", "end": 1782, "section": "abstract"}, {"text": "Early onset HER2-positive breast cancer is associated with germline TP53 mutations", "begin": 0, "document": "21761402", "end": 82, "section": "title"}, {"text": "Patients who tested positive for germlineTP53 mutations (n = 30) were compared with controls (n = 79). Human epidermal growth factor receptor 2 (HER2) amplification and/or overexpression was found in 67% of the tumors from the cases, compared with 25% for the controls (P = .0001).", "begin": 614, "document": "21761402", "end": 895, "section": "abstract"}, {"text": "This study suggests an association between germline TP53 mutations and early onset HER2-positive breast cancer.", "begin": 1445, "document": "21761402", "end": 1556, "section": "abstract"}, {"text": "A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations", "begin": 0, "document": "20805372", "end": 82, "section": "title"}, {"text": "The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages.", "begin": 14, "document": "20805372", "end": 143, "section": "abstract"}, {"text": "Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%);", "begin": 792, "document": "20805372", "end": 1037, "section": "abstract"}, {"text": "These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.", "begin": 1099, "document": "20805372", "end": 1253, "section": "abstract"}]}, {"documents": ["19619967"], "answer": ["missense substitution, Met1Val (M1V), in the DCX gene."], "id": "52f899952059c6d71c00004b", "snippets": [{"text": "We describe a 2-year-old girl affected by SBH with epilepsy and periodic limb movements (PLMs), in whom a novel \"de novo\" missense substitution, Met1Val (M1V), was identified in the DCX gene.", "begin": 541, "document": "19619967", "end": 732, "section": "abstract"}]}, {"documents": ["23427760", "22903482", "21895933", "20438565", "20432327", "19901837", "19238399", "18499168", "18335255", "17445666", "14511039", "11490298", "11002301", "8813311"], "answer": ["Ultrasound"], "id": "5324bdba9b2d7acc7e00001a", "snippets": [{"text": "Modifications of the bladder wall (organ damage) in patients with bladder outlet obstruction: ultrasound parameters.", "begin": 0, "document": "23427760", "end": 116, "section": "title"}, {"text": "Early identification of bladder changes by noninvasive transabdominal ultrasound", "begin": 434, "document": "23427760", "end": 514, "section": "abstract"}, {"text": "Measurement of the bladder wall thickness (BWT) or detrusor wall thickness (DWT) by US is reliable,", "begin": 1083, "document": "23427760", "end": 1182, "section": "abstract"}, {"text": "Also conventional US detects established signs of bladder damage: diverticulosis, trabecolations in the bladder wall (pseudo-diverticula),", "begin": 1971, "document": "23427760", "end": 2109, "section": "abstract"}, {"text": "non-invasive US of the bladder wall", "begin": 2455, "document": "23427760", "end": 2490, "section": "abstract"}, {"text": "BladderScan BVM 9500 device (Diagnostic Ultrasound, Bothell, WA) was used to measure bladder wall thickness", "begin": 563, "document": "22903482", "end": 670, "section": "abstract"}, {"text": "ultrasonography-estimated bladder weight and bladder wall thickness ", "begin": 24, "document": "21895933", "end": 92, "section": "title"}, {"text": "To identify measurements of ultrasonography (US)-derived bladder wall thickness (BWT) ", "begin": 11, "document": "21895933", "end": 97, "section": "abstract"}, {"text": "transabdominal US measurements of BWT and", "begin": 246, "document": "21895933", "end": 287, "section": "abstract"}, {"text": "Transvaginal ultrasound measurement of bladder wall thickness: ", "begin": 0, "document": "20438565", "end": 63, "section": "title"}, {"text": "ultrasound (US) techniques to measure bladder wall thickness (BWT).", "begin": 70, "document": "20438565", "end": 137, "section": "abstract"}, {"text": "Women underwent US measurement of BWT", "begin": 159, "document": "20438565", "end": 196, "section": "abstract"}, {"text": "Transabdominal and transperineal US for measuring BWT", "begin": 1342, "document": "20438565", "end": 1395, "section": "abstract"}, {"text": "ultrasound bladder and detrusor wall thickness", "begin": 136, "document": "20432327", "end": 182, "section": "title"}, {"text": "Ultrasonic measurements of urinary bladders are suitable to quantify bladder wall hypertrophy", "begin": 14, "document": "20432327", "end": 107, "section": "abstract"}, {"text": "ultrasonic bladder wall measurements t", "begin": 1548, "document": "20432327", "end": 1586, "section": "abstract"}, {"text": "Preliminary data on the automatic measurement of bladder wall thickness were reported, suggesting a good repeatability and agreement with conventional ultrasound imaging", "begin": 406, "document": "19901837", "end": 575, "section": "abstract"}, {"text": " conventional ultrasound bladder wall thickness (BWT) measurements ", "begin": 50, "document": "19238399", "end": 117, "section": "abstract"}, {"text": "Ultrasonographic measurement of bladder wall thickness ", "begin": 0, "document": "18499168", "end": 55, "section": "title"}, {"text": "All children underwent ultrasonography to measure bladder wall thickness", "begin": 378, "document": "18499168", "end": 450, "section": "abstract"}, {"text": "Ultrasonographic assessment of bladder wall thickness is a sensitive screening tool ", "begin": 1721, "document": "18499168", "end": 1805, "section": "abstract"}, {"text": "ultrasound for bladder wall thickness (BWT)", "begin": 238, "document": "18335255", "end": 281, "section": "abstract"}, {"text": "transabdominal ultrasonography for bladder volume and detrusor muscle thickness", "begin": 45, "document": "17445666", "end": 124, "section": "abstract"}, {"text": "Transabdominal ultrasonography with a high-frequency probe was performed to obtain the anterior, posterior, and lateral bladder wall thicknesses.", "begin": 450, "document": "17445666", "end": 595, "section": "abstract"}, {"text": "ultrasonographic estimate of bladder wall thickness. ", "begin": 852, "document": "14511039", "end": 905, "section": "abstract"}, {"text": "ultrasonographic estimate of bladder wall thickness. ", "begin": 1210, "document": "14511039", "end": 1263, "section": "abstract"}, {"text": "there are marked differences in sonographic findings in male and female neonates in regard to renal pelvic dilatation, renal size and bladder wall thickness", "begin": 1284, "document": "11490298", "end": 1440, "section": "abstract"}, {"text": "BWT was measured by suprapubic ultrasonography.", "begin": 250, "document": "11002301", "end": 297, "section": "abstract"}, {"text": "transvaginal ultrasound measurement of bladder wall thickness", "begin": 32, "document": "8813311", "end": 93, "section": "abstract"}, {"text": "The measurement of a mean bladder wall thickness greater than 5 mm with transvaginal ultrasound ", "begin": 934, "document": "8813311", "end": 1030, "section": "abstract"}]}, {"documents": ["24157834", "24155235"], "answer": ["Transcription activator-like effector nucleases (TALEN)", "Zinc-finger nucleases"], "id": "52fa74052059c6d71c00005a", "snippets": [{"text": "al-effector nucleases (TALENs) are engineered proteins that can stimulate precise genome editing through specific DNA double-strand breaks. Sickle cell disease and \u03b2-thalassemia are common genetic disorders caused by mutations in \u03b2-globin, and we engineered a pair of highly active TALENs that induce modification of 54% of human \u03b2-globin alleles near the site of the sickle mutation. These TALENS stimulate targeted integration of therapeutic, full-length beta-globin cDNA to the endogenous \u03b2-globin locus in 19% of cells prior to selection as quantified by single molecule real-time sequencing.", "begin": 1, "document": "24157834", "end": 597, "section": "abstract"}, {"text": "ranscription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free \u03b2-thalassemia induced pluripotent stem cells", "begin": 1, "document": "24155235", "end": 144, "section": "title"}, {"text": "Here, we describe a robust process combining efficient generation of integration-free \u03b2-Thal iPSCs from the cells of patients and transcription activator-like effector nuclease (TALEN)-based universal correction of HBB mutations in situ.", "begin": 569, "document": "24155235", "end": 806, "section": "abstract"}]}, {"documents": ["24126373", "23847141", "22970697", "16885236", "16044424", "7654063", "8090716"], "answer": [["Leigh syndrome"], ["Leber's hereditary optic neuropathy and/or dystonia"]], "id": "530c844e970c65fa6b000014", "snippets": [{"text": "It was shown that m14487T>C can also cause the unusual combination of optic atrophy, ptosis, and encephalomyopathy leading to intractable seizures. ", "begin": 1216, "document": "24126373", "end": 1364, "section": "abstract"}, {"text": " MTND6 genes were identified as 'hotspots' of mutations, with Leigh syndrome accounting for the large majority of associated phenotypes. ", "begin": 1289, "document": "23847141", "end": 1426, "section": "abstract"}, {"text": "he 14487T>C mutation in MTND6 were present in two probands with Leigh's-like and Leigh's syndrome, respectively. ", "begin": 425, "document": "16044424", "end": 538, "section": "abstract"}, {"text": "These results confirm the association of the MTND6*LDYT14459A mutation with Leber's hereditary optic neuropathy and/or dystonia. ", "begin": 1085, "document": "7654063", "end": 1214, "section": "abstract"}, {"text": "A novel point mutation in the ND6 subunit of complex I at position 14,459 of the mitochondrial DNA (MTND6*LDY T14459A) was identified as a candidate mutation for the highly tissue-specific disease. Leber's hereditary optic neuropathy plus dystonia.", "begin": 0, "document": "7654063", "end": 248, "section": "abstract"}, {"text": "Representative of these mutations is a heteroplasmic mutation in MTND6 at np 14459 whose clinical presentations range from adult-onset blindness to pediatric dystonia and basal ganglial degeneration. ", "begin": 939, "document": "8090716", "end": 1139, "section": "abstract"}]}, {"documents": ["20205639", "16338209", "23796662", "23574434", "22339463", "22277519", "21883222", "21592055", "21504387", "21091109"], "answer": [["Bapineuzumab"], ["Solanezumab"], ["Ponezumab"], ["Gantenerumab"]], "id": "52fc94db2059c6d71c000074", "snippets": [{"text": "The first active immunization clinical trial with AN1792 in AD patients was halted when a subset of patients developed meningoencephalitis.", "begin": 389, "document": "20205639", "end": 528, "section": "abstract"}, {"text": "The first passive immunotherapy trial with bapineuzumab,", "begin": 529, "document": "20205639", "end": 585, "section": "abstract"}, {"text": "Preliminary results of a prematurely terminated clinical trial where AD patients were actively vaccinated with aggregated Abeta ", "begin": 274, "document": "16338209", "end": 402, "section": "abstract"}, {"text": "strategies based on A\u03b21-42 peptide induced encephalomyelitis and possible microhemorrhages.", "begin": 112, "document": "23796662", "end": 203, "section": "abstract"}, {"text": "Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).", "begin": 649, "document": "23574434", "end": 852, "section": "abstract"}, {"text": "Solanezumab's two Phase III trials in AD patients failed to meet endpoints when analyzed independently. ", "begin": 853, "document": "23574434", "end": 957, "section": "abstract"}, {"text": "Unfortunately, the first active vaccine (AN1792, consisting of preaggregate A\u03b2 and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients", "begin": 794, "document": "22339463", "end": 995, "section": "abstract"}, {"text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed.", "begin": 997, "document": "22339463", "end": 1082, "section": "abstract"}, {"text": "several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different.", "begin": 57, "document": "22277519", "end": 321, "section": "abstract"}, {"text": "Several types of A\u03b2 peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact A\u03b2(42) , active immunization involving the administration of synthetic fragments of A\u03b2 peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against A\u03b2 peptide", "begin": 267, "document": "21883222", "end": 608, "section": "abstract"}, {"text": "An active anti-A\u03b2 vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned", "begin": 447, "document": "21592055", "end": 641, "section": "abstract"}, {"text": "The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-A\u03b2 monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce A\u03b2 burden in the brain of AD patients. ", "begin": 853, "document": "21592055", "end": 1083, "section": "abstract"}, {"text": "The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-A\u03b2 immunization is able to alter the course if this devastating disease.", "begin": 1331, "document": "21592055", "end": 1499, "section": "abstract"}, {"text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD. The drug is currently being investigated in Phase III trials as a disease-modifying treatment for AD. ", "begin": 125, "document": "21504387", "end": 353, "section": "abstract"}, {"text": "The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-A\u03b2 monoclonal antibodies that has been tested in two Phase II trials. ", "begin": 630, "document": "21091109", "end": 805, "section": "abstract"}, {"text": "The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-A\u03b2 immunization is able to alter the course of this devastating disease.", "begin": 1027, "document": "21091109", "end": 1218, "section": "abstract"}]}, {"documents": ["24276088", "23036591", "21160042", "20519953", "19863844", "18613841", "17875202", "16567358", "15692990", "15641091", "12060849"], "answer": [["Macrophages"], ["T-cells"], ["Fibroblast-like synoviocytes (FLS)"], ["Dendritic cells"], ["synovial fibroblasts"]], "id": "52b2d405f828ad283c000009", "snippets": [{"text": "Integration of GWAS results with cell-type specific gene expression or epigenetic marks have highlighted regulatory T cells and CD4 memory T cells as critical cell types in RA", "begin": 471, "document": "24276088", "end": 646, "section": "abstract"}, {"text": "A subset of synovial DCs is important in the response to cigarette smoke", "begin": 2100, "document": "23036591", "end": 2172, "section": "abstract"}, {"text": " we demonstrate that autoimmune patient (systemic lupus erythematosus and rheumatoid arthritis) serum activates both pDC and B cells, but IRAK1/4 kinase inhibition affects only the pDC response, underscoring the differential IRAK1/4 functional requirements in human immune cell", "begin": 882, "document": "21160042", "end": 1159, "section": "abstract"}, {"text": "In rheumatoid arthritis (RA), activated synovial fibroblasts (SFs) have the ability to invade joint cartilage, actively contributing to joint destruction in RA", "begin": 429, "document": "20519953", "end": 588, "section": "abstract"}, {"text": "Recently, RASFs have been shown to be able to migrate to non-affected areas and joints through the blood stream and to invade distant cartilage", "begin": 590, "document": "20519953", "end": 733, "section": "abstract"}, {"text": "MSC interaction with B cells provides stimuli for B-cell survival and therefore may contribute to the pathogenesis of rheumatoid arthritis", "begin": 1392, "document": "19863844", "end": 1530, "section": "abstract"}, {"text": "Fibroblast-like synoviocytes (FLS) are resident mesenchymal cells of synovial joints that have been recognized to play an increasingly important role in the pathogenesis of rheumatoid arthritis (RA)", "begin": 13, "document": "18613841", "end": 211, "section": "abstract"}, {"text": "This study investigates the production of CCL18 in polymorphonuclear neutrophils (PMN), the predominant cell type recruited into synovial fluid (SF)", "begin": 286, "document": "17875202", "end": 434, "section": "abstract"}, {"text": "In this regard, macrophages, T cells and their respective cytokines play a pivotal role in RA", "begin": 240, "document": "16567358", "end": 333, "section": "abstract"}, {"text": "it has been understood that resident, fibroblast-like cells contribute significantly to the perpetuation of disease, and that they may even play a role in its initiation", "begin": 461, "document": "16567358", "end": 630, "section": "abstract"}, {"text": "RASFs are no longer considered passive bystanders but active players in the complex intercellular network of RA", "begin": 1188, "document": "16567358", "end": 1299, "section": "abstract"}, {"text": "These rheumatoid arthritis synovial fibroblasts (RASFs) constitute a quite unique cell type that distinguishes RA from other inflammatory conditions of the joints", "begin": 632, "document": "16567358", "end": 794, "section": "abstract"}, {"text": "The molecular feature that defines the myofibroblast-like phenotype was reflected as an increased proportion of myofibroblast-like cells in the heterogeneous FLS population", "begin": 1520, "document": "15692990", "end": 1692, "section": "abstract"}, {"text": "ur findings support the notion that heterogeneity between synovial tissues is reflected in FLS as a stable trait, and provide evidence of a possible link between the behavior of FLS and the inflammation status of RA synovium", "begin": 1803, "document": "15692990", "end": 2027, "section": "abstract"}, {"text": "This change was accompanied by a significant decrease in the synovial monocyte/macrophage population", "begin": 972, "document": "15641091", "end": 1072, "section": "abstract"}, {"text": "In RA patients, both etanercept and infliximab are able to induce cell type-specific apoptosis in the monocyte/macrophage population", "begin": 1479, "document": "15641091", "end": 1611, "section": "abstract"}, {"text": "Furthermore, fluorescent double-staining showed that the HOXD9 protein was expressed in fibroblast-like synoviocytes (FLS)", "begin": 834, "document": "12060849", "end": 956, "section": "abstract"}, {"text": "AHR gene expression was demonstrated in rheumatoid synovial tissues and nodules with significantly greater expression in synovia.", "begin": 1122, "document": "23036591", "end": 1251, "section": "abstract"}, {"text": "Twenty synovial and eighteen subcutaneous nodule tissue samples from 31 patients with RA were studied. Patient smoking status at the time of tissue collection was established", "begin": 533, "document": "23036591", "end": 707, "section": "abstract"}, {"text": "Release of the chemokine CCL18 has been widely attributed to antigen-presenting cells, including macrophages and dendritic cells", "begin": 156, "document": "17875202", "end": 284, "section": "abstract"}]}, {"documents": ["12537197", "22358266", "15843233", "9010711", "6422832"], "answer": ["Low T3 syndrome occurs frequently after CABG"], "id": "532670e7d6d3ac6a34000008", "snippets": [{"text": "FT3 concentration dropped significantly (p < 0.0001), reaching its lowest value 12 hours postoperatively. There were no significant differences between CPB and OPCAB patients. ", "begin": 988, "document": "12537197", "end": 1164, "section": "abstract"}, {"text": "In on-pump CABG surgery, inflammatory effects encompass activation of total leukocytes, neutrophils and platelets, reduction of serum level of total proteins and albumin and decreased thyroid hormones levels, especially within first postoperative 24 hours.", "begin": 1127, "document": "22358266", "end": 1383, "section": "abstract"}, {"text": "Typical NTIS was observed in all patients, and the FT3 concentration was still reduced by postoperative day 5 (p<0.0001).", "begin": 966, "document": "15843233", "end": 1087, "section": "abstract"}, {"text": "We could demonstrate that CPB induces a low T3 syndrome up to 3 days after surgery. Those patients with low T3 concentrations prior to surgery demonstrate postoperatively a more severe degree of nonthyroidal illness (NTI).", "begin": 1740, "document": "9010711", "end": 1962, "section": "abstract"}, {"text": "It is concluded that the coronary bypass operation evokes a rapid decline in T3, which is not normalized by the TSH induced response of the thyroid gland, while the post-operative period is characterized by a \"low T3 state\". ", "begin": 647, "document": "6422832", "end": 872, "section": "abstract"}]}, {"documents": ["21959513", "19463607", "19303793", "14500064", "1929631", "21097430", "16677263", "15868525", "12475369"], "answer": ["Altered thyroid profile after cardiosurgery is associated with several events in adults and in children", ""], "id": "53265dd4d6d3ac6a34000007", "snippets": [{"text": " Patients with fT3 syndrome had the highest mortality (16.7%, NS), highest incidence of acute rejection (38.9%, NS), highest number of reoperations (27.8%, NS), and highest incidence of bacterial (16.7%, NS) and fungal infections (11.1%, NS).", "begin": 919, "document": "21959513", "end": 1161, "section": "abstract"}, {"text": "SCH appears to influence the postoperative outcome for patients by increasing the development of postoperative atrial fibrillation.", "begin": 1415, "document": "19463607", "end": 1546, "section": "abstract"}, {"text": "There was a significant inverse relationship between fT3 levels and global oxygen consumption.", "begin": 1244, "document": "19303793", "end": 1338, "section": "abstract"}, {"text": "However, in the high inotropic support group, FT4 was lower for a longer time. This group also had a significantly higher score on The Pediatric Risk of Mortality (PRISM; P < 0.042) and a longer duration of ventilation (P < 0.014). ", "begin": 637, "document": "16677263", "end": 869, "section": "abstract"}, {"text": " In a group of elderly patients undergoing cardiac surgery, there was a strong association between a postoperative decrease of serum triiodothyronine levels and atrial fibrillation.", "begin": 1878, "document": "15868525", "end": 2059, "section": "abstract"}, {"text": "Low basal fT3 concentration can reliably predict the occurrence of postoperative AF in CABG patients.", "begin": 1474, "document": "14500064", "end": 1575, "section": "abstract"}, {"text": "Those with an uneventful recovery had a higher serum free T4 level on the sixth day after operation than those with complications", "begin": 1359, "document": "1929631", "end": 1488, "section": "abstract"}, {"text": "Enhancement of T3 levels after mitral valve replacement may increase the probability of early spontaneous cardioversion of AF, but can not affect the duration of sinus rhythm. ", "begin": 1312, "document": "21097430", "end": 1488, "section": "abstract"}, {"text": "A relevant finding was that the days of post-operative hospitalization (10+/-3 days, means+/-S.D.) was inversely correlated with the slope of the recovery of T3 concentration (P<0.001) or with the area under the plasma curves of T3 (P=0.024, time range 72-144 h) and the FT3/FT4 ratio (P=0.037, time range 72-144 h) during the post-operative period.", "begin": 945, "document": "12475369", "end": 1294, "section": "abstract"}]}, {"documents": ["19926244", "15259379", "11021766", "16524802", "15521205", "12165115"], "answer": ["There is an inverse correlation between inflammatory markers and FT3 circulating levels"], "id": "53261e79600967d132000003", "snippets": [{"text": "Considering normal subjects, patients without and with low T3 syndrome, IL-6 and TNFalpha increased progressively from normal to patients with fT3<2 pg/ml (p<0.01 and p<0.01) while CRP only respect to the group with low T3 syndrome (p<0.01). The inflammatory markers were all inversely correlated with FT3 levels.", "begin": 1530, "document": "19926244", "end": 1843, "section": "abstract"}]}, {"documents": ["23259418", "20877609", "19296976", "17982750"], "answer": ["Artificial urethral sphincter", "AUS"], "id": "5325fdf0600967d132000001", "snippets": [{"text": "The initial treatment for SUI that persists after 12 months consists of conservative measures such as pelvic floor muscle exercises and behavioral therapy. Properly selected and informed patients can also be treated efficiently with minimally invasive procedures such as the implantation of a male suburethral sling, although the experience with such devices is not extensive. However, the implantation of artificial urinary sphincter is the gold standard therapy.", "begin": 315, "document": "23259418", "end": 779, "section": "abstract"}, {"text": "treatments such as periurethral injection of bulking agents, artificial urinary sphincter (AUS) implantation, and sub-urethral sling positioning. The artificial urethral sphincter has represented, until today, the gold standard but, in the recent years, sling systems have been investigated as minimally invasive alternative options.", "begin": 224, "document": "20877609", "end": 557, "section": "abstract"}, {"text": "Today, three different sling procedures are commonly performed: bone-anchored, readjustable, and trans-obturator slings systems.", "begin": 558, "document": "20877609", "end": 686, "section": "abstract"}, {"text": "The bone anchored suburethral synthetic sling is a simple and attractive procedure that can produce immediate good results with low morbidity, especially when strictly selected patients are treated. ", "begin": 1782, "document": "19296976", "end": 1981, "section": "abstract"}, {"text": "BAUS implantation is a safe, effective, minimally invasive option for iatrogenic male incontinence due to ISD. It compares favourably with AUS.", "begin": 1569, "document": "17982750", "end": 1712, "section": "abstract"}]}, {"documents": ["19089249", "16440883", "16354263", "11057397", "8830082", "2061407", "3359672"], "answer": ["Autosomal dominant"], "id": "52c7275103868f1b0600001c", "snippets": [{"text": "The Apert syndrome is a rare disorder of autosomal dominant inheritance caused by mutations in the FGFR2 gene at locus 10q26; patients with this syndrome present severe syndactyly, exophthalmia, ocular hypertelorism and hypoplastic midface with Class III malocclusion, besides systemic alterations.", "begin": 12, "document": "19089249", "end": 310, "section": "abstract"}, {"text": "The Apert syndrome is characterized by craniosynostosis and syndactyly of hands and feet. Although most cases are sporadic, an autosomal dominant mode of inheritance is well documented.", "begin": 0, "document": "16440883", "end": 185, "section": "abstract"}, {"text": "Apert syndrome, or acrocephalosyndactyly, is characterized by craniosynostosis and early epiphyseal closure resulting in various deformities of the skull, hands, and feet. Typically a sporadic condition, autosomal dominant inheritance with complete penetrance has been known to occur. ", "begin": 0, "document": "16354263", "end": 285, "section": "abstract"}, {"text": "We report two observations of antenatal diagnosis of Apert syndrome. This uncommon genetic disorder suggest an autosomal dominant inheritance, but almost all cases described are sporadic; the responsible gene is yet not located.", "begin": 0, "document": "8830082", "end": 228, "section": "abstract"}, {"text": "The familial cases, the equal number of affected males and females, and the increased paternal age in sporadic cases strongly suggest autosomal dominant inheritance. ", "begin": 406, "document": "2061407", "end": 572, "section": "abstract"}, {"text": "This report presents the first example of male transmission of Apert acrocephalosyndactyly syndrome. Female transmission has been reported in the five previous well-documented cases of dominant inheritance of the syndrome.", "begin": 0, "document": "3359672", "end": 222, "section": "abstract"}]}, {"documents": ["21567923", "16835897", "16323217", "14722917", "2129297"], "answer": ["Mutation in NF1 gene."], "id": "52f223e02059c6d71c00000e", "snippets": [{"text": "Neurofibromatosis type 1 and Noonan syndrome are both common genetic disorders with autosomal dominant inheritance.", "begin": 0, "document": "21567923", "end": 115, "section": "abstract"}, {"text": "Molecular analysis showed a missense mutation in exon 25 of the NF1 gene (4288A>G, p.N1430D)", "begin": 994, "document": "21567923", "end": 1086, "section": "abstract"}, {"text": "Identification of forty-five novel and twenty-three known NF1 mutations in Chinese patients with neurofibromatosis type 1", "begin": 0, "document": "16835897", "end": 121, "section": "title"}, {"text": "Neurofibromatosis type 1 (NF1), characterized by skin neurofibromas and an excess of caf\u00e9-au-lait spots, is due to mutations in the neurofibromin (NF1) gene. Identifying the genetic defect in individuals with the disease represents a significant challenge because the gene is extremely large with a high incidence of sporadic mutations across the entire gene ranging from single nucleotide substitutes to large deletions.", "begin": 0, "document": "16835897", "end": 421, "section": "abstract"}, {"text": "Fifty-eight were initially identified using heteroduplex analytical techniques and confirmed by sequence analysis. A further five were identified by direct sequence analysis alone. The reminders were shown to carry large deletions in the NF1 gene by demonstrating loss of heterozygosity that was confirmed by gene dosage measurements using quantitative-PCR techniques. Mis-sense, non-sense, frame-shift or splice-site mutations were identified across the entire gene of which the majority (45/68) were novel in nature.", "begin": 689, "document": "16835897", "end": 1207, "section": "abstract"}, {"text": "Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome affecting approximately 1 in 4,000 persons. It is an autosomal-dominant disorder with half of the cases resulting from spontaneous mutations.", "begin": 0, "document": "16323217", "end": 214, "section": "abstract"}, {"text": "Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors", "begin": 0, "document": "14722917", "end": 157, "section": "title"}, {"text": "Ninety-one tumors from 31 NF1 patients were screened for gross changes in the NF1 gene using microsatellite/restriction fragment length polymorphism (RFLP) markers; loss of heterozygosity (LOH) was found in 17 out of 91 (19%) tumors (including two out of seven MPNSTs). Denaturing high performance liquid chromatography (DHPLC) was then used to screen 43 LOH-negative and 10 LOH-positive tumors for NF1 microlesions at both RNA and DNA levels. Thirteen germline and 12 somatic mutations were identified, of which three germline (IVS7-2A>G, 3731delT, 6117delG) and eight somatic (1888delG, 4374-4375delCC, R2129S, 2088delG, 2341del18, IVS27b-5C>T, 4083insT, Q519P) were novel. A mosaic mutation (R2429X) was also identified in a neurofibroma by DHPLC analysis and cloning/sequencing.", "begin": 244, "document": "14722917", "end": 1026, "section": "abstract"}, {"text": "The region of DNA located between two translocation breakpoints has been cloned and a DNA sequence encoding a 11-13 kb mRNA identified. That this sequence shows deletions and point mutations in NF1 affected individuals and not in normal controls provides strong evidence that it is indeed the NF1 gene.", "begin": 434, "document": "2129297", "end": 736, "section": "abstract"}]}, {"documents": ["23489803", "22562359", "20219072", "19968287", "19700217", "18502124", "18223678", "17600088", "16820889", "16798224", "16462760", "15750352", "15254679", "15007389", "14965369", "14720367", "14586397", "12964003", "12851688", "12702576", "12680874", "9616291", "9492037", "9099905"], "answer": ["Lung"], "id": "52d63b2803868f1b0600003a", "snippets": [{"text": "on human non-small cell lung cancer cell lines, A549, NCI-H460 and NCI-H520.", "begin": 126, "document": "19700217", "end": 202, "section": "abstract"}, {"text": "NCI-H520 and NCI-H596 lung cancer cells. ", "begin": 342, "document": "18223678", "end": 383, "section": "abstract"}]}, {"documents": ["22941912", "21953191", "21133379", "16478717", "16249172"], "answer": ["The lock mass is a compound of known mass and is used to compensate for drifts in instrument calibration."], "id": "530b01a6970c65fa6b000008", "snippets": [{"text": "Benzyldimethylphenylammonium was used as an internal lock mass.", "begin": 1060, "document": "22941912", "end": 1123, "section": "abstract"}, {"text": "To compensate for drifts in instrument calibration, a compound of known mass is often employed. This 'lock mass' provides an internal mass standard in every spectrum.", "begin": 243, "document": "21953191", "end": 409, "section": "abstract"}, {"text": "The use of mass calibrants (lock masses) to reduce the systematic error of mass-to-charge measurements has also been reported and, in some cases, incorporated in the instrument control software by the instrument manufacturers.", "begin": 343, "document": "21133379", "end": 569, "section": "abstract"}, {"text": "We achieved absolute mass accuracies for intact proteins between 0.92 and 2.8 ppm using the \"lock mass\" mode of operation.", "begin": 723, "document": "16478717", "end": 845, "section": "abstract"}, {"text": "Real time recalibration on the \"lock mass\" by corrections of mass shift removes mass error associated with calibration of the mass scale.", "begin": 635, "document": "16249172", "end": 772, "section": "abstract"}]}, {"documents": ["23894087", "21255372", "19717633", "12368813", "23446832", "23416228", "23275510", "23038171", "22510989", "22432531", "22327592", "21337330", "21112694", "20010635", "19651424", "19346346", "21261921", "19129865", "18843300", "18497157", "18451051", "18450691", "18378664", "18279349", "18059491", "16204552", "15819846", "12788780", "12626092", "11976101"], "answer": [["Betaproteobacteria"], ["Firmicutes"], ["Geobacter", "Geobacteraceae", "Geobacter uraniireducens"], ["Shewanella oneidensis"], ["Pseudomonas aeruginosa"], ["Anaeromyxobacter dehalogenans"], ["strain Rf4T"]], "id": "530a3e18970c65fa6b000005", "snippets": [{"text": "Members of the Betaproteobacteria (i.e. Dechloromonas, Ralstonia, Rhodoferax, Polaromonas, Delftia, Chromobacterium) and the Firmicutes dominated the biostimulated aquifer community.", "begin": 406, "document": "23894087", "end": 588, "section": "abstract"}, {"text": "Shewanella oneidensis is an important model organism for bioremediation studies because of its diverse respiratory capabilities, conferred in part by multicomponent, branched electron transport systems.", "begin": 0, "document": "12368813", "end": 202, "section": "abstract"}, {"text": "metal-reducing Geobacter species", "begin": 687, "document": "23446832", "end": 719, "section": "abstract"}, {"text": " Identifications based on bacterial 16S rRNA sequence analysis showed that the dominant cultivable bacteria belonged to the genus Bacillus. Members of the genera Paenibacillus, Lysinibacillus, Klebsiella, Microbacterium and Chryseobacterium were also isolated from the LAAs soil samples.", "begin": 779, "document": "23416228", "end": 1066, "section": "abstract"}, {"text": " Geobacter", "begin": 60, "document": "23038171", "end": 70, "section": "abstract"}, {"text": "Geobacteraceae", "begin": 36, "document": "11976101", "end": 50, "section": "title"}, {"text": "Geobacteraceae will be responsible for much of the Fe(III) and U(VI) reduction during uranium bioremediation in these sediments.", "begin": 2262, "document": "11976101", "end": 2390, "section": "abstract"}, {"text": " Our previous studies have demonstrated that the microbial communities involved in uranium bioremediation and energy harvesting are both dominated by microorganisms in the family Geobacteraceae and that the organisms in this family are responsible for uranium bioremediation and electron transfer to electrodes. ", "begin": 533, "document": "12626092", "end": 845, "section": "abstract"}, {"text": "the organisms in the family Geobacteraceae that have been found to be associated with metal reduction in previous studies ", "begin": 179, "document": "12788780", "end": 301, "section": "abstract"}, {"text": "to stimulate the activity of Geobacter species during in situ uranium bioremediation.", "begin": 1475, "document": "15819846", "end": 1560, "section": "abstract"}, {"text": "Geobacteraceae", "begin": 1174, "document": "16204552", "end": 1188, "section": "abstract"}, {"text": " Geobacter species are known to be important members of the microbial community: (1) a uranium-contaminated aquifer located in Rifle, CO, USA undergoing in situ bioremediation;", "begin": 354, "document": "18059491", "end": 530, "section": "abstract"}, {"text": "Geobacteraceae feoB transcripts in groundwater samples from a site undergoing in situ uranium bioremediation ", "begin": 960, "document": "18279349", "end": 1069, "section": "abstract"}, {"text": " Geobacteraceae activity during metal reduction in carbon-amended microcosms, with the highest expression observed in the glucose treatment.", "begin": 1495, "document": "18378664", "end": 1635, "section": "abstract"}, {"text": "Geobacter uraniireducens sp. nov., isolated from subsurface sediment undergoing uranium bioremediation.", "begin": 0, "document": "18450691", "end": 103, "section": "title"}, {"text": "A Gram-negative, rod-shaped, motile bacterium, strain Rf4T, which conserves energy from dissimilatory Fe(III) reduction concomitant with acetate oxidation, was isolated from subsurface sediment undergoing uranium bioremediation. ", "begin": 0, "document": "18450691", "end": 229, "section": "abstract"}, {"text": ". Constant levels of Geobacter ompB transcripts were detected in groundwater during a field experiment in which acetate was added to the subsurface to promote in situ uranium bioremediation. ", "begin": 837, "document": "18451051", "end": 1028, "section": "abstract"}, {"text": "Geobacter species are the predominant organisms, ", "begin": 231, "document": "18497157", "end": 280, "section": "abstract"}, {"text": "Firmicutes were the predominant organisms whereas no Firmicutes sequences were detected in background sediments which did not have the capacity to sorb U(VI),", "begin": 1198, "document": "18497157", "end": 1356, "section": "abstract"}, {"text": "Geobacter species that predominates during in situ uranium bioremediation at this site.", "begin": 263, "document": "18843300", "end": 350, "section": "abstract"}, {"text": "As part of an effort to diagnose the physiological status of Geobacter species during in situ bioremediation of uranium-contaminated groundwater, ", "begin": 0, "document": "19129865", "end": 146, "section": "abstract"}, {"text": "Geobacter uraniireducens", "begin": 569, "document": "19129865", "end": 593, "section": "abstract"}, {"text": " Geobacter species are often the dominant members of the groundwater community during active bioremediation and the primary organisms catalysing U(VI) reduction.", "begin": 380, "document": "21261921", "end": 541, "section": "abstract"}, {"text": "Anaeromyxobacter dehalogenans strains implicated in hexavalent uranium reduction and immobilization are present in the fractured saprolite subsurface environment at the U.S. Department of Energy Integrated Field-Scale Subsurface Research Challenge (IFC) site near Oak Ridge, TN. ", "begin": 12, "document": "19346346", "end": 291, "section": "abstract"}, {"text": "Both enrichments were capable of reducing U(VI) rapidly. 16S rRNA gene clone libraries of the two enrichments revealed that Desulfovibrio spp. are dominant in the sulfate-reducing enrichment, and Clostridium spp. are dominant in the iron-reducing enrichment.", "begin": 346, "document": "19651424", "end": 604, "section": "abstract"}, {"text": ". The results demonstrate that Geobacter species can effectively reduce U(VI)", "begin": 1296, "document": "20010635", "end": 1373, "section": "abstract"}, {"text": "Uranium biomineralization by a metal-resistant Pseudomonas aeruginosa strain isolated from uranium mine waste was characterized for its potential in bioremediation. ", "begin": 0, "document": "21112694", "end": 165, "section": "abstract"}, {"text": "Uranium biomineralization by a metal resistant Pseudomonas aeruginosa strain isolated from contaminated mine waste.", "begin": 0, "document": "21112694", "end": 115, "section": "title"}, {"text": "Geobacter-mediated bioremediation of uranium", "begin": 358, "document": "21337330", "end": 402, "section": "abstract"}, {"text": "The cytochrome genes detected were primarily from Geobacter sp.", "begin": 772, "document": "22327592", "end": 835, "section": "abstract"}, {"text": "Acetate amendment at uranium contaminated sites in Rifle, CO. leads to an initial bloom of Geobacter accompanied by the removal of U(VI) from the groundwater, followed by an increase of sulfate-reducing bacteria (SRBs) which are poor reducers of U(VI).", "begin": 0, "document": "22510989", "end": 252, "section": "abstract"}, {"text": "Whole-genome microarray analyses of a subsurface isolate of Geobacter uraniireducens,", "begin": 186, "document": "23275510", "end": 271, "section": "abstract"}, {"text": " At the US Department of Energy's Integrated Field Research Challenge (IFRC) site in Rifle, CO, the stimulation of Geobacter growth and activity via subsurface acetate addition leads to precipitation of U(VI) from groundwater as U(IV)", "begin": 155, "document": "21255372", "end": 389, "section": "abstract"}, {"text": "Here, we report a proteomics-based approach for simultaneously documenting the strain membership and microbial physiology of the dominant Geobacter community members during in situ acetate amendment of the U-contaminated Rifle,", "begin": 215, "document": "19717633", "end": 442, "section": "abstract"}]}, {"documents": ["23667905", "22577022", "22367194", "21604129", "20305284"], "answer": ["TAILS: Terminal Amine Isotopic Labeling of Substrates"], "id": "530a5117970c65fa6b000007", "snippets": [{"text": ". It is important to identify what proteins are substrates of proteases and where their cleavage sites are so as to reveal the molecular mechanisms and specificity of signaling. ", "begin": 127, "document": "21604127", "end": 305, "section": "abstract"}, {"text": "It is important to identify what proteins are substrates of proteases and where their cleavage sites are so as to reveal the molecular mechanisms and specificity of signaling.", "begin": 129, "document": "21604127", "end": 304, "section": "abstract"}, {"text": "analysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence.", "begin": 414, "document": "23667905", "end": 712, "section": "abstract"}, {"text": "Several approaches to studying proteolytic activity as it relates to biology, pathophysiology, and drug therapy have been published, including the recently described terminal amine isotopic labeling of substrates (TAILS) strategy by Kleifeld and colleagues", "begin": 315, "document": "22577022", "end": 571, "section": "abstract"}, {"text": " The degradomics screen terminal amine isotopic labeling of substrates (TAILS), which enriches for neo-N-terminal peptides of cleaved substrates, was used to identify 58 new native substrates in fibroblast secretomes after incubation with MT6-MMP. ", "begin": 1170, "document": "22367194", "end": 1418, "section": "abstract"}, {"text": " Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment. ", "begin": 257, "document": "21604129", "end": 603, "section": "abstract"}, {"text": "Identification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS).", "begin": 0, "document": "21604129", "end": 127, "section": "title"}, {"text": " Incorporating iTRAQ whole protein labeling with terminal amine isotopic labeling of substrates (iTRAQ-TAILS) to enrich the N-terminome by negative selection of the blocked mature original N-termini and neo-N-termini has many advantages. ", "begin": 717, "document": "20305284", "end": 955, "section": "abstract"}]}, {"documents": ["24165189", "20038616"], "answer": ["Oxantel disrupts polymicrobial biofilm"], "id": "530c7f52970c65fa6b000010", "snippets": [{"text": "Oxantel disrupts polymicrobial biofilm development of periodontal pathogens", "begin": 0, "document": "24165189", "end": 75, "section": "title"}, {"text": "he anthelmintic drug oxantel has been shown to inhibit fumarate reductase (Frd) activity in some pathogenic bacteria and inhibit P. gingivalis homotypic biofilm formation.", "begin": 273, "document": "24165189", "end": 444, "section": "abstract"}, {"text": "Oxantel, a cholinergic anthelmintic and fumarate reductase inhibitor, significantly inhibited biofilm formation by P. gingivalis and disrupted established biofilms at concentrations below its MIC against planktonic cells.", "begin": 128, "document": "20038616", "end": 349, "section": "abstract"}]}, {"documents": ["24048081", "23884811", "23486871", "22530521", "22213222", "21963829", "21866560", "21676420"], "answer": ["The proposed mechanism for postvaccination narcolepsy is one in which an environmental trigger causes or enhances an antibody-mediated autoimmune response in patients with a preexisting genetic susceptibility."], "id": "530cf54dab4de4de0c000009", "snippets": [{"text": "The proposed mechanism for postvaccination narcolepsy is one in which an environmental trigger causes or enhances an antibody-mediated autoimmune response in patients with a preexisting genetic susceptibility. ", "begin": 747, "document": "24048081", "end": 957, "section": "abstract"}, {"text": "The loss of hypothalamic hypocretin/orexin (hcrt) producing neurons causes narcolepsy with cataplexy. An autoimmune basis for the disease has long been suspected and recent results have greatly strengthened this hypothesis. ", "begin": 0, "document": "21963829", "end": 224, "section": "abstract"}, {"text": "pointing towards processes such as molecular mimicry or bystander activation as crucial for disease development. ", "begin": 663, "document": "21963829", "end": 776, "section": "abstract"}, {"text": "Although no formal link can be established, the unusual characteristics of the reported cases and the striking temporal relationship suggests that narcolepsy may be the result of an autoimmune reaction triggered by H1N1\u00a0vaccination in susceptible individuals.", "begin": 581, "document": "21676420", "end": 840, "section": "abstract"}, {"text": "Pandemrix vaccination is a precipitating factor for narcolepsy, especially in combination with HLA-DQB1*0602. ", "begin": 1141, "document": "23486871", "end": 1251, "section": "abstract"}, {"text": "Recently identified autoantibodies to Tribbles homologue 2 in some patients, as well as cases associated with H1N1 vaccination, support an autoimmune mechanism. ", "begin": 363, "document": "22213222", "end": 524, "section": "abstract"}, {"text": "n China, narcolepsy onset is highly correlated with seasonal and annual patterns of upper airway infections, including H1N1 influenza. In 2010, the peak seasonal onset of narcolepsy was phase delayed by 6 months relative to winter H1N1 infections, and the correlation was independent of H1N1 vaccination in the majority of the sample.", "begin": 1367, "document": "21866560", "end": 1701, "section": "abstract"}, {"text": "H1N1 vaccination was strongly associated with an increased risk of narcolepsy-cataplexy in both children and adults in France", "begin": 2016, "document": "23884811", "end": 2141, "section": "abstract"}]}, {"documents": ["23811049", "23322582", "23227840", "22261725"], "answer": ["The identification and quantification of any protein."], "id": "530cf54dab4de4de0c00000c", "snippets": [{"text": "it is a valuable resource for the selection of candidate proteotypic peptides for targeted proteomic experiments via Selected Reaction Monitoring (SRM) or SWATH-MS", "begin": 829, "document": "23811049", "end": 992, "section": "abstract"}, {"text": "SWATH-MS is a data-independent acquisition method that generates, in a single measurement, a complete recording of the fragment ion spectra of all the analytes in a biological sample for which the precursor ions are within a predetermined m/z versus retention time window.", "begin": 0, "document": "23322582", "end": 272, "section": "abstract"}, {"text": "ew strategies, such as SWATH\u2122 MS, which allows us to systematically characterize and quantify query sample sets of 'any protein of interest' in complex biological samples,", "begin": 836, "document": "23227840", "end": 1007, "section": "abstract"}, {"text": "Here we present a new strategy that systematically queries sample sets for the presence and quantity of essentially any protein of interest. ", "begin": 375, "document": "22261725", "end": 516, "section": "abstract"}]}, {"documents": ["15890322", "16482041", "15569843", "17432514", "16255754", "16265378", "19829181", "17497253"], "answer": ["below 300-330 msec"], "id": "52fb7c512059c6d71c000069", "snippets": [{"text": "The short QT syndrome constitutes a new clinical entity that is associated with a high incidence of sudden cardiac death, syncope, and/or atrial fibrillation even in young patients and newborns. Patients with this congenital electrical abnormality are characterized by rate-corrected QT intervals<320 ms. ", "begin": 0, "document": "15890322", "end": 305, "section": "abstract"}, {"text": "QT interval is shortened when QTc is less than 350 ms (1st degree of shortening). In children with QTc below 330 ms (2nd degree of shortening) short QT syndrome should be excluded.", "begin": 1114, "document": "16482041", "end": 1294, "section": "abstract"}, {"text": "The short-QT syndrome is a new clinical entity characterized by corrected QT intervals <300 ms and a high incidence of ventricular tachycardia (VT) and fibrillation (VF). ", "begin": 12, "document": "15569843", "end": 183, "section": "abstract"}, {"text": "Short QT syndrome is a newly described cardiologic entity which associates a short OT interval (QT and QTc < or = 300 ms) on the surface ECG to a high risk of syncope or sudden death due to malignant ventricular arrhythmia.", "begin": 0, "document": "17432514", "end": 223, "section": "abstract"}]}, {"documents": ["24168007", "23378035", "23044018", "22622662", "21403557", "20592905", "19755431", "19449410", "19215249", "19086028", "18000976", "17414289", "17103449", "17036334", "15241680", "14963686", "12794698"], "answer": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "id": "52bf1d2e03868f1b0600000c", "snippets": [{"text": "Abstract Muenke is a fibroblast growth factor receptor 3 (FGFR-3) associated syndrome, which was first described in late 1990s. ", "begin": 12, "document": "24168007", "end": 140, "section": "abstract"}, {"text": "The syndrome is defined molecularly by a unique point mutation c.749C>G in exon 7 of the FGFR3 gene which results to an amino acid substitution p.Pro250Arg of the protein product. ", "begin": 295, "document": "24168007", "end": 475, "section": "abstract"}, {"text": "Muenke syndrome is an autosomal dominant craniosynostosis syndrome resulting from a defining point mutation in the Fibroblast Growth Factor Receptor3 (FGFR3) gene. ", "begin": 0, "document": "23378035", "end": 164, "section": "abstract"}, {"text": "Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.", "begin": 410, "document": "23044018", "end": 528, "section": "abstract"}, {"text": "Muenke syndrome is characterized by various craniofacial deformities and is caused by an autosomal-dominant activating mutation in fibroblast growth factor receptor 3 (FGFR3(P250R)               ).", "begin": 0, "document": "22622662", "end": 197, "section": "abstract"}, {"text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes. ", "begin": 267, "document": "21403557", "end": 437, "section": "abstract"}, {"text": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene.", "begin": 0, "document": "20592905", "end": 251, "section": "abstract"}, {"text": "Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. ", "begin": 648, "document": "20592905", "end": 788, "section": "abstract"}, {"text": " Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured.", "begin": 547, "document": "19755431", "end": 807, "section": "abstract"}, {"text": "We report on a set of identical twins with a de novo C749G mutation in the FGFR3 gene codon 250 after a pregnancy complicated by prenatal exposure to Nortriptyline.", "begin": 243, "document": "19449410", "end": 407, "section": "abstract"}, {"text": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).", "begin": 0, "document": "19215249", "end": 296, "section": "abstract"}, {"text": "The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. ", "begin": 418, "document": "19215249", "end": 542, "section": "abstract"}, {"text": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mu", "begin": 0, "document": "19086028", "end": 247, "section": "abstract"}, {"text": "Muenke syndrome is an autosomal dominant disorder characterized by coronal suture craniosynostosis, hearing loss, developmental delay, carpal and tarsal fusions, and the presence of the Pro250Arg mutation in the FGFR3 gene. ", "begin": 0, "document": "18000976", "end": 224, "section": "abstract"}, {"text": "To better define the clinical features of this syndrome, we initiated a study of the natural history of Muenke syndrome. To date, we have conducted a standardized evaluation of nine patients with a confirmed Pro250Arg mutation in FGFR3. ", "begin": 342, "document": "18000976", "end": 579, "section": "abstract"}, {"text": "The patients were either placed into the \"Muenke\" group (n=11) or the \"non-Muenke\" control group (n=12) on the basis of a test for the P250R mutation in the FGFR3 gene.", "begin": 364, "document": "17414289", "end": 532, "section": "abstract"}, {"text": "P250R mutation in the FGFR3 gene also known as Muenke syndrome is associated with coronal craniosynostosis, sensorineural deafness, craniofacial, and digital abnormalities.", "begin": 0, "document": "17103449", "end": 172, "section": "abstract"}, {"text": "However, Muenke et al. [(1997); Am J Hum Genet 91: 555-564] described a new subgroup carrying the Pro250Arg mutation in the fibroblast growth factor receptor (FGFR) 3 gene on chromosome 4p16.", "begin": 88, "document": "17036334", "end": 279, "section": "abstract"}, {"text": "Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3). ", "begin": 0, "document": "15241680", "end": 270, "section": "abstract"}, {"text": "In spite of a variable phenotype, Muenke syndrome has been related to a unique mutation on the FGFR3 gene, Pro 250 to Arg, which is characteristic of this disease. ", "begin": 323, "document": "14963686", "end": 487, "section": "abstract"}, {"text": "Hypochondroplasia (HCH) and Muenke syndrome (MS) are caused by mutations on FGFR3 gene.", "begin": 0, "document": "12794698", "end": 87, "section": "abstract"}]}, {"documents": ["21763255", "15262641", "11879111", "11130483", "11208236", "10392228", "23015869", "22869311", "11048776", "19706581", "17350382", "20086611", "7609749", "10338239"], "answer": [["baseball"], ["football"], ["soccer"], ["cricket"], ["hockey"], ["lacrosse"]], "id": "5300aad02059c6d71c000080", "snippets": [{"text": "This study sought to characterize the demographics of commotio cordis globally in comparison to the U.S. experience.", "begin": 309, "document": "21763255", "end": 425, "section": "abstract"}, {"text": "Not unexpectedly, the groups differed with baseball/softball and football predominant in the United States (55% of events) and soccer, cricket, and hockey most common internationally (47% of events). ", "begin": 1013, "document": "21763255", "end": 1213, "section": "abstract"}, {"text": "The authors reviewed 41 incidents of baseball injuries reported to the National Center for Catastrophic Sports Injury Research from 1982 until 2002.", "begin": 245, "document": "15262641", "end": 393, "section": "abstract"}, {"text": "Catastrophic injuries included 23 severe head injuries, 8 cervical injuries, 3 cases of commotio cordis, and 2 cases each of a collapsed trachea and facial fractures.", "begin": 701, "document": "15262641", "end": 867, "section": "abstract"}, {"text": "Commotio cordis events occurred most commonly during organized sporting events (79 [62%]), such as baseball, but 49 (38%) occurred as part of daily routine and recreational activities.", "begin": 674, "document": "11879111", "end": 858, "section": "abstract"}, {"text": "Twenty-two (28%) participants were wearing commercially available chest barriers, including 7 in whom the projectile made direct contact with protective padding (baseball catchers and lacrosse/hockey goalies), and 2 in whom the projectile was a baseball specifically designed to reduce risk.", "begin": 1075, "document": "11879111", "end": 1366, "section": "abstract"}, {"text": "In a recent study of fatal chest impacts by baseballs, 28% of the children were wearing a chest protector. This study evaluates the effectiveness of chest protectors in reducing the risk of commotio cordis. ", "begin": 12, "document": "11130483", "end": 219, "section": "abstract"}, {"text": "It has been described after blows to the chest from baseballs, softballs, hockey pucks, and other objects.", "begin": 411, "document": "11208236", "end": 517, "section": "abstract"}, {"text": "Commotio cordis due to blunt trauma to the precordium is a rare cause of death in young athletes, occurring less frequently than all of the other athletics-related deaths. Several measures, such as the use of safety baseballs and the use of chest protectors, can help protect young athletes from commotio cordis. ", "begin": 0, "document": "10392228", "end": 313, "section": "abstract"}]}, {"documents": ["10405448", "10378390", "8835601", "1867260", "3164411", "4056970", "18204753", "17188616", "16596673", "16181239", "15751610", "15108207", "23734615", "22719898", "20425788", "18824871"], "answer": [["Elevated Thyrotropin -", "Elevated TSH"], ["Low FT4", "Low Thyroxine"], ["Growth Hormone deficiency", "GHD"], ["Calcitonin deficiency"], ["Elevated Prolactin"], ["Elevated Cortisol"], ["Elevated Oxytocin", "Elevated OT"], ["Elevated Vasopressin", "Elevated AVP"]], "id": "52f88d292059c6d71c000036", "snippets": [{"text": "A girl with Williams syndrome (WS) presented with elevated thyrotropin (TSH) levels (7.0 microU/ml), normal free thyroid hormone concentrations, and absent antithyroid autoantibodies.", "begin": 0, "document": "10405448", "end": 183, "section": "abstract"}, {"text": "TSH response to thyrotropin-releasing hormone (TRH) injection (200 microg/mq, i.v.) was exaggerated and prolonged, suggesting subclinical hypothyroidism. The biological activity of circulating TSH was slightly below the normal range [TSH bioactivity (B) to immunoreactivity (I) ratio (TSH B/I) = 0.4, normal: 0.6-2.2].", "begin": 297, "document": "10405448", "end": 615, "section": "abstract"}, {"text": "We report a boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone deficiency and responded well to growth hormone therapy.", "begin": 251, "document": "10378390", "end": 411, "section": "abstract"}, {"text": "A 31-year-old man who had been under regular hemodialysis for 6 months was diagnosed as Williams syndrome (WS) by fluorescence in situ hybridization (FISH) chromosomal analysis. The association of WS and chronic renal failure (CRF) is only rarely encountered. Endocrinological examinations revealed hypergonadotropic hypogonadism. Prolonged and exaggerated responses of adrenocorticotropin (ACTH) to insulin-induced hypoglycemia and corticotropin releasing hormone (CRH) were also noted.", "begin": 0, "document": "8835601", "end": 487, "section": "abstract"}, {"text": "Involvement of the calcitonin/CGRP gene in Williams syndrome is postulated on the basis that Williams syndrome children often have infantile hypercalcemia and deficient expression of calcitonin, a hormone that lowers serum calcium levels. To test the hypothesis that mutations in the calcitonin/CGRP gene might be responsible for the reduced calcitonin levels", "begin": 148, "document": "1867260", "end": 507, "section": "abstract"}, {"text": "It has been suggested that a defect in calcitonin function may play a role in Williams syndrome", "begin": 125, "document": "3164411", "end": 220, "section": "abstract"}, {"text": "Imparied calcitonin secretion in patients with Williams syndrome.", "begin": 0, "document": "4056970", "end": 65, "section": "title"}, {"text": "in patients with Williams syndrome, we studied five such children, with intravenous calcium and parathyroid hormone infusions as provocative stimuli. These patients were found to have significantly higher mean baseline calcium concentrations, delayed clearance of calcium after intravenous calcium loading, and blunted calcitonin responses after calcium infusion", "begin": 148, "document": "4056970", "end": 510, "section": "abstract"}, {"text": "Our studies demonstrate that patients with Williams syndrome have a defect in the synthesis or release of immunoreactive calcitonin. A deficiency of calcitonin may explain the abnormalities of calcium metabolism seen in these patients and can serve as an important endocrine marker for Williams syndrome.", "begin": 684, "document": "4056970", "end": 988, "section": "abstract"}, {"text": "A 16-year-old male adolescent diagnosed to have the Williams-Beuren syndrome was referred to our obesity outpatient clinic, due to his morbid obesity (body mass index 39.2 kilograms per square metre) and gluttony. After several unsuccessful dietary treatments, we started therapy with sibutramine. As growth hormone (GH) deficiency was diagnosed by an additional GH-stimulation test, we commenced with a GH-treatment. ", "begin": 0, "document": "18204753", "end": 418, "section": "abstract"}, {"text": " Subclinical hypothyroidism is a frequent but stable finding in young children with WS.", "begin": 978, "document": "17188616", "end": 1065, "section": "abstract"}, {"text": "Thyroid involvement in Williams syndrome (WS) was recently reported in two small groups of patients, both showing an increased prevalence of elevation of TSH serum concentration; ", "begin": 0, "document": "16596673", "end": 179, "section": "abstract"}, {"text": "in a population of 95 WS patients, half of them followed for more than 5 years. Our study confirms the increased incidence of both elevated TSH serum values (37.9% in our sample)", "begin": 613, "document": "16596673", "end": 791, "section": "abstract"}, {"text": "This study confirms the presence of alterations of thyroid function in WS ", "begin": 1181, "document": "16181239", "end": 1255, "section": "abstract"}, {"text": "We report a female infant with confirmed WBS who, through provocative testing, was found to have GHD", "begin": 363, "document": "15751610", "end": 463, "section": "abstract"}, {"text": "the elevated levels of prolactin and the response of hGH to growth hormone releasing hormone (GHRH) administration are indicative of a hypothalamic rather than pituitary defect. In conclusion, GH deficiency might contribute to the growth failure in a number of patients with WBS", "begin": 693, "document": "15751610", "end": 971, "section": "abstract"}, {"text": " a female presenting with congenital heart defects, liver hemangiomas, and facial dysmorphisms admitted to hospital at 3 months of age because of feeding difficulties and poor growth. She had hypotonia and large tongue, \"coarse\" face, and umbilical hernia in presence of complex congenital cardiovascular malformations. In spite of normal neonatal screening we performed serum levels of thyroid hormones. Thyrotropin level was very high ", "begin": 18, "document": "15108207", "end": 455, "section": "abstract"}, {"text": "WS and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol late in the day in the novel setting when social demands were higher. ", "begin": 302, "document": "23734615", "end": 488, "section": "abstract"}, {"text": "Results suggest that adults with WS have a typical diurnal cortisol profile ", "begin": 616, "document": "23734615", "end": 692, "section": "abstract"}, {"text": "Oxytocin and vasopressin are dysregulated in Williams Syndrome, a genetic disorder affecting social behavior.", "begin": 0, "document": "22719898", "end": 109, "section": "title"}, {"text": "Results revealed significantly higher median levels of OT in WS versus controls at baseline, with a less marked increase in AVP", "begin": 969, "document": "22719898", "end": 1096, "section": "abstract"}, {"text": "high prevalence of impaired glucose regulation, adults with WS ", "begin": 583, "document": "20425788", "end": 646, "section": "abstract"}, {"text": "Thyroid function tests showed a raised TSH (42 mIU/l; normal range 0.5-4 mIU/l) with a low FT(4) concentration", "begin": 533, "document": "18824871", "end": 643, "section": "abstract"}, {"text": "WBS and abnormalities of thyroid function are common in patients with this feature. T", "begin": 1014, "document": "18824871", "end": 1099, "section": "abstract"}]}, {"documents": ["15251045", "14515407", "11600803", "11478226", "9096828", "9005271"], "answer": ["memory loss"], "id": "52f896d62059c6d71c000046", "snippets": [{"text": "memory loss", "begin": 1309, "document": "15251045", "end": 1320, "section": "abstract"}, {"text": "loss of memory,", "begin": 887, "document": "14515407", "end": 902, "section": "abstract"}, {"text": " loss of memory", "begin": 169, "document": "11600803", "end": 184, "section": "abstract"}, {"text": "dysmnesia", "begin": 392, "document": "11478226", "end": 401, "section": "abstract"}, {"text": "memory problems", "begin": 1292, "document": "9096828", "end": 1307, "section": "abstract"}, {"text": "\"impaired cognition,\" characterized by problems with attention, memory, and reasoning, as well as insomnia, depression, daytime sleepiness, and headaches", "begin": 1051, "document": "9005271", "end": 1204, "section": "abstract"}]}, {"documents": ["23621600", "21696651", "16172968", "16139655", "12414200", "17703631", "23607065", "20165722", "21947244", "19329361", "23210044", "23049642", "23964263", "18053204", "20808697", "21898188"], "answer": [["Barrow Ruptured Aneurysm Trial (BRAT)"], ["international subarachnoid aneurysmal trial (BRAT)"], ["FIAT study"]], "id": "530e0d6e5937551c09000001", "snippets": [{"text": "The authors report the 3-year results of the Barrow Ruptured Aneurysm Trial (BRAT). The objective of this ongoing randomized trial is to compare the safety and efficacy of microsurgical clip occlusion and endovascular coil embolization for the treatment of acutely ruptured cerebral aneurysms and to compare functional outcomes based on clinical and angiographic data. ", "begin": 8, "document": "23621600", "end": 377, "section": "abstract"}, {"text": "We report the design of the FIAT study, a clinical care trial aiming to compare angiographic and clinical outcomes following treatment with a Flow-Diverter or with the best conventional treatment option. The FIAT study will include both a randomized and a registry portion. Patients will be proposed randomization to either FD stenting or best conventional treatment option (observation, coiling, stenting, or clipping) as determined by the treating physician. ", "begin": 512, "document": "21696651", "end": 973, "section": "abstract"}, {"text": "The effect of clipping and coiling in acute severe subarachnoid hemorrhage after international subarachnoid aneurysmal trial (ISAT) results.", "begin": 0, "document": "16172968", "end": 140, "section": "title"}, {"text": "A critical appraisal of the ISAT of microsurgical clipping versus coiling is used for comparison of our results.", "begin": 1422, "document": "16172968", "end": 1534, "section": "abstract"}, {"text": "International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion.", "begin": 0, "document": "16139655", "end": 274, "section": "title"}, {"text": "International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial.", "begin": 0, "document": "12414200", "end": 177, "section": "title"}]}, {"documents": ["21862328", "21851209", "21742493", "19464884", "18755587", "17715908", "17664070"], "answer": [["quinoline-3-carbonitriles"], ["indazoles"], ["thieno-pyrimidines"]], "id": "530cf4d5e2bfff940c000003", "snippets": [{"text": "report here the synthesis and SAR of a new series of thieno[3,2-d]pyrimidines as potent Tpl2 kinase inhibitors", "begin": 3, "document": "21862328", "end": 113, "section": "abstract"}, {"text": " novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors", "begin": 50, "document": "21851209", "end": 119, "section": "title"}, {"text": "ynthesis, modeling and structure-activity relationship of indazoles as inhibitors of Tpl2 kinase are described", "begin": 1, "document": "21742493", "end": 111, "section": "abstract"}, {"text": "We have discovered that 8-halo-4-(3-chloro-4-fluoro-phenylamino)-6-[(1H-[1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles (4) are potent inhibitors of this enzyme", "begin": 163, "document": "19464884", "end": 335, "section": "abstract"}, {"text": "Optimization of these cyclic amine groups led to the identification of 8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile (34)", "begin": 673, "document": "19464884", "end": 879, "section": "abstract"}, {"text": "identified a novel series of 2,4-disubstituted thieno[2,3-c]pyridines as COT kinase inhibitors", "begin": 60, "document": "18755587", "end": 154, "section": "abstract"}, {"text": " selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles", "begin": 108, "document": "17715908", "end": 224, "section": "title"}, {"text": "Initial 4-anilino-6-aminoquinoline-3-carbonitrile leads showed poor selectivity for Tpl2 ", "begin": 383, "document": "17715908", "end": 472, "section": "abstract"}, {"text": "The 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles were prepared from the appropriate 2-substituted 4-nitroanilines", "begin": 857, "document": "17715908", "end": 982, "section": "abstract"}, {"text": "Further structure-activity based modifications led to the identification of 8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-methyl-1H-imidazol-4-yl)methylamino]quinoline-3-carbonitrile, which demonstrated in vitro as well as in vivo efficacy in inhibition of LPS-induced TNF-alpha production", "begin": 1235, "document": "17715908", "end": 1525, "section": "abstract"}, {"text": "a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles", "begin": 18, "document": "17664070", "end": 116, "section": "title"}, {"text": "In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles", "begin": 184, "document": "17664070", "end": 312, "section": "abstract"}, {"text": "have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tpl2) kinase inhibitors", "begin": 3, "document": "17664070", "end": 182, "section": "abstract"}]}, {"documents": ["23000022", "20981542", "19540844", "22461049", "20301308", "19490272", "16931984", "15950200", "15511625", "14756674", "12388934", "10973849", "10868746", "10560244", "10482963", "9848024", "9641694", "20850564", "18752142", "17560885", "16981927", "15306731", "11216980", "10953551", "10898405", "10613047", "10220144", "9791861", "9511785", "12442276", "16831322"], "answer": [["KCNQ1", "KVLQT1", "KCNA9"], ["KCNE1"], ["KCNE2"], ["KCNH2", "HERG"], ["SCN5A"], ["CAV3"], ["SCN4B"], ["AKAP9"], ["SNTA1"], ["KCNJ5"], ["Ankyrin-B gene"]], "id": "52eea509c8da89891000000d", "snippets": [{"text": "Long QT syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1 gene. ", "begin": 0, "document": "23000022", "end": 114, "section": "abstract"}, {"text": "This report describes a three-generation family with a severe phenotype of long-QT syndrome-1 (LQTS-1) caused by a single nucleotide mutation in the KQT-like, voltage-gated potassium channel-1 gene (KCNQ1; MIM 607542).", "begin": 0, "document": "20981542", "end": 218, "section": "abstract"}, {"text": "Mutations in a cardiac voltage-gated potassium channel, KCNQ1, account for the most common form of LQTS, LQTS1. ", "begin": 185, "document": "19540844", "end": 297, "section": "abstract"}, {"text": "Nine patients were diagnosed with LQT1 and nine with LQT2. The other six individuals were healthy, with no symptoms characteristic for prolonged QT syndrome, but came from families with confirmed disease occurrence. The study was conducted on members of four families. In order to search for mutations (using mSSCP and sequencing), genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1 and KCNH2 (HERG), involved in the occurrence of clinical signs of disease.", "begin": 185, "document": "22461049", "end": 684, "section": "abstract"}, {"text": "Diagnosis of RWS is established by prolongation of the QTc interval in the absence of specific conditions known to lengthen it (for example, QT-prolonging drugs) and/or molecular genetic testing of the genes known to be associated with RWS, of which KCNQ1 (locus name LQT1), KCNH2 (locus name LQT2) and SCN5A (locus name LQT3) are the most common. Other, less frequently involved genes are KCNE1 (locus name LQT5), KCNE2 (locus name LQT6), CAV3 (locus name LQT9), SCN4B (locus name LQT10), AKAP9 (locus name LQT11), SNTA1 (locus name LQT12) and KCNJ5 (locus name LQT13).", "begin": 925, "document": "20301308", "end": 1495, "section": "abstract"}, {"text": "Type-1 long-QT syndrome (LQT1) is caused by mutations in the KCNQ1 gene.", "begin": 12, "document": "19490272", "end": 84, "section": "abstract"}, {"text": "Congenital LQTS is most frequently caused by mutations in KCNQ1 (Kv7.1), whereas drug-induced LQTS is a consequence of HERG (human ether-a-go-go-related gene) channel inhibition. ", "begin": 88, "document": "16931984", "end": 267, "section": "abstract"}, {"text": "Mutations in the voltage-gated potassium channel subunit KCNQ1 induce the most common form of LQTS.", "begin": 201, "document": "15950200", "end": 300, "section": "abstract"}, {"text": "Genetic studies have identified mutations in six ion channel genes, KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2 and the accessory protein Ankyrin-B gene, to be responsible for this disorder. ", "begin": 241, "document": "15511625", "end": 425, "section": "abstract"}, {"text": "Seven family members were carriers of two amino acid alterations in cis (V254M-V417M) in the cardiac potassium channel gene KCNQ1. ", "begin": 550, "document": "14756674", "end": 681, "section": "abstract"}, {"text": "KCNQ1 (formerly called KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type of LQTS.", "begin": 0, "document": "12388934", "end": 127, "section": "abstract"}, {"text": "Five genes have been implicated in Romano-Ward syndrome, the autosomal dominant form of LQTS: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.", "begin": 174, "document": "10973849", "end": 306, "section": "abstract"}, {"text": "It usually is inherited as an autosomal dominant trait (Romano-Ward syndrome). The primary defect in LQT1 is a mutation in KVLQT1, a gene that encodes the pore-forming alpha-subunit of a K+ channel. ", "begin": 114, "document": "10868746", "end": 313, "section": "abstract"}, {"text": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG).", "begin": 0, "document": "10560244", "end": 328, "section": "abstract"}, {"text": "We describe a Swedish family with the proband and his brother suffering from severe Romano-Ward syndome (RWS) associated with compound heterozygosity for two mutations in the KVLQT1 (also known as KCNQ1 and KCNA9)", "begin": 0, "document": "10482963", "end": 213, "section": "abstract"}, {"text": "The cardiac sodium channel gene, SCN5A, is also mutated in some Romano-Ward cases to produce defects in INa, the cardiac inward Na+ current. ", "begin": 754, "document": "9848024", "end": 895, "section": "abstract"}, {"text": "These findings provide the first evidence for a recessive form of the Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1 do not invariably produce the Jervell and Lange-Nielsen syndrome. ", "begin": 1297, "document": "9641694", "end": 1511, "section": "abstract"}]}, {"documents": ["23990187", "23867451", "23500286", "22762717", "21475680", "20132378", "19850699", "19699347", "19419401", "18221594", "17652294", "15929624", "10957787", "20118111", "19791461", "17162272", "18033231", "2482379", "15856398", "9761089", "7787270"], "answer": [["myocardial fibrosis using late gadolinium enhancement"], ["J-wave on ECG"], ["Extreme left ventricular hypertrophy (>30mm)"], ["Nonsustained ventricular tachycardia"], ["Sustained ventricular tachycardia"], ["previous cardiac arrest"], ["family history of sudden cardiac death"], ["unexplained syncope"], ["hypotensive response to exercise"], ["high-risk genetic mutations"]], "id": "531375a6e3eabad021000011", "snippets": [{"text": "Cardiac magnetic resonance (CMR) is used in the diagnosis and risk stratification of hypertrophic cardiomyopathy (HCM) and can detect myocardial replacement fibrosis (anindependent predictor of adverse cardiac outcomes) using late gadolinium enhancement (LGE). ", "begin": 12, "document": "23990187", "end": 273, "section": "abstract"}, {"text": "J wave is associated with increased risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy.", "begin": 0, "document": "23867451", "end": 111, "section": "title"}, {"text": "The J wave may be a risk factor for SCA in patients with HCM.", "begin": 962, "document": "23867451", "end": 1023, "section": "abstract"}, {"text": "Extreme left ventricular hypertrophy was the most common risk factor present (alone or in combination with other markers) in patients experiencing primary prevention interventions (17 of 26 [65%]).", "begin": 1548, "document": "23500286", "end": 1745, "section": "abstract"}, {"text": "Extreme left ventricular hypertrophy was most frequently associated with appropriate interventions.", "begin": 2024, "document": "23500286", "end": 2123, "section": "abstract"}, {"text": "In conclusion, it is demonstrated that LGE has incremental value in addition to clinical risk factors for risk stratification and management of patients with HC.", "begin": 757, "document": "22762717", "end": 918, "section": "abstract"}, {"text": "Fibrosis as detected by CMR should be evaluated as an additional risk factor to further delineate risk of SCD in carriers of an HCM causing mutation.", "begin": 1047, "document": "21475680", "end": 1196, "section": "abstract"}, {"text": "Nonsustained VT was the only predictive risk factor (RF) for an appropriate ICD intervention in the PP (positive predictive value 22%, negative predictive value 96%).", "begin": 953, "document": "20132378", "end": 1119, "section": "abstract"}, {"text": "Nonsustained ventricular tachycardia seems to be the most predictive RF for appropriate device discharges. ", "begin": 1541, "document": "20132378", "end": 1648, "section": "abstract"}, {"text": "However, LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent SCD and/or ICD discharge after controlling for other variables. If replicated, LGE may be considered an important risk factor for sudden death in patients with HCM.", "begin": 2427, "document": "19850699", "end": 2709, "section": "abstract"}, {"text": "In conclusion, our cohort study results do not support LVOTO as an independent risk factor for SD in patients with hypertrophic cardiomyopathy.", "begin": 1272, "document": "19699347", "end": 1415, "section": "abstract"}, {"text": "The appearance of a \"hump\" at the ST segment during exercise testing appears to be a risk factor for SCD in patients with HCM. However, further studies are necessary to validate this finding in larger populations and to elucidate the mechanism of the appearance of the \"hump.\"", "begin": 1157, "document": "19419401", "end": 1433, "section": "abstract"}, {"text": "The ICD is definitely indicated for secondary prevention of sudden death in patients with HCM who have survived a cardiac arrest with documented ventricular fibrillation, or experienced one or more episodes of sustained ventricular tachycardia.", "begin": 423, "document": "18221594", "end": 667, "section": "abstract"}, {"text": "A number of risk markers are used to assess the magnitude of risk, including family history of premature sudden death; extreme left ventricular (LV) hypertrophy (> 30 mm) in young patients; nonsustained ventricular tachycardia on Holter electrocardiographic recording; unexplained (not neurally mediated) syncope, particularly in young patients; and blood pressure decrease or inadequate increase during upright exercise.", "begin": 786, "document": "18221594", "end": 1207, "section": "abstract"}, {"text": "Measured risk factors for sudden death included family history of sudden death, massive left ventricular hypertrophy, nonsustained ventricular tachycardia on Holter monitoring, and unexplained prior syncope.", "begin": 755, "document": "17652294", "end": 962, "section": "abstract"}, {"text": "The following risk factors were analyzed: 1) previous cardiac arrest or sustained ventricular tachycardia; 2) family history of sudden cardiac death; 3) high-risk genetic mutations; 4) syncope; 5) non-sustained ventricular tachycardia; 6) hypotensive response to exercise; and 7) marked left ventricular hypertrophy.", "begin": 995, "document": "15929624", "end": 1311, "section": "abstract"}, {"text": "Family history of sudden death was associated with a positive predictive value of 25% for appropriate therapies, 40% for syncope and 50% for non-sustained ventricular tachycardia. ", "begin": 1809, "document": "15929624", "end": 1989, "section": "abstract"}, {"text": "In patients with an implantable cardioverter-defibrillator for primary prevention, non-sustained ventricular tachycardia was the risk factor with the highest predictive value. ", "begin": 2592, "document": "15929624", "end": 2768, "section": "abstract"}, {"text": "It is concluded that there is an association of the mutation Arg719Trp in the beta-myosin heavy chain with sudden cardiac death in a young child. ", "begin": 1231, "document": "10957787", "end": 1377, "section": "abstract"}]}, {"documents": ["23986715", "18362229", "18281382", "15998695", "11827928", "10231857", "10066683", "9869991", "9045856", "18480046", "8614836", "8290568", "9884344"], "answer": [["R403Q", "Arg403Gln"], ["Q1065H"], ["Arg-249-->Gln"]], "id": "530cf4e0c8a0b4a00c000004", "snippets": [{"text": "Accordingly, pressure overload by transverse aortic constriction (TAC) was induced in 2-month-old, male mice with and without a FHC (R403Q) mutation in \u03b1-myosin heavy chain.", "begin": 209, "document": "23986715", "end": 382, "section": "abstract"}, {"text": "This model (designated TnI-203/MHC-403) was generated by crossbreeding mice with the Gly203Ser cardiac troponin I (TnI-203) and Arg403Gln alpha-myosin heavy chain (MHC-403) FHC-causing mutations. ", "begin": 537, "document": "18362229", "end": 733, "section": "abstract"}, {"text": "Male but not female mice carrying a single R403Q missense allele for cardiac alpha-myosin heavy chain (M-alphaMHC(R403Q/+) and F-alphaMHC(R403Q/+), respectively) develop significant hypertrophic cardiomyopathy (HCM) compared with male and female wild-type mice (M-alphaMHC(+/+) and F-alphaMHC(+/+), respectively) after approximately 30 wk of age.", "begin": 0, "document": "18281382", "end": 346, "section": "abstract"}, {"text": "A Q1065H mutation was detected in 1 of 21 HCM probands and was absent in 2 unaffected offspring.", "begin": 733, "document": "15998695", "end": 829, "section": "abstract"}, {"text": "To understand further the pathogenesis of familial hypertrophic cardiomyopathy, we determined how the cardiomyopathy induced by an Arg403-->Gln missense mutation in the alpha-myosin heavy chain (403) is affected by chronically enhancing sympathetic drive by mating the mice with those overexpressing G(s)alpha (G(s)alpha x403). ", "begin": 12, "document": "11827928", "end": 340, "section": "abstract"}, {"text": "A mouse model of FHC resulting from a mutation in the alpha-myosin heavy-chain (Arg403Gln) was used to study the electrophysiologic phenotype of this disease.", "begin": 252, "document": "10231857", "end": 410, "section": "abstract"}, {"text": "We used small-amplitude (0.25%) length-perturbation analysis to examine the mechanical properties of skinned left ventricular papillary muscle strips from mouse hearts bearing the R403Q mutation in the alpha-myosin heavy chain (alphaMHC403/+).", "begin": 148, "document": "10066683", "end": 391, "section": "abstract"}, {"text": "Genetically-manipulated mice harboring an alpha-myosin heavy chain Arg403Gln missense mutation (alpha-MHC403/+) display a phenotype characteristic of familial hypertrophic cardiomyopathy (FHC).", "begin": 0, "document": "9869991", "end": 193, "section": "abstract"}, {"text": "A new mouse cardiac electrophysiology method was used to study mice harboring an alpha-myosin heavy chain Arg403Gln missense mutation (alpha-MHC403/+), which results in histological and hemodynamic abnormalities characteristic of familial hypertrophic cardiomyopathy (FHC) and sudden death of uncertain etiology during exercise. ", "begin": 0, "document": "9045856", "end": 329, "section": "abstract"}, {"text": "The introduction of the mouse model for FHC (the mouse expresses predominantly alpha-MHC as opposed to the beta-isoform in larger mammals) created a new paradigm for FHC based on finding enhanced motor function for R403Q alpha-MHC.", "begin": 371, "document": "18480046", "end": 602, "section": "abstract"}, {"text": "A mouse model of familial hypertrophic cardiomyopathy (FHC) was generated by the introduction of an Arg 403 --> Gln mutation into the alpha cardiac myosin heavy chain (MHC) gene.", "begin": 0, "document": "8614836", "end": 178, "section": "abstract"}, {"text": "Biochemical analysis of one FHC mutant (Arg-249-->Gln) demonstrates that the structures formed by the mutant are solubilized at a lower ionic strength than those formed by wild-type MHC. We conclude that although the FHC mutant MHC is not labile, its assembly properties may be impaired.", "begin": 1095, "document": "8290568", "end": 1382, "section": "abstract"}]}, {"documents": ["24260207", "23425245", "22815480", "22489623", "21262074", "20566645", "20459070", "19439414", "18572189", "18285522", "16302972", "19506933"], "answer": [["L29Q"], ["A8V"], ["A31S"], ["E134D"], ["c.363dupG"], ["A23Q"], ["D145E"], ["C84Y"]], "id": "5314a7a4dae131f847000003", "snippets": [{"text": "Familial hypertrophic cardiomyopathy related cardiac troponin C L29Q mutation alters length-dependent activation and functional effects of phosphomimetic troponin I*.", "begin": 0, "document": "24260207", "end": 166, "section": "title"}, {"text": "The Ca(2+) binding properties of the FHC-associated cardiac troponin C (cTnC) mutation L29Q were examined in isolated cTnC, troponin complexes, reconstituted thin filament preparations, and skinned cardiomyocytes. ", "begin": 0, "document": "24260207", "end": 214, "section": "abstract"}, {"text": "Effects of calcium binding and the hypertrophic cardiomyopathy A8V mutation on the dynamic equilibrium between closed and open conformations of the regulatory N-domain of isolated cardiac troponin C", "begin": 0, "document": "23425245", "end": 198, "section": "title"}, {"text": "We also used PRE data to assess the structural effects of a familial hypertrophic cardiomyopathy point mutation located within the N-domain of cTnC (A8V). ", "begin": 1489, "document": "23425245", "end": 1644, "section": "abstract"}, {"text": "A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation.", "begin": 0, "document": "22815480", "end": 132, "section": "title"}, {"text": "Here, we report clinical and functional characterization of a novel TNNC1 mutation, A31S, identified in a pediatric HCM proband with multiple episodes of ventricular fibrillation and aborted sudden cardiac death.", "begin": 259, "document": "22815480", "end": 471, "section": "abstract"}, {"text": "In summary, we report a novel mutation in the TNNC1 gene that is associated with HCM pathogenesis and may predispose to the pathogenesis of a fatal arrhythmogenic subtype of HCM.", "begin": 1580, "document": "22815480", "end": 1758, "section": "abstract"}, {"text": "The objective of this work was to investigate the effect of hypertrophic cardiomyopathy-linked A8V and E134D mutations in cardiac troponin C (cTnC) on the response of reconstituted thin filaments to calcium upon phosphorylation of cardiac troponin I (cTnI) by protein kinase A.", "begin": 0, "document": "22489623", "end": 277, "section": "abstract"}, {"text": "We describe a novel type of mutation (c.363dupG) in Troponin C, a rare form of hypertrophic cardiomyopathy.", "begin": 311, "document": "21262074", "end": 418, "section": "abstract"}, {"text": "We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family.", "begin": 756, "document": "21262074", "end": 1030, "section": "abstract"}, {"text": "One mutant (A23Q) was found with HCM-like properties (increased Ca(2+) sensitivity of force and normal levels of ATPase inhibition).", "begin": 584, "document": "20566645", "end": 716, "section": "abstract"}, {"text": "In this study, we investigated the effects of hypertrophic cardiomyopathy-linked mutations A8V, E134D, and D145E in cardiac troponin C on the properties of the C-domain sites.", "begin": 110, "document": "20459070", "end": 285, "section": "abstract"}, {"text": "Recently four new hypertrophic cardiomyopathy mutations in cardiac troponin C (cTnC) (A8V, C84Y, E134D, and D145E) were reported, and their effects on the Ca(2+) sensitivity of force development were evaluated", "begin": 0, "document": "19439414", "end": 209, "section": "abstract"}, {"text": "Comprehensive open reading frame/splice site mutation analysis of TNNC1 performed on 1025 unrelated HCM patients enrolled over the last 10 years revealed novel missense mutations in TNNC1: A8V, C84Y, E134D, and D145E.", "begin": 770, "document": "18572189", "end": 987, "section": "abstract"}, {"text": "The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy.", "begin": 0, "document": "18285522", "end": 116, "section": "abstract"}, {"text": "These results demonstrate that the L29Q mutation enhances the Ca(2+)-binding characteristics of cTnC and that when incorporated into cardiac myocytes, this mutant alters myocyte contractility.", "begin": 1666, "document": "18285522", "end": 1858, "section": "abstract"}, {"text": "Cardiac troponin C-L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C.", "begin": 0, "document": "16302972", "end": 176, "section": "title"}, {"text": "This mutation leads to a leucine-glutamine exchange at position 29 in the nonfunctional calcium-binding site of cTnC. ", "begin": 304, "document": "16302972", "end": 422, "section": "abstract"}]}, {"documents": ["21167350", "17655857", "16829191", "12705874"], "answer": [["PLN L39X nonsense mutation"], ["PLN Leu39Ter"], ["PLN -42 C>G"], ["PLN -77A-->G"]], "id": "531376c8e3eabad021000012", "snippets": [{"text": "one L39X nonsense mutation was identified in 1 of 1,064 HCM proband cases with a family history of HCM, previously found to be negative for the current HCM genetic test panel. This mutation cosegregated with incidence of HCM in a multigenerational family.", "begin": 840, "document": "21167350", "end": 1095, "section": "abstract"}, {"text": "The PLN -42 C>G mutation was found in one patient with late onset familial apical hypertrophic cardiomyopathy. ", "begin": 737, "document": "16829191", "end": 848, "section": "abstract"}, {"text": "The PLN -42 C>G mutation is associated with a benign form of apical hypertrophic cardiomyopathy in this family, though the presence of a healthy adult carrier suggests that other genetic and environmental factors could be involved. ", "begin": 1121, "document": "16829191", "end": 1353, "section": "abstract"}, {"text": "We found a heterozygous single nucleotide transition from A to G at -77-bp upstream of the transcription start site in the phospholamban promoter region of one patient with familial hypertrophic cardiomyopathy.", "begin": 482, "document": "12705874", "end": 692, "section": "abstract"}, {"text": "Using neonatal rat cardiomyocytes, the mutation, -77A-->G, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy.", "begin": 755, "document": "12705874", "end": 1066, "section": "abstract"}, {"text": "Two novel mutations in the CALR3 gene were identified (Lys82Arg, Arg73Gln) and one truncation mutation in the PLN gene (Leu39Ter). ", "begin": 894, "document": "17655857", "end": 1025, "section": "abstract"}]}, {"documents": ["16449486", "16379031", "2315439", "3680580", "3826875", "3943269"], "answer": [["nausea"], ["dizziness / lightheadedness"], ["insomnia"], ["fatigue"], ["vomiting"], ["reduced caloric intake / apetite"], ["increased self-rated alertness"], ["decreased tiredness"], ["(horses) some passage of semifluid fecal material"], ["(horses) intermittent penile relaxation"], ["(horses) mild sedation"]], "id": "52bf1dea03868f1b06000012", "snippets": [{"text": "Adverse experiences included nausea, dizziness, and insomnia.", "begin": 1262, "document": "16449486", "end": 1323, "section": "abstract"}, {"text": "Side effects to nalmefene were of greater duration and intensity in the subjects receiving 10 mg of nalmefene vs. those receiving 6 or 2 mg. These included most notably fatigue, lightheadedness, nausea and vomiting.", "begin": 1447, "document": "16379031", "end": 1662, "section": "abstract"}, {"text": "The nalmefene treated group ate 22% less, both in terms of absolute weight and caloric intake, of a standardised buffet-meal than did the placebo group. ", "begin": 131, "document": "2315439", "end": 284, "section": "abstract"}, {"text": "Thus the apparent nutrient specificity of nalmefene appeared to be an indirect consequence of its effect on palatability. Nalmefene also caused slight increases in self-rated alertness, and decreases in ratings of tiredness and elation, although it was thought unlikely that these accounted for observed changes in eating behaviour.", "begin": 698, "document": "2315439", "end": 1030, "section": "abstract"}, {"text": "In the second study, six healthy men were initially administered a single 50-mg dose of drug, and plasma samples were obtained at selected time intervals for 48 hours. A dosing schedule of 20 mg q12h was then started and continued for seven days. Plasma samples were collected immediately before each dose and at selected times for up to 48 hours after the last dose. The drug was well tolerated by all subjects, and no clinically significant adverse effects were observed during the seven-day administration period.", "begin": 1038, "document": "3680580", "end": 1554, "section": "abstract"}, {"text": " In the first study, single ascending doses of 50, 100, 200, and 300 mg of nalmefene HCl were administered in double-blind fashion to four groups of healthy men. There were six subjects in each group; four received nalmefene and two received placebo. The drug was well tolerated at all dose levels with only mild and transient side effects, such as lightheadedness, at the higher doses. ", "begin": 137, "document": "3680580", "end": 524, "section": "abstract"}, {"text": "Doses of nalmefene as large as 0.4 mg/kg, IV, produced only minor side effects. These side effects included some passage of semifluid fecal material, intermittent penile relaxation, and mild sedation. Treated horses responded normally to external stimuli, retained their appetites, and performed appropriately when ridden. Sedation wore off during the course of prolonged infusions. ", "begin": 967, "document": "3826875", "end": 1350, "section": "abstract"}, {"text": "The drug was well tolerated at all dose levels with only mild and transient side effects, the most common of which was lightheadedness.", "begin": 262, "document": "3943269", "end": 397, "section": "abstract"}]}, {"documents": ["12596031", "11533860", "10746298", "10440458", "10320209", "8891947", "7952245", "9384923", "1618284", "17347940", "16625511", "16047503"], "answer": [["schizophrenia", "schizophrenia psychosis"], ["schizoaffective disorder"], ["delusional disorder"], ["psychotic relapse in neuroleptic malignant syndrome"], ["attention deficit hyperactivity disorder (ADHD) with negativism or conduct disorders"], ["psychotic disorders"]], "id": "52bf1f4503868f1b06000016", "snippets": [{"text": "Further clinical implications are described (capability of learning the therapeutic strategies, deliverability in broader clinical settings, acceptability by patients, combination with atypical neuroleptic drugs,and treatment of choice in risk populations).", "begin": 1297, "document": "12596031", "end": 1554, "section": "abstract"}, {"text": "Intervention strategies are a multimodal psychological programme for the intervention in early prodromal stages and a combination of psychotherapy with atypical neuroleptic drugs in the late prodromal stages. ", "begin": 1784, "document": "11533860", "end": 1993, "section": "abstract"}, {"text": "Atypical neuroleptic drugs have enriched our treatment programs, especially in childhood and adolescent schizophrenia. Reviewed here is the use of atypical neuroleptics in children and adolescents with a schizophrenic disorder. ", "begin": 0, "document": "10746298", "end": 228, "section": "abstract"}, {"text": "o prove whether weight gain is a relevant side effect of atypical neuroleptics, the charts of all patients admitted with DSM-III-R diagnoses of schizophrenia, schizoaffective disorder, or delusional disorder in the years 1991 to 1995 were evaluated.", "begin": 151, "document": "10440458", "end": 400, "section": "abstract"}, {"text": "The handwriting of 18 schizophrenic patients before and during treatment with typical (haloperidol, haloperidol decanoate) and atypical (clozapine, risperidone) neuroleptic drugs was examined.", "begin": 172, "document": "10320209", "end": 364, "section": "abstract"}, {"text": "Atypical and typical neuroleptics, when administered chronically, can bring about profound but contrasting changes in schizophrenic symptoms and motor activation and dramatically modulate brain neurochemistry", "begin": 0, "document": "8891947", "end": 208, "section": "abstract"}, {"text": "Recent studies suggest that clozapine is more effective than typical neuroleptics for patients with treatment-resistant schizophrenia.", "begin": 0, "document": "9384923", "end": 134, "section": "abstract"}, {"text": "Acute and late onset movement disorders frequently complicate the treatment of psychosis with typical neuroleptic drugs like haloperidol, but not with atypical neuroleptic drugs like clozapine. ", "begin": 0, "document": "1618284", "end": 194, "section": "abstract"}, {"text": "Only the group of boys presented other comorbidities such as negativism and conduct disorders; approximately 25% of them required treatment with atypical neuroleptic drugs.", "begin": 1052, "document": "17347940", "end": 1224, "section": "abstract"}, {"text": "Atypical neuroleptic drugs are the preferred treatment for symptoms such as delusions, hallucinations, agitation and aggressive behaviour.", "begin": 342, "document": "16625511", "end": 480, "section": "abstract"}, {"text": "Monotherapeutic treatment with new atypical neuroleptic drugs had a more positive effect on the mental health related quality of life (MCS) in comparison to treatment with polypharmacological treatment but not with oral conventional antipsychotics. ", "begin": 655, "document": "16047503", "end": 904, "section": "abstract"}]}, {"documents": ["19302373", "19052641", "17049789", "16687936", "16164422"], "answer": ["aging research"], "id": "52bf217003868f1b0600001b", "snippets": [{"text": "The short-lived annual fish Nothobranchius furzeri shows extremely short captive life span and accelerated expression of age markers, making it an interesting model system to investigate the effects of experimental manipulations on longevity and age-related pathologies.", "begin": 0, "document": "19302373", "end": 270, "section": "abstract"}, {"text": "Owing to large differences in aging phenotypes in different lines, N. furzeri could represent a model system for studying the genetic control of life-history traits in natural populations.", "begin": 1339, "document": "19052641", "end": 1527, "section": "abstract"}, {"text": "It is very close to the Japanese Medaka, and close to the pufferfishes and stickleback and might represent a very useful model for comparative genomics of aging.", "begin": 1201, "document": "17049789", "end": 1362, "section": "abstract"}, {"text": "In the last three years, N. furzeri has moved from biological curiosity to a promising model system for drug validation.", "begin": 991, "document": "17049789", "end": 1111, "section": "abstract"}, {"text": " This result identifies resveratrol as the first molecule which consistently retards aging in organisms as diverse as yeast, worm, fly and fish, but it also reveals the potential of this short-lived fish as an animal model for pharmacological research. Moreover, being related to stickleback (Gasterosteus aculeatus) the \"pufferfishes\" Takifugu and Tetraodon, and even more closely related to medaka (Oryzias latipes), it can greatly beneficiate from the recent development of genomic resources for these fish models and in the future become a complete model system for the aging research community.", "begin": 645, "document": "16687936", "end": 1244, "section": "abstract"}, {"text": "These fishes can become excellent models for aging studies. They can be employed to test the effects of experimental manipulation on aging at a pace comparable with that of Drosophila and to probe the effects of natural selection on the evolution of aging-related genes.", "begin": 1340, "document": "16164422", "end": 1610, "section": "abstract"}]}, {"documents": ["23648276", "23288091", "21861814", "21301338", "21271304", "20677583", "17461888", "17433624"], "answer": [["epilepsy", "refractory epilepsy", "refractory partial-onset seizures"], ["analgesic"], ["CNS disorders"]], "id": "52bf202003868f1b06000018", "snippets": [{"text": "The current article presents a concise review of network theory and its application to the characterization of AED use in children with refractory epilepsy.", "begin": 301, "document": "23648276", "end": 457, "section": "abstract"}, {"text": "Furthermore, first generation AEDs were often discontinued, while lacosamide and topiramate were most likely to be initiated. ", "begin": 766, "document": "23648276", "end": 892, "section": "abstract"}, {"text": "Overall, there is compelling evidence that salivary TDM can be usefully applied so as to optimize the treatment of epilepsy with carbamazepine, clobazam, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, primidone, topiramate, and zonisamide.", "begin": 1294, "document": "23288091", "end": 1593, "section": "abstract"}, {"text": "The first examples are carbamazepine, gabapentin, and lacosamide as drugs well established in epilepsy market as well as drug candidates such as valnoctamide, and other valproic acid derivatives, novel biphenyl pyrazole derivatives, etc.", "begin": 1421, "document": "21861814", "end": 1658, "section": "abstract"}, {"text": "Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures. ", "begin": 597, "document": "21301338", "end": 756, "section": "abstract"}, {"text": "A discussion is made of recent findings that the atypical antidepressant tianeptine increases CRMP2 expression, whereas other, neuroactive small molecules including the epilepsy drug lacosamide and the natural brain metabolite lanthionine ketimine appear to bind CRMP2 directly with concomitant affects on neural structure.", "begin": 1356, "document": "21271304", "end": 1679, "section": "abstract"}, {"text": "Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action.", "begin": 0, "document": "20677583", "end": 74, "section": "abstract"}, {"text": " It has shown potent and broad neuroprotective effects in vitro and in vivo animal models making it a potential candidate for long term treatment of epilepsy. In addition to this, it has demonstrated analgesic activity in various animal models. Apart from this, LCM has demonstrated potent effects in animal models for a variety of CNS disorders like schizophrenia and stress induced anxiety. ", "begin": 307, "document": "20677583", "end": 700, "section": "abstract"}, {"text": "Clinical trials have also suggested that LCM is a safe, effective, and well tolerated adjunctive treatment for reduction of seizure frequency in patients with highly refractory, partial seizures.", "begin": 790, "document": "20677583", "end": 985, "section": "abstract"}, {"text": "Lacosamide (LCM), (SPM 927, (R)-2-acetamido-N-benzyl-3-methoxypropionamide, previously referred to as harkoseride or ADD 234037) is a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsive drug candidates. LCM has demonstrated antiepileptic effectiveness in different rodent seizure models and antinociceptive potential in experimental animal models that reflect distinct types and symptoms of neuropathic as well as chronic inflammatory pain.", "begin": 0, "document": "17461888", "end": 490, "section": "abstract"}, {"text": "Recent results suggest that LCM has a dual mode of action underlying its anticonvulsant and analgesic activity.", "begin": 491, "document": "17461888", "end": 602, "section": "abstract"}, {"text": "Currently, LCM is in a late stage of clinical development as an adjunctive treatment for patients with uncontrolled partial-onset seizures, and it is being assessed as monotherapy in patients with painful diabetic neuropathy. ", "begin": 1750, "document": "17461888", "end": 1976, "section": "abstract"}, {"text": "Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice.", "begin": 203, "document": "17433624", "end": 491, "section": "abstract"}, {"text": "Lacosamide was inactive against clonic seizures induced by subcutaneous administration of the chemoconvulsants pentylenetetrazol, bicuculline, and picrotoxin, but it did inhibit NMDA-induced seizures in mice and showed full efficacy in the homocysteine model of epilepsy.", "begin": 935, "document": "17433624", "end": 1206, "section": "abstract"}, {"text": "These results suggest that lacosamide may have the potential to be clinically useful for at least the treatment of generalized tonic-clonic and partial-onset epilepsies, and support ongoing clinical trials in these indications.", "begin": 1381, "document": "17433624", "end": 1608, "section": "abstract"}]}, {"documents": ["20978564", "22870736", "19181292", "19006851", "15694896", "15642542", "12963854", "2358611", "17315395", "23555069", "19110971", "18221125", "16499159", "8333797", "23369135", "19917524", "23435988", "8960429", "2189307", "17893267", "17966446", "9489964", "15259379", "12165115", "17923583", "20024637"], "answer": ["There is a relationship between altered thyroid profile and mortality in patients with heart failure"], "id": "531b2fc3b166e2b80600003c", "snippets": [{"text": " Cumulative survival was significantly lower among patients with free triiodothyronine < 2.12 pg/mL and among patients with brain natriuretic peptide > 686 pg/mL. In multivariate analysis, the significant independent predictors of major cardiac events were age, free triiodothyronine, and brain natriuretic peptide", "begin": 1115, "document": "20978564", "end": 1429, "section": "abstract"}, {"text": "The T3 was more meaningful than the BNP in the prognosis of CHF. The BNP and T3 combination detection was more valuable in determining the severity of CHF and prognosis.", "begin": 1261, "document": "22870736", "end": 1430, "section": "abstract"}, {"text": "fT3 and BNP hold an independent and additive prognostic value in HF.", "begin": 1611, "document": "19181292", "end": 1679, "section": "abstract"}, {"text": "Univariate regression analysis showed that TSH (p<0.0001), fT3 (p<0.0001), fT4 (p=0.016) and fT3/fT4 (p<0.0001) were associated with heart failure progression but multivariate analysis showed that only TSH considered as a continuous variable (p = 0.001) as well as subclinical hypothyroidism (TSH > 5.5 mUI/l; p=0.014) remained significantly associated with the events.", "begin": 808, "document": "19006851", "end": 1177, "section": "abstract"}, {"text": "Low T(3) levels are an independent predictor of mortality in patients with chronic heart failure, adding prognostic information to conventional clinical and functional cardiac parameters.", "begin": 1816, "document": "15694896", "end": 2003, "section": "abstract"}, {"text": "Sixteen patients (14%) died during the follow-up period; their fT3/fT4 ratio was significantly lower than the patients who survived (1.31+/-0.37 vs. 2.01+/-0.72, p<0.001).", "begin": 1010, "document": "15642542", "end": 1181, "section": "abstract"}, {"text": "The authors conclude that among elderly patients with heart failure, lower triiodothyronine concentrations are more prevalent and are associated with a worse prognosis.", "begin": 1549, "document": "12963854", "end": 1717, "section": "abstract"}, {"text": "A low free T3 index/reverse T3 ratio is associated with poor ventricular function and nutritional status and is the strongest predictor yet identified for short-term outcome in patients with advanced heart failure.", "begin": 976, "document": "2358611", "end": 1190, "section": "abstract"}]}, {"documents": ["24164777", "23229252", "22957483", "22819057", "22669143", "22092585", "22044166", "22612823", "22040716", "21743413", "19450321", "1923398", "17287703", "23429751", "23772971", "22344742", "17541900", "20415927", "22750263", "11838624", "2098940", "10425973", "23201368", "10431669", "18558051", "11871678", "14650993", "12536654", "18625105", "15210564", "17849966", "8725589", "9830647", "11485137", "2726203", "11441716", "16637799", "2811814", "20969436", "17559486", "20597947", "10625850", "20690412", "18548844", "12110042", "1508523", "16903201", "9844361", "18588600", "22260804", "8543701", "19689438", "7629360", "18343329", "19658340", "14765022", "1776404", "8323246", "21223496", "24558551", "21743415", "19837207", "18976257", "15195716", "21528119", "14704612"], "answer": [["Dopaminergig drugs"], ["Catuama"], ["Capsaicina"], ["Alpha-lipoic acid"], ["Clonazepam"], ["Placebo therapy"]], "id": "531d7430267d7dd053000008", "snippets": [{"text": "On average, treatment with placebos produced a response that was 72% as large as the response to active drugs.", "begin": 269, "document": "24164777", "end": 379, "section": "abstract"}, {"text": "The concomitant prescription of tongue protector and AV is effective for treating patients with BMS.", "begin": 1128, "document": "22957483", "end": 1228, "section": "abstract"}, {"text": "We suggest that a subset of patients with BMS may be a phenotypic variant of RLS and a trial of dopaminergic drugs should be given in patients with BMS who has a history suggestive of RLS or in a patient who do not show a response to usual therapies for BMS.", "begin": 843, "document": "22819057", "end": 1101, "section": "abstract"}, {"text": "The systemic administration of Catuama reduces the symptoms of BMS and may be a novel therapeutic strategy for the treatment of this disease.", "begin": 862, "document": "22669143", "end": 1003, "section": "abstract"}, {"text": "Therapies that used capsaicin, alpha-lipoic acid (ALA), and clonazepam were those that showed more reduction in symptoms of BMS.", "begin": 766, "document": "22092585", "end": 894, "section": "abstract"}, {"text": "Topical clonazepam, which previous analyses of clinical evidence have shown to be the drug of choice for BMS, also proved to be the most cost-effective of the drugs analysed for this condition.", "begin": 1189, "document": "22044166", "end": 1382, "section": "abstract"}]}, {"documents": ["23990180", "23124142", "16330914", "11747849", "19609889"], "answer": ["Low T3 Syndrome isassociatedwithpoor prognosis in patients with acute myocardial infarction"], "id": "531d1998267d7dd053000001", "snippets": [{"text": "In-hospital cardiogenic shock (15% vs 3% in the control group; p<0.01) and death (7% vs 1% in the control group; p<0.01) were more frequently observed in the thyroid dysfunction group. ", "begin": 1073, "document": "23990180", "end": 1258, "section": "abstract"}, {"text": "Thyroid dysfunction, particularly sick euthyroid syndrome, was found to be related to in-hospital and long term mortality in patients with STEMI undergoing primary percutaneous intervention.", "begin": 1443, "document": "23990180", "end": 1633, "section": "abstract"}, {"text": "A low fT3 level, a common phenomenon in patients with acute myocardial infarctions, is a strong predictor of short-term and long-term poor prognoses in patients with acute myocardial infarctions.", "begin": 1387, "document": "23124142", "end": 1582, "section": "abstract"}, {"text": "Troponin T and creatine kinase-B with an M-type subunit levels were significantly higher in the nonsurvivors when compared with survivors. Survivors in the AMI group had higher TT3, TT4, and lower FT4 levels, while the nonsurvivors in the AMI group had higher thyrotrophin and lower TT3, FT3 and FT4 levels than controls.", "begin": 828, "document": "16330914", "end": 1149, "section": "abstract"}, {"text": "Reverse T3 levels >0.41 nmol/L were associated with an increased risk of 1-year mortality (hazard ratio = 3.0; 95% confidence interval: 1.4 to 6.3; P = 0.005), independent of age, previous myocardial infarction, prior angina, heart failure, serum creatinine level, and peak serum creatine kinase-MB fraction levels.", "begin": 1215, "document": "11747849", "end": 1530, "section": "abstract"}]}, {"documents": ["23216904", "22791394", "22019769", "20237562", "20227040", "20010815", "19150958", "19053174", "17664422", "17634581", "17409421", "16818632", "12581156", "12134086", "11971980", "21969595"], "answer": [["Ras"], ["c-Abl"], ["Raf"], ["Myc"], ["Skp2"], ["BRAF"], ["AKT"], ["HDAC2"], ["p38 MAPK"], ["Caveolin-1"], ["Mek1"]], "id": "5309f8f5970c65fa6b000001", "snippets": [{"text": "ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic Ras-induced premature senescence", "begin": 0, "document": "23216904", "end": 94, "section": "title"}, {"text": "Activated oncogenes induce premature cellular senescence, a permanent state of proliferative arrest in primary rodent and human fibroblasts. Recent studies suggest that generation of reactive oxygen species (ROS) is involved in oncogenic Ras-induced premature senescence.", "begin": 0, "document": "23216904", "end": 271, "section": "abstract"}, {"text": "these findings suggest that Nox1- and Nox4-generated ROS play an important role in Ras-induced premature senescence", "begin": 1282, "document": "23216904", "end": 1397, "section": "abstract"}, {"text": "A role for c-Abl in cell senescence and spontaneous immortalization", "begin": 0, "document": "22791394", "end": 67, "section": "title"}, {"text": "Here, we report an important role for c-Abl in replicative senescence and immortalization by regulating the expression of two tumor suppressors that induce cellular senescence, p53 and p16(INK4a).", "begin": 301, "document": "22791394", "end": 497, "section": "abstract"}, {"text": "The role for c-Abl in regulating cell senescence and immortalization might explain some of the developmental defects in c-Abl (-/-) mice and how BCR-ABL transforms cells.", "begin": 1249, "document": "22791394", "end": 1419, "section": "abstract"}, {"text": "Ras/Raf-prototypic oncogenes induce cellular senescence, a terminal cell-cycle arrest, as a default cellular safeguard program", "begin": 0, "document": "22019769", "end": 126, "section": "abstract"}, {"text": "oncogene-induced senescence, Myc style", "begin": 26, "document": "22019769", "end": 64, "section": "title"}, {"text": "We review and discuss here evidence for Myc-induced senescence - which is detectable to a limited degree as a cell-autonomous, direct response to Myc action, but occurs predominantly in a non-cell-autonomous fashion via crosstalk of the oncogene-driven cell population with non-neoplastic bystanders, namely cells of the host immune system, prompting them to release pro-senescent cytokines that strike back onto adjacent proliferating tumor cells.", "begin": 218, "document": "22019769", "end": 666, "section": "abstract"}, {"text": "genetic Skp2 inactivation evokes cellular senescence even in oncogenic conditions in which the p19(Arf)-p53 response is impaired, whereas a Skp2-SCF complex inhibitor can trigger cellular senescence in p53/Pten-deficient cells and tumour regression in preclinical studies.", "begin": 865, "document": "20237562", "end": 1137, "section": "abstract"}, {"text": "Activated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive barrier in early cancer development, at least in part, via an oncogene-evoked DNA damage response (DDR).", "begin": 0, "document": "20227040", "end": 183, "section": "abstract"}, {"text": "Cdk2 suppresses cellular senescence induced by the c-myc oncogene", "begin": 0, "document": "20010815", "end": 65, "section": "title"}, {"text": "Loss of Cdk2 also caused sensitization to Myc-induced senescence in pancreatic beta-cells or splenic B-cells in vivo", "begin": 528, "document": "20010815", "end": 644, "section": "abstract"}, {"text": "Myc also causes senescence in cells lacking the DNA repair protein Wrn.", "begin": 816, "document": "20010815", "end": 887, "section": "abstract"}, {"text": "In MEFs, Myc-induced senescence was genetically dependent on the ARF-p53-p21Cip1 and p16INK4a-pRb pathways, p21Cip1 and p16INK4a being selectively induced in Cdk2-/- cells.", "begin": 1053, "document": "20010815", "end": 1225, "section": "abstract"}, {"text": "We have found that expression of such an oncogene, Akt, causes senescence in primary mouse hepatoblasts in vitro.", "begin": 249, "document": "19150958", "end": 362, "section": "abstract"}, {"text": "hyperproliferative signaling through AKT might be a driving force of the senescence in activated hepatic stellate cells.", "begin": 533, "document": "19150958", "end": 653, "section": "abstract"}, {"text": "oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells,", "begin": 1151, "document": "19053174", "end": 1238, "section": "abstract"}, {"text": "Here we report that the suppression of the c-Myc (MYC) oncogene induces cellular senescence in diverse tumor types including lymphoma, osteosarcoma, and hepatocellular carcinoma.", "begin": 122, "document": "17664422", "end": 300, "section": "abstract"}, {"text": "Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation", "begin": 0, "document": "17664422", "end": 89, "section": "title"}, {"text": "MYC inactivation was associated with prototypical markers of senescence", "begin": 301, "document": "17664422", "end": 372, "section": "abstract"}, {"text": "only after lymphomas were repaired for p53 expression did MYC inactivation induce robust senescence and sustained tumor regression.", "begin": 807, "document": "17664422", "end": 938, "section": "abstract"}, {"text": "Replicative senescence due to telomere shortening can, for example, be induced by a dominant negative version of telomerase, premature senescence by the overexpression of oncogenic ras, or p16.", "begin": 1116, "document": "17634581", "end": 1309, "section": "abstract"}, {"text": "knockdown of HDAC2 induced cellular senescence.", "begin": 861, "document": "17409421", "end": 908, "section": "abstract"}, {"text": "MYC overexpression is thought to initiate tumorigenesis by inducing cellular proliferation and growth and to be restrained from causing tumorigenesis by inducing cell cycle arrest, cellular senescence, and/or apoptosis.", "begin": 0, "document": "16818632", "end": 219, "section": "abstract"}, {"text": "Several conditions, including oncogenic Ras over-expression and inappropriate culture conditions, also induce senescence without telomere shortening.", "begin": 191, "document": "12581156", "end": 340, "section": "abstract"}, {"text": "We demonstrate that p38 mitogen-activated protein kinase (MAPK) plays important causative roles in senescent cells following telomere shortening, Ras-Raf activation, oxidative stress or inappropriate culture conditions.", "begin": 481, "document": "12581156", "end": 700, "section": "abstract"}, {"text": "Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway", "begin": 0, "document": "12581156", "end": 85, "section": "title"}, {"text": "These results indicate that p38 comprises the senescence-executing pathway in response to diverse stimuli.", "begin": 1359, "document": "12581156", "end": 1465, "section": "abstract"}, {"text": "this p38-activating condition appears to be defined quantitatively as a sum of continuous and low-level stresses, and remains even after the initial stimuli are withdrawn, which may explain the well-known irreversible nature of cellular senescence. We also show that papilloma virus E7 abolishes the p38-induced growth arrest but not other senescence-associated phenotypes, indicating the differential role of pRb in the downstream of p38.", "begin": 907, "document": "12581156", "end": 1346, "section": "abstract"}, {"text": "Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts", "begin": 0, "document": "12134086", "end": 104, "section": "title"}, {"text": "Here, we demonstrate that mouse embryonic fibroblasts transgenically overexpressing caveolin-1 show: 1) a reduced proliferative lifespan; 2) senescence-like cell morphology; and 3) a senescence-associated increase in beta-galactosidase activity. These results indicate for the first time that the expression of caveolin-1 in vivo is sufficient to promote and maintain the senescent phenotype.", "begin": 832, "document": "12134086", "end": 1224, "section": "abstract"}, {"text": "Interestingly, premature senescence induced by hydrogen peroxide is greatly reduced in NIH 3T3 cells harboring antisense caveolin-1. Importantly, induction of premature senescence is recovered when caveolin-1 levels are restored.", "begin": 1799, "document": "12134086", "end": 2028, "section": "abstract"}, {"text": "these results clearly indicate a central role for caveolin-1 in promoting cellular senescence", "begin": 2045, "document": "12134086", "end": 2138, "section": "abstract"}, {"text": "Oncogenic activation of the mitogen-activated protein (MAP) kinase cascade in murine fibroblasts initiates a senescence-like cell cycle arrest that depends on the ARF/p53 tumor suppressor pathway.", "begin": 0, "document": "11971980", "end": 196, "section": "abstract"}, {"text": "In contrast, coexpression of oncogenic ras or activated mek1 with p53 enhanced both p53 levels and activity relative to that observed for p53 alone and produced an irreversible cell cycle arrest that displayed features of cellular senescence.", "begin": 599, "document": "11971980", "end": 841, "section": "abstract"}, {"text": "our results indicate that oncogenic activation of the MAP kinase pathway in murine fibroblasts converts p53 into a senescence inducer through both quantitative and qualitative mechanisms.", "begin": 1398, "document": "11971980", "end": 1585, "section": "abstract"}, {"text": "Myc-evoked apoptosis serves as a signal for macrophage attraction and activation, followed by the secretion of TGF-\u03b2 as a cytokine that is capable of terminally arresting Myc-driven lymphoma cells without causing further DNA damage and without launching a senescence-associated, pro-inflammatory, and, therefore, potentially detrimental cytokine response in the target population.", "begin": 697, "document": "22019769", "end": 1077, "section": "abstract"}, {"text": "The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction.", "begin": 0, "document": "21969595", "end": 229, "section": "abstract"}]}, {"documents": ["24180681", "23219029", "23007140", "22791573", "19889303", "19239998", "19133941", "16210669", "15221338", "14716484", "12618672", "11520735", "24304436"], "answer": [["epilepsy"], ["subependymal giant cell astrocytomas"], ["lymphangioleiomyomatosis"], ["rhabdomyoma"], ["renal angiomyolipomas"], ["cortical tubers"], ["neurofibromas"], ["angiofibromas"], ["mental retardation"], ["behavioral disorders"]], "id": "52ebb2c698d0239505000029", "snippets": [{"text": "Prevalence and long-term outcome of epilepsy in tuberous sclerosis complex (TSC) is reported to be variable", "begin": 11, "document": "24304436", "end": 118, "section": "abstract"}, {"text": "Subependymal giant cell astrocytomas (SEGAs) are benign tumors, most commonly associated with tuberous sclerosis complex (TSC).", "begin": 7, "document": "24180681", "end": 134, "section": "abstract"}, {"text": "Lymphangioleiomyomatosis (LAM) is a rare, progressive, frequently lethal cystic lung disease that almost exclusively affects women.", "begin": 11, "document": "23007140", "end": 142, "section": "abstract"}, {"text": "Rhabdomyoma is the most common type of cardiac tumor in fetuses and is often associated with tuberous sclerosis complex (TSC) with neurologic sequelae.", "begin": 11, "document": "22791573", "end": 162, "section": "abstract"}, {"text": "In contrast to renal angiomyolipomas, which are often associated with tuberous sclerosis,", "begin": 463, "document": "19889303", "end": 552, "section": "abstract"}, {"text": "clinical characteristics of subependymal nodule (SN) - subependymal giant cell astrocytoma (SGCA) complex in tuberous sclerosis", "begin": 56, "document": "19239998", "end": 183, "section": "abstract"}, {"text": "NMI patients had a lower incidence of brain findings on imaging studies, neurological features, and renal findings than those with TSC2 mutations. In contrast, NMI patients had a lower incidence of seizures than TSC patients with TSC1 mutations, but had a higher incidence of both renal angiomyolipomas and pulmonary lymphangioleiomyomatosis.", "begin": 488, "document": "19133941", "end": 830, "section": "abstract"}, {"text": "clinical characteristics of subjects with pulmonary lymphangioleiomyomatosis, both sporadic and tuberous sclerosis-related forms.", "begin": 327, "document": "16210669", "end": 456, "section": "abstract"}, {"text": "Women with tuberous sclerosis-related lymphangioleiomyomatosis were younger and had less impaired lung function compared with those with the sporadic form.", "begin": 1300, "document": "16210669", "end": 1455, "section": "abstract"}, {"text": "Balloon cells are histopathological hallmarks of various cortical malformations, i.e., focal cortical dysplasia (Taylor's type, FCD IIb), hemimegalencephaly (HME) or cortical tubers (tuberous sclerosis, TSC). ", "begin": 0, "document": "15221338", "end": 209, "section": "abstract"}, {"text": "Pulmonary lymphangioleiomyomatosis is a rare cause of recurrent pneumothorax and should be considered a differential diagnosis, especially in young women with diffuse bilateral bullous emphysema or tuberous sclerosis.", "begin": 1016, "document": "14716484", "end": 1233, "section": "abstract"}, {"text": "The disease is characterized by the development of benign hamartomatous tumors: neurofibromas and angiofibromas, located in the skin, central nervous system, mucosas and other organs. Abnormal neural cell migration plays an important role in the neurological dysfunctions found in TS, the predominant features being mental retardation, seizures and behavioral disorders.", "begin": 153, "document": "12618672", "end": 523, "section": "abstract"}, {"text": "The true prevalence of pulmonary lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex (TSC) is unknown.", "begin": 0, "document": "11520735", "end": 125, "section": "abstract"}, {"text": "We retrospectively reviewed a cohort of patients with TSC and refractory epilepsy who started CLB over a 5-year period. Clinical characteristics and number of tubers on MRI were assessed.", "begin": 113, "document": "23219029", "end": 300, "section": "abstract"}]}, {"documents": ["24323888", "23980734", "23800565", "23717772", "23717765", "23600891", "23436649", "23349254", "22828460", "22212240", "21990004", "22080314", "21830999", "21813916", "21400082", "21116022", "20308973", "19838998", "19597720", "19089749", "18562771", "16575496"], "answer": [["Resveratrol"], ["Quercetin"], ["Vitamin C"], ["Biostimine"], ["Astaxanthin"], ["Melatonin"], ["coenzyme Q(10)"], ["Creatine"], ["Isoquercetin"], ["Epigallocatechin gallate"], ["n-3 fatty acids"], ["L. rhamnosus IMC 501"], ["L. paracasei IMC 502"], ["docosahexanoic acid (DHA)"], ["eicosapentanoic acid (EPA)"], ["Rhodiola Rosea"], ["Vitamin E"], ["Zinc"], ["whey and/or soy proteins"], ["", ""]], "id": "52df8ce798d023950500000d", "snippets": [{"text": "Although these supplementations are increasingly used by master athletes, very few data are available on their effects on oxidative stress, muscle recovery, and physical performance. The potential benefits of supplement use in athletes are thus questionable. Some studies indicate no benefits, while others highlight potential negative side effects of vitamin supplementation. ", "begin": 1138, "document": "24323888", "end": 1515, "section": "abstract"}, {"text": "These data indicate that RQ significantly reduces exercise-induced lipid peroxidation without associated changes in inflammation or plasma antioxidant status.", "begin": 1525, "document": "23980734", "end": 1683, "section": "abstract"}, {"text": "Cr supplementation inhibited the increase of inflammation markers TNF-\u03b1 and CRP, but not oxidative stress markers, due to acute exercise.", "begin": 1563, "document": "23800565", "end": 1700, "section": "abstract"}, {"text": "Quercetin and vitamin C supplementation may not be beneficial in lipid profile improvement, although it may reduce induce muscle damage and body fat percent.", "begin": 1381, "document": "23717772", "end": 1538, "section": "abstract"}, {"text": "Vitamins C and E supplementation had no significant effect on any of the studied parameters.", "begin": 1321, "document": "23717765", "end": 1413, "section": "abstract"}, {"text": "Effects of the two treatments relative to placebo on mean performance in the incremental test and time trial were unclear, but runners faster by 1 SD of peak speed demonstrated a possible improvement on peak running speed with BC juice (1.9%; \u00b12.5%). ", "begin": 1116, "document": "23600891", "end": 1367, "section": "abstract"}, {"text": "Training status correlates more strongly with antioxidant status than diet does", "begin": 1722, "document": "23436649", "end": 1801, "section": "abstract"}, {"text": "Consequently, we can conclude that Biostimine supplementation reduces the postexercise level of TBARS by increasing the antioxidant activity of plasma but has no effect on inflammatory markers.", "begin": 1521, "document": "23349254", "end": 1714, "section": "abstract"}, {"text": "Supplementation with Asx could prevent exercise induced free radical production and depletion of non-enzymatic antioxidant defense in young soccer players.", "begin": 2215, "document": "22828460", "end": 2370, "section": "abstract"}, {"text": "In conclusion these results indicated that treatment with melatonin in acute sports exercise reversed oxidative stress, improved defenses and lipid metabolism, which would result in an improvement in fitness.", "begin": 1536, "document": "22212240", "end": 1744, "section": "abstract"}, {"text": "CoQ(10) supplementation before strenuous exercise decreases the oxidative stress and modulates the inflammatory signaling, reducing the subsequent muscle damage.", "begin": 1373, "document": "21990004", "end": 1534, "section": "abstract"}, {"text": "Heretofore, Cr's positive therapeutic benefits in various oxidative stress-associated diseases have been reported in the literature and, recently, Cr has also been shown to exert direct antioxidant effects.", "begin": 442, "document": "22080314", "end": 648, "section": "abstract"}, {"text": "These results indicate that Cr supplementation reduced oxidative DNA damage and lipid peroxidation induced by a single bout of RE.", "begin": 1932, "document": "22080314", "end": 2062, "section": "abstract"}, {"text": "Nevertheless, based upon the growing evidence that many athletic populations are vitamin D deficient or insufficient, it is recommended that athletes monitor their serum vitamin D concentration and consult with their health care professional and/or nutritionist to determine if they would derive health benefits from vitamin D supplementation.", "begin": 1241, "document": "21830999", "end": 1584, "section": "abstract"}, {"text": "This study examined the effects of 1,000 mg quercetin + 1,000 mg vitamin C (QC); 1,000 mg quercetin, 1,000 mg vitamin C, 400 mg isoquercetin, 30 mg epigallocatechin gallate, and 400 mg n-3 fatty acids (QFO)", "begin": 190, "document": "21813916", "end": 396, "section": "abstract"}, {"text": "The two strains, L. rhamnosus IMC 501(\u00ae) and L. paracasei IMC 502(\u00ae), exert strong antioxidant activity. Athletes and all those exposed to oxidative stress may benefit from the ability of these probiotics to increase antioxidant levels and neutralize the effects of reactive oxygen species.", "begin": 1097, "document": "21400082", "end": 1387, "section": "abstract"}, {"text": "These results indicate that supplementation with n-3 LCPUFAs significantly increased oxidative stress at rest and after a judo-training session.", "begin": 1647, "document": "21116022", "end": 1791, "section": "abstract"}, {"text": "Rhodiola Rosea, is an adaptogen plant which has been reported to promote fatty acids utilisation, to ameliorate antioxidant function, and to improve body resistance to physical strenuous efforts. ", "begin": 11, "document": "20308973", "end": 207, "section": "abstract"}, {"text": "Supplementation with antioxidant vitamin E to athletes at 267 mg (400 IUs) or greater has been reported to reduce levels of LP associated with exercise.", "begin": 238, "document": "19838998", "end": 390, "section": "abstract"}, {"text": "Results obtained at the end of the study indicate that zinc supplementation prevents production of free radicals by activating the antioxidant system.", "begin": 1606, "document": "19597720", "end": 1756, "section": "abstract"}, {"text": "The significant increase in the UI of erythrocyte membranes indicates the potential for harm, because a high intake of PUFA might increase susceptibility to lipid peroxidation not counterbalanced by a higher increase in TAA. Adherence to the Mediterranean diet seems to be the better choice.", "begin": 1295, "document": "18562771", "end": 1586, "section": "abstract"}, {"text": "A number of clinical trials have successfully been performed using whey and/or soy proteins in the treatment of many diseases. They both have antioxidant properties, which appears to be a factor in aerobic physical performance as well. ", "begin": 12, "document": "16575496", "end": 248, "section": "abstract"}, {"text": "The antioxidant effect of the two proteins is based on different mechanisms of action.", "begin": 1647, "document": "16575496", "end": 1733, "section": "abstract"}]}, {"documents": ["22811911", "23450998", "21435018", "20061269", "19574095", "18369530", "17436206", "11761838", "9177584", "8164540", "8450727", "2253729", "23241269", "20424397", "16389882", "17214401", "21618162", "18634917", "22625998", "17849604"], "answer": ["No clear results indicating improved life expectancy in professional athletes", ""], "id": "52e62bae98d0239505000015", "snippets": [{"text": "In conclusion, while regular physical activity increases life expectancy, it remains unclear if high-intensity sports activities further increase life expectancy.", "begin": 1197, "document": "22811911", "end": 1359, "section": "abstract"}, {"text": "Competitive exercise does not induce cardiac damage in individuals with healthy hearts, but does induce physiological functional and structural cardiac adaptations which have positive effects on life expectancy.", "begin": 1247, "document": "23450998", "end": 1458, "section": "abstract"}, {"text": "It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes.", "begin": 645, "document": "19574095", "end": 1039, "section": "abstract"}]}, {"documents": ["19178511", "17224473", "23329579", "18198294", "19014646", "21415143"], "answer": [["DIO 2 Thr92Ala"], ["rs7140952"]], "id": "52f65bf02059c6d71c000026", "snippets": [{"text": "In two large populations of elderly subjects, neither serum thyroid parameters nor polymorphisms in the type 2 deiodinase and the TSH receptor, were associated with blood pressure or the presence of hypertension", "begin": 1194, "document": "19178511", "end": 1405, "section": "abstract"}, {"text": "Type 2 iodothyronine deiodinase Thr92Ala allele frequencies differed significantly between hypertensive and normotensive subjects, with an excess of Ala92 carriers in hypertensive compared with normotensive subjects (64.8% versus 47.1%; P=0.011).", "begin": 692, "document": "17224473", "end": 938, "section": "abstract"}, {"text": "However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.", "begin": 1358, "document": "23329579", "end": 1487, "section": "abstract"}, {"text": "A significant gene-gene interaction was observed in the modulation of systolic (p = 0.01) and diastolic (p = 0.02) blood pressure and metabolic syndrome (p = 0.02), with carriers of both DIO2 A92 and PPARgamma2 A12 variants showing the worst phenotype.", "begin": 724, "document": "18198294", "end": 976, "section": "abstract"}]}, {"documents": ["22123068", "21896621", "23970761", "23307789", "23298477", "22947347", "23565368", "19903697", "18954857", "18386142", "18080776", "16384862", "7608251", "3730832", "20187783", "9001190", "1193013"], "answer": [["TRIAC", "TETRAC"]], "id": "52fb42752059c6d71c00005e", "snippets": [{"text": "Here, we evaluate the therapeutic potential of the TH analog 3,5,3',5'-tetraiodothyroacetic acid (tetrac) as a replacement for T(4) in brain development. ", "begin": 273, "document": "23307789", "end": 427, "section": "abstract"}, {"text": "This treatment was sufficient to promote TH-dependent neuronal differentiation in the cerebellum, cerebral cortex, and striatum but was ineffective in suppressing hypothalamic TRH expression. ", "begin": 1104, "document": "23307789", "end": 1296, "section": "abstract"}, {"text": "In the current study, we investigated the effect of a natural thyroid hormone analogue - 3, 3?, 5-triiodo-thyroacetic acid (TRIAC) on regulating proliferation and differentiation and its possible molecular mechanism in normal human epidermal keratinocytes and C57BL/6 mice.", "begin": 347, "document": "23298477", "end": 620, "section": "abstract"}, {"text": "TRIAC was effective and safe in ameliorating the effects of hyperthyroidism and ADHD symptoms in a child with known genetic RTH.", "begin": 1241, "document": "22947347", "end": 1369, "section": "abstract"}]}, {"documents": ["23392090", "22986150", "21459689", "18940949", "17574009", "17161330", "1422238", "8475937", "9092799", "21874823", "19541799", "12946875", "8115332", "17132274", "8594618", "17684393", "9350446", "8421095", "1580595", "7833674", "17040361", "2885829", "10687857"], "answer": ["TH monocarboxylate transporter 8 (MCT8) mutation is implicated in the TH resistance syndrome", ""], "id": "52f8b2902059c6d71c000053", "snippets": [{"text": "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.", "begin": 489, "document": "23392090", "end": 732, "section": "abstract"}, {"text": " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", "begin": 720, "document": "22986150", "end": 832, "section": "abstract"}, {"text": " Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.", "begin": 137, "document": "21459689", "end": 371, "section": "abstract"}, {"text": "One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;", "begin": 585, "document": "17574009", "end": 728, "section": "abstract"}]}, {"documents": ["22968828", "22023720", "19076295"], "answer": [["growth rate deficit in both roots and shoots"], ["lowered activity of specific mitochondrial enzymes associated with respiratory metabolism"], ["impaired seedling establishment"]], "id": "52e0141498d023950500000e", "snippets": [{"text": "Knockout in Arabidopsis (Arabidopsis thaliana) leads to a significant growth rate deficit in both roots and shoots and lowered activity of specific mitochondrial enzymes associated with respiratory metabolism. ", "begin": 95, "document": "22968828", "end": 305, "section": "abstract"}, {"text": "loss of Lon1 significantly modifies respiratory function and plant performance by small but broad alterations in the mitochondrial proteome gained by subtly changing steady-state protein assembly, stability, and damage of a range of components that debilitate an anaplerotic role for mitochondria in cellular carbon metabolism.", "begin": 1166, "document": "22968828", "end": 1493, "section": "abstract"}, {"text": "the lack of Lon selective proteolysis leading to growth retardation and impaired seedling establishment can be attributed to defects in the oil reserve mobilization pathway. ", "begin": 1071, "document": "22023720", "end": 1245, "section": "abstract"}, {"text": "Loss of Lon1 in Arabidopsis changes the mitochondrial proteome leading to altered metabolite profiles and growth retardation without an accumulation of oxidative damage.", "begin": 0, "document": "22968828", "end": 169, "section": "title"}, {"text": " a genetic screen was performed that led to the identification of Arabidopsis thaliana Lon1 protease mutants that exhibit a post-embryonic growth retardation phenotype.", "begin": 195, "document": "19076295", "end": 363, "section": "abstract"}, {"text": "mitochondria isolated from lon1 mutants had a lower capacity for respiration of succinate and cytochrome c via complexes II and IV, respectively. Furthermore, the activity of key enzymes of the tricarboxylic acid (TCA) cycle was significantly reduced. Additionally, mitochondria in lon1 mutants had an aberrant morphology. ", "begin": 944, "document": "19076295", "end": 1267, "section": "abstract"}, {"text": " AtLon1 protease in organelle biogenesis and seedling establishment.", "begin": 1402, "document": "19076295", "end": 1470, "section": "abstract"}]}, {"documents": ["23914949", "21215266"], "answer": ["RFX6"], "id": "52e92c6e98d0239505000024", "snippets": [{"text": "Mutations in rfx6 were recently associated with Mitchell-Riley syndrome, which involves neonatal diabetes, and other digestive system defects. ", "begin": 0, "document": "21215266", "end": 143, "section": "abstract"}, {"text": "bi-allelic mutations in the transcription factor RFX6 were described as the cause of a rare condition characterized by neonatal diabetes with pancreatic and biliary hypoplasia and duodenal/jejunal atresia.", "begin": 10, "document": "23914949", "end": 215, "section": "abstract"}]}, {"documents": ["23940258", "22486183", "21572129", "21287604", "18032746", "23227859"], "answer": [["LRRK2 gene mutation"], ["Human L-Ferritin"], ["The genotypes of five specific single-nucleotide polymorphisms (SNPs) in three genes"], ["Homozygosity for the T-allele of BTBD9 rs9296249"], ["MEIS1"], ["Intragenic guanosine triphosphate cyclohydrolase-1 duplication"]], "id": "52f8995b2059c6d71c00004a", "snippets": [{"text": "Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome.", "begin": 0, "document": "23940258", "end": 115, "section": "title"}, {"text": "We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). ", "begin": 438, "document": "23940258", "end": 644, "section": "abstract"}, {"text": "The genotypes of five specific single-nucleotide polymorphisms (SNPs) in three genes that have been previously associated with iron status and/or restless leg syndrome (RLS)", "begin": 433, "document": "22486183", "end": 606, "section": "abstract"}, {"text": "Homozygosity for the T-allele of BTBD9 rs9296249 was associated with lower serum ferritin. ", "begin": 914, "document": "22486183", "end": 1005, "section": "abstract"}, {"text": "A frequent polymorphism in BTBD9 was significantly associated with serum ferritin. This polymorphism has previously been associated with RLS, but not low iron stores in blood donors.", "begin": 1189, "document": "22486183", "end": 1371, "section": "abstract"}, {"text": "MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease", "begin": 0, "document": "21572129", "end": 90, "section": "title"}, {"text": " In the German sample, variants in MEIS1 and BTBD9 were associated with RLS in ESRD (P(nom)\u22640.004, ORs 1.52 and 1.55), whereas, in the Greek sample, there was a trend for association to MAP2K5/SKOR1 and BTBD9", "begin": 1088, "document": "21572129", "end": 1296, "section": "abstract"}, {"text": " This is the first demonstration of a genetic influence on RLS in ESRD patients with BTBD9 being significantly associated.", "begin": 1482, "document": "21572129", "end": 1604, "section": "abstract"}, {"text": "Four family members developed dopa-responsive dystonia, with onset in their late teens, and subsequently developed restless leg syndrome and migraine. CONCLUSIONS: This is the first report of an intragenic guanosine triphosphate cyclohydrolase-1 duplication in a dopa-responsive dystonia family.", "begin": 486, "document": "21287604", "end": 781, "section": "abstract"}, {"text": "To date, no gene mutation has been found, but five gene loci have been mapped in primary RLS to chromosomes 12q, 14q, 9p, 2q, and 20p (RLS1 through 5)", "begin": 185, "document": "18032746", "end": 335, "section": "abstract"}, {"text": "We demonstrate linkage to a locus on chromosome 9p that is probably distinct from RLS3. Our family with a rather homogeneous phenotype and very early disease onset represents a unique opportunity to further elucidate the genetic causes of the frequent restless leg syndrome.", "begin": 1340, "document": "18032746", "end": 1614, "section": "abstract"}, {"text": "A case of restless leg syndrome in a family with LRRK2 gene mutation.", "begin": 0, "document": "23227859", "end": 69, "section": "title"}, {"text": "The association between RLS and LRRK2 gene mutation may be casual, but it can hypothesized that RLS is a possible phenotypic presentation in PARK8.", "begin": 791, "document": "23227859", "end": 938, "section": "abstract"}]}, {"documents": ["23334070", "23334069", "22473769", "22134132", "21784350", "20505438", "20375655", "20360050", "20205639", "20189881", "20154508", "19923550", "22292124", "19585948", "19228370", "21987394", "21263194"], "answer": [["ponezumab"], ["solanezumab"], ["bapineuzumab"], ["Gantenerumab"]], "id": "530cefaaad0bf1360c000007", "snippets": [{"text": "Ponezumab is a humanized antiamyloid beta (A\u03b2) monoclonal antibody designed to treat Alzheimer disease (AD).", "begin": 11, "document": "23334070", "end": 119, "section": "abstract"}, {"text": "Ponezumab (PF-04360365) is a humanized anti-amyloid beta (A\u03b2) monoclonal antibody designed for treatment of Alzheimer disease (AD).", "begin": 11, "document": "23334069", "end": 142, "section": "abstract"}, {"text": "To our knowledge, this study is the first to show that passive A\u03b2 immunotherapy with bapineuzumab results in decreases in CSF T-tau and P-tau, which may indicate downstream effects on the degenerative process. ", "begin": 1570, "document": "22473769", "end": 1780, "section": "abstract"}, {"text": "The second set of baseline scans was from the EXPanding alzhEimer's Disease InvestigaTIONs (EXPEDITION) studies examining solanezumab, an anti-A\u03b2 monoclonal antibody (cohort 2, n = 2141). ", "begin": 793, "document": "21784350", "end": 981, "section": "abstract"}, {"text": "The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. ", "begin": 0, "document": "20505438", "end": 294, "section": "abstract"}, {"text": "LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.", "begin": 139, "document": "20375655", "end": 260, "section": "abstract"}, {"text": "The first passive immunotherapy trial with bapineuzumab, a humanized monoclonal antibody against the end terminus of Abeta, also encountered some dose dependent adverse events during the Phase II portion of the study, vasogenic edema in 12 cases, which were significantly over represented in ApoE4 carriers. ", "begin": 529, "document": "20205639", "end": 837, "section": "abstract"}, {"text": "We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer's disease.", "begin": 130, "document": "20189881", "end": 327, "section": "abstract"}, {"text": "The most developmentally advanced monoclonal antibody directly targeting Abeta is bapineuzumab, now being studied in a large Phase III clinical trial. ", "begin": 621, "document": "20154508", "end": 772, "section": "abstract"}, {"text": "Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.", "begin": 12, "document": "19923550", "end": 233, "section": "abstract"}, {"text": "To evaluate the effect of the anti-A\u03b2 monoclonal antibody bapineuzumab on cerebrospinal fluid (CSF) biomarkers reflecting A\u03b2 homeostasis, neuronal degeneration, and tau-related pathology in patients with Alzheimer disease.", "begin": 390, "document": "22473769", "end": 612, "section": "abstract"}, {"text": "Solanezumab is a humanized anti-amyloid \u03b2 monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD. ", "begin": 11, "document": "22134132", "end": 336, "section": "abstract"}, {"text": "When administered as a per-kilogram single dose of solanezumab, PK and pharmacodynamics (plasma total A\u03b21-40 concentration) in the Japanese patients with AD were comparable with those in the white patients with AD. In addition, solanezumab was generally well tolerated in both Japanese and white patients at all dose levels.", "begin": 1301, "document": "22134132", "end": 1625, "section": "abstract"}]}, {"documents": ["23512246", "19915381", "19778847", "19275513", "18309944", "18039954", "15869731", "15039804", "12447847", "9215839", "8468724", "22483155", "22538464"], "answer": [["deoxycoformycin"], ["pentostatin"], ["nelarabine"]], "id": "530cefaaad0bf1360c00000c", "snippets": [{"text": "Treatment with purine analogues and alemtuzumab has resulted in significantly higher response rates and improved survival. ", "begin": 259, "document": "19778847", "end": 382, "section": "abstract"}, {"text": " Treatment with purine analogs and the monoclonal antibody alemtuzumab has resulted in significantly higher response rates and increased survival.", "begin": 292, "document": "19275513", "end": 438, "section": "abstract"}, {"text": "Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabine was most promising. Determination of tumor cell ara-GTP levels may provide a predictive test for response to nelarabine.", "begin": 1671, "document": "18309944", "end": 1888, "section": "abstract"}, {"text": "T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy. With the use of the purine analogue pentostatin more than half of patients will have a major response and a minority will have a complete remission, usually lasting months.", "begin": 193, "document": "15869731", "end": 483, "section": "abstract"}, {"text": " T-cell prolymphocytic leukaemia (T-PLL) is a rare post-thymic T-cell malignancy with an aggressive clinical course. It has generally been resistant to alkylating chemotherapy, but some effect has been observed with the purine analog 2-deoxycoformicin with documented partial or complete response rates in up to 45% of patients.", "begin": 11, "document": "15039804", "end": 339, "section": "abstract"}, {"text": "Fifteen patients with T-PLL, most of whom had received the purine analog deoxycoformycin (DCF), were treated with CAMPATH-1H.", "begin": 293, "document": "9215839", "end": 418, "section": "abstract"}, {"text": "Pentostatin (2'-deoxycoformycin; DCF) is a purine analogue that has shown activity in treatment of chronic lymphoid malignancies.", "begin": 720, "document": "8468724", "end": 849, "section": "abstract"}, {"text": "Trials using DCF or other purine analogues alone or in combination with standard chemotherapeutic agents in front-line or salvage therapy are warranted to improve the prognosis of patients with prolymphocytic leukemia.", "begin": 2693, "document": "8468724", "end": 2911, "section": "abstract"}]}, {"documents": ["24156003", "21511940", "20624239", "19830065", "19646556", "19547821", "19037900", "18596536", "16943469", "11154546", "8457417", "2533403", "23969004", "23096483"], "answer": ["lumbosacral"], "id": "5313058de3eabad02100000e", "snippets": [{"text": "Bertolotti's syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae, is an important cause of low back pain in young patients. ", "begin": 12, "document": "24156003", "end": 155, "section": "abstract"}, {"text": " Common causes of back pain were the ipsilateral L5-S1 facet joint, neoarticulation, the SI joint, and disc degeneration. ", "begin": 728, "document": "24156003", "end": 850, "section": "abstract"}, {"text": "Patients with Bertolotti's syndrome have characteristic lumbosacral anomalies and often have severe sciatica. ", "begin": 0, "document": "21511940", "end": 110, "section": "abstract"}, {"text": "We suggest that the intractable sciatica in this syndrome could arise from impingement of the nerve root extraforaminally by compression caused by the enlarged transverse process.", "begin": 296, "document": "21511940", "end": 475, "section": "abstract"}, {"text": "Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral junction pseudarticulation (Bertolotti's syndrome): a case report.", "begin": 0, "document": "20624239", "end": 152, "section": "title"}, {"text": "She was found to have an elongated right L5 transverse process that articulated with the sacral ala (Bertolotti's syndrome).", "begin": 410, "document": "20624239", "end": 534, "section": "abstract"}, {"text": "Lumbosacral transitional vertebra causing Bertolotti's syndrome: a case report and review of the literature.", "begin": 0, "document": "19830065", "end": 108, "section": "title"}, {"text": "Lumbosacral transitional vertebra is an anatomical variation of the fifth lumbar vertebra in which an enlarged transverse process can form a joint or fusion with the sacrum or ilium. The association of that variant with low back pain and the change in the biomechanical properties of the lumbar spine is called Bertolotti's syndrome. ", "begin": 14, "document": "19830065", "end": 348, "section": "abstract"}, {"text": "Radiographic investigation revealed an anomalous enlargement of the left transverse process of the fifth lumbar vertebra forming a pseudarthrosis with the infrajacent ala of the sacrum. ", "begin": 517, "document": "19830065", "end": 703, "section": "abstract"}, {"text": "Transitional lumbosacral vertebrae and low back pain: diagnostic pitfalls and management of Bertolotti's syndrome.", "begin": 0, "document": "19547821", "end": 114, "section": "title"}, {"text": " Bertolotti's syndrome is a spine disorder characterized by the occurrence of a congenital lumbar transverse mega-apophysis in a transitional vertebral body that usually articulates with the sacrum or the iliac bone. ", "begin": 10, "document": "19547821", "end": 227, "section": "abstract"}, {"text": "It is characterized by an enlarged transverse process at the most caudal lumbar vertebra with a pseudoarticulation of the transverse process and the sacral ala. ", "begin": 327, "document": "18596536", "end": 488, "section": "abstract"}, {"text": "Bertolotti's syndrome is characterised by anomalous enlargement of the transverse process(es) of the most caudal lumbar vertebra which may articulate or fuse with the sacrum or ilium and cause isolated L4/5 disc disease. ", "begin": 0, "document": "16943469", "end": 221, "section": "abstract"}, {"text": "Case report of surgically treated mechanical low back pain from the facet joint contralateral to a unilateral anomalous lumbosacral articulation (Bertolotti's syndrome). ", "begin": 14, "document": "11154546", "end": 184, "section": "abstract"}, {"text": "Bertolotti's syndrome is mechanical low back pain associated with these transitional segments.", "begin": 530, "document": "11154546", "end": 624, "section": "abstract"}, {"text": "Repeated fluoroscopically guided injections implicated a symptomatic L6-S1 facet joint contralateral to an anomalous lumbosacral articulation. ", "begin": 944, "document": "11154546", "end": 1087, "section": "abstract"}, {"text": "We surgically treated 16 patients with Bertolotti's syndrome (chronic, persistent low back pain and radiographically diagnosed transitional lumbar vertebra).", "begin": 0, "document": "8457417", "end": 157, "section": "abstract"}, {"text": "Transitional vertebrae of the lumbar spine.", "begin": 33, "document": "2533403", "end": 76, "section": "title"}, {"text": "Bertolotti's syndrome refers to the association of back pain with lumbosacral transitional vertebrae. ", "begin": 0, "document": "2533403", "end": 102, "section": "abstract"}]}, {"documents": ["23392653", "15950200", "12051962", "11140949", "10704188", "9302275", "10593671", "7721491", "10654932", "10077519", "18595190", "12132284", "1917338", "9341873", "11140992", "1721555", "23400408"], "answer": ["autosomal recessive"], "id": "52eea4dcc8da89891000000c", "snippets": [{"text": "Homozygous or compound heterozygous mutations in KCNQ1 cause Jervell and Lange-Nielsen syndrome, a rare, autosomal-recessive form of long-QT syndrome characterized by deafness, marked QT prolongation, and a high risk of sudden death.", "begin": 12, "document": "23392653", "end": 245, "section": "abstract"}, {"text": "KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness", "begin": 301, "document": "15950200", "end": 514, "section": "abstract"}, {"text": "Jervell and Lange-Nielsen syndrome (JLNS) is characterized by sensorineural deafness, QT prolongation, abnormal T waves, ventricular tachyarrhythmias, and autosomal recessive inheritance.", "begin": 0, "document": "12051962", "end": 187, "section": "abstract"}, {"text": "Jervell and Lange-Nielsen syndrome (JLNS) is an autosomal recessive syndrome characterised by profound congenital sensorineural deafness and prolongation of the QT interval on the electrocardiogram, representing abnormal ventricular repolarisation.", "begin": 0, "document": "11140949", "end": 248, "section": "abstract"}, {"text": "Jervell and Lange-Nielsen syndrome (MIM 220400; JLNS), is a rare form of profound congenital deafness combined with syncopal attacks and sudden death due to prolonged QTc; it is an autosomal recessive trait. ", "begin": 0, "document": "10704188", "end": 208, "section": "abstract"}, {"text": "Different mutations in KVLQT1 cause the dominant Romano-Ward (RW) syndrome and the recessive Jervell and Lange-Nielsen (JLN) syndrome, which, in addition to cardiac abnormalities, includes congenital deafness. ", "begin": 402, "document": "9302275", "end": 612, "section": "abstract"}, {"text": "The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. ", "begin": 180, "document": "10593671", "end": 449, "section": "abstract"}]}, {"documents": ["23147248", "17947214"], "answer": ["via mutations in beta-MHC and alpha-TPM1"], "id": "530cf4e0c8a0b4a00c000002", "snippets": [{"text": "A novel alpha-tropomyosin mutation associates with dilated and non-compaction cardiomyopathy and diminishes actin binding", "begin": 0, "document": "23147248", "end": 121, "section": "title"}, {"text": "We show that a mutation in TPM1 is associated with DCM and a lethal, early onset form of NCCM, probably as a result of diminished actin binding caused by weakened charge-charge interactions.", "begin": 1337, "document": "23147248", "end": 1527, "section": "abstract"}, {"text": "We describe, in two separate autosomal-dominant NCCM families, the identification of mutations in the sarcomeric cardiac beta-myosin heavy chain gene (MYH7), known to be associated with hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), and dilated cardiomyopathy (DCM).", "begin": 644, "document": "17947214", "end": 931, "section": "abstract"}, {"text": "These results confirm the genetic heterogeneity of NCCM and suggest that the molecular classification of cardiomyopathies includes an MYH7-associated spectrum of NCCM with HCM, RCM, and DCM.", "begin": 943, "document": "17947214", "end": 1133, "section": "abstract"}]}, {"documents": ["23681420", "22846097", "21160605", "20962423", "20559995", "18384577", "20378375", "17853713", "17157688", "16352133", "12651044", "7788945", "8198037", "21234187", "22874472", "21716109", "19336382", "18325444", "17961794", "11886323", "6446987", "12793636", "10798028", "11043079", "19575162", "21858983", "9858396", "17322504", "1554567", "15929462", "6686529", "8667563", "1450882", "9636339"], "answer": ["hypertrophic cardiomyopathy"], "id": "530cf4e0c8a0b4a00c000006", "snippets": [{"text": "The most common cause of death was hypertrophic cardiomyopathy (30 %), followed by coronary artery anomalies (9 %), and myocarditis (9 %). ", "begin": 1077, "document": "23681420", "end": 1216, "section": "abstract"}, {"text": "The most common cause of this, hypertrophic cardiomyopathy (HCM), is a genetic disorder responsible for more than a third of cases and is manageable.", "begin": 170, "document": "22846097", "end": 319, "section": "abstract"}, {"text": "HCM is the most common cause of sudden death in young competitive athletes and preparticipation screening programs have to be implemented to avoid these tragic fatalities. ", "begin": 709, "document": "21160605", "end": 881, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young people, including trained athletes.", "begin": 0, "document": "20962423", "end": 133, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes). ", "begin": 0, "document": "20559995", "end": 141, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including trained athletes. ", "begin": 0, "document": "18384577", "end": 128, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes).", "begin": 0, "document": "20378375", "end": 134, "section": "abstract"}, {"text": "The most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy. ", "begin": 473, "document": "17853713", "end": 563, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in young athletes.", "begin": 0, "document": "17157688", "end": 164, "section": "abstract"}, {"text": "The most common cause of sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy (HCM). ", "begin": 0, "document": "16352133", "end": 179, "section": "abstract"}, {"text": "udden death in young competitive athletes is due to a variety of cardiovascular diseases (CVDs) and, most commonly, HCM. ", "begin": 140, "document": "12651044", "end": 261, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of death in the young, particularly in young competitive athletes.", "begin": 0, "document": "7788945", "end": 125, "section": "abstract"}, {"text": "Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication to continued participation in competitive sports. ", "begin": 0, "document": "8198037", "end": 217, "section": "abstract"}]}, {"documents": ["20301331", "15221641", "12048679", "10932008", "10881785", "9949234", "9115628", "7702086"], "answer": ["fibroblast growth factor receptor 3 (FGFR3)"], "id": "52b2e498f828ad283c000010", "snippets": [{"text": "She was subsequently diagnosed with hypochondroplasia at the age of 6 years when disproportional short stature, stocky habitus and macrocephaly were observed. These phenotypic findings were later confirmed by the presence of fibroblast growth factor receptor 3 (FGFR3) gene mutation N540K.", "begin": 418, "document": "21225389", "end": 707, "section": "abstract"}, {"text": "Achondroplasia can be diagnosed by characteristic clinical and radiographic findings in most affected individuals. In individuals who may be too young to diagnose with certainty or in individuals with atypical findings, molecular genetic testing can be used to detect a mutation in FGFR3.", "begin": 531, "document": "20301331", "end": 819, "section": "abstract"}, {"text": "Achondroplasia comes from the genetic point mutations in the fibroblastic growth factor receptor 3 gene (FGFR3), which enables abnormal cartilage growth-plate differentiation and insufficient bony development. The most common genetic mutations in this receptor are G to A at position 1138 (G1138A), which result in the substitution of glycine to arginine at codon 380.", "begin": 300, "document": "15221641", "end": 668, "section": "abstract"}, {"text": "To investigate the mutation at the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) nucleotide 1138 site for identifying the major pathologic mechanism of achondroplasia (ACH) and to evaluate the efficacy of denaturing gradient gel electrophoresis(DGGE) method for screening the point mutations. ", "begin": 23, "document": "12048679", "end": 338, "section": "abstract"}, {"text": "Nucleotide 1138 in transmembrane domain of FGFR3 gene is the hot point for mutation in ACH and hence its major pathologic cause. ", "begin": 1051, "document": "12048679", "end": 1180, "section": "abstract"}, {"text": "The nucleotide 1138 of FGFR3 gene is also the hotspot of mutation in Chinese patients with ACH. A simple and rapid molecular diagnostic method has been set up to differentiate ACH from other similar genetic dwarfism.", "begin": 834, "document": "10932008", "end": 1050, "section": "abstract"}, {"text": "The diagnosis of achondroplasia was based on the presence of clinical and radiographic findings and confirmed by the presence of a common FGFR3 gene mutation (Gly380Arg) detected by restriction enzyme analysis and sequencing of the polymerase chain reaction products.", "begin": 313, "document": "10881785", "end": 580, "section": "abstract"}, {"text": "All patients carried the same glycine-to-arginine mutation at codon 380(G380R) of the transmembrane domain of FGFR3. ", "begin": 290, "document": "9949234", "end": 407, "section": "abstract"}, {"text": "The results suggest that the G380R mutation of FGFR3 is also a frequent mutation causing achondroplasia in Chinese. Detecting FGFR 3 gene mutation with PCR-SSCP and restriction enzymes analysis is a convenient, rapid and reliable molecular diagnostic assay for prenatal and early diagnosis of achondroplasia.", "begin": 420, "document": "9949234", "end": 728, "section": "abstract"}, {"text": "To evaluate whether mutation in the exon 10 of the fibroblast growth factor receptor 3(FGFR3) gene in common in Chinese patients with achondroplasia.", "begin": 11, "document": "9949234", "end": 160, "section": "abstract"}, {"text": "Achondroplasia (ACH) is the most frequent form of short-limb dwarfism. Recently, the gene mutation responsible for ACH has been identified in the transmembrane domain of the fibroblast growth factor receptor 3 gene. The cause of ACH is a point mutation at nucleotide 1138 of the cDNA, resulting in the substitution of an arginine residue for a glycine. ", "begin": 0, "document": "9115628", "end": 353, "section": "abstract"}, {"text": "Recent studies mapped the achondroplasia gene on chromosome region 4p16.3 and identified a common mutation in the gene encoding the fibroblast growth factor receptor 3 (FGFR3). ", "begin": 243, "document": "7702086", "end": 420, "section": "abstract"}]}, {"documents": ["23390548", "22384042", "17553556", "17141847", "17113046", "16023708", "15275774", "11166288", "10884518", "7737328", "2760634"], "answer": ["L-Dopa"], "id": "52bf1f2d03868f1b06000015", "snippets": [{"text": "The present study utilizes in vivo amperometry to investigate the impact from unilateral 6-hydroxydopamine lesions and l-DOPA (4 mg/kg, including benserazide 15 mg/kg) -induced dyskinetic behavior on striatal basal extracellular glutamate concentration and potassium-evoked glutamate release in urethane-anesthetized rats. ", "begin": 327, "document": "23390548", "end": 650, "section": "abstract"}, {"text": "Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic treatment for PD.", "begin": 277, "document": "22384042", "end": 414, "section": "abstract"}, {"text": "In experiment 1, l-DOPA-primed rats were pre-treated with Vehicle (0.9% NaCl), various doses of the partial 5-HT(1A) agonist, buspirone (0.25, 1.0 or 2.5 mg/kg, ip) or buspirone (2.5 mg/kg, ip)+the 5-HT(1A) antagonist, WAY100635 (0.5 mg/kg, ip) 5 min prior to l-DOPA (12 mg/kg+15 mg/kg benserazide, ip). R", "begin": 475, "document": "17553556", "end": 780, "section": "abstract"}, {"text": "L-DOPA induced hyperalgesia occurred after conversion to dopamine because co-administration of benserazide, a DOPA decarboxylase inhibitor, completely abolished the L-DOPA-induced hyperalgesia. ", "begin": 446, "document": "17141847", "end": 640, "section": "abstract"}, {"text": "First, animals were treated with levodopa (50 mg/kg with benserazide 12.5 mg/kg, twice daily), intraperitoneally (i.p.) for 22 days. ", "begin": 439, "document": "17113046", "end": 572, "section": "abstract"}, {"text": "Chronic L-DOPA-treated rats received the D1 receptor antagonist SCH23390 (0.01, 0.1, and 1.0 mg/kg; i.p.), the D2 receptor antagonist Eticlopride (0.01, 0.1, and 1.0 mg/kg; i.p.), a mixture of both antagonists (0.01, 0.1, 1.0 mg/kg each; i.p.), or vehicle 30 min prior to L-DOPA (6 mg/kg; i.p.)+Benserazide (15 mg/kg; i.p.).", "begin": 213, "document": "16023708", "end": 537, "section": "abstract"}, {"text": "Nociceptive behaviors in mice after an intrathecal (i.t.) administration of substance P were evaluated. L-DOPA (i.t.) dose-dependently attenuated the substance P-induced nociceptive behaviors. Co-administration of benserazide (i.t.), a DOPA decarboxylase inhibitor, abolished the antinociceptive effect of L-DOPA.", "begin": 62, "document": "15275774", "end": 375, "section": "abstract"}, {"text": "They were injected subcutaneously (s.c.) with L-DOPA methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-DOPA/benserazide) alone or in combination with (-)-OSU6162 (1.0, 3.0, 6.0 or 10 mg/kg, s.c.)", "begin": 775, "document": "11166288", "end": 991, "section": "abstract"}, {"text": "They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.).", "begin": 582, "document": "10884518", "end": 806, "section": "abstract"}, {"text": "The administration of L-dopa (20 and 60 mg/kg p.o.) + benserazide (15 mg/kg p.o.) resulted in dose-dependent increase of dialysate levels of L-dopa and 3-O-methyl-DOPA. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. In another experiment, the administration of L-dopa + benserazide (30 + 15 mg/kg p.o.) resulted in increased extracellular levels of dopamine, DOPAC, HVA and 3-methoxytyramine.", "begin": 500, "document": "7737328", "end": 1035, "section": "abstract"}, {"text": "In healthy subjects and in patients with parkinsonism plasma ALAAD level fell after administration of L-dopa + benserazide, but returned to previous levels within 90 min.", "begin": 315, "document": "2760634", "end": 485, "section": "abstract"}, {"text": "In a cross-sectional study blood was obtained, 2 h after dosing, from 104 patients with idiopathic parkinsonism, divided into four groups: no L-dopa treatment (group 1), L-dopa alone (group 2), L-dopa + benserazide (Madopar) (group 3) and L-dopa + carbidopa (Sinemet) (group 4).", "begin": 486, "document": "2760634", "end": 764, "section": "abstract"}]}, {"documents": ["18799313", "18239272", "15975091", "14710188", "12925738", "11781102", "8055935"], "answer": [["pSer-Xaa-Xaa-Ser"], ["K/R-X-K/R-X-X-S/T"], ["SLS and acidic cluster motifs"], ["SerP/ThrP-Xaa-Xaa-Ser/Thr"]], "id": "52d832dd98d0239505000003", "snippets": [{"text": "Members of the protein kinase CK1 family usually phosphorylate residues of serine that are close to other phosphoserine in a consensus motif of pS-X-X-S,", "begin": 152, "document": "18799313", "end": 305, "section": "abstract"}, {"text": "a novel consensus phosphorylation motif (K/R-X-K/R-X-X-S/T) for CK1 ", "begin": 705, "document": "18239272", "end": 773, "section": "abstract"}, {"text": "CK1 acts as a 'phosphate-directed' kinase whose targeting is primed by a single phosphorylated side chain at position n-3 or n-4 relative to serine/threonine", "begin": 142, "document": "15975091", "end": 299, "section": "abstract"}, {"text": "The protein kinase CK1 phosphorylates serine residues that are located close to another phosphoserine in the consensus pSer-Xaa-Xaa-Ser.", "begin": 0, "document": "14710188", "end": 136, "section": "abstract"}, {"text": "The results demonstrate that SLS and acidic cluster motifs are crucial for CK1 recognition. ", "begin": 911, "document": "12925738", "end": 1003, "section": "abstract"}, {"text": "The common features include an SLS motif followed two to five residues downstream by a cluster of acidic residues.", "begin": 636, "document": "12925738", "end": 750, "section": "abstract"}, {"text": "These data provide the clear-cut demonstration that the consensus sequence with N-terminal prephosphorylated residue(s), SerP/ThrP-Xaa-Xaa-Ser/Thr", "begin": 1686, "document": "8055935", "end": 1832, "section": "abstract"}]}, {"documents": ["24316370", "23696099", "23534950", "23479361", "22639416", "24052930", "24152564", "24188096", "21403409", "24502194", "21929367", "9553792", "15906719", "3582603", "10403541"], "answer": ["Increased resistance to malaria, reduces the risk of coronary diseases, beneficial effect in terms of longevity"], "id": "53147b52e3eabad021000015", "snippets": [{"text": "A central position of the PPP for malaria parasites is supported by the fact that human G6PD deficiency protects to a certain degree from malaria infections.", "begin": 573, "document": "22639416", "end": 730, "section": "abstract"}, {"text": " The beneficial effect of thalassemia minor, sickle-cell trait, and glucose-6-phosphate dehydrogenase deficiency on survival of malaria infection may well be due to the shared feature of enhanced oxidative stress. This may inhibit parasite growth, enhance uptake of infected RBCs by spleen macrophages, and/or cause less cytoadherence of the infected cells to capillary endothelium.", "begin": 1126, "document": "24316370", "end": 1508, "section": "abstract"}, {"text": " In conclusion, genetic variants that confer resistance to malaria are associated with RBC traits in African-Americans.", "begin": 1604, "document": "23696099", "end": 1723, "section": "abstract"}, {"text": " G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.", "begin": 990, "document": "23534950", "end": 1240, "section": "abstract"}, {"text": "G6PD enzyme activity was directly related to susceptibility to malaria in the Brazilian Amazon, where P. vivax predominates. Severe G6PDd was associated with considerable higher risk of malaria-related transfusions.", "begin": 1632, "document": "23479361", "end": 1847, "section": "abstract"}, {"text": "and G6PD (Xq28)-were associated (P \u2264 1 \u00d7 10(-6)) with RBC traits in the discovery cohort", "begin": 857, "document": "23696099", "end": 945, "section": "abstract"}]}, {"documents": ["23818873", "21463569", "18515342", "16911001", "15556475", "15102446", "14711120", "14596799", "12220682", "12056890", "11278072", "11075932", "10645441", "9016640", "7748943", "8339930", "1549572", "1925023", "3282561", "6294066", "6253884", "667214", "656568"], "answer": [["HU"], ["H-NS"], ["IHF"]], "id": "52ef7754c8da898910000014", "snippets": [{"text": "We show that Histone-like Nucleoid Structuring (H-NS) protein can facilitate correct recognition of a promoter by RNA polymerase in AT-rich gene regulatory regions", "begin": 233, "document": "23818873", "end": 396, "section": "abstract"}, {"text": "One feature is a histone-like protein that is associated with the DNA, condensing it into subunits similar to those in eukaryotic chromatin", "begin": 138, "document": "656568", "end": 277, "section": "abstract"}, {"text": "Recently the histone-like proteins were found in some primitive eucaryotes and procaryotes", "begin": 466, "document": "667214", "end": 556, "section": "abstract"}, {"text": "The relationship between HMGs (1 + 2) and the \"primitive\" histone-like DNA-packaging proteins from prokaryotes and mitochondria is discussed", "begin": 359, "document": "6253884", "end": 499, "section": "abstract"}, {"text": "The amino acid composition of the protein resembled those of the other prokaryotic histone-like proteins and also to eukaryotic histones H2A and H2B", "begin": 445, "document": "6294066", "end": 593, "section": "abstract"}, {"text": "In prokaryotes and in the pool of vegetative phage DNA the most abundant histone-like protein HU is not associated with the bulk DNA, but localised in the border region with ribosomes where transcription and translation occur", "begin": 492, "document": "3282561", "end": 717, "section": "abstract"}, {"text": "Like the histones, HU is able to condense DNA in vitro and to introduce negative super-coiling in covalently closed circular, relaxed DNA molecules in the presence of topoisomerase I", "begin": 73, "document": "1925023", "end": 255, "section": "abstract"}, {"text": "HU is well conserved in all prokaryotes but surprisingly, it is also homologous to another E. coli DNA-binding protein, IHF", "begin": 257, "document": "1925023", "end": 380, "section": "abstract"}, {"text": "Here we describe the identification of two developmental stage-specific genes, one of which is predicted to encode a 26-kDa lysine- and alanine-rich protein that appears to be homologous to several eukaryotic histone H1 proteins", "begin": 149, "document": "1549572", "end": 377, "section": "abstract"}, {"text": "No sequence homology was observed between this protein and other bacterial \"histone-like\" chromosomal proteins, but homology does exist with two other recently described prokaryotic proteins", "begin": 472, "document": "1549572", "end": 662, "section": "abstract"}, {"text": "In this study we show that these proteins can substitute for the prokaryotic DNA-bending protein HU in promoting the assembly of the Hin invertasome, an intermediate structure in Hin-mediated site-specific DNA inversion", "begin": 139, "document": "8339930", "end": 358, "section": "abstract"}, {"text": "We have characterized the role of HU in assembling the invertasome, an intermediate nucleoprotein complex involved in Hin-mediated site-specific recombination", "begin": 101, "document": "7748943", "end": 259, "section": "abstract"}, {"text": "Using ligase-mediated circularization of short DNA fragments we also show that HU, the high mobility group (HMG) 1 and 2 proteins from mammals, and a protein from yeast can bend DNA extremely efficiently", "begin": 849, "document": "7748943", "end": 1052, "section": "abstract"}, {"text": "The repression of transcription of two overlapping promoters of the gal operon in Escherichia coli requires Gal repressor (GalR) and the histone-like protein HU", "begin": 352, "document": "9016640", "end": 512, "section": "abstract"}, {"text": "We report GalR mediated DNA looping in which HU plays an obligatory role by helping GalR tetramerization", "begin": 806, "document": "9016640", "end": 910, "section": "abstract"}, {"text": "The protein has unique dual domains with homology to both bacterial histone-like proteins (HU) and eukaryotic histone H1", "begin": 1758, "document": "10645441", "end": 1878, "section": "abstract"}, {"text": " Four out of seven multi-copy suppressors were identified to encode HU, (3 for HUalpha and 1 for HUB) a histone-like DNA binding protein", "begin": 957, "document": "11075932", "end": 1093, "section": "abstract"}, {"text": "oles of Escherichia coli histone-like protein HU in DNA replication", "begin": 1, "document": "11278072", "end": 68, "section": "title"}, {"text": "HU protein is a small, basic, heat-stable DNA-binding protein that is well-conserved in prokaryotes and is associated with the bacterial nucleoid", "begin": 4, "document": "11278072", "end": 149, "section": "abstract"}, {"text": "role of surface-exposed lysines in wrapping DNA about the bacterial histone-like protein HU", "begin": 4, "document": "12056890", "end": 95, "section": "title"}, {"text": "basic proteins, including the ubiquitous HU proteins, serve histone-like functions in prokaryotes", "begin": 8, "document": "12056890", "end": 105, "section": "abstract"}, {"text": "modification of E. coli histone-like protein H-NS and bovine histones by short-chain poly-(R)-3-hydroxybutyrate (cPHB)", "begin": 18, "document": "12220682", "end": 136, "section": "title"}, {"text": "Here we examine Escherichia coli protein H-NS and calf thymus histones, H1, H2A, H2B, H3, and H4, for the presence of cPHB", "begin": 362, "document": "12220682", "end": 484, "section": "abstract"}, {"text": "The process requires negatively supercoiled DNA and the presence of the histone-like protein HU", "begin": 488, "document": "14596799", "end": 583, "section": "abstract"}, {"text": "Characterization of the major DNA-binding proteins of nucleoids revealed essential differences in the two lineages of photosynthetic eukaryotes, namely nucleoids of green plants contain sulfite reductase as a major DNA-binding protein that represses the genomic activity, whereas the prokaryotic DNA-binding protein HU is abundant in plastid nucleoids of the rhodophyte lineage", "begin": 282, "document": "14711120", "end": 659, "section": "abstract"}, {"text": "In prokaryotes, IHF and HU are key architectural proteins present at high concentrations", "begin": 170, "document": "15102446", "end": 258, "section": "abstract"}, {"text": "The deficit of TFs in some genomes might be compensated by the presence of proteins organizing and compacting DNA, such as histone-like proteins", "begin": 224, "document": "15556475", "end": 368, "section": "abstract"}, {"text": "okaryotic histone-like proteins (Hlps) are abundant proteins found in bacterial and plastid nucleoids", "begin": 2, "document": "16911001", "end": 103, "section": "abstract"}, {"text": "NA protection by histone-like protein HU from the hyperthermophilic eubacterium Thermotoga maritim", "begin": 1, "document": "18515342", "end": 99, "section": "title"}, {"text": "n mesophilic prokaryotes, the DNA-binding protein HU participates in nucleoid organization as well as in regulation of DNA-dependent processes", "begin": 1, "document": "18515342", "end": 143, "section": "abstract"}, {"text": "We show here that HU from the hyperthermophilic eubacterium Thermotoga maritima HU bends DNA and constrains negative DNA supercoils in the presence of topoisomerase I", "begin": 217, "document": "18515342", "end": 383, "section": "abstract"}, {"text": " We suggest that T. maritima HU serves an architectural function when associating with a single 35 bp site, but generates a very stable and compact aggregate at higher protein concentrations that organizes and protects the genomic DNA", "begin": 1085, "document": "18515342", "end": 1319, "section": "abstract"}, {"text": "ittle is known about the structure and function of most nucleoid-associated proteins (NAPs) in bacteria", "begin": 1, "document": "21463569", "end": 104, "section": "abstract"}, {"text": "n this study, we investigate the distribution of HU in Caulobacter crescentus using a combination of super-resolution fluorescence imaging and spatial point statistics", "begin": 381, "document": "21463569", "end": 548, "section": "abstract"}]}, {"documents": ["23421080", "23116348", "21786507", "20584846", "19911411", "19408854", "18467377", "18156713", "18067809", "8248469"], "answer": ["1:5000"], "id": "52f350042059c6d71c000010", "snippets": [{"text": "dwards syndrome (trisomy 18) occurs in 1: 8000 live births and is closely related to the mother's age", "begin": 1, "document": "23421080", "end": 102, "section": "abstract"}, {"text": "Mean incidence was 390.06 (449.08 in boys and 327.93 in girls) per 10 000 live births", "begin": 1189, "document": "23116348", "end": 1274, "section": "abstract"}, {"text": "The incidence of Edwards syndrome is 1:5000 of live-born", "begin": 340, "document": "21786507", "end": 396, "section": "abstract"}, {"text": "The OR for Patau syndrome was 1.10 (95% CI 0.83 to 1.45); for Edwards syndrome, 1.15 (0.96 to 1.38); for Klinefelter syndrome, 1.35 (1.02 to 1.79); and for XYY syndrome, 1.99 (0.75 to 5.26)", "begin": 1121, "document": "20584846", "end": 1310, "section": "abstract"}, {"text": "The live birth prevalence in the absence of prenatal screening and selective termination in England and Wales from 1997 to 2004 was 1.4 (95% CI: 1.2-1.6) per 10 000 births for trisomy 13 and 2.3 (95% CI: 2.1-2.5) for trisomy 18", "begin": 710, "document": "19911411", "end": 937, "section": "abstract"}, {"text": "During the period under the study, following total numbers, mean relative incidences (per 10,000 live births, in brackets) and mean prenatal diagnostics efficiency (in %) were found in following chromosomal syndromes: Down syndrome 2,244 (16.58) and 63.37%, Edwards syndrome 521 (3.85) and 79.93%, Patau syndrome 201 (1.49) and 68.87%, Turner syndrome 380 (2.81) and 79.89%, 47,XXX syndrome 61 (0.45) and 59.74%, Klinefelter syndrome 163 (1.20) and 73.65% and 47,XYY syndrome 22 (0.16) and 54.76%", "begin": 1501, "document": "19408854", "end": 1997, "section": "abstract"}, {"text": "There was evidence of space-time clustering for Down syndrome (fixed threshold of close in space: P = 0.01, NN threshold: P = 0.02), but little or no clustering for Patau (P = 0.57, P = 0.19) or Edwards (P = 0.37, P = 0.06) syndromes. ", "begin": 1043, "document": "18467377", "end": 1278, "section": "abstract"}, {"text": "Of the 49,806 pregnant women between 15 and 23 weeks' gestational age who received prenatal serum screening with a cut-off value (a risk of 1:270 for Down and 1:100 for Edwards syndrome), 2,116 (4.2%) and 196 (0.4%) were screen positive for Down syndrome and for Edwards syndrome, respectively.", "begin": 542, "document": "18156713", "end": 836, "section": "abstract"}, {"text": "26,803 of the 27,313 women (98%) were screened. The average was 25.1, and 1.7% of them were over 35. Serum screening showed that 1,244 (5%) were Down syndrome positive and 105 (0.4%) were Edwards syndrome positive.", "begin": 1051, "document": "18067809", "end": 1265, "section": "abstract"}, {"text": "235 pregnancies of women delivered in units in the North West Thames region over a two-year period (1990-91) whose babies or fetuses were diagnosed as having Down, Edwards or Patau syndrome. RESULTS: 33% of Down syndrome, 68% of Edwards syndrome and 52% of Patau syndrome were diagnosed prenatally (before 28 weeks) in the region without the use of serum screening. ", "begin": 362, "document": "8248469", "end": 728, "section": "abstract"}]}, {"documents": ["23147248", "23800289", "22859017", "21789513", "20083571", "17947214", "18159245", "17956225", "23314057"], "answer": [["alpha-tropomyosin", "TPM1"], ["\u03b2-myosin heavy chain", "MYH7"], ["troponin T", "TNNT2"], ["Desmoplakin", "DSP"], ["mindbomb homolog 1", "MIB1"]], "id": "52ea605098d0239505000028", "snippets": [{"text": "A novel alpha-tropomyosin mutation associates with dilated and non-compaction cardiomyopathy", "begin": 0, "document": "23147248", "end": 92, "section": "title"}, {"text": "We show that a mutation in TPM1 is associated with DCM and a lethal, early onset form of NCCM", "begin": 1325, "document": "23147248", "end": 1418, "section": "abstract"}, {"text": "Mutation in MYH7B causes a classical LVNC phenotype", "begin": 1054, "document": "23800289", "end": 1105, "section": "abstract"}, {"text": "We report on two prenatal ultrasound diagnoses of left ventricular non-compaction cardiomyopathy (LVNC) associated with mutation of the cardiac \u03b2-myosin heavy chain gene (MYH7)", "begin": 0, "document": "22859017", "end": 176, "section": "abstract"}, {"text": "This novel homozygous truncating mutation in the isoform-1 specific region of the DSP C-terminus caused Carvajal syndrome comprising severe early-onset heart failure with features of non-compaction cardiomyopathy", "begin": 760, "document": "21789513", "end": 972, "section": "abstract"}, {"text": "Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2) mutation", "begin": 0, "document": "20083571", "end": 105, "section": "title"}, {"text": "we describe a family with LVNC due to a novel missense mutation, pE96K, in the cardiac troponin T gene", "begin": 289, "document": "20083571", "end": 391, "section": "abstract"}, {"text": "We describe, in two separate autosomal-dominant NCCM families, the identification of mutations in the sarcomeric cardiac beta-myosin heavy chain gene (MYH7)", "begin": 644, "document": "17947214", "end": 800, "section": "abstract"}, {"text": "the molecular classification of cardiomyopathies includes an MYH7-associated spectrum of NCCM", "begin": 1016, "document": "17947214", "end": 1109, "section": "abstract"}]}, {"documents": ["23392090", "21468521", "18334584", "17574009", "22986150", "19541799", "21825978", "17684393", "24170966"], "answer": ["MCT8", "monocarboxylate transporter 8"], "id": "52ece29f98d023950500002c", "snippets": [{"text": "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.", "begin": 489, "document": "23392090", "end": 732, "section": "abstract"}, {"text": "Novel mutation in MCT8 gene in a Brazilian boy with thyroid hormone resistance and severe neurologic abnormalities.", "begin": 0, "document": "21468521", "end": 115, "section": "title"}, {"text": "When thyroid hormone production was reduced by PTU, high doses of LT(4) (3.7 microg/kg.d) were needed to normalize serum TSH, confirming that mutation of MCT8 is a cause of resistance to thyroid hormone", "begin": 1440, "document": "18334584", "end": 1642, "section": "abstract"}, {"text": "One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8", "begin": 585, "document": "17574009", "end": 727, "section": "abstract"}]}, {"documents": ["22589293", "20382953", "17399643", "16571646", "12148092", "10190827", "16859779", "19570891", "10406668", "17119796", "20609799", "15831539", "15269659", "21317470", "8080508", "12032359", "12536108", "17272325", "19445372", "12909315", "20306271", "23644778", "18554214", "17395133", "15176430", "17582433", "16769944", "16877549", "12689820"], "answer": [["abnormal QT-U complex"], ["ventricular arrhythmia"], ["periodic paralysis"], ["facial dysmorphisms"], ["skeletal dysmorphisms"]], "id": "52eeddfcc8da898910000010", "snippets": [{"text": "Mutations of KCNJ2, the gene encoding the human inward rectifier potassium channel Kir2.1, cause Andersen-Tawil syndrome (ATS), a disease exhibiting ventricular arrhythmia, periodic paralysis, and dysmorphic features.", "begin": 12, "document": "22589293", "end": 229, "section": "abstract"}, {"text": "Andersen cardiodysrhythmic periodic paralysis or Andersen-Tawil syndrome includes the distinct clinical features of periodic paralysis, cardiac arrhythmia, and facial and skeletal dysmorphisms and exhibits autosomal dominant inheritance. ", "begin": 0, "document": "20382953", "end": 238, "section": "abstract"}, {"text": "The patient was a 19-year-old woman with familial periodic paralysis, abnormal QT-U complex, and nonsustained ventricular tachycardia. ", "begin": 109, "document": "17399643", "end": 244, "section": "abstract"}, {"text": "Andersen-Tawil syndrome (ATS) is a rare inherited disorder, characterised by periodic paralysis, cardiac dysarrhythmias, and dysmorphic features, and is caused by mutations in the gene KCNJ2, which encodes the inward rectifier potassium channel, Kir2.1.", "begin": 12, "document": "16571646", "end": 265, "section": "abstract"}, {"text": "Evaluation of candidate loci culminated in the identification of a heterozygous missense mutation (R67W) in KCNJ2, the gene encoding the inward-rectifying potassium current, Kir2.1, in 41 members of a kindred in which ventricular arrhythmias (13 of 16 female members [81%]) and periodic paralysis (10 of 25 male members [40%]) segregated as autosomal dominant traits with sex-specific variable expressivity. Some mutation carriers exhibited dysmorphic features, including hypertelorism, small mandible, syndactyly, clinodactyly, cleft palate, and scoliosis, which, together with cardiodysrhythmic periodic paralysis, have been termed \"Andersen syndrome.\" ", "begin": 0, "document": "12148092", "end": 655, "section": "abstract"}]}, {"documents": ["21435018", "18369530", "19574095", "17436206", "9177584", "8164540", "8450727", "2253729", "16389882", "17214401", "21618162"], "answer": ["longer than the general population"], "id": "52efc016c8da89891000001a", "snippets": [{"text": "In all 13 intervals, cumulative observed survival was smaller than cumulative expected survival, resulting in cumulative RSRs being <1. ", "begin": 655, "document": "21435018", "end": 791, "section": "abstract"}, {"text": "This impaired survival experience of the internationals translates into a loss of median residual lifetime of 1.9 years [95% confidence interval: 0.6, 3.2] years at the entry time into the cohort.", "begin": 890, "document": "21435018", "end": 1086, "section": "abstract"}, {"text": "All the obtained results proved that high level physical activity in youth positively influenced men's mortality, what was observed for the former athletes even after 40 years since the end of their professional carrier.", "begin": 1130, "document": "18369530", "end": 1350, "section": "abstract"}, {"text": "It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. ", "begin": 645, "document": "19574095", "end": 844, "section": "abstract"}, {"text": "On the other hand, there are inconsistent results among studies of power (anaerobic) athletes.", "begin": 945, "document": "19574095", "end": 1039, "section": "abstract"}, {"text": "When elite athletes engaging in various sports are analysed together, their mortality is lower than that of the general population.", "begin": 1040, "document": "19574095", "end": 1171, "section": "abstract"}, {"text": "Moderate exercise and intense physical training are associated with increased life expectancy (LE).", "begin": 0, "document": "17436206", "end": 99, "section": "abstract"}, {"text": "We found that former aerobic sports athletes (endurance and mixed sports) in particular have high total and active life expectancy and low risk for ischemic heart disease and diabetes in later years. ", "begin": 1324, "document": "9177584", "end": 1524, "section": "abstract"}, {"text": "Higher leisure aerobic activity and less frequent smoking after athletic years might explain higher life expectancy of Finnish athletes.", "begin": 1245, "document": "8164540", "end": 1381, "section": "abstract"}, {"text": "Increased life expectancy of world class male athletes.", "begin": 0, "document": "8450727", "end": 55, "section": "title"}, {"text": "The mean LE adjusted for occupational group, marital status, and the age at entry to the cohort (and its 95% confidence limits) was in endurance sports (long distance running and cross-country skiing) 75.6 (73.6, 77.5) yr; in team games (soccer, ice hockey, basketball, as well as jumpers and short-distance runners from track and field (73.9 (72.7, 75.1) yr; in power sports (boxing, wrestling, weight lifting, and throwers from field athletics) 71.5 (70.4, 72.2) yr; and in the reference group 69.9 (69.0, 70.9) yr. The increased mean life expectancies were mainly explained by decreased cardiovascular mortality (endurance sports mortality odds ratio OR = 0.49 (95% CL 0.26, 0.93), team sports OR = 0.61 (0.41, 0.92) compared with referents). ", "begin": 913, "document": "8450727", "end": 1659, "section": "abstract"}, {"text": "Thirty-four deaths were observed among males (vs 46.6 expected) with a O/E ratio of 0.73, while 3 deaths were observed among women (vs 6.2 expected) with a O/E ratio of 0.48. Neither of these differences was significant, but the O/E ratio for the group as a whole was quite significant (p = 0.0296). ", "begin": 422, "document": "2253729", "end": 722, "section": "abstract"}]}, {"documents": ["23329579", "17224473"], "answer": [["rs7140952 polymorphism of DIO2"], ["Ala92 type 2 deiodinase allele"]], "id": "52ecf2dd98d023950500002e", "snippets": [{"text": "However, rs7140952 polymorphism is associated with components of metabolic syndrome including blood pressure and central obesity.", "begin": 1358, "document": "23329579", "end": 1487, "section": "abstract"}, {"text": "Among euthyroid adults, the common Ala92 allele of the type 2 iodothyronine deiodinase increases risk for the development of hypertension. ", "begin": 1106, "document": "17224473", "end": 1245, "section": "abstract"}, {"text": "Ala92 type 2 deiodinase allele increases risk for the development of hypertension.", "begin": 0, "document": "17224473", "end": 82, "section": "title"}, {"text": "This study investigates the clinical and biochemical response to L-T4 replacement therapy in hypothyroid patients in correlation with genetic variation in Deiodinase type || (DIO2) gene. ", "begin": 93, "document": "23329579", "end": 280, "section": "abstract"}]}, {"documents": ["22801312", "22051823", "21246178", "17947214", "18700964", "24367719", "22574099", "19664240", "17174235", "15618076", "16170691", "20333604", "20386670", "17047599", "20860157", "19417170", "21193437", "12668828"], "answer": [["excessively thickened endocardial layer with deep intertrabecular recesses"], ["ratio of non-compacted to compacted myocardium >2"], ["heart failure"], ["syncope"], ["ventricular arrhythmias"], ["stroke"], ["Pulmonary hypertension"], ["complete left branch conductive block"], ["sick sinus syndrome"], ["paroxysmal supraventricular tachycardia"]], "id": "52f4f1d62059c6d71c00001c", "snippets": [{"text": "Non compaction cardiomyopathy is a rare disorder caused by the arrest of myocardial compaction during embryogenesis, leading to a non compacted endocardial layer with marked hypertrabeculation and deep recesses.", "begin": 12, "document": "22051823", "end": 223, "section": "abstract"}, {"text": "The form of presentation was heart failure in 53% of subjects, syncope in 20%o, ventricular arrhythmias in 13%o and stroke in 7%>. Left ventricular end-diastolic diameter was 66 \u00b1 11 mm and estimated ejection fraction was 27 \u00b1 10%>. Apical and/or mid-ventricular segments of the left ventricle were involved in all the cases. Pulmonary hypertension was present in 40%o.", "begin": 530, "document": "22051823", "end": 899, "section": "abstract"}, {"text": "Prominent hypertrabecularisation (ratio of non-compacted to compacted myocardium >2) in the apical and mid left ventricular segments is typical for non-compaction cardiomyopathy. ", "begin": 1639, "document": "21246178", "end": 1818, "section": "abstract"}, {"text": "Isolated ventricular non-compaction or non-compaction cardiomyopathy (NCCM) is characterized by an excessively thickened endocardial layer with deep intertrabecular recesses, reminiscent of the myocardium during early embryogenesis.", "begin": 171, "document": "17947214", "end": 403, "section": "abstract"}, {"text": "Sudden cardiac death (including 1 occurred while following-up) was reported in 7 family members (17.5%, 7/40). LVNC was diagnosed in 10 out of the 33 family members (30.3%) and heart enlargement was evidenced in 3, heart failure in 2, complete left branch conductive block in 3, serious sick sinus syndrome (SSS) treated with permanent pacemaker implantation in 1 and paroxysmal supraventricular tachycardia treated with radiofrequency ablation procedure in 1 out of these 10 LVNC patients. ", "begin": 533, "document": "22801312", "end": 1024, "section": "abstract"}]}, {"documents": ["22816548", "14646469", "11879111", "10894918", "10498299", "9703576", "6496438", "17957272", "23107651", "22869311", "22027166", "21699851", "20086611", "18691236", "19749607", "17229310", "15744544", "15331287", "11555799", "11334832", "11208236", "11048776", "10392228", "10338239", "9930916"], "answer": ["blunt thoracic impact causing sudden death"], "id": "53035d7c2059c6d71c000085", "snippets": [{"text": "Commotio cordis is a rare type of blunt cardiac injury in which low impact chest trauma causes sudden cardiac arrest, usually occurs from being struck by a projectile during sports.", "begin": 0, "document": "22816548", "end": 181, "section": "abstract"}, {"text": "Commotio cordis due to blunt trauma to the precordium is a rare cause of death in young athletes, occurring less frequently than all of the other athletics-related deaths. Commotio cordis is a term used to describe cases of blunt thoracic impact causing fatality without structural damage of the heart and internal organs. ", "begin": 0, "document": "14646469", "end": 323, "section": "abstract"}, {"text": "Although blunt, nonpenetrating chest blows causing sudden cardiac death (commotio cordis) are often associated with competitive sports, dangers implicit in such blows can extend into many other life activities. ", "begin": 12, "document": "11879111", "end": 223, "section": "abstract"}, {"text": "Sudden death following blunt chest trauma is a frightening occurrence known as 'commotio cordis' or 'concussion of the heart'.", "begin": 0, "document": "10894918", "end": 126, "section": "abstract"}, {"text": "Commotio cordis is a term used to describe cases of blunt thoracic impact causing fatality without gross structural damage of the heart and internal organs. ", "begin": 12, "document": "10498299", "end": 169, "section": "abstract"}, {"text": "Cardiac concussion, previously known as commotio cordis, occurs in structurally normal hearts without gross or microscopic injury to the myocardium, cardiac valves, or coronary arteries, as opposed to other sports-related deaths known to occur more frequently in structural or congenital heart disease. ", "begin": 0, "document": "9703576", "end": 303, "section": "abstract"}, {"text": "Nonpenetrating cardiac injuries due to direct precordial blunt impacts are a commonly encountered phenomenon in medicolegal offices.", "begin": 0, "document": "6496438", "end": 132, "section": "abstract"}, {"text": "less commonly occurring manifestation of nonpenetrating injury is a concussion of the heart (commotio cordis), often with dramatic physiological consequences but no morphologic cardiac injury. ", "begin": 279, "document": "6496438", "end": 472, "section": "abstract"}]}, {"documents": ["22362900", "20682064", "19734497", "17330410", "17143117", "19587604"], "answer": ["0.5  to 3  per 100,000 athletes per year"], "id": "53036faab24d855b11000001", "snippets": [{"text": "Sudden cardiac death is the leading cause of mortality among young athletes with an incidence of 1-2 per 100,000 athletes per annum.", "begin": 0, "document": "22362900", "end": 132, "section": "abstract"}, {"text": "The incidence of SCD is expected at one case for each 200,000 young athletes per year.", "begin": 392, "document": "20682064", "end": 478, "section": "abstract"}, {"text": "The incidence of sudden cardiac death (SCD) among young athletes is estimated to be 1-3 per 100,000 person years, and may be underestimated. ", "begin": 0, "document": "19734497", "end": 141, "section": "abstract"}, {"text": "Sudden cardiac death in a young athlete is a tragic and marking event, even though the media attention it gets is more important than its incidence (1-2/100000 per year). ", "begin": 0, "document": "17330410", "end": 171, "section": "abstract"}, {"text": "The sudden death of athletes under 35 years engaged in competitive sports is a well-known occurrence; the incidence is higher in athletes (approximately 2/100,000 per year) than in non-athletes (2.5 : 1), and the cause is cardiovascular in over 90%.", "begin": 267, "document": "17143117", "end": 516, "section": "abstract"}]}, {"documents": ["22639778", "21608438", "16922811", "12460666", "10199151", "6805141"], "answer": ["Diabetes mellitus"], "id": "52b2e1d8f828ad283c00000c", "snippets": [{"text": "Metformin and glibenclamide are now increasingly viewed as a rational alternative to insulin therapy--a treatment both preferred by the women and a less expensive one, during pregnancy and breastfeeding.", "begin": 1096, "document": "22639778", "end": 1299, "section": "abstract"}, {"text": "The effect of TFG on blood glucose were studied and the levels of lipid peroxidation [MDA (Malondialdehyde)] and antioxidant enzymes [SOD (Superoxide dismutase), GPx (Reduced Glutathione peroxidase)] were estimated and compared with standard drugs glibenclamide and insulin.", "begin": 574, "document": "21608438", "end": 848, "section": "abstract"}, {"text": "Treatment with TFG, insulin and glibenclamide resulted in significantly reduced blood glucose in LM (8.71%) and HM (3.87%) in comparison with normal controls.", "begin": 858, "document": "21608438", "end": 1016, "section": "abstract"}, {"text": "Potency of TFG in restoring several parameters to normal values is comparable to glibenclamide, though not as efficient as insulin, an indication of its antihyperglycemic and antioxidant effect.", "begin": 1418, "document": "21608438", "end": 1612, "section": "abstract"}, {"text": "However, dietary supplementation with PB (6 g/kg extract for 4 weeks administered orally using an intragastric tube) ameliorated the alloxan-induced diabetes in a manner comparable with that of the reference antidiabetic drug glibenclamide", "begin": 1217, "document": "16922811", "end": 1456, "section": "abstract"}, {"text": "Moreover, the potassium-specific effects of both diazoxide and nicorandil on oxidative phosphorylation in skeletal muscle mitochondria were completely abolished by the antidiabetic sulfonylurea derivative glibenclamide, a well-known inhibitor of ATP-regulated potassium channels (K(ATP) channels).", "begin": 650, "document": "12460666", "end": 947, "section": "abstract"}, {"text": "In mild NIDDM, gliclazide, tolbutamide or acetohexamide is used, and in more severe NIDDM glibenclamide is used.", "begin": 610, "document": "10199151", "end": 722, "section": "abstract"}, {"text": "An improvement of the glucose tolerance could be observed up to 3 years, whereas after a 5-year glibenclamide therapy no certain influence on the glucose tolerance and insulin secretion could be proved.", "begin": 648, "document": "6805141", "end": 850, "section": "abstract"}, {"text": "In general the improvement of the glucose tolerance was not associated with an increased secretion of insulin, so that an extrapancreatic effect of glibenclamide (improvement of the peripheral insulin sensitivity?) seems to be possible.", "begin": 851, "document": "6805141", "end": 1087, "section": "abstract"}, {"text": "From clinical and practical point of view the findings would support the opinion that normal weight persons with IGT, particularly in already decreased insulin secretion, have an indication for a glibenclamide therapy.", "begin": 1323, "document": "6805141", "end": 1541, "section": "abstract"}]}, {"documents": ["22014696", "7914051"], "answer": ["schizophrenia"], "id": "52b2e409f828ad283c00000e", "snippets": [{"text": "To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009.", "begin": 11, "document": "22014696", "end": 135, "section": "abstract"}, {"text": "Antipsychotic recommendations were estimated using CDTI data in which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. There were notable increases in recommendations for chlorpromazine, loxapine, zuclopenthixol, and flupentixol.", "begin": 575, "document": "22014696", "end": 972, "section": "abstract"}, {"text": "Loxapine has been prescribed in France since 1980. Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia, although some data suggest bipolar action.", "begin": 902, "document": "7914051", "end": 1212, "section": "abstract"}]}, {"documents": ["22551571", "22525183", "21795275", "19248726", "15307599", "10969520", "10864616", "10487912", "23573591", "7739631"], "answer": ["autosomal dominant"], "id": "52bf19c503868f1b06000001", "snippets": [{"text": "autosomal dominant FSHD1", "begin": 214, "document": "23143600", "end": 238, "section": "abstract"}, {"text": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement.", "begin": 0, "document": "22551571", "end": 206, "section": "abstract"}, {"text": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. ", "begin": 0, "document": "22525183", "end": 210, "section": "abstract"}, {"text": "Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing.", "begin": 525, "document": "21795275", "end": 659, "section": "abstract"}, {"text": " In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance.", "begin": 1205, "document": "19248726", "end": 1353, "section": "abstract"}, {"text": "Facioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance.", "begin": 0, "document": "15307599", "end": 111, "section": "abstract"}, {"text": "Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature.", "begin": 0, "document": "10969520", "end": 174, "section": "abstract"}, {"text": "Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses", "begin": 0, "document": "10864616", "end": 373, "section": "abstract"}, {"text": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant muscular disorder associated with a short (<35 kb) EcoRI/BlnI fragment resulting from deletion of an integral number of units of a 3.3-kb repeat located at 4q35.", "begin": 0, "document": "10487912", "end": 223, "section": "abstract"}, {"text": "In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. ", "begin": 212, "document": "23573591", "end": 369, "section": "abstract"}, {"text": "In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families.", "begin": 212, "document": "7739631", "end": 368, "section": "abstract"}]}, {"documents": ["16339652", "18844071", "21532337", "20959602", "17108004", "15920471", "15542823", "12032775"], "answer": [["Gfi-1b"], ["MeCP1"], ["ACF/WCRF complex"], ["FOG-1"], ["TAL-1"], ["Ldb1"], ["LMO2-C"], ["PIAS3"], ["RUNX1"], ["Ski"], ["EKLF"], ["SP1"], ["CBP/p300"], ["PU.1"]], "id": "52f89fd32059c6d71c000051", "snippets": [{"text": "Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. We also provide evidence that distinct GATA-1 complexes are associated with specific GATA-1 functions in erythroid differentiation, for example, GATA-1/Gfi-1b with the suppression of cell proliferation and GATA-1/FOG-1/MeCP1 with the repression of other hematopoietic transcription programs. We next applied the biotinylation tag to Ldb-1, a known partner of GATA-1, and characterized a number of novel interaction partners that are essential in erythroid development, in particular, Eto-2, Lmo4, and CdK9. ", "begin": 752, "document": "16339652", "end": 1519, "section": "abstract"}, {"text": "Endogenous GATA1 and LDB1 proteins were confirmed to bind to LMO2-C by MBP pull down analysis. ", "begin": 509, "document": "18844071", "end": 604, "section": "abstract"}, {"text": "LMO2-C can bind endogenous GATA1 and LDB1 protein in K562 cells and down regulates the expression of GPA.", "begin": 948, "document": "18844071", "end": 1053, "section": "abstract"}, {"text": "We identify novel transcription factor binding partners for PIAS3 including ETS, EGR1, NR1I2, and GATA1.", "begin": 483, "document": "21532337", "end": 587, "section": "abstract"}, {"text": "At other differentiation stages, additional combinatorial interactions occurred between RUNX1 and its coregulators, GATA1 and ETS. ", "begin": 1170, "document": "20959602", "end": 1301, "section": "abstract"}, {"text": "Ldb1, a ubiquitously expressed LIM domain binding protein, is essential in a number of tissues during development. It interacts with Gata1, Tal1, E2A and Lmo2 to form a transcription factor complex regulating late erythroid genes. ", "begin": 0, "document": "17108004", "end": 231, "section": "abstract"}, {"text": "Using a biotinylation tagging/proteomics approach in erythroid cells, we describe distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes. Importantly, we show that FOG-1 mediates GATA-1 interactions with the MeCP1 complex, thus providing an explanation for the overlapping functions of these two factors in erythropoiesis.", "begin": 365, "document": "15920471", "end": 850, "section": "abstract"}, {"text": "Here we show that Ski interacts with GATA1, a transcription factor essential in erythropoiesis. Using a Ski mutant deficient in GATA1 binding, we show that this Ski-GATA1 interaction is critical for Ski's ability to repress GATA1-mediated transcription and block erythroid differentiation. ", "begin": 578, "document": "15542823", "end": 868, "section": "abstract"}, {"text": "The zinc finger transcription factor GATA-1, a central mediator of erythroid gene expression, interacts with multiple proteins including FOG-1, EKLF, SP1, CBP/p300 and PU.1. ", "begin": 258, "document": "12032775", "end": 432, "section": "abstract"}, {"text": "tudies involving point mutants of GATA-1 have shown that a direct physical interaction between GATA-1 and FOG-1 is essential for normal human erythroid and megakaryocyte maturation in vivo. In addition, evidence has emerged that physical interaction between GATA-1 and the myeloid/lymphoid specific factor PU.1, an oncogene implicated in murine erythroleukemia, acts to functionally cross-antagonize one another. ", "begin": 742, "document": "12032775", "end": 1155, "section": "abstract"}]}, {"documents": ["19407629", "16740155", "9475589", "9014285", "8434615"], "answer": [["Type I"], ["Type II"], ["Type III"]], "id": "52bf1d6003868f1b0600000e", "snippets": [{"text": "Of 802 patients treated for craniosynostosis, 28 were identified with Pfeiffer syndrome: 17 were classified as type I (61 percent), seven were classified as type II (25 percent), and four were classified as type III (14 percent). ", "begin": 461, "document": "19407629", "end": 691, "section": "abstract"}, {"text": "Pfeiffer syndrome is divided into three clinical subtypes. Type 1 \"classic\" Pfeiffer syndrome involves individuals with mild manifestations including brachycephaly, midface hypoplasia and finger and toe abnormalities; it is associated with normal intelligence and generally good outcome. Type 2 consists of cloverleaf skull, extreme proptosis, finger and toe abnormalities, elbow ankylosis or synostosis, developmental delay and neurological complications. Type 3 is similar to type 2 but without a cloverleaf skull. ", "begin": 358, "document": "16740155", "end": 875, "section": "abstract"}, {"text": "Recently, based on clinical findings, the disorder has been divided into three subtypes: type 1, characterized by mild expression; type 2, in which clover leaf skull deformity and multiple congenital anomalies are present at birth; and type 3, which is similar to type 2, but lacks the presence of the clover leaf skull at birth. ", "begin": 212, "document": "9014285", "end": 542, "section": "abstract"}, {"text": "It is a clinically variable disorder and has been divided into three subtypes [Cohen, 1993: Am J Med Genet 45:300-307]. Type 1 represents the less severe cases, while types 2 and 3 are the more severe cases. These latter types tend to have a higher risk for neurodevelopmental problems and a reduced life expectancy.", "begin": 204, "document": "9475589", "end": 520, "section": "abstract"}, {"text": "Classic Pfeiffer syndrome is designated type I. Type 2 consists of cloverleaf skull with Pfeiffer hands and feet together with ankylosis of the elbows. Such patients do poorly with an early death. All reported instances to date have been sporadic. Type 3 is similar to type 2 but without cloverleaf skull. Ocular proptosis is severe in degree and the anterior cranial base is markedly short. These patients also do poorly and tend to have an early death. To date all cases have occurred sporadically. Although these 3 clinical subtypes do not have status as separate entities, their diagnostic and prognostic implications are important. Type 1 is commonly associated with normal intelligence, generally good outcome, and can be found dominantly inherited in some families. Types 2 and 3 generally have severe neurological compromise, poor prognosis, early death, and sporadic occurrence. ", "begin": 379, "document": "8434615", "end": 1267, "section": "abstract"}]}, {"documents": ["22859017", "22619057", "21789513", "21285074", "20083571", "19028670", "17956225", "17947214", "17101628", "14662268", "18159245", "21604106", "23800289", "23074372", "20542340", "19467449", "19438153", "20386670", "18395448", "21551322", "21894393", "24015429"], "answer": [["MYH7"], ["c.349G>A (p.D117N) in the ZASP gene"], ["pE96K mutation"], ["mutation in the isoform-1 specific region of the DSP C-terminus"]], "id": "52f637972059c6d71c000025", "snippets": [{"text": "The heterozygous mutation c.349G>A (p.D117N) in the ZASP gene could be found. This mutation had been previously associated with an adult-onset, isolated, dilated left ventricular non-compaction cardiomyopathy (OMIM*605906.0007), which was not present in our patients.", "begin": 584, "document": "22619057", "end": 851, "section": "abstract"}, {"text": "This novel homozygous truncating mutation in the isoform-1 specific region of the DSP C-terminus caused Carvajal syndrome comprising severe early-onset heart failure with features of non-compaction cardiomyopathy, woolly hair and an acantholytic form of palmoplantar keratoderma in our patient. ", "begin": 760, "document": "21789513", "end": 1055, "section": "abstract"}, {"text": "Familial co-segregation and the cardiomyopathy phenotype of mut cTNT mice strongly support a causal relationship of the pE96K mutation and disease in our index patient.", "begin": 1068, "document": "20083571", "end": 1236, "section": "abstract"}, {"text": "Conclusion These results confirm the genetic heterogeneity of NCCM and suggest that the molecular classification of cardiomyopathies includes an MYH7-associated spectrum of NCCM with HCM, RCM, and DCM.", "begin": 932, "document": "17947214", "end": 1133, "section": "abstract"}, {"text": "Cypher/ZASP is a newly identified gene encoding a protein that is a component of the Z-line in both skeletal and cardiac muscle.", "begin": 690, "document": "14662268", "end": 818, "section": "abstract"}]}, {"documents": ["23176795", "22292446", "22275759", "23808738", "24072084", "22878697", "23619228", "23820981", "22435392", "22412882", "21276223", "19236237", "21270237", "18925326", "17437648", "22247785", "23144896", "24090942", "23735317", "23702383", "17482151", "21440024", "9374813", "22983924"], "answer": [["Enistein"], ["ACE inhibitors"], [""]], "id": "52e7b7cb98d023950500001c", "snippets": [{"text": "enistein treatment could help reduce insulin resistance through the amelioration of OVX-induced metabolic dysfunction, and the GSEA approach may be useful in proposing putative targets related to insulin resistance.", "begin": 1481, "document": "23176795", "end": 1696, "section": "abstract"}, {"text": "he positive effects of ACE inhibitor drugs, particularly on hypertriglyceridemia and insulin resistance, might bring them forth as first-line drugs in the treatment of obese and hypertensive children. ", "begin": 1274, "document": "24072084", "end": 1475, "section": "abstract"}]}, {"documents": ["23159330", "20457704", "19506736", "18368626", "15562827", "15388940", "12766776", "12766775", "12711473", "12556239", "12172555"], "answer": ["Tuberous Sclerosis is caused by hyperactivation of the mTOR signalling pathway.", ""], "id": "52f11b922059c6d71c000004", "snippets": [{"text": "Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder caused by mutation in either Tsc1 or Tsc2 genes that leads to the hyper activation of the mTOR pathway, a key signalling pathway for synaptic plasticity. ", "begin": 0, "document": "23159330", "end": 221, "section": "abstract"}, {"text": "Tuberous sclerosis, caused by germline mutations in the TSC1 or TSC2 genes, is associated with aberrant upregulation of the mammalian target of rapamycin (mTOR) signalling pathway, resulting in growth of tumours, including renal angiomyolipomas (AMLs).", "begin": 0, "document": "20457704", "end": 252, "section": "abstract"}, {"text": "Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb.", "begin": 202, "document": "19506736", "end": 581, "section": "abstract"}, {"text": "TSC is an autosomal dominant disorder caused by mutation in either of two genes: TSC1, encoding hamartin, and TSC2, encoding tuberin. Both proteins form a complex inhibiting mTOR signalling pathway and thus regulate cell size and proliferation.", "begin": 297, "document": "18368626", "end": 541, "section": "abstract"}, {"text": "Recent findings from this laboratory and others suggests that the tumour suppressor complex made of two proteins TSC1/hamartin and TSC2/tuberin, acts as a negative regulator of mTOR/S6K1 signalling. Mutations in either TSC1 or TSC2 are genetically linked to tuberous sclerosis complex (TSC) syndrome, which can lead to severe pathological consequences, including mental retardation, epilepsy and autism, as well as cardiac, pulmonary and renal failure.", "begin": 606, "document": "15562827", "end": 1058, "section": "abstract"}, {"text": "Here we review recent findings demonstrating that the TSC1/TSC2 inhibitory complex normally acts on Rheb to mediate mTOR/S6K1-signalling.", "begin": 1774, "document": "15562827", "end": 1911, "section": "abstract"}, {"text": "Ras homologue enriched in brain (Rheb) represents a unique group of small GTPases and shares moderate sequence identity with the Ras/Rap subfamily. It acts downstream of nutrient signalling as the direct target of the tuberous sclerosis complex (TSC) and upstream of mTOR/S6K1/4EBP in the insulin-signalling pathway.", "begin": 0, "document": "15388940", "end": 316, "section": "abstract"}, {"text": "Recent studies suggest that the tuberous sclerosis complex Tsc1-Tsc2 may couple insulin signalling to Tor activity", "begin": 186, "document": "12766776", "end": 300, "section": "abstract"}, {"text": "Our genetic and biochemical analyses suggest that Rheb functions downstream of the tumour suppressors Tsc1 (tuberous sclerosis 1)-Tsc2 in the TOR (target of rapamycin) signalling pathway to control growth", "begin": 452, "document": "12766775", "end": 656, "section": "abstract"}, {"text": "Our results indicate activation of a mammalian target of rapamycin metabolic pathway in tuberous sclerosis lesions, which contributes to their growth.", "begin": 506, "document": "12711473", "end": 656, "section": "abstract"}, {"text": "Tuberous sclerosis (TSC) is an autosomal dominant hamartoma syndrome whose causative genes (TSC1 and TSC2) were identified 5 and 9 years ago respectively.", "begin": 0, "document": "12556239", "end": 154, "section": "abstract"}, {"text": "Recent studies in Drosophila have pinpointed a critical function for the DrosophilaTSC1/TSC2 homologues in the regulation of cell size. Epistasis experiments and a variety of biochemical studies that followed have indicated a critical function for these proteins in the highly conserved PI-3-kinase-Akt-mTOR signalling pathway.", "begin": 312, "document": "12556239", "end": 639, "section": "abstract"}, {"text": "Here, we show that tuberous sclerosis 1 (Tsc1) and Tsc2, tumour suppressors that are responsible for the tuberous sclerosis syndrome, antagonize this amino acid-TOR signalling pathway. We show that Tsc1 and Tsc2 can physically associate with TOR and function upstream of TOR genetically. In Drosophila melanogaster and mammalian cells, loss of Tsc1 and Tsc2 results in a TOR-dependent increase of S6K activity.", "begin": 166, "document": "12172555", "end": 576, "section": "abstract"}]}, {"documents": ["22723857", "20157369", "17178205", "17146684", "15841484", "7874122"], "answer": [["myotonic dystrophy type 2"], ["Friedreich ataxia"], ["spinocerebellar ataxia type 10"], ["autosomal dominant optic atrophy"], ["Menkes disease"], ["hyper-IgM with immunodeficiency syndrome (HIGM)"], ["anterior pituitary aplasia"], ["HNPCC"], ["FAP"]], "id": "52f129d92059c6d71c000009", "snippets": [{"text": "The unstable CCTG repeat responsible for myotonic dystrophy type 2 originates from an AluSx element insertion into an early primate genome", "begin": 0, "document": "22723857", "end": 138, "section": "title"}, {"text": "Alu elements are known to be the source of microsatellite repeats responsible for two other repeat expansion disorders: Friedreich ataxia and spinocerebellar ataxia type 10.", "begin": 1254, "document": "22723857", "end": 1427, "section": "abstract"}, {"text": "Alu-element insertion in an OPA1 intron sequence associated with autosomal dominant optic atrophy", "begin": 0, "document": "20157369", "end": 97, "section": "title"}, {"text": "We identified an Alu-element insertion located in intron 7 of OPA1 causing an in-frame deletion of exon 8 in 18 family members.", "begin": 764, "document": "20157369", "end": 891, "section": "abstract"}, {"text": "Autosomal dominant optic atrophy (ADOA) is the most common form of hereditary optic neuropathy caused by mutations in the optic atrophy 1 (OPA1) gene.", "begin": 9, "document": "20157369", "end": 159, "section": "abstract"}, {"text": "However, this is the first report of a pathogenic OPA1 gene mutation resulting from an Alu insertion.", "begin": 1105, "document": "20157369", "end": 1206, "section": "abstract"}, {"text": "The first reported case of Menkes disease caused by an Alu insertion mutation", "begin": 0, "document": "17178205", "end": 77, "section": "title"}, {"text": "We present the first reported case of Menkes disease caused by an Alu element insertion mutation that interfered with splicing regulatory elements.", "begin": 0, "document": "17178205", "end": 147, "section": "abstract"}, {"text": "HIGM syndrome caused by insertion of an AluYb8 element in exon 1 of the CD40LG gene", "begin": 0, "document": "17146684", "end": 83, "section": "title"}, {"text": "A new mutation of the CD40LG gene that encodes the CD40 ligand molecule was characterized in a young patient harboring a hyper-IgM with immunodeficiency syndrome. Inactivation of CD40LG gene resulted from the insertion of an AluYb8 element in exon 1 responsible for a total deficiency of CD40 ligand expression by T lymphocytes.", "begin": 0, "document": "17146684", "end": 328, "section": "abstract"}, {"text": "Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary", "begin": 0, "document": "15841484", "end": 87, "section": "title"}, {"text": "One patient, who also has retinal coloboma, carries a HESX1 defect in the homozygous state: an Alu insertion in exon 3, a sequence that encodes the major part of the homeodomain.", "begin": 697, "document": "15841484", "end": 875, "section": "abstract"}, {"text": "Anterior pituitary aplasia is a new example of a human disease caused by a germline retrotransposition event involving an Alu sequence.", "begin": 1199, "document": "15841484", "end": 1334, "section": "abstract"}, {"text": "Myotonic dystrophy (DM) is associated with abnormal expansions of the CTG repeats in the 3' untranslated region of its gene. Previous studies in individuals of European origin demonstrated strong linkage disequilibrium between different CTG repeat length alleles and an Alu element insertion/deletion polymorphism in intron 8 of the DM gene", "begin": 0, "document": "7874122", "end": 340, "section": "abstract"}]}, {"documents": ["23580068", "22392042", "21761402", "20805372"], "answer": ["Positive"], "id": "52f21b722059c6d71c00000b", "snippets": [{"text": "Breast cancer is the most frequent tumor in Li-Fraumeni syndrome (LFS), a rare inherited cancer syndrome associated with germline mutations in the TP53 gene. Recent data show that breast cancer in germline TP53 mutation carriers is commonly HER2+ (63-83 %).", "begin": 0, "document": "23580068", "end": 257, "section": "abstract"}, {"text": "Breast cancers in TP53 mutation carriers recently have more often been reported to be hormone receptor and HER-2 positive by immunohistochemistry and FISH in small series.", "begin": 232, "document": "22392042", "end": 403, "section": "abstract"}, {"text": "Most DCIS and invasive ductal carcinomas in LFS are hormone receptor positive and/or HER-2 positive.", "begin": 1682, "document": "22392042", "end": 1782, "section": "abstract"}, {"text": "Early onset HER2-positive breast cancer is associated with germline TP53 mutations.", "begin": 0, "document": "21761402", "end": 83, "section": "title"}, {"text": "Germline TP53 mutations predispose to early onset breast cancer in women and are associated with Li-Fraumeni syndrome.", "begin": 12, "document": "21761402", "end": 130, "section": "abstract"}, {"text": "Patients who tested positive for germlineTP53 mutations (n = 30) were compared with controls (n = 79). Human epidermal growth factor receptor 2 (HER2) amplification and/or overexpression was found in 67% of the tumors from the cases, compared with 25% for the controls (P = .0001).", "begin": 614, "document": "21761402", "end": 895, "section": "abstract"}, {"text": "This study suggests an association between germline TP53 mutations and early onset HER2-positive breast cancer.", "begin": 1445, "document": "21761402", "end": 1556, "section": "abstract"}, {"text": "A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.", "begin": 0, "document": "20805372", "end": 83, "section": "title"}, {"text": "The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages.", "begin": 12, "document": "20805372", "end": 141, "section": "abstract"}, {"text": "Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%);", "begin": 790, "document": "20805372", "end": 1035, "section": "abstract"}, {"text": "breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.", "begin": 1126, "document": "20805372", "end": 1252, "section": "abstract"}]}, {"documents": ["22357256"], "answer": ["BRCA1 dysfunction"], "id": "52f21e8f2059c6d71c00000c", "snippets": [{"text": "We have previously reported an array comparative genomic hybridization profile that identifies triple-negative breast cancers (TNBC), with BRCA1 dysfunction", "begin": 12, "document": "22357256", "end": 168, "section": "abstract"}, {"text": "BRCA1-like status was assessed in 101 patients with early-stage TNBC receiving adjuvant cyclophosphamide-based chemotherapy.", "begin": 470, "document": "22357256", "end": 594, "section": "abstract"}, {"text": "Sixty-six tumors (65%) had a BRCA1-like profile.", "begin": 701, "document": "22357256", "end": 749, "section": "abstract"}]}, {"documents": ["21249368", "19594452", "18988631", "18556259", "12719540"], "answer": [["Agrobacterium-mediated delivery"], ["direct delivery methods"], ["methods using plant artificial chromosomes"], ["site-directed plasmid mutagenesis"], ["combined use of Red/ET recombination and unique restriction site elimination"], ["Bacterial artificial chromosomes (BACs)"], ["direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli"], ["transformation-competent artificial chromosome (TAC)-based acceptor vector, by exploiting the CreloxP recombination system and homing endonucleases"]], "id": "52fa73e82059c6d71c000059", "snippets": [{"text": "For efficient genetic transformation, Agrobacterium-mediated as well as direct delivery methods have been used successfully. However, these methods suffer from many disadvantages especially in terms of transfer of large genes, gene complexes and gene silencing. To overcome these problems, recently, some efforts have been made to develop genetic transformation systems based on engineered plant chromosomes called minichromosomes or plant artificial chromosomes. ", "begin": 285, "document": "21249368", "end": 749, "section": "abstract"}, {"text": "Existing methods for site-directed plasmid mutagenesis are restrained by the small spectrum of modifications that can be introduced by mutagenic primers and the amplicon size limitations of in vitro DNA synthesis. As demonstrated here, the combined use of Red/ET recombination and unique restriction site elimination enables extensive manipulation regardless of plasmid size and DNA sequence elements.", "begin": 0, "document": "19594452", "end": 401, "section": "abstract"}, {"text": "Bacterial artificial chromosomes (BACs) derived from genomes of large DNA viruses are powerful tools for functional delineation of viral genes.", "begin": 0, "document": "18988631", "end": 143, "section": "abstract"}, {"text": "Here, we describe a novel method for cloning the genomes of large DNA viruses as BACs, which entails direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli. Determination of insertion sites and adjacent viral sequences identify the BAC clones for genetic manipulation and functional characterization.", "begin": 433, "document": "18988631", "end": 790, "section": "abstract"}, {"text": "Here, we describe a vector system for efficient multigene assembly and transformation. The system consists of a transformation-competent artificial chromosome (TAC)-based acceptor vector together with two donor vectors. By exploiting the CreloxP recombination system and homing endonucleases, multiple rounds of gene assembly cycling were carried out with alternate use of the donor vectors, and multiple genes were sequentially delivered into the TAC vector.", "begin": 219, "document": "12719540", "end": 678, "section": "abstract"}]}, {"documents": ["21798057", "18627056", "18086025", "14749005", "9613204", "9629378", "8957518", "8630505", "1608955"], "answer": [["15q11-13 deletions of paternal origin"], ["maternal chromosome 15 uniparental disomy"], ["rare imprinting mutations"], ["monoallelic expression of the paternal alleles"]], "id": "5306158358348c0f52000001", "snippets": [{"text": "Prader-Willi syndrome is a complex genetic disease caused by lack of expression of paternally inherited genes on chromosome 15q11-q13.", "begin": 14, "document": "21798057", "end": 148, "section": "abstract"}, {"text": "Prader-Willi syndrome (PWS) is caused by the disturbed expression of genes from the imprinted region of 15q11-q13, but the specific contributions of individual genes remain unknown.", "begin": 0, "document": "18627056", "end": 181, "section": "abstract"}, {"text": "Prader-Willi syndrome (PWS) is a rare disorder caused by genetic defects in certain regions of chromosome 15q11-13.", "begin": 12, "document": "18086025", "end": 127, "section": "abstract"}, {"text": "Prader-Willi syndrome (PWS) is an example of a human genetic disorder that involves imprinting genes on the proximal long arm of chromosome 15 and SNRPN gene as a candidate gene for this syndrome.", "begin": 11, "document": "14749005", "end": 207, "section": "abstract"}, {"text": "Genomic imprinting plays an important role in the molecular pathogenesis of PWS that caused by paternal microdeletions of 15q11-q13 or maternal UPD of chromosome 15. The basic defect seemed to be an absence of function of PWS genes that are normally expressed only from the paternal chromosome 15.", "begin": 1331, "document": "14749005", "end": 1628, "section": "abstract"}, {"text": "Abnormalities in imprinted inheritance occur in several genetic diseases and cancer, and are exemplified by the diverse genetic defects involving chromosome 15q11-q13 in Prader-Willi (PWS) and Angelman (AS) syndromes.", "begin": 161, "document": "9613204", "end": 378, "section": "abstract"}, {"text": "The predominant genetic defects in PW are 15q11-13 deletions of paternal origin and maternal chromosome 15 uniparental disomy.", "begin": 167, "document": "9629378", "end": 293, "section": "abstract"}, {"text": "In both disorders, these mutations are associated with parent-of-origin specific methylation at several 15q11-13 loci.", "begin": 435, "document": "9629378", "end": 553, "section": "abstract"}, {"text": "Prader-Willi syndrome (PWS) is caused by absence of a paternal contribution of the chromosome region 15q11-q13, resulting from paternal deletions, maternal uniparental disomy, or rare imprinting mutations.", "begin": 0, "document": "8957518", "end": 205, "section": "abstract"}, {"text": "Because methylation analysis can detect all three major classes of genetic defects associated with PWS (deletion, UPD, or imprinting mutations), methylation analysis with either PW71 or SNRPN is an efficient primary screening test to rule out a diagnosis of PWS.", "begin": 1284, "document": "8957518", "end": 1546, "section": "abstract"}, {"text": "The predominant genetic defects in Prader-Willi syndrome (PWS) are 15q11-q13 deletions of paternal origin and maternal chromosome 15 uniparental disomy (UPD).", "begin": 0, "document": "8630505", "end": 158, "section": "abstract"}, {"text": "In both disorders, these mutations are associated with parent-of-origin specific methylation at several 15q11-q13 loci. The critical PWS region has been narrowed to a approximately 320-kb region between D15S63 and D15S174, encoding several imprinted transcripts, including PAR5, IPW, PAR1 (refs 7,8) and SNRPN, which has so far been considered a strong candidate for the PWS gene.", "begin": 301, "document": "8630505", "end": 681, "section": "abstract"}, {"text": "The genetic defects in Prader-Willi syndrome (PWS) and Angelman syndrome (AS) map to 15q11-13.", "begin": 0, "document": "1608955", "end": 94, "section": "abstract"}]}, {"documents": ["22551571"], "answer": ["autosomal dominant"], "id": "52e8e93498d023950500001e", "snippets": [{"text": "autosomal dominant mode of inheritance", "begin": 94, "document": "22551571", "end": 132, "section": "abstract"}]}, {"documents": ["19407629", "16740155", "15305355", "11807866", "11556600", "9475589", "9014285", "8434615"], "answer": [["Type I (1)"], ["Type II (2)"], ["Type III (3)"]], "id": "52e8e9d298d0239505000022", "snippets": [{"text": "type I ", "begin": 572, "document": "19407629", "end": 579, "section": "abstract"}, {"text": "type II", "begin": 618, "document": "19407629", "end": 625, "section": "abstract"}, {"text": "type III", "begin": 668, "document": "19407629", "end": 676, "section": "abstract"}, {"text": "Pfeiffer syndrome is divided into three clinical subtypes", "begin": 358, "document": "16740155", "end": 415, "section": "abstract"}, {"text": "Type 1 \"classic\" Pfeiffer syndrome involves individuals with mild manifestations including brachycephaly, midface hypoplasia and finger and toe abnormalities; it is associated with normal intelligence and generally good outcome. Type 2 consists of cloverleaf skull, extreme proptosis, finger and toe abnormalities, elbow ankylosis or synostosis, developmental delay and neurological complications. Type 3 is similar to type 2 but without a cloverleaf skull. ", "begin": 417, "document": "16740155", "end": 875, "section": "abstract"}, {"text": "three subtypes", "begin": 179, "document": "15305355", "end": 193, "section": "abstract"}, {"text": "Three clinical subtypes have been classified", "begin": 180, "document": "11556600", "end": 224, "section": "abstract"}, {"text": "divided into three subtypes", "begin": 254, "document": "9475589", "end": 281, "section": "abstract"}, {"text": "Type 1 represents the less severe cases, while types 2 and 3 are the more severe cases.", "begin": 324, "document": "9475589", "end": 411, "section": "abstract"}, {"text": "the disorder has been divided into three subtypes: type 1, characterized by mild expression; type 2, in which clover leaf skull deformity and multiple congenital anomalies are present at birth; and type 3, which is similar to type 2, but lacks the presence of the clover leaf skull at birth. ", "begin": 250, "document": "9014285", "end": 542, "section": "abstract"}, {"text": "Classic Pfeiffer syndrome is designated type I. Type 2 consists of cloverleaf skull with Pfeiffer hands and feet together with ankylosis of the elbows. Such patients do poorly with an early death. All reported instances to date have been sporadic. Type 3 is similar to type 2 but without cloverleaf skull. ", "begin": 379, "document": "8434615", "end": 685, "section": "abstract"}]}, {"documents": ["24315484", "24293564", "24211371", "24124122", "24096295", "23994547", "23621888", "23536326", "23516405", "23270976", "23141534", "23123587", "22958973", "22802640", "22726567", "22677272", "22560338", "22492990", "22249109", "22016815", "21908517", "21878566", "21484200", "21182206", "21093492", "21079609", "20699105"], "answer": [["maternal immune activation (MIA) mouse model of gestational poly(IC) exposure", "C58/J", "Grin1", "Shank3-deficient mice", "C57BL/6J", "SYNGAP1", "Tsc2f/-", "MALTT", "(Dp(11)17/+)", "NR1(neo-/-)", "TS2-neo mouse", "Tbx1 heterozygous (HT) mice"], ["BTBR T+tf/J (BTBR)", "VPA600", "ProSAP1/Shank2"]], "id": "52f5417b2059c6d71c000024", "snippets": [{"text": "maternal immune activation (MIA) mouse model that is known to display features of ASD.", "begin": 275, "document": "24315484", "end": 361, "section": "abstract"}, {"text": "BTBR T+tf/J (BTBR), a model of ASD with cognitive deficits,", "begin": 540, "document": "24293564", "end": 599, "section": "abstract"}, {"text": "C58/J mouse strain, a model of ASD core symptoms. ", "begin": 524, "document": "24211371", "end": 574, "section": "abstract"}, {"text": "the C58/J mouse model of autism", "begin": 67, "document": "24211371", "end": 98, "section": "title"}, {"text": "Both C58/J and Grin1 knockdown mice, another model of ASD-like behavior, ", "begin": 865, "document": "24211371", "end": 938, "section": "abstract"}, {"text": "Mice injected subcutaneously with 600\u2009mg/kg valproic acid (VPA600) at gestational day 12.5 show reduced social interaction in adulthood (at 8 weeks of age), and they have been proposed as a mouse model of autism.", "begin": 286, "document": "24124122", "end": 498, "section": "abstract"}, {"text": "BTBR T+tf/J (BTBR), a commonly-used model presenting all core autism-related phenotypes ", "begin": 764, "document": "24096295", "end": 852, "section": "abstract"}, {"text": "The Autism ProSAP1/Shank2 mouse model ", "begin": 0, "document": "23994547", "end": 38, "section": "title"}, {"text": "Shank3-deficient mice", "begin": 843, "document": "23621888", "end": 864, "section": "abstract"}, {"text": "a panel of Shank mutant mouse models", "begin": 593, "document": "23536326", "end": 629, "section": "abstract"}, {"text": "maternal immune activation (MIA) mouse model of gestational poly(IC) exposure ", "begin": 604, "document": "23516405", "end": 682, "section": "abstract"}, {"text": "poly(IC) mouse model of autism spectrum disorders", "begin": 1424, "document": "23516405", "end": 1473, "section": "abstract"}, {"text": "BTBR T+ tf/J strain, a mouse model of autism.", "begin": 79, "document": "23270976", "end": 124, "section": "title"}, {"text": "The inbred BTBR T+ tf/J (BTBR) strain, a putative mouse model of autism,", "begin": 121, "document": "23270976", "end": 193, "section": "abstract"}, {"text": "C57BL/6J strain", "begin": 321, "document": "23270976", "end": 336, "section": "abstract"}, {"text": "SYNGAP1 mouse model of ID/ASD", "begin": 256, "document": "23141534", "end": 285, "section": "abstract"}, {"text": "Tsc2f/-;Cre mice demonstrated increased repetitive behavior as assessed with marble burying activity", "begin": 687, "document": "23123587", "end": 787, "section": "abstract"}, {"text": "BTBR T+ tf/J mouse model for autism spectrum disorders", "begin": 4, "document": "22958973", "end": 58, "section": "title"}, {"text": "Furthermore, maternal infection (maternal immune activation, MIA) is a risk factor for ASD.", "begin": 223, "document": "22802640", "end": 314, "section": "abstract"}, {"text": "NR1(neo-/-) mice", "begin": 415, "document": "22726567", "end": 431, "section": "abstract"}, {"text": "mice heterozygous for the Gabrb3 gene", "begin": 583, "document": "20699105", "end": 620, "section": "abstract"}, {"text": "Gestational immune activation and Tsc2 haploinsufficiency", "begin": 0, "document": "21079609", "end": 57, "section": "title"}, {"text": "novel transgenic mouse, MALTT,", "begin": 402, "document": "21093492", "end": 432, "section": "abstract"}, {"text": "sing a mouse model, CD38, a transmembrane protein expressed in immune cells but also in brain, was found to be critical for social behavior via regulation of oxytocin secretion. ", "begin": 238, "document": "21182206", "end": 416, "section": "abstract"}, {"text": "fmr1 knockout mouse model", "begin": 562, "document": "21484200", "end": 587, "section": "abstract"}, {"text": "TS2-neo mouse", "begin": 1119, "document": "21878566", "end": 1132, "section": "abstract"}, {"text": "Congenic Tbx1 heterozygous (HT) mice ", "begin": 698, "document": "21908517", "end": 735, "section": "abstract"}, {"text": "the valproic acid (VPA) mouse model of autism", "begin": 644, "document": "22016815", "end": 689, "section": "abstract"}, {"text": " indicates that the MeCP2+/- model may be useful for preclinical development targeting specific cortical processing abnormalities in RTT with potential relevance to ASD.", "begin": 1527, "document": "22249109", "end": 1696, "section": "abstract"}, {"text": "(Dp(11)17/+) ", "begin": 378, "document": "22492990", "end": 391, "section": "abstract"}, {"text": "BTBR T+tf/J (BTBR) inbred mice are frequently used as a model of autism spectrum disorders (ASD)", "begin": 0, "document": "22677272", "end": 96, "section": "abstract"}, {"text": "Intact and impaired executive abilities in the BTBR mouse model of autism.", "begin": 0, "document": "22677272", "end": 74, "section": "title"}]}, {"documents": ["16339652", "18844071"], "answer": [["LMO2-C"], ["Gfi-1b"], ["MeCP1 complex"], ["ACF/WCRF complex"], ["FOG-1"], ["TAL-1"], ["Ldb-1"]], "id": "52e929eb98d0239505000023", "snippets": [{"text": "Our work describes, for the first time, distinct GATA-1 interactions with the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex, and the chromatin remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/TAL-1 complexes.", "begin": 752, "document": "16339652", "end": 1011, "section": "abstract"}, {"text": "LMO2-C can bind endogenous GATA1", "begin": 948, "document": "18844071", "end": 980, "section": "abstract"}, {"text": "Ldb-1, a known partner of GATA-1", "begin": 1345, "document": "16339652", "end": 1377, "section": "abstract"}]}, {"documents": ["22975329", "20845110", "16136188", "12972430", "12399470", "10454561", "9566872", "8692272", "8804077", "7809091"], "answer": [["I-kBs"], ["Sef"], ["NF-kB1 (p105)"], ["NF-kB2 (p100)"]], "id": "530db83b38c1322806000002", "snippets": [{"text": "Sef is an inhibitor of proinflammatory cytokine signaling, acting by cytoplasmic sequestration of NF-\u03baB", "begin": 0, "document": "22975329", "end": 103, "section": "title"}, {"text": "According to the classical model, NF-\u03baB is retained in the cytoplasm of resting cells via binding to inhibitory, I\u03baB proteins and translocates into the nucleus upon their ligand-induced degradation.", "begin": 70, "document": "22975329", "end": 268, "section": "abstract"}, {"text": "Like I\u03baBs, Sef sequesters NF-\u03baB in the cytoplasm of resting cells.", "begin": 583, "document": "22975329", "end": 649, "section": "abstract"}, {"text": "The activity of NF-\u03baB is tightly controlled through its cytoplasmic sequestration by specific inhibitors, I\u03baBs.", "begin": 122, "document": "20845110", "end": 233, "section": "abstract"}, {"text": "The inhibitor of NF-kappaB (IkappaB) family of proteins is believed to regulate NF-kappaB activity by cytoplasmic sequestration.", "begin": 0, "document": "16136188", "end": 128, "section": "abstract"}, {"text": "IkappaBalpha is an inhibitory molecule that sequesters NF-kappaB dimers in the cytoplasm of unstimulated cells.", "begin": 0, "document": "12972430", "end": 111, "section": "abstract"}, {"text": "p105.Ikappa Bgamma and prototypical Ikappa Bs use a similar mechanism to bind but a different mechanism to regulate the subcellular localization of NF-kappa B", "begin": 0, "document": "12399470", "end": 158, "section": "title"}, {"text": "We show that the death domain of p105 (also of IkappaBgamma) is essential for the cytoplasmic sequestration of NF-kappaB by p105 and IkappaBgamma.", "begin": 1355, "document": "12399470", "end": 1501, "section": "abstract"}, {"text": "In unstimulated cells, NF-kappaB transcription factors are retained in the cytoplasm by inhibitory IkappaB proteins.", "begin": 0, "document": "10454561", "end": 116, "section": "abstract"}, {"text": "The ability of the IkappaB alpha protein to sequester dimeric NF-kappaB/Rel proteins in the cytoplasm provides an effective mechanism for regulating the potent transcriptional activation properties of NF-kappaB/Rel family members.", "begin": 0, "document": "9566872", "end": 230, "section": "abstract"}, {"text": "The presence of a discrete nuclear import sequence in IkappaB alpha suggests that cytoplasmic sequestration of the NF-kappaB/Rel-IkappaB alpha complex is a consequence of the mutual masking of the NLS within NF-kappaB/Rel proteins and the import sequence within IkappaB alpha.", "begin": 925, "document": "9566872", "end": 1201, "section": "abstract"}, {"text": "The viral Tax protein, which is encoded by human T-cell leukaemia virus HTLV-I, activates nuclear translocation of the NF-kappa B/Rel transcription factors and relieves cytoplasmic sequestration of RelA and Rel by heterodimerization with NF-kappa B1/p1O5 (refs 1,2).", "begin": 0, "document": "8692272", "end": 266, "section": "abstract"}, {"text": "The I-kappa B protein, which is necessary for the cytoplasmic sequestration of the NF-kappa B transcription factor complex, was identified specifically in regions of limbic, hypothalamic, and autonomic nuclei.", "begin": 502, "document": "8804077", "end": 711, "section": "abstract"}, {"text": "Human T-cell leukemia virus type I Tax-protein-mediated activation of NF-kappa B from p100 (NF-kappa B2)-inhibited cytoplasmic reservoirs", "begin": 0, "document": "7809091", "end": 137, "section": "title"}, {"text": "The preexisting NF-kappa B proteins are retained in the cytoplasm of cells by association with inhibitory ankyrin-motif-containing I kappa B proteins, primarily I kappa B-alpha but also including the precursor proteins p105 (NF-kappa B1) and p100 (NF-kappa B2).", "begin": 407, "document": "7809091", "end": 668, "section": "abstract"}]}, {"documents": ["18976161", "9624027", "8824885"], "answer": [["altered morphology"], ["arrested cell-cycle progression"], ["development of aberrant gene expression with proinflammatory behavior"], ["telomere shortening"]], "id": "53061af558348c0f52000002", "snippets": [{"text": "Cellular senescence is recognized as a critical cellular response to prolonged rounds of replication and environmental stresses. Its defining characteristics are arrested cell-cycle progression and the development of aberrant gene expression with proinflammatory behavior.", "begin": 0, "document": "18976161", "end": 272, "section": "abstract"}, {"text": "telomeres are the central timing mechanism for cellular aging", "begin": 307, "document": "9624027", "end": 368, "section": "abstract"}, {"text": "Recent research has shown that inserting a gene for the protein component of telomerase into senescent human cells reextends their telomeres to lengths typical of young cells, and the cells then display all the other identifiable characteristics of young, healthy cells.", "begin": 0, "document": "9624027", "end": 270, "section": "abstract"}, {"text": "Our data demonstrate that Sod1 transfected cell lines that have an elevation in the ratio of Sod1 activity to Gpx1 activity produce higher levels of H2O2 and exhibit well characterised markers of cellular senescence viz. slower proliferation and altered morphology.", "begin": 390, "document": "8824885", "end": 655, "section": "abstract"}]}, {"documents": ["23994756", "23301832", "23261661", "22442756", "18980246", "18451231", "17728765", "17041625", "15901852", "15627018", "15163844", "14508096"], "answer": ["mTOR"], "id": "53124bdae3eabad02100000b", "snippets": [{"text": "molecular target of rapamycin (mTOR", "begin": 1170, "document": "23994756", "end": 1205, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR)", "begin": 643, "document": "23301832", "end": 679, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR) ", "begin": 4, "document": "23261661", "end": 41, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR)", "begin": 1839, "document": "22442756", "end": 1875, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR)", "begin": 1363, "document": "18980246", "end": 1399, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR) ", "begin": 55, "document": "18451231", "end": 92, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR)", "begin": 4, "document": "17728765", "end": 40, "section": "abstract"}, {"text": "the molecular Target Of Rapamycin, TOR", "begin": 325, "document": "17041625", "end": 363, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR)", "begin": 1537, "document": "15901852", "end": 1573, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR", "begin": 14, "document": "15627018", "end": 49, "section": "title"}, {"text": "molecular target of rapamycin (mTOR) ", "begin": 1930, "document": "15163844", "end": 1967, "section": "abstract"}, {"text": "molecular target of rapamycin (mTOR),", "begin": 4, "document": "14508096", "end": 41, "section": "abstract"}]}, {"documents": ["15887238", "15844661"], "answer": [["BCR-ABL"], ["Platelet-derived growth factor receptor (PDGFR)"], ["c-Kit"]], "id": "53188992b166e2b806000019", "snippets": [{"text": "Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.", "begin": 0, "document": "15887238", "end": 128, "section": "abstract"}, {"text": "Imatinib mesylate is a novel anti-tumor agent useful in the clinical management of chronic myelogenous leukemia and gastrointestinal stromal tumors with minimal toxicity relative to other forms of cancer therapy. Its clinical activity and minimal toxicity are related to specific inhibition of cellular targets including BCR-ABL, platelet-derived growth factor receptor and c-kit kinases, resulting in the collapse of downstream signaling cascades important for transformation.", "begin": 0, "document": "15844661", "end": 477, "section": "abstract"}]}, {"documents": ["16614251", "16318699", "7989542", "22223483", "18571757", "23181535", "23239357", "23518650", "23925142"], "answer": [["mouse lethality assay"], ["by mass spectrometry"], ["bioassay"], ["differentiated cell models"], ["peptide cleavage assay"], ["FDC (functional dual coating) microtitre plate immuno-biochemical assay"], ["endopeptidase activity monitored via UV-Visible spectroscopy"]], "id": "531d6bfc267d7dd053000007", "snippets": [{"text": "The neurotoxin detection is based on the mouse lethality assay. ", "begin": 513, "document": "16614251", "end": 577, "section": "abstract"}, {"text": "Botulinum neurotoxin detection and differentiation by mass spectrometry.", "begin": 0, "document": "16318699", "end": 72, "section": "title"}, {"text": "which could be shown by bioassay to produce biologically active type B toxin in culture.", "begin": 753, "document": "7989542", "end": 841, "section": "abstract"}, {"text": "Human induced pluripotent stem cells (hiPSC) hold great promise for providing various differentiated cell models for in vitro toxigenicity testing. ", "begin": 0, "document": "22223483", "end": 148, "section": "abstract"}, {"text": "A direct comparison of BoNT detection using primary rat spinal cord cells and hiPSC-derived neurons showed equal or increased sensitivity", "begin": 1398, "document": "22223483", "end": 1535, "section": "abstract"}, {"text": "BoNT/A intoxication studies demonstrate that the hiPSC-derived neurons reproducibly and quantitatively detect biologically active BoNT/A with high sensitivity (EC(50) \u223c0.3 U).", "begin": 1043, "document": "22223483", "end": 1218, "section": "abstract"}, {"text": " these data suggest that neurons derived from hiPSCs provide an ideal and highly sensitive platform for BoNT potency determination, neutralizing antibody detection and for mechanistic studies.", "begin": 1655, "document": "22223483", "end": 1847, "section": "abstract"}, {"text": "Detection of botulinum neurotoxin-A activity in food by peptide cleavage assay.", "begin": 0, "document": "18571757", "end": 79, "section": "title"}, {"text": "his study reports the successful use of an enzymatic assay employing an internally quenched fluorogenic peptide as a fast, simple and inexpensive alternative to the mouse bioassay. ", "begin": 354, "document": "18571757", "end": 535, "section": "abstract"}, {"text": "BoNT endopeptidase assays", "begin": 512, "document": "23181535", "end": 537, "section": "abstract"}, {"text": "in vivo mouse bioassay has for years been the 'gold standard' assay used for this purpose", "begin": 708, "document": "23239357", "end": 797, "section": "abstract"}, {"text": "Cell-based assays are currently the only in vitro alternative that detect fully functional BoNTs in a single assay and have been utilized for years for research purposes.", "begin": 903, "document": "23239357", "end": 1073, "section": "abstract"}, {"text": "mouse bioassay (MBA) is traditionally used to confirm the presence of toxin in serum or food", "begin": 422, "document": "23518650", "end": 514, "section": "abstract"}, {"text": "A novel FDC (functional dual coating) microtitre plate immuno-biochemical assay,", "begin": 625, "document": "23518650", "end": 705, "section": "abstract"}, {"text": "A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold", "begin": 0, "document": "23925142", "end": 124, "section": "title"}, {"text": "This report demonstrates a novel assay that utilises the endopeptidase activity of the toxin to detect Botulinum neurotoxin in a pharmaceutical sample. The cleaving of SNAP-25 is monitored via UV-Visible spectroscopy with a limit of detection of 373 fg/mL and has been further developed into a high throughput method using a microplate reader detecting down to 600 fg/mL of active toxin. ", "begin": 374, "document": "23925142", "end": 762, "section": "abstract"}]}, {"documents": ["24170634", "21061765", "20689478", "12410672", "20426708", "20300365", "15099321"], "answer": [["Minoxidil"], ["Finasteride"], ["Laser hair comb"]], "id": "5324d0169b2d7acc7e000022", "snippets": [{"text": "Topical minoxidil 2%-5% 1 mL twice daily or finasteride 1 mg daily are recommended as first line treatments, followed by the use of Food and Drug Administration-cleared HairMax LaserComb\u00ae in patients who do not respond to first line modalities.", "begin": 530, "document": "24170634", "end": 774, "section": "abstract"}, {"text": "Recently, in addition to the two currently approved U.S. Food and Drug Administration (FDA) medications (minoxidil and finasteride), a novel device was FDA-approved for the treatment of hair loss, the laser hair comb.", "begin": 505, "document": "21061765", "end": 722, "section": "abstract"}, {"text": "In addition, low-level light therapy (LLLT) has recently been approved by the United States Food and Drug Administration (FDA) for the treatment of hair loss. ", "begin": 330, "document": "20689478", "end": 489, "section": "abstract"}, {"text": "Currently there are two U.S. Food and Drug Administration (FDA)-approved agents that promote hair regrowth: over-the-counter topical minoxidil solution for men and women and prescription oral finasteride tablets for men. ", "begin": 460, "document": "12410672", "end": 681, "section": "abstract"}, {"text": "Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials.", "begin": 824, "document": "20426708", "end": 1043, "section": "abstract"}, {"text": "The only FDA-approved dermatological indication of finasteride is androgenetic alopecia.", "begin": 227, "document": "20300365", "end": 315, "section": "abstract"}, {"text": "Finasteride (Propecia) was approved by the FDA in 1998 for treating men with androgenetic alopecia.", "begin": 12, "document": "15099321", "end": 111, "section": "abstract"}]}, {"documents": ["22196295", "15162318", "12564817", "11818821", "9719378", "9145139", "9002682", "1648464", "211577"], "answer": [["complex syndactyly with bony fusion involving the index"], ["polydactyly"], ["short thumb with radial clinodactyly"], ["long and ring fingers"], ["symphalangism"], ["simple syndactyly of the fourth web space"], ["intrinsic muscle anomalies"], ["extrinsic tendon insertions"], ["neurovascular bundles"]], "id": "52bf1cb303868f1b0600000b", "snippets": [{"text": "Five patients, ranging from Upton type 1 to type 3 Apert hand deformities, have had preoperative computed tomography angiography that delineated the vascular anatomy. This allowed planning and execution of a single-stage syndactyly release in all patients.", "begin": 360, "document": "22196295", "end": 616, "section": "abstract"}, {"text": "The protocol presented allows preoperative planning and single-stage operation for complete release of syndactyly in patients with Apert syndrome.", "begin": 758, "document": "22196295", "end": 904, "section": "abstract"}, {"text": "In patients with Apert syndrome, the hands demonstrate many disturbances of soft tissue and bony structures. These include a short thumb with radial clinodactyly, complex syndactyly with a bony fusion involving the index, long and ring fingers, symphalangism and simple syndactyly of the fourth web space. The soft tissue anomalies involve the intrinsic muscles, the extrinsic tendon insertions and the neurovascular bundles. ", "begin": 0, "document": "15162318", "end": 426, "section": "abstract"}, {"text": "Two of the patients had Apert syndrome (syndromic craniosynostosis with symmetrical syndactyly) and two had polydactyly. ", "begin": 115, "document": "12564817", "end": 236, "section": "abstract"}, {"text": "The overall strategy involved early bilateral separation of syndactylous border digits at 1 year of age, followed by sequential unilateral middle syndactyly mass separation with thumb osteotomy and bone grafting as needed. In these 10 patients, a total of 53 web spaces were released, 49 of which involved osteotomies for complex syndactyly. ", "begin": 454, "document": "11818821", "end": 796, "section": "abstract"}, {"text": "Apert syndrome, characterised by craniosynostosis, craniofacial anomalies, and symmetrical syndactyly of the digits (cutaneous and bony fusion), has been associated with two canonical mutations in the FGFR2 gene (S252W, P253R) in the great majority of cases. ", "begin": 0, "document": "9719378", "end": 259, "section": "abstract"}, {"text": "The Apert syndrome hand demonstrates many typical clinical features including syndactyly, symbrachyphalangism, and growth disturbances.", "begin": 0, "document": "9145139", "end": 135, "section": "abstract"}, {"text": "In Apert syndrome, characterised by syndactyly of the hands and feet, recurrent mutations of a serine-proline dipeptide (either Ser252Trp or Pro253Arg) in the linker between the IgII and IgIII extracellular immunoglobulin-like domains, have been documented in more than 160 unrelated individuals. ", "begin": 149, "document": "9002682", "end": 446, "section": "abstract"}, {"text": "urgical correction of syndactyly of the Apert hand should begin by 6 months and be completed by 3 years of age. As much surgery as possible is carried out at each sitting. ", "begin": 1, "document": "1648464", "end": 173, "section": "abstract"}, {"text": "The syndactyly cases were more complicated than the average, among them 4 cases of Apert syndrome were noted. ", "begin": 1140, "document": "211577", "end": 1250, "section": "abstract"}]}, {"documents": ["23940258", "22486183", "21358851", "21211209", "20814842", "20598107", "19935988", "19467991", "18360657", "19039990", "17804903", "16982219", "16828857", "12530992", "11863398", "11799409", "11310286", "21779527", "24101430", "23257652", "22377249", "22258033", "21398376", "20303704", "14643912", "22096645", "24267148"], "answer": ["iron"], "id": "530cefaaad0bf1360c000012", "snippets": [{"text": "We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). We show that L chain ferritin is undetectable in primary fibroblasts from the patient, and thus ferritin consists only of H chains.", "begin": 438, "document": "23940258", "end": 775, "section": "abstract"}, {"text": "Our results demonstrate for the first time the pathophysiological consequences of L-ferritin deficiency in a human and help to define the concept for a new disease entity hallmarked by idiopathic generalized seizure and atypical RLS.", "begin": 1136, "document": "23940258", "end": 1369, "section": "abstract"}, {"text": "These results when viewed along with prior RLS SPECT and autopsy studies of DAT, and cell culture studies with iron deficiency and DAT, suggest that membrane-bound striatal DAT, but not total cellular DAT, may be decreased in RLS.", "begin": 1332, "document": "21358851", "end": 1562, "section": "abstract"}, {"text": " Compared with the PD or healthy group, the level of serum ferritin and the H-reflex latency of tibial nerve were significantly decreased in PD with RLS group (P < 0.05).", "begin": 690, "document": "21211209", "end": 860, "section": "abstract"}, {"text": "Deficiency of iron and decreased inhibition function of spinal cord may lead to the occurrence of RLS in PD patients. ", "begin": 913, "document": "21211209", "end": 1031, "section": "abstract"}, {"text": "Association of iron deficiency with febrile seizures, pica, breath holding spells, restless leg syndrome and thrombosis is increasingly being recognized.", "begin": 538, "document": "20814842", "end": 691, "section": "abstract"}, {"text": " Iron status was generally poor among regular blood donors, especially in women, with a high incidence of iron depletion (>20%) and RLS (18%). ", "begin": 714, "document": "20598107", "end": 857, "section": "abstract"}, {"text": "Iron status is poor in regular blood donors, restless legs syndrome is common, and the routine iron supplementation is insufficient. ", "begin": 1217, "document": "20598107", "end": 1350, "section": "abstract"}, {"text": "Furthermore, there appears to be an association between iron deficiency and those suffering from Restless Leg Syndrome (RLS). ", "begin": 1240, "document": "19935988", "end": 1366, "section": "abstract"}, {"text": "The authors propose that PPIs, such as omeprazole, may interfere with iron absorption in certain patients and that a subpopulation of patients who develop significant iron deficiency characterized by low serum ferritin levels while on PPIs may also develop RLS-like symptoms (including RLSAP).", "begin": 1491, "document": "19935988", "end": 1784, "section": "abstract"}, {"text": "Clinical studies have implicated the dopaminergic system in RLS, while others have suggested that it is associated with insufficient levels of brain iron. ", "begin": 56, "document": "19467991", "end": 211, "section": "abstract"}, {"text": "The results are consistent with the hypothesis that a primary iron insufficiency produces a dopaminergic abnormality characterized as an overly activated dopaminergic system as part of the RLS pathology.", "begin": 1674, "document": "19467991", "end": 1877, "section": "abstract"}, {"text": "RLS may also be secondary to a number of conditions including iron deficiency, pregnancy and end-stage renal failure and, perhaps, neuropathy.", "begin": 466, "document": "18360657", "end": 608, "section": "abstract"}, {"text": "The pathogenesis of RLS probably involves the interplay of systemic or brain iron deficiency and impaired dopaminergic neurotransmission in the subcortex of the brain. ", "begin": 692, "document": "18360657", "end": 860, "section": "abstract"}, {"text": "All patients showed low levels of ferritin and iron supplementation was effective in five cases. ", "begin": 861, "document": "19039990", "end": 958, "section": "abstract"}, {"text": "Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.", "begin": 432, "document": "17804903", "end": 724, "section": "abstract"}, {"text": "Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are considered to be a continuum of a neurological sleep disorder associated with abnormal iron metabolism or deficiency. I describe a case of RLS and PLMD in a cystic fibrosis patient with iron deficiency from chronic hemoptysis. This is the first case that reports RLS and PLMD manifesting from iron deficiency caused by chronic hemoptysis in advanced cystic fibrosis lung disease.", "begin": 0, "document": "16982219", "end": 454, "section": "abstract"}, {"text": "Restless leg syndrome manifested by iron deficiency from chronic hemoptysis in cystic fibrosis.", "begin": 0, "document": "16982219", "end": 95, "section": "title"}, {"text": "Diurnal effects on motor control are evident in the human disease of Restless Leg Syndrome (RLS), which is purported to be linked to brain iron deficiency as well as alterations in dopaminergic systems. ", "begin": 0, "document": "16828857", "end": 203, "section": "abstract"}, {"text": "Iron deficiency in the central nervous system is known to cause motor impairment and cognitive deficits; more recently, it has been suggested that it may play a role in the pathophysiology of the restless leg syndrome. ", "begin": 755, "document": "12530992", "end": 974, "section": "abstract"}, {"text": "Restless leg syndrome (RLS), aging, pregnancy, uraemia, iron deficiency, polyneuropathy are some of the common causes of secondary PLMD.", "begin": 276, "document": "11799409", "end": 412, "section": "abstract"}, {"text": "The syndrome is increasingly often diagnosed, particularly in association with iron deficiency, during pregnancy, in chronic renal failure and in patients with peripheral neuropathy. ", "begin": 479, "document": "11310286", "end": 662, "section": "abstract"}, {"text": "Clinical, EEG, electromyographic and polysomnographic studies in restless legs syndrome caused by magnesium deficiency.", "begin": 0, "document": "8363978", "end": 119, "section": "title"}, {"text": "A frequent polymorphism in BTBD9 was significantly associated with serum ferritin. This polymorphism has previously been associated with RLS, but not low iron stores in blood donors.", "begin": 1191, "document": "22486183", "end": 1373, "section": "abstract"}]}, {"documents": ["15251045", "14515407", "12446953", "11600803", "11478226", "9096828", "9005271", "14590665", "21930452"], "answer": [["loss of memory"], ["dysmnesia"]], "id": "530cefaaad0bf1360c000011", "snippets": [{"text": "The strongest associations were for mood swings (OR 20.9, 95%CI 16.2-27.0), memory loss/lack of concentration (OR 19.6, 95% CI 15.5-24.8), night sweats (OR 9.9, 95% CI 6.5-15.2), general fatigue (OR 9.6, 95% CI 8.3-11.1) and sexual dysfunction (OR 4.6, 95%CI 3.2-6.6).", "begin": 1233, "document": "15251045", "end": 1501, "section": "abstract"}, {"text": "The symptoms include incapacitating fatigue, musculoskeletel and joint pains, headaches, neuropsychiatric disorders, affect changes, confusion, visual problems, changes of gait, loss of memory, lymphadenopathies, respiratory impairment, impotence, and urinary tract morphological and functional alterations. ", "begin": 709, "document": "14515407", "end": 1017, "section": "abstract"}, {"text": "In early 1992, U.S. troops returning from the Gulf War began reporting a variety of nonspecific symptoms such as fatigue, skin rash, headache, muscle and joint pain, and loss of memory. These reports marked the beginning of what was to be identified as the Gulf War Syndrome (GWS). ", "begin": 0, "document": "11600803", "end": 282, "section": "abstract"}, {"text": "We report on a 29-year-old man who suffered from dysmnesia, disturbance of orientation, cognitive impairment, and double vision. His history revealed several front-line operations in 1990 and 1991 during the Gulf War. ", "begin": 343, "document": "11478226", "end": 561, "section": "abstract"}, {"text": "Neuropsychological tests disclosed severe cognitive impairment especially concerning memory.", "begin": 967, "document": "11478226", "end": 1059, "section": "abstract"}, {"text": "A cluster of common health problems included: skin rash, cough, depression, unintentional weight loss, insomnia, and memory problems.", "begin": 1175, "document": "9096828", "end": 1308, "section": "abstract"}, {"text": "Syndromes 1 (\"impaired cognition,\" characterized by problems with attention, memory, and reasoning, as well as insomnia, depression, daytime sleepiness, and headaches), 2 (\"confusion-ataxia,\" characterized by problems with thinking, disorientation, balance disturbances, vertigo, and impotence), and 3 (\"arthro-myo-neuropathy,\" characterized by joint and muscle pains, muscle fatigue, difficulty lifting, and extremity paresthesias) represented strongly clustered symptoms; whereas, syndromes 4 (\"phobia-apraxia\"), 5 (\"fever-adenopathy\"), and 6 (\"weakness-incontinence\") involved weaker clustering and mostly overlapped syndromes 2 and 3. ", "begin": 1038, "document": "9005271", "end": 1677, "section": "abstract"}]}, {"documents": ["23734615", "22719898", "20425788", "20301427", "18824871", "18204753", "17188616", "16596673", "16473313", "16181239", "15751610", "15108207", "10405448", "10378390", "8835601", "7789182", "1867260", "3405972", "3164411", "4056970", "21209713"], "answer": ["thyroid"], "id": "530cefaaad0bf1360c00000d", "snippets": [{"text": "WS and TD participants had similar profiles in a familiar setting, while participants with WS had elevated cortisol late in the day in the novel setting when social demands were higher. The cortisol awakening response in WS was associated with parent-reported levels of somatic complaints and social difficulties. Results suggest that adults with WS have a typical diurnal cortisol profile that may be sensitive to social and activity transitions throughout the day.", "begin": 302, "document": "23734615", "end": 768, "section": "abstract"}, {"text": "Oxytocin and vasopressin are dysregulated in Williams Syndrome, a genetic disorder affecting social behavior.", "begin": 0, "document": "22719898", "end": 109, "section": "title"}, {"text": "Results revealed significantly higher median levels of OT in WS versus controls at baseline, with a less marked increase in AVP. Further, in WS, OT and AVP increased in response to music and to cold, with greater variability and an amplified peak release compared to controls. In WS, baseline OT but not AVP, was correlated positively with approach, but negatively with adaptive social behaviors. These results indicate that WS deleted genes perturb hypothalamic-pituitary release not only of OT but also of AVP, implicating more complex neuropeptide circuitry for WS features and providing evidence for their roles in endogenous regulation of human social behavior. ", "begin": 969, "document": "22719898", "end": 1636, "section": "abstract"}, {"text": "Three quarters of the WS subjects showed abnormal glucose curves, meeting diagnostic criteria for either diabetes or the pre-diabetic state of impaired glucose tolerance. Fasting mean glucose and median insulin levels did not differ significantly in the total WS cohort versus age-gender-BMI matched controls, though the glucose area under the curve was greater in the WS subjects. ", "begin": 105, "document": "20425788", "end": 487, "section": "abstract"}, {"text": "Williams syndrome (WS) is characterized by cardiovascular disease (elastin arteriopathy, peripheral pulmonary stenosis, supravalvular aortic stenosis, hypertension), distinctive facies, connective tissue abnormalities, intellectual disability (usually mild), a specific cognitive profile, unique personality characteristics, growth abnormalities, and endocrine abnormalities (hypercalcemia, hypercalciuria, hypothyroidism, and early puberty).", "begin": 25, "document": "20301427", "end": 467, "section": "abstract"}, {"text": "In the Williams-Beuren syndrome (WBS), disorders of the thyroid function and morphology have been reported and programs of thyroid screening and surveillance are recommended. ", "begin": 0, "document": "18824871", "end": 175, "section": "abstract"}, {"text": "In this report we describe an infant with WBS and congenital hypothyroidism, due to an important thyroid hypoplasia. The patient, a 1-month-old female, negative at primary neonatal thyroid screening, was referred to our hospital for dyspnea. Thyroid function tests showed a raised TSH (42 mIU/l; normal range 0.5-4 mIU/l) with a low FT(4) concentration (10.21 pmol/l; normal range: 10.29-24.45 pmol/l). Ultrasound examination of the neck showed a significant thyroid hypoplasia, whereas (99m)Tc-pertechnetate thyroid scintigraphy evidenced a thyroid gland in normal position, with reduced shape and overall weak fixation. ", "begin": 291, "document": "18824871", "end": 913, "section": "abstract"}, {"text": "Thyroid hypoplasia is a frequent characteristic of WBS and abnormalities of thyroid function are common in patients with this feature. Therefore, the possibility of congenital hypothyroidism should always be taken into consideration too and, even if congenital hypothyroidism neonatal screening is negative, thyroid (morphology and function) evaluation should be regularly assessed when the diagnosis is made and, thereafter, every year in the first years of life.", "begin": 963, "document": "18824871", "end": 1427, "section": "abstract"}, {"text": "As growth hormone (GH) deficiency was diagnosed by an additional GH-stimulation test, we commenced with a GH-treatment. ", "begin": 298, "document": "18204753", "end": 418, "section": "abstract"}, {"text": "None of our patients had overt hypothyroidism; 29 patients (31.5%) had subclinical hypothyroidism. ", "begin": 527, "document": "17188616", "end": 626, "section": "abstract"}, {"text": "Thyroid involvement in Williams syndrome (WS) was recently reported in two small groups of patients, both showing an increased prevalence of elevation of TSH serum concentration; in one of the two reports, 70% of the patients demonstrated a hypoplasia of thyroid gland as well. ", "begin": 0, "document": "16596673", "end": 278, "section": "abstract"}, {"text": "Our study confirms the increased incidence of both elevated TSH serum values (37.9% in our sample) and thyroid gland hypoplasia (74.7%).", "begin": 693, "document": "16596673", "end": 829, "section": "abstract"}, {"text": "A WS patient with CPP is presented, whose pubertal development and bone age progression were arrested by administration of GnRH analogues. ", "begin": 300, "document": "16473313", "end": 439, "section": "abstract"}, {"text": " This study confirms the presence of alterations of thyroid function in WS and also suggests the frequent occurrence of abnormalities of thyroid morphology in these patients.", "begin": 1180, "document": "16181239", "end": 1354, "section": "abstract"}, {"text": "We report a female infant with confirmed WBS who, through provocative testing, was found to have GHD and who responded satisfactorily to hGH therapy. ", "begin": 363, "document": "15751610", "end": 513, "section": "abstract"}, {"text": "In conclusion, GH deficiency might contribute to the growth failure in a number of patients with WBS and in such cases hGH therapy will most likely improve final height.", "begin": 871, "document": "15751610", "end": 1040, "section": "abstract"}, {"text": "Thyrotropin level was very high (>50 microU/ml; normal value 0.2-4 microU/ml), while serum free T(3) (FT3) and free T(4) (FT4) levels were normal (FT3 3.6 pg/ml, normal value 2.8-5.6 pg/ml; FT4 11.6 pg/ml, normal value 6.6-14 pg/ml); antithyroid autoantibodies were absent. ", "begin": 423, "document": "15108207", "end": 697, "section": "abstract"}, {"text": "Recently a case of thyroid hemiagenesis in a child with WS has been reported; our patient underscores the association of hypothyroidism and WS. ", "begin": 1186, "document": "15108207", "end": 1330, "section": "abstract"}, {"text": "Thyroid hemiagenesis and elevated thyrotropin levels in a child with Williams syndrome.", "begin": 0, "document": "10405448", "end": 87, "section": "title"}, {"text": "A girl with Williams syndrome (WS) presented with elevated thyrotropin (TSH) levels (7.0 microU/ml), normal free thyroid hormone concentrations, and absent antithyroid autoantibodies.", "begin": 0, "document": "10405448", "end": 183, "section": "abstract"}, {"text": "TSH response to thyrotropin-releasing hormone (TRH) injection (200 microg/mq, i.v.) was exaggerated and prolonged, suggesting subclinical hypothyroidism. The biological activity of circulating TSH was slightly below the normal range [TSH bioactivity (B) to immunoreactivity (I) ratio (TSH B/I) = 0.4, normal: 0.6-2.2]. These abnormalities are similar to those seen in patients with hypothalamic hypothyroidism.", "begin": 297, "document": "10405448", "end": 707, "section": "abstract"}, {"text": "However, abnormalities of the hypothalamic-pituitary-thyroid (HPT) axis and thyroid dysgenesis have been found in other WS cases. ", "begin": 800, "document": "10405448", "end": 930, "section": "abstract"}, {"text": "We report a boy with confirmed Williams-Beuren syndrome, who was found to have classical growth hormone deficiency and responded well to growth hormone therapy. ", "begin": 251, "document": "10378390", "end": 412, "section": "abstract"}, {"text": "Although growth hormone deficiency is not likely to be a common cause of short stature in Williams-Beuren syndrome, we nevertheless recommend evaluation of the growth hormone-insulin-like growth factor I axis in all cases.", "begin": 425, "document": "10378390", "end": 647, "section": "abstract"}, {"text": "Endocrinological examinations revealed hypergonadotropic hypogonadism. Prolonged and exaggerated responses of adrenocorticotropin (ACTH) to insulin-induced hypoglycemia and corticotropin releasing hormone (CRH) were also noted. ", "begin": 260, "document": "8835601", "end": 488, "section": "abstract"}, {"text": "Involvement of the calcitonin/CGRP gene in Williams syndrome is postulated on the basis that Williams syndrome children often have infantile hypercalcemia and deficient expression of calcitonin, a hormone that lowers serum calcium levels. ", "begin": 148, "document": "1867260", "end": 387, "section": "abstract"}, {"text": "These findings suggest that the calcitonin deficiency might be due either to mutations elsewhere in the gene or to defects in the cellular machinery needed for calcitonin synthesis and/or secretion.", "begin": 1004, "document": "1867260", "end": 1202, "section": "abstract"}, {"text": "It has been suggested that a defect in calcitonin function may play a role in Williams syndrome. ", "begin": 125, "document": "3164411", "end": 222, "section": "abstract"}, {"text": " These patients were found to have significantly higher mean baseline calcium concentrations, delayed clearance of calcium after intravenous calcium loading, and blunted calcitonin responses after calcium infusion, compared with a group of seven normal children.", "begin": 297, "document": "4056970", "end": 559, "section": "abstract"}, {"text": "Our studies demonstrate that patients with Williams syndrome have a defect in the synthesis or release of immunoreactive calcitonin. A deficiency of calcitonin may explain the abnormalities of calcium metabolism seen in these patients and can serve as an important endocrine marker for Williams syndrome.", "begin": 684, "document": "4056970", "end": 988, "section": "abstract"}, {"text": "Additional periodic evaluations during childhood: serum concentration of calcium, thyroid function, hearing, and renal and bladder ultrasound examination. Periodic evaluations during adulthood: glucose tolerance; cardiac evaluation for mitral valve prolapse, aortic insufficiency, and arterial stenosis; and ophthalmologic evaluation for cataracts.", "begin": 2146, "document": "20301427", "end": 2494, "section": "abstract"}, {"text": "Subclinical hypothyroidism is a frequent but stable finding in young children with WS. The great majority of patients with WS >10 years, either with normal or hypoplastic thyroid, have normal thyroid function.", "begin": 979, "document": "17188616", "end": 1188, "section": "abstract"}, {"text": " Three cases (15%) of subclinical hypothyroidism were identified. Overt hypothyroidism was diagnosed in two cases (10%).", "begin": 401, "document": "16181239", "end": 521, "section": "abstract"}]}, {"documents": ["19536338", "9725240", "8543806", "1741388", "3996596"], "answer": [["TA"], ["CG"], ["(PuPy)n"], ["GCA/TGC"], ["CTA/TAG"]], "id": "52e203bc98d0239505000011", "snippets": [{"text": "Unusual frequencies of certain alternating purine-pyrimidine runs in natural DNA sequences", "begin": 0, "document": "3996596", "end": 90, "section": "title"}, {"text": "Octanucleotides are the most deficient, occurring at only 60% of the frequency expected in random sequences. An unexpectedly high proportion of these octamers consists of alternating tetramers with the repeat structure (PuPyPuPy)2 or (PyPuPyPu)2", "begin": 379, "document": "3996596", "end": 624, "section": "abstract"}, {"text": "For dinucleotides, TA is almost universally under-represented, with the exception of vertebrate mitochondrial genomes, and CG is strongly under-represented in vertebrates and in mitochondrial genomes", "begin": 289, "document": "1741388", "end": 488, "section": "abstract"}, {"text": "For trinucleotides, GCA.TGC tends to be under-represented in phage, human viral, and eukaryotic sequences, and CTA.TAG is strongly under-represented in many prokaryotic, eukaryotic, and viral sequences", "begin": 903, "document": "1741388", "end": 1104, "section": "abstract"}, {"text": "The dinucleotide CpG is significantly under-represented in vertebrate DNA and is usually methylated", "begin": 153, "document": "8543806", "end": 252, "section": "abstract"}, {"text": "One such pattern recognition system is based on unmethylated CpG dinucleotides in particular sequence contexts (CpG motifs); these motifs are common in bacterial DNA but are under-represented (\"CpG suppression\") and methylated in vertebrate DNA", "begin": 150, "document": "9725240", "end": 394, "section": "abstract"}, {"text": "We argue that the significant under-represented motif pattern of CpG in an AU context--which is found in both the ssRNA viruses and innate genes, and has decreased throughout the history of H1N1 influenza replication in humans--is immunostimulatory and has been selected against during the co-evolution of viruses and host innate immune genes", "begin": 976, "document": "19536338", "end": 1318, "section": "abstract"}]}, {"documents": ["23562479", "23439889", "21888900", "21508988", "24213134", "20940262", "20119530", "19778997", "18411404", "18314594", "16314512", "12953060", "12906131", "12217960", "10655499", "12011073", "9465302", "9605877"], "answer": ["CENPA is preferentially localized in eukaryotic centromeres"], "id": "52fbe2bf2059c6d71c00006c", "snippets": [{"text": "In our model, the formation of a bridge between CenpA and an H3 containing nucleosome only occurs efficiently for higher protein concentration realized during S-phase but may be not in G1", "begin": 1027, "document": "23562479", "end": 1214, "section": "abstract"}, {"text": "sing a previously isolated mouse centromere protein A (Cenpa) probe, we have localized the gene to the proximal region of mouse Chromosome 5, between the known Il6 and Yes1 loci near [Adra2C-D5H4S43-Hdh]", "begin": 1, "document": "9605877", "end": 204, "section": "abstract"}, {"text": "CENPA is a member of the histone H3-like proteins and is thought to replace histone H3 in centromeric nucleosomes", "begin": 94, "document": "9465302", "end": 207, "section": "abstract"}, {"text": "entromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated", "begin": 1, "document": "12011073", "end": 124, "section": "title"}, {"text": "Here we investigated the interaction of this protein with, and poly(ADP-ribosyl)ation of, three constitutive centromere proteins, Cenpa, Cenpb, and Cenpc, and a spindle checkpoint protein, Bub3", "begin": 631, "document": "12011073", "end": 824, "section": "abstract"}, {"text": "arly disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice", "begin": 1, "document": "10655499", "end": 96, "section": "title"}, {"text": "entromere protein A (Cenpa for mouse, CENP-A for other species) is a histone H3-like protein that is thought to be involved in the nucleosomal packaging of centromeric DNA", "begin": 1, "document": "10655499", "end": 172, "section": "abstract"}, {"text": "These results suggest that Cenpa is essential for kinetochore targeting of Cenpc and plays an early role in organizing centromeric chromatin at interphase", "begin": 789, "document": "10655499", "end": 943, "section": "abstract"}, {"text": "The evidence is consistent with the proposal of a critical epigenetic function for CENP-A in marking a chromosomal region for centromere formation", "begin": 945, "document": "10655499", "end": 1091, "section": "abstract"}, {"text": "oly(ADP-ribose) polymerase 2 localizes to mammalian active centromeres and interacts with PARP-1, Cenpa, Cenpb and Bub3, but not Cenpc", "begin": 1, "document": "12217960", "end": 135, "section": "title"}, {"text": "Co-immunoprecipitation assay demonstrates interaction between PARP-2 and its functional homolog PARP-1, constitutive centromere proteins Cenpa and Cenpb, and spindle checkpoint protein Bub3, but not with a third constitutive centromere protein Cenpc", "begin": 634, "document": "12217960", "end": 883, "section": "abstract"}, {"text": "ENP-A is an essential histone H3-like protein that localizes to the centromeric region of eukaryotic chromosomes", "begin": 1, "document": "12906131", "end": 113, "section": "abstract"}, {"text": "Centromere activity of the alphoid YAC was suppressed at ectopic locations on the host chromosome, as indicated by the absent or reduced assembly of CENP-A and -C", "begin": 271, "document": "12953060", "end": 433, "section": "abstract"}, {"text": "Using quantitative chromatin immunoprecipitation and expression assays, we show that FoxM1 is essential for transcription of the mitotic regulatory genes Cdc25B, Aurora B kinase, survivin, centromere protein A (CENPA), and CENPB", "begin": 556, "document": "16314512", "end": 784, "section": "abstract"}, {"text": "Many well characterized markers of embryonic stem cells including CD9, PODXL and centromere-specific histone-H3-like protein CENPA are consistently expressed in TGCTs", "begin": 207, "document": "18314594", "end": 373, "section": "abstract"}, {"text": " key element for defining the centromere identity is the incorporation of a specific histone H3, CENPA, known as Cnp1p in Schizosaccharomyces pombe", "begin": 1, "document": "18411404", "end": 148, "section": "abstract"}, {"text": "We studied the dynamics of constitutive heterochromatin in the stages prior to embryonic genome activation by distribution analysis of heterochromatin protein CBX1 (HP1), centromeric proteins CENPA and CENPB, and histone H3 three-methylated at lysine 9", "begin": 421, "document": "19778997", "end": 673, "section": "abstract"}, {"text": "A specific histone H3 variant, CENPA, replaces conventional histone H3 and together with centromere-specific-DNA-binding factors directs the assembly of active kinetochores", "begin": 407, "document": "20119530", "end": 579, "section": "abstract"}, {"text": "This review highlights the role and dynamics of CENPA assembly into centromeres and the potential contribution of this kinetochore protein to autoimmune and cancer diseases in humans", "begin": 802, "document": "20119530", "end": 984, "section": "abstract"}, {"text": "ropagation of centromere identity during cell cycle progression in higher eukaryotes depends critically on the faithful incorporation of a centromere-specific histone H3 variant encoded by CENPA in humans and cid in Drosophila", "begin": 1, "document": "20940262", "end": 227, "section": "abstract"}, {"text": "Centromere protein -A (CENPA) is a centromere-specific histone-H3-like variant gene involved in regulating chromosome segregation during cell division", "begin": 133, "document": "24213134", "end": 283, "section": "abstract"}, {"text": "These include the histone H3 variant centromeric protein A (CENPA), the composition and deposition of which have been widely investigated", "begin": 385, "document": "21508988", "end": 522, "section": "abstract"}, {"text": "Major centromere autoantigens described so far include constitutive kinetochore proteins such as CENPA, CENPB, CENPC and CENPH and facultative proteins such as CENPE, CENPF and INCENP", "begin": 160, "document": "21888900", "end": 343, "section": "abstract"}, {"text": "ENPA/Cse4 assembles centromeric chromatin on diverse DNA", "begin": 1, "document": "23439889", "end": 57, "section": "abstract"}, {"text": "By systematic deletion of CENPA chromatin-containing regions of variable length of different chromosomes, followed by mapping of neocentromere loci in C. albicans and its related species Candida dubliniensis, which share similar centromere properties, we demonstrate that the chromosomal location is an evolutionarily conserved primary determinant of CENPA deposition", "begin": 591, "document": "23439889", "end": 958, "section": "abstract"}, {"text": "Interestingly, repositioning of CENPA chromatin from the neocentromere to the native centromere occurs by gene conversion in C. albicans", "begin": 1087, "document": "23439889", "end": 1223, "section": "abstract"}]}, {"documents": ["15950200", "9272155", "19862833", "10593671", "9302275", "8223759", "8048706", "8098062", "2771275", "8180509", "7695867", "10560244", "7994803"], "answer": ["autosomal dominant"], "id": "52ee9f55c8da898910000009", "snippets": [{"text": "KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias.", "begin": 301, "document": "15950200", "end": 550, "section": "abstract"}, {"text": "The Romano Ward long QT syndrome (LQTS) has an autosomal dominant mode of inheritance.", "begin": 0, "document": "9272155", "end": 86, "section": "abstract"}, {"text": "The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions.", "begin": 662, "document": "19862833", "end": 875, "section": "abstract"}, {"text": "The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. ", "begin": 180, "document": "10593671", "end": 449, "section": "abstract"}, {"text": "Different mutations in KVLQT1 cause the dominant Romano-Ward (RW) syndrome and the recessive Jervell and Lange-Nielsen (JLN) syndrome, which, in addition to cardiac abnormalities, includes congenital deafness. ", "begin": 402, "document": "9302275", "end": 612, "section": "abstract"}, {"text": "The Romano-Ward syndrome shows an autosomal dominant pattern of inheritance and normal hearing. ", "begin": 354, "document": "8223759", "end": 450, "section": "abstract"}, {"text": "The Romano-Ward syndrome is of autosomal dominant inheritance, and the Jervell and Lange-Nielson syndrome, with associated deafness, of autosomal recessive inheritance. ", "begin": 126, "document": "8048706", "end": 295, "section": "abstract"}, {"text": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. ", "begin": 0, "document": "8098062", "end": 96, "section": "abstract"}, {"text": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. ", "begin": 0, "document": "2771275", "end": 233, "section": "abstract"}]}, {"documents": ["19482666", "16812977", "19829181"], "answer": ["autosomal dominant mode of inheritance"], "id": "52f509512059c6d71c000020", "snippets": [{"text": "Congenital short QT syndrome is a new familial primary electrical disease of the heart, which is characterized by abnormally short QT interval and paroxysmal atrial and ventricular tachyarrhythmias, including sudden cardiac death. An autosomal dominant mode of inheritance has been suggested. ", "begin": 259, "document": "19482666", "end": 552, "section": "abstract"}, {"text": "From 1993, the Short QT Syndrome (SQTS) came to our attention, as a new inherited \"electrical disease\" associated with increased risk of sudden cardiac death and atrial fibrillation. Mutations of Ikr, Iks, Ikl channels cause dysfunctional Iks, Ikr, Ikl channels with an increase in the net outward K current leading to shortening of repolarization. This in turn leads to a shorter QT interval on the ECG and shorter atrial and ventricular refractory periods with increased susceptibility to VF and AF. There seems to be an autosomal dominant mode of inheritance.", "begin": 362, "document": "16812977", "end": 924, "section": "abstract"}]}, {"documents": ["24317018", "23538271", "22984773", "22277643", "20609320", "20129283", "19345130", "19377070", "17675083", "17399644", "17081365", "15863661", "15851320", "11823453", "11150514", "19272188", "19648062", "11786529", "23085483", "22529811", "22490985", "21397042", "21321465", "19406494", "18341814", "16325048", "11748104", "15338453", "15277732", "12051963", "10690282", "11960580", "10727653", "15877619", "12693506", "11420310", "14625171", "10664447", "17141278", "17075016", "17442746", "18599870"], "answer": [["I137M"], ["p.W1095X, c.3284G>A"], ["R27H"], ["E901K"], ["G1743R"], ["V728I"], ["N1443S"], ["E1152X"], ["c.664C>T; p.Arg222X"], ["Ala2>Thr, Ala735"], ["Ala735>Thr"], ["Val1340>Ile"], ["IVS18-1G>A"], ["E1784K (14x)"], ["F861WfsX90 (11x)"], ["D356N (8x)"], ["G1408R (7x)"], ["G400A"], ["H558R"], ["W822X"], ["Q55X"], ["V95I"], ["A1649V"], ["delF1617"], ["c.4810+3_4810+6dupGGGT"], ["K1527R"], ["A1569P"], ["R367H"], ["A735V"], ["R1192Q"], ["D1795"], ["p.I848fs"], ["p.R965C"], ["p.1876insM"], ["R1232W/T1620M"]], "id": "52fb78d82059c6d71c000068", "snippets": [{"text": "This was the first study to systematically investigate sodium channel variants in Chinese patients with ARVD; a new SCN5A mutation, I137M, was found. ", "begin": 1594, "document": "24317018", "end": 1744, "section": "abstract"}, {"text": "We describe a family showing the association between Brugada syndrome and epilepsy in which a known mutation in the SCN5A gene (p.W1095X, c.3284G>A) was identified. ", "begin": 407, "document": "23538271", "end": 572, "section": "abstract"}, {"text": "Direct sequencing and multiplex ligation-dependent probe amplification (MLPA) of the SCN5A gene for identification of mutations and larger rearrangements were performed, respectively. Eight patients (10.5%) had point mutations (R27H, E901K, G1743R (detected in three families), V728I, N1443S and E1152X).", "begin": 463, "document": "22984773", "end": 767, "section": "abstract"}, {"text": "Brugada syndrome (BrS) is a life-threatening arrhythmia disorder associated with autosomal-dominant mutations in the SCN5A gene. We aimed to characterize the diagnostic challenges and clinical manifestations of a novel SCN5A mutation associated with BrS. RESULTS: From a novel SCN5A mutation (c.664C>T; p.Arg222X) identified in a proband with the characteristic electrocardiographic pattern and the history of sudden collapse, 122 family members were studied including 40 carriers of the mutation. ", "begin": 11, "document": "22277643", "end": 509, "section": "abstract"}, {"text": "We analyzed the sequence of this gene in 25 Spanish patients with Brugada syndrome. In 4 (16%), we found mutations that had not previously been described: three were amino acid changes (i.e. Ala2>Thr, Ala735>Thr and Val1340>Ile) and one was an intron mutation that affected messenger RNA processing (i.e. IVS18-1G>A).", "begin": 225, "document": "20609320", "end": 542, "section": "abstract"}, {"text": "The 4 most frequent BrS1-associated mutations were E1784K (14x), F861WfsX90 (11x), D356N (8x), and G1408R (7x).", "begin": 1175, "document": "20129283", "end": 1286, "section": "abstract"}, {"text": "One missense mutation (G400A) in SCN5A was detected in a conserved region among the cohort of 19 patients. A H558R polymorphism was detected on the same allele. ", "begin": 566, "document": "19345130", "end": 727, "section": "abstract"}, {"text": "Thus, we studied the functional restoration of nonsense-mutated SCN5A. RESULTS: HEK293 cells were transfected with SCN5A cDNA or its mutant carrying W822X, a nonsense mutation associated with Brugada syndrome and sudden cardiac death. ", "begin": 372, "document": "19377070", "end": 607, "section": "abstract"}, {"text": "Among the cohort of 19 patients, one missense mutation (G400A) in SCN5A was detected in a conserved region. An H558R polymorphism was detected on the same allele.", "begin": 655, "document": "17675083", "end": 817, "section": "abstract"}, {"text": "Novel SCN5A mutation (Q55X) associated with age-dependent expression of Brugada syndrome presenting as neurally mediated syncope.", "begin": 0, "document": "17399644", "end": 129, "section": "title"}, {"text": "A novel nonsense SCN5A mutation (Q55X) was identified in the proband, his mother, and his asymptomatic brother.", "begin": 1226, "document": "17399644", "end": 1337, "section": "abstract"}, {"text": "Novel SCN5A gene mutations associated with Brugada syndrome: V95I, A1649V and delF1617", "begin": 1, "document": "17081365", "end": 87, "section": "title"}, {"text": "An intronic mutation (c.4810+3_4810+6dupGGGT) in the SCN5A gene, located outside the consensus splice site, was detected in this study in a family with a highly variable clinical phenotype of Brugada syndrome and/or conduction disease and in a patient with Brugada syndrome.", "begin": 419, "document": "15863661", "end": 693, "section": "abstract"}, {"text": "We genetically screened 30 asymptomatic probands (29 men and 1 woman; mean age 47.1 years) exhibiting a spontaneous Brugada-type ECG. Family members of patients with Brugada syndrome were excluded from the study. ", "begin": 395, "document": "15851320", "end": 608, "section": "abstract"}, {"text": "Genetic screening failed to identify SCN5A mutations in most cases but demonstrated a novel double missense mutation (K1527R and A1569P) located on the same allele in another asymptomatic subject (case 2).", "begin": 962, "document": "15851320", "end": 1167, "section": "abstract"}, {"text": "We screened patients with SUNDS for mutations in SCN5A, the gene known to cause Brugada syndrome, as well as genes encoding ion channels associated with the long-QT syndrome.", "begin": 274, "document": "11823453", "end": 448, "section": "abstract"}, {"text": "One mutation, R367H, lies in the first P segment of the pore-lining region between the DIS5 and DIS6 transmembrane segments of SCN5A. A second mutation, A735V, lies in the first transmembrane segment of domain II (DIIS1) close to the first extracellular loop between DIIS1 and DIIS2, whereas the third mutation, R1192Q, lies in domain III.", "begin": 688, "document": "11823453", "end": 1027, "section": "abstract"}, {"text": "The substitution (D1790G) causes LQTS and the insertion (D1795) induces both LQTS and Brugada syndromes in carrier patients.", "begin": 273, "document": "11150514", "end": 397, "section": "abstract"}]}, {"documents": ["21855519", "18543308", "18070308", "17679619", "19303371"], "answer": ["0.01% -0.1%"], "id": "52fb78572059c6d71c000067", "snippets": [{"text": "We chose patients with a short Bazett QTc interval from a database consisting of 114,334 patients to determine the clinical characteristics and prognostic value of a short QT interval. RESULTS: A total of 427 patients (mean age 43.4 \u00b1 22.4 years) had a short QT interval with about a 1.2 times higher male predominance (234 men). ", "begin": 384, "document": "21855519", "end": 714, "section": "abstract"}, {"text": "Among 5,511 males, 69 subjects (1.25%) exhibited QTc < 354 msec(1/2) (2 standard deviations [SDs] below the mean in males), and among 5,473 females, 89 subjects (1.63%) exhibited QTc < 364 msec(1/2) (2 SDs below the mean in females). Only 3 subjects (0.03% in all subjects and 0.05% in males) exhibited QTc < 300 msec(1/2), however, none had clinical symptoms of short QT syndrome. ", "begin": 965, "document": "18543308", "end": 1347, "section": "abstract"}, {"text": "Of the 19,153 subjects, two met the criteria of short QT interval and allowed for prevalence and incidence estimates for short QT interval as 0.01% and 0.39/100,000 person-years, respectively. ", "begin": 447, "document": "18070308", "end": 640, "section": "abstract"}, {"text": "The prevalence of QT interval <320 ms based on QTc, QTfc, and QTnc was 0.10%, 0.08%, and 0.06%, and the prevalence of QT interval <340 ms was 0.4%, 0.3%, and 0.3%, respectively. ", "begin": 887, "document": "17679619", "end": 1065, "section": "abstract"}]}, {"documents": ["22155372", "21798421", "21593722", "21383000", "21130771", "20126594", "19340359", "19013996", "17497253", "17432514", "19804087", "16226079", "16076272", "16887036", "15159330", "14676148", "18382206", "15890322", "15828882"], "answer": [["KCNJ2", "inward rectifier potassium channel gene"], ["HERG", "KCNH2"], ["CACNA2D1"], ["KCNQ1"], ["CACNB2b"]], "id": "52f509232059c6d71c00001f", "snippets": [{"text": "A novel gain-of-function KCNJ2 mutation associated with short-QT syndrome impairs inward rectification of Kir2.1 currents.", "begin": 0, "document": "22155372", "end": 122, "section": "title"}, {"text": "In this study, we identified a novel KCNJ2 gain-of-function mutation, M301K, associated with SQTS. ", "begin": 1504, "document": "22155372", "end": 1603, "section": "abstract"}, {"text": "A mutation in genes related to SQTS was found in 23% of the probands; most of them had a gain of function mutation in HERG (SQTS1).", "begin": 625, "document": "21798421", "end": 756, "section": "abstract"}, {"text": "We present, for the first time, a novel loss-of-function mutation coding for an L-type calcium channel subunit. ", "begin": 267, "document": "21383000", "end": 379, "section": "abstract"}, {"text": "however, a new variant at a heterozygous state was identified in the CACNA2D1 gene (nucleotide c.2264G > C; amino acid p.Ser755Thr), coding for the Ca(v)\u03b1(2)\u03b4-1 subunit of the L-type calcium channel.", "begin": 772, "document": "21383000", "end": 971, "section": "abstract"}, {"text": "In the present study, we report the first pathogenic mutation in the CACNA2D1 gene in humans, which causes a new variant of SQTS.", "begin": 1993, "document": "21383000", "end": 2122, "section": "abstract"}, {"text": "A novel mutation in the KCNH2 gene associated with short QT syndrome.", "begin": 0, "document": "21130771", "end": 69, "section": "title"}, {"text": "The altered function of T618I-HERG channels suggests that this mutation in the KCNH2 gene is responsible for the SQTS phenotype in this family. ", "begin": 1339, "document": "21130771", "end": 1483, "section": "abstract"}, {"text": "Gain of function mutations in three genes encoding K(+) channels have been identified, explaining the abbreviated repolarization seen in this condition: KCNH2 for I(kr) (SQT1), KCNQ1 for I(ks) (SQT2) and KCNJ2 for I(k1) (SQT3). ", "begin": 557, "document": "20126594", "end": 785, "section": "abstract"}, {"text": "To evaluate the possible diagnosis of SQTS, DNA sequencing of genes known to be associated with SQTS was performed and identified a novel mutation in the KCNH2 gene.", "begin": 354, "document": "19340359", "end": 519, "section": "abstract"}, {"text": "The mutation of genes (KCNH2, KCNQ1, and KCNJ2) encoding for cardiac potassium channels plays a central role in SQTS. ", "begin": 162, "document": "19013996", "end": 280, "section": "abstract"}, {"text": "To date, different mutations in genes encoding for cardiac ion channels (KCNH2, KCNQ1, and KCNJ2) have been identified to cause the short QT syndrome. ", "begin": 121, "document": "17497253", "end": 272, "section": "abstract"}, {"text": "Mutations in 3 different genes KCNQ1, KCNH2, and KCNJ2, all encoding cardiac ionic potassium channels have been identified in affected patients. ", "begin": 382, "document": "17432514", "end": 527, "section": "abstract"}, {"text": "Genetic analysis has, to date, identified three distinct forms of the condition, involving gain-of-function mutations to three different cardiac potassium channel genes: KCNH2 (SQT1), KCNQ1 (SQT2) and KCNJ2 (SQT3). ", "begin": 275, "document": "19804087", "end": 490, "section": "abstract"}, {"text": "Three different gain-of-function mutations in genes encoding for cardiac potassium channels (KCNH2, KCNQ1, and KCNJ2) have been identified up to now to cause short QT syndrome. ", "begin": 126, "document": "16226079", "end": 303, "section": "abstract"}, {"text": "To date, three different mutations in genes encoding cardiac ion channels (KCNH2, KCNQ1 and KCNJ2) have been identified as causing short QT syndrome.", "begin": 123, "document": "16076272", "end": 272, "section": "abstract"}]}, {"documents": ["23378035", "22038757", "21403557", "19755431", "19215249", "15241680"], "answer": ["One"], "id": "52c7311903868f1b0600001d", "snippets": [{"text": "Muenke syndrome is an autosomal dominant craniosynostosis syndrome resulting from a defining point mutation in the Fibroblast Growth Factor Receptor3 (FGFR3) gene. ", "begin": 0, "document": "23378035", "end": 164, "section": "abstract"}, {"text": "The associated of FGFR3 mutations with craniosynostosis has been restricted to three mutations, the common p.Pro250Arg in Muenke syndrome, p.Ala391Glu in Crouzon syndrome with acanthosis nigricans, and p.Pro250Leu identified in a family with isolated craniosynostosis. ", "begin": 214, "document": "22038757", "end": 483, "section": "abstract"}, {"text": "The Pro250Arg mutation in the FGFR3 gene is found in patients with Muenke syndrome and is one of the most frequently encountered mutations in craniosynostosis syndromes. ", "begin": 267, "document": "21403557", "end": 437, "section": "abstract"}, {"text": " Fibroblasts from 10 individuals each with Apert syndrome (FGFR2 substitution S252W), Muenke syndrome (FGFR3 substitution P250R), Saethre-Chotzen syndrome (various mutations in TWIST1) and non-syndromic sagittal synostosis (no mutation detected) were cultured. ", "begin": 547, "document": "19755431", "end": 808, "section": "abstract"}, {"text": "The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. ", "begin": 418, "document": "19215249", "end": 542, "section": "abstract"}, {"text": "Muenke syndrome, also known as FGFR3-associated coronal synostosis, is defined molecularly by the presence of a heterozygous nucleotide transversion, c.749C>G, encoding the amino acid substitution Pro250Arg, in the fibroblast growth factor receptor type 3 gene (FGFR3). ", "begin": 0, "document": "15241680", "end": 270, "section": "abstract"}]}, {"documents": ["24289293", "24198283", "24170099", "23709214", "24116901", "23759318", "23634277", "23558379", "23494602", "23459567", "23122652", "19878629", "20088763", "20236038", "21550857", "21899662", "22229582", "22252465", "23122650", "10568572", "15049789", "16231285", "17920549", "18075272", "18283404", "18713579", "18946064", "19296065", "19740383", "7914262", "8624684", "10482259", "23448220", "22056965"], "answer": [["Alemtuzumab"], ["Campath-1H"]], "id": "530cefaaad0bf1360c000003", "snippets": [{"text": "Alemtuzumab offers induction strategy for very active relapsing MS patients who have failed conventional therapy, and possibly selected treatment-naive patients.", "begin": 1395, "document": "24289293", "end": 1556, "section": "abstract"}, {"text": "Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.", "begin": 0, "document": "24198283", "end": 187, "section": "title"}, {"text": "Alemtuzumab (anti-CD52 mAb) provides long-lasting disease activity suppression in relapsing-remitting multiple sclerosis (RRMS).", "begin": 0, "document": "24198283", "end": 128, "section": "abstract"}, {"text": "Alemtuzumab, an anti-CD52 monoclonal antibody, increased the risk of thyroid dysfunction in CAMMS223, a phase 2 trial in relapsing-remitting multiple sclerosis.", "begin": 9, "document": "24170099", "end": 169, "section": "abstract"}, {"text": "Since then, one phase II and two phase III trials have shown that alemtuzumab reduces the relapse rate, compared with the active comparator interferon beta-1a (IFN\u03b2-1a), in treatment-na\u00efve and treatment-experienced MS up to 10 years from disease onset. Furthermore, in two of these trials, alemtuzumab reduced the risk of accumulating disability compared with IFN\u03b2-1a; indeed alemtuzumab treatment led to an improvement in disability and reduction in cerebral atrophy.", "begin": 846, "document": "23709214", "end": 1314, "section": "abstract"}, {"text": "Alemtuzumab is a humanized monoclonal antibody specific for the CD52 protein present at high levels on the surface of B and T lymphocytes. In clinical trials, alemtuzumab has shown a clinical benefit superior to that of interferon-\u03b2 in relapsing-remitting multiple sclerosis patients.", "begin": 0, "document": "24116901", "end": 284, "section": "abstract"}, {"text": "These results potentially help explain the level of immunocompetence observed in alemtuzumab-treated MS patients.", "begin": 583, "document": "23759318", "end": 696, "section": "abstract"}, {"text": "Alemtuzumab was first used in multiple sclerosis in 1991. It is a monoclonal antibody which is directed against CD52, a protein of unknown function on lymphocytes. ", "begin": 0, "document": "23634277", "end": 164, "section": "abstract"}, {"text": "Against an active comparator and the current first-line therapy for relapsing-remitting multiple sclerosis (interferon-beta), alemtuzumab showed a significant reduction in annualized relapse rate as well as a significant reduction in the accumulation of disability. ", "begin": 518, "document": "23558379", "end": 784, "section": "abstract"}, {"text": "Alemtuzumab (previously known as Campath(\u00ae)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. ", "begin": 0, "document": "23494602", "end": 218, "section": "abstract"}, {"text": "Compared to interferon beta-1a, alemtuzumab reduced the relapse rate by 49%-74% (P < 0.0001), and in two studies it reduced the risk of sustained disability accumulation by 42%-71% (P < 0.01). In one study (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CARE-MS1), there was no significant difference compared to interferon, perhaps reflecting the surprisingly low frequency of disability events in the comparator group.", "begin": 619, "document": "23494602", "end": 1060, "section": "abstract"}, {"text": "Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe.", "begin": 2103, "document": "23494602", "end": 2222, "section": "abstract"}, {"text": "Alemtuzumab was associated with a greater chance of improved contrast sensitivity in patients with RRMS and may delay the worsening of visual function. ", "begin": 1513, "document": "23459567", "end": 1665, "section": "abstract"}, {"text": "The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. ", "begin": 12, "document": "23122652", "end": 180, "section": "abstract"}, {"text": "Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit in terms of disability endpoints noted in previous trials was not observed here. ", "begin": 2640, "document": "23122652", "end": 2919, "section": "abstract"}, {"text": "Alemtuzumab, formally known as Campath-1H, is a humanized monoclonal antibody directed against CD52, a protein on the surface of lymphocytes and monocytes with unknown function. A single dose of alemtuzumab leads to a rapid, profound and prolonged lymphopenia. A Phase II trial has shown that alemtuzumab reduces the risk of relapse and accumulation of disability by over 70% compared with interferon beta in patients with early relapsing-remitting multiple sclerosis (MS).", "begin": 0, "document": "19878629", "end": 473, "section": "abstract"}, {"text": "Alemtuzumab, targeting CD52 expressed on T-cells, B-cells, monocytes and macrophages, has also shown to be effective in early RRMS and phase III trials are currently ongoing. ", "begin": 788, "document": "20088763", "end": 963, "section": "abstract"}, {"text": "monoclonal antibody therapy has provided the opportunity to rationally direct the therapeutic intervention by specifically targeting mechanisms of the immune system such as CD52 (alemtuzumab), CD25 (daclizumab), VLA-4 (natalizumab) and CD20 (rituximab)", "begin": 748, "document": "20236038", "end": 1000, "section": "abstract"}, {"text": "Alemtuzumab is a humanized monoclonal antibody targeting CD52, a broadly expressed cell surface molecule on immune cells.", "begin": 0, "document": "21550857", "end": 121, "section": "abstract"}, {"text": "Alemtuzumab-treatment of MS patients with relapsing-remitting forms of the disease significantly reduced the risk of relapse and accumulation of disability compared to interferon \u03b2-1a treatment in a phase II trial. ", "begin": 226, "document": "21550857", "end": 441, "section": "abstract"}, {"text": "Alemtuzumab (CD52-specific humanized monoclonal antibody) was found to be an effective therapy for treatment-naive patients with relapsing-remitting multiple sclerosis. ", "begin": 12, "document": "21899662", "end": 181, "section": "abstract"}, {"text": "Alemtuzumab effectively reduced relapse rates and improved clinical scores in patients with active relapsing-remitting multiple sclerosis not controlled by interferon therapy.", "begin": 1458, "document": "21899662", "end": 1633, "section": "abstract"}, {"text": "Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). ", "begin": 0, "document": "22252465", "end": 111, "section": "abstract"}, {"text": "The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. ", "begin": 12, "document": "23122650", "end": 161, "section": "abstract"}, {"text": "For patients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability. ", "begin": 2454, "document": "23122650", "end": 2636, "section": "abstract"}, {"text": "Campath-1H causes the immune response to change from the Th1 phenotype, suppressing multiple sclerosis disease activity, but permitting the generation of antibody-mediated thyroid autoimmunity.", "begin": 1028, "document": "10568572", "end": 1221, "section": "abstract"}, {"text": "Campath-1H is a humanized monoclonal antibody directed at CD52 expressed on lymphocytes and other cells of the immune system. It has been tested extensively in lymphoid malignancies, autoimmune diseases including rheumatoid arthritis, multiple sclerosis, and organ transplantation.", "begin": 0, "document": "15049789", "end": 281, "section": "abstract"}, {"text": "Campath 1-H (Alemtuzumab) is a humanised monoclonal antibody which targets the CD52 antigen, a low molecular weight glycoprotein present on the surface of most lymphocyte lineages, causing complement mediated lysis and rapid and prolonged T lymphocyte depletion. Following encouraging initial data from other centres we report our open label experience of using Campath 1-H as a treatment in aggressive relapsing multiple sclerosis in a consecutive series of 39 highly selected patients treated across three regional centres and followed for a mean of 1.89 years.", "begin": 0, "document": "18283404", "end": 563, "section": "abstract"}, {"text": "Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. ", "begin": 12, "document": "18946064", "end": 165, "section": "abstract"}, {"text": "In patients with early, relapsing-remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura.", "begin": 2023, "document": "18946064", "end": 2242, "section": "abstract"}, {"text": "Alemtuzumab, a monoclonal antibody targeting CD52, is a highly promising agent currently being studied in two phase III clinical trials. In this review, data from the recently published phase II clinical trial in the treatment of early relapsing remitting MS is summarized and analyzed in light of the development of alemtuzumab for MS and its potential role in treating this disease is discussed.", "begin": 622, "document": "19296065", "end": 1019, "section": "abstract"}, {"text": "Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on the surface of normal and malignant lymphocytes. It is approved for the treatment of B-cell chronic lymphocytic leukaemia and is undergoing Phase III clinical trials for the treatment of multiple sclerosis. ", "begin": 0, "document": "19740383", "end": 288, "section": "abstract"}, {"text": "To assess the effect of systemic lymphocyte depletion on disease activity, seven patients with MS received a 10-day intravenous course of the humanised monoclonal antibody CAMPATH-1H (anti-CDw52).", "begin": 226, "document": "7914262", "end": 422, "section": "abstract"}, {"text": "The effect of CAMPATH-1H on disease activity provides direct, but preliminary, evidence that disease activity in MS depends on the availability of circulating lymphocytes and can be prevented by lymphocyte depletion.", "begin": 1207, "document": "7914262", "end": 1423, "section": "abstract"}, {"text": "The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) monoclonal antibody (Campath-1H), has illuminated mechanisms that underlie the clinical course of the disease. ", "begin": 0, "document": "10482259", "end": 211, "section": "abstract"}, {"text": "Alemtuzumab is currently under review to treat relapsing multiple sclerosis (MS) in the United States, based on positive Phase II and Phase III trials in both treatment-na\u00efve and treated relapsing MS patients. ", "begin": 334, "document": "24289293", "end": 544, "section": "abstract"}, {"text": "Alemtuzumab has recently been approved by the European authorities for active relapsing MS, in essence as a first-line agent.", "begin": 756, "document": "24289293", "end": 881, "section": "abstract"}, {"text": "Alemtuzumab is a humanized monoclonal antibody directed against CD52. ", "begin": 0, "document": "23709214", "end": 70, "section": "abstract"}]}, {"documents": ["24112897", "21736514", "19727257", "19284243", "19137233", "19092783", "17498883", "17429407", "16816792", "15481726", "18704495", "23230531", "22473055"], "answer": [["subgenual cingulate gyrus"], ["anterior limb of the capsula interna"], ["nucleus accumbens"], ["medial forebrain bundle"], ["habenula"], ["ventral caudate nucleus"]], "id": "530cefaaad0bf1360c000002", "snippets": [{"text": "Deep brain stimulation (DBS) is under scientific evaluation as a new treatment option for these treatment-resistant patients. First clinical studies with small samples have been stimulated at the subgenual cingulate gyrus (Cg25/24), the anterior limb of the capsula interna (ALIC), and the nucleus accumbens (NAcc). ", "begin": 200, "document": "24112897", "end": 516, "section": "abstract"}, {"text": "New hypothesis-guided targets (e.g., medial forebrain bundle, habenula) are about to be assessed in clinical trials. ", "begin": 900, "document": "24112897", "end": 1017, "section": "abstract"}, {"text": "Deep brain stimulation (DBS) to the nucleus accumbens (NAcc-DBS) has antidepressant effects in patients suffering from treatment-resistant depression (TRD). ", "begin": 11, "document": "21736514", "end": 168, "section": "abstract"}, {"text": "The ventral striatum, including the head of the caudate nucleus and the nucleus accumbens, is a putative target for deep brain stimulation (DBS) in the treatment of obsessive-compulsive disorder (OCD) and major depression (MD). ", "begin": 0, "document": "19284243", "end": 228, "section": "abstract"}, {"text": "High frequency stimulation was successfully applied in several small samples of patients with treatment-resistant depression when the stimulation focused on different areas, e.g., nucleus accumbens, the lateral habenula or cortical areas.", "begin": 1434, "document": "19137233", "end": 1672, "section": "abstract"}, {"text": "We recorded electrophysiological activity directly from the nucleus accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression. ", "begin": 310, "document": "19092783", "end": 485, "section": "abstract"}, {"text": "Functional inhibition of the lateral habenula via deep brain stimulation (DBS) has antidepressive properties.", "begin": 1022, "document": "17498883", "end": 1131, "section": "abstract"}, {"text": "Because a prominent clinical feature of depression is anhedonia--the inability to experience pleasure from previously pleasurable activities--and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus accumbens might offer a new possibility to target depressive symptomatology in otherwise treatment-resistant depression.", "begin": 135, "document": "17429407", "end": 504, "section": "abstract"}, {"text": "These preliminary findings suggest that DBS to the nucleus accumbens might be a hypothesis-guided approach for refractory major depression.", "begin": 1692, "document": "17429407", "end": 1831, "section": "abstract"}, {"text": "Deep brain stimulation of the ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation (HDRS < or = 7 and HARS < or = 10).", "begin": 1153, "document": "15481726", "end": 1380, "section": "abstract"}, {"text": "No neuropsychological deterioration was observed, indicating that DBS of the ventral caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD and major depression.", "begin": 1572, "document": "15481726", "end": 1773, "section": "abstract"}, {"text": "Comparisons of clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation improved depressive symptoms. ", "begin": 478, "document": "19284243", "end": 710, "section": "abstract"}]}, {"documents": ["23506580", "23150151", "21806387", "21099121", "20826260", "19463375", "15933261"], "answer": ["cytochrome P450, CYPC19"], "id": "531a34d5b166e2b806000036", "snippets": [{"text": "The CYP2C19 G681A single polymorphism has been proven to affect clopidogrel responsiveness. ", "begin": 12, "document": "23506580", "end": 104, "section": "abstract"}, {"text": "This study investigated the effect of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and adverse clinical events in Chinese patient", "begin": 220, "document": "23506580", "end": 380, "section": "abstract"}, {"text": "ssociation of a functional polymorphism in the clopidogrel target receptor gene, P2Y12", "begin": 1, "document": "15933261", "end": 87, "section": "title"}, {"text": "We tested for an association of gene sequence variations in P2Y12 and occurrence of neurological adverse events in patients with symptomatic peripheral artery disease (PAD) during clopidogrel treatment", "begin": 129, "document": "15933261", "end": 330, "section": "abstract"}, {"text": "Variability in clopidogrel response might be influenced by polymorphisms in genes coding for drug metabolism enzymes (cytochrome P450 [CYP] family), transport proteins (P-glycoprotein) and/or target proteins for the drug (adenosine diphosphate-receptor P2Y12)", "begin": 118, "document": "19463375", "end": 377, "section": "abstract"}, {"text": "Polymerase chain reaction-based genotyping evaluated polymorphisms in the CYP2C19, CYP2C9, CYP3A4, CYP3A5, ABCB1, P2Y12, and CES genes. ", "begin": 695, "document": "19463375", "end": 831, "section": "abstract"}, {"text": "The prodrug clopidogrel requires activation by cytochrome P-450 (CYP) enzymes for its antiplatelet effect", "begin": 12, "document": "20826260", "end": 117, "section": "abstract"}, {"text": "Carriers of the CYP2C19*2 and *4 alleles showed reduced platelet inhibition after a clopidogrel 600-mg loading dose but responded to higher loading and maintenance dose regimens", "begin": 1381, "document": "19463375", "end": 1558, "section": "abstract"}, {"text": "Carriers of the CYP2C19*17 T-allele, with increased clopidogrel activation, had a 37% relative reduction in the TLR incidence, the primary end point", "begin": 797, "document": "20826260", "end": 945, "section": "abstract"}, {"text": "The cytochrome P450 (CYP) 2C19*2 polymorphism is associated with reduced responsiveness to clopidogrel and poor clinical outcome after stent implantation", "begin": 12, "document": "21099121", "end": 165, "section": "abstract"}, {"text": "From these results it is suggested that CYP2C19*2 polymorphism is associated with subclinical thrombus formation among Japanese patients receiving clopidogrel. ", "begin": 1464, "document": "21099121", "end": 1624, "section": "abstract"}, {"text": "To determine the effect of various SNPs on post-clopidogrel platelet reactivity and clinical outcome. MATERIALS & METHODS: Cytochrome 2C19 (CYP2C19) loss-of-function (LOF; *2, *3) and gain-of-function (GOF; *17) allelic variants, together with ABCB1 (3435 C\u2192T and 2677 G\u2192T/A) and paraoxonase-1 (PON-1; 192 Q\u2192R) SNPs were analyzed in 189 patients after elective stent implantation who participated in a randomized, placebo-controlled trial (NCT00638326)", "begin": 5, "document": "21806387", "end": 457, "section": "abstract"}, {"text": "Chinese people are more frequent carriers of cytochrome P450 2C19 (CYP2C19) loss-of-function alleles than Caucasians.", "begin": 9, "document": "23150151", "end": 126, "section": "abstract"}, {"text": "The aim of this study was to investigate the effect of the CYP2C19, ABCB1, and PON1 variants on clopidogrel pharmacodynamics and clinical outcomes in these patients", "begin": 391, "document": "23150151", "end": 555, "section": "abstract"}, {"text": "The risk of a low response to clopidogrel and composite ischemic events increased with the number of CYP2C19 loss-of-function alleles.", "begin": 1210, "document": "23150151", "end": 1344, "section": "abstract"}, {"text": "However, there were not significant differences in clopidogrel pharmacodynamics and clinical outcomes across the ABCB1 and PON1 genotype groups; bleeding was not significantly different across the CYP2C19, ABCB1, and PON1 genotype groups", "begin": 1345, "document": "23150151", "end": 1582, "section": "abstract"}, {"text": "The CYP2C19 loss-of-function alleles had a gene dose effect on the pharmacodynamics and composite ischemic events of clopidogrel in our study population. Neither the ABCB1 nor the PON1 genotype significantly influenced the antiplatelet effect and clinical outcomes of clopidogrel in these patients", "begin": 1597, "document": "23150151", "end": 1894, "section": "abstract"}]}, {"documents": ["24260251", "24219996", "24110485", "23855662", "23696895", "23633938", "23434623", "23185389", "23028459", "22893106", "22808075", "22719993", "22654636", "22570409", "22430954", "21731658", "21699738", "21668950", "21609954", "21602267", "20840752", "20823330", "20823322", "20576703", "20074336", "19602527", "19465376", "19346957", "18689812", "18508807", "18433471", "17939863", "17646288", "17267438", "16680138"], "answer": [["network-based methods"]], "id": "530cf4d5e2bfff940c000004", "snippets": [{"text": "We developed a new network inference algorithm called the Knowledge Network Gene Prioritization (KNGP) algorithm which can incorporate both link and node knowledge", "begin": 587, "document": "24260251", "end": 750, "section": "abstract"}, {"text": " In recent years, network-based methods - which utilize a knowledge network derived from biological knowledge - have been utilized for gene prioritization", "begin": 166, "document": "24260251", "end": 320, "section": "abstract"}, {"text": "o-expression network analysis and genetic algorithms for gene prioritization", "begin": 1, "document": "24219996", "end": 77, "section": "title"}, {"text": "We describe a bioinformatics approach, together with a freely accessible, interactive and flexible software termed Endeavour, to prioritize candidate genes underlying biological processes or diseases, based on their similarity to known genes involved in these phenomena", "begin": 80, "document": "16680138", "end": 349, "section": "abstract"}, {"text": " We intend to use the ensemble boosting learning techniques to combine variant computational approaches for gene prioritization in order to improve the overall performance.", "begin": 104, "document": "24110485", "end": 276, "section": "abstract"}, {"text": "The experimental results show that our ensemble learning approach outperforms the four gene-prioritization methods in ToppGene suite in the ranking results of the 13 known genes in terms of mean average precision, ROC and AUC measures", "begin": 743, "document": "24110485", "end": 977, "section": "abstract"}, {"text": "The proposed enhanced RaJoLink rare-term model combines text mining and gene prioritization approaches.", "begin": 597, "document": "23855662", "end": 700, "section": "abstract"}, {"text": "a network-based disease gene prioritization approach", "begin": 79, "document": "23696895", "end": 131, "section": "title"}, {"text": " Computational gene prioritization is based on various pieces of correlative evidence that associate each gene with the given disease and suggest possible causal links", "begin": 315, "document": "23633938", "end": 482, "section": "abstract"}, {"text": "Recently, many network-based methods have been proposed that implicitly utilize the modularity principle, which states that genes causing the same or similar diseases tend to form physical or functional modules in gene/protein relationship networks", "begin": 108, "document": "23434623", "end": 356, "section": "abstract"}, {"text": "the random walk with restart (RWR) algorithm is considered to be a state-of-the-art approach, but the modularity principle has not been fully considered in traditional RWR approaches", "begin": 376, "document": "23434623", "end": 558, "section": "abstract"}, {"text": "Therefore, we propose a novel method called ORIENT (neighbor-favoring weight reinforcement) to improve the performance of RWR through proper intensification of the weights of interactions close to the known disease genes", "begin": 560, "document": "23434623", "end": 780, "section": "abstract"}, {"text": "Network-based methods have been successfully exploiting this concept by capturing the interaction of genes or proteins into a score", "begin": 243, "document": "23185389", "end": 374, "section": "abstract"}, {"text": " Over the last years, computational approaches exploiting interaction network topology have been successfully applied to prioritize individual genes involved in diseases.", "begin": 354, "document": "23028459", "end": 524, "section": "abstract"}, {"text": "Here, we propose a genome-wide network-based prioritization framework named GUILD", "begin": 953, "document": "23028459", "end": 1034, "section": "abstract"}, {"text": "The traditional approach to reduce the number of candidate genes entails fine-mapping studies using markers and pedigrees", "begin": 213, "document": "22893106", "end": 334, "section": "abstract"}, {"text": "For this purpose, we evaluate our rule-based evolutionary machine learning systems, BioHEL and GAssist, on three public microarray cancer datasets, obtaining simple rule-based models for sample classification. ", "begin": 599, "document": "22808075", "end": 809, "section": "abstract"}, {"text": "mproving disease gene prioritization by comparing the semantic similarity of phenotypes in mice with those of human diseases", "begin": 1, "document": "22719993", "end": 125, "section": "title"}, {"text": "hus, comparing the similarity between experimentally identified phenotypes and the phenotypes associated with human diseases can be used to suggest causal genes underlying a disease. In this manuscript, we present a method for disease gene prioritization based on comparing phenotypes of mouse models with those of human diseases.", "begin": 316, "document": "22719993", "end": 646, "section": "abstract"}, {"text": "We present biomarker identification problem using gene prioritization method called gene prioritization from microarray data based on shortest paths, extended with structural and biological properties and edge flux using voting scheme (GP-MIDAS-VXEF).", "begin": 239, "document": "22654636", "end": 490, "section": "abstract"}, {"text": "ensemble approach to microarray data-based gene prioritization after missing value imputation", "begin": 3, "document": "17267438", "end": 96, "section": "title"}, {"text": "Recently, we have introduced the data mining tool ENDEAVOUR (Aerts et al., 2006), which performs this task automatically by relying on different genome-wide data sources, such as Gene Ontology, literature, microarray, sequence and more", "begin": 699, "document": "17646288", "end": 934, "section": "abstract"}, {"text": "So far, biologists have relied on literature studies, extensive queries to multiple databases and hunches about expected properties of the disease gene to determine such an ordering", "begin": 516, "document": "17646288", "end": 697, "section": "abstract"}, {"text": " human disease candidate gene prioritization using mouse phenotype", "begin": 8, "document": "17939863", "end": 74, "section": "title"}, {"text": "We study the effect of different data integration methods, and based on the validation studies, we show that our approach, ToppGene http://toppgene.cchmc.org, outperforms two of the existing candidate gene prioritization methods, SUSPECTS and ENDEAVOU", "begin": 684, "document": "17939863", "end": 935, "section": "abstract"}, {"text": " Extending on an earlier hypothesis that the majority of genes that impact or cause disease share membership in any of several functional relationships we, for the first time, show the utility of mouse phenotype data in human disease gene prioritization", "begin": 429, "document": "17939863", "end": 682, "section": "abstract"}, {"text": "onserved co-expression for candidate disease gene prioritization", "begin": 1, "document": "18433471", "end": 65, "section": "title"}, {"text": "We use co-expression data from yeast (S. cerevisiae), nematode worm (C. elegans), fruit fly (D. melanogaster), mouse and human and find that the use of evolutionary conservation can indeed improve the predictive value of co-expression", "begin": 506, "document": "18433471", "end": 740, "section": "abstract"}, {"text": "Using a training set of genes known to be involved in a biological process of interest, our approach consists of (i) inferring several models (based on various genomic data sources), (ii) applying each model to the candidate genes to rank those candidates against the profile of the known genes and (iii) merging the several rankings into a global ranking of the candidate genes", "begin": 193, "document": "18508807", "end": 571, "section": "abstract"}, {"text": "vocabularies, representations and ranking algorithms for gene prioritization by text mining", "begin": 14, "document": "18689812", "end": 105, "section": "title"}, {"text": "Recently, text mining techniques have been applied to extract prior knowledge from text-based genomic information sources and this knowledge can be used to improve the prioritization process", "begin": 150, "document": "18689812", "end": 340, "section": "abstract"}, {"text": "We present an approach to prioritize single nucleotide polymorphisms for further follow-up in genome-wide association studies of type 2 diabetes", "begin": 11, "document": "19346957", "end": 155, "section": "abstract"}, {"text": "The proposed method combines both the use of open data access from two type 2 diabetes-genome-wide association studies (granted by the Diabetes Genetics Initiative and the Welcome Trust Case Control Consortium) and the comprehensive analysis of candidate regions generated by the freely accessible ENDEAVOUR software.", "begin": 166, "document": "19346957", "end": 483, "section": "abstract"}, {"text": "ToppGene Suite (http://toppgene.cchmc.org; this web site is free and open to all users and does not require a login to access) is a one-stop portal for (i) gene list functional enrichment, (ii) candidate gene prioritization using either functional annotations or network analysis and (iii) identification and prioritization of novel disease candidate genes in the interactome.", "begin": 0, "document": "19465376", "end": 376, "section": "abstract"}, {"text": "The protein-protein interaction network (PPIN)-based disease candidate gene prioritization uses social and Web networks analysis algorithms (extended versions of the PageRank and HITS algorithms, and the K-Step Markov method)", "begin": 770, "document": "19465376", "end": 995, "section": "abstract"}, {"text": "We present gene prioritization system (GPSy), a cross-species gene prioritization system that facilitates the arduous but critical task of prioritizing genes for follow-up functional analyses", "begin": 0, "document": "22570409", "end": 191, "section": "abstract"}, {"text": "GPEC: a Cytoscape plug-in for random walk-based gene prioritization and biomedical evidence collection", "begin": 0, "document": "22430954", "end": 102, "section": "title"}, {"text": "Among these, network-based approaches are recently proposed and outperformed functional annotation-based ones", "begin": 156, "document": "22430954", "end": 265, "section": "abstract"}, {"text": "In the plug-in, gene prioritization is performed through a random walk with restart algorithm, a state-of-the art network-based method, along with a gene/protein relationship networ", "begin": 411, "document": "22430954", "end": 592, "section": "abstract"}, {"text": "Here we present a multi-dimensional evidence-based candidate gene prioritization approach for complex diseases and demonstrate it in schizophrenia", "begin": 626, "document": "19602527", "end": 772, "section": "abstract"}, {"text": "Gene prioritization and clustering by multi-view text mining", "begin": 0, "document": "20074336", "end": 60, "section": "title"}, {"text": "We present a multi-view approach to retrieve biomedical knowledge using different controlled vocabularies", "begin": 734, "document": "20074336", "end": 839, "section": "abstract"}, {"text": "Given a query list, GeneMANIA extends the list with functionally similar genes that it identifies using available genomics and proteomics data", "begin": 194, "document": "20576703", "end": 336, "section": "abstract"}, {"text": "Genomic linkage and association studies are commonly performed for identifying disease-related gene", "begin": 113, "document": "20823322", "end": 212, "section": "abstract"}, {"text": "Here, we introduce MedSim, a novel approach for ranking candidate genes for a particular disease based on functional comparisons involving the Gene Ontology", "begin": 485, "document": "20823322", "end": 641, "section": "abstract"}, {"text": "MedSim uses functional annotations of known disease genes for assessing the similarity of diseases as well as the disease relevance of candidate genes", "begin": 643, "document": "20823322", "end": 793, "section": "abstract"}, {"text": "Here, we report a large-scale analysis of spatial, i.e. 3D, gene-expression data from an entire organ (the mouse brain) for the purpose of evaluating and ranking positional candidate genes, showing that the spatial gene-expression patterns can be successfully exploited for the prediction of gene-phenotype associations not only for mouse phenotypes, but also for human central nervous system-related Mendelian disorders", "begin": 494, "document": "20823330", "end": 914, "section": "abstract"}, {"text": "In this paper, we propose an expandable framework for gene prioritization that can integrate multiple heterogeneous data sources by taking advantage of a unified graphic representation", "begin": 349, "document": "21731658", "end": 533, "section": "abstract"}, {"text": "We demonstrate that existing methods are likely to favor highly connected genes, making prioritization sensitive to the skewed degree distribution of PPI networks, as well as ascertainment bias in available interaction and disease association data", "begin": 581, "document": "21699738", "end": 828, "section": "abstract"}, {"text": "Motivated by this observation, we propose several statistical adjustment methods to account for the degree distribution of known disease and candidate genes, using a PPI network with associated confidence scores for interactions", "begin": 830, "document": "21699738", "end": 1058, "section": "abstract"}, {"text": "Here we employ a previously described method of candidate gene prioritization based mainly on gene annotation, in accompaniment with a technique based on the evaluation of pertinent sequence motifs or signatures, in an attempt to refine the gene prioritization approach.", "begin": 375, "document": "21668950", "end": 645, "section": "abstract"}, {"text": "We introduce the novel G\u00e9nie algorithm that overcomes these problems by evaluating the literature attached to all genes in a genome and to their orthologs according to a selected topic", "begin": 419, "document": "21609954", "end": 603, "section": "abstract"}, {"text": "PINTA (available at http://www.esat.kuleuven.be/pinta/; this web site is free and open to all users and there is no login requirement) is a web resource for the prioritization of candidate genes based on the differential expression of their neighborhood in a genome-wide protein-protein interaction network", "begin": 0, "document": "21602267", "end": 306, "section": "abstract"}, {"text": "Candidate gene prioritization by network analysis of differential expression using machine learning approaches", "begin": 0, "document": "20840752", "end": 110, "section": "title"}, {"text": "We have recently developed a computational method for constitutional genetic disorders that identifies the most promising candidate genes by replacing prior knowledge by experimental data of differential gene expression between affected and healthy individual", "begin": 323, "document": "20840752", "end": 582, "section": "abstract"}]}, {"documents": ["19901442", "19901441", "19200838", "23016781", "21245659", "20593935", "21289891", "18482556", "18055075", "17318575"], "answer": ["Cervical precancer and similar neoplasias were reduced by 84-100%"], "id": "531a3a58b166e2b806000037", "snippets": [{"text": "The success of HPV vaccination as a major public health prevention opportunity, however, will entirely depend on efficient infrastructures to deliver the vaccines and on the acceptance by individuals, parents and health care providers.", "begin": 891, "document": "17318575", "end": 1126, "section": "abstract"}, {"text": "The most effective strategy therein was vaccination of 12-year-olds, plus a temporary 12-24-year-old catch-up program covering both sexes; whereby HPV 6/11/16/18-related cervical cancer, high-grade cervical precancer, and genital wart incidence was reduced by 84-98% during year 50 following vaccine introduction", "begin": 499, "document": "18055075", "end": 811, "section": "abstract"}, {"text": "the introduction of cervical screening programs, the incidence and mortality of cervical cancer has been drastically reduced", "begin": 5, "document": "18482556", "end": 129, "section": "abstract"}, {"text": "On the assumption that the vaccine provided lifelong immunity, the cost-effectiveness ratio of vaccination of 12-year-old girls was $43,600 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice", "begin": 855, "document": "18716299", "end": 1088, "section": "abstract"}, {"text": "Vaccine efficacy in prevention of CIN 2 or higher lesions in HPV 16 or HPV 18 negative women, who received all vaccination doses, ranges between 98% and 100%", "begin": 1573, "document": "21289891", "end": 1730, "section": "abstract"}, {"text": "Life expectancy gained from vaccination is 13.04 years and average Quality Adjusted Life Years saved (QALYs) is 24.4 in vaccinated vs 6.29 in unvaccinated", "begin": 1055, "document": "20593935", "end": 1209, "section": "abstract"}, {"text": "Organized vaccination programs against HPV have the potential to prevent about 70% of cervical cancers and the vast majority of the other HPV-related conditions. ", "begin": 700, "document": "21245659", "end": 862, "section": "abstract"}, {"text": "However, existing data strongly suggests that as many as 440,000 cervical cancer cases and 220,000 deaths due to this malignancy will be prevented with the establishment of an effective worldwide HPV immunization program", "begin": 158, "document": "23016781", "end": 378, "section": "abstract"}, {"text": "Prophylactic HPV vaccination against HPV 16 and 18 has been shown to be highly effective in preventing HPV related malignancy in clinical trials", "begin": 271, "document": "19200838", "end": 415, "section": "abstract"}, {"text": "Nevertheless women up to 45 years of age have been shown to exhibit strong immune responses to the bivalent HPV vaccine which might be expected to reduce the risk of HPV re-infection and address the second peak of HPV related malignancy in later life, evident over 45 years of age", "begin": 1138, "document": "19200838", "end": 1418, "section": "abstract"}, {"text": "Reduced costs, simple vaccine regimes and strengthening vaccine delivery platforms for adolescents should eventually facilitate HPV vaccine introduction in developing countries.", "begin": 971, "document": "19901441", "end": 1148, "section": "abstract"}, {"text": "Besides cost, there are several socio-cultural and ethical issues involved with the implementation of already developed vaccines including the acceptability of HPV vaccination by preadolescent girls and their parents in India.", "begin": 1013, "document": "19901442", "end": 1239, "section": "abstract"}]}, {"documents": ["23880940", "22249256", "20168079", "19604397", "19295128", "19029937", "18611248", "16080193"], "answer": [["ZEB"], ["SNAIL"], ["SIRT1"], ["EGF"], ["TGFb"], ["aPKC"], ["Par6"]], "id": "531b3ff3b166e2b80600003d", "snippets": [{"text": "conserved polarity proteins Par6 and aPKC regulate cell polarization processes", "begin": 4, "document": "23880940", "end": 82, "section": "abstract"}, {"text": " In addition to signaling pathways that alter genetic programes that trigger the loss of cell-cell adhesion, alternative pathways can alter cell plasticity to regulate cell-cell cohesion and increase invasive potential", "begin": 425, "document": "23880940", "end": 643, "section": "abstract"}, {"text": "One such pathway involves TGF\u03b2-induced phosphorylation of Par6", "begin": 645, "document": "23880940", "end": 707, "section": "abstract"}, {"text": "Recently, we found that aPKC can also phosphorylate Par6 to drive EMT and increase the migratory potential of non-small cell lung cancer cells", "begin": 865, "document": "23880940", "end": 1007, "section": "abstract"}, {"text": "Here, we propose a novel mechanism through which the nicotinamide adenine dinucleotide-dependent histone deacetylase SIRT1 regulates EMT in prostate cancer cells through cooperation with the EMT inducing transcription factor ZEB1", "begin": 264, "document": "22249256", "end": 493, "section": "abstract"}, {"text": "In contrast, silencing SIRT1 in metastatic prostate tumor cells restores cell-cell adhesion and induces a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers", "begin": 750, "document": "22249256", "end": 993, "section": "abstract"}, {"text": "We also found that SIRT1 has a physiologically relevant role in endogenous EMT induced by EGF signaling in prostate cancer cells", "begin": 995, "document": "22249256", "end": 1123, "section": "abstract"}, {"text": "We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1", "begin": 1125, "document": "22249256", "end": 1260, "section": "abstract"}, {"text": "We thus identify a necessary role for ZEB1 in SIRT1-mediated EMT", "begin": 1523, "document": "22249256", "end": 1587, "section": "abstract"}, {"text": "Numb has been shown to play an important role in the proper functions of Par protein complex and in cell-cell junctions, both of which are associated with EMT", "begin": 147, "document": "20168079", "end": 305, "section": "abstract"}, {"text": "Recently, we showed that Numb is capable of binding to both Par3 and E-cadherin", "begin": 371, "document": "20168079", "end": 450, "section": "abstract"}, {"text": "Knockdown of Numb by shRNA in MDCK cells led to a lateral to apical translocation of E-cadherin and beta-catenin, active F-actin polymerization, mis-localization of Par3 and aPKC, a decrease in cell-cell adhesion and an increase in cell migration and proliferation", "begin": 609, "document": "20168079", "end": 873, "section": "abstract"}, {"text": "EGF-mediated EMT", "begin": 23, "document": "19604397", "end": 39, "section": "title"}, {"text": "This is coupled with the transcriptional repression of E-cadherin, often mediated by Snail1, Snail2 and Zeb1/deltaEF1.", "begin": 210, "document": "19604397", "end": 328, "section": "abstract"}, {"text": "EGF induces EMT in the breast cancer cell line PMC42-LA and the kinase inhibitor staurosporine (ST) induces EMT in embryonic neural epithelial cells, with F-actin de-bundling and disruption of cell-cell adhesion, via inhibition of aPKC", "begin": 535, "document": "19604397", "end": 770, "section": "abstract"}, {"text": "ST in combination with EGF directed a greater EMT via actin depolymerisation and focal contact size reduction, resulting in a loosening of cell-ECM attachment along with Snail1-Zeb1/deltaEF1 induction", "begin": 2071, "document": "19604397", "end": 2271, "section": "abstract"}, {"text": "This appeared fundamentally different to the EGF-induced EMT, highlighting the multiple pathways which can regulate EMT", "begin": 2273, "document": "19604397", "end": 2392, "section": "abstract"}, {"text": "unctional loss of the cell-cell adhesion molecule E-cadherin is an essential event for epithelial-mesenchymal transition (EMT), a process that allows cell migration during embryonic development and tumour invasion", "begin": 1, "document": "19295128", "end": 214, "section": "abstract"}, {"text": "Transcriptional and post-transcriptional regulatory mechanisms mediated by several inducers of EMT, in particular the ZEB and Snail factors, downregulate the expression and/or functional organization of core polarity complexes", "begin": 713, "document": "19029937", "end": 939, "section": "abstract"}, {"text": "TGFbeta has pleiotropic effects that range from regulation of proliferation and apoptosis to morphological changes and epithelial-mesenchymal transition (EMT)", "begin": 12, "document": "18611248", "end": 170, "section": "abstract"}, {"text": "Morphological changes were accompanied by decrease in E-cadherin and increased Snail expression but the mesenchymal markers (N-cadherin, SMAalpha and Vimentin) studied remained unchanged", "begin": 1194, "document": "18611248", "end": 1380, "section": "abstract"}, {"text": "Neutralising E-cadherin function promoted the invasion and inhibited the aggregation of endocrine-sensitive MCF7 cells, whilst having little effect on the behaviour of TamR cells", "begin": 616, "document": "16080193", "end": 794, "section": "abstract"}]}, {"documents": ["23574521", "23381558", "23288628", "23251581", "23251214", "21542789", "21427575", "21383967", "20453842", "19772830", "18082339", "16000323"], "answer": ["more than 30"], "id": "531af8cbb166e2b80600003a", "snippets": [{"text": "Genome-Wide Association Studies (GWAS) have allowed the characterization of more than 40 new susceptibility genes and the confirmation of a marked differential genetic background between patients expressing anti-cyclic citrullinated peptide antibodies (ACPA, approximately 80% of all RA patients) and ACPA negative RA patients", "begin": 275, "document": "23574521", "end": 601, "section": "abstract"}, {"text": "Firstly, we review here the major advances in identifying RA genetic susceptibility markers both within and outside of the MHC. ", "begin": 273, "document": "23381558", "end": 401, "section": "abstract"}, {"text": "The most relevant non-HLA gene single nucleotide polymorphisms (SNPs) associated with RA include PTPN22, IL23R, TRAF1, CTLA4, IRF5, STAT4, CCR6, PADI4. Large genome-wide association studies (GWAS) have identified more than 30 loci involved in RA pathogenesis.", "begin": 727, "document": "23288628", "end": 986, "section": "abstract"}, {"text": "The meta-analysis results showed that: (1) 30, 28 and 26 SNPs were significantly associated with RA (P<0.01) for the allele, dominant, and recessive models, respectively.", "begin": 929, "document": "23251581", "end": 1099, "section": "abstract"}, {"text": "This paper compares corresponding non-MHC genomic regions identified in rodent and human genome-wide association studies (GWAS). To date, over 30 non-MHC RA-associated loci have been identified in humans, and over 100 arthritis-associated loci have been identified in rodent models of RA", "begin": 285, "document": "23251214", "end": 572, "section": "abstract"}, {"text": "Interestingly, a series of candidate genes have been identified outside of the classical major histocompatibility (MHC) locus, which had long been regarded as the major contributor to the pathogenesis of this disease", "begin": 296, "document": "21542789", "end": 512, "section": "abstract"}, {"text": "Among these genes, PTPN22 plays an outstanding role. CD40, STAT4, PRM1, and TNFAIP3 also seem to be of relevance", "begin": 514, "document": "21542789", "end": 626, "section": "abstract"}, {"text": "Genome-wide association studies (GWASs) added about 10 new loci to the list of already more than 20 loci associated with RA, so the list is now over 30", "begin": 334, "document": "21427575", "end": 485, "section": "abstract"}, {"text": "Previous studies demonstrate that 6 of the established non-HLA CD and RA risk loci (out of 26 loci for each disease) are shared between both diseases.", "begin": 196, "document": "21383967", "end": 346, "section": "abstract"}, {"text": "These new associations bring the total number of confirmed rheumatoid arthritis risk loci to 31 among individuals of European ancestry", "begin": 766, "document": "20453842", "end": 900, "section": "abstract"}, {"text": "An additional 11 SNPs replicated at P < 0.05, many of which are validated autoimmune risk alleles, suggesting that most represent genuine rheumatoid arthritis risk alleles.", "begin": 902, "document": "20453842", "end": 1074, "section": "abstract"}, {"text": "Genome-wide association studies have expanded the number of validated RA risk loci beyond HLA-DRB1 \"shared epitope\" alleles to include additional major histocompatibility complex (MHC) risk alleles and more than 10 regions outside the MHC.", "begin": 111, "document": "19772830", "end": 350, "section": "abstract"}, {"text": "We successfully identified 41 significant SNPs relevant to RA, 25 associated genes and a number of important SNP-SNP interactions (SNP patterns)", "begin": 521, "document": "18082339", "end": 665, "section": "abstract"}, {"text": "A total of 47 candidate regions were identified. ", "begin": 911, "document": "16000323", "end": 960, "section": "abstract"}]}, {"documents": ["23694722", "23322639", "23104054", "20385584", "19723660", "17525233", "16537902"], "answer": [["H3K27me3"], ["H3K27Ac"], ["H3K9me3"], ["H3K36me"]], "id": "531b1e3cb166e2b80600003b", "snippets": [{"text": "The PcG proteins are well-conserved chromatin factors that repress transcription of numerous target genes. They bind the genome at specific sites, forming chromatin domains of associated histone modifications as well as higher-order chromatin structures.", "begin": 267, "document": "23694722", "end": 521, "section": "abstract"}, {"text": "A component of Polycomb repressive complex 2 (PRC2), which mediates the addition of K27me3 to histone H3 (Suz12), was also recruited by 14 dpi", "begin": 852, "document": "23322639", "end": 994, "section": "abstract"}, {"text": "We found that a component of the PRC1 complex (Bmi1), which binds to H3K27me3, was not enriched at promoters found previously to be enriched for H3K27me3", "begin": 1228, "document": "23322639", "end": 1381, "section": "abstract"}, {"text": " Here we show that the HSV DNA first associates with histone H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3), a modification associated with heterochromatin", "begin": 1837, "document": "23322639", "end": 2080, "section": "abstract"}, {"text": "Here we show that direct recognition of methylated histone H3 Lys36 (H3K36me), a mark associated with activation, by the PRC2 subunit Phf19 is required for the full enzymatic activity of the PRC2 complex", "begin": 303, "document": "23104054", "end": 506, "section": "abstract"}, {"text": "Furthermore, we show that Phf19 binds to a subset of PRC2 targets in mouse embryonic stem cells and that this is required for their repression and for H3K27me3 deposition", "begin": 585, "document": "23104054", "end": 755, "section": "abstract"}, {"text": "The Polycomb repressive complex 2 (PRC2) catalyzes trimethylation (me3) of histone H3 lysine 27 (K27), and it is believed that this activity mediates transcriptional repression", "begin": 206, "document": "20385584", "end": 382, "section": "abstract"}, {"text": "We show that loss of PRC2 activity results in a global increase in H3K27 acetylation", "begin": 812, "document": "20385584", "end": 896, "section": "abstract"}, {"text": "Moreover, we provide evidence that the acetylation of H3K27 is catalyzed by the acetyltransferases p300 and CBP.", "begin": 1092, "document": "20385584", "end": 1204, "section": "abstract"}, {"text": "Taken together, these studies suggest that patterns of epigenetic modifiers and the histone code influence the propensity of a gene to become hypermethylated in cancer and that DNMT3B plays an important role in regulating PRC1 function", "begin": 1255, "document": "19723660", "end": 1490, "section": "abstract"}, {"text": "During differentiation, binding of polycomb repressive complex 2 (PRC2), which mediates trimethylation of lysine 27 on histone H3 (K27me3), is lost on developmental genes that are transcriptionally induced", "begin": 91, "document": "17525233", "end": 296, "section": "abstract"}, {"text": "chromodomain (CD) of the Drosophila Polycomb protein exhibits preferential binding affinity for histone H3 when trimethylated at lysine 27", "begin": 4, "document": "16537902", "end": 142, "section": "abstract"}, {"text": "Not all CDs bind preferentially to K27me3; rather, some display affinity towards both histone H3 trimethylated at K9 and H3K27me3, and one CD prefers K9me3", "begin": 363, "document": "16537902", "end": 518, "section": "abstract"}]}, {"documents": ["24040647", "23715514", "18223678", "16877704", "16549820", "14720367", "11830536", "11598125", "9616291", "8822090"], "answer": ["Non-small cell lung cancer", "Squamous cell carcinoma"], "id": "52f89fc62059c6d71c000050", "snippets": [{"text": "The nanostructures target the cells with high affinity and specificity via the specific interaction between the aptamer (a 45-base oligonucleotide) and the cell, and distinguish A549 cells from other types of cancer cells (HeLa and MCF-7 cells) and subtypes of lung cancer cells (NCI-H157, NCI-H520, NCI-H1299, and NCI-H446 cells). ", "begin": 509, "document": "24040647", "end": 841, "section": "abstract"}, {"text": "Functional studies in A549 bronchioalveolar carcinoma and NCI-H520 squamous cell carcinoma cells revealed that Msi1 was enriched in spheroid cultures of tumor cells and in the CD133+ cell population. ", "begin": 409, "document": "23715514", "end": 609, "section": "abstract"}, {"text": "BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. ", "begin": 279, "document": "18223678", "end": 383, "section": "abstract"}, {"text": "Cellular proliferation was inhibited in non-small cell lung cancer (NSCLC) cell lines NCI-H460, NCI-H520, NCI-H1299, and SK-MES-1 by CTGF overexpression.", "begin": 585, "document": "16877704", "end": 738, "section": "abstract"}, {"text": "Human NCI-H520 cancer cells transfected with PDCD5 cDNA showed decreased colony-forming ability. ", "begin": 1113, "document": "16549820", "end": 1210, "section": "abstract"}, {"text": "In 4 lung cancer cell strains, BNIP3L protein was not detected in A549, NCI-H460, NCI-H446, except for NCI-H520, in which the protein expression level was slightly lower than that in immortal bronchial epithelial cell strain HBE4-E6/E7.", "begin": 788, "document": "14720367", "end": 1024, "section": "abstract"}, {"text": "We show that CLN3 mRNA and protein are overexpressed in glioblastoma (U-373G and T98g), neuroblastoma (IMR-32 and SK-N-MC), prostate (Du145, PC-3, and LNCaP), ovarian (SK-OV-3, SW626, and PA-1), breast (BT-20, BT-549, and BT-474), and colon (SW1116, SW480, and HCT 116) cancer cell lines but not in pancreatic (CAPAN and As-PC-1) or lung (A-549 and NCI-H520) cancer cell lines.", "begin": 762, "document": "11830536", "end": 1139, "section": "abstract"}, {"text": "NSCLC cell lines NCI-H520 and H460, which have no endogenous Cyr61, formed 60-90% fewer colonies after being transfected with a Cyr61 cDNA expression vector than cells transfected with the same amount of empty vector.", "begin": 442, "document": "11598125", "end": 659, "section": "abstract"}, {"text": "Importantly, the non-small cell lung carcinoma cell lines expressed either liver-specific (non-neuronal) mRNA (cell line A549) or predominantly the neuronal (cell line NCI-H520) AADC message. ", "begin": 1057, "document": "9616291", "end": 1249, "section": "abstract"}, {"text": "The antitumor effect of CGP41251 (4'-N-benzoyl staurosporine), a selective protein kinase C (PKC) inhibitor, was examined on two kinds of human non-small cell lung cancer (NSCLC) cell lines (adenocarcinoma: A549 and squamous cell carcinoma: NCI-H520).", "begin": 0, "document": "8822090", "end": 251, "section": "abstract"}]}, {"documents": ["22942672", "21784908", "20978102", "20850498", "21364800", "17956224", "17350933", "16980466", "16321966", "15337158", "14526006", "11967086", "2541880", "17392430", "12646230"], "answer": ["Multiple"], "id": "52ef7786c8da898910000015", "snippets": [{"text": " different replication origins in some archaeal genomes leave quite different patterns of strand asymmetry, suggesting that different replication origins in the same genome may be differentially used", "begin": 716, "document": "22942672", "end": 915, "section": "abstract"}, {"text": "In the process of identifying the minimum replication origin sequence required for autonomous plasmid replication in P. furiosus, we discovered that several features of the origin predicted by bioinformatic analysis and in vitro binding studies were not essential for stable autonomous plasmid replication", "begin": 275, "document": "21784908", "end": 580, "section": "abstract"}, {"text": "However, because some archaeal genomes contain multiple origins of replication, bias in gene dosage caused by delayed replication should be minimized and hence the substitution rate of genes should associate less with chromosome position", "begin": 205, "document": "20978102", "end": 442, "section": "abstract"}, {"text": "Ortholog families were grouped by their consensus position and designated by their proximity to one of the three origins (O1, O2, O3)", "begin": 683, "document": "20978102", "end": 816, "section": "abstract"}, {"text": "In perfectly shaped isochore-like structures (in \"protoisochores\") from Sulfolobus acidocaldarius and Thermofilum pendens genomes the difference in 3GC levels between genes from different \"protoisochores\" is about 30%", "begin": 166, "document": "20850498", "end": 383, "section": "abstract"}, {"text": "The number of Ori sites varies in prokaryotes and eukaryotes", "begin": 186, "document": "21364800", "end": 246, "section": "abstract"}, {"text": "Replication starts at a single Ori site in bacteria, but in eukaryotes multiple Ori sites are used for fast copying across all chromosomes", "begin": 248, "document": "21364800", "end": 386, "section": "abstract"}, {"text": "The situation becomes complex in archaea, where some groups have single and others have multiple origins of replication", "begin": 388, "document": "21364800", "end": 507, "section": "abstract"}, {"text": "Results from this in silico analysis show that the Themococcales have a single origin of replication", "begin": 1221, "document": "21364800", "end": 1321, "section": "abstract"}, {"text": "The analysis of pHH1 deletion variants led to a 4 kilobase pair DNA region containing the origin of replication of the pHH1 plasmid.", "begin": 927, "document": "2541880", "end": 1059, "section": "abstract"}, {"text": "The low point in cumulative GC-skew, near the left end, was a region rich in short repeats and lacking ORFs, which is likely to be an origin of replication", "begin": 1184, "document": "11967086", "end": 1339, "section": "abstract"}, {"text": "We report on the identification and first cloning of an autonomously replicating sequence element from the chromosome of an archaeon, the extreme halophile Halobacterium strain NRC-1", "begin": 0, "document": "14526006", "end": 182, "section": "abstract"}, {"text": "The putative replication origin was identified by association with the orc7 gene and replication ability in the host strain, demonstrated by cloning into a nonreplicating plasmid", "begin": 184, "document": "14526006", "end": 362, "section": "abstract"}, {"text": "Multiple origins of replication in archaea", "begin": 0, "document": "15337158", "end": 42, "section": "title"}, {"text": "Until recently, the only archaeon for which a bona fide origin of replication was reported was Pyrococcus abyssi, where a single origin was identified", "begin": 0, "document": "15337158", "end": 150, "section": "abstract"}, {"text": "Although several in silico analyses have suggested that some archaeal species might contain more than one origin, this has only been demonstrated recently", "begin": 152, "document": "15337158", "end": 306, "section": "abstract"}, {"text": "Two studies have shown that multiple origins of replication function in two archaeal species", "begin": 308, "document": "15337158", "end": 400, "section": "abstract"}, {"text": "One study identified two origins of replication in the archaeon Sulfolobus solfataricus, whereas a second study used a different technique to show that both S. solfataricus and Sulfolobus acidocaldarius have three functional origins", "begin": 402, "document": "15337158", "end": 634, "section": "abstract"}, {"text": "These are the first reports of archaea having multiple origins", "begin": 636, "document": "15337158", "end": 698, "section": "abstract"}, {"text": "To date, methanogens are the only group within the archaea where firing DNA replication origins have not been demonstrated in vivo", "begin": 0, "document": "17956224", "end": 130, "section": "abstract"}, {"text": "In the present study we show that a previously identified cluster of ORB (origin recognition box) sequences do indeed function as an origin of replication in vivo in the archaeon Methanothermobacter thermautotrophicus", "begin": 132, "document": "17956224", "end": 349, "section": "abstract"}, {"text": " Two cdc6 genes are present, but neither could be linked unambiguously to an origin of replication", "begin": 438, "document": "17350933", "end": 536, "section": "abstract"}, {"text": "A cryptic 36-kbp plasmid sequence that contains an orc1 gene flanked by a presumptive origin of replication consisting of 38 tandem repeats of a 143-nucleotide motif was detected in M. barkeri", "begin": 1012, "document": "16980466", "end": 1204, "section": "abstract"}, {"text": "We draw the conclusion that multiple functional sites of origin of replication may exist in the genomes of most archaea and in some exceptional cases of eubacteria, while in the majority of eubacteria, replication occurs through a single fixed origin", "begin": 499, "document": "16321966", "end": 749, "section": "abstract"}]}, {"documents": ["21459714", "9244653", "8723065"], "answer": ["In HNPCC, the mismatch DNA repair system is involved."], "id": "53161545b166e2b806000002", "snippets": [{"text": "The HNPCC syndrome (hereditary non polyposis colon cancer) or Lynch syndrome stands for an autosomic dominant condition leading to the most prevalent hereditary colo-rectal cancers (CCR). MMR (mismatch repair)'s genes are involved in carcinogenesis as they play a role in ADNA mismatch repair.", "begin": 0, "document": "21459714", "end": 293, "section": "abstract"}, {"text": "Mutations in the genes of the mismatch DNA repair system and of the TGF-beta-II-receptor, the main defects of the HNPCC (hereditary nonpolyposis colorectal cancer), are exclusively identified in sequences of microsatellites. ", "begin": 799, "document": "9244653", "end": 1024, "section": "abstract"}, {"text": "In HNPCC families, germline mutations in any of four genes encoding proteins of a specialized DNA repair system, the mismatch repair, predispose to cancer development. ", "begin": 498, "document": "8723065", "end": 666, "section": "abstract"}]}, {"documents": ["23255952", "19276163", "18089711"], "answer": ["Epidermal growth factor receptor (EGFR)"], "id": "53188480b166e2b806000018", "snippets": [{"text": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines.", "begin": 0, "document": "23255952", "end": 126, "section": "abstract"}, {"text": "Gefitinib (Iressa) is a specific and effective epidermal growth factor receptor inhibitor.", "begin": 0, "document": "19276163", "end": 90, "section": "abstract"}, {"text": "Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR.", "begin": 0, "document": "18089711", "end": 185, "section": "abstract"}]}, {"documents": ["21555518", "20501657", "23562577", "22698995", "22107958", "21812759", "20388958", "20345481", "20127796", "19897490", "19439223", "19282658", "19119918", "19011633", "18555605", "18426999", "17942419", "17701549", "17257585", "16894358", "16724942", "16530877", "16487043", "15855052", "15743416", "15734732", "15613547", "15464985", "15175654", "15068251", "14660636", "14580148", "14504288", "12511571", "12356737", "11387216"], "answer": ["Repressor"], "id": "52fa6ac72059c6d71c000055", "snippets": [{"text": "the impact of BACH1 repression on transcription", "begin": 948, "document": "21555518", "end": 995, "section": "abstract"}, {"text": "Bach1 is a repressor of the oxidative stress response", "begin": 215, "document": "20501657", "end": 268, "section": "abstract"}, {"text": "transcriptional repressor Bach-1, ", "begin": 2113, "document": "23562577", "end": 2147, "section": "abstract"}, {"text": "Bach1, a transcriptional repressor of the HMOX1 gene", "begin": 423, "document": "22698995", "end": 475, "section": "abstract"}, {"text": "The mechanism underlying Bach1-mediated HO-1 repression is less well understood", "begin": 236, "document": "22107958", "end": 315, "section": "abstract"}, {"text": "Transcription factor BACH1 [BTB (broad-complex, tramtrack and bric-a-brac) and CNC (cap'n'collar protein) homology 1] binds to ARE-like sequences, functioning as a transcriptional repressor ", "begin": 715, "document": "21812759", "end": 905, "section": "abstract"}, {"text": "Bach1) is a transcriptional repressor of heme oxygenase-1 (HO-1)", "begin": 23, "document": "20388958", "end": 87, "section": "abstract"}, {"text": " its regulatory mechanism by the transcriptional repressor, BTB and CNC homology 1 (Bach1),", "begin": 346, "document": "20345481", "end": 437, "section": "abstract"}, {"text": "Bach1, a basic leucine zipper mammalian transcriptional repressor, negatively regulates heme oxygenase 1 (HMOX1),", "begin": 88, "document": "20127796", "end": 201, "section": "abstract"}, {"text": "Bach1, the negative regulator of Nrf2", "begin": 258, "document": "19897490", "end": 295, "section": "abstract"}, {"text": "ach1 is a transcriptional repressor of the heme oxygenase (HO)-1 gene. ", "begin": 1, "document": "19439223", "end": 72, "section": "abstract"}, {"text": "The inhibitory role for Bach1 may stem from its activity to repress gene expression including HO-1", "begin": 1570, "document": "19282658", "end": 1668, "section": "abstract"}, {"text": "Bach1 is a transcriptional repressor of the HO-1 gene (Hmox-1)", "begin": 228, "document": "19119918", "end": 290, "section": "abstract"}, {"text": "Here we show that the transcription factor Bach1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1), which inhibits oxidative stress-inducible genes, is a crucial negative regulator of oxidative stress-induced cellular senescence", "begin": 165, "document": "19011633", "end": 413, "section": "abstract"}, {"text": "Bach1 is a transcriptional repressor of the HO-1 gene", "begin": 374, "document": "18555605", "end": 427, "section": "abstract"}, {"text": "Bach1 repressively controls myocardial HO-1 expression ", "begin": 1590, "document": "18426999", "end": 1645, "section": "abstract"}, {"text": " the transcriptional repressor BACH1 binds ARE-like enhancers", "begin": 202, "document": "17942419", "end": 263, "section": "abstract"}, {"text": " transcription factor Bach1 functions as a repressor of the enhancers of heme oxygenase-1 (HO-1) gene (Hmox-1)", "begin": 13, "document": "17701549", "end": 123, "section": "abstract"}, {"text": "Bach1, a transcription factor that suppresses the HO-1 gene", "begin": 238, "document": "17257585", "end": 297, "section": "abstract"}, {"text": "Bach1, a transcriptional repressor that is negatively regulated by heme in mammalian cells", "begin": 652, "document": "16894358", "end": 742, "section": "abstract"}, {"text": "Bach1 normally represses HO-1 expression. ", "begin": 1142, "document": "16724942", "end": 1184, "section": "abstract"}, {"text": "Bach1, a heme binding protein that represses gene expression", "begin": 240, "document": "16530877", "end": 300, "section": "abstract"}, {"text": "complexes with Bach1 repress MARE-dependent gene expression", "begin": 1078, "document": "16487043", "end": 1137, "section": "abstract"}, {"text": "transcriptional repressor Bach1", "begin": 24, "document": "15855052", "end": 55, "section": "title"}, {"text": "bach1-ablation resulted in increased expression of HO-1 ", "begin": 469, "document": "15743416", "end": 525, "section": "abstract"}, {"text": "Bach1 contributes to the down-regulation of ARE-regulated genes", "begin": 1478, "document": "15734732", "end": 1541, "section": "abstract"}, {"text": "evidence that BACH1 acts as a transcriptional repressor in the regulation of MARE-dependent genes", "begin": 1361, "document": "15613547", "end": 1458, "section": "abstract"}, {"text": "Bach1 forms a heterodimer with small Maf family, and functions as a repressor of the Maf recognition element (MARE) in vivo", "begin": 27, "document": "15464985", "end": 150, "section": "abstract"}, {"text": "ach1 is a transcriptional repressor of heme oxygenase-1 and beta-globin genes,", "begin": 1, "document": "15175654", "end": 79, "section": "abstract"}, {"text": "BACH1 suppresses expression of HO1", "begin": 1460, "document": "15068251", "end": 1494, "section": "abstract"}, {"text": "transcription factor Bach1 heterodimerizes with small Maf proteins to repress Maf recognition element (MARE)-dependent gene expression", "begin": 4, "document": "14660636", "end": 138, "section": "abstract"}, {"text": " Bach1 as a heme-regulated and hypoxia-inducible repressor for transcription of the HO-1 gene", "begin": 901, "document": "14580148", "end": 994, "section": "abstract"}, {"text": "Bach1, a transcriptional repressor of heme oxygenase-1 gene", "begin": 34, "document": "14504288", "end": 93, "section": "title"}, {"text": "Bach1, a heme-regulated transcriptional repressor", "begin": 570, "document": "12511571", "end": 619, "section": "abstract"}, {"text": "a heme-binding factor, Bach1, is a critical physiological repressor of ho-1", "begin": 238, "document": "12356737", "end": 313, "section": "abstract"}, {"text": "transcription repressor Bach1", "begin": 80, "document": "11387216", "end": 109, "section": "title"}]}, {"documents": ["24244333", "21437181", "20064468", "18623069", "17553932", "18190519", "17229476", "16842202", "16714300", "15987638", "14579121"], "answer": [["HSP90"], ["CDC37"], ["GRP75"], ["HSP60"], ["LRPPRC"], ["TUFM"], ["PICK1"], ["PSMA7", "XAPC7"], ["Pael receptor"]], "id": "5318380bb166e2b806000013", "snippets": [{"text": "In addition to two known binding partners (HSP90, CDC37), 12 proteins were identified using the TAP assay; four of which are mitochondrially localized (GRP75, HSP60, LRPPRC, and TUFM).", "begin": 482, "document": "21437181", "end": 666, "section": "abstract"}, {"text": "We find that parkin binds PICK1 via a PDZ-mediated interaction, which predominantly promotes PICK1 monoubiquitination rather than polyubiquitination. ", "begin": 445, "document": "17553932", "end": 595, "section": "abstract"}, {"text": "We have identified the 20S proteasomal subunit alpha4 (synonyms: PSMA7, XAPC7, subunit alpha type 7) as a new interacting partner of parkin.", "begin": 276, "document": "15987638", "end": 416, "section": "abstract"}, {"text": "we cloned parkin-binding protein using a yeast two-hybrid system and identified a putative G protein-coupled receptor protein,which we named the Pael receptor (Pael-R)", "begin": 402, "document": "14579121", "end": 569, "section": "abstract"}, {"text": ", whose interactions with CASK are reviewed here, include the Parkinson's disease molecule parkin, ", "begin": 636, "document": "16842202", "end": 735, "section": "abstract"}]}, {"documents": ["24323900", "24273091", "24261963", "24085367", "24060900", "24014301", "24009233", "23847354", "23617253"], "answer": ["PI3K-\u03b4", "phosphoinositol-3 kinase delta isoform"], "id": "5321bc309b2d7acc7e00000d", "snippets": [{"text": " PI3K\u03b4 (idelalisib). ", "begin": 1348, "document": "24323900", "end": 1369, "section": "abstract"}, {"text": "Idelalisib (PI3K inhibitor) ", "begin": 1962, "document": "24273091", "end": 1990, "section": "abstract"}, {"text": "In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed, and at least fifteen compounds have progressed into clinical trials as new anticancer drugs. Among these, idelalisib", "begin": 425, "document": "24261963", "end": 656, "section": "abstract"}, {"text": " idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform.", "begin": 1000, "document": "24085367", "end": 1112, "section": "abstract"}, {"text": "PI3K inhibitor idelalisib ", "begin": 551, "document": "24014301", "end": 577, "section": "abstract"}, {"text": "the PI3K inhibitor idelalisib ", "begin": 1181, "document": "24009233", "end": 1211, "section": "abstract"}, {"text": "PI3K-\u03b4 inhibitor idelalisib", "begin": 37, "document": "23847354", "end": 64, "section": "abstract"}, {"text": "idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor.", "begin": 1007, "document": "23617253", "end": 1077, "section": "abstract"}]}, {"documents": ["23952327", "23650931", "23526674", "23521456", "23106053", "23097569", "22973348", "22797727", "23449218", "23194995", "22257305", "20978142", "2510609"], "answer": [["Blood Tests"], ["Imaging Tests"], ["Kidney Biopsy"], ["Urine Tests"], ["estimated GFR (eGFR)"], ["Decreased tryptophan (TRP)"]], "id": "5311b99ae3eabad021000004", "snippets": [{"text": "kidney dysfunction and decreased glomerular filtration rate (GFR) are diagnosed by the evaluation of changes in the serum creatinine (SCr) and blood urea nitrogen (BUN) concentrations. ", "begin": 11, "document": "23952327", "end": 196, "section": "abstract"}, {"text": "Renal biomarkers, especially those present in urine, may be useful for the study of both acute and chronic nephropathies.", "begin": 525, "document": "23952327", "end": 646, "section": "abstract"}, {"text": "The International Renal Interest Society (IRIS) canine AKI grading system and the implementation of urinary biomarkers", "begin": 824, "document": "23952327", "end": 942, "section": "abstract"}, {"text": "Decreased tryptophan (TRP) and increased kynurenine (KYN) and kynurenic acid (KYNA) in blood have been reported in patients and experimental animals with renal diseases.", "begin": 12, "document": "23650931", "end": 181, "section": "abstract"}, {"text": "Acute kidney injury was defined as a decrease in estimated glomerular filtration rate of 50% or more from the beginning of vancomycin therapy. ", "begin": 779, "document": "23526674", "end": 922, "section": "abstract"}, {"text": " In critically ill children, the development of reversible AKI during vancomycin therapy is associated with administration of nephrotoxic drugs and an elevated BUN: Scr ratio.", "begin": 1810, "document": "23526674", "end": 1985, "section": "abstract"}, {"text": "The physiologic determination of renal status is the measured glomerular filtration rate (mGFR). Serum creatinine, blood urea nitrogen, cystatin C, and estimated GFR (eGFR), based on serum creatinine have failed to replace mGFR.", "begin": 136, "document": "23521456", "end": 364, "section": "abstract"}, {"text": "After kidney donation, renal function measured by blood urea nitrogen (BUN) and serum creatinine of all donors returned to normal within one week, and no serious complications were noticed.", "begin": 943, "document": "23106053", "end": 1132, "section": "abstract"}, {"text": " In living kidney donors GFR is not significantly correlated with age or sex.", "begin": 1402, "document": "23106053", "end": 1479, "section": "abstract"}, {"text": "Increased proteinuria would lead to a larger risk for renal failure in the long term", "begin": 12, "document": "22973348", "end": 96, "section": "abstract"}, {"text": "A reduction of proteinuria in patients with non-diabetic renal disease was observed during the 4-month treatment with pioglitazone which continued for 2 months after the cessation of the treatment. However, 4 months after the cessation of the treatment, a little increase was detected in the level of proteinuria.", "begin": 1392, "document": "22973348", "end": 1705, "section": "abstract"}, {"text": "We identify pleiotropic associations among these loci with kidney function-related traits and risk of CKD.", "begin": 953, "document": "22797727", "end": 1059, "section": "abstract"}]}, {"documents": ["23529100", "21971974", "21250829", "20925563", "20875149", "20597833", "19163770", "18002454", "18002293", "17272161", "15718654"], "answer": [["Sleep monitoring"], ["Body weight"], ["Blood pressure control"], ["Heart failure control"], ["vital signs"], ["fetal heart signal"], ["uterine contractions"], ["Electrocardiograms", "ECG"], ["Temperature"], ["Oxygen saturation", "SaO2"], ["breath rate"], ["Step-counting"], ["Falls detector"]], "id": "52f895602059c6d71c000040", "snippets": [{"text": "Home-polysomnography (HPSG) has been proposed as a cost-effective alternative for obstructive sleep apnea (OSA) diagnosis. We assessed, in a feasibility study, whether telematic transmission using the Dream\u00ae and Sleepbox\u00ae technologies was associated with low HPSG failure rate", "begin": 11, "document": "23529100", "end": 287, "section": "abstract"}, {"text": " In this study, we monitored remotely self-measured body weight and blood pressure, in parallel with the data automatically transmitted by implantable cardioverter-defibrillators.", "begin": 163, "document": "21971974", "end": 342, "section": "abstract"}, {"text": "Body weight, patient activity, and the difference between MHR and RHR are mutually correlated and may reasonably contribute to an algorithm for predicting heart failure deterioration. Blood pressure appears to offer no additional value. As both genesis and symptoms of heart failure exacerbation are non-uniform and complex, the telemonitoring concepts for heart failure patients should employ continuous monitoring of multiple diagnostic parameters, rather than rely on a single parameter.", "begin": 1198, "document": "21971974", "end": 1688, "section": "abstract"}, {"text": "System and can collect users' vital signs with a set of wireless sensors", "begin": 276, "document": "21250829", "end": 348, "section": "abstract"}, {"text": "this terminal is very helpful in special circumstances such as disaster relief, dangerous outdoor sports and adventure monitoring, and antiterrorism activities.", "begin": 580, "document": "21250829", "end": 740, "section": "abstract"}, {"text": "A new, phonocardiography-based telemetric fetal home monitoring system.", "begin": 0, "document": "20925563", "end": 71, "section": "title"}, {"text": "The input element of the system was the home monitor with two sensors for recording the trans-abdominal fetal heart signal and the uterine contractions. T", "begin": 207, "document": "20925563", "end": 361, "section": "abstract"}, {"text": "Health technology assessment review: remote monitoring of vital signs--", "begin": 0, "document": "20875149", "end": 71, "section": "title"}, {"text": "Telemonitoring is currently being used in community-based healthcare, at the scene of medical emergencies, by ambulance services and in hospitals. ", "begin": 977, "document": "20875149", "end": 1124, "section": "abstract"}, {"text": "Mobile telemonitoring for achieving tighter targets of blood pressure control in patients with complicated diabetes: ", "begin": 0, "document": "20597833", "end": 117, "section": "title"}, {"text": "Patients in the intervention arm transmitted weekly blood pressure readings wirelessly, using adapted sensors via mobile phones to a central server. ", "begin": 449, "document": "20597833", "end": 598, "section": "abstract"}, {"text": "In patients with diabetes, mobile telemonitoring has potential for delivering intensified care to improve blood pressure control, and its use may be associated with reduced exposure to hyperglycemia.", "begin": 1284, "document": "20597833", "end": 1483, "section": "abstract"}, {"text": "A new codivilla-spring prosthesis with sensors for telemonitoring / telerehabilitation has been designed and constructed. It provides step counting", "begin": 441, "document": "19163770", "end": 588, "section": "abstract"}, {"text": "This article is a survey of systems, algorithms and sensors, for the automatic early detection of the fall of elderly persons. ", "begin": 224, "document": "18002293", "end": 351, "section": "abstract"}, {"text": "We describe a vital sign telemonitor (VST) that acquires, records, displays, and provides readings such as: electrocardiograms (ECGs), temperature (T), and oxygen saturation (SaO2) over the Internet to any site. The design of this system consisted of three parts: sensors, analog signal processing circuits, and a user-friendly graphical user interface (GUI). ", "begin": 0, "document": "17272161", "end": 360, "section": "abstract"}, {"text": "The paper describes the development of biomedical clothing for ambulatory telemonitoring of human vital parameters. VTAM (Vetement de Tele-Assistance Medicale) presents a T-shirt made from textile with woven wires and incorporating four smooth dry ECG electrodes, a breath rate sensor, a shock/fall detector and two temperature sensors. ", "begin": 0, "document": "15718654", "end": 337, "section": "abstract"}]}, {"documents": ["24139770", "24073184", "24067948", "23821609", "22942063", "21689119", "21591562"], "answer": [["weight loss"], ["exercise", "physical activity", "fitness"], ["dermatology"], ["alcohol-use behavior change"], ["urine flow"], ["fluid intake"]], "id": "5324cca79b2d7acc7e00001d", "snippets": [{"text": "Evidence-based strategies in weight-loss mobile apps", "begin": 0, "document": "24139770", "end": 52, "section": "title"}, {"text": "Weight-loss mobile applications (apps) have the potential to be a helpful tool", "begin": 168, "document": "24139770", "end": 246, "section": "abstract"}, {"text": "Mobile apps for pediatric obesity prevention and treatment, healthy eating, and physical activity promotion", "begin": 0, "document": "24073184", "end": 107, "section": "title"}, {"text": "Mobile applications (apps) offer a novel way to engage children in behavior change,", "begin": 0, "document": "24073184", "end": 83, "section": "abstract"}, {"text": "Mobile applications in dermatology", "begin": 0, "document": "24067948", "end": 34, "section": "title"}, {"text": "A total of 229 dermatology-related apps were identified in the following categories: general dermatology reference (61 [26.6%]), self-surveillance/diagnosis (41 [17.9%]), disease guide (39 [17.0%]), educational aid (20 [8.7%]), sunscreen/UV recommendation (19 [8.3%]), calculator (12 [5.2%]), teledermatology (8 [3.5%]), conference (6 [2.6%]), journal (6 [2.6%]), photograph storage/sharing (5 [2.2%]), dermoscopy (2 [0.9%]), pathology (2 [0.9%]), and other (8 [3.5%]). The most reviewed apps included Ultraviolet\u2009~\u2009UV Index (355 reviews), VisualDx (306), SPF (128), iSore (61), and SpotMole (50).", "begin": 782, "document": "24067948", "end": 1379, "section": "abstract"}, {"text": " Twenty-seven mobile apps were identified and reviewed that involved general pharmacy practice, including apps that involved drug references, clinical references, medical calculators, laboratory references, news and continuing medical education, and productivity.", "begin": 1381, "document": "23821609", "end": 1644, "section": "abstract"}, {"text": "Today, many high quality mobile apps are available for users and health professionals and cover the whole health care chain, i.e. information collection, prevention, diagnosis, treatment and monitoring", "begin": 103, "document": "22942063", "end": 304, "section": "abstract"}, {"text": "Our team has developed a mobile health and fitness app called myFitnessCompanion\u00ae ", "begin": 306, "document": "22942063", "end": 388, "section": "abstract"}, {"text": "to examine the current available mobile smartphone applications (e.g., apps) that utilize principles of ecological momentary assessment (EMA)-daily self-monitoring or near real-time self-assessment of alcohol-use behavior-to promote positive behavior change, alcohol harm reduction, psycho-education about alcohol use, or abstinence from alcohol.", "begin": 342, "document": "21689119", "end": 688, "section": "abstract"}, {"text": "few apps addressed alcohol-use behavior change or recovery. Aside from tracking drinking consumption, a minority utilized empirically based components of alcohol treatment.", "begin": 1018, "document": "21689119", "end": 1190, "section": "abstract"}, {"text": "More than 17,000 mHealth apps now are available for smart phones and other devices, and they do everything from monitoring urine flow for patients with enlarged prostates to reminding people prone to kidney stones to drink more water.", "begin": 0, "document": "21591562", "end": 234, "section": "abstract"}]}, {"documents": ["17653994", "23235657", "21975791", "18840008"], "answer": ["Pregabalin"], "id": "5324ce779b2d7acc7e00001e", "snippets": [{"text": "Multimodal approaches seem to be the treatment of choice in fibromyalgia", "begin": 78, "document": "17653994", "end": 150, "section": "abstract"}, {"text": "A multidisciplinary program was developed and implemented for patients with fibromyalgia in the primary care setting. The program included education (seven sessions) and physical therapy (25 sessions).", "begin": 152, "document": "17653994", "end": 353, "section": "abstract"}, {"text": "Amitriptyline for neuropathic pain and fibromyalgia in adults.", "begin": 0, "document": "23235657", "end": 62, "section": "title"}, {"text": "Amitriptyline is a tricyclic antidepressant that is widely used to treat chronic neuropathic pain (pain due to nerve damage) and fibromyalgia, and is recommended in many guidelines. ", "begin": 12, "document": "23235657", "end": 194, "section": "abstract"}, {"text": "Amitriptyline should continue to be used as part of the treatment of neuropathic pain or fibromyalgia, but only a minority of patients will achieve satisfactory pain relief.", "begin": 3926, "document": "23235657", "end": 4099, "section": "abstract"}, {"text": "Valproic acid and its sodium salt (sodium valproate) are antiepileptic drugs that are sometimes used to treat chronic neuropathic pain and fibromyalgia, although they are not licensed for this use. ", "begin": 12, "document": "21975791", "end": 210, "section": "abstract"}, {"text": "Oral pregabalin, a calcium channel alpha(2)delta-subunit ligand with analgesic, anxiolytic and antiepileptic activity, has shown efficacy in the treatment of fibromyalgia.", "begin": 0, "document": "18840008", "end": 171, "section": "abstract"}, {"text": "Pregabalin is, therefore, a valuable option in the first-line treatment of patients with fibromyalgia.", "begin": 837, "document": "18840008", "end": 939, "section": "abstract"}]}, {"documents": ["23425613", "23093633", "22760463", "22712761", "22473248", "22136212", "21601255", "21176430", "21077473", "20235039", "18371047", "18360636", "18330528", "16481094", "16310120", "15928960", "15643101", "15291651", "15062207"], "answer": [["depression during childhood and adolescence"], ["Premature ejaculation", "PE"], ["erectile dysfunction"], ["Insomnia"], ["postprostatectomy established stress urinary incontinence", "SUI"], ["mood and anxiety disorders during pregnancy and breast feeding"], ["hot flashes", "postmenopausal symptoms"], ["bulimia"], ["benzodiazepine/alcohol dependence"], ["fibromyalgia"], ["behavioral disorders in dementia"], ["schizophrenia"], ["chronic pain disease"], ["diabetic neuropathy"]], "id": "5324cf139b2d7acc7e00001f", "snippets": [{"text": "The present analysis evaluates the prevalence and medication use in inpatients with depression during childhood and adolescence", "begin": 11, "document": "23425613", "end": 138, "section": "abstract"}, {"text": "Fluoxetine and mirtazapine were the most frequently prescribed substances. Sertraline, escitalopram, and citalopram were also prescribed. CONCLUSION: A reserved medical treatment can be observed in child and adolescence psychiatry. Off-label use seems to be nearly unavoidable due to the lack of newly authorized medicine. Moreover, the numerous prescriptions for fluoxetine, the only SSRI currently approved for this age group in Germany, lead to the question of possible unauthorized alternatives.", "begin": 979, "document": "23425613", "end": 1478, "section": "abstract"}, {"text": "Premature ejaculation (PE) is a common sexual dysfunction affecting 20% to 30% of men worldwide", "begin": 0, "document": "23093633", "end": 95, "section": "abstract"}, {"text": "Treatment of PE typically involves pharmacotherapy, particularly when lifelong. Although there are numerous reports on the off-label use of selective serotonin reuptake inhibitors (SSRIs) and other compounds, only 2 treatments have been evaluated in randomized controlled phase 3 clinical trials: PSD502 and dapoxetine (SSRI)", "begin": 329, "document": "23093633", "end": 654, "section": "abstract"}, {"text": "Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].", "begin": 1, "document": "22760463", "end": 88, "section": "title"}, {"text": "Amitriptyline and-in case of comorbid depressive disorder or generalized anxiety disorder-duloxetine are recommended. Off-label use of duloxetine and pregabalin can be considered in case of no comorbid mental disorder.", "begin": 1526, "document": "22760463", "end": 1744, "section": "abstract"}, {"text": "Trazodone is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors. It is approved by the FDA for the treatment of depression. Insomnia is the most frequent reason for prescription of trazodone. It has also been proven useful in the treatment of anxiety disorders. Other off-label uses include the treatment of bulimia, benzodiazepine/alcohol dependence, fibromyalgia, central nervous system degenerative diseases (behavioral disorders in dementia and other organic disorders), schizophrenia, chronic pain disease and diabetic neuropathy, sexual dysfunction.", "begin": 14, "document": "22712761", "end": 617, "section": "abstract"}, {"text": "symptoms of vasomotor dysregulation (hot flashes) associated with the menopausal transition and sex hormone deprivation. Implication of changes in central neurotransmission in the pathogenesis of hot flashes has prompted the off-label use of serotonergic and \u03b3-aminobutyric acid-ergic drugs as a therapeutic alternative,", "begin": 85, "document": "22473248", "end": 405, "section": "abstract"}, {"text": "Sertraline was the most prescribed antidepressant for the treatment of major depressive disorder, followed by fluvoxamine and tianeptine. Fluvoxamine was the most prescribed antidepressant for the treatment of anxiety disorders and mixed disorders of emotions and conduct. Off-label prescribing of antidepressants was found in 85.6% of young patients.", "begin": 701, "document": "22136212", "end": 1052, "section": "abstract"}, {"text": "Our results suggest that duloxetine is a possible alternative treatment of postprostatectomy established stress urinary incontinence.", "begin": 1653, "document": "21601255", "end": 1786, "section": "abstract"}, {"text": "Pharmacological treatment of fibromyalgia.", "begin": 0, "document": "21176430", "end": 42, "section": "title"}, {"text": "different classes of drugs with different mechanisms of action are used off-label, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs)", "begin": 664, "document": "21176430", "end": 838, "section": "abstract"}, {"text": "Gynaecological cancer patients generally suffer from an earlier and more severe menopausal syndrome than the general female population. Hormone replacement therapy is often contraindicated and there are non-hormonal treatments that are proven to be more effective than placebo in randomized controlled trials, e.g., some antidepressants, gabapentine and clonidine. The main limits to the use of these drugs in controlling hot flashes are the off-label use for this purpose,", "begin": 0, "document": "21077473", "end": 473, "section": "abstract"}, {"text": "ymptomatic therapy for patients with erectile dysfunction.", "begin": 92, "document": "20235039", "end": 150, "section": "abstract"}, {"text": "a oral daily off label use therapy with selective serotonin re-uptake inhibitors (paroxetine, fluoxetine, sertraline) can be offered.", "begin": 940, "document": "20235039", "end": 1073, "section": "abstract"}, {"text": "Without the Food and Drug Administration approval, dapoxetine, as well as other SSRIs in PE, is an off-label drug for PE.", "begin": 1547, "document": "18371047", "end": 1668, "section": "abstract"}, {"text": "the treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors (SSRIs) via either on-demand or daily delivery. ", "begin": 360, "document": "18360636", "end": 512, "section": "abstract"}, {"text": "The results of this off-label use show that Duloxetine is effective in men with SUI after prostate surgery even if standard pelvic floor exercises have failed.", "begin": 802, "document": "18330528", "end": 961, "section": "abstract"}, {"text": "Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy.", "begin": 0, "document": "16481094", "end": 138, "section": "title"}, {"text": "the number of children and adolescents whose visits involved prescription of antidepressants, particularly SSRIs, has increased markedly through 2002. Although fluoxetine remained the most commonly prescribed, other SSRIs were increasingly prescribed through 2002. These trends raise concerns regarding the widespread off-label use of antidepressants lacking reliable evidence of safety and efficacy for use in children and adolescents.", "begin": 1536, "document": "16310120", "end": 1972, "section": "abstract"}, {"text": "Given the presumed efficacy of these new compounds and the off-label use of the current SSRIs, one might conclude that psychotherapy\\behavior therapy for rapid ejaculation is an obsolete and antiquated intervention", "begin": 518, "document": "15928960", "end": 732, "section": "abstract"}, {"text": "The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding:", "begin": 0, "document": "15643101", "end": 87, "section": "title"}, {"text": "The use of selective serotonin reuptake inhibitors during pregnancy or lactation is, to date, not promoted because of lack of safety documentation. However, the off-label use of these drugs has been common for several years. In the treatment of mood and anxiety disorders during pregnancy, the serotonin reuptake inhibitors are often preferred over tricyclic antidepressants because of their relatively few adverse effects and safety in overdose. ", "begin": 171, "document": "15643101", "end": 618, "section": "abstract"}, {"text": "The last few years have seen a remarkable rise in the off-label use of trazodone for inducing sleep in nondepressed patients, to a degree that it is prescribed for this purpose as commonly as the leading hypnotic", "begin": 12, "document": "15291651", "end": 224, "section": "abstract"}, {"text": "Since the mid-1980s there has been a rapid rise in the off-label use of antidepressants, particularly trazodone, for treating insomnia.", "begin": 558, "document": "15062207", "end": 693, "section": "abstract"}]}, {"documents": ["22170717", "19204208"], "answer": [["Any patient with adrenocortical cancer (ACC), irrespective of age and family history."], ["All families with a p53 mutation must have at least one family member with a sarcoma, breast, brain, or adrenocortical carcinoma (ACC)."]], "id": "531778ddb166e2b80600000f", "snippets": [{"text": "According to the Chompret criteria for LFS, any patient with adrenocortical cancer (ACC), irrespective of age and family history, is at high risk for a TP53 germline mutation. ", "begin": 116, "document": "22170717", "end": 292, "section": "abstract"}, {"text": "All families with a p53 mutation had at least one family member with a sarcoma, breast, brain, or adrenocortical carcinoma (ACC).", "begin": 725, "document": "19204208", "end": 854, "section": "abstract"}]}, {"documents": ["16932613", "20662462", "22610954", "8615372", "12152840", "8186659", "1940586", "2724779", "6620327", "6109943", "759736", "838566", "1248830"], "answer": ["autosomal recessive"], "id": "52bf1b0a03868f1b06000009", "snippets": [{"text": "The disease has an autosomal recessive mode of inheritance, and is characterized by excessive copper deposition, predominantly in the liver and brain.", "begin": 122, "document": "16932613", "end": 272, "section": "abstract"}, {"text": " The inheritance is autosomal recessive. ", "begin": 178, "document": "20662462", "end": 219, "section": "abstract"}, {"text": "Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation. ", "begin": 0, "document": "22610954", "end": 156, "section": "abstract"}, {"text": "Inheritance seems most likely to be autosomal recessive", "begin": 138, "document": "14580665", "end": 193, "section": "abstract"}, {"text": "When familial, it is inherited recessively and has been linked to chromosome 20. ", "begin": 1268, "document": "14580665", "end": 1349, "section": "abstract"}, {"text": "Inheritance of a pair of alleles of an autosomal recessive gene on chromosome 13 is necessary and sufficient to cause such copper accumulation in WD; reducing the dietary intake of copper cannot prevent the development of WD. ", "begin": 183, "document": "8615372", "end": 409, "section": "abstract"}, {"text": "Wilson's disease is a treatable movement disorder with autosomal recessive inheritance which is associated with severe morbidity and mortality if not treated early. ", "begin": 12, "document": "12152840", "end": 177, "section": "abstract"}, {"text": "The patient was considered heterozygote for hemochromatosis on the basis of the autosomal recessive inheritance for hemochromatosis, the frequency of the hemochromatosis gene, and the laboratory parameters defining her iron overload. ", "begin": 154, "document": "8186659", "end": 388, "section": "abstract"}, {"text": "Wilson's disease (WD) is an autosomal recessive disorder of copper accumulation leading to liver and/or brain damage. ", "begin": 0, "document": "1940586", "end": 118, "section": "abstract"}, {"text": "Autosomal recessive inheritance indicates that siblings of affected patients are at 25% risk of having the disease. ", "begin": 189, "document": "1940586", "end": 305, "section": "abstract"}, {"text": "Wilson's disease is a rare genetic disorder of copper metabolism with autosomal recessive inheritance.", "begin": 0, "document": "2724779", "end": 102, "section": "abstract"}, {"text": "Recessive inheritance is, however, supported. ", "begin": 994, "document": "6620327", "end": 1040, "section": "abstract"}, {"text": "The autosomal recessive mode of inheritance strongly suggests that mutation of a single gene causes the impairment of both caeruloplasmin synthesis and biliary copper excretion.", "begin": 161, "document": "6109943", "end": 338, "section": "abstract"}, {"text": "This is consistent with the autosomal-recessive pattern of inheritance", "begin": 1190, "document": "759736", "end": 1260, "section": "abstract"}, {"text": "The overall sex ratio of patients was nearly 1:1, and genetic analysis of 20 families confirmed an autosomal recessive mode of inheritance. ", "begin": 268, "document": "838566", "end": 408, "section": "abstract"}, {"text": "Dermatoglyphics of 11 patients with Wilson's disease and 16 of their clinically asymptomatic relatives of first degree were investigated; 11 of the latter ones were heterozygous in agreement with the turn over rates of Cu-67, 12 under the assumption of autosomal recessive inheritance.", "begin": 0, "document": "1248830", "end": 285, "section": "abstract"}]}, {"documents": ["18052993", "17666061", "15336972"], "answer": ["autosomal dominant"], "id": "52bf19f703868f1b06000002", "snippets": [{"text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrythmogenic disease characterized by exercise--or stress--induced ventricular tachyarrythmias, syncope, or sudden death, usually in the pediatric age group. Familial occurrence has been noted in about 30% of cases. Inheritance may be autosomal dominant or recessive, usually with high penetrance. The causative genes have been mapped to chromosome 1. Mutations of the cardiac ryanodine receptor gene (RyR2) have been identified in autosomal dominant pedigrees, while calsequestrin gene (CASQ2) mutations are seen in recessive cases.", "begin": 12, "document": "18052993", "end": 617, "section": "abstract"}, {"text": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. ", "begin": 12, "document": "17666061", "end": 194, "section": "abstract"}, {"text": "Several mutations in the genes encoding RyR1 and RyR2 have been identified in autosomal dominant diseases of skeletal and cardiac muscle, such as malignant hyperthermia (MH), central core disease (CCD), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic right ventricular dysplasia type 2 (ARVD2). ", "begin": 985, "document": "15336972", "end": 1313, "section": "abstract"}]}, {"documents": ["19725597", "11772283", "11154213", "9814660"], "answer": ["cytomegalovirus"], "id": "52bf1cad03868f1b0600000a", "snippets": [{"text": "Currently, there are four antivirals available that are active against CMV: ganciclovir, valganciclovir, foscarnet, and cidofovir. ", "begin": 326, "document": "19725597", "end": 457, "section": "abstract"}, {"text": "At present, the antiviral drugs ganciclovir, foscarnet and cidofovir are commonly used in the treatment of CMV infection and disease.", "begin": 598, "document": "11772283", "end": 731, "section": "abstract"}, {"text": "Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy.", "begin": 1245, "document": "11154213", "end": 1360, "section": "abstract"}, {"text": "dditional drugs like lobucavir and cidofovir have been used for specific indications. ", "begin": 1042, "document": "9814660", "end": 1128, "section": "abstract"}]}, {"documents": ["23616122", "23241893", "22815651", "23139212", "22815185", "22401778", "22338309", "22322981", "21677475", "21623686", "21243489", "20671739", "20703154", "19098925", "18632461", "16527005", "16188502"], "answer": ["RANKL"], "id": "52bf1d9e03868f1b06000010", "snippets": [{"text": "Whether the factor has the same role in humans is of clinical interest because an inhibitor for RANKL, denosumab, is already used for the treatment of bone disease and might benefit breast cancer patients.", "begin": 414, "document": "23616122", "end": 619, "section": "abstract"}, {"text": "Treatment of AML cells with the clinically available RANKL Ab Denosumab resulted in enhanced NK cell anti-leukemia reactivity. ", "begin": 901, "document": "23241893", "end": 1028, "section": "abstract"}, {"text": "The emerging clinical implication, supported by recent epidemiological studies, is that \u03b2AR-blockers and drugs interfering with RANKL signaling, such as Denosumab, could increase patient survival if used as adjuvant therapy to inhibit both the early colonization of bone by metastatic breast cancer cells and the initiation of the \"vicious cycle\" of bone destruction induced by these cells.", "begin": 1263, "document": "22815651", "end": 1653, "section": "abstract"}, {"text": "Both the effects of RANKL on osteoclastogenesis and cytokine production by malignant cells could be blocked by disruption of RANK-RANKL interaction with denosumab.", "begin": 659, "document": "23139212", "end": 822, "section": "abstract"}, {"text": "In the future, the armamentarium against osteoporotic fractures will likely be enriched by (1.) new bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1, PTH and PTHrp analogues, and possibly calcilytics; (2.) new inhibitors of bone resorption such as cathepsin K inhibitors which may suppress osteoclast function without impairing osteoclast viability and thus maintain bone formation by preserving the osteoclast-osteoblast crosstalk, and denosumab, an already widely available antibody against RANKL which inhibits osteoclast formation, function, and survival; and (3.) new therapeutic strategies based on an extended understanding of the pathophysiology of osteoporosis which may include sequential therapies with two or more bone active substances aimed at optimising the management of bone capital acquired during adolescence and maintained during adulthood in terms of both quantity and quality. ", "begin": 617, "document": "22815185", "end": 1598, "section": "abstract"}, {"text": "Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years.", "begin": 374, "document": "22401778", "end": 606, "section": "abstract"}, {"text": "Denosumab is a fully human monoclonal antibody to RANK Ligand that is administered as a 60-mg subcutaneous injection every 6 months.", "begin": 1922, "document": "22338309", "end": 2054, "section": "abstract"}, {"text": "More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "begin": 1478, "document": "22322981", "end": 1617, "section": "abstract"}, {"text": "Denosumab is a neutralizing monoclonal antibody to RANKL and has recently been found to inhibit SRE more effectively than BP. ", "begin": 1819, "document": "21677475", "end": 1945, "section": "abstract"}, {"text": "Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. ", "begin": 975, "document": "21623686", "end": 1210, "section": "abstract"}, {"text": "Denosumab, an anti-RANKL monoclonal antibody with proven antiosteoclast activity, may suppress immune responses. ", "begin": 1268, "document": "21243489", "end": 1381, "section": "abstract"}, {"text": "We also review unresolved controversies surrounding the management of these conditions by administration of nutritional vitamin D (ergocalciferol and cholecalciferol), vitamin D receptor activators (calcitriol, alphacalcidiol, doxercalciferol), D-mimetics (paricalcitol, maxacalcitol), calcimimetics (cinacalcet), recombinant PTH (teriparatide), and receptor activator of nuclear factor-kappaB ligand modulators (denosumab); compare mortality predictability of PTH and alkaline phosphatase; and examine potential risks of bone disorders and mineral disarrays in CKD patients.", "begin": 1078, "document": "20671739", "end": 1653, "section": "abstract"}, {"text": "New therapies such as the antibody to RANKL (denosumab) are undergoing phase III clinical testing. ", "begin": 495, "document": "20703154", "end": 594, "section": "abstract"}, {"text": "Receptor activator of nuclear factor kappa B ligand is an important cytokine involved in osteoclast activation; denosumab, a fully human monoclonal antibody to this molecule, has finished a major fracture trial. ", "begin": 460, "document": "19098925", "end": 672, "section": "abstract"}, {"text": "Initials studies have demonstrated that targeting RANK/ RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. ", "begin": 731, "document": "18632461", "end": 947, "section": "abstract"}, {"text": "A highly specific, fully human antibody against RANKL has been produced (denosumab) that in early studies in humans reduces bone turnover and improves bone density.", "begin": 799, "document": "16527005", "end": 963, "section": "abstract"}, {"text": "Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "begin": 612, "document": "16188502", "end": 802, "section": "abstract"}]}, {"documents": ["23217568", "22853635", "21340496", "20889597", "20810033", "19158113", "18759162", "17965425", "16418123", "15083883", "12723987", "1563036"], "answer": ["Women"], "id": "5118dd1305c10fae75000001", "snippets": [{"text": "Intense anti-CCP2 reaction was 19.8-fold higher in females vs. males,", "begin": 993, "document": "21340496", "end": 1062, "section": "abstract"}, {"text": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome.", "begin": 0, "document": "1563036", "end": 162, "section": "abstract"}, {"text": "in 244 female and 91 male patients with rheumatoid arthritis.", "begin": 453, "document": "16418123", "end": 514, "section": "abstract"}]}, {"documents": ["1915889", "1993703", "6194440", "7901430", "1712333", "2513486"], "answer": [["AATAAA"], ["AAUAAA"]], "id": "5133b9455274a5fb0700000c", "snippets": [{"text": "the cannonical polyadenylation signal sequence AATAAA", "begin": 364, "document": "1915889", "end": 417, "section": "abstract"}, {"text": "Two AATAAA motifs are coded in the last exon of this gene", "begin": 1178, "document": "1993703", "end": 1235, "section": "abstract"}, {"text": "The results demonstrate that the intact AAUAAA is not required for RNA polyadenylation but is required for the cleavage step preceding polyadenylation to occur efficiently", "begin": 236, "document": "6194440", "end": 407, "section": "abstract"}, {"text": "the early poly(A) consensus signal was mutated from AAUAAA to UGUAAA", "begin": 464, "document": "7901430", "end": 532, "section": "abstract"}, {"text": "Functional polyadenylation [poly(A)] sites consist of two sequence elements, the AAUAAA and G/U box signals, that closely flank the site of mRNA 3'-end formation", "begin": 0, "document": "1712333", "end": 161, "section": "abstract"}, {"text": " Two AATAAA hexanucleotide sequences are present in the 2092 nucleotide interval. The first one functions as the major polyA signal", "begin": 189, "document": "2513486", "end": 320, "section": "abstract"}]}, {"documents": ["22517745", "22496347", "22399514", "22289392", "21956421"], "answer": [["adipose tissue"], ["fibrotic tissue"]], "id": "513f45abbee46bd34c000013", "snippets": [{"text": "GD orbital fibroblasts, which comprise a mixture of CD34(+) and CD34(-) cells, express much lower levels of Tg and TSHR", "begin": 1217, "document": "22517745", "end": 1336, "section": "abstract"}, {"text": "Previously, we found that CD34(+) progenitor cells, known as fibrocytes, express functional TSHR, infiltrate the orbit, and comprise a large subset of orbital fibroblasts in TAO. ", "begin": 552, "document": "22517745", "end": 731, "section": "abstract"}, {"text": "TSH induced lipolysis in adipose tissues.", "begin": 882, "document": "22496347", "end": 923, "section": "abstract"}, {"text": "TSH worked as a lipolytic factor in white adipose tissues,", "begin": 1376, "document": "22496347", "end": 1434, "section": "abstract"}]}, {"documents": ["8441638", "11208790", "7607467", "8065896", "7578083", "1584813", "15273274"], "answer": ["S-adenosyl-L-methionine"], "id": "51404dd723fec90375000002", "snippets": [{"text": "The product of the dcm gene is the only DNA cytosine-C5 methyltransferase of Escherichia coli K-12; it catalyses transfer of a methyl group from S-adenosyl methionine (SAM) to the C-5 position of the inner cytosine residue of the cognate sequence CCA/TGG. ", "begin": 0, "document": "8441638", "end": 256, "section": "abstract"}, {"text": "Deoxycytosine methylase (Dcm) enzyme activity causes mutagenesis in vitro either directly by enzyme-induced deamination of cytosine to uracil in the absence of the methyl donor, S-adenosylmethionine (SAM), or indirectly through spontaneous deamination of [5-methyl]cytosine to thymine", "begin": 0, "document": "11208790", "end": 284, "section": "abstract"}, {"text": "In the absence of DNA substrate, the DNA methyltransferase (MTase) M.BspRI can methylate itself using the methyl donor S-adenosyl-L-methionine (AdoMet). The methyl group is transferred to two Cys residues of the MTase.", "begin": 0, "document": "7607467", "end": 218, "section": "abstract"}, {"text": "The reaction is fairly insensitive to the methyl donor in the reaction, S-adenosylmethionine.", "begin": 446, "document": "7578083", "end": 539, "section": "abstract"}, {"text": "Formation of the complex was dependent upon the presence of the methyl donor S-adenosylmethionine, suggesting that it comprises an enzyme-linked 5-substituted dihydrocytosine moiety in DNA. ", "begin": 641, "document": "1584813", "end": 831, "section": "abstract"}, {"text": "The DNA (cytosine-5)-methyltransferase (m5C-MTase) M.BspRI is able to accept the methyl group from the methyl donor S-adenosyl-L-methionine (AdoMet) in the absence of DNA. Transfer of the methyl group to the enzyme is a slow reaction relative to DNA methylation. S", "begin": 0, "document": "8065896", "end": 264, "section": "abstract"}, {"text": "Here, we report the structure of HhaI methyltransferase in complex with DNA containing a south-constrained abasic carbocyclic sugar at the target site in the presence of the methyl donor byproduct AdoHcy.", "begin": 170, "document": "15273274", "end": 374, "section": "abstract"}]}, {"documents": ["23435440", "23279763", "23024266", "21613051", "21302639", "20175448", "18172277", "17455252", "11914929", "10664520", "10614532", "10502325", "10496602", "9820618", "9735087", "9236523", "7962349"], "answer": [["parathyroid gland"], ["pancreas"], ["pituitary gland"]], "id": "51477de5d24251bc05000020", "snippets": [{"text": "Multiple endocrine neoplasia type 1 (MEN1; formerly known as Wermer syndrome) is a rare disorder characterized by the combined occurrence of two or more tumors involving parathyroid, pancreatic islets and anterior pituitary glands; some other tumors have also been described.", "begin": 0, "document": "23435440", "end": 275, "section": "abstract"}, {"text": " Hyperparathyroidism is the most common feature of MEN1 (95% of patients), pancreatic islet tumors or pancreatic NET (neuroendocrine tumor) occur in 40-70% and pituitary tumors in 30-40% of MEN 1 patients", "begin": 950, "document": "23435440", "end": 1154, "section": "abstract"}, {"text": " In addition, other tumors, such as adrenal cortical tumors, carcinoid tumors, lipomas, angiofibromas, colagenomas and meningiomas may be present. ", "begin": 1155, "document": "23435440", "end": 1302, "section": "abstract"}, {"text": "the most important causes malignant pancreatic neuroendocrine tumors (NET) and thymic carcinoids. ", "begin": 1705, "document": "23435440", "end": 1803, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) is inherited in an autosomal dominant fashion and predisposes to the development of hyperplastic or neoplastic changes in the parathyroid and pituitary glands and the endocrine pancreas, along with numerous other characteristic tumors and features. ", "begin": 0, "document": "23279763", "end": 292, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the combined occurrence of parathyroid and adrenocortical tumors, and neuroendocrine tumors (NETs) of the pancreas and pituitary. ", "begin": 0, "document": "23024266", "end": 224, "section": "abstract"}, {"text": "The pancreatic NETs are predominantly gastrinomas and insulinomas, and the pituitary NETs are mostly prolactinomas and somatotrophinomas. ", "begin": 224, "document": "23024266", "end": 362, "section": "abstract"}, {"text": "MEN1 and MEN2 are rare inherited cancer syndromes which express a variety of endocrine and nonendocrine tumors.", "begin": 0, "document": "21302639", "end": 111, "section": "abstract"}, {"text": "Multiple endocrine neoplasia Type 1 (MEN1) is a rare hereditary tumor syndrome predisposing to tumor development in several endocrine organs.", "begin": 0, "document": "20175448", "end": 141, "section": "abstract"}, {"text": " Its major manifestations include hyperparathyroidism, tumors of endocrine pancreas and pituitary. ", "begin": 141, "document": "20175448", "end": 240, "section": "abstract"}, {"text": "eside these three, several other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma) tumors have been described to be associated with this syndrome", "begin": 241, "document": "20175448", "end": 459, "section": "abstract"}, {"text": "Both familial and sporadic forms of the disease are known. The diagnosis of MEN1 can be established if two of the three major manifestations are found in the same patient, whereas the diagnosis of familial MEN1 requires one MEN1 patient and a first degree relative with at least one MEN1 manifestation. ", "begin": 461, "document": "20175448", "end": 764, "section": "abstract"}, {"text": "Both benign (parathyroid, anterior pituitary) and malignant (gastrinoma, glucagonoma) lesions may develop in MEN1 patients", "begin": 875, "document": "20175448", "end": 997, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) is a classic hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine neoplasias and hormone excess syndromes.", "begin": 0, "document": "11914929", "end": 203, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN 1) is a familial syndrome characterized by parathyroid, enteropancreatic and pituitary tumors. ", "begin": 0, "document": "10664520", "end": 136, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome characterized by the development of multiple endocrine tumors", "begin": 0, "document": "9820618", "end": 154, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder characterized by nodular proliferation of the parathyroid glands and tumors of the anterior pituitary gland, the endocrine pancreas, and the neuroendocrine cell system of the gut.", "begin": 0, "document": "7962349", "end": 266, "section": "abstract"}, {"text": "We report here a genetic study of a female MEN1 patient with the association of nodular hyperplasia of two parathyroid glands, an insulinoma, multiple duodenal gastrinomas, a prolactinoma, and a gastric carcinoid.", "begin": 400, "document": "7962349", "end": 613, "section": "abstract"}, {"text": "In support of previous findings in islet tumors, we found down-regulation of the cell-cycle regulator, p18, in both the pancreatic islet and pituitary adenomas, suggesting that reduced p18 levels may be important for Men1-related tumorigenesis in multiple tissues. Surprisingly, we identified increased p16 transcript in pancreatic islet and pituitary tumors. ", "begin": 1125, "document": "17455252", "end": 1485, "section": "abstract"}, {"text": " The patient was studied and diagnosed with a multiple endocrine neoplasia type I (MEN I), familiar (mother with MEN I). A scintigraphic study with 99mTc-MIBI was performed in order to localize hyperfunctioning parathyroid glands because of biochemical diagnosis of primary hyperparathyroidism. ", "begin": 163, "document": "10614532", "end": 458, "section": "abstract"}, {"text": "The tumor was removed and histologically confirmed as a carcinoid within a thymus in a MEN type I syndrome. ", "begin": 761, "document": "10614532", "end": 869, "section": "abstract"}, {"text": "MEN I patients can benefit from the examination with this agent which can potentially localize not only parathyroid endocrine pathology but also unknown associated tumors.", "begin": 869, "document": "10614532", "end": 1040, "section": "abstract"}, {"text": "Pancreatic endocrine tumors occur sporadically and as part of the multiple endocrine neoplasia type 1 (MEN 1) and von Hippel-Lindau (VHL) syndromes. ", "begin": 0, "document": "10502325", "end": 149, "section": "abstract"}, {"text": "We have analyzed 22 nonfamilial and 16 MEN 1-associated pancreatic endocrine tumors for loss of heterozygosity (LOH) at 3p, 11q13, and 18q. LOH at 3p was revealed in 45% and 36% of tumors from 31 patients with nonfamilial and MEN 1-associated disease, respectively.", "begin": 436, "document": "10502325", "end": 701, "section": "abstract"}, {"text": "The data indicate involvement of tumor suppressor genes on 3p and 18q, in addition to the MEN1 gene at 11q13, in the tumorigenesis of both nonfamilial and MEN 1-associated pancreatic endocrine tumors.", "begin": 1470, "document": "10502325", "end": 1670, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) is characterized by the development of endocrine tumors of the parathyroid and pituitary glands, pancreas, and duodenum. Less frequently occurring tumors associated with MEN1 include non-endocrine tumors such as lipomas and angiofibromas. ", "begin": 0, "document": "10496602", "end": 282, "section": "abstract"}, {"text": "An increased incidence of thyroid neoplasms, leiomyomas, adrenal cortical hyperplasia, hepatic focal nodular hyperplasia, and renal angiomyolipoma has been noted in the MEN1 population. ", "begin": 282, "document": "10496602", "end": 468, "section": "abstract"}, {"text": "A germline mutation of the MEN1 gene was detected, and deletions of the MEN1 gene were consistently detected in multiple neuroendocrine tumors involving the parathyroid glands and the pancreas and a hepatic neuroendocrine tumor metastasis, as predicted by Knudson's \"two hit\" hypothesis.", "begin": 768, "document": "10496602", "end": 1055, "section": "abstract"}, {"text": "Twelve unrelated (German MEN1 families and their associated tumors (5 parathyroid tumors, 1 vipoma, 1 gastrinoma, 1 insulinoma) were characterized for MEN1 gene mutations by single-strand conformational variant (SSCV) analysis and DNA sequence analysis as well as for loss of heterozygosity on chromosome 11q13. ", "begin": 312, "document": "9820618", "end": 624, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 1 (MEN1) consists of benign, and sometimes malignant, tumors (often multiple in a tissue) of the parathyroids, enteropancreatic neuroendocrine system, anterior pituitary, and other tissues. Skin angiofibromas and skin collagenomas are common. ", "begin": 0, "document": "9735087", "end": 277, "section": "abstract"}]}, {"documents": ["21328290", "21133188", "20663605", "21815707", "15610702", "21845054"], "answer": [["neostigmine"], ["pyridostigmine"]], "id": "5149199dd24251bc05000040", "snippets": [{"text": "Pyridostigmine is the most widely used acetylcholinesterase inhibitor.", "begin": 1251, "document": "21133188", "end": 1321, "section": "abstract"}, {"text": "This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine.", "begin": 476, "document": "21815707", "end": 571, "section": "abstract"}, {"text": "Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. ", "begin": 572, "document": "21815707", "end": 768, "section": "abstract"}, {"text": "Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising.", "begin": 1071, "document": "21815707", "end": 1197, "section": "abstract"}, {"text": " Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments.", "begin": 178, "document": "21815707", "end": 475, "section": "abstract"}, {"text": "Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. ", "begin": 768, "document": "21815707", "end": 1071, "section": "abstract"}]}, {"documents": ["21044832", "17849242", "11130352", "11015242", "9562190", "8907145", "1470965"], "answer": ["naloxone"], "id": "5149f494d24251bc0500004c", "snippets": [{"text": "For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression", "begin": 2841, "document": "17849242", "end": 3085, "section": "abstract"}, {"text": "Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. ", "begin": 200, "document": "11130352", "end": 394, "section": "abstract"}, {"text": "Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. ", "begin": 394, "document": "11130352", "end": 567, "section": "abstract"}, {"text": "To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. ", "begin": 243, "document": "8907145", "end": 518, "section": "abstract"}, {"text": "Management of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid antagonists. ", "begin": 1150, "document": "1470965", "end": 1360, "section": "abstract"}, {"text": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. ", "begin": 0, "document": "8907145", "end": 243, "section": "abstract"}]}, {"documents": ["23082254", "22051200", "21766433", "19490036", "17075842", "11077457", "10339792", "8075508", "2707392", "3939491"], "answer": ["Valproate"], "id": "51588bb2d24251bc05000091", "snippets": [{"text": "The teratogenicity of antiepilepsy drug valproic acid (VPA) mostly is found in genetic and somatic levels, causing teratogenesis involving neurotubular defects (NTDs), anencephaly, lumbosacral meningomyelocele, and leg dysfunction due to spina bifida aperta.", "begin": 0, "document": "22051200", "end": 258, "section": "abstract"}, {"text": "The summary odds ratio estimate for the association between valproic acid and spina bifida was 11.9 (95% uncertainty interval (UI): 4.0-21.2); for valproic acid and cleft palate 5.8 (95% UI: 3.3-9.5); for carbamazepine and spina bifida 3.6 (95% UI: 1.3-7.8); and for carbamazepine and cleft palate 2.4 (95% UI: 1.1-4.5) in the United States.", "begin": 721, "document": "21766433", "end": 1062, "section": "abstract"}, {"text": "Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population. Failure of the neural tube to close during development results in exencephaly or anencephaly, as well as spina bifida.", "begin": 0, "document": "17075842", "end": 316, "section": "abstract"}, {"text": "Fetal exposure to valproic acid or carbamazepine increases the risk of neural tube defect (NTD)", "begin": 0, "document": "10339792", "end": 95, "section": "abstract"}, {"text": "Women with epilepsy giving birth during 1973 to 1991 were identified by record linkage of Swedish health registries. Among 3,625 identified infants, 9 had spina bifida. A nested case-control study was performed, comparing drugs used in early pregnancy in the 9 cases and in 18 controls, matched for year of delivery, maternal age, and parity. Six of the spina bifida mothers had used carbamazepine and two had used valproic acid. Among the controls, 5 women used carbamazepine and one valproic acid. There is an apparent excess risk for spina bifida after use of either of these two drugs, but it is not statistically significant when the analysis is restricted to drug-using women. T", "begin": 0, "document": "8075508", "end": 684, "section": "abstract"}, {"text": "A significant association was seen between maternal use of valproic acid and spina bifida, and a weaker, non-significant one between carbamazepine and spina bifida.", "begin": 459, "document": "2707392", "end": 623, "section": "abstract"}, {"text": "A statistically significant association between Spina Bifida and Valproic Acid (odds ratio 22.7; Fisher p value = 0.0364) was observed: no other anticonvulsant tested showed any association with any type of malformation.", "begin": 768, "document": "3939491", "end": 988, "section": "abstract"}]}, {"documents": ["23456457", "23213374", "23115304", "22976301", "22898782", "22521416", "22261722", "21766470", "20392737", "19454482", "19321663", "19293139", "18851962", "17681131", "16240430", "14983524", "11781336", "10842375"], "answer": ["centrosome"], "id": "51596a8ad24251bc0500009e", "snippets": [{"text": "CEP family protein is the active component of centrosome ", "begin": 163, "document": "23456457", "end": 220, "section": "abstract"}, {"text": " Cep135 was associated mostly with mother centrioles", "begin": 1179, "document": "23213374", "end": 1231, "section": "abstract"}, {"text": "Cep135/Bld10 is a conserved centriolar protein required for the formation of the central cartwheel, an early intermediate in centriole assembly.", "begin": 0, "document": "22976301", "end": 144, "section": "abstract"}, {"text": "Thus, in flies, Cep135/Bld10 is not essential for cartwheel assembly or for establishing the ninefold symmetry of centrioles; rather, it appears to stabilize the connection between inner and outer centriole components.", "begin": 939, "document": "22976301", "end": 1157, "section": "abstract"}, {"text": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells ", "begin": 0, "document": "14983524", "end": 110, "section": "abstract"}, {"text": "In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins.", "begin": 301, "document": "18851962", "end": 415, "section": "abstract"}, {"text": " Drosophila Bld10, the ortholog of Chlamydomonas reinhardtii Bld10p and human Cep135, is a ubiquitous centriolar protein that also localizes to the spermatid basal body. M", "begin": 349, "document": "19321663", "end": 520, "section": "abstract"}, {"text": "BLD10/CEP135 is a microtubule-associated protein that controls the formation of the flagellum central microtubule pair.", "begin": 0, "document": "22898782", "end": 119, "section": "title"}, {"text": "We found an evolutionarily cohesive and ancestral module, which we term UNIMOD and is defined by three components (SAS6, SAS4/CPAP and BLD10/CEP135), that correlates with the occurrence of CBBs.", "begin": 683, "document": "20392737", "end": 877, "section": "abstract"}, {"text": "pericentriolar material proteins including pericentrin and CEP135.", "begin": 717, "document": "22261722", "end": 783, "section": "abstract"}, {"text": "hereas Cep135 and CPAP formed a core structure within the proximal lumen of both parental and nascent centrioles", "begin": 690, "document": "17681131", "end": 802, "section": "abstract"}, {"text": ". Centrosome components, including \u03b3-tubulin and Cep135, ", "begin": 960, "document": "21766470", "end": 1017, "section": "abstract"}, {"text": "suggesting that Cep135 is a structural component of the centrosome.", "begin": 257, "document": "10842375", "end": 324, "section": "abstract"}, {"text": "Characterization of Cep135, a novel coiled-coil centrosomal protein involved in microtubule organization in mammalian cells.", "begin": 0, "document": "11781336", "end": 124, "section": "title"}]}, {"documents": ["22057813", "19543403", "15871047", "11591470", "9931467", "8828040", "7723057", "6572942"], "answer": [["H2"], ["H3"]], "id": "515bd543298dcd4e51000001", "snippets": [{"text": " the vast majority of Alu sequences were shown to have the highest density in GC-rich isochores", "begin": 146, "document": "22057813", "end": 241, "section": "abstract"}, {"text": "Alu sequences being unstable in the GC-poor isochores but stable in the compositionally matching GC-rich isochores,", "begin": 988, "document": "22057813", "end": 1103, "section": "abstract"}, {"text": "Alu retrotransposons do not show a homogeneous distribution over the human genome but have a higher density in GC-rich (H) than in AT-rich (L) isochores", "begin": 0, "document": "15871047", "end": 152, "section": "abstract"}, {"text": "This result, together with the known higher selective disadvantage of recombination products in H isochores, points to Alu-Alu recombination as the main agent provoking the density shift of Alus toward the GC-rich parts of the genome", "begin": 1230, "document": "15871047", "end": 1463, "section": "abstract"}, {"text": "whereas GC-rich Alus are mostly present in GC-rich isochores", "begin": 175, "document": "11591470", "end": 235, "section": "abstract"}, {"text": "the present results on Alu and LINE stability/exclusion predict significant losses of Alu DNA from the GC-poor isochores during evolution, a phenomenon apparently due to negative selection against sequences that differ from the isochore composition", "begin": 1221, "document": "11591470", "end": 1469, "section": "abstract"}, {"text": "The frequency of Alu sequences also increases with increasing GC, but attains a maximum in H2 isochores, in agreement with previous experimental data", "begin": 780, "document": "9931467", "end": 929, "section": "abstract"}, {"text": "The CpG levels of both Alus and CpG islands increase with their GC levels", "begin": 1570, "document": "9931467", "end": 1643, "section": "abstract"}, {"text": "characterized as a GC-rich isochore enriched for CpG islands, genes, and Alu-like repeats", "begin": 327, "document": "8828040", "end": 416, "section": "abstract"}, {"text": "Microsatellites and SINES (Alu, B1, B2) are found at roughly equal frequencies in introns from all isochore classes", "begin": 1299, "document": "7723057", "end": 1414, "section": "abstract"}, {"text": "The results indicate that the short repeats of the B1 family of mouse and of the Alu I family of man are most frequent in the heavy components, whereas the long repeats of the BamHI family of mouse and of the Kpn I family of man are mainly present in the two light components.", "begin": 500, "document": "6572942", "end": 776, "section": "abstract"}]}, {"documents": ["23457529", "23064365", "22451924", "21267413", "20935675", "15575964"], "answer": [["Skin cancer"], ["ADI prostate cancer"], ["gastric adenocarcinoma"], ["colon adenocarcinoma"], ["colitis-associated cancer (CAC)"], ["breast cancer"], ["Hodgkin lymphoma"], ["nasopharyngeal carcinoma"], ["T-cell neoplasia"]], "id": "515bf6d6298dcd4e51000004", "snippets": [{"text": "increased skin tumorigenesis in tpl2 knockout mice", "begin": 44, "document": "23457529", "end": 94, "section": "title"}, {"text": "These findings establish a mesenchyme-specific role for Tpl2 in the regulation of HGF production and suppression of epithelial tumorigenesis.", "begin": 1344, "document": "23064365", "end": 1485, "section": "abstract"}, {"text": "Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis", "begin": 0, "document": "23064365", "end": 96, "section": "title"}, {"text": "Tpl2 ablation promotes intestinal inflammation and tumorigenesis", "begin": 0, "document": "22451924", "end": 64, "section": "title"}, {"text": "TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth", "begin": 0, "document": "21267413", "end": 102, "section": "title"}, {"text": "Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis", "begin": 0, "document": "20935675", "end": 113, "section": "title"}, {"text": " Previously identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers", "begin": 170, "document": "20935675", "end": 281, "section": "abstract"}, {"text": "These studies indicate that Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis, with its absence contributing to both tumorigenesis and inflammation", "begin": 1189, "document": "20935675", "end": 1390, "section": "abstract"}, {"text": "Expression of the Tpl2/Cot oncogene in human T-cell neoplasias", "begin": 0, "document": "15575964", "end": 62, "section": "title"}]}, {"documents": ["23420787", "23397482", "23298766", "22956279", "22925689", "22752264", "22480369", "21324422", "20461508", "17697977", "17451943", "12146646", "1366363"], "answer": [["Aspergillus terreus"], ["Aspergillus niger"], ["Ustilago maydis"]], "id": "515ffc2b298dcd4e51000035", "snippets": [{"text": "continuous itaconic acid production from sucrose with Aspergillus terreus", "begin": 4, "document": "1366363", "end": 77, "section": "abstract"}, {"text": "A potent itaconic acid producing strain, Aspergillus terreus SKR10, was isolated from horticulture waste", "begin": 0, "document": "12146646", "end": 104, "section": "abstract"}, {"text": "Two high itaconic acid yielding mutants, N45 and UNCS1 were obtained by gradient plating", "begin": 526, "document": "12146646", "end": 614, "section": "abstract"}, {"text": "Itaconic acid production using sago starch hydrolysate by Aspergillus terreus TN484-M1.", "begin": 0, "document": "17451943", "end": 87, "section": "title"}, {"text": "production of itaconic acid and lovastatin by Aspergillus terreus ATCC 20542", "begin": 34, "document": "17697977", "end": 110, "section": "title"}, {"text": "Fermentation products of Aspergillus terreus ATCC 20542 (a parent strain for lovastatin production) were collected, and the coexistence of itaconic acid (IA) with lovastatin was confirmed in this study", "begin": 0, "document": "17697977", "end": 201, "section": "abstract"}, {"text": "Enhancing itaconic acid production by Aspergillus terreus", "begin": 0, "document": "20461508", "end": 57, "section": "title"}, {"text": "Aspergillus terreus is successfully used for industrial production of itaconic acid", "begin": 0, "document": "20461508", "end": 83, "section": "abstract"}, {"text": "From a number of different Aspergillus terreus controlled batch fermentations, those cultures with the largest difference in itaconic acid titer and productivity were selected for mRNA isolation", "begin": 250, "document": "21324422", "end": 444, "section": "abstract"}, {"text": " a systematic process optimization was performed with an own isolated strain of Aspergillus terreus", "begin": 236, "document": "22752264", "end": 335, "section": "abstract"}, {"text": "Enhanced itaconic acid production in Aspergillus niger", "begin": 0, "document": "22925689", "end": 54, "section": "title"}, {"text": "Cells of Aspergillus terreus, free and immobilized in polyurethane foam, were employed in itaconic acid fermentation processes on glycerol-based media.", "begin": 0, "document": "22956279", "end": 151, "section": "abstract"}, {"text": "current biotechnological production processes with the fungus Aspergillus terreus has to be improved", "begin": 206, "document": "23298766", "end": 306, "section": "abstract"}, {"text": "Reduced by-product formation and modified oxygen availability improve itaconic acid production in Aspergillus niger", "begin": 0, "document": "23397482", "end": 115, "section": "title"}, {"text": " Previously, it was shown that expression of the cis-aconitate decarboxylase gene (cadA) from Aspergillus terreus converted A. niger into an itaconic acid producer ", "begin": 140, "document": "23397482", "end": 304, "section": "abstract"}, {"text": "Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different host organism.", "begin": 768, "document": "23420787", "end": 926, "section": "abstract"}, {"text": "Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media", "begin": 247, "document": "23420787", "end": 416, "section": "abstract"}]}, {"documents": ["21963854", "15200950", "12208845", "12086618"], "answer": [["H4K20 monomethylation"], ["H3K4 monomethylation"]], "id": "5160412d298dcd4e5100003c", "snippets": [{"text": "the loss of H4 lysine 20 methylation", "begin": 190, "document": "12086618", "end": 226, "section": "abstract"}, {"text": "Transcriptionally competent regions lack H4 lysine 20 methylation", "begin": 286, "document": "12086618", "end": 351, "section": "abstract"}, {"text": "a human histone H4 lysine 20 methyltransferase and cloned the encoding gene, PR/SET07", "begin": 17, "document": "12086618", "end": 102, "section": "abstract"}, {"text": "Localization of PR-Set7 to mitotic chromosomes and subsequent increase in H4 Lys 20 methylation", "begin": 338, "document": "12208845", "end": 433, "section": "abstract"}, {"text": "the H4-K20 methyltransferase PR-Set7. Indeed, upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation", "begin": 698, "document": "15200950", "end": 842, "section": "abstract"}]}, {"documents": ["23349612", "18266676", "16791377", "16585054", "15967842", "12424964", "11863303", "11799477", "11731280", "10080180", "9781539", "9536090", "8042665", "8445613", "2230849", "2163170", "3203701", "3729752", "3701378", "4022362"], "answer": [["X-linked"], ["autosomal dominant"], ["autosomal recessive"]], "id": "51656c94298dcd4e51000058", "snippets": [{"text": "Emery-Dreifuss myopathy can be associated with a cardiomyopathy and cardiac dysrhythmias. The inheritance pattern of Emery-Dreifuss muscular dystrophy (EDMD) is X linked, whereas EDMD2 is autosomal dominant. EDMD2 is caused by lamin A/C gene (LMNA) mutations that produce alterations in the lamin proteins that are integral to nuclear and cell integrity.", "begin": 0, "document": "23349612", "end": 354, "section": "abstract"}, {"text": "EDMD2 with familial dilated cardiomyopathy and cardiac dysrhythmias in whom LMNA gene sequencing was performed. A novel mutation was identified and additional unusual clinical features were described.", "begin": 690, "document": "23349612", "end": 890, "section": "abstract"}, {"text": ". Loss-of-function truncation mutations in EMD, encoding the nuclear membrane protein emerin, cause X-linked Emery-Dreifuss muscular dystrophy (EDMD) characterized by localized contractures and skeletal myopathy in adolescence, sinus node dysfunction (SND) in early adulthood, and atrial fibrillation as a variably associated trait.", "begin": 139, "document": "18266676", "end": 471, "section": "abstract"}, {"text": "The Emery-Dreifuss muscular dystrophy is a form of muscular dystrophy that frequently presents early contractures and cardiac conduction defects, caused by emerin deficiency in the inner nuclear membrane of the muscular fibers.", "begin": 0, "document": "16791377", "end": 227, "section": "abstract"}, {"text": "compatible with X-linked inheritance form", "begin": 407, "document": "16791377", "end": 448, "section": "abstract"}, {"text": "The first patient was a member of a family with molecularly proven X-linked EDMD.", "begin": 486, "document": "16585054", "end": 567, "section": "abstract"}, {"text": "As these resemble the cardiac features of patients with the autosomal dominant variant of EDMD, we examined the lamin A/C gene, identifying a de-novo mutation in the propositus.", "begin": 1102, "document": "16585054", "end": 1279, "section": "abstract"}, {"text": "contribute to disease severity in autosomal dominant EDMD.", "begin": 2077, "document": "16585054", "end": 2135, "section": "abstract"}, {"text": "The STA gene encodes emerin and is one of the genes that is affected in Emery-Dreifuss muscular dystrophy (EDMD). Although it has been reported that EDMD caused by the STA gene mutation is associated with X-linked recessive inheritance, the genotype-phenotype correlations, with special reference to cardiac manifestations, are not well defined.", "begin": 12, "document": "15967842", "end": 357, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy (EDMD) is a muscular disorder characterized by 1) early contracture of the elbows. Achilles tendons and post-cervical muscles, 2) slowly progressive muscle wasting and weakness with a humeroperoneal distribution, and 3) life-threatening cardiomyopathy with conduction block. Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin. A rare autosomal dominant form of EDMD (AD-EDMD) is caused by mutations in lamin A/C gene (LMNA) on chromosome 1q21. Both emerin and lamin A/C are located in the inner surface membrane of the nucleus.", "begin": 0, "document": "12424964", "end": 661, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy is an X-linked recessive myopathy. The patient had no familial background of the disease. This patient might have a sporadic inheritance pattern with severe cardiac involvement.", "begin": 451, "document": "11863303", "end": 662, "section": "abstract"}, {"text": "autosomal dominant Emery-Dreifuss muscular dystrophy,", "begin": 1498, "document": "11799477", "end": 1551, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy is characterized by the clinical triad of early onset contractures of elbows, Achilles tendons and spine, wasting and weakness with a predominantly humero-peroneal distribution and life-threatening cardiac conduction defects and/or cardiomyopathy. Two main types of inheritance have been described: the X-linked form is caused by mutations in the STA gene on locus Xq28 and the gene for the autosomal dominant form (LMNA gene) has been localized on chromosome 1q11-q23. Recently, mutations in this LMNA gene have been also found to be responsible for the less frequent autosomal recessive form of the disease.", "begin": 0, "document": "11731280", "end": 643, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and a cardiomyopathy with conduction blocks which is life-threatening. Two modes of inheritance exist, X-linked (OMIM 310300) and autosomal dominant (EDMD-AD; OMIM 181350). EDMD-AD is clinically identical to the X-linked forms of the disease. Mutations in EMD, the gene encoding emerin, are responsible for the X-linked form.", "begin": 0, "document": "10080180", "end": 485, "section": "abstract"}, {"text": "Seventeen families with Emery-Dreifuss muscular dystrophy (EDMD) have been studied both by DNA sequencing and by emerin protein expression. Fourteen had mutations in the X-linked emerin gene, while three showed evidence of autosomal inheritance. Twelve of the 14 emerin mutations caused early termination of translation.", "begin": 0, "document": "9536090", "end": 320, "section": "abstract"}, {"text": "One family presented a rare autosomal dominant variant of Emery-Dreifuss muscular dystrophy, another with X-linked recessive inheritance showed unusual intrafamilial variability.", "begin": 75, "document": "8042665", "end": 253, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy (EMD) is characterised by (1) early contractures of the Achilles tendons, elbows, and postcervical muscles, (2) slowly progressive muscle wasting and weakness with a predominantly humeroperoneal distribution in the early stages, and (3) cardiomyopathy with conduction defects and risk of sudden death. Inheritance is usually X linked recessive but can be autosomal dominant.", "begin": 0, "document": "8445613", "end": 408, "section": "abstract"}, {"text": "Tendon contractures may be a partial expression of this myopathic disorder, suggesting an autosomal dominant inheritance with variable penetrance. A muscular dystrophy clinically similar to that of the Emery-Dreifuss (EDMD) type can thus occur in women.", "begin": 438, "document": "2230849", "end": 691, "section": "abstract"}, {"text": "Since the disease was diagnosed in 3 brothers, the X-coupled recessive type of its inheritance is assumed. An opinion is advanced that the described form is a clinical variety of Emery-Dreyfus myodystrophy.", "begin": 334, "document": "2163170", "end": 540, "section": "abstract"}, {"text": "Emery-Dreifuss syndrome (EDS)", "begin": 48, "document": "3203701", "end": 77, "section": "abstract"}, {"text": "the term Emery-Dreifuss muscular dystrophy should be avoided. Instead, each case of EDS should be classified as myopathic or neurogenic with X chromosome recessive or autosomal dominant inheritance.", "begin": 385, "document": "3203701", "end": 583, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy is a syndrome with five salient features: early and unusual contractures; humeroperoneal muscle wasting; the slow progression of weakness, beginning in childhood; cardiac conduction defects; and X-linked inheritance. We present two cases and detail other reports with a similar constellation of findings with apparent autosomal dominant inheritance.", "begin": 0, "document": "3729752", "end": 383, "section": "abstract"}, {"text": "Emery-Dreifuss muscular dystrophy with proximal weakness in both the upper and lower limbs and X-linked scapuloperoneal muscular dystrophy represent the same disorder.", "begin": 420, "document": "3701378", "end": 587, "section": "abstract"}, {"text": "There is at least one other report of autosomal dominant transmission of this clinical picture, which had previously only been reported as Emery-Dreifuss muscular dystrophy with X-linked recessive inheritance.", "begin": 329, "document": "4022362", "end": 538, "section": "abstract"}]}, {"documents": ["22939093", "19685082", "19631009", "18471057", "17346361", "15252984", "11427261", "9802086", "7815482", "1337231", "14422369", "13383364", "22913287", "22452970", "21771532", "21593276", "21254926", "19925041", "18841330", "18823640", "18602711", "18562534", "12560576", "12557579", "12519399", "12233771"], "answer": ["Ixodes ricinus"], "id": "51716e808ed59a060a00000b", "snippets": [{"text": "Deer are the key hosts of the vector (Ixodes ricinus) that transmits LIV to red grouse Lagopus lagopus scoticus, causing high mortality.", "begin": 528, "document": "22939093", "end": 664, "section": "abstract"}, {"text": "n Europe the primary arthropod vectors of zoonotic diseases are ticks, which transmit Borrelia burgdorferi sensu lato (the agent of Lyme disease), tick-borne encephalitis virus and louping ill virus between humans, livestock and wildlife. Ixodes ricinus ticks and reported tick-borne disease cases are currently increasing in the UK", "begin": 94, "document": "19685082", "end": 426, "section": "abstract"}, {"text": "Many vector-borne pathogens whose primary vectors are generalists, such as Ixodid ticks, can infect a wide range of host species and are often zoonotic.", "begin": 0, "document": "19631009", "end": 152, "section": "abstract"}, {"text": "Tick-borne encephalitis virus (TBEV) and Louping ill virus (LIV) are viruses in the Mammalian tick-borne virus group/genus Flavivirus, causing central nervous system disease.", "begin": 0, "document": "18471057", "end": 174, "section": "abstract"}, {"text": "The complex pathogen-host-vector system of the tick-borne louping-ill virus causes economic losses to sheep and red grouse in upland United Kingdom.", "begin": 0, "document": "17346361", "end": 148, "section": "abstract"}, {"text": "For pathogens transmitted by biting vectors, one of the fundamental assumptions is often that vector bites are the sole or main route of host infection. Here, we demonstrate experimentally a transmission route whereby hosts (red grouse, Lagopus lagopus scoticus) became infected with a member of the tick-borne encephalitis virus complex, louping ill virus, after eating the infected tick vector.", "begin": 0, "document": "15252984", "end": 396, "section": "abstract"}, {"text": "We used Susceptible Infected Recovered (SIR) models parameterized for the tick-borne louping ill virus (LIV) system.", "begin": 411, "document": "22939093", "end": 527, "section": "abstract"}, {"text": "This study has examined the efficacy following intramuscular administration of a recombinant Semliki Forest virus (rSFV) vaccine, encoding the prME and NS1 proteins of louping ill virus (LIV), in sheep.", "begin": 0, "document": "11427261", "end": 202, "section": "abstract"}, {"text": "Since the recognition that louping-ill, known for well over 100 years as an epizootic disease of sheep in Scotland, was caused by a virus transmitted by arthropods, many other arthropod-borne viruses capable of causing encephalitis in domestic animals or man have been discovered.", "begin": 0, "document": "14422369", "end": 280, "section": "abstract"}]}, {"documents": ["20823303", "19908360"], "answer": [["miRNA"], ["snRNA"], ["snoRNAs"], ["scaRNAs"], ["piRNAS"]], "id": "517295c18ed59a060a000016", "snippets": [{"text": "Some of these RNA classes, in particular microRNAs and snoRNAs, undergo maturation processes that lead to the production of shorter RNAs.", "begin": 292, "document": "19908360", "end": 429, "section": "abstract"}]}, {"documents": ["23478244", "23011019", "22561055", "22475741", "21277394", "20457157", "19533356"], "answer": [["proton pump inhibitors"], ["immunosoppressive drugs"], ["budesonide"]], "id": "518ba4b5310faafe08000005", "snippets": [{"text": "Current therapeutic options include use of proton-pump inhibitors, immunosuppressive drugs, elimination diets, and esophageal dilatation.", "begin": 722, "document": "23478244", "end": 859, "section": "abstract"}]}, {"documents": ["23242657", "23047984", "21690193", "21311168", "20724368", "19440340"], "answer": [["miR-1"], ["miR-133"], ["miR-208a"], ["miR-206"], ["miR-494"], ["miR-146a"], ["miR-222"], ["miR-21"], ["miR-221"], ["miR-20a"], ["miR-133a"], ["miR-133b"], ["miR-23"], ["miR-107"], ["miR-181"]], "id": "518cca6f310faafe0800000a", "snippets": [{"text": "Some miRNAs as miR-1, miR-133 and miR-208a are highly expressed in the heart and strongly associated with the development of cardiac hypertrophy. Recent data indicate that these miRNAs as well as miR-206 change their expression quickly in response to physical activity.", "begin": 345, "document": "23242657", "end": 614, "section": "abstract"}, {"text": "the miR-494 content significantly decreased after endurance exercise in C57BL/6J mice, accompanied by an increase in expression of mtTFA and Foxj3 proteins. These results suggest that miR-494 regulates mitochondrial biogenesis by downregulating mtTFA and Foxj3 during myocyte differentiation and skeletal muscle adaptation to physical exercise.", "begin": 909, "document": "23047984", "end": 1253, "section": "abstract"}, {"text": "1) c-miRNA up-regulated by acute exercise before and after sustained training (miR-146a and miR-222), (2) c-miRNA responsive to acute exercise before but not after sustained training (miR-21 and miR-221), (3) c-miRNA responsive only to sustained training (miR-20a),", "begin": 1003, "document": "21690193", "end": 1268, "section": "abstract"}, {"text": "MicroRNA 1 expression was decreased independent of the training modality, and was paralleled by an increased expression of IGF-1 representing a potential target.", "begin": 1255, "document": "21311168", "end": 1416, "section": "abstract"}, {"text": "we investigated the expression of these myomiRs, including miR-1, miR-133a, miR-133b and miR-206 in muscle biopsies from vastus lateralis of healthy young males (n = 10) in relation to a hyperinsulinaemic\u2013euglycaemic clamp as well as acute endurance exercise before and after 12 weeks of endurance training.", "begin": 169, "document": "20724368", "end": 476, "section": "abstract"}, {"text": "In resting biopsies, endurance training for 12 weeks decreased basal expression of all four myomiRs (P < 0.05)", "begin": 824, "document": "20724368", "end": 934, "section": "abstract"}, {"text": "These results suggest that miR-494 regulates mitochondrial biogenesis by downregulating mtTFA and Foxj3 during myocyte differentiation and skeletal muscle adaptation to physical exercise.", "begin": 1066, "document": "23047984", "end": 1253, "section": "abstract"}]}, {"documents": ["2264817", "22848616", "22126386", "19656809", "21669844", "19559031", "18726512", "18523546", "17289402", "16458019", "15373777"], "answer": ["10 nanometers", "10 nm"], "id": "515db3d8298dcd4e51000015", "snippets": [{"text": "Negative staining showed that supernatants from the centrifugation assays contained protofilaments, protofibrils and short particles (less than 300 nm), but pellets contained long filaments (greater than 1 micron) with an average diameter of 10 nm.", "begin": 553, "document": "2264817", "end": 801, "section": "abstract"}, {"text": "Ultrastructurally, rhabdoid cells showed paranuclear aggregates and whorls of intermediate filaments with a 9-10 nm diameter.", "begin": 1072, "document": "22126386", "end": 1197, "section": "abstract"}, {"text": "After removing IFs by calcination, electron microscopy revealed hollow silica nanotubes several micrometers long, with outer diameters of 35-55 nm and an average inner diameter of 10 nm (comparable to that of IFs)", "begin": 437, "document": "19656809", "end": 650, "section": "abstract"}, {"text": "Intermediate filaments are filaments 10\u2009nm in diameter that make up an important component of the cytoskeleton in most metazoan taxa.", "begin": 0, "document": "21669844", "end": 133, "section": "abstract"}, {"text": "Neurofilaments (NFs) are essential cytoskeletal filaments that impart mechanical integrity to nerve cells. They are assembled from three distinct molecular mass proteins that bind to each other to form a 10-nm-diameter filamentous rod with sidearm extensions.", "begin": 0, "document": "19559031", "end": 259, "section": "abstract"}, {"text": "Scanning tunneling microscope (STM) and transmission electron microscope (TEM) micrographs showed that acidic keratins and basic keratins can assemble into dimers and further into 10 nm filamentsin vitro.", "begin": 108, "document": "18726512", "end": 312, "section": "abstract"}, {"text": "Intermediate in diameter between microtubules and microfilaments, IFs constitute the third cytoskeletal filament system of metazoan cells.", "begin": 151, "document": "17289402", "end": 289, "section": "abstract"}, {"text": "Just above the bulb, the filaments are characterized by a diameter of 100 Angstroms and a low-density core.", "begin": 613, "document": "16458019", "end": 720, "section": "abstract"}, {"text": "Further, using cryo-transmission electron microscopy on native, fully hydrated, vitreous epidermis we show that the subfilametous keratin electron density pattern consists, both in corneocytes and in viable keratinocytes, of one axial subfilament surrounded by an undetermined number of peripheral subfilaments forming filaments with a diameter of approximately 8 nm.", "begin": 1656, "document": "15373777", "end": 2023, "section": "abstract"}]}, {"documents": ["23176720", "22699304", "22381702", "22353937", "22189222", "22087865", "22028144", "21839906", "21751810", "21634429", "21501555", "21223249", "20685499", "20079210", "19190249", "18410447", "18381602", "18327587", "17133426", "16470606", "15985470", "15626743"], "answer": ["multiple myeloma"], "id": "51631154298dcd4e5100004e", "snippets": [{"text": "patients with multiple myeloma (MM)", "begin": 5, "document": "23176720", "end": 40, "section": "abstract"}, {"text": "bortezomib, and lenalidomide have shown improved outcomes in these patients.", "begin": 166, "document": "23176720", "end": 242, "section": "abstract"}, {"text": "we provide data comparing sFLC with M protein as biomarkers of response in newly diagnosed patients with MM undergoing induction therapy with the novel agents thalidomide, lenalidomide and/or bortezomib.", "begin": 615, "document": "22028144", "end": 818, "section": "abstract"}, {"text": "Bortezomib, a dipeptidyl boronic acid and potent inhibitor of the 26S proteasome, is remarkably effective against multiple myeloma (MM) but not against solid tumors.", "begin": 0, "document": "21634429", "end": 165, "section": "abstract"}, {"text": "efficacy and safety of bortezomib (BOR) for treatment of multiple myeloma in comparison with thalidomide (THAL) by reference to adverse events, and searched for laboratory markers that could be used for prognostication of patients.", "begin": 26, "document": "21501555", "end": 257, "section": "abstract"}, {"text": "Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells. These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM.", "begin": 1065, "document": "21223249", "end": 1404, "section": "abstract"}, {"text": "Bortezomib (BZM) is a proteasome inhibitor in clinical use for multiple myeloma. Here, we investigated whether the combination of these compounds would yield increased antitumor efficacy in multiple myeloma and glioblastoma cell lines in vitro and in vivo.", "begin": 240, "document": "19190249", "end": 496, "section": "abstract"}, {"text": "Taken together, our results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of BZM and suggest that consumption of green tea products may be contraindicated during cancer therapy with BZM.", "begin": 1170, "document": "19190249", "end": 1404, "section": "abstract"}, {"text": "Relapsed/refractory myeloma has a poor outcome because of multi-drug resistance, patient low-performance status and toxicity of conventional chemotherapy.", "begin": 0, "document": "18410447", "end": 154, "section": "abstract"}, {"text": "Bortezomib, by inhibiting proteasome function, may enhance chemosensitivity to other drugs and overcome drug-resistance. Notably, doxorubicin and bortezomib may reciprocally increase their efficacy. Thus, to improve outcome whilst minimizing therapy-related toxicity, liposomal doxorubicin was added to a bortezomib-based combination.", "begin": 273, "document": "18410447", "end": 607, "section": "abstract"}, {"text": "the growth inhibitory and pro-apoptotic effects of the proteasome inhibitor bortezomib in combination with anti-EGFR drugs, such as gefitinib, vandetanib, and cetuximab in EGFR-expressing human cancer cell lines. Bortezomib determined dose-dependent growth inhibition in a nine cancer cell line panel (IC(50) values, range 6-42 nM).", "begin": 371, "document": "18381602", "end": 703, "section": "abstract"}, {"text": "overexpression of a constitutively active P-Akt protected A549 cells by cell growth inhibition and apoptosis following treatment with bortezomib and EGFR inhibitors. The combined treatment with bortezomib and EGFR inhibitors has a synergistic growth inhibitory and pro-apoptotic activity in different human cancer cells which possess a functional EGFR-dependent autocrine growth pathway through to a more efficient and sustained inhibition of Akt.", "begin": 1280, "document": "18381602", "end": 1727, "section": "abstract"}, {"text": "Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown enhanced anti-tumor activity. We conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors.", "begin": 11, "document": "18327587", "end": 265, "section": "abstract"}, {"text": "Bortezomib, a proteasome inhibitor, has been used for patients with refractory and relapsed multiple myeloma, lymphoma and leukemia.", "begin": 0, "document": "17133426", "end": 132, "section": "abstract"}, {"text": "Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD). Bortezomib was given on days 1, 4, 8, and 11 from 0.90 to 1.50 mg/m2 and PegLD on day 4 at 30 mg/m2 to 42 patients with advanced hematologic malignancies.", "begin": 0, "document": "15626743", "end": 444, "section": "abstract"}, {"text": "Antitumor activity was seen against multiple myeloma, with 8 of 22 evaluable patients having a complete response (CR) or near-CR, including several with anthracycline-refractory disease, and another 8 having partial responses (PRs). One patient with relapsed/refractory T-cell non-Hodgkin lymphoma (NHL) achieved a CR, whereas 2 patients each with acute myeloid leukemia and B-cell NHL had PRs. Bortezomib/PegLD was safely administered in this study with promising antitumor activity, supporting further testing of this regimen.", "begin": 943, "document": "15626743", "end": 1471, "section": "abstract"}]}, {"documents": ["16006304", "12803695", "9771977", "9443464", "8710121", "7714921", "8263140", "8464926", "8381208", "2135382", "6859058"], "answer": [["Insulin Dependent Diabetes Mellitus", "type I (insulin-dependent) diabetes mellitus (IDDM)"], ["Grave's disease"], ["Breast Cancer"], ["Dementia"]], "id": "515df86a298dcd4e5100002e", "snippets": [{"text": "The triad of stiff-man syndrome, breast cancer, and autoantibodies against amphiphysin identifies a new autoimmune paraneoplastic syndrome of the CNS.", "begin": 474, "document": "9443464", "end": 624, "section": "abstract"}, {"text": "GAD has been suggested as an autoantigen in insulin-dependent diabetes mellitus and stiff-man syndrome", "begin": 128, "document": "7714921", "end": 230, "section": "abstract"}, {"text": "Stiff-man syndrome (SMS) is a rare disorder of the central nervous system of probable autoimmune origin.", "begin": 0, "document": "8263140", "end": 104, "section": "abstract"}, {"text": "Patients with SMS often have other autoimmune diseases, in particular type I (insulin-dependent) diabetes mellitus (IDDM).", "begin": 105, "document": "8263140", "end": 227, "section": "abstract"}, {"text": "GAD-65 is a dominant autoantigen in stiff-man syndrome and insulin-dependent diabetes mellitus.", "begin": 319, "document": "8464926", "end": 414, "section": "abstract"}, {"text": "We have previously reported the presence of autoantibodies against glutamic acid decarboxylase (GAD) in a patient with stiff-man syndrome, epilepsy, and insulin-dependent diabetes mellitus.", "begin": 93, "document": "2135382", "end": 282, "section": "abstract"}, {"text": "These findings support the hypothesis that stiff-man syndrome is an autoimmune disease and suggest that GAD is the primary autoantigen involved in stiff-man syndrome and the associated insulin-dependent diabetes mellitus.", "begin": 773, "document": "2135382", "end": 994, "section": "abstract"}, {"text": "An elderly man with progressive dementia and concomitant development of stiff-man syndrome is described. He had not had stiff-man syndrome one year earlier, when he had only mild dementia. An association between stiff-man syndrome and dementia has not been previously described.", "begin": 488, "document": "6859058", "end": 766, "section": "abstract"}, {"text": "It is possible that this patient represents an exaggerated form of such motor disturbances in dementia, and that clinical and electromyographic features of stiff-man syndrome may be present with increased incidence in patients with dementia.", "begin": 970, "document": "6859058", "end": 1211, "section": "abstract"}]}, {"documents": ["23557020", "23011794", "22924785", "22904200", "22781932", "22665483", "22420752", "22357272", "21940714", "21936531", "21546573", "20556507", "20567762", "19860425", "23379261", "23139138", "23092945", "23077658", "22964322", "22560341", "22522911", "22429326"], "answer": [["BIX-01294"], ["TM2-115"], ["2,4-pyridinedicarboxylic acid", "2,4-PDCA"], ["3-deazaneplanocin A", "DZNep"], ["Trichostatin A", "TSA"], ["Psammaplin A", "PsA"], ["Sulforaphane", "SFN"]], "id": "5166f41a298dcd4e5100005b", "snippets": [{"text": "Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum.", "begin": 0, "document": "23011794", "end": 143, "section": "title"}, {"text": "We synthesized a compound library based upon a known specific inhibitor (BIX-01294) of the human G9a histone methyltransferase. Two compounds, BIX-01294 and its derivative TM2-115, inhibited P. falciparum 3D7 parasites in culture with IC(50) values of ~100 nM, values at least 22-fold more potent than their apparent IC(50) toward two human cell lines and one mouse cell line.", "begin": 299, "document": "23011794", "end": 675, "section": "abstract"}, {"text": "Together, these results suggest that BIX-01294 and TM2-115 inhibit malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death.", "begin": 1323, "document": "23011794", "end": 1486, "section": "abstract"}, {"text": "Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.", "begin": 0, "document": "22924785", "end": 130, "section": "title"}, {"text": "A total of 55 adenosine-containing compounds were designed and synthesized, among which several potent DOT1L inhibitors were identified with K(i) values as low as 0.5 nM.", "begin": 159, "document": "22924785", "end": 329, "section": "abstract"}, {"text": "Several new reagents and assays were developed to aid in the identification of EZH2 inhibitors, and these were used to execute two high-throughput screening campaigns.", "begin": 606, "document": "22904200", "end": 773, "section": "abstract"}, {"text": "Of the five histone methyltransferases known to mediate methylation of the lysine 9 residue of histone H3 (H3K9), euchromatic histone-lysine N-methyltransferase 2 (EHMT2; also known as G9a) has been shown to be a primary mediator of H3K9 dimethylation; BIX-01294 has been shown to be a specific inhibitor of EHMT2", "begin": 83, "document": "22781932", "end": 396, "section": "abstract"}, {"text": "We hypothesised that inhibition of EHMT2 by BIX-01294 would result in reduced levels of H3K9 dimethylation and compromised embryo development.", "begin": 533, "document": "22781932", "end": 675, "section": "abstract"}, {"text": "We also demonstrate that peptides that mimic SET1 family Win motif sequences inhibit H3K4 dimethylation by the MLL1 core complex with varying degrees of efficiency.", "begin": 971, "document": "22665483", "end": 1135, "section": "abstract"}, {"text": "Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.", "begin": 0, "document": "22420752", "end": 184, "section": "title"}, {"text": "Inhibition studies of ccKDM5B showed both in vitro and in cell inhibition of ccKDM5B by 2,4-pyridinedicarboxylic acid (2,4-PDCA) with a potency similar to that reported for the HDM KDM4C.", "begin": 1264, "document": "22420752", "end": 1451, "section": "abstract"}, {"text": "Treatment with 3-deazaneplanocin A (DZNep), an inhibitor of H3K27me3 and H4K20me3, significantly enhanced the BZLF1 transcription in Raji cells when in combination with an HDAC inhibitor, trichostatin A (TSA).", "begin": 1011, "document": "22357272", "end": 1220, "section": "abstract"}, {"text": "All assays allowed profiling of known SET7/9 and LSD1 inhibitors. The results demonstrate that the optimized LANCE Ultra and AlphaLISA assay formats provide a relevant biochemical screening approach toward the identification of small-molecule inhibitors of HMTs and HDMs that could lead to novel epigenetic therapies.", "begin": 1235, "document": "21940714", "end": 1552, "section": "abstract"}, {"text": "Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.", "begin": 0, "document": "21936531", "end": 105, "section": "title"}, {"text": "We used structure- and mechanism-based design to discover several potent inhibitors of DOT1L with IC(50) values as low as 38 nM.", "begin": 145, "document": "21936531", "end": 273, "section": "abstract"}, {"text": "Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.", "begin": 0, "document": "21546573", "end": 155, "section": "title"}, {"text": "Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression.", "begin": 1032, "document": "21546573", "end": 1205, "section": "abstract"}, {"text": "DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown.", "begin": 1352, "document": "21546573", "end": 1449, "section": "abstract"}, {"text": "Recent evidence shows that S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors (AHI) such as 3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2. We investigated the biological effects of AdoHcy hydrolase inhibition using DZNep and its structural analogues 3-deazaadenosine (DZA) and neplanocin A (Nep A) in breast cancer cells.", "begin": 296, "document": "20556507", "end": 693, "section": "abstract"}, {"text": "A chemiluminescence-based method for identification of histone lysine methyltransferase inhibitors.", "begin": 0, "document": "20567762", "end": 99, "section": "title"}, {"text": "The method is particularly well suited for detection of inhibitors acting by the desired histone peptide competitive mechanism and is applicable to testing other HMTs, demonstrated here with the G9a homolog EHMT1, also known as GLP.", "begin": 994, "document": "20567762", "end": 1226, "section": "abstract"}, {"text": "This study reports the pharmacokinetics and tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A (PsA), in mice.", "begin": 0, "document": "23139138", "end": 160, "section": "abstract"}, {"text": "Human diet contains many histone deacetylase (HDAC) inhibitors, such as the bioactive component sulforaphane (SFN), whose epigenetic effects on MSTN gene in satellite cells are unknown.", "begin": 328, "document": "23092945", "end": 513, "section": "abstract"}, {"text": "We found that DNA methyltransferase inhibitor (5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin receptor expression.", "begin": 515, "document": "22560341", "end": 672, "section": "abstract"}, {"text": "However, histone deacetylase (HDAC) inhibitors trichostatin A (TSA) and sodium butyrate (NaBt) significantly increased Wnt5a mRNA expression in SW620.", "begin": 735, "document": "22522911", "end": 885, "section": "abstract"}]}, {"documents": ["23405174", "23382752", "23349974", "23342028", "23326533", "23293353", "23088152", "23046708", "22929299", "22819049", "22628552", "22563351", "22543099", "22359643", "22341220", "22222968", "22216006", "22095915", "22028927", "21698217", "21329764", "21297002", "21209090", "20702404", "20635416", "20610151", "20500669", "20353400", "20078859", "19931645", "19801158", "19706885", "19706490", "19666593", "19666023", "19267910", "19184366", "18989463", "18563912", "18925948", "18628947", "18295508", "18248630", "18221799", "18082626", "17868038", "17822713", "17024857", "16458301", "16222020", "16203971", "16042788", "15950069", "15878595", "15703443", "15701514", "15339111", "15293910", "15265796", "15246528", "15147974", "15117937", "15073329", "15033330", "15003844", "14638789", "14627712", "14609342", "14556002", "14514358", "12930149", "12929205", "12626578", "12139027", "12125103", "11796125", "11839179", "11687659", "11559352", "11504465", "11087748", "11115107", "11085920", "10744765", "10703207", "10585859", "9927744", "9874251", "9514077", "8816746", "8631352", "7715553", "8300589", "1474844", "1813841", "1648659", "15463447", "2067482", "2067470", "2191201", "3011062", "3911876", "4047719", "6728514", "6760901", "23246819", "22990975", "22592550", "22524128", "22507744", "22057268", "22019287", "21989409", "21904052", "21866942", "21771420", "21670272", "21601941", "21570407", "21206476", "20034997", "19779742", "19768685", "19380379", "19038338", "19020475", "19013823", "18672695", "18611947", "18522993", "18164079", "23484017", "23483940"], "answer": ["Plasmodium species", "Plasmodium spp."], "id": "517194ef8ed59a060a000011", "snippets": [{"text": "Moreover, the identification of uric acid precipitates in P. falciparum- and P. vivax-infected erythrocytes obtained directly from malaria patients underscores the in vivo and clinical relevance of our findings.", "begin": 975, "document": "23405174", "end": 1186, "section": "abstract"}, {"text": "Moreover, the identification of uric acid precipitates in P. falciparum- and P. vivax-infected erythrocytes obtained directly from malaria patients underscores the in vivo and clinical relevance of our findings.", "begin": 975, "document": "23405174", "end": 1186, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of malaria, a disease that kills almost one million persons each year, mainly in sub-Saharan Africa. P. falciparum is transmitted to the human host by the bite of an Anopheles female mosquito, and Anopheles gambiae sensus stricto is the most tremendous malaria vector in Africa, widespread throughout the afro-tropical belt.", "begin": 0, "document": "23349974", "end": 369, "section": "abstract"}, {"text": "Fluorescence imaging microscopy of erythrocytes infected with Plasmodium falciparum, a causative agent of malaria in humans, showed that only the parasite was stained.", "begin": 351, "document": "23342028", "end": 518, "section": "abstract"}, {"text": "Human malaria is among the most ubiquitous and destructive tropical, parasitic diseases in the world today. The causative agent, Plasmodium falciparum, contains an unusual, essential organelle known as the apicoplast.", "begin": 0, "document": "23326533", "end": 217, "section": "abstract"}, {"text": "Overcoming antigenic variation is one of the major challenges in the development of an effective vaccine against Plasmodium falciparum, a causative agent of human malaria.", "begin": 0, "document": "23293353", "end": 171, "section": "abstract"}, {"text": "[The vivax malaria causative agent Plasmodium ovale: the present global area, intraspecies polymorphism, importation to the Russian Federation (1992-2011)].", "begin": 0, "document": "23088152", "end": 156, "section": "title"}, {"text": "The global area for Plasmodium ovale is small as compared with that for other species of human malaria pathogens.", "begin": 0, "document": "23088152", "end": 113, "section": "abstract"}, {"text": "Parasites that have been described to affect the central nervous system (CNS), either as the dominant or as a collateral feature, include cestodes (Taenia solium (neurocysticerciasis), Echinococcus granulosus (cerebral cystic echinococcosis), E. multilocularis (cerebral alveolar echinococcosis), Spirometra mansoni (neurosparganosis)), nematodes (Toxocara canis and T. cati (neurotoxocariasis), Trichinella spiralis (neurotrichinelliasis), Angiostrongylus cantonensis and A. costaricensis (neuroangiostrongyliasis), Gnathostoma spinigerum (gnathostomiasis)), trematodes (Schistosoma mansoni (cerebral bilharziosis), Paragonimus westermani (neuroparagonimiasis)), or protozoa (Toxoplasma gondii (neurotoxoplasmosis), Acanthamoeba spp. or Balamuthia mandrillaris (granulomatous amoebic encephalitis), Naegleria (primary amoebic meningo-encephalitis), Entamoeba histolytica (brain abscess), Plasmodium falciparum (cerebral malaria), Trypanosoma brucei gambiense/rhodesiense (sleeping sickness) or Trypanosoma cruzi (cerebral Chagas disease))", "begin": 109, "document": "23046708", "end": 1148, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the deadliest form of malaria, and human immunodeficiency virus type-1 (HIV-1) are among the most important health problems worldwide, being responsible for a total of 4 million deaths annually.", "begin": 0, "document": "22929299", "end": 240, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of malaria, a deadly infectious disease for which treatments are scarce and drug-resistant parasites are now increasingly found.", "begin": 0, "document": "22819049", "end": 173, "section": "abstract"}, {"text": "In contrast, it has been thought that Plasmodium spp., the causative agent of malaria, rely mainly on cytosolic glycolysis but not mitochondrial oxidative phosphorylation for energy production during blood stages.", "begin": 107, "document": "22628552", "end": 320, "section": "abstract"}, {"text": "Whereas no biological activity was previously identified for 1, the material derived from the efficient synthesis enabled additional bioactivity tests leading to the identification of a notable activity against insect cells and Plasmodium falciparum, the causative agent of malaria.", "begin": 165, "document": "22563351", "end": 447, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of malaria, encodes an SSB protein that localizes to the apicoplast and likely functions in the replication and maintenance of its genome.", "begin": 102, "document": "22543099", "end": 283, "section": "abstract"}, {"text": "Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum.", "begin": 0, "document": "22359643", "end": 111, "section": "title"}, {"text": "While observing cells by time-lapse imaging is a standard procedure in many systems, this technique was until recently not available for blood stages of Plasmodium falciparum, the causative agent of the most severe form of human malaria.", "begin": 174, "document": "22341220", "end": 411, "section": "abstract"}, {"text": "The causative agent of malaria, Plasmodium, possesses three translationally active compartments: the cytosol, the mitochondrion and a relic plastid called the apicoplast.", "begin": 0, "document": "22222968", "end": 170, "section": "abstract"}, {"text": "The genus Plasmodium, the causative agent of malaria, has the smallest mt genome in the form of a tandemly repeated, linear element of 6 kb.", "begin": 115, "document": "21329764", "end": 255, "section": "abstract"}, {"text": "The culminating step of the intraerythrocytic development of Plasmodium falciparum, the causative agent of malaria, is the spectacular release of multiple invasive merozoites on rupture of the infected erythrocyte membrane.", "begin": 0, "document": "21297002", "end": 223, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of human malaria, lacks a conventional tricarboxylic acid cycle and depends exclusively on glycolysis for ATP production.", "begin": 158, "document": "21209090", "end": 322, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the most deadly form of human malaria, is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival.", "begin": 0, "document": "20702404", "end": 169, "section": "abstract"}, {"text": "The Hsp90 protein from the parasite Plasmodium falciparum, the causative agent of malaria, is critical for this organism's survival; the anti-Hsp90 drug geldanamycin is toxic to P. falciparum growth.", "begin": 126, "document": "20635416", "end": 325, "section": "abstract"}, {"text": "A novel family of 1H-imidazol-2-yl-pyrimidine-4,6-diamines has been identified with potent activity against the erythrocyte-stage of Plasmodium falciparum (Pf), the most common causative agent of malaria.", "begin": 0, "document": "20610151", "end": 204, "section": "abstract"}, {"text": "The Plasmodium parasite, causative agent of malaria, infects RBC that are phagocytosed by DC and macrophages during the course of infection.", "begin": 186, "document": "20500669", "end": 326, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of malaria, a disease where new drug targets are required due to increasing resistance to current anti-malarials.", "begin": 0, "document": "20353400", "end": 158, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of human malaria, invades host erythrocytes using several proteins on the surface of the invasive merozoite, which have been proposed as potential vaccine candidates.", "begin": 0, "document": "19931645", "end": 209, "section": "abstract"}, {"text": "Few studies have investigated the pathophysiologic mechanisms responsible for what seems to be a possible interaction between Plasmodium falciparum, the causative agent of malaria, and HIV-1 in dually infected patients.", "begin": 0, "document": "19801158", "end": 219, "section": "abstract"}, {"text": "We show that orthochromatic cells are the earliest stages that may be invaded by Plasmodium falciparum, the causative agent of fatal human malaria.", "begin": 309, "document": "19706885", "end": 456, "section": "abstract"}, {"text": "Infection by Plasmodium, the causative agent of malaria, is associated with hemolysis and therefore with release of hemoglobin from RBC.", "begin": 0, "document": "19706490", "end": 136, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of malignant malaria, is among the most severe human infectious diseases", "begin": 0, "document": "19666593", "end": 115, "section": "abstract"}, {"text": "Plasmodium falciparum, the most important causative agent of human malaria, undergoes antigenic variation as a means of prolonging infection and ensuring transmission between hosts.", "begin": 0, "document": "19666023", "end": 181, "section": "abstract"}, {"text": "L-Malate dehydrogenase (PfMDH) from Plasmodium falciparum, the causative agent for the most severe form of malaria, has shown remarkable similarities to L: -lactate dehydrogenase (PfLDH).", "begin": 0, "document": "19184366", "end": 187, "section": "abstract"}, {"text": "FQ is able to overcome the chloroquine (CQ) resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria.", "begin": 138, "document": "18563912", "end": 303, "section": "abstract"}, {"text": "The causative agent of malaria, Plasmodium falciparum posses a single aquaglyceroporin (PfAQP) which represents a potential drug target for treatment of the disease.", "begin": 0, "document": "18295508", "end": 165, "section": "abstract"}, {"text": "An essential requisite for transmission of Plasmodium, the causative agent of malaria, is the successful completion of a complex developmental cycle in its mosquito vector.", "begin": 0, "document": "18248630", "end": 172, "section": "abstract"}, {"text": "In Plasmodium falciparum, the causative agent of cerebral malaria, silent information regulator 2 (Sir2) has been implicated in pathogenesis through its role in var gene silencing.", "begin": 0, "document": "18221799", "end": 180, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of human malaria, is totally dependent on de novo pyrimidine biosynthetic pathway.", "begin": 0, "document": "18082626", "end": 125, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the fatal form of malaria, synthesizes GMP primarily from IMP and, hence, needs active GMPS (GMP synthetase) for its survival.", "begin": 0, "document": "17868038", "end": 172, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of the most severe type of malaria, a life-threatening disease affecting the lives of over three billion people.", "begin": 0, "document": "17822713", "end": 157, "section": "abstract"}, {"text": "Plasmodium vivax is an important human pathogen causing malaria in more temperate climates of the world. Similar to Plasmodium falciparum, the causative agent for malaria tropica, drug resistance is beginning to emerge for this parasite species and this hampers adequate treatment of infection.", "begin": 0, "document": "16458301", "end": 294, "section": "abstract"}, {"text": "Malaria kills more than one million people a year, and understanding the historical association between its most notorious causative agent, Plasmodium falciparum, and its mosquito vectors is important in fighting the disease.", "begin": 0, "document": "16222020", "end": 225, "section": "abstract"}, {"text": "We show here that macrophages are mandatory for NK cell IFN-gamma secretion in response to erythrocytes infected with Plasmodium falciparum (Pf), a causative agent of human malaria.", "begin": 166, "document": "16203971", "end": 347, "section": "abstract"}, {"text": "Plasmodium falciparum is the main causative agent of tropical malaria, the most severe parasitic disease in the world. Growing resistance of Plasmodia towards available drugs is an increasing problem in countries where malaria is endemic.", "begin": 0, "document": "15878595", "end": 238, "section": "abstract"}, {"text": "The presence of antisense RNA in Plasmodium falciparum, the causative agent of severe malaria, remains controversial.", "begin": 117, "document": "15703443", "end": 234, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of malaria, is sensitive to oxidative stress and therefore the family of antioxidant enzymes, peroxiredoxins (Prxs) represent a target for antimalarial drug design.", "begin": 0, "document": "15701514", "end": 207, "section": "abstract"}, {"text": "In the Republic of Yemen, Plasmodium falciparum is the predominant causative agent of malaria and is associated with adverse consequences for pregnant women and their babies.", "begin": 0, "document": "15339111", "end": 174, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, uses multiple ligand-receptor interactions to invade host red blood cells (RBCs).", "begin": 0, "document": "15265796", "end": 166, "section": "abstract"}, {"text": "Comparative genomic analysis of the malaria causative agent, Plasmodium falciparum, with other eukaryotes for which the complete genome is available, revealed that the genome from P. falciparum was more similar to the genome of a plant, Arabidopsis thaliana, than to other non-apicomplexan taxa.", "begin": 0, "document": "15246528", "end": 295, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, totally depends on de novo pyrimidine biosynthetic pathway.", "begin": 0, "document": "15147974", "end": 144, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermentation during its blood-borne stages for energy production.", "begin": 0, "document": "15117937", "end": 177, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of the most severe form of human malaria. The rapid multiplication of the parasite within human erythrocytes requires an active production of new membranes.", "begin": 0, "document": "15073329", "end": 201, "section": "abstract"}, {"text": "Seven sPLA(2)s from groups IA, IB, IIA and III, were tested here in different culture conditions for inhibition of the in vitro intraerythrocytic development of Plasmodium falciparum, the causative agent of the most severe form of human malaria", "begin": 157, "document": "15033330", "end": 401, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, relies on de novo pyrimidine biosynthesis.", "begin": 0, "document": "15003844", "end": 127, "section": "abstract"}, {"text": "In spite of research efforts to develop vaccines against the causative agent of human malaria, Plasmodium falciparum, effective control remains elusive.", "begin": 0, "document": "14638789", "end": 152, "section": "abstract"}, {"text": "Plasmodium, the causative agent of malaria, has to undergo sexual differentiation and development in anopheline mosquitoes for transmission to occur.", "begin": 0, "document": "14627712", "end": 149, "section": "abstract"}, {"text": "For Plasmodium falciparum, a causative agent of tropical malaria, TrxR is an essential protein which has been validated as a drug target.", "begin": 117, "document": "14609342", "end": 254, "section": "abstract"}, {"text": "Plasmodium, the causative agent of malaria, must first infect hepatocytes to initiate a mammalian infection.", "begin": 0, "document": "14556002", "end": 108, "section": "abstract"}, {"text": "Cyclin dependent protein kinases (CDKs) have become attractive drug targets in an effort to identify effective inhibitors of the parasite Plasmodium falciparum, the causative agent of the most severe form of human malaria.", "begin": 0, "document": "12930149", "end": 222, "section": "abstract"}, {"text": "It is well established that protection against one such disease, malaria, requires strong CD8(+) T cell responses targeted against the liver stages of the causative agent, Plasmodium spp.", "begin": 190, "document": "12626578", "end": 377, "section": "abstract"}, {"text": "A novel method for the in vitro detection of the protozoan Plasmodium, the causative agent of malaria, has been developed.", "begin": 0, "document": "12139027", "end": 122, "section": "abstract"}, {"text": "Trypanosomes do not inhabit or grow in anopheles mosquitoes, the vector for the transmission of Plasmodium parasites the causative agent for malaria.", "begin": 0, "document": "12125103", "end": 149, "section": "abstract"}, {"text": "The genome sequence of Plasmodium falciparum, the causative agent of the most severe form of malaria in humans, rapidly approaches completion, but our ability to genetically manipulate this organism remains limited.", "begin": 0, "document": "11796125", "end": 215, "section": "abstract"}, {"text": "It is caused by a number of species of the genus Plasmodium, and Plasmodium falciparum is the causative agent of the most lethal form.", "begin": 95, "document": "11839179", "end": 229, "section": "abstract"}, {"text": "To complete its life cycle in the mosquito, Plasmodium, the causative agent of malaria, has to traverse the epithelia of the midgut and salivary glands.", "begin": 181, "document": "11687659", "end": 333, "section": "abstract"}, {"text": "In Plasmodium falciparum, the causative agent of human malaria, the catalytic subunit gene of cAMP-dependent protein kinase (Pfpka-c) exists as a single copy.", "begin": 0, "document": "11559352", "end": 158, "section": "abstract"}, {"text": "A putative glutathione peroxidase gene (Swiss-Prot accession number Z 68200) of Plasmodium falciparum, the causative agent of tropical malaria, was expressed in Escherichia coli and purified to electrophoretic homogeneity.", "begin": 0, "document": "11087748", "end": 222, "section": "abstract"}, {"text": "Apical membrane antigen 1 (AMA1) is an asexual blood-stage protein expressed in the invasive merozoite form of Plasmodia species, which are the causative agent of malaria.", "begin": 0, "document": "11115107", "end": 171, "section": "abstract"}, {"text": "In the case of Plasmodium falciparum, the causative agent of malaria tropica, this approach is especially interesting, because here both key enzymes, ODC and AdoMetDC, are combined in a bifunctional protein, ODC/AdoMetDC.", "begin": 350, "document": "11085920", "end": 571, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, is incapable of de novo purine synthesis, and thus, purine acquisition from the host is an indispensable nutritional requirement.", "begin": 0, "document": "10744765", "end": 214, "section": "abstract"}, {"text": "A laboratory model of circulation of the malaria causative agent P. gallinaceum has been used to show that the effect of precocene (antijuvenoid) leads to a statistically significant reduction in the proportion of infected females developing eggs after blood suction.", "begin": 0, "document": "10703207", "end": 267, "section": "abstract"}, {"text": "A cell-free incubation system prepared from asexual erythrocytic stages of Plasmodium falciparum, the causative agent of malaria in humans, is capable of synthesizing the same spectrum of GPIs as that found in metabolically labelled parasites.", "begin": 447, "document": "10585859", "end": 690, "section": "abstract"}, {"text": "The Plasmodium falciparum malaria parasite is the causative agent of malaria tropica.", "begin": 0, "document": "9927744", "end": 85, "section": "abstract"}, {"text": "The gene of an NADP+-specific glutamate dehydrogenase was cloned from Plasmodium falciparum, the causative agent of tropical malaria.", "begin": 0, "document": "9874251", "end": 133, "section": "abstract"}, {"text": "This study describes the synergistic interaction of two calcium channel blockers, verapamil (VR) and SR33557 or fantofarone (SR), in reversing chloroquine resistance in Plasmodium falciparum, the causative agent of human malaria.", "begin": 0, "document": "9514077", "end": 229, "section": "abstract"}, {"text": "Plasmodium falciparum is the major causative agent of malaria, a disease of worldwide importance.", "begin": 0, "document": "8816746", "end": 97, "section": "abstract"}, {"text": "Two enzymes were purified to homogeneity from the intraerythrocytic malarial parasite Plasmodium falciparum: glutathione disulfide reductase, an antioxidative enzyme, which appears to play an essential role for parasite growth and differentiation, and glutamate dehydrogenase, an enzyme not occurring in the host erythrocyte.", "begin": 97, "document": "8631352", "end": 422, "section": "abstract"}, {"text": "The paper provides evidence that the An. sacharovi females which do not develop mature eggs after blood-sucking on the malaria-infected donor could not be infected by the bird malaria agent P. gallinaceum.", "begin": 0, "document": "7715553", "end": 205, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of malaria tropica in man.", "begin": 0, "document": "8300589", "end": 71, "section": "abstract"}, {"text": "Plastid origin of an extrachromosomal DNA molecule from Plasmodium, the causative agent of malaria.", "begin": 0, "document": "1474844", "end": 99, "section": "title"}, {"text": "[New models of the circulation of the causative agent of malaria Plasmodium gallinaceum using malarial mosquitoes in the fauna of the USSR].", "begin": 0, "document": "1813841", "end": 140, "section": "title"}, {"text": "[Experimental research on the effect of biologically active substances on the susceptibility of mosquitoes to the causative agent of malaria. 3. Algae, fertilizers].", "begin": 0, "document": "1648659", "end": 165, "section": "title"}, {"text": "On a model pair Aedes aegypti--Plasmodium gallinaceum in has been shown that changes in the conditions of larvae development caused by the addition into the water medium of the live culture of Synochocystis sp. cyanobacteria or green seaweeds Chlorella vulgaris, acetone extracts from the live culture precipitate or Chlorella powder, as well as nitrogen-containing fertilizer--ammonium chloride did not lower the sensitivity of the imago flying to malaria parasites.", "begin": 0, "document": "1648659", "end": 467, "section": "abstract"}, {"text": "The mechanism of chloroquine resistance has not been known but recent evidence from Plasmodium falciparum, the causative agent of the most severe form of human malaria, suggested similarities to the multidrug resistance phenotype (MDR) of mammalian tumour cells which is mediated by a protein molecule termed P-glycoprotein.", "begin": 155, "document": "15463447", "end": 479, "section": "abstract"}, {"text": "The feasibility was determined of influencing Ae. aegypti sensitivity to bird malaria agent P. gallinaceum by sublethal concentrations of herbicides (ordram and propanide) and fungicides (fundozol and blue vitriol) introduced into the larvae habitation medium or into the imago feed.", "begin": 0, "document": "2067482", "end": 283, "section": "abstract"}, {"text": "[An experimental study of the effect of different biologically active substances on the susceptibility of mosquitoes to the causative agent of malaria. 1. Insect development regulators].", "begin": 0, "document": "2067470", "end": 186, "section": "title"}, {"text": "It has been shown on the model pair Ae. aegypti-P. gallinaceum that dimilin, an inhibitor of insect chitin synthesis has practically no effect on female sensitivity to malaria agent.", "begin": 0, "document": "2067470", "end": 182, "section": "abstract"}, {"text": "[The absence of an action of the pyrethroids deltamethrin and cypermethrin on mosquito susceptibility to the causative agent of malaria].", "begin": 0, "document": "2191201", "end": 137, "section": "title"}, {"text": "Mosquitos Ae. aegypti and An. stephensi contact with sublethal doses of deltametrin and cypermetrin pyretroids at larval stage and in grown state, when diet includes sugar with pyretroids, had no influence on the sensitivity of survived females to malaria agents P. gallinaceum and P. berghei.", "begin": 0, "document": "2191201", "end": 293, "section": "abstract"}, {"text": "This prompted us to purify and characterize the topoisomerases I and II present in the erythrocytes of protozoan parasites of the genus Plasmodium, the causative agent of malaria, in order to later use these enzymatic systems in antimalarial drug assays.", "begin": 114, "document": "3011062", "end": 368, "section": "abstract"}, {"text": "The problem of drug resistance of Plasmodium falciparum, the causative agent of tropical malaria and its role in the general system of malaria control are discussed.", "begin": 0, "document": "3911876", "end": 165, "section": "abstract"}, {"text": "[Effect of mosquito contact with DDT and their susceptibility to the causative agent of malaria].", "begin": 0, "document": "4047719", "end": 97, "section": "title"}, {"text": "[Lack of an effect from repeated blood sucking by mosquitoes on their infectivity with the causative agent of malaria].", "begin": 0, "document": "6728514", "end": 119, "section": "title"}, {"text": "The lack of repeated bloodsucking does not affect essentially the infection of Ae. aegypti mosquitoes with malaria agent, P. gallinaceum.", "begin": 0, "document": "6728514", "end": 137, "section": "abstract"}, {"text": "High resolution 31P-NMR has been used for the non-invasive observation of metabolites and metabolic rates in blood of normal mice and of mice infected with Plasmodium berghei, the causative agent of malaria.", "begin": 0, "document": "6760901", "end": 207, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of malaria, a disease that kills almost one million persons each year, mainly in sub-Saharan Africa.", "begin": 0, "document": "23349974", "end": 145, "section": "abstract"}, {"text": "The causative agent, Plasmodium falciparum, contains an unusual, essential organelle known as the apicoplast.", "begin": 108, "document": "23326533", "end": 217, "section": "abstract"}, {"text": "In this study bioinformatic analyses indicated a single copy orthologue of the putative SM synthase from the apicomplexan Plasmodium falciparum (the causative agent of malaria) was a bona fide sphingolipid synthase in the related model parasite, Toxoplasma gondii (TgSLS).", "begin": 672, "document": "23246819", "end": 944, "section": "abstract"}, {"text": "The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei.", "begin": 0, "document": "22990975", "end": 226, "section": "abstract"}, {"text": "Infection by Plasmodium species, the causative agent of malaria, is currently treated with drug-based therapies, but an increase in drug resistance has led to the need for new methods of treatment.", "begin": 351, "document": "22592550", "end": 548, "section": "abstract"}, {"text": "The 23-megabase genome of Plasmodium falciparum, the causative agent of severe human malaria, contains \u223c5300 genes, most of unknown function or lacking homologs in other organisms.", "begin": 0, "document": "22057268", "end": 180, "section": "abstract"}, {"text": "Results of the present study indicate that malaria is endemic in Nouakchott and that P. vivax is the principal causative agent.", "begin": 1193, "document": "22019287", "end": 1320, "section": "abstract"}, {"text": "Toxoplasma gondii is a member of the phylum Apicomplexa that includes several important human pathogens, such as Cryptosporidium and Plasmodium falciparum, the causative agent of human malaria.", "begin": 0, "document": "21670272", "end": 193, "section": "abstract"}, {"text": "Plasmodium falciparum, the major causative agent of human malaria, contains three separate genomes.", "begin": 0, "document": "21570407", "end": 99, "section": "abstract"}, {"text": "Plasmodium parasites, the causative agent of malaria, are transmitted through the bites of infected Anopheles mosquitoes resulting in over 250 million new infections each year.", "begin": 0, "document": "21206476", "end": 176, "section": "abstract"}, {"text": "The genus Plasmodium, causative agent of malaria, of the phylum Apicomplexa, has the smallest mt genome in the form of a circular and/or tandemly repeated linear element of 6 kb, encoding only three protein genes (cox1, cox3, and cob).", "begin": 116, "document": "20034997", "end": 351, "section": "abstract"}, {"text": "Plasmodium falciparum is the causative agent of the most lethal form of human malaria.", "begin": 141, "document": "19779742", "end": 227, "section": "abstract"}, {"text": "In Plasmodium falciparum, the causative agent of the most lethal form of malaria, fatty acid biosynthesis occurs in the apicoplast organelle during the liver stage of the parasite life cycle.", "begin": 146, "document": "19768685", "end": 337, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of malignant malaria, is among the most severe human infectious diseases.", "begin": 0, "document": "19666593", "end": 116, "section": "abstract"}, {"text": "For transmission to occur, Plasmodium, the causative agent of malaria, must complete a complex developmental cycle in its mosquito vector.", "begin": 34, "document": "19038338", "end": 172, "section": "abstract"}, {"text": "FQ is able to overcome the CQ resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria.", "begin": 267, "document": "19020475", "end": 418, "section": "abstract"}, {"text": "Some lycorine ester derivatives including LT1 were examined for their inhibitory activity against Trypanosoma brucei brucei, the parasite associated with sleeping sickness, and against Plasmodium falciparum, the causative agent of malaria.", "begin": 272, "document": "19013823", "end": 511, "section": "abstract"}, {"text": "A three-dimensional structure of histo-aspartic protease (HAP), a pepsin-like enzyme from the causative agent of malaria Plasmodium falciparum, is suggested on the basis of homologous modeling followed by equilibration by the method of molecular dynamics.", "begin": 0, "document": "18672695", "end": 255, "section": "abstract"}, {"text": "Plasmodium falciparum, the causative agent of malaria, relies on a complex protein-secretion system for protein targeting into numerous subcellular destinations.", "begin": 0, "document": "18522993", "end": 161, "section": "abstract"}, {"text": "We have evaluated a technology called transcriptionally active PCR (TAP) for high throughput identification and prioritization of novel target antigens from genomic sequence data using the Plasmodium parasite, the causative agent of malaria, as a model.", "begin": 0, "document": "18164079", "end": 253, "section": "abstract"}]}, {"documents": ["19223320", "16782878", "16230358", "10809727", "20417644", "19467292", "19279205", "17346238", "15208449", "14978508", "11839807", "10444382", "8898393", "8614619"], "answer": [["eFSec"], ["SBP2"], ["SECp43"], ["PSTK"], ["Sec synthase", "Sec S", "SLA/LP"], ["SPS2", "SelD"], ["tRNASec"], ["SECIS element"], ["(L30)"], ["SPS1"]], "id": "51766e438ed59a060a000031", "snippets": [{"text": "The process requires the Sec insertion sequence (SECIS) element, tRNASec, and protein factors including the SECIS binding protein 2 (SBP2)", "begin": 185, "document": "16782878", "end": 323, "section": "abstract"}, {"text": "Taken together, these data establish the role of SECp43 and SLA in selenoprotein biosynthesis through interaction with tRNA([Ser]Sec) in a multiprotein complex.", "begin": 1232, "document": "16230358", "end": 1392, "section": "abstract"}, {"text": "Selenophosphate synthetase (SelD) generates the selenium donor for selenocysteine biosynthesis in eubacteria. One homologue of SelD in eukaryotes is SPS1 (selenophosphate synthetase 1) and a second one, SPS2, was identified as a selenoprotein in mammals.", "begin": 0, "document": "17346238", "end": 254, "section": "abstract"}, {"text": "These in vivo studies indicate that SPS2 is essential for generating the selenium donor for selenocysteine biosynthesis in mammals, whereas SPS1 probably has a more specialized, non-essential role in selenoprotein metabolism.", "begin": 838, "document": "17346238", "end": 1063, "section": "abstract"}]}, {"documents": ["20471717", "18755209", "16806196", "16687499", "12212772"], "answer": [["Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) transplantation"], ["Administration of 7-nitroindazole  (neuronal nitric oxide synthase inhibitor)"], ["Administration of Memantine  (un-competitive inhibitor of N-methyl-D-aspartate receptors)"], ["Administration glycogen synthase kinase-3  (GSK-3) inhibitors"], ["Administration of M1 muscarinic agonists such as AF150(S) and AF267B"]], "id": "517775c78ed59a060a000033", "snippets": [{"text": "tau hyperphosphorylation were dramatically reduced in hUCB-MSC transplanted APP/PS1 mice", "begin": 529, "document": "20471717", "end": 617, "section": "abstract"}, {"text": "Administration of 7-nitroindazole to CMS-exposed old rats significantly (p=0.002) increased GAD activity, decreased glutamate levels (7.19+/-3.19 vs. 763.9+/-91 micromol/g tissue protein; p=0.0005), and decreased phosphorylation of tau proteins compared to CMS exposed rats.", "begin": 1110, "document": "18755209", "end": 1384, "section": "abstract"}, {"text": "Changes in glutamate decarboxylase enzyme activity and tau-protein phosphorylation in the hippocampus of old rats exposed to chronic mild stress: reversal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole.", "begin": 0, "document": "18755209", "end": 221, "section": "title"}, {"text": "Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine.", "begin": 0, "document": "16806196", "end": 96, "section": "title"}, {"text": "Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.", "begin": 0, "document": "16687499", "end": 131, "section": "title"}, {"text": "Here, we show that transgene shutdown in symptomatic mice leads to normal GSK-3 activity, normal phospho-tau levels, diminished neuronal death, and suppression of the cognitive deficit, thus further supporting the potential of GSK-3 inhibitors for AD therapeutics.", "begin": 1590, "document": "16687499", "end": 1854, "section": "abstract"}, {"text": "These effects can be combined with the beneficial effects of these compounds on some other major hallmarks of Alzheimer's disease (AD) (e.g. tau hyperphosphorylation and paired helical filaments [PHF]; and loss of cholinergic function conducive to cognitive impairments.)", "begin": 524, "document": "12212772", "end": 795, "section": "abstract"}, {"text": "The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren's Syndrome), AF150(S) and AF267B--1) are neurotrophic and synergistic with neurotrophins such as nerve growth factor and epidermal growth factor; 2) elevate the non-amyloidogenic amyloid precursor protein (alpha-APPs) in vitro and decrease beta-amyloid (A beta) levels in vitro and in vivo; and 3) inhibit A beta- and oxidative-stress-induced cell death and apoptosis in PC12 cells transfected with the M1 muscarinic receptor", "begin": 0, "document": "12212772", "end": 522, "section": "abstract"}]}, {"documents": ["16757361", "8613066", "21886451", "21779504", "12697967", "19783717", "19826477", "19509115", "16166322", "8178941", "21626008"], "answer": ["Point mutations"], "id": "5177def18ed59a060a000034", "snippets": [{"text": "activating mutations in KRAS are identified in most pancreatic cancers", "begin": 9, "document": "16757361", "end": 79, "section": "abstract"}, {"text": "Activating point mutations in the K-Ras oncogene are among the most common genetic alterations in pancreatic cancer, occurring early in the progression of the disease.", "begin": 0, "document": "19509115", "end": 167, "section": "abstract"}, {"text": "Activating K-ras mutations are found in approximately 90% of pancreatic carcinomas and may contribute to the poor prognosis of these tumors.", "begin": 0, "document": "16166322", "end": 140, "section": "abstract"}, {"text": "Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one.", "begin": 1056, "document": "8178941", "end": 1216, "section": "abstract"}, {"text": "gain-of-function mutations in ras genes were the first specific genetic alterations identified in human cancer", "begin": 9, "document": "21779504", "end": 119, "section": "abstract"}]}, {"documents": ["23449173", "22670134", "11269512", "22982301", "21982064", "19495527", "18337588", "18332345", "17387578", "17089071", "12111643", "11960578", "11738860", "10577905", "10767337", "11055898", "11524741", "11462237", "11402105", "11313756"], "answer": ["Rett syndrome"], "id": "517818508ed59a060a000035", "snippets": [{"text": "Recently, this syndrome has been associated with mutations of the MECP2 gene, a transcriptional repressor of still unknown target genes. Here we report a detailed mutational analysis of 62 patients from UK and Italian archives, representing the first comparative study among different populations and one of the largest number of cases so far analyzed.", "begin": 189, "document": "11269512", "end": 541, "section": "abstract"}, {"text": "Mutation screening revealed 31 different mutations in 68 patients and 12 non-pathogenic polymorphisms.", "begin": 821, "document": "17387578", "end": 923, "section": "abstract"}, {"text": "In this study, the MECP2 sequences in 121 unrelated Chinese patients with classical or atypical RTT were screened for deletions and mutations. In all, we identified 45 different MECP2 mutations in 102 of these RTT patients.", "begin": 151, "document": "17089071", "end": 374, "section": "abstract"}, {"text": "Mutations in MECP2 were found in about 55%", "begin": 387, "document": "12111643", "end": 429, "section": "abstract"}, {"text": "We identified mutations in the MECP2 gene and documented the clinical manifestations in 65 Rett syndrome patients to characterize the genotype-phenotype spectrum.", "begin": 206, "document": "11960578", "end": 368, "section": "abstract"}, {"text": "We searched for mutations by sequencing the MECP2 coding region in 45 sporadic cases (35 with classic RTT, eight with variant forms and two males) and in seven families with two or more affected females. Following our previous report of mutations in two families and eight sporadic cases, we here present 18 additional mutations.", "begin": 177, "document": "11738860", "end": 506, "section": "abstract"}, {"text": "The responsible gene, encoding methyl-CpG binding protein 2 (MeCP2), was recently discovered. Here we explore the spectrum of phenotypes resulting from MECP2 mutations. Both nonsense (R168X and R255X) and missense (R106W and R306C) mutations have been found, with multiple recurrences.", "begin": 148, "document": "10577905", "end": 433, "section": "abstract"}, {"text": "Mutations were identified in 44/55 (80%) unrelated classical sporadic and familial RTT patients, but only 1/5 (20%) sporadic cases with suggestive but non-diagnostic features of RTT", "begin": 566, "document": "10767337", "end": 747, "section": "abstract"}, {"text": "Collectively, we tested 228 unrelated female patients with a diagnosis of possible (209) or classic (19) RTT and found MECP2 mutations in 83 (40%) of 209 and 16 (84%) of 19 of the patients, respectively. Thirty-two different mutations were identified (8 missense, 9 nonsense, 1 splice site, and 14 frameshifts), of which 12 are novel and 9 recurrent in unrelated patients.", "begin": 872, "document": "11055898", "end": 1244, "section": "abstract"}, {"text": "Mutations in MECP2 were identified from most of the patients with classical and variant RTT (25 of 27 cases)", "begin": 405, "document": "11524741", "end": 513, "section": "abstract"}, {"text": "In our series, 19 different de novo MECP2 mutations, eight of which were previously unreported, were found in 35 out of 50 Rett girls (70%)", "begin": 855, "document": "11462237", "end": 994, "section": "abstract"}, {"text": "We have identified 15 different MECP2 mutations in 26 of 30 Danish RTT patients.", "begin": 426, "document": "11313756", "end": 506, "section": "abstract"}]}, {"documents": ["22658851", "20980390", "20564195", "19920070", "19575460", "19349584", "18846549", "16951252", "16837631"], "answer": [["Ablation of ILK in heart results in dilated cardiomyopathy and spontaneous heart failure"], ["Ablation of ILK in fibroblasts leads to impaired healing due to a severe reduction in the number of myofibroblasts"], ["Ablation of ILK in osteoclasts inhibits bone resorption"], ["Ablation of ILK in liver results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration and in abnormal histology"], ["Ablation of ILK in podocytes caused an aberrant distribution of nephrin and alpha-actinin-4"]], "id": "5179602c8ed59a060a00003d", "snippets": [{"text": "ILK knockdown had no effect on the viability or survival pathway activity pattern of MM cells.", "begin": 450, "document": "22658851", "end": 544, "section": "abstract"}, {"text": "We conclude that ILK does not play a prominent role in the promotion or sustenance of established MM.", "begin": 768, "document": "22658851", "end": 869, "section": "abstract"}, {"text": "Defective granulation tissue formation in mice with specific ablation of integrin-linked kinase in fibroblasts", "begin": 0, "document": "20980390", "end": 110, "section": "title"}, {"text": "Here, we show that fibroblast-restricted inactivation of ILK in mice leads to impaired healing due to a severe reduction in the number of myofibroblasts, whereas inflammatory infiltrate and vascularization of the granulation tissue are unaffected.", "begin": 311, "document": "20980390", "end": 558, "section": "abstract"}, {"text": "in fibroblasts, ILK is crucial for limiting RhoA activity, thus promoting TGF\u03b21 production, which is essential for dermal repair following injury.", "begin": 1006, "document": "20980390", "end": 1152, "section": "abstract"}, {"text": "Our results show that ILK is important for the function, but not the differentiation, of osteoclasts.", "begin": 1429, "document": "20564195", "end": 1530, "section": "abstract"}, {"text": "Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption.", "begin": 0, "document": "20564195", "end": 94, "section": "title"}, {"text": "ack of ILK in the hepatocytes imparts prolonged proliferative response not only to stimuli related to liver regeneration but also to xenobiotic chemical mitogens, such as PB.", "begin": 1448, "document": "19920070", "end": 1622, "section": "abstract"}, {"text": "Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration.", "begin": 0, "document": "19920070", "end": 163, "section": "title"}, {"text": "Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase.", "begin": 0, "document": "19575460", "end": 120, "section": "title"}, {"text": "ILK deficiency caused an aberrant distribution of nephrin and alpha-actinin-4 in podocytes, whereas the localization of podocin and synaptopodin remained relatively intact.", "begin": 794, "document": "16837631", "end": 966, "section": "abstract"}, {"text": "Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure.", "begin": 0, "document": "16951252", "end": 111, "section": "title"}, {"text": "Here we show that targeted ablation of the integrin-linked kinase (ILK) expression results in spontaneous cardiomyopathy and heart failure by 6 wk of age.", "begin": 155, "document": "16951252", "end": 309, "section": "abstract"}, {"text": "Together, these results suggest that ILK plays a central role in protecting the mammalian heart against cardiomyopathy and failure.", "begin": 637, "document": "16951252", "end": 768, "section": "abstract"}, {"text": "Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly.", "begin": 0, "document": "18846549", "end": 135, "section": "title"}, {"text": "Integrin-linked kinase is required for radial sorting of axons and Schwann cell remyelination in the peripheral nervous system.", "begin": 0, "document": "19349584", "end": 127, "section": "title"}]}, {"documents": ["15072569", "9389494", "9709961", "9794474", "8550759", "7629231"], "answer": ["Type 1 deiodinase", "type 3 deiodinase"], "id": "517a8b768ed59a060a00003f", "snippets": [{"text": "Iodothyronine deiodinase in vitro activity studies in the chicken showed the presence of type I and type III iodothyronine deiodinase activity in both liver and kidney.", "begin": 0, "document": "15072569", "end": 168, "section": "abstract"}, {"text": "In embryonic chicken liver (ECL) two types of iodothyronine deiodinases are expressed: D1 and D3.", "begin": 0, "document": "9389494", "end": 97, "section": "abstract"}, {"text": "In liver homogenates, D1 activity was not correlated with age, whereas D3 activity showed a strong negative correlation with age (r -0.84), with high D3 activities in preterm infants and (except in 1 infant of 35 weeks) absent D3 activity in full-term infants. In microsomes, D1 activities amounted to 4.3-60 pmol/min/mg protein in fetal livers and to 170-313 pmol/min/mg protein in adult livers, whereas microsomal D3 activities were 0.15-1.45 pmol/min/mg protein in fetuses and <0.1 pmol/min/mg protein in all but one adult.", "begin": 1140, "document": "9709961", "end": 1666, "section": "abstract"}, {"text": "high D1 and D3 activities in fetal human liver, and high D1 and mostly absent D3 activities in adult human liver.", "begin": 1822, "document": "9709961", "end": 1935, "section": "abstract"}]}, {"documents": ["22719854", "22294745", "16728541", "15062548", "12072404", "10426574", "8663170", "7768329", "8444882", "1417847"], "answer": [["Type 2 deiodinase"], ["Type 3 deiodinase"]], "id": "517a8bab8ed59a060a000040", "snippets": [{"text": "In brain, the presence of type III iodothyronine deiodinase (D3) seems to be important to maintain homeostasis of T(3) levels.", "begin": 181, "document": "12072404", "end": 307, "section": "abstract"}, {"text": "We were able to detect a protein fragment corresponding to the expected molecular mass (30 kDa) for type III deiodinase by means of Western blot analysis. RT-PCR as well as Northern blot analysis confirmed the presence of D3 mRNA in the cerebellum.", "begin": 1502, "document": "12072404", "end": 1750, "section": "abstract"}, {"text": "The presence of 5D (type-III) together with our previous report of 5'-deiodinase (type-I in euthyroidism and type-II in hypothyroidism) shows that the isozymes of deiodinases in the neurohypophysis are quite similar to those in the brain.", "begin": 345, "document": "1417847", "end": 583, "section": "abstract"}]}, {"documents": ["23396445", "19293265", "17986277", "16127464"], "answer": [["Type 2 deiodinase"], ["Tipe 3 deiodinase"]], "id": "517a8bef8ed59a060a000041", "snippets": [{"text": "Type 2 deiodinase (D2), the thyroid hormone (TH)-activating enzyme, is sharply upregulated during myoblast differentiation", "begin": 251, "document": "23396445", "end": 373, "section": "abstract"}, {"text": "The iodothyronine deiodinases D1, D2, and D3 enable tissue-specific adaptation of thyroid hormone levels in response to various conditions, such as hypothyroidism or fasting. The possible expression of D2 mRNA in skeletal muscle is intriguing because this enzyme could play a role in systemic as well as local T3 production", "begin": 12, "document": "19293265", "end": 335, "section": "abstract"}, {"text": "Deiodinase activities were then assayed in cell sonicates. The ratio of T3 production in cell sonicates (catalytic efficiency) was multiplied by the tissue activities reported in human liver (D1) and skeletal muscle (D2)", "begin": 338, "document": "16127464", "end": 558, "section": "abstract"}]}, {"documents": ["22975810", "22852678", "22278059", "21500720", "23331310", "23250067", "23003992", "22714377", "22665786", "22653729", "22330507", "22286383", "21293374", "21293373", "20164644", "16642197", "11390993", "23412482", "23396131", "23291355", "23263128", "23214818", "23196907", "23083249", "23031037", "23031030", "22893239", "22575364", "22565760", "22355576", "22181929", "21517525", "21230665", "21190672"], "answer": [["high resolution protein structure determination"], ["molecular imaging", "single-particle imaging"], ["study of enzyme kinetics", "time resolved protein crystallography"]], "id": "51475d5cd24251bc0500001b", "snippets": [{"text": "In conjunction with the XFEL temporal profile and high-flux, it is a powerful tool for studying the dynamics of time-dependent systems. Photo-induced processes and fast catalytic reaction kinetics, ranging from femtoseconds to milliseconds, will be resolvable in a wide array of systems circumventing radiation damage.", "begin": 662, "document": "22852678", "end": 980, "section": "abstract"}, {"text": "We discuss the pertinent physics of the intense X-ray-matter interactions, and illustrate the importance of electron-ion collisions. Detailed simulations of the interaction process conducted with a radiative-collisional code show good qualitative agreement with the experimental results. We obtain insights into the evolution of the charge state distribution of the system, the electron density and temperature, and the timescales of collisional processes. Our results should inform future high-intensity X-ray experiments involving dense samples, such as X-ray diffractive imaging of biological systems, material science investigations, and the study of matter in extreme conditions.", "begin": 1027, "document": "22278059", "end": 1711, "section": "abstract"}, {"text": "employment of \"exotic\" systems, such as the Free Electron LASER (FEL), that are expected to focus on the fundamental processes of life, following chemical reactions and biological processes as they happen, on unprecedented time and size scales.", "begin": 449, "document": "21500720", "end": 693, "section": "abstract"}, {"text": "New data analysis approaches are outlined for the correlated fluctuations in fast WAXS, for protein nanocrystals just a few molecules on a side, and for the continuous x-ray scattering from a single virus", "begin": 858, "document": "22975810", "end": 1062, "section": "abstract"}, {"text": "Research opportunities and techniques are reviewed for the application of hard x-ray pulsed free-electron lasers (XFEL) to structural biology. These include the imaging of protein nanocrystals, single particles such as viruses, pump--probe experiments for time-resolved nanocrystallography, and snapshot wide-angle x-ray scattering (WAXS) from molecules in solution. The use of femtosecond exposure times, rather than freezing of samples, as a means of minimizing radiation damage is shown to open up new opportunities for the molecular imaging of biochemical reactions at room temperature in solution", "begin": 0, "document": "22975810", "end": 601, "section": "abstract"}, {"text": "New opportunities for solving the phase problem for XFEL data are outlined. A summary of the latest results is given, which now extend to atomic resolution for nanocrystals. Possibilities for time-resolved chemistry using fast WAXS (solution scattering) from mixtures is reviewed, toward the general goal of making molecular movies of biochemical processes.", "begin": 1232, "document": "22975810", "end": 1589, "section": "abstract"}, {"text": "Molecular imaging using X-ray free-electron lasers.", "begin": 0, "document": "23331310", "end": 51, "section": "title"}, {"text": "The recent development of X-ray free-electron laser sources has created new opportunities for the structural analysis of protein nanocrystals.", "begin": 0, "document": "23250067", "end": 142, "section": "abstract"}, {"text": "X-ray free electron lasers hold the promise of enabling atomic-resolution diffractive imaging of single biological molecules.", "begin": 0, "document": "23003992", "end": 125, "section": "abstract"}, {"text": "The emergence of femtosecond diffractive imaging with X-ray lasers has enabled pioneering structural studies of isolated particles, such as viruses, at nanometer length scales.", "begin": 0, "document": "22714377", "end": 176, "section": "abstract"}, {"text": "In this paper we report room temperature X-ray diffraction data of PS\u00a0II microcrystals obtained using ultrashort (<\u00a050\u00a0fs) 9\u00a0keV X-ray pulses from a hard X-ray free electron laser, namely the Linac Coherent Light Source.", "begin": 575, "document": "22665786", "end": 795, "section": "abstract"}, {"text": "High-resolution protein structure determination by serial femtosecond crystallography", "begin": 0, "document": "22653729", "end": 85, "section": "title"}, {"text": "We applied serial femtosecond crystallography (SFX) using an x-ray free-electron laser (XFEL) to obtain high-resolution structural information from microcrystals (less than 1 micrometer by 1 micrometer by 3 micrometers) of the well-characterized model protein lysozyme.", "begin": 210, "document": "22653729", "end": 479, "section": "abstract"}, {"text": "Time-resolved protein nanocrystallography using an X-ray free-electron laser", "begin": 0, "document": "22330507", "end": 76, "section": "title"}, {"text": "We demonstrate the use of an X-ray free electron laser synchronized with an optical pump laser to obtain X-ray diffraction snapshots from the photoactivated states of large membrane protein complexes in the form of nanocrystals flowing in a liquid jet.", "begin": 0, "document": "22330507", "end": 252, "section": "abstract"}, {"text": "We describe the experimental setup and obtain the first time-resolved femtosecond serial X-ray crystallography results from an irreversible photo-chemical reaction at the Linac Coherent Light Source. This technique opens the door to time-resolved structural studies of reaction dynamics in biological systems.", "begin": 651, "document": "22330507", "end": 960, "section": "abstract"}, {"text": "X-ray free electron laser (X-FEL)-based serial femtosecond crystallography is an emerging method with potential to rapidly advance the challenging field of membrane protein structural biology. Here we recorded interpretable diffraction data from micrometer-sized lipidic sponge phase crystals of the Blastochloris viridis photosynthetic reaction center delivered into an X-FEL beam", "begin": 0, "document": "22286383", "end": 381, "section": "abstract"}, {"text": "Here we show that high-quality diffraction data can be obtained with a single X-ray pulse from a non-crystalline biological sample, a single mimivirus particle, which was injected into the pulsed beam of a hard-X-ray free-electron laser, the Linac Coherent Light Source.", "begin": 490, "document": "21293374", "end": 760, "section": "abstract"}, {"text": "Single mimivirus particles intercepted and imaged with an X-ray laser", "begin": 0, "document": "21293374", "end": 69, "section": "title"}, {"text": "Femtosecond X-ray protein nanocrystallography", "begin": 0, "document": "21293373", "end": 45, "section": "title"}, {"text": "Here we present a method for structure determination where single-crystal X-ray diffraction 'snapshots' are collected from a fully hydrated stream of nanocrystals using femtosecond pulses from a hard-X-ray free-electron laser, the Linac Coherent Light Source. We prove this concept with nanocrystals of photosystem I, one of the largest membrane protein complexes.", "begin": 548, "document": "21293373", "end": 912, "section": "abstract"}, {"text": "These methods can be used to image biological and materials science samples at high resolution with x-ray undulator radiation and establishes the techniques to be used in atomic-resolution ultrafast imaging at x-ray free-electron laser sources.", "begin": 711, "document": "16642197", "end": 955, "section": "abstract"}, {"text": "With the prospects of the x-ray free electron lasers, this approach could provide a major new opportunity for the high-resolution three-dimensional structure determination of single biomolecules.", "begin": 1063, "document": "11390993", "end": 1258, "section": "abstract"}, {"text": "X-ray free-electron lasers (XFELs) generate sequences of ultra-short spatially coherent pulses of X-ray radiation.", "begin": 0, "document": "23412482", "end": 114, "section": "abstract"}, {"text": "Diffractive imaging using the intense and coherent beam of X-ray free-electron lasers opens new perspectives for structural studies of single nanoparticles and biomolecules.", "begin": 0, "document": "23396131", "end": 173, "section": "abstract"}, {"text": "The opening of hard X-ray free-electron laser facilities, such as the Linac Coherent Light Source (LCLS) at SLAC National Accelerator Laboratory in the United States, has ushered in a new era in structural determination.", "begin": 0, "document": "23331310", "end": 220, "section": "abstract"}, {"text": "Where possible we also highlight areas that we think could push this field forward with emerging technologies, such as X-ray free electron lasers (X-feL), which could have a big impact on the membrane protein structural biology community.", "begin": 805, "document": "23291355", "end": 1043, "section": "abstract"}, {"text": "X-ray free electron lasers (XFELs) deliver short (<100 fs) and intense (\u223c10(12) photons) pulses of hard X-rays, making them excellent sources for time-resolved studies.", "begin": 0, "document": "23281652", "end": 168, "section": "abstract"}, {"text": "Modern imaging techniques at the molecular scale rely on utilizing novel coherent light sources like X-ray free electron lasers for the ultimate goal of visualizing such objects as individual biomolecules rather than crystals.", "begin": 248, "document": "23263128", "end": 474, "section": "abstract"}, {"text": "In single-particle coherent x-ray diffraction imaging experiments, performed at x-ray free-electron lasers (XFELs), samples are exposed to intense x-ray pulses to obtain single-shot diffraction patterns.", "begin": 0, "document": "23214818", "end": 203, "section": "abstract"}, {"text": "The structure reveals the mechanism of native TbCatB inhibition and demonstrates that new biomolecular information can be obtained by the \"diffraction-before-destruction\" approach of x-ray free-electron lasers from hundreds of thousands of individual microcrystals.", "begin": 619, "document": "23196907", "end": 884, "section": "abstract"}, {"text": "Coherent diffraction imaging (CDI) of single molecules at atomic resolution is a major goal for the x-ray free-electron lasers (XFELs).", "begin": 0, "document": "23031037", "end": 135, "section": "abstract"}, {"text": "Ultrashort X-ray pulses from free-electron laser X-ray sources make it feasible to conduct small- and wide-angle scattering experiments on biomolecular samples in solution at sub-picosecond timescales.", "begin": 0, "document": "22893239", "end": 201, "section": "abstract"}, {"text": "The short and intense pulses of the new X-ray free electron lasers, now operational or under construction, may make possible diffraction experiments on single molecule-sized objects with high resolution, before radiation damage destroys the sample.", "begin": 0, "document": "22575364", "end": 248, "section": "abstract"}, {"text": "The recent development of x-ray free electron lasers providing coherent, femtosecond-long pulses of high brilliance and variable energy opens new areas of scientific research in a variety of disciplines such as physics, chemistry, and biology.", "begin": 0, "document": "22565760", "end": 243, "section": "abstract"}, {"text": "X-ray free electron laser (X-FEL)-based serial femtosecond crystallography is an emerging method with potential to rapidly advance the challenging field of membrane protein structural biology.", "begin": 0, "document": "22286383", "end": 192, "section": "abstract"}, {"text": "X-ray free-electron lasers (FELs) show promise for revealing the structure of single molecules or nanocrystals, but the phase problem remains largely unsolved.", "begin": 171, "document": "22181929", "end": 330, "section": "abstract"}, {"text": "Coherent diffractive imaging using x-ray free-electron lasers (XFELs) may provide a unique opportunity for high-resolution structural analysis of single particles sprayed from an aqueous solution into the laser beam.", "begin": 0, "document": "21517525", "end": 216, "section": "abstract"}, {"text": "Here we present a method for structure determination where single-crystal X-ray diffraction 'snapshots' are collected from a fully hydrated stream of nanocrystals using femtosecond pulses from a hard-X-ray free-electron laser, the Linac Coherent Light Source.", "begin": 548, "document": "21293373", "end": 807, "section": "abstract"}, {"text": "This work is directly relevant to the time-resolved imaging of magnetic dynamics using coherent and ultrafast radiation from x-ray free-electron lasers and also to broader classes of diffractive imaging experiments which suffer noisy data, missing data, or both.", "begin": 639, "document": "21230665", "end": 901, "section": "abstract"}, {"text": "By combining serial nanocrystallography with x-ray free-electron laser sources in the future, it may be possible to produce molecular-resolution electron-density maps using membrane protein crystals that contain only a few hundred or thousand unit cells.", "begin": 1042, "document": "21190672", "end": 1296, "section": "abstract"}, {"text": "Very strong soft X-ray free electron laser (FEL) pulses must be short to allow for investigations of ultra-fast wet chemistry, according to the principle of collect and destroy.", "begin": 707, "document": "22684196", "end": 884, "section": "abstract"}]}, {"documents": ["22332444", "18228241", "12970845", "12577208", "8154209"], "answer": ["autosomal dominant"], "id": "51635202298dcd4e5100004f", "snippets": [{"text": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene.", "begin": 0, "document": "18228241", "end": 131, "section": "abstract"}, {"text": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3.", "begin": 0, "document": "12970845", "end": 362, "section": "abstract"}, {"text": "proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9.", "begin": 470, "document": "12970845", "end": 677, "section": "abstract"}, {"text": "All patients have the DM2 (CCTG)(n) expansion.", "begin": 859, "document": "12970845", "end": 905, "section": "abstract"}, {"text": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type.", "begin": 0, "document": "8154209", "end": 99, "section": "abstract"}]}, {"documents": ["22952936", "22669941", "22170608", "22140039", "21236481", "20825493", "20100521", "20023637", "19858287", "19833968", "19405859", "18974860", "16777965", "16731656", "16061665", "15980066", "15047890", "14712914", "12495442", "12381662", "12121621", "23471982"], "answer": ["component of the central and peripheral circadian clocks for generation of circadian rhythms in mice"], "id": "51680a6d298dcd4e51000063", "snippets": [{"text": "Malfunction of the circadian clock has been linked to the pathogenesis of a variety of diseases. We show that mice lacking the core clock components Cryptochrome-1 (Cry1) and Cryptochrome-2 (Cry2) (Cry-null mice) show salt-sensitive hypertension due to abnormally high synthesis of the mineralocorticoid aldosterone by the adrenal gland.", "begin": 0, "document": "20023637", "end": 337, "section": "abstract"}, {"text": "The Cryptochrome 1 and 2 genes are indispensable for molecular core oscillator function, as evident from the arrhythmic wheel-running behavior and lack of rhythmic clock gene expression in mCry1/mCry2 double-mutant mice in constant darkness.", "begin": 313, "document": "12121621", "end": 554, "section": "abstract"}, {"text": "Among the components driving the mammalian circadian clock are the Period 1 and 2 (mPer1 and mPer2) and Cryptochrome 1 and 2 (mCry1 and mCry2) genes. A mutation in the mPer2 gene leads to a gradual loss of circadian rhythmicity in mice kept in constant darkness (DD). Here we show that inactivation of the mCry2 gene in mPer2 mutant mice restores circadian rhythmicity and normal clock gene expression patterns. Thus, mCry2 can act as a nonallelic suppressor of mPer2, which points to direct or indirect interactions of PER2 and CRY2 proteins. In marked contrast, inactivation of mCry1 in mPer2 mutant mice does not restore circadian rhythmicity but instead results in complete behavioral arrhythmicity in DD, indicating different effects of mCry1 and mCry2 in the clock mechanism", "begin": 442, "document": "12381662", "end": 1222, "section": "abstract"}, {"text": "Cryptochrome 1 and 2 gene products act in the negative feedback loop and are indispensable for molecular core oscillator function, as evident from the arrhythmic wheel running behaviour and absence of cyclic clock gene expression in mCry1/mCry2 double mutant mice in constant darkness.", "begin": 289, "document": "14712914", "end": 574, "section": "abstract"}, {"text": ", when mCry-deficient mice are housed in normal light-dark cycles, a single non-circadian peak in neuronal activity can be detected in SCN slices prepared two hours after the beginning of the day. This light-induced increase in electric activity of the SCN suggests that deletion of the mCry genes converts the core oscillator in an hour-glass-like timekeeper and may explain why in normal day-night cycles mCry-deficient mice show apparently normal behaviour.", "begin": 963, "document": "14712914", "end": 1423, "section": "abstract"}, {"text": "Cryptochrome 1 and 2 act as essential components of the central and peripheral circadian clocks for generation of circadian rhythms in mammals", "begin": 0, "document": "15980066", "end": 142, "section": "abstract"}, {"text": "cryptochrome-1 mRNA was found in DA cells, immunocytochemistry was extended to other components of the circadian clock machinery. This analysis showed that DA cells contain the most common clock-related proteins.", "begin": 1288, "document": "15047890", "end": 1500, "section": "abstract"}, {"text": "Cryptochrome 1 and cryptochrome 2 proteins are core components of the mammalian circadian clock and mice mutated in both genes are arrhythmic.", "begin": 193, "document": "16061665", "end": 335, "section": "abstract"}, {"text": "a domain in the extreme C terminus of BMAL1 that plays an essential role in the rhythmic control of E-box-mediated circadian transcription. Remarkably, the last 43 aa of BMAL1 are required for transcriptional activation, as well as for association with the circadian transcriptional repressor CRYPTOCHROME 1 (CRY1), depending on the coexistence of CLOCK protein.", "begin": 417, "document": "16777965", "end": 779, "section": "abstract"}, {"text": "Studying mouse fibroblasts, we demonstrated that the nutrient-responsive adenosine monophosphate-activated protein kinase (AMPK) phosphorylates and destabilizes the clock component cryptochrome 1 (CRY1). In mouse livers, AMPK activity and nuclear localization were rhythmic and inversely correlated with CRY1 nuclear protein abundance. Stimulation of AMPK destabilized cryptochromes and altered circadian rhythms, and mice in which the AMPK pathway was genetically disrupted showed alterations in peripheral clocks. Thus, phosphorylation by AMPK enables cryptochrome to transduce nutrient signals to circadian clocks in mammalian peripheral organs.", "begin": 362, "document": "19833968", "end": 1010, "section": "abstract"}, {"text": "Cytoplasmic hnRNP D levels displayed a pattern that was reciprocal to the mcry1 oscillation. Knockdown of hnRNP D stabilized mcry1 mRNA and resulted in enhancement of the oscillation amplitude and a slight delay of the phase. Our results suggest that hnRNP D plays a role as a fine regulator contributing to the mcry1 mRNA turnover rate and the modulation of circadian rhythm.", "begin": 866, "document": "19858287", "end": 1242, "section": "abstract"}, {"text": "more than three mutations of conserved PER2 residues impaired not only binding to CRY1 but also subsequent nuclear translocation, although mutations of non-conserved residues did not affect interaction with CRY1. Thus, the conserved amino acid residues of 1179-1198 in PER2 are apparently responsible for binding to CRY1.", "begin": 546, "document": "20100521", "end": 867, "section": "abstract"}, {"text": "Cryptochrome 1 and 2 (Cry1 and Cry2) are considered essential for generating circadian rhythms in mammals. The role of Cry1 and Cry2 in circadian rhythm expression and acute light-induced suppression of pineal melatonin was assessed using Cry1 and Cry2 double-deficient mice (Cry1(-/-) /Cry2(-/-) ) developed from the C3H strain that synthesizes melatonin.", "begin": 0, "document": "20825493", "end": 356, "section": "abstract"}, {"text": "Cryptochrome 1 (Cry1), an essential clock component, displays evening-time expression and serves as a strong repressor at morning-time elements (E box/E' box).", "begin": 119, "document": "21236481", "end": 278, "section": "abstract"}, {"text": "A genetic complementation assay in Cry1(-/-):Cry2(-/-) cells revealed that substantial delay of Cry1 expression is required to restore circadian rhythmicity, and its prolonged delay slows circadian oscillation. Taken together, our data suggest that phase delay in Cry1 transcription is required for mammalian clock function.", "begin": 713, "document": "21236481", "end": 1037, "section": "abstract"}, {"text": "the 24-h mRNA rhythms of the following genes were suppressed in db/db mice compared with control mice: the clock genes period homolog 1/2 (Per1/2) and cryptochrome 1/2 (Cry1/2) and their target genes D site albumin promoter-binding protein (Dbp) and peroxisome proliferator-activated receptor-\u03b3 (Pparg) in the aorta and mesenteric arteries; Dbp in the heart; Per1, nuclear receptor subfamily 1, group D, member 1 (Rev-erba), and Dbp in the kidney; and Per1 in the suprachiasmatic nucleus.", "begin": 635, "document": "22140039", "end": 1123, "section": "abstract"}, {"text": "In mammals, circadian rhythms in behavior and physiology are controlled by a central pacemaker, the SCN, and subordinated clocks throughout the body. On the molecular level, these clocks are based on transcriptional/translational feedback loops involving a set of clock genes that regulate their own transcription. Among the components driving the mammalian circadian clock are the Period 1 and 2 (Per1 and Per2) and Cryptochrome 1 and 2 (Cry1 and Cry2) genes. I", "begin": 0, "document": "16731656", "end": 462, "section": "abstract"}, {"text": "The mammalian clock protein, cryptochrome 1 (CRY1), is degraded via the FBXL3-mediated ubiquitination pathway, suggesting that it is also likely to be targeted by the deubiquitination pathway. Here, we identified that USP2a, a circadian-controlled deubiquitinating enzyme, interacts with CRY1 and enhances its protein stability via deubiquitination upon serum shock. Depletion of Usp2a by shRNA greatly enhances the ubiquitination of CRY1 and dampens the oscillation amplitude of the CRY1 protein during a circadian cycle. By stabilizing the CRY1 protein, USP2a represses the Per2 promoter activity as well as the endogenous Per2 gene expression. We also demonstrated that USP2a-dependent deubiquitination and stabilization of the CRY1 protein occur in the mouse liver.", "begin": 611, "document": "22669941", "end": 1380, "section": "abstract"}, {"text": "The mammalian circadian clock is composed of interlocking feedback loops. Cryptochrome is a central component in the core negative feedback loop, whereas Rev-Erb\u03b1, a member of the nuclear receptor family, is an essential component of the interlocking loop.", "begin": 0, "document": "23471982", "end": 256, "section": "abstract"}, {"text": "By analyzing the Fbxl3 and Cryptochrome 1 double-mutant mice, we found that FBXL3 also regulates the amplitudes of E-box-driven gene expression. These two separate roles of FBXL3 in circadian feedback loops provide a mechanism that contributes to the period determination and robustness of the clock.", "begin": 765, "document": "23471982", "end": 1065, "section": "abstract"}]}, {"documents": ["22737219", "22140515", "22134929", "22133874", "22088914", "21846773", "21559294", "21549127", "21378119", "20838592", "20679393", "20071334", "19386473", "19173286", "23033272", "22815530", "22328086", "22210859", "20547750", "19626461", "19576953", "19322801", "18974146", "18544619", "18437543", "18413740", "18367714", "17929180", "17890317", "17616512", "17371843", "17182866", "16999741", "16575165", "16236173", "15962389", "23302691"], "answer": [["DNMT1"], ["DNMT2"], ["DNMT3"]], "id": "516c3960298dcd4e51000073", "snippets": [{"text": "Of the DNMTs, DNMT1 and DNMT3a are most highly expressed in postmitotic neurons.", "begin": 449, "document": "22134929", "end": 529, "section": "abstract"}, {"text": "DNA methyltransferase 3B (Dnmt3b) belongs to a family of enzymes responsible for methylation of cytosine residues in mammals.", "begin": 0, "document": "22133874", "end": 125, "section": "abstract"}, {"text": "Bovine DNA methylation imprints are established in an oocyte size-specific manner, which are coordinated with the expression of the DNMT3 family proteins.", "begin": 0, "document": "22088914", "end": 154, "section": "title"}, {"text": "The DNMT3B de novo DNA methyltransferase (DNMT) plays a major role in establishing DNA methylation patterns in early mammalian development, but its catalytic mechanism remains poorly characterized.", "begin": 0, "document": "21549127", "end": 197, "section": "abstract"}, {"text": "Dnmt2 proteins are the most conserved members of the DNA methyltransferase enzyme family, but their substrate specificity and biological functions have been a subject of controversy.", "begin": 0, "document": "20679393", "end": 182, "section": "abstract"}, {"text": "This promoter hypermethylation may be mediated not only by DNMT-1 but also by an entire family of de novo DNA-methyltransferases, such as DNA-methyltransferase-3a (DNMT-3a) and -3b (DNMT-3b).", "begin": 265, "document": "19386473", "end": 456, "section": "abstract"}, {"text": "Within the family of DNA methyltransferases (Dnmts), Dnmt3a and 3b establish methylation marks during early development, while Dnmt1 maintains methylation patterns after DNA replication. The maintenance function of Dnmt1 is regulated by its large regulatory N-terminal domain that interacts with other chromatin factors and is essential for the recognition of hemi-methylated DNA.", "begin": 114, "document": "19173286", "end": 494, "section": "abstract"}, {"text": "In this study, we examined a role for the DNA methyltransferase DNMT3B, in particular, the truncated isoform DNMT3B7, which is generated frequently in cancer.", "begin": 166, "document": "22815530", "end": 324, "section": "abstract"}, {"text": "DNMT1 is a widely expressed DNA methyltransferase maintaining methylation patterns in development, and mediating transcriptional repression by direct binding to HDAC2.", "begin": 741, "document": "22328086", "end": 908, "section": "abstract"}, {"text": "DNA methyltransferases (DNMTs) are a family of related proteins that both catalyze the de novo formation of 5-methylcytosine and maintain these methylation marks in cell-specific patterns in virtually all mitotic cells of the body.", "begin": 106, "document": "22134929", "end": 337, "section": "abstract"}, {"text": "This methylation is critical for imprinting; a reduction in the DNA methyltransferase DNMT1 causes a widespread loss of imprinting.", "begin": 209, "document": "20547750", "end": 340, "section": "abstract"}, {"text": "DNA methyltransferases (DNMTs) are a family of enzymes that methylate DNA at the C5 position of cytosine residues, and their inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers.", "begin": 0, "document": "19322801", "end": 252, "section": "abstract"}, {"text": "These results suggest that DNMT1 and DNMT3B regulate BAG-1 expression via insulator protein DNA-binding and chromatin dynamics by regulating histone dimethylation.", "begin": 1194, "document": "18413740", "end": 1357, "section": "abstract"}, {"text": "Here we show that human miR-148 represses DNA methyltransferase 3b (Dnmt3b) gene expression through a region in its coding sequence.", "begin": 336, "document": "18367714", "end": 468, "section": "abstract"}, {"text": "DNA methylation is catalyzed by a family of DNA methyltransferases (DNMTs) including the maintenance enzyme DNMT 1 and de novo methyltransferases DNMT 3a and DNMT 3b.", "begin": 0, "document": "17929180", "end": 166, "section": "abstract"}, {"text": "Among the reported down-regulated miRNAs in lung cancer, the miRNA (miR)-29 family (29a, 29b, and 29c) has intriguing complementarities to the 3'-UTRs of DNA methyltransferase (DNMT)3A and -3B (de novo methyltransferases), two key enzymes involved in DNA methylation, that are frequently up-regulated in lung cancer and associated with poor prognosis.", "begin": 325, "document": "17890317", "end": 676, "section": "abstract"}, {"text": "Furthermore, we have examined the roles of the de novo methyltransferases (Dnmt3a and Dnmt3b) and related protein (Dnmt3L) in this process.", "begin": 658, "document": "17616512", "end": 797, "section": "abstract"}, {"text": "DNA methyltransferase 1 (DNMT1) has been reported to interact with a wide variety of factors and to contain intrinsic transcriptional repressor activity.", "begin": 0, "document": "17371843", "end": 153, "section": "abstract"}, {"text": "Inactivation of both Dnmt3a and Dnmt3b, DNA methyltransferases essential for the initiation of de novo DNA methylation, abolished the establishment of DNA methylation and the silencing of Rhox cluster genes in the embryo proper.", "begin": 462, "document": "17182866", "end": 690, "section": "abstract"}, {"text": "Rather, in vitro analysis indicates that Dnmt3L stimulates DNA methylation by both Dnmt3a and Dnmt3b through direct binding to these proteins.", "begin": 411, "document": "16999741", "end": 553, "section": "abstract"}, {"text": "OBJECTIVE: To investigate the association between single nucleotide polymorphism (SNP) in promoter of the DNA methyltransferase 3B (DNMT3B) gene and risk for development and lymphatic metastasis of gastric cardiac adenocarcinoma (GCA).", "begin": 0, "document": "15962389", "end": 235, "section": "abstract"}, {"text": "Methylation at the 5-position of DNA cytosine on the vertebrate genomes is accomplished by the combined catalytic actions of three DNA methyltransferases (DNMTs), the de novo enzymes DNMT3A and DNMT3B and the maintenance enzyme DNMT1.", "begin": 0, "document": "23393137", "end": 234, "section": "abstract"}, {"text": "There are two major categories of DNA methyltransferases: de novo and maintenance.", "begin": 221, "document": "23357425", "end": 303, "section": "abstract"}, {"text": "Some, but not all, murine H1 subtypes interact with DNA methyltransferases DNMT1 and DNMT3B.", "begin": 274, "document": "23302691", "end": 366, "section": "abstract"}]}, {"documents": ["22940609", "20207713", "19748458", "19423664", "11411692", "23060619", "21940641", "21899420", "21851592", "22289866", "15008414", "12857639", "7544864"], "answer": [["bootstrap"], ["jackknife"]], "id": "516ec97f298dcd4e51000087", "snippets": [{"text": "For robustness evaluation, we apply bootstrap and jackknife techniques to input data.", "begin": 388, "document": "22940609", "end": 473, "section": "abstract"}, {"text": "An alignment confidence score capturing robustness to guide tree uncertainty.", "begin": 0, "document": "20207713", "end": 77, "section": "title"}, {"text": "We build on the widely used bootstrap method for perturbing the phylogenetic tree.", "begin": 735, "document": "20207713", "end": 817, "section": "abstract"}, {"text": "SuperTRI: A new approach based on branch support analyses of multiple independent data sets for assessing reliability of phylogenetic inferences.", "begin": 0, "document": "19748458", "end": 145, "section": "title"}, {"text": "To overcome these limitations, we propose a new approach, called SuperTRI, which is based on the branch support analyses of the independent data sets, and where the reliability of the nodes is assessed using three measures: the supertree Bootstrap percentage and two other values calculated from the separate analyses: the mean branch support (mean Bootstrap percentage or mean posterior probability) and the reproducibility index.", "begin": 645, "document": "19748458", "end": 1076, "section": "abstract"}, {"text": "In contrast to other similar software, the program FreeTree (available at http://www.natur.cuni.cz/~flegr/programs/freetree or http://ijs.sgmjournals.org/content/vol51/issue3/) can also assess the robustness of the tree topology by bootstrap, jackknife or operational taxonomic unit-jackknife analysis.", "begin": 215, "document": "11411692", "end": 517, "section": "abstract"}, {"text": "Unlike any previous tool for inferring phylogenies from rearrangement data, TIBA uses novel methods of robustness estimation to provide support values for the edges in the inferred tree.", "begin": 479, "document": "23060619", "end": 665, "section": "abstract"}, {"text": "ImOSM: intermittent evolution and robustness of phylogenetic methods.", "begin": 0, "document": "21940641", "end": 69, "section": "title"}, {"text": "Fast and accurate phylogenetic reconstruction from high-resolution whole-genome data and a novel robustness estimator.", "begin": 0, "document": "21899420", "end": 118, "section": "title"}, {"text": "Moreover, whereas phylogenetic analyses from sequence data are deemed incomplete unless bootstrapping scores (a measure of confidence) are given for each tree edge, no equivalent to bootstrapping exists for rearrangement-based phylogenetic analysis.", "begin": 518, "document": "21899420", "end": 767, "section": "abstract"}, {"text": "We also describe a novel approach to estimate the robustness of results-an equivalent to the bootstrapping analysis used in sequence-based phylogenetic reconstruction.", "begin": 920, "document": "21899420", "end": 1087, "section": "abstract"}, {"text": "The standard deviation also suggests the reliability level of the branch order.", "begin": 1431, "document": "15008414", "end": 1510, "section": "abstract"}, {"text": "Assessment of the reliability of a given phylogenetic hypothesis is an important step in phylogenetic analysis.", "begin": 0, "document": "12857639", "end": 111, "section": "abstract"}, {"text": "The reliability of the phylogenetic trees was probed with the bootstrapping of 100 replicates of the original sequence alignments.", "begin": 806, "document": "7544864", "end": 936, "section": "abstract"}]}, {"documents": ["22675518", "22158541", "22150006", "21642962", "19367498", "10803511"], "answer": [["TP53"], ["ATM"], ["NOTCH1"], ["XPO1"], ["MYD88"], ["KLHL6"], ["SF3B1"], ["ZMYM3"], ["MAPK1"], ["FBXW7"], ["DDX3X"]], "id": "5171a1498ed59a060a000012", "snippets": [{"text": "Among these genes, SF3B1, encoding a subunit of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP), is somatically mutated in 9.7% of affected individuals.", "begin": 333, "document": "22158541", "end": 497, "section": "abstract"}, {"text": "Further analysis of these mutations in 363 patients with CLL identified four genes that are recurrently mutated: notch 1 (NOTCH1), exportin 1 (XPO1), myeloid differentiation primary response gene 88 (MYD88) and kelch-like 6 (KLHL6).", "begin": 583, "document": "21642962", "end": 815, "section": "abstract"}]}, {"documents": ["21714130", "20370891", "14668231", "12804086", "9021270", "16522182", "11301301", "1774068"], "answer": ["quadratic"], "id": "51724fca8ed59a060a000013", "snippets": [{"text": "The problem of finding an optimal structural alignment for a pair of superimposed proteins is often amenable to the Smith-Waterman dynamic programming algorithm, which runs in time proportional to the product of lengths of the sequences being aligned.", "begin": 0, "document": "21714130", "end": 251, "section": "abstract"}, {"text": "While this result is not an asymptotic improvement over the original Smith-Waterman algorithm, its complexity is characterized in terms of some sparse features of the matrix and it yields the fastest software implementation to date for such searches.", "begin": 531, "document": "12804086", "end": 781, "section": "abstract"}, {"text": "If we use N, M and C to represent the size of an amino acid sequence, the size of a structure template, and the maximum cut size of long-range interactions, respectively, the algorithm finds an optimal structure-sequence alignment in O(21C NM) time, a polynomial function of N and M when C = O(log(N + M)). When running on structure-sequence alignment problems without long-range intersections, i.e. C = 0, the algorithm achieves the same asymptotic computational complexity of the Smith-Waterman sequence-sequence alignment algorithm.", "begin": 1269, "document": "9021270", "end": 1804, "section": "abstract"}, {"text": "The algorithm is based on fractional programming and its running time is O(n2log n). In practice, normalized local alignment is only 3-5 times slower than the standard Smith-Waterman algorithm.", "begin": 1277, "document": "11301301", "end": 1470, "section": "abstract"}]}, {"documents": ["18256531", "22388545", "23159862", "21852228", "21459846", "20615966", "20528922", "20613985", "19148480", "19139399", "18611950", "18583365", "16980297", "15138575", "23362263", "23188674", "22508983", "22484480", "22457351", "22056305", "21946516", "21807636", "21643019", "20926182", "20842728", "20807817", "20803057", "20733477", "20581467", "20298673", "20194434", "19885566", "19861456", "19777343", "19671150", "19615968", "19509292", "19363520", "19103865", "18546269", "18477895", "18469517", "18421303", "18350258", "18342333", "18039564", "17912537", "17626635", "17446929", "17076661", "17047653", "17029218", "16964385", "16773194", "16630058", "16467208", "16380414", "16322298", "16290057", "16254107", "16083956", "15975558", "15889017", "15803372", "15781249", "15752257", "15741235", "15610529", "15467455", "15059898", "14676279", "14634023", "12944917", "12920125", "12897129", "11859407", "11830511", "11753569", "23470527", "23414597", "22740507", "23436675", "12235210", "17637683", "20146801", "23271007", "17430565"], "answer": ["seven", "7"], "id": "5173bdb38ed59a060a000020", "snippets": [{"text": "A member of the p53 family, p73, has several isoforms and differentially regulates transcription of genes involved in the control of the cell cycle and apoptosis.", "begin": 0, "document": "18256531", "end": 162, "section": "abstract"}, {"text": "Due to the presence in the 5' flanking region of two promoters, there are two N-terminal variants, TAp73, which retains a fully active transactivation domain (TA), and \u0394Np73, in which the N terminus is truncated. In addition, extensive 3' splicing gives rise to at least seven distinctive isoforms; TAp73-selective knockout highlights its role as a regulator of cell death, senescence and tumor suppressor.", "begin": 42, "document": "23159862", "end": 448, "section": "abstract"}, {"text": "The p73 gene, a homologue of the p53 tumor suppressor, is expressed as TA and \u0394N isoforms. TAp73 has similar activity as p53 and functions as a tumor suppressor whereas \u0394Np73 has both pro- and anti-survival functions.", "begin": 0, "document": "21852228", "end": 217, "section": "abstract"}, {"text": "Transcription from two different promoters on the p73 gene results in generation of transcriptionally active TAp73 isoforms and dominant negative DeltaNp73 isoforms with opposing pro- and anti-apoptotic functions.", "begin": 103, "document": "20615966", "end": 316, "section": "abstract"}, {"text": "We have evaluated the differential expression and subcellular localization of the functionally distinct apoptotic (TA) and anti-apoptotic (DeltaN) isoforms of p73 in non-small cell lung cancer (NSCLC), their possible association with p53 expression and determined the methylation status of the two p73 gene promoters (P1 and P2) in this tumor type.", "begin": 78, "document": "19148480", "end": 426, "section": "abstract"}, {"text": "The role of various p73 isoforms in tumorigenesis has been controversial. However, as we have recently shown, the generation of TAp73-deficient (TAp73(-/-)) mice reveals that TAp73 isoforms exert tumor-suppressive functions, indicating an emerging role for Trp-73 in the maintenance of genomic stability. Unlike mice lacking all p73 isoforms, TAp73(-/-) mice show a high incidence of spontaneous tumors.", "begin": 0, "document": "19139399", "end": 403, "section": "abstract"}, {"text": "Alternative promoters and N-terminal splicing result in the transcription and processing of either full-length (TA) or N-terminally truncated (deltaN) p73 isoforms. TAp73 possesses pro-apoptotic functions, while deltaNp73 has anti-apoptotic properties via functional inhibition of TAp73 and p53.", "begin": 150, "document": "16980297", "end": 445, "section": "abstract"}, {"text": "The p73 gene is able to encode transcriptionaly active TAp73, as well as a dominant-negatively acting DeltaNp73 transcript isoforms.", "begin": 0, "document": "15138575", "end": 132, "section": "abstract"}, {"text": "Since some mutant p53 proteins and \u0394Np73 isoforms form heterocomplexes with TAp73, we asked whether p53 isoforms can do the same and potentially act as dominant-negative inhibitors of TAp73.", "begin": 143, "document": "23188674", "end": 333, "section": "abstract"}, {"text": "p73, a p53 family tumor suppressor, is expressed as TA and \u0394N isoforms.", "begin": 0, "document": "22508983", "end": 71, "section": "abstract"}, {"text": "p73 is expressed as TA and \u0394N isoforms, both of which are implicated in tumor suppression and/or promotion.", "begin": 0, "document": "22457351", "end": 107, "section": "abstract"}, {"text": "We found that TAp73 isoforms are down regulated in oocytes from women older than 38 years.", "begin": 881, "document": "21946516", "end": 971, "section": "abstract"}, {"text": "p73 possesses an extrinsic P1 promoter and an intrinsic P2 promoter controlling the expression of the pro-apoptotic TAp73 isoforms and the anti-apoptotic \u0394\u039dp73 isoforms respectively.", "begin": 0, "document": "20926182", "end": 182, "section": "abstract"}, {"text": "BRCA1-deficient ovarian carcinoma cells exhibit hypermethylation within a p73 regulatory region, which includes the binding site for the p73 transcriptional repressor ZEB1, leading to the abrogation of ZEB1 binding and increased expression of transactivating p73 isoforms (TAp73).", "begin": 870, "document": "20807817", "end": 1150, "section": "abstract"}, {"text": "In this study, we investigated the expression and subcellular distribution of two N-terminal isoforms, TAp73 and \u0394Np73, in medulloblastoma cells using immunofluorescence microscopy.", "begin": 359, "document": "20803057", "end": 540, "section": "abstract"}, {"text": "Proteasomal degradation of p73 is mediated by polyubiquitination-dependent and -independent processes both of which appear, thus far, to lack selectivity for the TAp73 and DeltaNp73 isoforms.", "begin": 409, "document": "20615966", "end": 600, "section": "abstract"}, {"text": "The p73 gene possesses an extrinsic P1 promoter and an intrinsic P2 promoter, resulting in TAp73 and DeltaNup73 isoforms, respectively.", "begin": 0, "document": "20528922", "end": 135, "section": "abstract"}, {"text": "Mice with a complete deficiency of p73 have severe neurological and immunological defects due to the absence of all TAp73 and DeltaNp73 isoforms.", "begin": 0, "document": "20194434", "end": 145, "section": "abstract"}, {"text": "Moreover, we also found that subcellular location of p73 isoforms changes with the culture density increases.", "begin": 713, "document": "19885566", "end": 822, "section": "abstract"}, {"text": "Moreover, ectopic expression of DeltaNp73alpha (but not other p73 isoforms) increased alphaB-crystallin mRNA levels in the absence of p53.", "begin": 1133, "document": "19777343", "end": 1271, "section": "abstract"}, {"text": "Like wt p53, TAp63 and TAp73 isoforms transactivate target genes that activate apoptosis signaling pathways.", "begin": 329, "document": "19615968", "end": 437, "section": "abstract"}, {"text": "The TP73 gene gives rise to transactivation domain-p73 isoforms (TAp73) as well as DeltaNp73 variants with a truncated N terminus.", "begin": 0, "document": "19509292", "end": 130, "section": "abstract"}, {"text": "In contrast, antiapoptotic DeltaNp73 isoforms lack the TA domain and are dominant-negative inhibitors of p53 and TAp73.", "begin": 225, "document": "19363520", "end": 344, "section": "abstract"}, {"text": "The expression of all 5 N-terminal isoforms (TAp73, DeltaNp73, DeltaN'p73, Ex2p73 and Ex2/3p73) was measured by real-time RT-PCR and p53 status was analyzed by immunohistochemistry. TAp73, DeltaNp73 and DeltaN'p73 were significantly upregulated in tumors.", "begin": 347, "document": "16964385", "end": 602, "section": "abstract"}, {"text": "Consequently, different p73 isoforms can be degraded by calpains, i.e., both N-terminal isoforms (TAp73 and DeltaNp73) as well as the C-terminal isoforms (alpha, beta, gamma, delta).", "begin": 552, "document": "15975558", "end": 734, "section": "abstract"}, {"text": "Variants lacking the TA domain (DeltaN isoforms) are induced by TAp73 and by p53, and inhibit their transcriptional activity.", "begin": 218, "document": "15781249", "end": 343, "section": "abstract"}, {"text": "Indeed, tazarotene modulates the expression of the p73 gene in immortalized keratinocyte cell lines by inducing the pro-apoptotic and anti-proliferative TAp73 isoforms and by repressing the anti-apoptotic and pro-proliferative DeltaNp73 isoforms.", "begin": 429, "document": "15610529", "end": 675, "section": "abstract"}, {"text": "p73, the first p53 gene homologue, encodes an array of p73 proteins including p73 alpha full-length (TAp73 alpha) and amino-truncated isoforms (Delta Np73 alpha), two proteins with opposite biological functions.", "begin": 0, "document": "14676279", "end": 211, "section": "abstract"}, {"text": "We further showed that DeltaNp73 is a potent transdominant inhibitor of wild-type p53 and TAp73 in cultured human tumor cells by efficiently counteracting their target gene transactivations, apoptosis, and growth suppression functions (A.", "begin": 329, "document": "12897129", "end": 567, "section": "abstract"}, {"text": "In developing sympathetic neurons of mice, p73 is predominantly expressed as a truncated anti-apoptotic isoform (DeltaNp73), which antagonizes both p53 and the full-length p73 protein (TAp73).", "begin": 216, "document": "11859407", "end": 408, "section": "abstract"}, {"text": "Interestingly, expression of the Delta Np73 is strongly up-regulated by the TA isoforms and by p53, thus creating a feedback loop that tightly regulates the function of TAp73 and more importantly of p53.", "begin": 1358, "document": "11753569", "end": 1561, "section": "abstract"}]}, {"documents": ["23359070", "22974708", "22891273", "22210878", "21562564", "20823234", "19289631", "17584081", "23095891", "22488849", "22156581", "21196490", "20087400", "18775957", "16773578", "15712272", "12497640", "11180599", "9585603", "9207788"], "answer": [["Alagille syndrome"], ["spondylocostal dysostosis"], ["CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)"], ["T-cell acute lymphoblastic leukemia"]], "id": "5173eb428ed59a060a000021", "snippets": [{"text": "We show that Notch signaling is silenced in human AML samples, as well as in AML-initiating cells in an animal model of the disease.", "begin": 479, "document": "23359070", "end": 611, "section": "abstract"}, {"text": "Mutations in NOTCH2, a gene required for marginal-zone (MZ) B cell development, represent the most frequent lesion in SMZL, accounting for \u223c20% of cases.", "begin": 268, "document": "22891273", "end": 421, "section": "abstract"}, {"text": "Here, we performed whole transcriptome sequencing on a discovery cohort of 18 primary tissue MCL samples and 2 cell lines. We found recurrent mutations in NOTCH1, a finding that we confirmed in an extension cohort of 108 clinical samples and 8 cell lines.", "begin": 450, "document": "22210878", "end": 705, "section": "abstract"}, {"text": "We found activating mutations in Notch in more than 30% of ATL patients. These activating mutations are phenotypically different from those previously reported in T-ALL leukemias and may represent polymorphisms for activated Notch in human cancers.", "begin": 466, "document": "20823234", "end": 714, "section": "abstract"}, {"text": "Importantly, mutations of the Notch protein and components of its signaling pathway have been implicated in an array of human diseases (T-cell leukemia and other cancers, Multiple Sclerosis, CADASIL, Alagille Syndrome, Spondylocostal Dysostosis).", "begin": 114, "document": "17584081", "end": 360, "section": "abstract"}, {"text": "Here, we demonstrate that endothelial-specific deletion of Jag1 leads to cardiovascular defects in both embryonic and adult mice that are reminiscent of those in Alagille syndrome.", "begin": 606, "document": "23095891", "end": 786, "section": "abstract"}, {"text": "In this study, analysis of 21 Vietnamese ALGS individuals led to the identification of 19 different mutations (18 JAG1 and 1 NOTCH2), 17 of which are novel, including the third reported NOTCH2 mutation in Alagille Syndrome.", "begin": 270, "document": "22488849", "end": 493, "section": "abstract"}, {"text": "Genetics of Holoprosencephaly (HPE), a congenital malformation of the developing human forebrain, is due to multiple genetic defects. Most genes that have been implicated in HPE belong to the sonic hedgehog signaling pathway. Here we describe a new candidate gene isolated from array comparative genomic hybridization redundant 6qter deletions, DELTA Like 1 (DLL1), which is a ligand of NOTCH.", "begin": 0, "document": "21196490", "end": 393, "section": "abstract"}, {"text": "Four genes causing a subset of autosomal recessive forms of this disease have been identified: DLL3 (SCDO1: MIM 277300), MESP2 (SCDO2: MIM 608681), LFNG (SCDO3: MIM609813) and HES7 (SCDO4). These genes are all essential components of the Notch signalling pathway, which has multiple roles in development and disease. Previously, only a single SCD-causative missense mutation was described in HES7. In this study, we have identified two new missense mutations in the HES7 gene in a single family,", "begin": 344, "document": "20087400", "end": 839, "section": "abstract"}, {"text": "Here we have used autozygosity mapping to identify a mutation in a fourth Notch pathway gene, Hairy-and-Enhancer-of-Split-7 (HES7), in an autosomal recessive SCD family.", "begin": 647, "document": "18775957", "end": 816, "section": "abstract"}, {"text": "Alagille syndrome (AGS) is caused by mutations in the gene for the Notch signaling pathway ligand Jagged1 (JAG1), which are found in 94% of patients. To identify the cause of disease in patients without JAG1 mutations, we screened 11 JAG1 mutation-negative probands with AGS for alterations in the gene for the Notch2 receptor (NOTCH2). We found NOTCH2 mutations segregating in two families and identified five affected individuals.", "begin": 0, "document": "16773578", "end": 432, "section": "abstract"}, {"text": "Mutations in the JAG1 (Jagged 1) gene, coding a ligand in the evolutionarily conserved Notch signaling pathway, are responsible for AGS. Here we present sixteen different JAG1 gene mutations, among them twelve novel, not described previously.", "begin": 139, "document": "15712272", "end": 381, "section": "abstract"}, {"text": "Altogether 226 different JAG1 mutations have been described in association with AGS, including our novel 36 mutations.", "begin": 1050, "document": "12497640", "end": 1168, "section": "abstract"}, {"text": "Previous studies have demonstrated that a wide spectrum of JAG1 mutations result in AGS. These include total gene deletions, protein truncating, splicing and missense mutations which are distributed across the coding region of the gene. Here we present results of JAG1 mutation screening by SSCP and FISH in 105 patients with AGS. For these studies, new primers were designed for 12 exons. Mutations were identified in 63/105 patients (60%)", "begin": 163, "document": "11180599", "end": 603, "section": "abstract"}, {"text": "We have screened 54 AGS probands and family members to determine the frequency of mutations in JAG1. Three patients (6%) had deletions of the entire gene. Of the remaining 51 patients, 35 (69%) had mutations within JAG1, identified by SSCP analysis. Of the 35 identified intragenic mutations, all were unique, with the exceptions of a 5-bp deletion in exon 16, seen in two unrelated patients, and a C insertion at base 1618 in exon 9, also seen in two unrelated patients.", "begin": 445, "document": "9585603", "end": 916, "section": "abstract"}, {"text": "Analyses of many patients with cytogenetic deletions or rearrangements have mapped the gene to chromosome 20p12, although deletions are found in a relatively small proportion of patients (< 7%). We have mapped the human Jagged1 gene (JAG1), encoding a ligand for the developmentally important Notch transmembrane receptor, to the Alagille syndrome critical region within 20p12.", "begin": 157, "document": "9207788", "end": 534, "section": "abstract"}]}, {"documents": ["12225634", "1331777", "7763274"], "answer": [["subunit 6 of ATP synthase", "ATPase-6"], ["mitochondrial II and III subunits of cytochrome-c oxidase"], ["NADH dehydrogenase subunit 3", "ND3"]], "id": "517539e68ed59a060a000028", "snippets": [{"text": "We used a polymerase chain reaction (PCR)-based mRNA differential display (DD) analysis to obtain a profile of thyroid hormone-responsive genes in osteoblast-like cells", "begin": 76, "document": "12225634", "end": 244, "section": "abstract"}, {"text": "At the 2-hour time point, 1 true-positive novel clone was identified and shown to be the mitochondrial gene, subunit 6 of ATP synthase (ATPase-6).", "begin": 503, "document": "12225634", "end": 649, "section": "abstract"}, {"text": "We studied the coordination of the two genomes by measuring transcript levels for nuclear (IV, Va, and VIc) and mitochondrial (II and III) subunits of cytochrome-c oxidase after altering the mitochondrial content of rat muscle and liver by altering the thyroid state of the animals. Tissue levels of these mRNAs were generally decreased in hypothyroid animals and were up-regulated again after thyroid hormone (T3) treatment.", "begin": 124, "document": "1331777", "end": 549, "section": "abstract"}, {"text": "Following this procedure, we now report the identification of the mitochondrial NADH dehydrogenase subunit 3 (ND3) gene as target of thyroid hormone.", "begin": 186, "document": "7763274", "end": 335, "section": "abstract"}, {"text": "Sequencing and electrophoretic mobility shift assays confirmed the presence of a thyroid hormone receptor (TR)/c-erbA specific binding site in the mitochondrial ND3 gene.", "begin": 412, "document": "7763274", "end": 582, "section": "abstract"}]}, {"documents": ["21710477", "21577144", "20460501", "18483370", "23460532", "23263823"], "answer": ["PD-1"], "id": "517901bc8ed59a060a00003b", "snippets": [{"text": "we find that using an anti-PD-1 antibody (CT-011)", "begin": 293, "document": "21710477", "end": 342, "section": "abstract"}, {"text": "PD-1 blockade by CT-011, anti-PD-1 antibody,", "begin": 0, "document": "21577144", "end": 44, "section": "title"}, {"text": ". Presence of CT-011, an anti-PD1 antibody,", "begin": 862, "document": "21577144", "end": 905, "section": "abstract"}, {"text": "CT-011, a novel monoclonal anti-PD-1 antibody", "begin": 111, "document": "20460501", "end": 156, "section": "title"}, {"text": "CT-011, a humanized antibody interacting with PD-1,", "begin": 44, "document": "18483370", "end": 95, "section": "title"}, {"text": "Anti-PD1 (nivolumab and MK-3475)", "begin": 1021, "document": "23460532", "end": 1053, "section": "abstract"}, {"text": "anti-PD-1 antibodies MK-3475", "begin": 481, "document": "23263823", "end": 509, "section": "abstract"}]}, {"documents": ["15072569", "9794474", "7768329", "3197644", "3595535"], "answer": [["Type 1 deiodinase"], ["Tipe 3 deiodinase"]], "id": "517a8c238ed59a060a000042", "snippets": [{"text": "Iodothyronine deiodinase in vitro activity studies in the chicken showed the presence of type I and type III iodothyronine deiodinase activity in both liver and kidney.", "begin": 0, "document": "15072569", "end": 168, "section": "abstract"}, {"text": "Co-expression of the deiodinases was also found in the kidney.", "begin": 977, "document": "15072569", "end": 1039, "section": "abstract"}, {"text": "high ID-I activities were found in liver, kidney", "begin": 437, "document": "7768329", "end": 485, "section": "abstract"}, {"text": "the kidney microsome 5'-deiodinase is type I.", "begin": 1347, "document": "3595535", "end": 1392, "section": "abstract"}]}, {"documents": ["21135419", "19675515", "16910349", "16544025", "12727944", "11901034", "9217642", "7946779", "2781955"], "answer": [["Antithyroid drugs"], ["Corticosteroids"], ["Lithium"], ["Radioiodine"]], "id": "518cb4b5310faafe08000006", "snippets": [{"text": "Treatment consists in the use of a high dose of anti-thyroid drugs and steroids in an isolated form or in combination.", "begin": 144, "document": "16544025", "end": 262, "section": "abstract"}, {"text": "the addition of lithium carbonate to the two other drugs resulted in a successful and safety therapy in controlling amiodarone-induced thyrotoxicosis.", "begin": 818, "document": "16544025", "end": 968, "section": "abstract"}, {"text": "Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued.", "begin": 0, "document": "7946779", "end": 167, "section": "abstract"}, {"text": "Amiodarone-induced thyrotoxicosis seems to be a transient condition that can be treated successfully with a short course of antithyroid drugs without stopping amiodarone treatment.", "begin": 365, "document": "7946779", "end": 545, "section": "abstract"}, {"text": "Both patients were successfully treated with propylthiouracil (PTU) and dexamethasone (DXT).", "begin": 551, "document": "2781955", "end": 643, "section": "abstract"}]}, {"documents": ["23388847", "23021657", "22404517", "22322786", "20485704", "20429828", "19490560"], "answer": [["amoxicillin"], ["metronidazole"], ["claritromycin"], ["Proton pump inhibithors"], ["rifabutin"], ["Eudragit L100"]], "id": "518cb5ab310faafe08000008", "snippets": [{"text": "Triple therapy, which has been the mainstay of treatment in many countries over the last decade, now has suboptimal results in many parts of the world.", "begin": 181, "document": "23388847", "end": 332, "section": "abstract"}, {"text": "equential therapy and quadruple therapy (either bismuth-based or non-bismuth-based) are the best current options to replace initial treatment with triple therapy.", "begin": 620, "document": "23388847", "end": 782, "section": "abstract"}, {"text": "olecular tests can be used to detect H. pylori and clarithromycin and/or fluoroquinolone resistance in gastric biopsies without necessitating culture. In regions of high clarithromycin resistance, such as France, sequential treatment or bismuth-containing quadruple therapies are replacing standard triple therapies for the first-line empirical treatment.", "begin": 725, "document": "23021657", "end": 1080, "section": "abstract"}, {"text": "Chitosan microspheres with multiple Eudragit L100 cores were easily prepared by a new emulsification/coagulation encapsulating method.", "begin": 323, "document": "22322786", "end": 457, "section": "abstract"}, {"text": "the multi-core chitosan microspheres could serve as a satisfactory vehicle for stomach-specific delivery of hydrophilic antibiotics.", "begin": 894, "document": "22322786", "end": 1026, "section": "abstract"}]}, {"documents": ["22467916", "22199385", "20167116", "18923675", "10689191", "18457591"], "answer": [["LaTcOm"], ["%MinMax"], ["PAUSE"], ["Sherlocc"], ["Sliding Window", "RiboTempo"]], "id": "51be411b047fa84d1d000006", "snippets": [{"text": "LaTcOm: a web server for visualizing rare codon clusters in coding sequences", "begin": 0, "document": "22199385", "end": 76, "section": "title"}, {"text": "three RCC detection schemes are implemented: the recently described %MinMax algorithm and a simplified sliding window approach, along with a novel modification of a linear-time algorithm for the detection of maximally scoring subsequences tailored to the RCC detection problem", "begin": 209, "document": "22199385", "end": 485, "section": "abstract"}, {"text": "The PAUSE software has been developed as a new tool to study translational control over protein targeting. This makes it possible to correlate the position of clusters of rare codons in a gene, predicted to cause a translational pause, with the position of hydrophobic stretches in the encoded protein, predicted to span a membrane or to act as a cleavable signal for targeting to the secretory pathway.", "begin": 0, "document": "10689191", "end": 403, "section": "abstract"}]}, {"documents": ["22379032", "21881980", "19854715", "21177290", "18420660"], "answer": ["Etanercept"], "id": "512d0e635274a5fb07000005", "snippets": [{"text": "higher rates are observed with anti-TNF Abs (e.g., infliximab) as compared with TNF receptor fusion protein (etanercept).", "begin": 128, "document": "22379032", "end": 249, "section": "abstract"}, {"text": "Two of them received etanercept and the remainder adalimumab.", "begin": 140, "document": "21881980", "end": 201, "section": "abstract"}]}, {"documents": ["22627569", "18442953", "18243066", "15970608", "15266396", "11336401"], "answer": ["0.7\u20137/100000 inhabitants"], "id": "513ce5f2bee46bd34c00000a", "snippets": [{"text": "The results of literature reviews, surveys, and registry analyses revealed a mean prevalence of 0.737/10,000 in the 27 EU countries, which is similar to the value of 0.797 in the United States, and only one outlier, namely the Republic of Ireland at 2.98", "begin": 111, "document": "18442953", "end": 365, "section": "abstract"}, {"text": "A theoretical estimate of the prevalence of cystic fibrosis based on anthropological data suggested a frequency of 25 affected individuals/100,000 inhabitants. However, our data indicated that the true prevalence in the population was considerably lower (6.9 cases/100,000 inhabitants)", "begin": 845, "document": "15266396", "end": 1130, "section": "abstract"}, {"text": "CF mutations were identified in 374 (4.0%) individuals.", "begin": 856, "document": "11336401", "end": 911, "section": "abstract"}, {"text": "The aim of this study was to evaluate the screening policies of cystic fibrosis (CF) in the Jewish population.", "begin": 0, "document": "11336401", "end": 110, "section": "abstract"}]}, {"documents": ["22021377", "12684058", "10777687", "9261349", "8702907", "8063775"], "answer": ["(G/T)GGGCGG(G/A)(G/A)(C/T)"], "id": "515d692c298dcd4e5100000a", "snippets": [{"text": "a GC-rich element (Sp1-binding site)", "begin": 609, "document": "12684058", "end": 645, "section": "abstract"}, {"text": "Further analysis revealed that the DNA sequence, TTCAAGTCCCGCCCTCCGCT from -65 to -46", "begin": 658, "document": "10777687", "end": 743, "section": "abstract"}, {"text": "Sp1 motif in the UCR", "begin": 1295, "document": "9261349", "end": 1315, "section": "abstract"}, {"text": "upstream control region (UCR) containing a GC-rich motif (5'-GGGCGGG-3') and to a unique enhancer core (5'-TGCGGTC-3')", "begin": 327, "document": "9261349", "end": 445, "section": "abstract"}, {"text": "A GC-rich region containing Sp1 and Sp1-like binding sites", "begin": 0, "document": "8702907", "end": 58, "section": "title"}, {"text": "Gel shift competition studies and DNase I footprinting analyses revealed that Sp1 specifically interacts with the CACCC motif", "begin": 699, "document": "8063775", "end": 824, "section": "abstract"}, {"text": "In an effort to identify transcription factors that bind to the CACCC element, we found that purified human Sp1, as well as Sp1 in HeLa nuclear extract, can specifically bind to a DNA probe", "begin": 440, "document": "8063775", "end": 629, "section": "abstract"}, {"text": "Sp1 binds through an inverted CACCC motif", "begin": 75, "document": "8063775", "end": 116, "section": "title"}]}, {"documents": ["22735246", "22401313", "22147611", "21332246", "18820538", "18363625", "15265351", "12712053", "11902308", "7561230"], "answer": [["Oxcarbazepine"], ["Opioids alone, in rotations or with Analgesics (e.g. Ketamine and Lidocaine infusion)"], ["Opioids and Benzodiazepines - for terminal care"], ["Pregabalin"], ["Tricyclic Antidepressants"], ["Lidocaine 5% patches for chronic localized neuropathic pain"], ["Ketamine"]], "id": "515da6e2298dcd4e51000010", "snippets": [{"text": "Oxcarbazepine, a metabolite of carbamazepine, is used as an antiepileptic, analgesic for neuropathic pain and in the treatment of affective disorders. It has been approved by the Food and Drug Administration for partial seizures in adults as both adjunctive and monotherapy, and as adjunctive therapy in children aged from 2 to 16 years", "begin": 0, "document": "22735246", "end": 336, "section": "abstract"}, {"text": "For difficult to treat neuropathic pain from cancer, adjuvant analgesics are often used with opioids", "begin": 0, "document": "22401313", "end": 100, "section": "abstract"}, {"text": "Ketamine and lidocaine can be safely infused together with concomitant opioids for the treatment of refractory neuropathic pain caused by cancer.", "begin": 448, "document": "22401313", "end": 593, "section": "abstract"}, {"text": "Patient-controlled analgesia with morphine as continuous subcutaneous or intravenous infusions and the possibility of a bolus injection is suited for children aged 6 years.", "begin": 1245, "document": "22147611", "end": 1417, "section": "abstract"}, {"text": "In neuropathic pain or phantom pain coanalgetics should be used to effectively treat pain in young patients.", "begin": 1773, "document": "22147611", "end": 1881, "section": "abstract"}, {"text": "We describe a case series of five adolescents who were managed with lidocaine 5% patches for chronic localized neuropathic pain from a variety of causes with minimal adverse effects. Treatment was effective in four of five patients with only one patient complaining of minimal pain relief", "begin": 0, "document": "18363625", "end": 288, "section": "abstract"}, {"text": "Twenty-two children or 14% of children on opioid therapy underwent 30 opioid rotations. Mucositis was the cause of pain in 19 (70%) children, bone pain in 3 (11%) children, and postoperative, visceral, or neuropathic pain in the remainder. The opioid was rotated either for excessive side effects with adequate analgesia (70%), excessive side effects with inadequate analgesia (16.7%), or tolerance (6.7%). Five (23%) children required two rotations, 3 during the same admission. The favored rotations were morphine to fentanyl in 20 (67%) children and fentanyl to hydromorphone in 6 (20%). Adverse opioid effects were resolved in 90% of cases, all failures occurred when morphine was rotated to fentanyl.", "begin": 317, "document": "15265351", "end": 1022, "section": "abstract"}, {"text": "To test the hypothesis that children with terminal cancer and neuropathic pain require rapid increases of opioids and benzodiazepines immediately before death, we compared drug usage in the last 72 hours of life in children with and without neuropathic pain", "begin": 11, "document": "12712053", "end": 268, "section": "abstract"}, {"text": "ketamine treatment may be effective in children with severe neuropathic pain not responsive to other analgesics. This patient also demonstrates the feasibility of long-term ketamine treatment in pediatric oncology and that such treatment can be administered in a home care setting.", "begin": 1299, "document": "11902308", "end": 1580, "section": "abstract"}, {"text": "Oral amitriptyline has been used as an analgesic in a wide range of pain settings. Despite long-term availability of a parenteral form, the few reports about this formulation have been limited to pharmacokinetic studies in normal volunteers, trials in depressed patients, and analyses of electroencephalogram (EEG) activation. We retrospectively reviewed our experience using intravenous (IV) amitriptyline at Children's Hospital, Boston and at Children's Hospital at Stanford. Eight children (aged 5-16.6 years), who were unable to tolerate medications by the oral route, received IV amitriptyline for a variety of indications, including neuropathic pain, depression, sleep disturbance, and as an adjuvant agent for opioid analgesia.", "begin": 0, "document": "7561230", "end": 734, "section": "abstract"}]}, {"documents": ["23466885", "23034525", "22647927", "21898261", "21249157", "20879039", "20848673", "20707390", "20486121", "20202861", "18381279", "18302345", "17967882", "17652096", "17569892", "16457589", "16457588", "16457587", "15025441", "14976258"], "answer": [["isoform characteriztion"], ["determination of the type and location of post translational modifications"]], "id": "51630226298dcd4e5100004d", "snippets": [{"text": "recent advances in MS technology, such as high-field Fourier transform ion cyclotron resonance (FTICR)-mass spectrometry, have permitted the study of intact proteins and their modifications. On-line and off-line protein separation instruments coupled to FTICR-MS allow the characterization of PTMs previously undetectable with bottom-up approaches.", "begin": 648, "document": "21898261", "end": 996, "section": "abstract"}, {"text": "With just \u223c24\u2009\u03bcg on-column of core histones (H4, H2B, H2A, and H3) purified from human fibroblasts, 41 H4 isoforms were identified, with the type and location of PTMs unambiguously mapped for 20 of these variants.", "begin": 252, "document": "20879039", "end": 465, "section": "abstract"}, {"text": "This synopsis emphasizes how the advances in high resolution MS, from \"Bottom Up\" to \"Top Down\" analysis, together with the uptake of quantitative proteomics methods by chromatin biologists, have made MS a well-established method in the epigenetics field, enabling the acquisition of original information, highly complementary to that offered by more conventional, antibody-based, assays.", "begin": 917, "document": "23466885", "end": 1305, "section": "abstract"}, {"text": "Our results indicated that dH1 is extensively modified by phosphorylation, methylation, acetylation and ubiquitination, with most PTMs falling in the N-terminal domain", "begin": 714, "document": "22647927", "end": 881, "section": "abstract"}, {"text": "Optimized for the intricacies of whole proteins, new software modules visualize proteome-scale data based on the LC retention time and intensity of intact masses and enable selective detection of PTMs to automatically screen for acetylation, phosphorylation, and methylation.", "begin": 615, "document": "20848673", "end": 890, "section": "abstract"}, {"text": "our UHPLC-MS approach for histone profiling offers a sensitive and reproducible tool that will be of great value for exploring PTMs and variants", "begin": 1252, "document": "20707390", "end": 1396, "section": "abstract"}, {"text": "This work demonstrates the power of top-down MS for a detailed structural confirmation of recombinant proteins, even without prior information on aa substitutions or modifications.", "begin": 1105, "document": "20486121", "end": 1285, "section": "abstract"}, {"text": "Top and Middle Down MS were utilized to identify the most commonly occurring combinatorially modified forms.", "begin": 1079, "document": "20202861", "end": 1187, "section": "abstract"}, {"text": "In this paper we investigate the application of spectral alignment to the problem of identifying protein forms in top-down mass spectra (i.e., identifying the modifications, mutations, insertions, and deletions).", "begin": 321, "document": "18302345", "end": 533, "section": "abstract"}, {"text": "This work represents the most comprehensive analysis of histone H4 forms present in human cells reported to date.", "begin": 1351, "document": "18381279", "end": 1464, "section": "abstract"}, {"text": "Metabolic labeling and top-down mass spectrometry reveal that newly synthesized H4 is progressively methylated at K20 during the G(2), M, and G(1) phases of the cell cycle in a process that is largely inescapable and irreversible.", "begin": 280, "document": "17967882", "end": 510, "section": "abstract"}, {"text": "The \"top down\" mass spectrometry approach detected dramatic decreases in acetylation on H3 and H2B in gcn5Delta cells versus wild type.", "begin": 370, "document": "17652096", "end": 505, "section": "abstract"}, {"text": "In sum, we have defined the \"basis set\" of histone forms present in yeast chromatin using a current mass spectrometric approach that both quickly profiles global changes and directly probes the connectivity of modifications on the same histone.", "begin": 1207, "document": "17652096", "end": 1451, "section": "abstract"}, {"text": "Recent developments in top down mass spectrometry have enabled closely related histone variants and their modified forms to be identified and quantitated with unprecedented precision, facilitating efforts to better understand how histones contribute to the epigenetic regulation of gene transcription and other nuclear processes.", "begin": 0, "document": "17569892", "end": 329, "section": "abstract"}, {"text": "This unequivocal identification of H2A forms illustrates the advantages of Top Down Mass Spectrometry and provides a global perspective of H2A regulation through the cell cycle.", "begin": 347, "document": "16457589", "end": 524, "section": "abstract"}, {"text": "The modification of H3 in asynchronous HeLa cells was profiled using Top Down Mass Spectrometry.", "begin": 0, "document": "16457588", "end": 96, "section": "abstract"}, {"text": "The basis set of protein forms expressed by human cells from the H2B gene family was determined by Top Down Mass Spectrometry.", "begin": 0, "document": "16457587", "end": 126, "section": "abstract"}, {"text": "To help crack this code more efficiently, we demonstrate a new strategy for protein characterization wherein complete PTM descriptions are obtained by database retrieval instead of manual interpretation of information-rich data from high-resolution tandem mass spectrometry (MS/MS).", "begin": 176, "document": "15025441", "end": 458, "section": "abstract"}, {"text": "Targeted analysis and discovery of posttranslational modifications in proteins from methanogenic archaea by top-down MS.", "begin": 0, "document": "14976258", "end": 120, "section": "title"}, {"text": "This study illustrates a significant evolutionary step for the MS tools available for characterization of WT proteins from complex proteomes without proteolysis.", "begin": 1268, "document": "14976258", "end": 1429, "section": "abstract"}]}, {"documents": ["17846275", "15336686", "2213842"], "answer": ["autosomal dominant", "autosomal recessive"], "id": "516be1d6298dcd4e5100006a", "snippets": [{"text": "Autosomal recessive inheritance had been verified or appeared likely in all nebulin cases", "begin": 346, "document": "15336686", "end": 435, "section": "abstract"}, {"text": "Most cases were sporadic, but in addition there were instances of both autosomal dominant and autosomal recessive inheritance, while two families showed mosaicism for dominant mutations.", "begin": 664, "document": "15336686", "end": 850, "section": "abstract"}, {"text": "Finding the causative mutation(s) determines the mode of inheritance", "begin": 1046, "document": "15336686", "end": 1114, "section": "abstract"}, {"text": "We conclude that in the Finnish CNM patients, the mode of inheritance appears to be recessive. Apart from a few instances of dominant inheritance, most cases published also seem compatible with recessive inheritance.", "begin": 751, "document": "2213842", "end": 967, "section": "abstract"}]}, {"documents": ["19916081", "19324998", "10319950", "9832432", "9224811"], "answer": [["LDL receptor"], ["ChREBP", "Carbohydrate response element binding protein"], ["ME", "malic enzyme"], ["cytochrome P450 oxidoreductase"]], "id": "516c0ebc298dcd4e5100006e", "snippets": [{"text": "These data suggest that ChREBP mRNA expression is positively regulated by TR-beta1 and TH at the transcriptional level in mammals. This novel observation indicates that TH fine-tunes hepatic lipogenesis via regulating SREBP-1c and ChREBP gene expression reciprocally.", "begin": 1182, "document": "19324998", "end": 1449, "section": "abstract"}, {"text": "In contrast treatment with L-T3 produced an increase in S14 and ME but no change in TR beta-/- mice. From these results, it can be concluded that regulation of HR and EE are independent of TR beta. With the exception of serum cholesterol concentration and liver ME mRNA accumulation, all other markers of TH action examined during TH deprivation exhibited the expected responses in the absence of TR beta.", "begin": 1842, "document": "9832432", "end": 2247, "section": "abstract"}, {"text": "However, the T3-activated expression of the GH gene in GH3-PV and ME gene in SK-Hep-1-PV was repressed by approximately 30% and 90%, respectively, indicating the lack of correlation of PV/TRpbeta1 protein ratio with the dominant negative potency of mutant PV.", "begin": 773, "document": "10319950", "end": 1032, "section": "abstract"}, {"text": "Transient cotransfection of P450R promoter/chloramphenicol acetyl transferase (CAT) constructs and the thyroid hormone receptor beta1 (TR beta1) expression plasmid into rat hepatoma H4IIE cells resulted in a 2.4-fold induction of promoter activity that was both T3 and TR beta1 dependent.", "begin": 656, "document": "9224811", "end": 944, "section": "abstract"}]}, {"documents": ["22120008", "19639607", "18974140", "18667590", "18162535", "16317087", "15574462"], "answer": ["Global hypomethylation is coupled with focal hypermethylation at CpG islands"], "id": "516e5f10298dcd4e5100007c", "snippets": [{"text": "Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer", "begin": 0, "document": "22120008", "end": 89, "section": "title"}, {"text": "Regions of focal hypermethylation in the tumor were located primarily at CpG islands and were concentrated within regions of long-range (>100 kb) hypomethylation. These hypomethylated domains covered nearly half of the genome and coincided with late replication and attachment to the nuclear lamina in human cell lines", "begin": 458, "document": "22120008", "end": 776, "section": "abstract"}, {"text": "the confluence of hypermethylation and hypomethylation", "begin": 791, "document": "22120008", "end": 845, "section": "abstract"}, {"text": "Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer", "begin": 0, "document": "19639607", "end": 117, "section": "title"}, {"text": "CpG island hypermethylation and genomic DNA hypomethylation are found not only in gastric cancers but also in associated premalignant lesions", "begin": 0, "document": "19639607", "end": 141, "section": "abstract"}, {"text": "Methylation of repetitive DNA elements in gastric lesions generally decreased with progression of the gastric lesion along the multistep carcinogenesi", "begin": 1100, "document": "19639607", "end": 1250, "section": "abstract"}, {"text": "our findings suggest that CpG island hypermethylation and repetitive DNA hypomethylation are enhanced with progression of the gastric lesion", "begin": 1580, "document": "19639607", "end": 1720, "section": "abstract"}, {"text": "DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation", "begin": 0, "document": "18974140", "end": 96, "section": "title"}, {"text": "Hypomethylation of CpG dinucleotides in genomic DNA was one of the first somatic epigenetic alterations discovered in human cancers. DNA hypomethylation is postulated to occur very early in almost all human cancers, perhaps facilitating genetic instability and cancer initiation and progression.", "begin": 0, "document": "18974140", "end": 295, "section": "abstract"}, {"text": "Contrary to the prevailing view that global DNA hypomethylation changes occur extremely early in all human cancers, we show that reductions in (5me)C content in the genome occur very late in prostate cancer progression, appearing at a significant extent only at the stage of metastatic disease", "begin": 406, "document": "18974140", "end": 699, "section": "abstract"}, {"text": "These findings provide evidence that DNA hypomethylation changes occur later in prostate carcinogenesis than the CpG island hypermethylation changes and occur heterogeneously during prostate cancer progression and metastatic dissemination.", "begin": 1557, "document": "18974140", "end": 1796, "section": "abstract"}, {"text": "revealed a high incidence of hypermethylation only in poorly differentiated (early and late) tumors.", "begin": 735, "document": "18667590", "end": 835, "section": "abstract"}, {"text": "In contrast to gene hypermethylation, genomic DNA hypomethylation, including hypomethylation of repetitive elements and loss of genomic 5-methyldeoxycytidine, occurred in both early and late stages of prostate cancer.", "begin": 1187, "document": "18667590", "end": 1404, "section": "abstract"}, {"text": "Tumors have reduced levels of genomic DNA methylation and contain hypermethylated CpG islands", "begin": 85, "document": "18162535", "end": 178, "section": "abstract"}, {"text": "The results are consistent with a specific defect in methylation of repetitive DNA sequences in human cancer.", "begin": 1113, "document": "18162535", "end": 1222, "section": "abstract"}, {"text": "Both hypomethylation and hypermethylation in a 0.2-kb region of a DNA repeat in cancer", "begin": 0, "document": "16317087", "end": 86, "section": "title"}, {"text": "Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer", "begin": 0, "document": "15574462", "end": 85, "section": "title"}, {"text": "Cancer cells are characterized by a generalized disruption of the DNA methylation pattern involving an overall decrease in the level of 5-methylcytosine together with regional hypermethylation of particular CpG islands", "begin": 0, "document": "15574462", "end": 218, "section": "abstract"}, {"text": "We conclude that DNA hypermethylation and hypomethylation are independent processes and appear to play different roles in colorectal tumor progression", "begin": 1589, "document": "15574462", "end": 1739, "section": "abstract"}]}, {"documents": ["23432975", "22991675", "22303793", "22269667", "20689175", "20684013", "18773673", "16359492", "15706485", "14974086", "7630403"], "answer": ["Mutations or/and deletions in the genes of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) at 22q13 (5%)."], "id": "516e5f41298dcd4e5100007f", "snippets": [{"text": "The Rubinstein-Taybi syndrome (RTS) is a well-defined syndrome with facial abnormalities, broad thumbs, broad big toes and mental retardation as the main clinical features", "begin": 0, "document": "7630403", "end": 171, "section": "abstract"}, {"text": "Many patients with RTS have been shown to have breakpoints in, and microdeletions of, chromosome 16p13.3", "begin": 173, "document": "7630403", "end": 277, "section": "abstract"}, {"text": "these breakpoints are restricted to a region that contains the gene for the human CREB binding protein (CBP), a nuclear protein participating as a co-activator in cyclic-AMP-regulated gene expression", "begin": 314, "document": "7630403", "end": 513, "section": "abstract"}, {"text": "RTS was shown to be associated with disruption of the CREB-binding protein gene CBP (CREBBP), either by gross chromosomal rearrangements or by point mutations", "begin": 193, "document": "14974086", "end": 351, "section": "abstract"}, {"text": "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease", "begin": 0, "document": "15706485", "end": 107, "section": "title"}, {"text": "A certain level of CREB-binding protein is essential for normal development, since inactivation of one allele causes Rubinstein-Taybi syndrome (RSTS)", "begin": 199, "document": "15706485", "end": 348, "section": "abstract"}, {"text": "In 92 patients, we were able to identify a total of 36 mutations in CBP", "begin": 666, "document": "15706485", "end": 737, "section": "abstract"}, {"text": "We extended the search for mutations to the EP300 gene and showed that mutations in EP300 also cause this disorder.", "begin": 908, "document": "15706485", "end": 1023, "section": "abstract"}, {"text": "Mutations in the CREBBP (CREB-binding protein gene) cause Rubinstein-Taybi syndrome (RSTS).", "begin": 0, "document": "16359492", "end": 91, "section": "abstract"}, {"text": "Heterozygous CREBBP mutations were identified in 12 of the 21 patients: five frameshift mutations, three nonsense mutations, two splice-site mutations, and two missense mutations.", "begin": 1063, "document": "16359492", "end": 1242, "section": "abstract"}, {"text": "It could be possible that genetic heterogeneity is related with novel mutations in other genes.", "begin": 661, "document": "18773673", "end": 756, "section": "abstract"}, {"text": "identified a novel CREBBP missense mutation, c.2728A > G (predicting p.Thr910Ala)", "begin": 599, "document": "20684013", "end": 680, "section": "abstract"}, {"text": "The p.Thr910Ala variant is outside the crucial histone acetyltransferase domain, and this may explain the mild and variable phenotype", "begin": 730, "document": "20684013", "end": 863, "section": "abstract"}, {"text": "Rubinstein-Taybi syndrome (RSTS), a developmental disorder comprising abnormalities that include mental retardation, an unusual facial appearance, broad thumbs and big toes is frequently associated with molecular lesions in the CREB-binding protein gene, CREBBP", "begin": 0, "document": "20689175", "end": 261, "section": "abstract"}, {"text": "Direct sequencing of CREBBP performed in 13 RSTS patients identified the three zinc fingers (CH1, CH2, CH3) and HAT domain as mutational hotspots in which ten novel pathogenic mutations were localized", "begin": 395, "document": "20689175", "end": 595, "section": "abstract"}, {"text": "Chromosomal 16p microdeletion in Rubinstein-Taybi syndrome detected by oligonucleotide-based array comparative genomic hybridization", "begin": 0, "document": "22269667", "end": 132, "section": "title"}, {"text": "Novel cAMP binding protein-BP (CREBBP) mutation in a girl with Rubinstein-Taybi syndrome", "begin": 0, "document": "23432975", "end": 88, "section": "title"}, {"text": "Rubinstein-Taybi syndrome (RTS) is a rare autosomal dominant disorder (prevalence 1:125,000) characterised by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa and short stature. The known genetic causes are point mutations or deletions of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) (5%)", "begin": 12, "document": "23432975", "end": 470, "section": "abstract"}]}, {"documents": ["21779408", "18393372", "18693240", "14633678", "11309147", "10747987", "17640894", "20303346", "23236167", "23086207", "22624060", "22561085", "21958314", "21782458", "21736313", "18852888", "18790802", "17440941", "15292170", "12819771", "8123667", "6282265", "2461933", "196592", "164278", "16086857", "20936105"], "answer": ["S-adenosyl-L\u2013methionine", "SAM", "AdoMet", "S-Adenosylmethionine", "adenosylmethionine", "S-Adenosyl methionine"], "id": "516e7fda298dcd4e51000081", "snippets": [{"text": "While SAMe is a methyl donor, MTA is an inhibitor of methylation. SAMe can convert to MTA spontaneously, so the effect of exogenous SAMe may be mediated by MTA.", "begin": 424, "document": "18393372", "end": 584, "section": "abstract"}, {"text": "Based on known SET domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon-amino group", "begin": 727, "document": "18693240", "end": 985, "section": "abstract"}, {"text": "Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and other H3 lysine 9 methylation activities.", "begin": 598, "document": "14633678", "end": 713, "section": "abstract"}, {"text": "Angiosperms synthesize S-methylmethionine (SMM) from methionine (Met) and S-adenosylmethionine (AdoMet) in a unique reaction catalyzed by Met S-methyltransferase (MMT). SMM serves as methyl donor for Met synthesis from homocysteine, catalyzed by homocysteine S-methyltransferase (HMT).", "begin": 0, "document": "11309147", "end": 285, "section": "abstract"}, {"text": "Plants synthesize S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis from homocysteine (Hcy).", "begin": 0, "document": "10747987", "end": 216, "section": "abstract"}, {"text": "AtHMT-1 and -2 both utilize l-SMM or (S,S)-AdoMet as a methyl donor in vitro and have higher affinities for SMM.", "begin": 813, "document": "10747987", "end": 925, "section": "abstract"}, {"text": "When the serine residue is mutated to glutamic acid, which mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine and diminished histone methylation activity.", "begin": 481, "document": "17640894", "end": 715, "section": "abstract"}, {"text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was fed with ethanol for 1month in order to modify the effects of ethanol on rat liver.", "begin": 0, "document": "20303346", "end": 171, "section": "abstract"}, {"text": "To investigate if tumor growth is dependent on the enzymatic activity of Ezh2, we developed a potent and selective small molecule inhibitor, EI1, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine.", "begin": 391, "document": "23236167", "end": 684, "section": "abstract"}, {"text": "The enzyme was capable of transferring methyl groups to selected lysine residues in a substrate protein using S-adenosyl-l-methionine (SAM) as the methyl donor.", "begin": 397, "document": "23086207", "end": 557, "section": "abstract"}, {"text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.", "begin": 289, "document": "22561085", "end": 423, "section": "abstract"}, {"text": "To control the enzymatic activity of vSET in vivo with an engineered S-adenosyl-l-methionine (SAM) analogue as methyl donor cofactor, we have carried out structure-guided design, synthesis, and characterization of orthogonal vSET methyltransferase mutant/SAM analogue pairs using a \"bump-and-hole\" strategy.", "begin": 232, "document": "21958314", "end": 539, "section": "abstract"}, {"text": "Protein lysine methyltransferases are important regulators of epigenetic signaling.", "begin": 0, "document": "21782458", "end": 83, "section": "abstract"}, {"text": "One of the well-studied PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor.", "begin": 124, "document": "21736313", "end": 265, "section": "abstract"}, {"text": "While SAMe is a methyl donor, MTA is an inhibitor of methylation.", "begin": 424, "document": "18393372", "end": 489, "section": "abstract"}, {"text": "The purified cytochrome can act as a methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine as methyl donor.", "begin": 184, "document": "6282265", "end": 337, "section": "abstract"}, {"text": "This enzyme utilizes S-adenosyl-L-methionine as the methyl donor.", "begin": 194, "document": "196592", "end": 259, "section": "abstract"}]}, {"documents": ["22897906", "23448600", "22223433", "22033927", "21830056", "21596839", "21369828", "22242120", "21094707", "21060834", "20950435", "20860631", "20568999", "20493168", "20308527", "19798443", "19279158", "19205716", "19142019", "18450745", "18369641", "17603073", "17428788", "17101786", "16949368", "16613610", "16537902", "16407326", "16183644", "16095617", "12819141", "15457214", "16339723", "16157682", "12397079", "11956312", "11859155", "11500496", "12137948", "10908644", "10199952", "8663349", "8460153", "23471993", "23417793", "23403278", "23388053", "23320494", "23319608", "23318260", "23314848", "23285239", "23285124", "23282990", "23239876", "23202694", "23142031", "23071553", "23071455", "23071088", "23022495", "23020525", "22892537", "22855185", "22834704", "22815475", "22768949", "22728643", "22727667", "22715096", "22705977", "22691070", "22683269", "22646239", "22607268", "22569290", "22569126", "22551706", "22528993", "22514736", "22491446", "22462537", "22427862", "22419124", "22412383", "22325148", "22302795", "22235338", "22231402", "22219182", "22216243", "22212480", "22203189", "22193973", "22186629", "22179824", "22172672", "22086334", "22083958", "22083954", "22081016", "22081013", "22073269", "22052799", "22039057", "22033296", "22022377", "22009739", "21979373", "21972924", "21953552", "21901784", "21875659", "21860208", "21799255", "21730028", "21726377", "21720545", "21669865", "21659642", "21646535", "21636313", "21623345", "21505064", "21448134", "21447119", "21419134", "21358630", "21278251", "21245376", "21224386", "21211724", "21195088", "21177652", "21158681", "21146514", "23271156", "20389031", "17253929", "15304225", "7720711", "19897549", "21047797", "19956676", "17224041", "19808672", "19029895", "12186646", "19399177", "18846226", "21836164", "22145013", "16412250", "20657587", "18725928", "16738128", "17542647"], "answer": [["HP1 alpha"], ["CHD proteins", "Chromodomain helicase DNA-binding protein"], ["CReMM"], ["cmt3"], ["chromointegrases"], ["Polycomb group (PcG) proteins"], ["Cbx2"], ["TgMYST-A"], ["MRG15"], ["MSL3"], ["Swi6"], ["Chp1"], ["dMi-2"], ["Corto"], ["ScoHET1"], ["cpSRP43"], ["CDY", "chromodomain Y chromosome"], ["transposable elements"], ["like heterochromatin protein", "LHP1"], ["ADP/ATP translocase 1"], ["CDYL", "CDY-like protein"], ["CHD1L", "CHD1-like"], ["NlMof"], ["TIP60"], ["Kismet"], ["Chriz"], ["PICKLE", "PKL"], ["HP1 beta"], ["HP1 gamma"], ["TgMYST \u2013B"], ["Cbx4"], ["Cbx6"], ["Cbx7"], ["Cbx8"], ["ScoHET2"], ["Cbx3"], ["MPP8"], ["MRG1"]], "id": "517137c18ed59a060a000001", "snippets": [{"text": "Their hallmark is the presence of a chromodomain at the C-terminus of the integrase. The chromodomain exhibits structural characteristics similar to proteins of the heterochromatin protein 1 (HP1) family, which mediate the binding of each chromovirus type to specific histone variants.", "begin": 292, "document": "23448600", "end": 577, "section": "abstract"}, {"text": "Chromodomain helicase DNA-binding protein 2 affects the repair of X-ray and UV-induced DNA damage.", "begin": 0, "document": "22223433", "end": 98, "section": "title"}, {"text": "Chromodomain helicase DNA-binding proteins (CHD) belong to a group of highly conserved chromatin remodeling proteins that are implicated in regulation of transcription. In an effort to understand the physiological role of one of the CHD members in a mammalian model system, we developed a mutant mouse model for the Chd2 gene.", "begin": 408, "document": "22223433", "end": 734, "section": "abstract"}, {"text": "Crystal structure of the chromodomain helicase DNA-binding protein 1 (Chd1) DNA-binding domain in complex with DNA.", "begin": 0, "document": "22033927", "end": 115, "section": "title"}, {"text": "Mutations in CHD7, the gene encoding chromodomain helicase DNA binding protein 7, are present in 60-80% of individuals with the CHARGE syndrome.", "begin": 197, "document": "21596839", "end": 341, "section": "abstract"}, {"text": "Chromodomain is present in the integrase structures of blastopia and 412 subgroup LTR-retrotransposons and may facilitate the process of non-specific integration.", "begin": 1252, "document": "21369828", "end": 1414, "section": "abstract"}, {"text": "The CHARGE syndrome is a multiple congenital malformation syndrome that usually results from deletion or heterozygous loss of function mutations of the chromodomain helicase DNA-binding protein 7 (CHD7) gene at 8q12.1.", "begin": 0, "document": "21094707", "end": 218, "section": "abstract"}, {"text": "A causative mutation within the chromodomain helicase DNA-binding protein-7 gene, which plays an important role in the embryonic development, is present in 2/3 of affected patients.", "begin": 193, "document": "20860631", "end": 374, "section": "abstract"}, {"text": "CHD1 is a subfamily member of the CHD family, which possesses a chromodomain, a helicase domain, and a DNA-binding domain.", "begin": 0, "document": "20568999", "end": 122, "section": "abstract"}, {"text": "The chromatin organizer modifier domain (chromodomain) is present in proteins that contribute to chromatin organization and mediates their binding to methylated histone H3.", "begin": 0, "document": "20493168", "end": 172, "section": "abstract"}, {"text": "Mass spectrometric analysis revealed serine-42, a conserved amino acid in the chromodomain, as a phosphorylation site of Cbx2. Phosphorylation of the chromodomain of Cbx2 on this residue in vitro resulted in a reduced level of binding to an H3 peptide containing trimethylated lysine-9 as well as an increase in the extent of binding to an H3 peptide containing trimethylated lysine-27, suggesting that such phosphorylation changes the binding specificity of Cbx2 for modified histone H3. Phosphorylation of the chromodomain of Cbx2 may therefore serve as a molecular switch that affects the reading of the histone modification code and thereby controls epigenetic cellular memory.", "begin": 761, "document": "20493168", "end": 1442, "section": "abstract"}, {"text": "Here we identify the ATP-dependent chromatin remodeling factor chromodomain helicase DNA-binding protein 8 (CHD8) as a novel coregulator of androgen-responsive transcription.", "begin": 327, "document": "20308527", "end": 501, "section": "abstract"}, {"text": "Mutations in CHD7, a chromodomain gene, are present in a majority of individuals with CHARGE syndrome, a multiple anomaly disorder characterized by ocular Coloboma, Heart defects, Atresia of the choanae, Retarded growth and development, Genital hypoplasia and Ear anomalies.", "begin": 0, "document": "19279158", "end": 274, "section": "abstract"}, {"text": "Two new chromodomain-containing proteins that associate with heterochromatin in Sciara coprophila chromosomes.", "begin": 0, "document": "19205716", "end": 110, "section": "title"}, {"text": "Both proteins, ScoHET1 of 37 kDa and ScoHET2 of 44 kDa, display two chromodomain motifs that contain the conserved residues essential for the recognition of methylated histone H3 at lysine 9.", "begin": 219, "document": "19205716", "end": 410, "section": "abstract"}, {"text": "Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs.", "begin": 0, "document": "18450745", "end": 107, "section": "title"}, {"text": "Previous studies have shown two homologous chromodomain modules in the HP1 and Polycomb proteins exhibit discriminatory binding to related methyllysine residues (embedded in ARKS motifs) of the histone H3 tail.", "begin": 0, "document": "18450745", "end": 210, "section": "abstract"}, {"text": "In vertebrates, HP1-like chromodomains are also present in the chromodomain Y chromosome (CDY) family of proteins adjacent to a putative catalytic motif. The human genome encodes three CDY family proteins, CDY, CDYL, and CDYL2.", "begin": 440, "document": "18450745", "end": 667, "section": "abstract"}, {"text": "The CDY chromodomain exhibits discriminatory binding to lysine-methylated ARK(S/T) motifs, whereas the CDYL2 chromodomain binds with comparable strength to multiple ARK(S/T) motifs. Interestingly, subtle amino acid changes in the CDYL chromodomain prohibit such binding interactions in vitro and in vivo.", "begin": 1016, "document": "18450745", "end": 1320, "section": "abstract"}, {"text": "We assessed mRNA transcript abundance of seven genes that code for proteins with established roles in epigenetically-mediated gene silencing [transcriptional co-repressor SIN3A, DNA (cytosine-5-) methyltransferase 1, methyl CpG binding protein 2, chromodomain helicase DNA binding protein 4, histone binding protein rbbp4, histone deacetylase 1 and nuclear receptor co-repressor 2] using qRT-PCR.", "begin": 487, "document": "18369641", "end": 883, "section": "abstract"}, {"text": "CHD7 is a member of the chromodomain helicase DNA binding domain (CHD) family of ATP-dependent chromatin remodelling enzymes.", "begin": 0, "document": "17603073", "end": 125, "section": "abstract"}, {"text": "The cysteine-rich CXXC domains of MBD1 bound to Ring1b and the chromodomain of hPc2.", "begin": 284, "document": "17428788", "end": 368, "section": "abstract"}, {"text": "Methylation of lysine 9 within histone H3 and the subsequent binding of the chromodomain protein heterochromatin protein 1 (HP1) are thought to initiate heterochromatin formation in vivo and to propagate a heterochromatic state lasting through several cell divisions.", "begin": 228, "document": "17101786", "end": 495, "section": "abstract"}, {"text": "Here, we show that the SNF2-like chromodomain helicase protein CHD8 interacts with the insulator binding protein CTCF. C", "begin": 200, "document": "16949368", "end": 320, "section": "abstract"}, {"text": "The chromodomain (CD) of the Drosophila Polycomb protein exhibits preferential binding affinity for histone H3 when trimethylated at lysine 27.", "begin": 0, "document": "16537902", "end": 143, "section": "abstract"}, {"text": "Despite a high degree of conservation, the Cbx chromodomains display significant differences in binding preferences.", "begin": 246, "document": "16537902", "end": 362, "section": "abstract"}, {"text": "Three-dimensional solution structures of the chromodomains of cpSRP43.", "begin": 0, "document": "16183644", "end": 70, "section": "title"}, {"text": "Recently, three functionally distinct chromodomains (CDs) have been identified in cpSRP43.", "begin": 194, "document": "16183644", "end": 284, "section": "abstract"}, {"text": "The C-terminal helical segment typically found in the nuclear chromodomains is absent in CD1.", "begin": 520, "document": "16183644", "end": 613, "section": "abstract"}, {"text": "Critical comparison of the structures of the chromodomains of cpSRP43 with those found in nuclear chromodomain proteins revealed that the diverse protein-protein interactions mediated by the CDs appear to stem from the differences that exist in the surface charge potentials of each CD.", "begin": 853, "document": "16183644", "end": 1139, "section": "abstract"}, {"text": "Characterization and functional analysis of CReMM, a novel chromodomain helicase DNA-binding protein.", "begin": 0, "document": "16095617", "end": 101, "section": "title"}, {"text": "The present study describes a newly identified protein named CReMM (chromatin-related mesenchymal modulator). The protein was studied by bioinformatic means and classified as a member of the third subfamily of chromodomain helicase DNA-binding proteins (CHD). In silico translation defined CReMM as a multiple domains protein including two chromodomains, SNF2/ATPase, helicase C domain and an A/T-DNA-binding domain (DBD).", "begin": 0, "document": "16095617", "end": 422, "section": "abstract"}, {"text": "Identification and analysis of chromodomain-containing proteins encoded in the mouse transcriptome.", "begin": 0, "document": "12819141", "end": 99, "section": "title"}, {"text": "The chromodomain is 40-50 amino acids in length and is conserved in a wide range of chromatic and regulatory proteins involved in chromatin remodeling. Chromodomain-containing proteins can be classified into families based on their broader characteristics, in particular the presence of other types of domains, and which correlate with different subclasses of the chromodomains themselves.", "begin": 0, "document": "12819141", "end": 389, "section": "abstract"}, {"text": "Here we show that the chromodomain of CMT3 can directly interact with the N-terminal tail of histone H3, but only when it is simultaneously methylated at both the H3K9 and H3K27 positions.", "begin": 434, "document": "15457214", "end": 622, "section": "abstract"}, {"text": "In addition to the canonical MYST HAT catalytic domain, both TgMYST-A and -B possess an atypical C2HC zinc finger and a chromodomain.", "begin": 894, "document": "16339723", "end": 1027, "section": "abstract"}, {"text": "Clr7 and Clr8 are required for localization of the Swi6 chromodomain protein and for histone H3 lysine 9 methylation, thereby influencing not only mating-type switching but also transcriptional silencing in all previously characterized heterochromatic regions, chromosome segregation, and meiotic recombination in the mating-type region.", "begin": 416, "document": "16157682", "end": 753, "section": "abstract"}, {"text": "MRG15, a novel chromodomain protein, is present in two distinct multiprotein complexes involved in transcriptional activation.", "begin": 0, "document": "12397079", "end": 126, "section": "title"}, {"text": "MRG15 is a novel chromodomain protein that is a member of a family of genes related to MORF4. MORF4 (mortality factor on chromosome 4) induces senescence in a subset of human tumor cell lines.", "begin": 0, "document": "12397079", "end": 192, "section": "abstract"}, {"text": "Analysis of deletion mutants of MRG15 indicated that the leucine zipper at the C-terminal region of MRG15 was important for the protein associations in MAF1 and that the N-terminal chromodomain was required for the assembly of the MAF2 protein complex. Consistent with these data was the fact that a histone acetyltransferase activity associated with MRG15 was lost when the chromodomain was deleted and that both mutant MRG15 proteins failed to activate the B-myb promoter. The various mechanisms by which MRG15 could activate gene transcription are discussed.", "begin": 640, "document": "12397079", "end": 1201, "section": "abstract"}, {"text": "The chromodomain (CD) is a highly conserved motif present in a variety of animal and plant proteins, and its probable role is to assemble a variety of macromolecular complexes in chromatin.", "begin": 0, "document": "11956312", "end": 189, "section": "abstract"}, {"text": "Structure of HP1 chromodomain bound to a lysine 9-methylated histone H3 tail.", "begin": 0, "document": "11859155", "end": 77, "section": "title"}, {"text": "The chromodomain of the HP1 family of proteins recognizes histone tails with specifically methylated lysines. Here, we present structural, energetic, and mutational analyses of the complex between the Drosophila HP1 chromodomain and the histone H3 tail with a methyllysine at residue 9, a modification associated with epigenetic silencing. The histone tail inserts as a beta strand, completing the beta-sandwich architecture of the chromodomain. The methylammonium group is caged by three aromatic side chains, whereas adjacent residues form discerning contacts with one face of the chromodomain.", "begin": 0, "document": "11859155", "end": 596, "section": "abstract"}, {"text": "The MORF4-Related Gene on chromosome 15 (MRG15) is a member of a novel family of genes originally identified in studies to reveal cell senescence-inducing factors. MRG15 contains several predicted protein motifs, including a nuclear localization signal, a helix-loop-helix region, a leucine zipper, and a chromodomain.", "begin": 0, "document": "11500496", "end": 318, "section": "abstract"}, {"text": "Four alleles of dMi-2 mutants were further characterized in molecular nature; dMi-2(BL1) was found to have a mutation in the ATP-binding motif of the ATPase domain, dMi-2(BL7) in the core histidine of the first plant homeodomain zinc finger and dMi-2(BL12) in a conserved serine in the chromodomain.", "begin": 737, "document": "12137948", "end": 1036, "section": "abstract"}, {"text": "These analyses also suggest that the msl-3/MRG15 duplication occurred after the fungus/animal split, while an independent duplication occurred in plants. The proteins encoded by these genes have similar structures, including a putative chromodomain close to their N-terminal end and a putative leucine zipper at their C-terminus.", "begin": 1114, "document": "10908644", "end": 1443, "section": "abstract"}, {"text": "CHD1 interacts with SSRP1 and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin.", "begin": 0, "document": "10199952", "end": 137, "section": "title"}, {"text": "Interaction between an integral protein of the nuclear envelope inner membrane and human chromodomain proteins homologous to Drosophila HP1.", "begin": 0, "document": "8663349", "end": 140, "section": "title"}, {"text": "A mammalian DNA-binding protein that contains a chromodomain and an SNF2/SWI2-like helicase domain.", "begin": 0, "document": "8460153", "end": 99, "section": "title"}, {"text": "A Southern blot analysis indicated that this protein, which we have named CHD-1, for chromodomain-helicase-DNA-binding protein, is present in most, if not all, mammalian species.", "begin": 472, "document": "8460153", "end": 650, "section": "abstract"}, {"text": "Here we show that chromodomain helicase DNA-binding protein 4 (Chd4) forms a complex with Gata3 in Th2 cells that both activates Th2 cytokine transcription and represses the Th1 cytokine IFN-\u03b3.", "begin": 271, "document": "23471993", "end": 464, "section": "abstract"}, {"text": "Chromodomain helicase DNA-binding protein 4 (CHD4), the defining subunit of the nucleosome remodeling and deacetylase (NuRD) complex, is a nucleosome-remodeling protein of the SNF2/ISWI2 family, members of which contain two chromo domains and an ATP-dependent helicase module.", "begin": 195, "document": "23417793", "end": 471, "section": "abstract"}, {"text": "Among those proteins with >40% regulation were Macrophage Capping protein (CAPG) and Chromodomain Helicase DNA binding protein 4 (CHD4) proteins which were significantly upregulated by pp32r1 and pp32r1Y140H overexpression.", "begin": 1097, "document": "23403278", "end": 1320, "section": "abstract"}, {"text": "This heterochromatin coordinates expression levels by associating with a chromodomain protein Chp1 and an antisilencing factor Epe1.", "begin": 316, "document": "23388053", "end": 448, "section": "abstract"}, {"text": "Within NCCs, Brg1 partners with chromatin remodeler Chromodomain-helicase-DNA-binding protein 7 (Chd7) on the PlexinA2 promoter to activate PlexinA2, which encodes a receptor for semaphorin to guide NCCs into the OFT.", "begin": 1040, "document": "23319608", "end": 1257, "section": "abstract"}, {"text": "Chromodomain Helicase DNA binding protein 5 (CHD5) is a tumor suppressor mapping to 1p36, a genomic region that is frequently deleted in human cancer.", "begin": 0, "document": "23318260", "end": 150, "section": "abstract"}, {"text": "Here, we identify ENHANCED PHOTOMORPHOGENIC1 (EPP1), previously known as PICKLE (PKL), an ATP-dependent chromatin remodeling factor of the chromodomain/helicase/DNA binding family, as a repressor of photomorphogenesis in Arabidopsis thaliana.", "begin": 271, "document": "23314848", "end": 513, "section": "abstract"}, {"text": "In this study, the structure of the chromodomain of human SUV39H1 was determined by X-ray crystallography.", "begin": 266, "document": "23285239", "end": 372, "section": "abstract"}, {"text": "Chromodomain on Y-like (CDYL) is a chromodomain protein that has sequence homology to members of the enoyl CoA hydratase family.", "begin": 0, "document": "23282990", "end": 128, "section": "abstract"}, {"text": "Our previous structural work demonstrated that a coiled-coil interaction between MBD2 and GATA zinc finger domain containing 2A (GATAD2A/p66\u03b1) proteins recruits the chromodomain helicase DNA-binding protein (CHD4/Mi2\u03b2) to the NuRD complex and is necessary for MBD2-mediated DNA methylation-dependent gene silencing in vivo (Gnanapragasam, M. N., Scarsdale, J. N., Amaya, M. L., Webb, H. D., Desai, M. A., Walavalkar, N. M., Wang, S. Z., Zu Zhu, S., Ginder, G. D., and Williams, D. C., Jr. (2011) p66\u03b1-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex.", "begin": 232, "document": "23239876", "end": 850, "section": "abstract"}, {"text": "Sequence analysis showed that NlElp3 contains GNAT-type HAT domain and Radical SAM domain, and NlMof contains chromodomain and MOZ-SAS acetyltransferase domain.", "begin": 972, "document": "23142031", "end": 1132, "section": "abstract"}, {"text": "We examined requirements for individual domains of chromodomain helicase DNA-binding protein 4 (CHD4), a core catalytic component of NuRD complexes, as well as the NuRD subunit methyl-binding domain protein 2 (MBD2) and methylated DNA, for NuRD function in the context of tissue-specific transcription.", "begin": 152, "document": "23071088", "end": 454, "section": "abstract"}, {"text": "Twelve rare copy number variants segregate with talipes equinovarus in multiplex pedigrees, and contain the developmentally expressed transcription factors and transcriptional regulators PITX1, TBX4, HOXC13, UTX, CHD (chromodomain protein)1, and RIPPLY2.", "begin": 1093, "document": "22892537", "end": 1347, "section": "abstract"}, {"text": "The chromodomain, helicase, DNA-binding protein 5 (CHD5) is a chromatin remodeling enzyme which is implicated in tumor suppression.", "begin": 0, "document": "22834704", "end": 131, "section": "abstract"}, {"text": "The methyl-mark determines a highly flexible and very dynamic interaction of the chromodomain of hHP1\u03b2 with the H3-tail.", "begin": 543, "document": "22815475", "end": 663, "section": "abstract"}, {"text": "To test this hypothesis, we performed a comprehensive molecular dynamics study in which we analyzed a crystallographically defined complex that involves the HP1 chromodomain and an H3 tail peptide.", "begin": 359, "document": "22768949", "end": 556, "section": "abstract"}, {"text": "Whereas the molecular target of the MRG15 chromodomain (CD) has been suggested to be H3K36me(2/3), the precise molecular target of the Pf1 plant homeodomain 1 (PHD1) has remained elusive.", "begin": 567, "document": "22728643", "end": 754, "section": "abstract"}, {"text": "Chp1, a chromodomain (CD) protein, forms the Ago1-containing RNA-induced transcriptional silencing (RITS) complex and recruits siRNA-bound RITS to methylated histone H3 lysine 9 (H3K9me) via its CD.", "begin": 81, "document": "22727667", "end": 279, "section": "abstract"}, {"text": "In addition, cells expressing S473A also displayed defective mobilization of the HP1-\u03b2 chromodomain protein.", "begin": 968, "document": "22715096", "end": 1076, "section": "abstract"}, {"text": "CHD7 is a chromodomain-containing, ATP dependent helicase protein that is highly expressed in the developing ear and is required for semicircular canal development in both humans and mice.", "begin": 300, "document": "22705977", "end": 488, "section": "abstract"}, {"text": "Moreover, the LTR retrotransposon fraction in BAC clones harboring genes is disproportionately composed of chromodomain-containing Gypsy LTR retrotransposons ('chromoviruses'), and the majority of the intact chromoviruses contain tandem chromodomain duplications.", "begin": 734, "document": "22691070", "end": 997, "section": "abstract"}, {"text": "Stimulated by positively charged residues in the hinge region, RNA competes with methylated histone H3K9 for binding to the chromodomain of HP1(Swi6).", "begin": 483, "document": "22683269", "end": 633, "section": "abstract"}, {"text": "CHD7 is one of the nine members of the chromodomain helicase DNA-binding family of ATP-dependent chromatin remodeling enzymes.", "begin": 0, "document": "22646239", "end": 126, "section": "abstract"}, {"text": "Therefore, p53, ZNF237, and Chromodomain helicase DNA-binding protein 3 inhibit the function ER Ca\u00b2\u207a leak channels to regulate both ER and cytoplasmic Ca\u00b2\u207a levels and may potentially control Ca\u00b2\u207a-signaling function of PS1.", "begin": 1847, "document": "22607268", "end": 2069, "section": "abstract"}, {"text": "We show that chromodomain helicase DNA-binding domain 2 (Chd2), a SNF2 chromatin remodelling enzyme family member, interacts with MyoD and myogenic gene regulatory sequences to specifically mark these loci via deposition of the histone variant H3.3 prior to cell differentiation.", "begin": 79, "document": "22569126", "end": 358, "section": "abstract"}, {"text": "Analysis of the Neurospora crassa chromodomain protein CDP-2, a component of a newly characterized HP1-containing complex, reveals a second gene-silencing mechanism and provides insights into the dynamic nature of chromatin domains that possess shared components.", "begin": 0, "document": "22551706", "end": 263, "section": "abstract"}, {"text": "Mutagenesis of Tf1 integrase revealed that the complete Tf1 integrase protein (excluding its chromodomain) is required for stimulating the Tf1 RT primer removal activity.", "begin": 1035, "document": "22491446", "end": 1205, "section": "abstract"}, {"text": "About 80% of patients with a clinical diagnose, have a mutation or a deletion in the gene encoding chromodomain helicase DNA-binding protein 7 (CHD7).", "begin": 212, "document": "22462537", "end": 362, "section": "abstract"}, {"text": "Owing to different polyadenylation sites and alternative splicing events, the human CBX2 locus produces two transcripts: a 5-exon transcript that encodes the 532-amino acid CBX2-1 isoform that contains the conserved chromodomain and Pc box and a 4-exon transcript encoding a shorter isoform, CBX2-2, lacking the Pc box but still possessing a chromodomain.", "begin": 853, "document": "22419124", "end": 1208, "section": "abstract"}, {"text": "Chromodomain helicase DNA-binding protein 4 (Chd4) is the core catalytic subunit of the nucleosome remodeling and deacetylase (NuRD) chromatin remodeling complex.", "begin": 236, "document": "22302795", "end": 398, "section": "abstract"}, {"text": "Chromodomain helicase DNA-binding proteins (CHD) belong to a group of highly conserved chromatin remodeling proteins that are implicated in regulation of transcription.", "begin": 408, "document": "22223433", "end": 576, "section": "abstract"}, {"text": "Here, we report that chromodomain helicase DNA-binding protein 4 (CHD4) is a novel BRIT1 binding partner that regulates the HR repair process.", "begin": 545, "document": "22219182", "end": 687, "section": "abstract"}, {"text": "Here, we report that the chromodomain-containing protein MRG-1 is an important factor for genomic integrity in meiosis in Caenorhabditis elegans.", "begin": 315, "document": "22212480", "end": 460, "section": "abstract"}, {"text": "The chromodomain protein, Chromator, can be divided into two main domains, a NH(2)-terminal domain (NTD) containing the chromodomain (ChD) and a COOH-terminal domain (CTD) containing a nuclear localization signal.", "begin": 0, "document": "22203189", "end": 213, "section": "abstract"}, {"text": "Chromodomain helicase DNA binding protein 5 (CHD5) is a potent tumor suppressor that serves as a master regulator of a tumor-suppressive network.", "begin": 0, "document": "22186629", "end": 145, "section": "abstract"}, {"text": "By high-resolution tiling array CGH, the smallest common deletion targeted just one gene, the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1).", "begin": 466, "document": "22179824", "end": 631, "section": "abstract"}, {"text": "Here we report direct evidence for presynaptic pairing activity intrinsic to non-PC regions, which is facilitated by a conserved chromodomain protein, MRG-1.", "begin": 629, "document": "22172672", "end": 786, "section": "abstract"}, {"text": "The chromodomain of MPP8 recognizes the dimethylated Dnmt3aK44me2.", "begin": 390, "document": "22086334", "end": 456, "section": "abstract"}, {"text": "Members of the chromodomain helicase DNA-binding (CHD) family of proteins are thought to regulate gene expression.", "begin": 0, "document": "22083958", "end": 114, "section": "abstract"}, {"text": "It has been shown that the methylation mark of vertebrate histone H1 is specifically recognized by the chromodomain of HP1.", "begin": 161, "document": "22083954", "end": 284, "section": "abstract"}, {"text": "To this end, we have performed mutation studies on the Drosophila HP1\u03b1 chromodomain, which binds H3K9Me(2)  and H3K9Me(3)  with approximately equal affinities.", "begin": 602, "document": "22052799", "end": 761, "section": "abstract"}, {"text": "We are interested in defining which elements of the chromodomain helicase DNA-binding protein 1 (Chd1) remodeler are necessary and sufficient for sliding nucleosomes.", "begin": 110, "document": "22039057", "end": 276, "section": "abstract"}, {"text": "Chromatin remodelers are ATP-dependent machines that dynamically alter the chromatin packaging of eukaryotic genomes by assembling, sliding, and displacing nucleosomes.", "begin": 0, "document": "22033927", "end": 168, "section": "abstract"}, {"text": "Ocular coloboma, heart malformation, choanal atresia, retardation of growth and/or development, genital hypoplasia, and ear anomalies associated with deafness (CHARGE) syndrome is a rare, usually sporadic, autosomal dominant disorder, caused by mutations within the CHD7 (chromodomain helicase DNA-binding protein 7) gene, in nearly 70% of cases.", "begin": 0, "document": "22033296", "end": 346, "section": "abstract"}, {"text": "Here we report that the chromodomain-containing protein CDYL specifically recognizes di- and tri-methylated H3K27 (H3K27me2 and H3K27me3) and directly interacts with EZH2, the catalytic subunit of PRC2.", "begin": 366, "document": "22009739", "end": 568, "section": "abstract"}, {"text": "Murine Chd1 (chromodomain helicase DNA-binding protein 1), a chromodomain-containing chromatin remodeling protein, is necessary for embryonic stem (ES) cell pluripotency.", "begin": 0, "document": "21979373", "end": 170, "section": "abstract"}, {"text": "Here, we investigate the function of chromodomain helicase DNA binding protein 7 (chd7) during zebrafish somitogenesis.", "begin": 230, "document": "21901784", "end": 349, "section": "abstract"}, {"text": "Heterozygous mutations in the gene encoding chromodomain-DNA-binding-protein 7 (CHD7) cause CHARGE syndrome, a multiple anomaly condition which includes vestibular dysfunction and hearing loss.", "begin": 0, "document": "21875659", "end": 193, "section": "abstract"}, {"text": "Because, in plants, DNA methylation can serve as a signal for H3-lysine9-dimethylation (H3K9me2), and subsequently for non-CG-context DNA methylation, SET-domain histone methyltransferase and chromodomain dna methyltransferase 3 (cmt3) mutations were introgressed.", "begin": 581, "document": "21830056", "end": 845, "section": "abstract"}, {"text": "Previously, we have shown that the chromodomain protein Chriz and the zinc-finger protein Z4 are essentially required for the maintenance of polytene chromosome structure.", "begin": 122, "document": "21799255", "end": 293, "section": "abstract"}, {"text": "In brain, Family with sequence similarity 174 member b (Fam174b) had increased expression in 318 females, whereas Chromodomain helicase DNA binding protein 2 (Chd2-2) had reduced expression in 318 males.", "begin": 1011, "document": "21730028", "end": 1214, "section": "abstract"}, {"text": "Fractionation of the extract identified a single protein, chromodomain helicase DNA binding protein 1 (Chd1), capable of the remodeling activity.", "begin": 323, "document": "21646535", "end": 468, "section": "abstract"}, {"text": "Chromodomain helicase DNA-binding protein 5 (CHD5) has been found to be a candidate tumor suppressor gene (TSG) in malignant neural tumors.", "begin": 0, "document": "21636313", "end": 139, "section": "abstract"}, {"text": "Similarly, CenH3-GFP distribution was altered in the absence of HP1, the chromodomain protein that binds to H3K9me3.", "begin": 1128, "document": "21505064", "end": 1244, "section": "abstract"}, {"text": "ChIP-Seq reveals that KDM5B is predominantly targeted to intragenic regions and that it is recruited to H3K36me3 via an interaction with the chromodomain protein MRG15.", "begin": 463, "document": "21448134", "end": 631, "section": "abstract"}, {"text": "We determined the crystal structure of MPP8 chromodomain in complex with H3K9me3 peptide.", "begin": 239, "document": "21419134", "end": 328, "section": "abstract"}, {"text": "On this gene the chromodomain protein HP1\u03b3, frequently defined as a transcriptional repressor, facilitates inclusion of the alternative exons via a mechanism involving decreased RNA polymerase II elongation rate.", "begin": 338, "document": "21358630", "end": 550, "section": "abstract"}, {"text": "Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a core component of the NuRD complex and contains a nucleosome remodeling ATPase domain along with two chromodomains and two plant homeodomain (PHD) fingers.", "begin": 492, "document": "21278251", "end": 703, "section": "abstract"}, {"text": "H3-Lys-9-Me2 interacts with the chromodomain of Swi6/HP1.", "begin": 289, "document": "21224386", "end": 346, "section": "abstract"}, {"text": "The chromodomain (CD) of HP1 proteins specifically recognizes the methyl mark on H3 peptides, but the same extent of specificity is not observed within chromatin.", "begin": 108, "document": "21211724", "end": 270, "section": "abstract"}, {"text": "We have performed simulations on models of chromodomain helicase DNA-binding protein 1 complexed with a variety of histone H3 modifications.", "begin": 328, "document": "21195088", "end": 468, "section": "abstract"}, {"text": "CHARGE syndrome is an autosomal dominant multisystem disorder caused by mutation in the CHD7 gene, encoding chromodomain helicase DNA-binding protein 7. Molecular diagnostic testing for CHD7 mutation has been available in a clinical setting since 2005.", "begin": 0, "document": "21158681", "end": 252, "section": "abstract"}, {"text": "In this work we identified Kismet, a chromodomain-containing protein of the SNF2-like family of ATPases, as a novel component of the hedgehog transcriptional repression mechanism in anterior compartment cells.", "begin": 613, "document": "21146514", "end": 822, "section": "abstract"}]}, {"documents": ["23210566", "22199277", "21678021", "21542403", "21422799", "20152359", "19826964", "19177457", "18062802", "17525482", "16712668", "15991157", "9745455", "7641404"], "answer": ["Ret"], "id": "5171438a8ed59a060a000007", "snippets": [{"text": "Activating germline RET mutations are presented in patients with familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia (MEN) types 2A and 2B, whereas inactivating germline mutations in patients with Hirschsprung's disease (HSCR). The aim of this study was to evaluate genotype-phenotype correlations of the frequently discussed Tyr791Phe mutation in exon 13 of the RET proto-oncogene. Screening of three groups of patients was performed (276 families with medullary thyroid carcinoma (MTC), 122 families with HSCR, and 29 patients with pheochromocytoma). We found this mutation in 3 families with apparently sporadic MTC, 3 families with FMTC/MEN2, 1 patient with pheochromocytoma, and 3 families with HSCR.", "begin": 0, "document": "19826964", "end": 730, "section": "abstract"}, {"text": "Multiple endocrine neoplasia type 2 (MEN2) is an inherited, autosomal-dominant disorder caused by deleterious mutations within the RET protooncogene. MEN2 RET mutations are mainly heterozygous, missense sequence changes found in RET exons 10, 11, and 13-16", "begin": 0, "document": "19177457", "end": 256, "section": "abstract"}, {"text": "Medullary thyroid carcinoma (MTC) occurs both sporadically and in the context of autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN2) syndromes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC), which are caused by activating germline mutations in the RET proto-oncogene.", "begin": 11, "document": "16712668", "end": 316, "section": "abstract"}, {"text": "Germline mutations of the ret protooncogene are the underlying cause of the MEN2 syndromes and a proportion of cases of HSCR. In this report, we describe a new kindred in which the MEN2 and HSCR phenotypes are associated with a single C620S point mutation at one of the cysteine codons of the extracellular domain of the ret protooncogene.", "begin": 123, "document": "9745455", "end": 462, "section": "abstract"}, {"text": "Medullary thyroid carcinoma (MTC) occurs both sporadically and in the autosomal dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes. The distinction between true sporadic MTC and a new mutation familial case is important for future clinical management of both the patient and family. The susceptibility gene for MEN 2 is the RET proto-oncogene.", "begin": 11, "document": "7641404", "end": 376, "section": "abstract"}]}, {"documents": ["21901742", "21901741", "17332020", "16925832", "15593401", "14965344", "12176826", "11673234", "11738707", "11337477", "9789092", "9253604", "19564452", "19329068", "16925843", "16314312", "15961499", "15924626", "15691859", "15613242", "14764563", "12538242", "12023806", "10779488", "19099578", "16925833"], "answer": [["Genscan"], ["Glimmer"], ["Fgenesh"], ["Augustus"], ["GeneID"]], "id": "51716a438ed59a060a00000a", "snippets": [{"text": "This unit describes how to use the gene-finding programs GeneMark.hmm-E and GeneMark-ES for finding protein-coding genes in the genomic DNA of eukaryotic organisms.", "begin": 0, "document": "21901742", "end": 164, "section": "abstract"}, {"text": "YACOP parses and combines the output of the three gene-predicting systems Criticia, Glimmer and ZCURVE.", "begin": 348, "document": "14965344", "end": 451, "section": "abstract"}, {"text": "Phat is based on a generalized hidden Markov model (GHMM) similar to the models used in GENSCAN, Genie and HMMgene.", "begin": 164, "document": "11738707", "end": 279, "section": "abstract"}, {"text": "We present an independent comparative analysis of seven recently developed gene-finding programs: FGENES, GeneMark.hmm, Genie, Genescan, HMMgene, Morgan, and MZEF.", "begin": 0, "document": "11337477", "end": 163, "section": "abstract"}, {"text": "JIGSAW, GeneZilla, and GlimmerHMM: puzzling out the features of human genes in the ENCODE regions", "begin": 0, "document": "16925843", "end": 97, "section": "title"}, {"text": "FGENES; Gene-Mark.hmm; Genie; Genescan; HMMgene; Morgan and MZEF,", "begin": 625, "document": "12023806", "end": 690, "section": "abstract"}]}, {"documents": ["23468975", "22560084", "20353875", "20090781", "19500131", "19127482", "17786276", "16825496", "16014569", "16083281"], "answer": ["The mutational status of the IGHV genes."], "id": "51739df58ed59a060a00001c", "snippets": [{"text": "Mutational status of the immunoglobulin heavy chain variable regions (IGHVs) of CLL cells offers useful prognostic information for high-risk patients", "begin": 119, "document": "20090781", "end": 268, "section": "abstract"}, {"text": "but time and economical costs originally prevented it from being routinely used in a clinical setting. Instead, alternative markers of IGHV status, such as zeta-associated protein (ZAP70) or messenger RNA levels are often used", "begin": 270, "document": "20090781", "end": 496, "section": "abstract"}, {"text": "Patients with unmutated IgV(H) gene show a shorter progression-free and overall survival than patients with immunoglobulin heavy chain variable regions (IgV(H)) gene mutated", "begin": 109, "document": "19127482", "end": 282, "section": "abstract"}]}, {"documents": ["21056007", "19329068", "18801175", "18801164", "16306388", "15374869", "14764557", "14654703", "11337482", "10764574", "10487869", "9521933", "7584460", "22537006", "20726803", "16963498", "16772025", "15980556", "15784153", "15608279", "15564294"], "answer": [["WPSS"], ["SCGPred"], ["TICO"], ["GLIMMER"], ["MetWAMer"], ["WebScipio"], ["GeneSeqer"], ["SplicePredictor"], ["DGSplicer"], ["TAP"], ["GeneBuilder"], ["SeqHelp"], ["FGENE", "FGENEH"], ["HSPL"], ["RNASPL"], ["HEXON"], ["CDSB"], ["HBR"]], "id": "51740da48ed59a060a000024", "snippets": [{"text": "The prediction of the complete structure of genes is one of the very important tasks of bioinformatics, especially in eukaryotes. A crucial part in the gene structure prediction is to determine the splice sites in the coding region. Identification of splice sites depends on the precise recognition of the boundaries between exons and introns of a given DNA sequence. This problem can be formulated as a classification of sequence elements into 'exon-intron' (EI), 'intron-exon' (IE) or 'None' (N) boundary classes.", "begin": 0, "document": "21056007", "end": 515, "section": "abstract"}, {"text": "The proposed WPSS method poses efficient results compared with the performance of many methods proposed in the literature.", "begin": 892, "document": "21056007", "end": 1014, "section": "abstract"}, {"text": "SCGPred: a score-based method for gene structure prediction by combining multiple sources of evidence.", "begin": 0, "document": "19329068", "end": 102, "section": "title"}, {"text": "Moreover, computational gene finding in newly sequenced genomes is especially a difficult task due to the absence of a training set of abundant validated genes. Here we present a new gene-finding program, SCGPred, to improve the accuracy of prediction by combining multiple sources of evidence.", "begin": 267, "document": "19329068", "end": 561, "section": "abstract"}, {"text": "Therefore, SCG-Pred can serve as an alternative gene-finding tool for newly sequenced eukaryotic genomes. The program is freely available at http://bio.scu.edu.cn/SCGPred/.", "begin": 1088, "document": "19329068", "end": 1260, "section": "abstract"}, {"text": "WebScipio: an online tool for the determination of gene structures using protein sequences.", "begin": 0, "document": "18801164", "end": 91, "section": "title"}, {"text": "Incorporation of splice site probability models for non-canonical introns improves gene structure prediction in plants.", "begin": 0, "document": "16306388", "end": 119, "section": "title"}, {"text": "We pursued one such approach and describe the training and implementation of GC-donor splice site models for Arabidopsis and rice, with the goal of exploring whether specific modeling of non-canonical introns can enhance gene structure prediction accuracy.", "begin": 704, "document": "16306388", "end": 960, "section": "abstract"}, {"text": "Prediction of splice sites with dependency graphs and their expanded bayesian networks.", "begin": 0, "document": "15374869", "end": 87, "section": "title"}, {"text": "Gene structure prediction from consensus spliced alignment of multiple ESTs matching the same genomic locus.", "begin": 0, "document": "14764557", "end": 108, "section": "title"}, {"text": "We have developed a software tool, Transcript Assembly Program (TAP), to delineate gene structures using genomically aligned EST sequences.", "begin": 352, "document": "11337482", "end": 491, "section": "abstract"}, {"text": "GeneBuilder: interactive in silico prediction of gene structure.", "begin": 0, "document": "10487869", "end": 64, "section": "title"}, {"text": "The computer program SeqHelp organizes information from database searches, gene structure prediction, and other information to generate multiply aligned, hypertext-linked reports to allow for fast analysis of molecular sequences.", "begin": 138, "document": "9521933", "end": 367, "section": "abstract"}, {"text": "Identification of human gene structure using linear discriminant functions and dynamic programming.", "begin": 0, "document": "7584460", "end": 99, "section": "title"}, {"text": "Development of advanced technique to identify gene structure is one of the main challenges of the Human Genome Project.", "begin": 0, "document": "7584460", "end": 119, "section": "abstract"}, {"text": "A gene structure prediction system FGENE has been developed based on the exon recognition functions.", "begin": 369, "document": "7584460", "end": 469, "section": "abstract"}, {"text": "Analysis of uncharacterized human sequences based on our methods for splice site (HSPL, RNASPL), internal exons (HEXON), all type of exons (FEXH) and human (FGENEH) and bacterial (CDSB) gene structure prediction and recognition of human and bacterial sequences (HBR) (to test a library for E. coli contamination) is available through the University of Houston, Weizmann Institute of Science network server and a WWW page of the Human Genome Center at Baylor College of Medicine.", "begin": 1277, "document": "7584460", "end": 1755, "section": "abstract"}, {"text": "In the bioinformatics field, many computer algorithmic and data mining technologies have been developed for gene prediction, protein-protein interaction analysis, sequence analysis, and protein folding predictions, to name a few.", "begin": 0, "document": "20726803", "end": 229, "section": "abstract"}]}, {"documents": ["18277927", "18039618", "14993139", "8199011", "2641165", "3889351"], "answer": [["Enterovirus"], ["Adenovirus"], ["Coxsackie B virus"]], "id": "517a8c918ed59a060a000043", "snippets": [{"text": "Coxsackie B viruses (types 1 to 5) are the most frequent reported cause of acute viral myocarditis.", "begin": 0, "document": "3889351", "end": 99, "section": "abstract"}]}, {"documents": ["20034334", "20207278", "19214293", "17622371", "17574515", "12055771", "11477833"], "answer": [["antiinflammatory steroid and non steroid drugs"], ["inotropic agents"], ["mechanical support"]], "id": "517a8cc68ed59a060a000044", "snippets": [{"text": "ibuprofen 400 mg twice a day as therapy", "begin": 2394, "document": "20034334", "end": 2433, "section": "abstract"}, {"text": "Acute fulminant myocarditis commonly manifests itself as severe, rapidly progressive hemodynamic deterioration and circulatory collapse that may be resistant to high doses of inotropic agents and steroids and to mechanical support by intra-aortic balloon pump", "begin": 0, "document": "17622371", "end": 259, "section": "abstract"}, {"text": "the TandemHeart percutaneous ventricular assist device, can enable patients to recover in a few days.", "begin": 478, "document": "17622371", "end": 579, "section": "abstract"}, {"text": "he authors report a typical case of fulminating myocarditis with electromechanical dissociation, which recovered completely after a period of circulatory assistance.", "begin": 477, "document": "12055771", "end": 642, "section": "abstract"}]}, {"documents": ["23532677", "20228172", "19832729", "19629520", "19171649", "18622044", "17317766", "16155104", "15831522", "15808842", "15687816", "14704232", "11577024"], "answer": [["\u03b2-myosin heavy chain"], ["alpha-myosin heavy chain"], ["SR(Ca)ATPase"], ["phospholamban"], ["nucleotide-gated potassium channel 2"], ["KCNE1"], ["HCN2"], ["HCN4"], ["KCND2"], ["KCND3"], ["KCNA4"]], "id": "515c4f05298dcd4e51000006", "snippets": [{"text": "A group of mice was treated with debutyl-dronedarone (DBD), a selective TR\u03b11 inhibitor (AMI-DBD)", "begin": 547, "document": "23532677", "end": 643, "section": "abstract"}, {"text": "Furthermore, AMI resulted in \u03b2-myosin heavy chain overexpression and reduction in the ratio of SR(Ca)ATPase to phospholamban (PLB). The latter further declined in AMI-DBD mainly due to increased expression of PLB", "begin": 1223, "document": "23532677", "end": 1435, "section": "abstract"}, {"text": "We identified that mice expressing the mutant TRalpha1R384C (TRalpha1+m mice) displayed a mild bradycardia, which becomes more pronounced during night activity or on stress and is accompanied by a reduced expression of nucleotide-gated potassium channel 2 mRNA in the heart", "begin": 501, "document": "20228172", "end": 774, "section": "abstract"}, {"text": "Consistently, TR alpha 1-infected myocytes exhibited larger I(f) current densities along with increased HCN2 and HCN4 mRNA and protein levels.", "begin": 965, "document": "19629520", "end": 1107, "section": "abstract"}, {"text": "T3 stimulation enhanced KCND2 and KCND3 expression and decreased KCNA4 transcription, while KCNIP2 remained unaffected.", "begin": 530, "document": "19171649", "end": 649, "section": "abstract"}, {"text": "TRalpha1 increased I(to), while TRbeta1 significantly reduced I(to) in size, which was associated with TRalpha1-mediated increase and TRbeta1-mediated reduction of KCND2/3 transcription.", "begin": 824, "document": "19171649", "end": 1010, "section": "abstract"}, {"text": "While the TRalpha1 aporeceptor enhanced KCND3 transcription, the TRbeta1 aporeceptor suppressed KCND3 expression, with both effects exhibiting ligand-dependent amplification upon T3 stimulation.", "begin": 1280, "document": "19171649", "end": 1474, "section": "abstract"}, {"text": "PE, in the absence of T3, resulted in 5.0 fold increase in TRalpha1 expression in nucleus and 2.0 fold decrease in TRalpha1 expression in cytosol, P<0.05. As a result, a fetal pattern of myosin isoform expression with marked expression of beta-MHC was observed in PE treated vs the untreated cells, P<0.05.", "begin": 791, "document": "18622044", "end": 1097, "section": "abstract"}, {"text": "PKC alpha overexpression in cardiomyocytes caused marked repression of triiodothyronine (T3)-responsive genes, alpha-myosin heavy chain, and the sarcoplasmic reticulum calcium-activated adenosinetriphosphatase SERCA2. Treatment with T3 for 4 h resulted in significant reductions of PKC alpha in nuclear and cytosolic compartments, and decreased TR alpha1 mRNA and protein, with normalization of phenotype.", "begin": 1597, "document": "16155104", "end": 2002, "section": "abstract"}, {"text": "The mechanism of TH and TRalpha1-specific hypertrophy is novel for a nuclear hormone receptor and involves the transforming growth factor beta-activated kinase (TAK1) and p38", "begin": 444, "document": "15831522", "end": 618, "section": "abstract"}, {"text": "Excised TRalpha(1)+/m hearts showed an increased expression of phospholamban (PLB)", "begin": 1301, "document": "15808842", "end": 1383, "section": "abstract"}, {"text": "administration of dronedarone, an amiodarone-like compound that has been shown to preferentially antagonize thyroid hormone binding to thyroid hormone receptor alpha1 (TRalpha1),", "begin": 112, "document": "15687816", "end": 290, "section": "abstract"}, {"text": "lpha-Myosin heavy chain (alpha-MHC) decreased in DRON while beta-myosin heavy chain (beta-MHC) and sarcoplasmic reticulum Ca2+ adenosine triphosphatase (ATPase) expression (SERCA) was similar to CONT.", "begin": 776, "document": "15687816", "end": 976, "section": "abstract"}, {"text": "The activity of TR DNA binding to the transcriptional regulatory region in the alpha-MHC and SR Ca(2+)-ATPase genes and the mRNA and protein expression of alpha-MHC and SR Ca(2+)-ATPase in the heart and plasma 3,3'-triiodothyronine and thyroxine levels were altered in association with changes in the myocardial TR protein levels.", "begin": 1094, "document": "14704232", "end": 1424, "section": "abstract"}, {"text": "addition, TR cotransfection and treatment with the TRbeta1-selective agonist GC-1 suggested different functional coupling of the TR isoforms, TRbeta1 to transcription of beta-MyHC, SERCA, and TRbeta1, and TRalpha1 to alpha-MyHC transcription and increased myocyte size", "begin": 1173, "document": "11577024", "end": 1441, "section": "abstract"}, {"text": "OBJECTIVE: The reduced heart rate and prolonged QT(end) duration in mice deficient in thyroid hormone receptor (TR) alpha1 may involve aberrant expression of the K(+) channel alpha-subunit KCNQ1 and its regulatory beta-subunit KCNE1.", "begin": 0, "document": "19832729", "end": 233, "section": "abstract"}, {"text": "OBJECTIVE: The reduced heart rate and prolonged QT(end) duration in mice deficient in thyroid hormone receptor (TR) alpha1 may involve aberrant expression of the K(+) channel alpha-subunit KCNQ1 and its regulatory beta-subunit KCNE1.", "begin": 0, "document": "19832729", "end": 233, "section": "abstract"}]}, {"documents": ["21149577", "19629520", "19171649", "17317766", "11577024", "9927321"], "answer": [["\u03b2-MHC"], ["HCN4"], ["KCND2/3"], ["SERCA"], ["TRbeta1"], ["alpha-MHC"]], "id": "515c4f1f298dcd4e51000007", "snippets": [{"text": "we identified thyroid hormone receptor \u03b21 (TR\u03b21), which negatively regulates \u03b2-MHC transcription, as a target of miR-27a", "begin": 959, "document": "21149577", "end": 1079, "section": "abstract"}, {"text": "HCN2 gene expression was not significantly affected by TR beta 1. TR beta 1 exclusively suppressed HCN4 transcription.", "begin": 1121, "document": "19629520", "end": 1239, "section": "abstract"}, {"text": "TRalpha1 increased I(to), while TRbeta1 significantly reduced I(to) in size, which was associated with TRalpha1-mediated increase and TRbeta1-mediated reduction of KCND2/3 transcription.", "begin": 824, "document": "19171649", "end": 1010, "section": "abstract"}, {"text": "he TRbeta1 aporeceptor suppressed KCND3 expression", "begin": 1342, "document": "19171649", "end": 1392, "section": "abstract"}, {"text": "increasing TR expression in the hypertrophied heart is associated with an improvement in contractile function and increased SERCA expression.", "begin": 1651, "document": "17317766", "end": 1792, "section": "abstract"}, {"text": "TRbeta1 to transcription of beta-MyHC, SERCA, and TRbeta1,", "begin": 1315, "document": "11577024", "end": 1373, "section": "abstract"}, {"text": "Our study investigates both the regulation of cardiac-specific genes and contractile behavior of the heart in the presence of a mutant thyroid hormone receptor beta1 (T3Rbeta1-delta337T) derived from the S kindred", "begin": 75, "document": "9927321", "end": 288, "section": "abstract"}, {"text": "The messenger RNA levels for MHC alpha and SERCA2 were markedly down-regulated, MHC beta messenger RNA was up-regulated. Although T3 levels were normal in these animals, this pattern of cardiac gene expression mimics a hypothyroid phenotype.", "begin": 698, "document": "9927321", "end": 939, "section": "abstract"}]}, {"documents": ["22934707", "22493428", "22421047", "22378194", "22315219", "20962578", "20581802", "20578184", "19544407", "19415763", "19139263", "16518401", "14728807"], "answer": [["cell proliferation"], ["pluripotency"], ["cell fate determination"], ["G1 to S transition"], ["germ cell migration"], ["tumour development"]], "id": "515d1ff7298dcd4e51000009", "snippets": [{"text": "critical for the regulation of cancer stem cells.", "begin": 487, "document": "22934707", "end": 536, "section": "abstract"}, {"text": "the effect of FAK and Nanog cross-regulation on cancer cell morphology, invasion, and growth that plays a significant role in carcinogenesis", "begin": 1525, "document": "22493428", "end": 1665, "section": "abstract"}, {"text": "Nanog-like regulates endoderm formation", "begin": 0, "document": "22421047", "end": 39, "section": "title"}, {"text": "In mammalian embryonic stem cells, the acquisition of pluripotency is dependent on Nanog", "begin": 0, "document": "22421047", "end": 88, "section": "abstract"}, {"text": "we identified a zebrafish Nanog ortholog and found that its\u00a0knockdown impaired endoderm formation", "begin": 241, "document": "22421047", "end": 338, "section": "abstract"}, {"text": "establishes a role for Nanog-like in regulating the formation of the extraembryonic tissue required for endoderm induction", "begin": 925, "document": "22421047", "end": 1047, "section": "abstract"}, {"text": "Nanog regulates molecules involved in stemness and cell cycle-signaling pathway for maintenance of pluripotency", "begin": 0, "document": "22378194", "end": 111, "section": "title"}, {"text": "Nanog, a key transcription factor in the maintenance of pluripotency of embryonic stem (ES) and embryonal carcinoma (EC) cells", "begin": 44, "document": "22378194", "end": 170, "section": "abstract"}, {"text": "Nanog, a positive regulator of ESC proliferation and G1/S transition", "begin": 947, "document": "22315219", "end": 1015, "section": "abstract"}, {"text": "Nanog is a stem cell transcription factor required for self-renewal and for maintaining pluripotency", "begin": 0, "document": "20962578", "end": 100, "section": "abstract"}, {"text": "NANOG regulates glioma stem cells", "begin": 0, "document": "20581802", "end": 33, "section": "title"}, {"text": "We find that NANOG modulates gliomasphere clonogenicity, CD133(+) stem cell cell behavior and proliferation", "begin": 519, "document": "20581802", "end": 626, "section": "abstract"}, {"text": "NANOG is essential for GBM tumourigenicity", "begin": 789, "document": "20581802", "end": 831, "section": "abstract"}, {"text": "Nanog regulates primordial germ cell migration", "begin": 0, "document": "20578184", "end": 46, "section": "title"}, {"text": "Nanog mediates PGC migration by regulating Cxcr4b expression", "begin": 1274, "document": "20578184", "end": 1334, "section": "abstract"}, {"text": "Nanog regulates proliferation during early fish development.", "begin": 0, "document": "19544407", "end": 60, "section": "title"}, {"text": "Nanog is necessary for S-phase transition and proliferation in the developing embryo", "begin": 693, "document": "19544407", "end": 777, "section": "abstract"}, {"text": "our results demonstrate that NANOG, a cell-fate regulatory molecule known to be important for ESC self-renewal, also plays a novel role in tumor development", "begin": 1137, "document": "19415763", "end": 1293, "section": "abstract"}, {"text": "the self-renewal gene NANOG regulates human tumor development", "begin": 25, "document": "19415763", "end": 86, "section": "title"}, {"text": "A role for NANOG in G1 to S transition in human embryonic stem cells", "begin": 0, "document": "19139263", "end": 68, "section": "title"}, {"text": "The emerging picture is one in which Oct4 and Nanog control a cascade of pathways that are intricately connected to govern pluripotency, self-renewal, genome surveillance and cell fate determination", "begin": 936, "document": "16518401", "end": 1134, "section": "abstract"}, {"text": "the pluripotency sustaining factor nanog", "begin": 58, "document": "14728807", "end": 98, "section": "title"}]}, {"documents": ["22879880", "10364522"], "answer": ["9"], "id": "515db083298dcd4e51000012", "snippets": [{"text": "Both children are heterozygous for a deletion that eliminates at least eight (HOXD3-HOXD13) of the nine genes in the HOXD cluster", "begin": 699, "document": "10364522", "end": 828, "section": "abstract"}]}, {"documents": ["23404595", "12108800", "20429947", "18341545", "16675030"], "answer": [["Cognitive-behavioral treatment (CBT)", "CBT", "group treatment", "manualised cognitive-behavioural therapy, FRIENDS"], ["Sertraline", "SSRI"]], "id": "515db20e298dcd4e51000014", "snippets": [{"text": "The present study compares an individual versus a group format in the delivery of manualised cognitive-behavioural therapy (FRIENDS) for children with anxiety disorders. Clinically referred children (aged 8 to 12) diagnosed with Separation Anxiety Disorder (n = 52), Generalised Anxiety Disorder (n = 37), Social Phobia (n = 22) or Specific Phobia (n = 16) were randomly assigned to individual (n = 65) or group (n = 62) treatment.", "begin": 12, "document": "18341545", "end": 443, "section": "abstract"}]}, {"documents": ["23038750", "22162939", "21777702", "21682553", "21647425", "18227490", "16479100", "15830173", "22787067", "22080542", "21205325", "20687931", "20334446", "19339045", "15670547"], "answer": [["UMPIRE"], ["CRUCIAL"], ["AVALON"], ["ASCOT"], ["GEMINI"], ["GEMINI-AALA"], ["JEWEL 1"], ["JEWEL 2"], ["CAPABLE54"], ["CUSP"], ["TOGETHER"], ["TIPS"], ["TIPS-2"], ["IMPACT"]], "id": "515de572298dcd4e51000021", "snippets": [{"text": "Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.", "begin": 0, "document": "23038750", "end": 197, "section": "title"}, {"text": "The 'Use of a Multidrug Pill In Reducing cardiovascular Events' (UMPIRE) trial assesses whether a polypill strategy (by combining aspirin, a statin and two blood pressure lowering agents) would improve adherence to guideline-indicated therapies and would lower both blood pressure and cholesterol, in people with established cardiovascular disease.", "begin": 404, "document": "23038750", "end": 752, "section": "abstract"}, {"text": "IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care", "begin": 0, "document": "21777702", "end": 124, "section": "title"}, {"text": "An international randomised placebo-controlled trial of a four-component combination pill (\"polypill\") in people with raised cardiovascular risk", "begin": 0, "document": "21647425", "end": 144, "section": "title"}, {"text": "Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.", "begin": 0, "document": "22787067", "end": 240, "section": "title"}, {"text": "Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk.", "begin": 0, "document": "20687931", "end": 228, "section": "title"}, {"text": "Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.", "begin": 0, "document": "19339045", "end": 157, "section": "title"}]}, {"documents": ["22929880", "22789835", "22363762", "21464883", "21073206", "20726677", "20099379", "20032453", "19584824", "22793867", "17033447", "17024483", "16444286", "15671523", "12401900", "11831069"], "answer": [["Chronic myelogenous leukemia (CML)"], ["Gastrointestinal stromal tumor (GIST)"], ["Dermatofibrosarcoma protuberans (DFSP)"]], "id": "515de748298dcd4e51000023", "snippets": [{"text": "Dermatofibrosarcoma protuberans (DFSP) is an uncommon cutaneous neoplasm", "begin": 0, "document": "21464883", "end": 72, "section": "abstract"}, {"text": "Moreover, even when surgery is utilized, there are cases where positive margins remain, in which case imatinib would be an option, often in combination with surgery. Imatinib can decrease tumor size preoperatively and help to improve postsurgical aesthetic appearance and minimize functional impairment.", "begin": 516, "document": "21464883", "end": 819, "section": "abstract"}, {"text": "Imatinib mesylate, an orally administered kinase inhibitor that targets the Kit (CD117) protein, currently has 10 approved indications including treatment of chronic myelogenous leukemia and metastatic gastrointestinal stromal tumors (GIST). Treatment with adjuvant imatinib following surgical resection of localized Kit-positive GIST, the most recent FDA-approved indication (December 2008), has been shown to significantly improve recurrence-free survival (RFS) compared with surgical resection alone", "begin": 12, "document": "20726677", "end": 514, "section": "abstract"}, {"text": "Currently, there are no clinical recommendations regarding how to incorporate imatinib drug plasma monitoring in patients with either chronic myeloid leukemia or gastrointestinal stromal tumors, indications for which imatinib is approved.", "begin": 458, "document": "20099379", "end": 696, "section": "abstract"}, {"text": "The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications.", "begin": 759, "document": "19584824", "end": 872, "section": "abstract"}, {"text": "More micro-GIST are discovered with the development of investigations, rising the question of wait and see policy for some of them. In locally advanced inoperable patients and metastatic patients, Imatinib is the standard treatment.", "begin": 249, "document": "22793867", "end": 481, "section": "abstract"}, {"text": "The introduction of alternative therapies has challenged well-established indications such as imatinib for chronic myeloid leukaemia.", "begin": 742, "document": "16444286", "end": 875, "section": "abstract"}, {"text": "Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in (a) chronic phase after failure of IFN-alpha therapy, (b) accelerated phase, and (c) blast crisis.", "begin": 0, "document": "15671523", "end": 284, "section": "abstract"}, {"text": "Gleevec (imatinib mesylate), a highly promising new drug for the treatment of chronic myelogenous leukemia in blast crisis, in accelerated phase, and in chronic phase after interferon failure or intolerance, received orphan drug status from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development on January 31, 2001, and accelerated approval from the FDA for the above three indications on May 10, 2001.", "begin": 0, "document": "12401900", "end": 430, "section": "abstract"}]}, {"documents": ["23118256", "22964266", "22934167", "22735897", "22588377", "22299802", "21571763", "20694508", "18437549", "17171539"], "answer": [["Mindfulness Based Therapy (MBT)"], ["Multimodal Anxiety and Social Skills Intervention (MASSI) program"], ["modified version of the Coping Cat program", "(cognitive-behavioral therapy; CBT"], ["Family cognitive-behavioral therapy"], ["Individual cognitive-behavioral therapy"], ["Conflict management for couples", "even when conflict and family distress is low"], ["Sertraline"]], "id": "515de993298dcd4e51000024", "snippets": [{"text": "Mindfulness-based therapy (MBT) has been found effective in reducing anxiety and depression symptoms, however research in autism is limited.", "begin": 129, "document": "22964266", "end": 269, "section": "abstract"}, {"text": "Therefore, we examined the effects of a modified MBT protocol (MBT-AS) in high-functioning adults with ASD.", "begin": 270, "document": "22964266", "end": 377, "section": "abstract"}, {"text": "the present study is the first controlled trial to demonstrate that adults with ASD can benefit from MBT-AS.", "begin": 715, "document": "22964266", "end": 823, "section": "abstract"}, {"text": "This pilot, randomized controlled trial evaluated the feasibility and preliminary outcomes of the Multimodal Anxiety and Social Skills Intervention (MASSI) program in a sample of 30 adolescents with ASD and anxiety symptoms of moderate or greater severity.", "begin": 167, "document": "22735897", "end": 423, "section": "abstract"}, {"text": "These findings suggest MASSI is a feasible treatment program and further evaluation is warranted.", "begin": 736, "document": "22735897", "end": 833, "section": "abstract"}, {"text": "The purpose of this pilot study was to evaluate whether a modified version of the Coping Cat program could be effective in reducing anxiety in children with autism spectrum disorder (ASD).", "begin": 0, "document": "22588377", "end": 188, "section": "abstract"}, {"text": "the Coping Cat program (cognitive-behavioral therapy; CBT)", "begin": 315, "document": "22588377", "end": 373, "section": "abstract"}, {"text": "Results provide preliminary evidence that a modified version of the Coping Cat program may be a feasible and effective program for reducing clinically significant levels of anxiety in children with high-functioning ASD.", "begin": 572, "document": "22588377", "end": 791, "section": "abstract"}, {"text": "The intent of this article is to explore the efficacy of both the literal and concrete externalization aspects within narrative therapy, and the implementation of interactive metaphors as a combined psychotherapeutic approach for decreasing anxiety with people who present with high-functioning autism.", "begin": 11, "document": "22299802", "end": 313, "section": "abstract"}, {"text": "This paper reports a case series of children and adolescents with ASD and an anxiety disorder who were treated with a standard cognitive behaviour therapy (CBT) rationale adapted to take account of the neuropsychological features of ASD.", "begin": 752, "document": "21571763", "end": 989, "section": "abstract"}, {"text": "children with moderate autistic symptomology (per SRS-P) were significantly more likely to improve from family CBT (FCBT) than individual CBT (ICBT; OR\u00a0=\u00a08.67)", "begin": 249, "document": "20694508", "end": 408, "section": "abstract"}, {"text": "Though both treatments reduced anxiety, FCBT outperformed ICBT for children with moderate ASD symptoms, a benefit potentially linked to more at-home exposures and greater child involvement in FCBT.", "begin": 653, "document": "20694508", "end": 850, "section": "abstract"}, {"text": "A structural model-building approach was used to test the extent to which family and peer variables directly or indirectly affected ASD via child anxiety/depression.", "begin": 412, "document": "18437549", "end": 577, "section": "abstract"}, {"text": "The key findings were that anxiety/depression and ASD symptomatology were significantly related, and family conflict was more predictive of ASD symptomatology than positive family/peer influences. The results point to the utility of expanding interventions to include conflict management for couples, even when conflict and family distress is low.", "begin": 950, "document": "18437549", "end": 1297, "section": "abstract"}, {"text": "A family-based, cognitive behavioural treatment for anxiety in 47 children with comorbid anxiety disorders and High Functioning Autism Spectrum Disorder (HFA) was evaluated.", "begin": 0, "document": "17171539", "end": 173, "section": "abstract"}, {"text": "Following treatment, 71.4% of the treated participants no longer fulfilled diagnostic criteria for an anxiety disorder. Comparisons between the two conditions indicated significant reductions in anxiety symptoms as measured by self-report, parent report and teacher report", "begin": 402, "document": "17171539", "end": 674, "section": "abstract"}]}, {"documents": ["22607127", "16003132", "12907332", "11007230", "10547242", "9585670"], "answer": [["Reflux esophagitis"], ["Achalasia"], ["chronic gastritis"], ["chronic duodenitis"], ["inflammation of the small bowel and colorectum"], ["Ileo-colonic lymphoid nodular hyperplasia (LNH)"]], "id": "515deafd298dcd4e51000025", "snippets": [{"text": "Autism and esophageal achalasia in childhood: a possible correlation?", "begin": 0, "document": "22607127", "end": 69, "section": "title"}, {"text": "In the last case, a 15-year-old male underwent barium swallow and endoscopy that confirmed achalasia.", "begin": 801, "document": "22607127", "end": 902, "section": "abstract"}, {"text": "Intestinal mucosal pathology, characterized by ileo-colonic lymphoid nodular hyperplasia (LNH) and mild acute and chronic inflammation of the colorectum, small bowel and stomach, has been reported in children with autistic spectrum disorder (ASD)", "begin": 12, "document": "16003132", "end": 258, "section": "abstract"}, {"text": "A relationship between autism and gastrointestinal (GI) immune dysregulation has been postulated based on incidence of GI complaints as well as macroscopically observed lymphonodular hyperplasia and microscopically determined enterocolitis in pediatric patients with autism.", "begin": 11, "document": "12907332", "end": 285, "section": "abstract"}, {"text": "This study describes some of the endoscopic and pathological characteristics in a group of children with developmental disorders (affected children) that are associated with behavioral regression and bowel symptoms, and compares them with pediatric controls. METHODS: Ileocolonoscopy and biopsy were performed on 60 affected children (median age 6 yr, range 3-16; 53 male). Developmental diagnoses were autism (50 patients), Asperger's syndrome (five), disintegrative disorder (two), attention deficit hyperactivity disorder (ADHD) (one), schizophrenia (one), and dyslexia (one).", "begin": 173, "document": "11007230", "end": 752, "section": "abstract"}, {"text": "Ileal LNH was present in 54 of 58 (93%) affected children and in five of 35 (14.3%) controls (p < 0.001). Colonic LNH was present in 18 of 60 (30%) affected children and in two of 37 (5.4%) controls (p < 0.01). Histologically, reactive follicular hyperplasia was present in 46 of 52 (88.5%) ileal biopsies from affected children and in four of 14 (29%) with UC, but not in non-IBD controls (p < 0.01). Active ileitis was present in four of 51 (8%) affected children but not in controls. Chronic colitis was identified in 53 of 60 (88%) affected children compared with one of 22 (4.5%) controls and in 20 of 20 (100%) with UC", "begin": 1265, "document": "11007230", "end": 1889, "section": "abstract"}, {"text": "Histologic examination in these 36 children revealed grade I or II reflux esophagitis in 25 (69.4%), chronic gastritis in 15, and chronic duodenitis in 24. The number of Paneth's cells in the duodenal crypts was significantly elevated in autistic children compared with non-autistic control subjects. Low intestinal carbohydrate digestive enzyme activity was reported in 21 children (58.3%), although there was no abnormality found in pancreatic function. Seventy-five percent of the autistic children (27/36) had an increased pancreatico-biliary fluid output after intravenous secretin administration. Nineteen of the 21 patients with diarrhea had significantly higher fluid output than those without diarrhea.", "begin": 524, "document": "10547242", "end": 1235, "section": "abstract"}, {"text": "three children with autistic spectrum disorders who underwent upper gastrointestinal endoscopy and intravenous administration of secretin to stimulate pancreaticobiliary secretion. All three had an increased pancreaticobiliary secretory response when compared with nonautistic patients (", "begin": 10, "document": "9585670", "end": 297, "section": "abstract"}]}, {"documents": ["22108462", "20477251", "11498704"], "answer": ["Reduction of number of exacerbations"], "id": "515df063298dcd4e51000029", "snippets": [{"text": "Yet recent well-designed studies have demonstrated that prophylactic antibiotic use is of significant benefit to patients prone to developing infections. Study patients suffered from recurrent urinary tract infections, COPD or were mechanically ventilated in intensive care units. In the first 2 populations, use of antibiotics was associated with an increase in carriage of antibiotic-resistant bacteria, but in intensive care patients the opposite was documented", "begin": 193, "document": "22108462", "end": 657, "section": "abstract"}, {"text": "Guidelines do not recommend the use of prophylactic antibiotics in COPD but there is preliminary evidence to suggest that they may reduce the number of exacerbations.", "begin": 1293, "document": "20477251", "end": 1459, "section": "abstract"}, {"text": "A short prophylactic treatment course with azithromycin is a good alternative in the management of patients with severe, advanced COPD, and could lead to an improvement in social and healthcare costs", "begin": 585, "document": "11498704", "end": 784, "section": "abstract"}]}, {"documents": ["23523158", "23402260", "23380649", "23354606", "23301864", "23202144", "23034121", "22951366", "22687168", "22648477", "22640501", "22155803", "22088659", "21876515", "21856578", "21839654", "21838669", "21808631", "21803799", "21755134", "21679067", "21136256", "21107001", "20373339", "20351675", "21687341", "19958985"], "answer": ["LIberation therapy"], "id": "515df199298dcd4e5100002a", "snippets": [{"text": "patients with relapsing-remitting (RR) multiple sclerosis (MS) receiving standard medical treatment who had been diagnosed with chronic cerebrospinal venous insufficiency (CCSVI) and underwent percutaneous transluminal angioplasty (PTA)", "begin": 130, "document": "23523158", "end": 366, "section": "abstract"}, {"text": "Although it is debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients undergo endovascular treatment (ET) of CCSVI", "begin": 0, "document": "23380649", "end": 194, "section": "abstract"}, {"text": "Endovascular treatment of CCSVI in patients with multiple sclerosis", "begin": 0, "document": "23354606", "end": 67, "section": "title"}, {"text": "Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI.", "begin": 0, "document": "23354606", "end": 203, "section": "abstract"}, {"text": "Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: possible improvement by venous angioplasty. Results of a prospective study.", "begin": 0, "document": "23202144", "end": 179, "section": "title"}, {"text": "venous angioplasty of the extracranial veins for multiple sclerosis.", "begin": 23, "document": "23034121", "end": 91, "section": "title"}, {"text": "Despite a wide variability among studies, it has been found to be associated with MS. Data from a few small case series suggest possible improvement of the clinical course and quality of life by performing percutaneous balloon angioplasty (PTA) of the stenotic veins.", "begin": 379, "document": "23034121", "end": 646, "section": "abstract"}, {"text": "Clinical improvement after extracranial venoplasty in multiple sclerosis", "begin": 0, "document": "22951366", "end": 72, "section": "title"}, {"text": "Twenty-nine patients with clinically definite relapsing-remitting MS underwent percutaneous transluminal angioplasty for CCSVI, outside a clinical relapse.", "begin": 204, "document": "22687168", "end": 359, "section": "abstract"}, {"text": "The European Society of Neurosonology and Cerebral Hemodynamics (ESNCH) has considerable concerns regarding the accuracy of the proposed criteria for CCSVI in MS. Therefore, any potentially harmful interventional treatment such as transluminal angioplasty and/or stenting should be strongly discouraged.", "begin": 1192, "document": "22648477", "end": 1495, "section": "abstract"}, {"text": "Catheter venography and endovascular treatment of chronic cerebrospinal venous insufficiency.", "begin": 0, "document": "22640501", "end": 93, "section": "title"}, {"text": "The work of Dr. Zamboni, et al, who reported that treating the venous stenoses causing CCSVI with angioplasty resulting in significant improvement in the symptoms and quality of life of patients with MS (2", "begin": 898, "document": "22640501", "end": 1103, "section": "abstract"}, {"text": "Endovascular treatment of patients with chronic cerebrospinal venous insufficiency and multiple sclerosis", "begin": 0, "document": "22155803", "end": 105, "section": "title"}, {"text": "Endovascular treatment (percutaneous transluminal angioplasty (PTA) with or without stenting) of CCSVI was reported to be feasible with a minor complication rate", "begin": 478, "document": "22155803", "end": 639, "section": "abstract"}, {"text": "Safety of endovascular treatment of chronic cerebrospinal venous insufficiency:", "begin": 0, "document": "22088659", "end": 79, "section": "title"}, {"text": "An endovascular treatment of Chronic Cerebro-Spinal Venous Insufficiency in multiple sclerosis patients", "begin": 0, "document": "21876515", "end": 103, "section": "title"}, {"text": "Chronic cerebrospinal venous insufficiency (CCSVI) is associated with multiple sclerosis (MS). The objective of the study was to see if percutaneous transluminal angioplasty (PTA) of duplex-detected lesions, of the internal jugular and/or azygous veins, was safe,", "begin": 11, "document": "21839654", "end": 274, "section": "abstract"}, {"text": "CCSVI theory has generated a scientific and mass media debate with a great hope for the miracle of a new possible endovascular treatment of MS (\"liberation procedure\").", "begin": 434, "document": "21838669", "end": 602, "section": "abstract"}, {"text": "Endovascular therapy for chronic cerebrospinal venous insufficiency in multiple sclerosis.", "begin": 0, "document": "21808631", "end": 90, "section": "title"}, {"text": "Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency.", "begin": 0, "document": "21803799", "end": 91, "section": "title"}, {"text": "The treatment based on the CCSVI theory has appealingly been called \"liberation treatment\"", "begin": 900, "document": "21755134", "end": 990, "section": "abstract"}, {"text": "A potential shift in the treatment paradigm of MS involving endovascular balloon angioplasty or venous stent placement has been proposed as well as conducted in small patient series", "begin": 341, "document": "20373339", "end": 522, "section": "abstract"}, {"text": "She underwent percutaneous balloon angioplasty of the associated chronic cerebrospinal venous insufficiency (CCSVI)", "begin": 730, "document": "20351675", "end": 845, "section": "abstract"}, {"text": "Endovascular treatment for multiple sclerosis:", "begin": 0, "document": "21687341", "end": 46, "section": "title"}, {"text": "A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency", "begin": 0, "document": "19958985", "end": 102, "section": "title"}]}, {"documents": ["23420787", "23397482", "23298766", "22956279", "22925689", "22752264", "22480369", "21324422", "20461508", "17697977", "17451943", "12146646", "1366363"], "answer": [["Aspergillus terreus"], ["Aspergillus niger"], ["Ustilago maydis"]], "id": "515ffc2b298dcd4e51000035", "snippets": [{"text": "continuous itaconic acid production from sucrose with Aspergillus terreus", "begin": 4, "document": "1366363", "end": 77, "section": "abstract"}, {"text": "A potent itaconic acid producing strain, Aspergillus terreus SKR10, was isolated from horticulture waste", "begin": 0, "document": "12146646", "end": 104, "section": "abstract"}, {"text": "Two high itaconic acid yielding mutants, N45 and UNCS1 were obtained by gradient plating", "begin": 526, "document": "12146646", "end": 614, "section": "abstract"}, {"text": "Itaconic acid production using sago starch hydrolysate by Aspergillus terreus TN484-M1.", "begin": 0, "document": "17451943", "end": 87, "section": "title"}, {"text": "production of itaconic acid and lovastatin by Aspergillus terreus ATCC 20542", "begin": 34, "document": "17697977", "end": 110, "section": "title"}, {"text": "Fermentation products of Aspergillus terreus ATCC 20542 (a parent strain for lovastatin production) were collected, and the coexistence of itaconic acid (IA) with lovastatin was confirmed in this study", "begin": 0, "document": "17697977", "end": 201, "section": "abstract"}, {"text": "Enhancing itaconic acid production by Aspergillus terreus", "begin": 0, "document": "20461508", "end": 57, "section": "title"}, {"text": "Aspergillus terreus is successfully used for industrial production of itaconic acid", "begin": 0, "document": "20461508", "end": 83, "section": "abstract"}, {"text": "From a number of different Aspergillus terreus controlled batch fermentations, those cultures with the largest difference in itaconic acid titer and productivity were selected for mRNA isolation", "begin": 250, "document": "21324422", "end": 444, "section": "abstract"}, {"text": "a systematic process optimization was performed with an own isolated strain of Aspergillus terreus", "begin": 237, "document": "22752264", "end": 335, "section": "abstract"}, {"text": "Enhanced itaconic acid production in Aspergillus niger", "begin": 0, "document": "22925689", "end": 54, "section": "title"}, {"text": "Cells of Aspergillus terreus, free and immobilized in polyurethane foam, were employed in itaconic acid fermentation processes on glycerol-based media.", "begin": 0, "document": "22956279", "end": 151, "section": "abstract"}, {"text": "current biotechnological production processes with the fungus Aspergillus terreus has to be improved", "begin": 206, "document": "23298766", "end": 306, "section": "abstract"}, {"text": "Reduced by-product formation and modified oxygen availability improve itaconic acid production in Aspergillus niger", "begin": 0, "document": "23397482", "end": 115, "section": "title"}, {"text": "Previously, it was shown that expression of the cis-aconitate decarboxylase gene (cadA) from Aspergillus terreus converted A. niger into an itaconic acid producer", "begin": 141, "document": "23397482", "end": 303, "section": "abstract"}, {"text": "Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different host organism.", "begin": 768, "document": "23420787", "end": 926, "section": "abstract"}, {"text": "Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media", "begin": 247, "document": "23420787", "end": 416, "section": "abstract"}]}, {"documents": ["23423380", "23264878", "23175609", "23161677", "22673230", "22303960", "22065584", "18426915", "16652154", "15138591"], "answer": [["Amyotrophic lateral sclerosis (ALS)"], ["frontotemporal dementia (FTD)"], ["Alzheimer's disease"], ["fibrosis"], ["acute myeloid leukemia"]], "id": "51600ab3298dcd4e51000036", "snippets": [{"text": "Large expansions of a non-coding GGGGCC-repeat in the first intron of the C9orf72 gene are a common cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)", "begin": 0, "document": "23264878", "end": 183, "section": "abstract"}, {"text": "We recently reported that a guanosine-rich 40-mer DNA aptamer (LJM-3064) mediates remyelination in the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis", "begin": 0, "document": "23175609", "end": 177, "section": "abstract"}, {"text": "There is a growing recognition for their profound roles in a wide spectrum of diseases, such as cancer, diabetes and cardiovascular disease", "begin": 289, "document": "23161677", "end": 428, "section": "abstract"}, {"text": "Myocardial fibrosis is a key pathological change in a variety of heart diseases contributing to the development of heart failure, arrhythmias, and sudden death. Recent studies have shown that relaxin prevents and reverses cardiac fibrosis. Endogenous expression of relaxin was elevated in the setting of heart disease; the extent of such up-regulation, however, is insufficient to exert compensatory actions, and the mechanism regulating relaxin expression is poorly defined. In the rat relaxin-1 (RLN1, Chr1) gene promoter region we found presence of repeated guanine (G)-rich sequences, which allowed formation and stabilization of G-quadruplexes with the addition of a G-quadruplex interactive ligand berberine.", "begin": 0, "document": "22673230", "end": 714, "section": "abstract"}, {"text": "Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action", "begin": 0, "document": "22673230", "end": 98, "section": "title"}, {"text": "Our findings document a novel therapeutic strategy for fibrosis through up-regulating expression of endogenous relaxin.", "begin": 1685, "document": "22673230", "end": 1804, "section": "abstract"}, {"text": "We identified a G-rich sequence within exon 3 of BACE1 involved in controlling splice site selection", "begin": 368, "document": "22303960", "end": 468, "section": "abstract"}, {"text": "\u03b2-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is the transmembrane aspartyl protease that catalyzes the first cleavage step in the proteolysis of the APP to the amyloid \u03b2-protein (A\u03b2), a process involved in the pathogenesis of Alzheimer disease", "begin": 0, "document": "22303960", "end": 263, "section": "abstract"}, {"text": "Anti-amyloidogenic processing of the amyloid precursor protein APP by \u03b1-secretase prevents formation of the amyloid-\u03b2 peptide, which accumulates in senile plaques of Alzheimer disease patients. \u03b1-Secretase belongs to the family of a disintegrin and metalloproteases (ADAMs), and ADAM10 is the primary candidate for this anti-amyloidogenic activity", "begin": 0, "document": "22065584", "end": 347, "section": "abstract"}, {"text": "Using circular dichroism spectroscopy, we demonstrate that a G-rich region between nucleotides 66 and 94 of the ADAM10 5'-UTR forms a highly stable, intramolecular, parallel G-quadruplex secondary structure under physiological conditions", "begin": 700, "document": "22065584", "end": 937, "section": "abstract"}, {"text": "FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability.", "begin": 0, "document": "18426915", "end": 115, "section": "title"}, {"text": "Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia", "begin": 0, "document": "16652154", "end": 127, "section": "title"}, {"text": "Recently, we have demonstrated that treatment with a G-quadruplex-interactive agent, telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines", "begin": 120, "document": "16652154", "end": 304, "section": "abstract"}, {"text": "A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia", "begin": 0, "document": "15138591", "end": 156, "section": "title"}, {"text": "We examined G-quadruplex interactive agent, telomestatin (SOT-095), for its ability to inhibit the proliferation of human leukemia cells, including freshly obtained leukemia cells.", "begin": 432, "document": "15138591", "end": 612, "section": "abstract"}]}, {"documents": ["23533646", "23527566", "23514126", "22521592", "22434357", "22261504", "21993656", "20671958", "20127115", "19179021", "17291333", "16848907", "16107075", "12531326", "11257410"], "answer": [["Neisseria meningitidis (serogroup B)"], ["Porphyromonas gingivalis"], ["Streptococcus pneumoniae"], ["Chlamydia pneumoniae"], ["Bacillus anthracis"], ["group B streptococci"], ["Helicobacter pylori"], ["Mycobacterium tuberculosis"], ["Theileria parva"], ["Brachyspira hyodysenteriae"], ["Echinococcus granulosus"], ["Ehrlichia ruminantium"], ["Leishmania spp"], ["Rhipicephalus microplus"], ["Brucella melitensis"]], "id": "51601071298dcd4e51000038", "snippets": [{"text": "The potential of this new approach is illustrated by the use of reverse vaccinology for the development of a vaccine against serogroup B meningococcus", "begin": 762, "document": "11257410", "end": 912, "section": "abstract"}, {"text": "The Neisseria meningitidis serogroup B project, the first example of Reverse Vaccinology", "begin": 858, "document": "12531326", "end": 946, "section": "abstract"}, {"text": "Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis", "begin": 0, "document": "16107075", "end": 71, "section": "title"}, {"text": "This process, first applied to serogroup B Neisseria meningitidis, has been termed as reverse vaccinology", "begin": 434, "document": "16107075", "end": 539, "section": "abstract"}, {"text": "A reverse vaccinology approach to swine dysentery vaccine development", "begin": 0, "document": "19179021", "end": 69, "section": "title"}, {"text": "Swine dysentery (SD) is a mucohaemorrhagic colitis of pigs resulting from infection of the large intestine with the anaerobic intestinal spirochaete Brachyspira hyodysenteriae", "begin": 0, "document": "19179021", "end": 175, "section": "abstract"}, {"text": "Reverse vaccinology approach identify an Echinococcus granulosus tegumental membrane protein enolase as vaccine candidate", "begin": 0, "document": "20127115", "end": 121, "section": "title"}, {"text": "Reverse vaccinology process identified E. granulosus tegumental membrane protein enolase as vaccine candidate", "begin": 2039, "document": "20127115", "end": 2148, "section": "abstract"}, {"text": "The application of RV to Neisseria meningitidis serogroup B represents the first success of this novel approach", "begin": 868, "document": "21993656", "end": 979, "section": "abstract"}, {"text": "Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy", "begin": 0, "document": "22261504", "end": 125, "section": "title"}, {"text": "Ehrlichia ruminantium is an obligate intracellular bacterial pathogen which causes heartwater, a serious tick-borne disease of ruminants throughout sub-Saharan Africa", "begin": 0, "document": "22261504", "end": 166, "section": "abstract"}, {"text": "A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp", "begin": 0, "document": "22434357", "end": 105, "section": "title"}, {"text": "A systematic, functional genomics, and reverse vaccinology approach to the identification of vaccine candidates in the cattle tick, Rhipicephalus microplus", "begin": 0, "document": "22521592", "end": 155, "section": "title"}, {"text": "Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology", "begin": 0, "document": "23514126", "end": 107, "section": "title"}, {"text": "Immunogenic and Invasive Properties of Brucella melitensis 16M Outer Membrane Protein Vaccine Candidates Identified via a Reverse Vaccinology Approach", "begin": 0, "document": "23533646", "end": 150, "section": "title"}]}, {"documents": ["21963854", "15200950", "12208845", "12086618"], "answer": [["H4K20 monomethylation"], ["H3K4 monomethylation"]], "id": "5160412d298dcd4e5100003c", "snippets": [{"text": "the loss of H4 lysine 20 methylation", "begin": 190, "document": "12086618", "end": 226, "section": "abstract"}, {"text": "Transcriptionally competent regions lack H4 lysine 20 methylation", "begin": 286, "document": "12086618", "end": 351, "section": "abstract"}, {"text": "a human histone H4 lysine 20 methyltransferase and cloned the encoding gene, PR/SET07", "begin": 17, "document": "12086618", "end": 102, "section": "abstract"}, {"text": "Localization of PR-Set7 to mitotic chromosomes and subsequent increase in H4 Lys 20 methylation", "begin": 338, "document": "12208845", "end": 433, "section": "abstract"}, {"text": "the H4-K20 methyltransferase PR-Set7. Indeed, upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation", "begin": 698, "document": "15200950", "end": 842, "section": "abstract"}]}, {"documents": ["23485197", "22906719", "22499769", "22499768", "22369663", "22345495", "21822884", "20927383", "20340162", "17372656"], "answer": [["enriched for phosphorylated peptides using titanium dioxide"], ["sequential elution from IMAC"], ["simple derivatization procedure based on phosphoramidate chemistry"], ["antiphosphotyrosine antibodies"]], "id": "516281e6298dcd4e51000040", "snippets": [{"text": "Phosphopeptide enrichment by SCX and TiO2 lead to the identification of a total of 10,096 phosphorylation sites on 2,551 protein groups, and quantified the ratios of 8,275 phosphorylation sites between the two lifecycle stages.", "begin": 156, "document": "23485197", "end": 383, "section": "abstract"}, {"text": "TiSH--a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC.", "begin": 0, "document": "22906719", "end": 113, "section": "title"}, {"text": "An initial TiO(2) phosphopeptide pre-enrichment step is followed by post-fractionation using sequential elution from IMAC (SIMAC) to separate multi- and mono-phosphorylated peptides, and hydrophilic interaction liquid chromatography (HILIC) of the mono-phosphorylated peptides (collectively abbreviated \"TiSH\").", "begin": 429, "document": "22906719", "end": 740, "section": "abstract"}, {"text": "After enrichment by anti-phosphotyrosine antibodies, we identified 29 potential novel c-Src substrate proteins.", "begin": 618, "document": "22499769", "end": 729, "section": "abstract"}, {"text": "Combining immunoprecipitation with an antiphosphotyrosine antibody, titanium dioxide phosphopeptide enrichment, isobaric tag for the relative and absolute quantitation methodology, and strong cation exchange separation, we were able to identify 2814 phosphopeptides.", "begin": 579, "document": "22499768", "end": 845, "section": "abstract"}, {"text": "Phosphopeptide fractionation by strong cation exchange chromatography combined with immobilized metal affinity chromatography (IMAC) enrichment enabled quantification of more than 8000 distinct phosphorylation sites in Ppt1 wild-type versus Ppt1-deficient yeast cells", "begin": 443, "document": "22369663", "end": 710, "section": "abstract"}, {"text": "By employing titanium dioxide in addition to antiphosphotyrosine antibodies as enrichment methods, we identified 4164 phosphopeptides on 1670 phosphoproteins.", "begin": 710, "document": "22345495", "end": 868, "section": "abstract"}, {"text": "Our method combines the use of strong cation exchange (SCX) and titanium dioxide (TiO(2)) for phosphopeptide enrichment, high-resolution MS for peptide and protein identification, and stable isotope labeling by amino acids in cell culture (SILAC) for quantification.", "begin": 676, "document": "21822884", "end": 942, "section": "abstract"}, {"text": "Phosphopeptides were isolated with high specificity through a simple derivatization procedure based on phosphoramidate chemistry.", "begin": 1007, "document": "17372656", "end": 1136, "section": "abstract"}]}, {"documents": ["22751177", "21304989", "17760499", "19469700", "23503602", "23378928", "22114052", "20817034"], "answer": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]], "id": "5162e44f298dcd4e5100004a", "snippets": [{"text": "A single intracardiac administration of the vector carrying neprilysin gene in AD-model mice", "begin": 510, "document": "23503602", "end": 602, "section": "abstract"}, {"text": "This technique provides a safe and efficient non-viral method for in vivo gene delivery with potential applications in both basic research and in gene therapy of neuronal disease.", "begin": 1494, "document": "20817034", "end": 1673, "section": "abstract"}, {"text": "A novel system for in vivo neprilysin gene delivery using a syringe electrode.", "begin": 0, "document": "20817034", "end": 78, "section": "title"}, {"text": "Previous studies have demonstrated the therapeutic potential of viral vector-mediated neprilysin (NEP) gene therapy in mouse models of Alzheimer's disease (AD).", "begin": 97, "document": "22751177", "end": 257, "section": "abstract"}, {"text": "Convection-enhanced delivery of neprilysin: a novel amyloid-\u03b2-degrading therapeutic strategy.", "begin": 0, "document": "22751177", "end": 93, "section": "title"}, {"text": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "begin": 0, "document": "17760499", "end": 139, "section": "title"}, {"text": "Thus, researchers have explored virus-mediated NEP gene delivery. However, such strategies may entail unexpected risks, and thus exploration of a new possibility for NEP delivery is also required. Here, we show that human adipose tissue-derived mesenchymal stem cells (ADSCs) secrete exosomes carrying enzymatically active NEP", "begin": 235, "document": "23378928", "end": 561, "section": "abstract"}, {"text": "suggesting the therapeutic relevance of ADSC-derived exosomes for AD.", "begin": 968, "document": "23378928", "end": 1037, "section": "abstract"}, {"text": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "begin": 0, "document": "23378928", "end": 97, "section": "title"}]}, {"documents": ["22513121", "20470249", "8396675", "19534676", "19035566", "18991746", "22039536", "21249176", "19555498", "16225688", "22031952"], "answer": ["three", "3"], "id": "51651e24298dcd4e51000054", "snippets": [{"text": "Within a project aimed at discovering new Flaviviridae inhibitors, new variously substituted 2-phenylbenzimidazoles were synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against viruses representatives of the three genera of the Flaviviridae family, i.e.: Pestivirus (BVDV), Flavivirus (YFV) and Hepacivirus (HCV).", "begin": 0, "document": "22513121", "end": 352, "section": "abstract"}, {"text": "Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Pestiviruses and Flaviviruses;", "begin": 172, "document": "20470249", "end": 340, "section": "abstract"}, {"text": "The RNA-stimulated NTPase activity of this protein from prototypic members of the Pestivirus and Flavivirus genera has recently been established and enzymologically characterized.", "begin": 189, "document": "8396675", "end": 368, "section": "abstract"}, {"text": "Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae).", "begin": 196, "document": "19534676", "end": 539, "section": "abstract"}, {"text": "Forty-three 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles, bearing either linear (dialkylamino)alkyl- or bulkier (quinolizidin-1-yl)alkyl moieties at position 1, were evaluated in cell-based assays for cytotoxicity and antiviral activity against viruses representative of two of the three genera of the Flaviviridae family, i.e. Flaviviruses (Yellow Fever Virus (YFV)) and Pestiviruses (Bovine Viral Diarrhoea Virus (BVDV)), as Hepaciviruses can hardly be used in routine cell-based assays.", "begin": 0, "document": "19035566", "end": 490, "section": "abstract"}, {"text": "Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae).", "begin": 360, "document": "18991746", "end": 703, "section": "abstract"}, {"text": ": Pestivirus (BVDV), Flavivirus (YFV) and Hepacivirus (HCV).", "begin": 292, "document": "22513121", "end": 352, "section": "abstract"}, {"text": "The family Flaviviridae contains three genera of positive-strand RNA viruses, namely, Flavivirus, Hepacivirus (e.g., hepatitis C virus [HCV]), and Pestivirus.", "begin": 0, "document": "22031952", "end": 158, "section": "abstract"}]}, {"documents": ["23505126", "20795312", "18598283", "14617316", "12430675", "9745158", "1304158", "1823954", "1703877", "6522937", "889425"], "answer": ["SMIM1"], "id": "516545a8298dcd4e51000056", "snippets": [{"text": "Disruption of SMIM1 causes the Vel- blood type.", "begin": 0, "document": "23505126", "end": 47, "section": "title"}, {"text": "he protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen.", "begin": 208, "document": "23505126", "end": 647, "section": "abstract"}, {"text": "Anti-Vel is an uncommon antibody to a high-prevalence antigen. Its clinical significance and management in the prenatal setting are not well characterized.", "begin": 0, "document": "20795312", "end": 155, "section": "abstract"}, {"text": "Haemolytic disease of the newborn because of rare anti-Vel.", "begin": 0, "document": "18598283", "end": 59, "section": "title"}]}, {"documents": ["19282388", "11222747"], "answer": [["phosphoenolpyruvate-carboxykinase"], ["pyruvate kinase"], ["D1", "deiodinase 1"]], "id": "516c0ed3298dcd4e5100006f", "snippets": [{"text": "Mice expressing the mutant thyroid hormone receptor TRalpha1R384C, which has a 10-fold reduced affinity to the ligand T(3), exhibit hypermetabolism due to an overactivation of the sympathetic nervous system. To define the consequences in the liver, we analyzed hepatic metabolism and the regulation of liver genes in the mutant mice. Our results showed that hepatic phosphoenolpyruvate-carboxykinase was up-regulated and pyruvate kinase mRNA down-regulated, contrary to what observed after T(3) treatment", "begin": 0, "document": "19282388", "end": 504, "section": "abstract"}, {"text": "Remarkably, there was an obligatory requirement for a TR, whether TRbeta or TRalpha1, for any detectable D1 expression in liver.", "begin": 1147, "document": "11222747", "end": 1275, "section": "abstract"}, {"text": "Liver and kidney D1 mRNA and activity levels were reduced in TRbeta(-/-) but not TRalpha1(-/-) mice", "begin": 345, "document": "11222747", "end": 444, "section": "abstract"}]}, {"documents": ["22490049", "22127645", "21188112", "19047165", "16450374", "11850431", "11724358", "10416608", "8996519", "8895198", "8567402", "7947097", "8040892", "8297104", "8104687", "1310509", "1655244", "2159380", "2154411"], "answer": [["Etoposide (VP-16)"], ["Teniposide (VM-26)"], ["Doxorubicin"], ["Daunorubicin"], ["Aclarubicin"], ["Mitoxantrone"], ["Amsacrine (m-AMSA)"]], "id": "516e5f25298dcd4e5100007d", "snippets": [{"text": "Etoposide is effective as an anti-tumour drug by inhibiting eukaryotic DNA topoisomerase II via establishing a covalent complex with DNA", "begin": 0, "document": "22490049", "end": 136, "section": "abstract"}, {"text": "benzoxazoles, benzimidazoles and related fused heterocyclic compounds, which exhibited significant eukaryotic DNA topoisomerase II inhibitory activity", "begin": 312, "document": "22490049", "end": 462, "section": "abstract"}, {"text": "F14512, a polyamine-containing inhibitor of DNA topoisomerase II", "begin": 55, "document": "22127645", "end": 119, "section": "title"}, {"text": "F14512, an epipodophyllotoxin derivative equipped with a spermine moiety, is selectively taken up by the polyamine transport system over-active in tumor cells", "begin": 0, "document": "22127645", "end": 158, "section": "abstract"}, {"text": "F14512 combines an epipodophyllotoxin core-targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine tail supports three complementary functions: (a) facilitate formulation of a water-soluble compound, (b) increase DNA binding to reinforce topoisomerase II inhibition, and (c) facilitate selective uptake by tumor cells via the PTS", "begin": 240, "document": "19047165", "end": 615, "section": "abstract"}, {"text": "Twenty previously synthesized fused heterocyclic DNA-topoisomerase II (Topo II)-inhibiting compounds were investigated for their potential efficacy in various human cancer cell lines that were derived from different tumor entities", "begin": 0, "document": "16450374", "end": 230, "section": "abstract"}, {"text": "In conclusion, compounds BD 13, BD 14, BD 16, D 23 and D 24 may be useful for the treatment of different multidrug-resistant cancer cells with cross resistance against \"classical\" Topo II-targeting drugs.", "begin": 1447, "document": "16450374", "end": 1651, "section": "abstract"}, {"text": "ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization", "begin": 0, "document": "11850431", "end": 155, "section": "title"}, {"text": "We tested the effects of two DNA topoisomerase II poisons, etoposide and doxorubicin", "begin": 241, "document": "11724358", "end": 325, "section": "abstract"}, {"text": "the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187", "begin": 66, "document": "10416608", "end": 134, "section": "title"}, {"text": "Bisdioxopiperazine drugs such as ICRF-187 are catalytic inhibitors of DNA topoisomerase II, with at least two effects on the enzyme: namely, locking it in a closed-clamp form and inhibiting its ATPase activity", "begin": 0, "document": "10416608", "end": 209, "section": "abstract"}, {"text": "Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines", "begin": 0, "document": "8895198", "end": 119, "section": "title"}, {"text": "topoisomerase II-targeting anticancer agents, etoposide (VP-16) and teniposide (VM-26)", "begin": 98, "document": "8567402", "end": 184, "section": "abstract"}, {"text": "the anti-cancer DNA topoisomerase II poison etoposide (VP-16", "begin": 76, "document": "7947097", "end": 136, "section": "abstract"}, {"text": "n an attempt to clarify the role of drug-induced protein-associated DNA breaks (i.e., DNA topoisomerase II-mediated DNA cleavage) in the cytotoxic activity of doxorubicin and etoposide", "begin": 1, "document": "2154411", "end": 185, "section": "abstract"}, {"text": "The effect of combinations of the anthracycline aclarubicin and the topoisomerase II targeting drugs 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyra noside) (VP-16) and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) was investigated in a clonogenic assay", "begin": 0, "document": "2159380", "end": 282, "section": "abstract"}, {"text": "Antagonistic effect of aclarubicin", "begin": 0, "document": "2159380", "end": 34, "section": "title"}, {"text": "The effect of combinations of the anthracyclines aclarubicin and daunorubicin was investigated in a clonogenic assay using the human small cell lung cancer cell line OC-NYH and a multidrug-resistant (MDR) murine subline of Ehrlich ascites tumor (EHR2/DNR+)", "begin": 0, "document": "1655244", "end": 256, "section": "abstract"}, {"text": "the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines", "begin": 28, "document": "1310509", "end": 121, "section": "title"}, {"text": "cells are cross-resistant to some drugs that interact with topoisomerase II but not mitoxantrone", "begin": 427, "document": "8104687", "end": 523, "section": "abstract"}, {"text": "suramin decreases the phosphorylation of Topo II mediated by PKC. This effect of suramin might cause the inhibition of Topo II activity resulting in the growth inhibition of tumor cells.", "begin": 1194, "document": "8297104", "end": 1380, "section": "abstract"}]}, {"documents": ["19079621"], "answer": [["human kallikrein-related peptidase 3"], ["hK3"]], "id": "5171651e8ed59a060a000009", "snippets": [{"text": "Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.", "begin": 0, "document": "19079621", "end": 115, "section": "title"}, {"text": "Human kallikrein-related peptidase 3 (hK3), also known as prostate-specific antigen (PSA), is a 33 kDa single chain glycoprotein belonging to the kallikrein family of serine proteases.", "begin": 0, "document": "19079621", "end": 184, "section": "abstract"}]}, {"documents": ["23438514", "20301416", "19439584", "17072020", "16645197", "16498763", "11978730", "11814461", "11493025", "10448809", "10090061", "9875712", "9441867", "8940268", "8577041", "7581365", "8297359", "8281145", "8399327", "1521344", "2079710", "85413"], "answer": ["Galactocerebrosidase is an enzyme that is deficient in Krabbe disease (also known as globoid-cell leukodystrophy). This leads to accumulation of psychosine (galactosylsphingosine) primarily in oligodendrocytes."], "id": "5147c8a6d24251bc05000027", "snippets": [{"text": "Krabbe disease is a lethal, demyelinating condition caused by genetic deficiency of galactocerebrosidase (GALC) and resultant accumulation of its cytotoxic substrate, psychosine (galactosylsphingosine), primarily in oligodendrocytes (OLs).", "begin": 0, "document": "23438514", "end": 239, "section": "abstract"}, {"text": "In this study, we report that accumulation of endogenous psychosine under GALC deficient Krabbe conditions impedes OL differentiation process both by decreasing the expression of myelin lipids and protein and by inducing the cell death of maturating OLs.", "begin": 692, "document": "23438514", "end": 946, "section": "abstract"}, {"text": "This chapter describes in detail a practical procedure for the preparation of radiolabeled galactocerebroside and its use in the assay of galactocerebrosidase (GalCase), the enzyme deficient in globoid cell leukodystrophy (Krabbe disease).", "begin": 0, "document": "17072020", "end": 239, "section": "abstract"}, {"text": "Globoid cell leukodystrophy (Krabbe disease) is an inherited neurological disorder caused by the pathogenomic accumulation of psychosine (galactosylsphingosine), a substrate for the deficient enzyme galactocerebroside beta-galactosidase.", "begin": 0, "document": "16645197", "end": 237, "section": "abstract"}, {"text": "Krabbe disease is an extremely rare condition with an incidence of 1 in 1,00,000 live births. It is caused by deficient activity of the Iysosomal hydrolase galactosylceramide beta-galactosidase.", "begin": 0, "document": "16498763", "end": 194, "section": "abstract"}, {"text": "Globoid cell leukodystrophy (Krabbe disease) is characterized by the accumulation of a toxic metabolite, psychosine (galactosylsphingosine), which is a substrate for the deficient enzyme (galactocerebroside beta-galactosidase).", "begin": 0, "document": "11978730", "end": 227, "section": "abstract"}, {"text": "Globoid cell leukodystrophy, or Krabbe disease, is a severe disorder of the peripheral and central nervous system myelin caused by deficient galactocerebrosidase (GALC) activity.", "begin": 0, "document": "10090061", "end": 178, "section": "abstract"}, {"text": "Globoid cell leukodystrophy (GCL or Krabbe disease) is a recessive disease caused by mutations of the lysosomal enzyme galactocerebrosidase (GALC) and twitcher is the murine model of GCL.", "begin": 0, "document": "9875712", "end": 187, "section": "abstract"}, {"text": "Galactocerebrosidase (GALC) is the lysosomal enzyme deficient in human and certain animal species with globoid cell leukodystrophy (GLD) or Krabbe disease.", "begin": 0, "document": "9441867", "end": 155, "section": "abstract"}, {"text": "Globoid-cell leukodystrophy (GLD) is an autosomal recessive inherited disorder caused by the deficiency of galactocerebrosidase, the lysosomal enzyme responsible for the degradation of the myelin glycolipid galactocerebroside.", "begin": 0, "document": "8940268", "end": 226, "section": "abstract"}, {"text": "Krabbe disease is an autosomal recessive inherited demyelinating disease, which is deficient in lysosomal enzyme, galactocerebrosidase.", "begin": 0, "document": "8577041", "end": 135, "section": "abstract"}, {"text": "Galactocerebrosidase (GALC) activity is deficient in all patients with globoid cell leukodystrophy (GLD).", "begin": 0, "document": "7581365", "end": 105, "section": "abstract"}, {"text": "Human galactocerebrosidase, the enzyme deficient in Krabbe disease, was purified, through several hydrophobic column steps and gel filtration, 22,650-fold from human lymphocytes", "begin": 0, "document": "8297359", "end": 177, "section": "abstract"}, {"text": "Globoid cell leukodystrophy (Krabbe disease) is an autosomal recessive disorder resulting from the deficiency of galactocerebrosidase (GALC) activity.", "begin": 0, "document": "8281145", "end": 150, "section": "abstract"}, {"text": "6-Hexadecanoylamino-4-methylumbelliferyl-beta-D-galactopyranoside (HMGal) has been shown to be a specific fluorogenic substrate of galactocerebrosidase and to facilitate the simple enzymatic diagnosis of Krabbe disease in human patients and in twitcher mice.", "begin": 0, "document": "1521344", "end": 258, "section": "abstract"}, {"text": "The inherited deficiency of galactosylceramide beta-galactosidase (E.C. 3.2.1.46: galactocerebrosidase) activity results in globoid cell leukodystrophy in humans (Krabbe disease) and in mice (twitcher mutant).", "begin": 0, "document": "2079710", "end": 209, "section": "abstract"}, {"text": "The lack of complementation between Krabbe disease patient and twitcher mutant mouse cells provides further evidence that the twitcher mouse is an authentic murine model for Krabbe disease and supports the hypothesis that the mutations in both species are within the structural gene for the galactocerebrosidase enzyme.", "begin": 997, "document": "2079710", "end": 1316, "section": "abstract"}, {"text": "Galactosylceramide beta-galactosidase cross reacting material was demonstrated in brain, liver, and skin fibroblasts from patients with Krabbe disease.", "begin": 0, "document": "85413", "end": 151, "section": "abstract"}, {"text": ". In this study, LRs in the brain of the twitcher (TWI) mouse, a bona-fide model for infant variants of human globoid cell leukodystrophy or Krabbe disease, were investigated. This mouse has deficient activity of GALC (beta-galactosylceramidase) that leads to a progressive accumulation of some galactosyl-sphingolipids in the brain.", "begin": 385, "document": "19439584", "end": 718, "section": "abstract"}, {"text": "Galactocerebrosidase (GALC) is deficient in all tissues from human patients and animal models with globoid cell leukodystrophy (GLD) or Krabbe disease.", "begin": 0, "document": "11493025", "end": 151, "section": "abstract"}, {"text": "The purification of GALC and the securing of amino acid sequence information will aid in the cloning of the GALC gene. This enzyme is deficient in human patients with Krabbe disease and several animal species.", "begin": 1530, "document": "8399327", "end": 1739, "section": "abstract"}]}, {"documents": ["23297037", "22987359", "22540951", "22247276", "21967762", "21426944", "21328706", "20488436", "19429691", "19421989", "17958348", "18006547", "18467177", "17597895", "17520325", "16844989", "15769290", "15647112", "15215419", "15162482", "15141026", "15070403", "12192075", "12169530", "11274469", "22148174", "21531175", "18355838", "16858668", "16674095", "15215418", "12798041", "12070338", "10698111", "22031179", "21064129", "19622743", "21935968", "19153681", "15980447", "18218108", "16225682", "17088282", "16597327", "17597890", "18312695", "23530628", "19470175", "18989393"], "answer": [["BBF", "beta-barrel finder"], ["BETAWARE"], ["BOCTOPUS"], ["BOMP"], ["BTMX", "Beta barrel TransMembrane eXposure"], ["HHomp"], ["HMM-B2TMR"], ["OMBBpred"], ["PROFtmb"], ["PRED-TMBB"], ["TMB-Hunt"], ["TBBPred"], ["TMBETAPRED-RBF"], ["TMBHMM"], ["TransFold"], ["TMBpro"], ["TMBKNN"], ["Wimley"], ["TMBETA-NET"]], "id": "5149a61ed24251bc05000044", "snippets": [{"text": "BETAWARE: a machine-learning tool to detect and predict transmembrane beta-barrel proteins in prokaryotes", "begin": 0, "document": "23297037", "end": 105, "section": "title"}, {"text": "Recently, we developed two top-performing methods based on machine-learning approaches to tackle both the detection of TMBBs in sets of proteins and the prediction of their topology. Here, we present our BETAWARE program that includes both approaches and can run as a standalone program on a linux-based computer to easily address in-home massive protein annotation or filtering.", "begin": 684, "document": "23297037", "end": 1063, "section": "abstract"}, {"text": "We introduce a graph-theoretic model for predicting the supersecondary structure of transmembrane \u03b2-barrel proteins--a particular class of proteins that performs diverse important functions but it is difficult to determine their structure with experimental methods. This ab initio model resolves the protein folding problem based on pseudo-energy minimization with the aid of a simple probabilistic filter. It also allows for determining structures whose barrel follows a given permutation on the arrangement of \u03b2-strands, and allows for rapidly discriminating the transmembrane \u03b2-barrels from other kinds of proteins.", "begin": 0, "document": "22987359", "end": 618, "section": "abstract"}, {"text": "BOCTOPUS: improved topology prediction of transmembrane \u03b2 barrel proteins", "begin": 0, "document": "22247276", "end": 73, "section": "title"}, {"text": "Improving the detection of transmembrane \u03b2-barrel chains with N-to-1 extreme learning machines", "begin": 0, "document": "21967762", "end": 94, "section": "title"}, {"text": "TMBHMM: a frequency profile based HMM for predicting the topology of transmembrane beta barrel proteins and the exposure status of transmembrane residues", "begin": 0, "document": "21426944", "end": 153, "section": "title"}, {"text": "We present here TMBHMM, a computational method based on a hidden Markov model for predicting the structural topology of putative TMBs from sequence. In addition to predicting transmembrane strands, TMBHMM also predicts the exposure status (i.e., exposed to the membrane or hidden in the protein structure) of the residues in the transmembrane region, which is a novel feature of the TMBHMM method. Furthermore, TMBHMM can also predict the membrane residues that are not part of beta barrel forming strands.", "begin": 332, "document": "21426944", "end": 838, "section": "abstract"}, {"text": "Prediction of the exposure status of transmembrane beta barrel residues from protein sequence", "begin": 0, "document": "21328706", "end": 93, "section": "title"}, {"text": "We present BTMX (Beta barrel TransMembrane eXposure), a computational method to predict the exposure status (i.e. exposed to the bilayer or hidden in the protein structure) of transmembrane residues in transmembrane beta barrel proteins (TMBs).", "begin": 0, "document": "21328706", "end": 244, "section": "abstract"}, {"text": "Combined prediction of transmembrane topology and signal peptide of beta-barrel proteins: using a hidden Markov model and genetic algorithms", "begin": 0, "document": "20488436", "end": 140, "section": "title"}, {"text": "HHomp--prediction and classification of outer membrane proteins", "begin": 0, "document": "19429691", "end": 63, "section": "title"}, {"text": "In this work, we propose a method based on radial basis networks for predicting the number of beta-strands in OMPs and identifying their membrane spanning segments.", "begin": 168, "document": "19421989", "end": 332, "section": "abstract"}, {"text": "We have developed a web server, TMBETAPRED-RBF for predicting the transmembrane beta-strands from amino acid sequence and it is available at http://rbf.bioinfo.tw/~sachen/tmrbf.html", "begin": 624, "document": "19421989", "end": 805, "section": "abstract"}, {"text": "We have developed a novel approach for dissecting transmembrane beta-barrel proteins (TMBs) in genomic sequences. The features include (i) the identification of TMBs using the preference of residue pairs in globular, transmembrane helical (TMH) and TMBs, (ii) elimination of globular/TMH proteins that show sequence identity of more than 70% for the coverage of 80% residues with known structures, (iii) elimination of globular/TMH proteins that have sequence identity of more than 60% with known sequences in SWISS-PROT, and (iv) exclusion of TMH proteins using SOSUI, a prediction system for TMH proteins.", "begin": 0, "document": "17958348", "end": 607, "section": "abstract"}, {"text": "TMBpro: secondary structure, beta-contact and tertiary structure prediction of transmembrane beta-barrel proteins", "begin": 0, "document": "18006547", "end": 113, "section": "title"}, {"text": "This paper presents a k-nearest neighbor (K-NN) method for discriminating TMB and non-TMB proteins.", "begin": 100, "document": "18467177", "end": 199, "section": "abstract"}, {"text": "Beta barrel trans-membrane proteins: Enhanced prediction using a Bayesian approach", "begin": 0, "document": "17597895", "end": 82, "section": "title"}, {"text": "In this paper, based on the concept of pseudo amino acid composition (PseAA) that can incorporate sequence-order information of a protein sequence so as to remarkably enhance the power of discrete models (Chou, K. C., Proteins: Structure, Function, and Genetics, 2001, 43: 246-255), cellular automata and Lempel-Ziv complexity are introduced to predict the TM regions of integral membrane proteins including both alpha-helical and beta-barrel membrane proteins, validated by jackknife test", "begin": 533, "document": "17520325", "end": 1022, "section": "abstract"}, {"text": "transFold: a web server for predicting the structure and residue contacts of transmembrane beta-barrels", "begin": 0, "document": "16844989", "end": 103, "section": "title"}, {"text": "TMB-Hunt: an amino acid composition based method to screen proteomes for beta-barrel transmembrane proteins", "begin": 0, "document": "15769290", "end": 107, "section": "title"}, {"text": "Evaluation of methods for predicting the topology of beta-barrel outer membrane proteins and a consensus prediction method", "begin": 0, "document": "15647112", "end": 122, "section": "title"}, {"text": "PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins", "begin": 0, "document": "15215419", "end": 90, "section": "title"}, {"text": "We present here a web server (PRED-TMBB, http://bioinformatics.biol.uoa.gr/PRED-TMBB) which is capable of predicting the transmembrane strands and the topology of beta-barrel outer membrane proteins of Gram-negative bacteria. The method is based on a Hidden Markov Model, trained according to the Conditional Maximum Likelihood criterion.", "begin": 346, "document": "15215419", "end": 684, "section": "abstract"}, {"text": "Prediction of transmembrane regions of beta-barrel proteins using ANN- and SVM-based methods", "begin": 0, "document": "15162482", "end": 92, "section": "title"}, {"text": "his article describes a method developed for predicting transmembrane beta-barrel regions in membrane proteins using machine learning techniques: artificial neural network (ANN) and support vector machine (SVM). The ANN used in this study is a feed-forward neural network with a standard back-propagation training algorithm.", "begin": 1, "document": "15162482", "end": 325, "section": "abstract"}, {"text": "We have also developed an SVM-based method using a primary sequence as input and achieved an accuracy of 77.4%. The SVM model was modified by adding 36 physicochemical parameters to the amino acid sequence information. Finally, ANN- and SVM-based methods were combined to utilize the full potential of both techniques.", "begin": 527, "document": "15162482", "end": 845, "section": "abstract"}, {"text": "we have developed a Web server, TBBPred, for predicting transmembrane beta-barrel regions in proteins", "begin": 1190, "document": "15162482", "end": 1291, "section": "abstract"}, {"text": "Predicting transmembrane beta-barrels in proteomes", "begin": 0, "document": "15141026", "end": 50, "section": "title"}, {"text": "Here we introduced the design, statistics and results of a novel profile-based hidden Markov model for the prediction and discrimination of TMBs.", "begin": 241, "document": "15141026", "end": 386, "section": "abstract"}, {"text": "All proteome predictions and the PROFtmb prediction method are available", "begin": 1381, "document": "15141026", "end": 1453, "section": "abstract"}, {"text": "A Hidden Markov Model method, capable of predicting and discriminating beta-barrel outer membrane proteins", "begin": 0, "document": "15070403", "end": 106, "section": "title"}, {"text": "The beta-barrel finder (BBF) program, allowing identification of outer membrane beta-barrel proteins encoded within prokaryotic genomes", "begin": 0, "document": "12192075", "end": 135, "section": "title"}, {"text": "We here report computational analyses of six outer membrane proteins of known 3D structures with respect to (1) secondary structure, (2) hydropathy, and (3) amphipathicity. Using these characteristics, as well as the presence of an N-terminal targeting sequence, a program was developed allowing prediction of integral membrane beta-barrel proteins encoded within any completely sequenced prokaryotic genome. This program, termed the beta-barrel finder (BBF) program, was used to analyze the proteins encoded within the Escherichia coli genome.", "begin": 251, "document": "12192075", "end": 795, "section": "abstract"}, {"text": "A sequence-profile-based HMM for predicting and discriminating beta barrel membrane proteins", "begin": 0, "document": "12169530", "end": 92, "section": "title"}, {"text": "We develop a HMM model, which can predict the topology of beta barrel membrane proteins using, as input, evolutionary information. The model is cyclic with 6 types of states: two for the beta strand transmembrane core, one for the beta strand cap on either side of the membrane, one for the inner loop, one for the outer loop and one for the globular domain state in the middle of each loop. The development of a specific input for HMM based on multiple sequence alignment is novel.", "begin": 1003, "document": "12169530", "end": 1485, "section": "abstract"}, {"text": "Prediction of the transmembrane regions of beta-barrel membrane proteins with a neural network-based predictor", "begin": 0, "document": "11274469", "end": 110, "section": "title"}, {"text": "A method based on neural networks is trained and tested on a nonredundant set of beta-barrel membrane proteins known at atomic resolution with a jackknife procedure. The method predicts the topography of transmembrane beta strands with residue accuracy as high as 78% when evolutionary information is used as input to the network.", "begin": 0, "document": "11274469", "end": 330, "section": "abstract"}, {"text": "A web server based on the proposed method is available at http://yanbioinformatics.cs.usu.edu:8080/TMBKNNsubmit.", "begin": 570, "document": "18467177", "end": 682, "section": "abstract"}, {"text": "Predicting three-dimensional structures of transmembrane domains of \u03b2-barrel membrane proteins", "begin": 0, "document": "22148174", "end": 94, "section": "title"}, {"text": "We have developed a computational method for predicting structures of the transmembrane (TM) domains of \u03b2-barrel membrane proteins. Based on physical principles, our method can predict structures of the TM domain of \u03b2-barrel membrane proteins of novel topology, including those from eukaryotic mitochondria. Our method is based on a model of physical interactions, a discrete conformational state space, an empirical potential function, as well as a model to account for interstrand loop entropy.", "begin": 391, "document": "22148174", "end": 887, "section": "abstract"}, {"text": "exposure status classification of transmembrane beta barrel residues", "begin": 25, "document": "21531175", "end": 93, "section": "title"}, {"text": "Several computational methods exist for the identification of transmembrane beta barrel proteins (TMBs) from sequence. Some of these methods also provide the transmembrane (TM) boundaries of the putative TMBs. The aim of this study is to (1) derive the propensities of the TM residues to be exposed to the lipid bilayer and (2) to predict the exposure status (i.e. exposed to the bilayer or hidden in protein structure) of TMB residues.", "begin": 0, "document": "21531175", "end": 436, "section": "abstract"}, {"text": "The modified Mahalanobis Discriminant for predicting outer membrane proteins by using Chou's pseudo amino acid composition.", "begin": 0, "document": "18355838", "end": 123, "section": "title"}, {"text": "In this study, a method that combines increment of diversity with modified Mahalanobis Discriminant, called IDQD, is presented to predict 208 OMPs, 206 transmembrane helical proteins (TMHPs) and 673 globular proteins (GPs) by using Chou's pseudo amino acid compositions as parameters.", "begin": 224, "document": "18355838", "end": 508, "section": "abstract"}, {"text": "Predicting transmembrane beta-barrels and interstrand residue interactions from sequence", "begin": 0, "document": "16858668", "end": 88, "section": "title"}, {"text": "A novel method using pairwise interstrand residue statistical potentials derived from globular (nonouter membrane) proteins is introduced to predict the supersecondary structure of transmembrane beta-barrel proteins. The algorithm transFold employs a generalized hidden Markov model (i.e., multitape S-attribute grammar) to describe potential beta-barrel supersecondary structures and then computes by dynamic programming the minimum free energy beta-barrel structure.", "begin": 460, "document": "16858668", "end": 928, "section": "abstract"}, {"text": "Predicting the solvent accessibility of transmembrane residues from protein sequence", "begin": 0, "document": "16674095", "end": 84, "section": "title"}, {"text": "In this study, we propose a novel method to predict the solvent accessible surface areas of transmembrane residues. For both transmembrane alpha-helix and beta-barrel residues, the correlation coefficients between the predicted and observed accessible surface areas are around 0.65.", "begin": 0, "document": "16674095", "end": 282, "section": "abstract"}, {"text": "BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria", "begin": 0, "document": "15215418", "end": 120, "section": "title"}, {"text": "This work describes the development of a program that predicts whether or not a polypeptide sequence from a Gram-negative bacterium is an integral beta-barrel outer membrane protein. The program, called the beta-barrel Outer Membrane protein Predictor (BOMP), is based on two separate components to recognize integral beta-barrel proteins. The first component is a C-terminal pattern typical of many integral beta-barrel proteins. The second component calculates an integral beta-barrel score of the sequence based on the extent to which the sequence contains stretches of amino acids typical of transmembrane beta-strands.", "begin": 0, "document": "15215418", "end": 623, "section": "abstract"}, {"text": "A HMM-based method to predict the transmembrane regions of beta-barrel membrane proteins", "begin": 0, "document": "12798041", "end": 88, "section": "title"}, {"text": "A novel method is developed to model and predict the transmembrane regions of beta-barrel membrane proteins. It is based on a Hidden Markov model (HMM) with architecture obeying those proteins' construction principles.", "begin": 0, "document": "12798041", "end": 218, "section": "abstract"}, {"text": "First, an algorithm that calculates the mean hydrophobicity of one side of putative beta-strands predicted the positions of 16 transmembrane segments, a structure common to known porins. Second, outer loops typical of porins were assigned using an artificial neural network trained to predict the topology of bacterial outer-membrane proteins with a predominance of beta-strands", "begin": 271, "document": "12070338", "end": 649, "section": "abstract"}, {"text": "Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia", "begin": 0, "document": "12070338", "end": 97, "section": "title"}, {"text": "Topology prediction of Brucella abortus Omp2b and Omp2a porins after critical assessment of transmembrane beta strands prediction by several secondary structure prediction methods", "begin": 0, "document": "10698111", "end": 179, "section": "title"}, {"text": "Four porins of known structure were selected as test-cases and their secondary structure delineated. The specificity and sensitivity of 11 methods were separately evaluated. Our critical assessment shows that some secondary structure prediction methods (PHD, Dsc, Sopma) originally designed to predict globular protein structure are useful on porin topology prediction. The overall best prediction is obtained by combining these three \"generalist\" methods with a transmembrane beta strand prediction technique", "begin": 162, "document": "10698111", "end": 671, "section": "abstract"}, {"text": "A knowledge-based potential highlights unique features of membrane \u03b1-helical and \u03b2-barrel protein insertion and folding", "begin": 0, "document": "22031179", "end": 119, "section": "title"}, {"text": "In previous work, a depth-dependent insertion potential, E(z) , was derived for \u03b1-helical inner membrane proteins. We have generated an equivalent potential for TM \u03b2-barrel proteins. The similarities and differences between these two potentials provide insight into unique aspects of the folding and insertion of \u03b2-barrel membrane proteins. This potential can predict orientation within the membrane and identify functional residues involved in intermolecular interactions.", "begin": 323, "document": "22031179", "end": 796, "section": "abstract"}, {"text": "Improved identification of outer membrane beta barrel proteins using primary sequence, predicted secondary structure, and evolutionary information", "begin": 0, "document": "21064129", "end": 146, "section": "title"}, {"text": "We present an accurate sequence-based predictor of OMBBs, called OMBBpred, which utilizes a Support Vector Machine classifier and a custom-designed set of 34 novel numerical descriptors derived from predicted secondary structures, hydrophobicity, and evolutionary information.", "begin": 759, "document": "21064129", "end": 1035, "section": "abstract"}, {"text": "Predicting weakly stable regions, oligomerization state, and protein-protein interfaces in transmembrane domains of outer membrane proteins.", "begin": 0, "document": "19622743", "end": 140, "section": "title"}, {"text": "We have also discovered that out-clamps, in-plugs, and oligomerization are 3 general mechanisms for stabilizing weakly stable TM regions. In addition, we have found that extended and contiguous weakly stable regions often signal the existence of an oligomer and that strands located in the interfaces of protein-protein interactions are considerably less stable. Based on these observations, we can predict oligomerization states and can identify the interfaces of protein-protein interactions for beta-barrel membrane proteins by using either structure or sequence information", "begin": 884, "document": "19622743", "end": 1461, "section": "abstract"}, {"text": "We introduce a graph-theoretic model for predicting the supersecondary structure of transmembrane \u03b2-barrel proteins--a particular class of proteins that performs diverse important functions but it is difficult to determine their structure with experimental methods.", "begin": 0, "document": "22987359", "end": 265, "section": "abstract"}, {"text": "To conquer this limitation, we developed a new computational model that can be used for predicting the ASA of both TM \u03b1-helix and \u03b2-barrel residues.", "begin": 563, "document": "21935968", "end": 711, "section": "abstract"}, {"text": "Transmembrane beta barrel (TMB) proteins are found in the outer membranes of bacteria, mitochondria and chloroplasts.", "begin": 0, "document": "21426944", "end": 117, "section": "abstract"}, {"text": "Prediction of membrane spanning segments in beta-barrel outer membrane proteins (OMP) and their topology is an important problem in structural and functional genomics.", "begin": 0, "document": "19421989", "end": 167, "section": "abstract"}, {"text": "In the simplest of these, the target \"model\" is another protein sequence, while the more elaborate methods group together the entire set of t ansmembrane helical or transmembrane beta-barrel proteins.", "begin": 331, "document": "19153681", "end": 531, "section": "abstract"}, {"text": "Based on this study, we have developed a Web server, TBBPred, for predicting transmembrane beta-barrel regions in proteins (available at http://www.imtech.res.in/raghava/tbbpred).", "begin": 1169, "document": "15162482", "end": 1348, "section": "abstract"}]}, {"documents": ["23325628", "23221174", "22693219", "21062765", "19234603", "18834492", "18508809", "20671319", "20122157", "19850753", "18283029", "18204916", "15998455", "18834498", "18834495", "18834496", "18237434", "15941473", "18487273", "22513129", "15719064", "19828077", "18834500", "12689350", "21106487", "19594875"], "answer": [["BioCreative Meta Server"], ["BioMap"], ["eFIP", "Extracting Functional Impact of Phosphorylation"], ["GeneView"], ["Hidden Vector State model"], ["iHop"], ["LAITOR"], ["OntoGene"], ["PIE", "Protein interaction information extraction system"], ["PPI finder", "Paired-PPI Finder"], ["PPInterFinder"], ["PPIs"], ["PreBind", "Textomy"], ["STRING"], ["TafTalent"], ["PolySearch"], ["Protopia"], ["OpenDMAP"], ["HAPPI"]], "id": "5149aafcd24251bc05000045", "snippets": [{"text": "We implemented, PPInterFinder--a web-based text mining tool to extract human PPIs from biomedical literature. PPInterFinder uses relation keyword co-occurrences with protein names to extract information on PPIs from MEDLINE abstracts", "begin": 296, "document": "23325628", "end": 529, "section": "abstract"}, {"text": "PPInterFinder--a mining tool for extracting causal relations on human proteins from literature", "begin": 0, "document": "23325628", "end": 94, "section": "title"}, {"text": "eFIP system for text mining of protein interaction networks of phosphorylated proteins", "begin": 4, "document": "23221174", "end": 90, "section": "title"}, {"text": "We have developed the Extracting Functional Impact of Phosphorylation (eFIP) text mining system, which combines several natural language processing techniques to find relevant abstracts mentioning phosphorylation of a given protein together with indications of protein-protein interactions (PPIs) and potential evidences for impact of phosphorylation on the PPIs. eFIP integrates our previously developed tools, Extracting Gene Related ABstracts (eGRAB) for document retrieval and name disambiguation, Rule-based LIterature Mining System (RLIMS-P) for Protein Phosphorylation for extraction of phosphorylation information, a PPI module to detect PPIs involving phosphorylated proteins and an impact module for relation extraction.", "begin": 539, "document": "23221174", "end": 1269, "section": "abstract"}, {"text": "PPI finder: a mining tool for human protein-protein interactions", "begin": 0, "document": "19234603", "end": 64, "section": "title"}, {"text": "PIE: an online prediction system for protein-protein interactions from text", "begin": 0, "document": "18508809", "end": 75, "section": "title"}, {"text": "We describe a system for the detection of mentions of protein-protein interactions in the biomedical scientific literature. The original system was developed as a part of the OntoGene project", "begin": 0, "document": "20671319", "end": 191, "section": "abstract"}, {"text": "Extracting Protein-Protein Interactions from MEDLINE using the Hidden Vector State model", "begin": 0, "document": "18283029", "end": 88, "section": "title"}, {"text": "We have constructed an information extraction system based on the Hidden Vector State (HVS) model for protein-protein interactions.", "begin": 153, "document": "18283029", "end": 284, "section": "abstract"}, {"text": "When applied in extracting protein-protein interactions, we found that it performed better than other established statistical methods", "begin": 438, "document": "18283029", "end": 571, "section": "abstract"}, {"text": "The developed BioMap system allows discovering implicit P-P interactions from large quantity of biomedical literature data.", "begin": 1732, "document": "18204916", "end": 1855, "section": "abstract"}, {"text": "In this paper we examine if P-P interactions in regenerating tissues and cells of the anuran Xenopus laevis can be discovered from biomedical literature using computational and literature mining techniques. Using literature mining techniques, we have identified a set of implicitly interacting proteins in regenerating tissues and cells of Xenopus laevis that may interact with Cdc2 to control cell division.", "begin": 669, "document": "18204916", "end": 1077, "section": "abstract"}, {"text": "P-P interactions that are implicitly appearing in literature can be effectively discovered using literature mining techniques.", "begin": 1434, "document": "18204916", "end": 1560, "section": "abstract"}]}, {"documents": ["23365410", "18081932", "18025684", "15701682", "15215406", "12519996", "11820254", "10573422", "23236161", "17963500", "11752322", "15130848", "22250127", "21729286", "18949021", "21342538"], "answer": [["fdfBLAST"], ["FusionDB"], ["InPrePPI", "Integrated method for Prediction of Protein-Protein Interactions"], ["MosaicFinder"], ["Phydbac2"], ["PLEX"], ["Predictome"], ["Rosetta Stone method"], ["STRING"]], "id": "5149af96d24251bc05000046", "snippets": [{"text": "MosaicFinder: Identification of fused gene families in sequence similarity networks", "begin": 0, "document": "23365410", "end": 83, "section": "title"}, {"text": "Inference of gene function based on gene fusion events: the rosetta-stone method.", "begin": 0, "document": "18025684", "end": 81, "section": "title"}, {"text": "The basic idea is based on the principle of \"guilt by association.\" It is assumed that two proteins, which are found to be transcribed by a single transcript in one (or several) genomes are likely to be functionally linked, for example by acting in a same metabolic pathway or by forming a multiprotein complex. This method is of particular interest for studying genes that exhibit no, or only remote, homologies with already well-characterized proteins", "begin": 106, "document": "18025684", "end": 559, "section": "abstract"}, {"text": "This chapter uses the FusionDB database (http://www.igs.cnrs-mrs.fr/FusionDB/) as source of information. FusionDB provides a characterization of a large number of gene fusion events at hand of multiple sequence alignments.", "begin": 836, "document": "18025684", "end": 1058, "section": "abstract"}, {"text": "PLEX can be searched iteratively and also enables searches for chromosomal gene neighbors and Rosetta Stone linkages.", "begin": 351, "document": "15701682", "end": 468, "section": "abstract"}, {"text": "While phylogenomic profiles remain the central focus of Phydbac2, it now integrates chromosomal proximity and gene fusion analyses as two additional non-similarity-based indicators for inferring pairwise gene functional relationships.", "begin": 466, "document": "15215406", "end": 700, "section": "abstract"}, {"text": "Functional links between proteins can often be inferred from genomic associations between the genes that encode them: groups of genes that are required for the same function tend to show similar species coverage, are often located in close proximity on the genome (in prokaryotes), and tend to be involved in gene-fusion events. The database STRING is a precomputed global resource for the exploration and analysis of these associations.", "begin": 0, "document": "12519996", "end": 437, "section": "abstract"}, {"text": "Functional associations of proteins in entire genomes by means of exhaustive detection of gene fusions", "begin": 0, "document": "11820254", "end": 102, "section": "title"}, {"text": "Protein interaction maps for complete genomes based on gene fusion events", "begin": 0, "document": "10573422", "end": 73, "section": "title"}, {"text": "Here we present a method that identifies gene-fusion events in complete genomes, solely based on sequence comparison.", "begin": 642, "document": "10573422", "end": 759, "section": "abstract"}, {"text": "Gene fusions have been suggested to be useful characters for identifying evolutionary relationships because they constitute synapomorphies or cladistic characters. To investigate the fidelity of gene-fusion characters, we developed an approach for identifying differentially distributed gene fusions among whole-genome datasets: fdfBLAST.", "begin": 232, "document": "23236161", "end": 570, "section": "abstract"}, {"text": "Genome-scale comparative analysis of gene fusions, gene fissions", "begin": 0, "document": "23236161", "end": 64, "section": "title"}, {"text": "Here we present Predictome, a database of predicted links between the proteins of 44 genomes based on the implementation of three computational methods--chromosomal proximity, phylogenetic profiling and domain fusion", "begin": 604, "document": "11752322", "end": 820, "section": "abstract"}, {"text": "Pairs of genes that function together in a pathway or cellular system can sometimes be found fused together in another organism as a Rosetta Stone protein--a fusion protein whose separate domains are homologous to the two functionally-related proteins.", "begin": 0, "document": "15130848", "end": 252, "section": "abstract"}, {"text": "Using the Rosetta Stone method and this scoring scheme, we find all significant functional linkages for proteins of E. coli, P. horikshii and S. cerevisiae, and measure the extent of the resulting protein networks.", "begin": 781, "document": "15130848", "end": 995, "section": "abstract"}]}, {"documents": ["23371464", "23347730", "22738860", "22553468", "21479927", "21347257", "21291290", "21151591", "21081926", "20359886", "20204499", "20094918", "19214742", "19126254", "18786252", "18483364"], "answer": ["70 genes"], "id": "514a0f4ad24251bc05000053", "snippets": [{"text": "The 70-gene signature (MammaPrint\u2122)", "begin": 0, "document": "23371464", "end": 35, "section": "abstract"}, {"text": "n FDA-cleared 70-gene signature of MammaPrint panel", "begin": 1433, "document": "21479927", "end": 1484, "section": "abstract"}, {"text": "70-gene MammaPrint signature", "begin": 22, "document": "21291290", "end": 50, "section": "title"}, {"text": "70-gene signature", "begin": 26, "document": "20359886", "end": 43, "section": "title"}, {"text": "70-gene signature", "begin": 26, "document": "20359886", "end": 43, "section": "title"}, {"text": "70-gene signature", "begin": 26, "document": "20359886", "end": 43, "section": "title"}, {"text": "the 70-gene MammaPrint signature for chemotherapy (CT) benefit", "begin": 158, "document": "20204499", "end": 220, "section": "abstract"}, {"text": "the 70-gene MammaPrint signature", "begin": 61, "document": "20094918", "end": 93, "section": "title"}, {"text": "The 70-gene signature (MammaPrint) is a prognostic tool used to guide adjuvant treatment decisions.", "begin": 0, "document": "19214742", "end": 99, "section": "abstract"}, {"text": "the 70-gene profile", "begin": 214, "document": "19214742", "end": 233, "section": "abstract"}]}, {"documents": ["20821198"], "answer": ["none", "0", "zero"], "id": "5150b807d24251bc05000072", "snippets": []}, {"documents": ["22925379", "22386826", "21591526", "21324833", "21054594", "20338870", "14662775"], "answer": [["Elonza"], ["Caverta"], ["Zenegra-100"], ["Vega Asia"], ["Suhagra-100"], ["Vega"]], "id": "5150f401d24251bc05000075", "snippets": []}, {"documents": ["18434328", "11001925", "23346162", "22068590", "9541111", "8664565", "23390130", "22987702", "22435031", "21488203", "20682747", "20434914", "19846786", "19084976", "18358876", "17621527", "17005396", "14660569", "12391329", "12031625", "11456308", "10714588", "10502779", "10323249", "10063835", "9781038", "9736772", "9305655", "9450905"], "answer": ["MTM1 gene test"], "id": "51542dabd24251bc0500007d", "snippets": [{"text": "X-linked myotubular myopathy (MTM) is a severe neuromuscular disease of infancy caused by mutations of MTM1, which encodes the phosphoinositide lipid phosphatase, myotubularin", "begin": 0, "document": "22068590", "end": 175, "section": "abstract"}, {"text": "As a gene for X linked MTM was recently identified in Xq28, we screened the obligatory carrier mothers for mutation. We found a 4 bp deletion in exon 4 of the MTM1 gene,", "begin": 169, "document": "9541111", "end": 338, "section": "abstract"}, {"text": "X-linked Myotubular Myopathy has clearly shown the benefits to be gained from a multinational research consortium with a common interest in identifying and cloning the MTM1 gene.", "begin": 88, "document": "8664565", "end": 266, "section": "abstract"}, {"text": "Myotubular myopathy (MTM1) is an X-linked disease, characterized by severe neonatal hypotonia and generalized muscle weakness, with pathological features suggesting an impairment in maturation of muscle fibres. The MTM1 gene encodes a protein (myotubularin) with a phosphotyrosine phosphatase consensus.", "begin": 0, "document": "11001925", "end": 303, "section": "abstract"}, {"text": "myotubular myopathy (XLMTM), a severe congenital muscular disorder due to loss-of-function mutations in the MTM1 gene,", "begin": 154, "document": "23390130", "end": 272, "section": "abstract"}, {"text": "We established a colony of dogs that harbor an X-linked MTM1 missense mutation.Muscle from affected male dogs exhibits reduction and altered localization of the MTM1 gene product, myotubularin, and provides a model analogous to X-linked myotubular myopathy (XLMTM)", "begin": 12, "document": "22987702", "end": 276, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM) is a rare congenital myopathy, usually characterized by severe hypotonia and respiratory insufficiency at birth, in affected, male infants. The disease is causally associated with mutations in the MTM1 gene, coding for phosphatase myotubularin.", "begin": 0, "document": "22435031", "end": 281, "section": "abstract"}, {"text": "Mutations in the MTM1 gene encoding myotubularin cause X-linked myotubular myopathy (XLMTM), a well-defined subtype of human centronuclear myopathy.", "begin": 0, "document": "20682747", "end": 148, "section": "abstract"}, {"text": "MTM1 gene sequencing revealed a unique exon 7 variant in all seven affected males, causing a nonconservative missense change, p.N155K, which haplotype data suggest derives from a recent founder in the local population.", "begin": 690, "document": "20682747", "end": 908, "section": "abstract"}, {"text": "X-linked centronuclear myopathy (XLMTM), also called myotubular myopathy, is a severe congenital myopathy characterized by generalized hypotonia and weakness at birth and the typical histological finding of centralization of myo-nuclei. It is caused by mutations in the MTM1 gene encoding the 3-phosphoinositides phosphatase myotubularin.", "begin": 0, "document": "20434914", "end": 338, "section": "abstract"}, {"text": "sequencing all MTM1 exons", "begin": 551, "document": "20434914", "end": 576, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM), a severe congenital disorder due to loss of function mutations in the MTM1 gene, encoding myotubularin, a phosphoinositide phosphatase thought to have a role in plasma membrane homeostasis and endocytosis.", "begin": 377, "document": "19846786", "end": 620, "section": "abstract"}, {"text": "Mutations in the gene encoding the phosphoinositide phosphatase myotubularin 1 protein (MTM1) are usually associated with severe neonatal X-linked myotubular myopathy (XLMTM). However, mutations in MTM1 have also been recognized as the underlying cause of \"atypical\" forms of XLMTM in newborn boys, female infants, female manifesting carriers and adult men.", "begin": 0, "document": "19084976", "end": 357, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM), a recessive disorder, is caused by mutations affecting the myotubulatin (MTM1) gene located on the X chromosome. Most of the affected males die in the early postnatal period whereas female carriers are usually asymptomatic.", "begin": 12, "document": "18358876", "end": 273, "section": "abstract"}, {"text": "The authors present a patient with the most severe X-linked recessive type (XLMTM).", "begin": 114, "document": "17621527", "end": 197, "section": "abstract"}, {"text": "The diagnosis was confirmed and further specified by genetic analysis, revealing a novel frameshift mutation (1314-1315insT) of the myotubularin-coding MTM1 gene.", "begin": 380, "document": "17621527", "end": 542, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM) is a congenital muscle disorder caused by mutations in the MTM1 gene.", "begin": 0, "document": "17005396", "end": 106, "section": "abstract"}, {"text": "MTM1, the gene encoding myotubularin (MTM1), is mutated in the X-linked myotubular myopathy (XLMTM), a severe genetic muscular disorder", "begin": 0, "document": "14660569", "end": 135, "section": "abstract"}, {"text": "Myotubularin is a ubiquitously expressed phosphatase that acts on phosphatidylinositol 3-monophosphate [PI(3)P], a lipid implicated in intracellular vesicle trafficking and autophagy. It is encoded by the MTM1 gene, which is mutated in X-linked myotubular myopathy (XLMTM), a muscular disorder characterized by generalized hypotonia and muscle weakness at birth leading to early death of most affected males.", "begin": 0, "document": "12391329", "end": 408, "section": "abstract"}, {"text": "The entire coding sequence of the gene was screened in 10 XLMTM patients using this technique.", "begin": 776, "document": "12031625", "end": 870, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM; OMIM# 310400) is a severe congenital muscle disease caused by mutations in the myotubularin (MTM1) gene.", "begin": 0, "document": "12031625", "end": 141, "section": "abstract"}, {"text": "Mutations in the MTM1 gene cause X-linked recessive myotubular myopathy (XLMTM; MIM310400).", "begin": 0, "document": "11456308", "end": 91, "section": "abstract"}, {"text": "We screened 29 independant patients with XLMTM phenotype and four with centronuclear myopathy. 87% (21/24) of patients with known MTM1 mutations showed abnormal myotubularin levels, including some with missense mutations.", "begin": 445, "document": "11456308", "end": 666, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM) characteristically causes severe or fatal muscle weakness in male infants. Mutations in the gene MTM1, encoding the protein myotubularin, can be identified in most families.", "begin": 0, "document": "10714588", "end": 210, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM) is a congenital muscular disease characterized by severe hypotonia and generalized muscle weakness, leading in most cases to early postnatal death. The gene responsible for the disease, MTM1, encodes a dual specificity phosphatase, named myotubularin, which is highly conserved throughout evolution.", "begin": 0, "document": "10502779", "end": 336, "section": "abstract"}, {"text": "X-linked recessive myotubular myopathy (XLMTM) is a muscle disorder usually affecting newborn males. In the majority of cases, muscle weakness and hypotonia lead to a rapid demise at neonatal age. The responsible MTM1 gene is located in proximal Xq28.", "begin": 0, "document": "10323249", "end": 251, "section": "abstract"}, {"text": "X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disorder due to mutations in the MTM1 gene.", "begin": 0, "document": "9736772", "end": 110, "section": "abstract"}, {"text": "X-linked recessive myotubular myopathy (XLMTM) is characterized by severe hypotonia and generalized muscle weakness, with impaired maturation of muscle fibres. The gene responsible, MTM1, was identified recently by positional cloning, and encodes a protein (myotubularin) with a tyrosine phosphatase domain (PTP).", "begin": 0, "document": "9305655", "end": 313, "section": "abstract"}, {"text": "X-linked recessive myotubular myopathy (XLMTM; MTM1) is a severe neonatal disorder often causing perinatal death of the affected males. The responsible gene, designated MTM1, was localized to proximal Xq28 and recently isolated. The characterization of MTM1 allowed us to screen for causing mutations in three families, previously investigated by linkage analysis. Using exon amplification, single strand conformation polymorphism, and subsequent sequencing analysis, three new mutations and their mutational origin were characterized by analyzing 10 exons.", "begin": 0, "document": "9450905", "end": 557, "section": "abstract"}]}, {"documents": ["18855539", "17245797", "12719670", "12869229"], "answer": [["fever"], ["enathema"], ["skin rash"], ["nausea"], ["vomiting"], ["diarrhea"], ["cough"], ["gastrointestinal disorders"], ["anaphylactic shock"], ["respiratory symptoms"]], "id": "51542dc3d24251bc0500007e", "snippets": [{"text": "patients receiving abacavir develop a hypersensitivity reaction, characterized by rash, fever and, occasionally, multisystemic involvement", "begin": 148, "document": "18855539", "end": 286, "section": "abstract"}, {"text": "patients who receive abacavir develop an idiosyncratic hypersensitivity reaction. The most common symptoms are fever, skin rash and gastrointestinal disorders. Respiratory symptoms occurred in approximately 20% of patients who have hypersensitivity reaction. We describe the first case, to our knowledge, of hypesensitivity reaction characterized by enanthema and fever without skin rash promptly resolved after discontinuation of abacavir", "begin": 176, "document": "12719670", "end": 615, "section": "abstract"}, {"text": "Rash was associated with hypersensitivity (odds ratio [OR] = 13.1, P = 0.02) as was the presence of nausea (OR = 30, P < 0.001), vomiting (OR = 17.1, P = 0.001) or diarrhoea (OR = 22, P < 0.001). The number of gastrointestinal symptoms was also predictive of hypersensitivity reaction (", "begin": 229, "document": "12869229", "end": 515, "section": "abstract"}, {"text": "the number of gastrointestinal symptoms (OR = 8.6, P = 0.0032), cough (OR = 0.039, P = 0.02) and rash (OR = 16.9, P = 0.07). Abacavir hypersensitivity is strongly associated with gastrointestinal (GI) symptoms.", "begin": 747, "document": "12869229", "end": 957, "section": "abstract"}]}, {"documents": ["23332287", "22738915", "22263058", "21904575", "21777765", "21430269", "20948254", "20705455", "20007486", "19808904", "18997733", "16730855", "16705038", "16049312", "15737014", "23507588", "22920167", "22806307", "20647703", "20512075", "19063875", "18799900", "18726117", "17575237", "17145836", "16199108", "16009451", "15329413"], "answer": ["epidermal growth factor receptor (EGFR) gene"], "id": "51542e44d24251bc05000081", "snippets": [{"text": "Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in non-small-cell lung cancer (NSCLC),", "begin": 0, "document": "23332287", "end": 124, "section": "abstract"}, {"text": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group.", "begin": 223, "document": "23332287", "end": 445, "section": "abstract"}, {"text": "Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib,", "begin": 53, "document": "22738915", "end": 361, "section": "abstract"}, {"text": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer (NSCLC). Patients with somatic activating mutations in the EGFR gene have dramatic response initially, but would eventually develop resistance to these TKIs.", "begin": 0, "document": "22263058", "end": 341, "section": "abstract"}, {"text": "NSCLCs with EGFR mutations (exon 19 deletions or the exon 21 L858R) attain responses to EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, with improved response rate (RR), progression-free survival (PFS) and in some reports overall survival (OS) when compared with EGFR wildtype (WT) cases.", "begin": 242, "document": "21904575", "end": 546, "section": "abstract"}, {"text": "Patients presenting with non-small cell lung cancer (NSCLC) and active EGFR mutation have a high response rate (60-70%) to EGFR tyrosine kinase inhibitors (TKI) with little immediate progression (primary resistance).", "begin": 0, "document": "21777765", "end": 216, "section": "abstract"}, {"text": "Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges.", "begin": 0, "document": "21430269", "end": 163, "section": "abstract"}, {"text": "lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib;", "begin": 24, "document": "20007486", "end": 188, "section": "abstract"}, {"text": "The development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) seems almost inevitable, even in patients with lung cancer that initially respond well to EGFR-TKIs.", "begin": 0, "document": "19808904", "end": 204, "section": "abstract"}, {"text": "Gefitinib- or erlotinib-resistant sublines were established by exposing the parental PC-9 cell line to chronic, repeated treatments with these drugs. These resistant sublines showed more than 100-fold more resistance to gefitinib and erlotinib and acquired cross-resistance to other EGFR-TKIs. The T790M EGFR mutation was found by pyrosequencing, and this seemed to be the cause of drug resistance.", "begin": 425, "document": "19808904", "end": 823, "section": "abstract"}, {"text": "Patients with advanced pulmonary adenocarcinoma exhibiting overexpression or mutation of epidermal growth factor receptor tend to respond better to targeted therapy with tyrosine kinase inhibitors such as gefitinib and erlotinib.", "begin": 0, "document": "18997733", "end": 229, "section": "abstract"}, {"text": "Mutations of the epidermal growth factor receptor (EGFR) gene have been reported in non-small-cell lung cancer (NSCLC), especially in patients with adenocarcinoma and never smokers. Some common somatic mutations in EGFR, including deletion mutations in exon 19 and leucine-to-arginine substitution at amino acid position 858 (L858R) in exon 21, have been examined for their ability to predict sensitivity to gefitinib or erlotinib, which are selective EGFR tyrosine kinase inhibitors (EGFR-TKIs).", "begin": 0, "document": "16730855", "end": 496, "section": "abstract"}, {"text": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.", "begin": 0, "document": "16705038", "end": 249, "section": "abstract"}, {"text": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib.", "begin": 0, "document": "16049312", "end": 196, "section": "abstract"}, {"text": "Epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)(such as gefitinib or erlotinib)treatment of lung cancer harboring EGFR gene mutation is one of the prototypes of such therapies.", "begin": 325, "document": "23507588", "end": 523, "section": "abstract"}, {"text": "The evidence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) such as gefitinib and erlotinib was first confirmed as the second-line treatment for non-selective patients with advanced NSCLC.", "begin": 491, "document": "20647703", "end": 707, "section": "abstract"}, {"text": "patients with EGFR-mutated advanced NSCLC, the first-line treatment with gefitinib had achieved a significant prolongation of progression-free survival compared with standard platinum doublet chemotherapy in a few phase III trials, and became a new standard of care. Gefitinib is highly effective for patients with advanced NSCLC with EGFR mutation even if their performance status is poor, although one should always pay careful attention to fatal interstitial lung disease.", "begin": 927, "document": "20647703", "end": 1402, "section": "abstract"}, {"text": "EGFR tyrosine kinase inhibitors (gefitinib, erlotinib), which are molecularly targeted drugs, and it has now become possible to select treatment methods by choosing from a number of anticancer drugs. EGFR tyrosine kinase inhibitors have been demonstrated to have a very high cytoreductive effect on lung cancers that have EGFR gene mutations.", "begin": 1051, "document": "18799900", "end": 1393, "section": "abstract"}, {"text": "the epidermal growth factor receptor (EGFR) was a therapeutic target in non-small cell lung cancer (NSCLC) and other cancers led to development of the small-molecule receptor tyrosine kinase inhibitors gefitinib and erlotinib.", "begin": 28, "document": "17145836", "end": 254, "section": "abstract"}, {"text": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy.", "begin": 0, "document": "16199108", "end": 170, "section": "abstract"}, {"text": "Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib.", "begin": 0, "document": "16009451", "end": 262, "section": "abstract"}, {"text": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.", "begin": 0, "document": "15329413", "end": 204, "section": "abstract"}, {"text": "frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "begin": 1567, "document": "15329413", "end": 1689, "section": "abstract"}]}, {"documents": ["22211527", "21424386", "21306565", "21169036", "20345939", "19915237", "19694795", "18855540", "18637831", "16415921", "15057820"], "answer": ["Han Chinese and other Asian populations, except Japanese"], "id": "51542e6fd24251bc05000082", "snippets": [{"text": "A strong association between human leukocyte antigen (HLA)-B*1502 and CBZ-induced SJS/TEN has been reported in Han Chinese, Thai, Malaysian and Indian populations, but not in Caucasian or Japanese populations.", "begin": 229, "document": "22211527", "end": 438, "section": "abstract"}, {"text": "A strong association between HLA-B*1502 and carbamazepine-induced SJS/TEN has been identified in Chinese and Thai.", "begin": 274, "document": "21306565", "end": 388, "section": "abstract"}, {"text": "A strong association between HLA-B*1502 and CBZ-induced SJS/TEN has been reported in Han Chinese but not in Caucasian and Japanese populations. A case-control study was conducted to determine whether HLA-B*1502 is a valid pharmacogenetic test for SJS/TEN caused by CBZ in a Thai population.", "begin": 189, "document": "20345939", "end": 479, "section": "abstract"}, {"text": "Results from this study suggest that HLA-B*1502 may be a useful pharmacogenetic test for screening Thai individuals who may be at risk for CBZ-induced SJS and TEN.", "begin": 1120, "document": "20345939", "end": 1283, "section": "abstract"}, {"text": "A strong association has been reported between human leucocyte antigen (HLA)-B*1502 and carbamazepine-induced SJS in Han Chinese patients. European studies suggested that HLA-B*1502 is not a universal marker but is ethnicity-specific for Asians.", "begin": 169, "document": "19915237", "end": 414, "section": "abstract"}, {"text": "the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese.", "begin": 189, "document": "19694795", "end": 308, "section": "abstract"}, {"text": "the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese,", "begin": 134, "document": "18855540", "end": 265, "section": "abstract"}, {"text": "This allele is seen in high frequency in many Asian populations other than Han Chinese, but there are few data on whether the allele is a marker for this severe outcome in anyone other than Han Chinese.", "begin": 323, "document": "18855540", "end": 525, "section": "abstract"}, {"text": "A very strong association of carbamazepine-induced SJS with HLA-B*1502 has recently been described in the Han Chinese population.", "begin": 234, "document": "16415921", "end": 363, "section": "abstract"}, {"text": "there is a strong association in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and Stevens-Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures", "begin": 172, "document": "15057820", "end": 394, "section": "abstract"}]}, {"documents": ["22974536", "22674970", "22624833", "22464343", "22154242", "22088980", "21803320", "20435227", "20083681", "19706858", "18577829", "18004210", "17681590"], "answer": ["CYP2C19 genotyping"], "id": "5156be04d24251bc05000085", "snippets": [{"text": "polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics.", "begin": 607, "document": "22674970", "end": 677, "section": "abstract"}, {"text": "polymorphisms in the CYP2C19 gene affect clopidogrel pharmacokinetics. These polymorphisms may be useful to identify clopidogrel nonresponders who may benefit from taking an alternative antiplatelet agent such as prasugrel and ticagrelor. Although both drugs have pharmacogenomic tests available for clinical use,", "begin": 607, "document": "22674970", "end": 920, "section": "abstract"}, {"text": "The CYP2C19*2 allele is a common genetic variant associated with increased rates of major adverse events in individuals given clopidogrel after percutaneous coronary intervention (PCI). We used a novel point-of-care genetic test to identify carriers of the CYP2C19*2 allele and aimed to assess a pharmacogenetic approach to dual antiplatelet treatment after PCI", "begin": 136, "document": "22464343", "end": 497, "section": "abstract"}, {"text": "The antiplatelet effect of clopidogrel has been linked to cytochrome P450 2C19 (CYP2C19) carrier status. The presence of loss of function and gain of function variants were found to have a gene-dose effect on clopidogrel metabolism. However, genotyping is only one aspect of predicting response to clopidogrel and several platelet function tests are available to measure platelet response.", "begin": 12, "document": "22154242", "end": 401, "section": "abstract"}, {"text": "The cytochrome P450 (CYP) 2C19*2 loss-of-function allele has been associated with impaired clopidogrel response and worse prognosis in clopidogrel-treated patients.", "begin": 0, "document": "21803320", "end": 164, "section": "abstract"}, {"text": "The present study was designed to evaluate the benefit of tailored therapy with a higher maintenance dose according to CYP2C19 genotypes in patients identified as nonresponders who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.", "begin": 357, "document": "21803320", "end": 637, "section": "abstract"}, {"text": "The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in clopidogrel metabolization. A recently explored CYP2C19*17 allelic variant has been linked to increased transcriptional activity, resulting in extensive metabolization of CYP2C19 substrates, which may lead to an enhanced platelet response to clopidogrel treatment.", "begin": 12, "document": "20083681", "end": 344, "section": "abstract"}, {"text": "to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment.", "begin": 37, "document": "18004210", "end": 285, "section": "abstract"}, {"text": "Genetic polymorphisms significantly influence responses to warfarin and clopidogrel.", "begin": 0, "document": "22674970", "end": 84, "section": "abstract"}, {"text": "A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel.", "begin": 12, "document": "22974536", "end": 286, "section": "abstract"}]}, {"documents": ["21810886", "21071407", "19034656", "19016570", "17440145", "19412502", "16280409", "15520364", "15052512", "12908614", "21810375", "23018612"], "answer": ["major depression"], "id": "5156be17d24251bc05000086", "snippets": [{"text": "mirtazapine will make it the first-choice drug in depressive patients with gastric ulcers.", "begin": 1475, "document": "19034656", "end": 1565, "section": "abstract"}, {"text": "If antidepressants are used to treat insomnia, sedating ones should be preferred over activating agents such as serotonin reuptake inhibitors. In general, drugs lacking strong cholinergic activity should be preferred. Drugs blocking serotonin 5-HT2A or 5-HT2C receptors should be preferred over those whose sedative property is caused by histamine receptor blockade only. The dose should be as low as possible (e.g. as an initial dose: doxepin 25 mg, mirtazapine 15 mg, trazodone 50 mg, trimipramine 25 mg). Regarding the lack of substantial data allowing for evidence-based recommendations, we are facing a clear need for well designed, long-term, comparative studies to further define the role of antidepressants versus other agents in the management of insomnia.", "begin": 1695, "document": "19016570", "end": 2460, "section": "abstract"}, {"text": "A case report involving linezolid with citalopram and mirtazepine in the precipitation of serotonin syndrome in a critically ill bone marrow transplant patient is described in this article.", "begin": 521, "document": "16280409", "end": 710, "section": "abstract"}, {"text": "Mirtazapine was the most common AD in 2001, followed by citalopram, sertraline, and doxepin.", "begin": 997, "document": "15052512", "end": 1089, "section": "abstract"}, {"text": "antidepressant treatment with mirtazapine", "begin": 350, "document": "12908614", "end": 391, "section": "abstract"}]}, {"documents": ["23560086", "23485811", "23269581", "23001356", "22659469", "22518321", "22315408", "21807765", "21035445", "20949564", "21136867", "17314675"], "answer": [["neurodegenerative disease"], ["epilepsy"], ["schizophrenia"], ["Huntington's disease (HD)"], ["Alzheimer's disease (AD)"], ["neuroinflammation"], ["osteosarcoma"], ["chronic lymphocytic leukemia (CLL)"], ["angiogenesis"], ["eye disease"], ["alcoholic liver disease"], ["progressive supranuclear palsy (PSP taupathy)"], ["mild cognitive impairment"]], "id": "5156be75d24251bc05000088", "snippets": [{"text": "Chronic lymphocytic leukemia (CLL) is a disease with variable clinical outcome. Several prognostic factors such as the immunoglobulin heavy chain variable genes (IGHV) mutation status are linked to the B-cell receptor (BCR) complex, supporting a role for triggering the BCR in vivo in the pathogenesis.", "begin": 0, "document": "23560086", "end": 302, "section": "abstract"}, {"text": "miRNA and mRNA expression was measured using hybridization arrays and qPCR. We found both IGHV mutated and unmutated CLL cells to respond with increased expression of MYC and other genes associated with BCR activation, and a phenotype of cell cycle progression. Genome-wide expression studies showed hsa-miR-132-3p/hsa-miR-212 miRNA cluster induction associated with a set of downregulated genes, enriched for genes modulated by BCR activation and amplified by Myc.", "begin": 502, "document": "23560086", "end": 967, "section": "abstract"}, {"text": "Levels of six candidate miRNAs (miR-21, miR-199a-3p, miR-143, miR-34, miR-140, and miR-132) that were previously demonstrated to be regulated in osteosarcoma were examined in plasma of 40 osteosarcoma patients and 40 matched healthy controls by quantitative reverse-transcription polymerase chain reaction assays.", "begin": 588, "document": "23269581", "end": 901, "section": "abstract"}, {"text": "Early stages of many neurodegenerative diseases, such as Alzheimer's disease, vascular and frontotemporal dementia, and Parkinson's disease, are frequently associated with Mild Cognitive Impairment (MCI).", "begin": 0, "document": "23001356", "end": 204, "section": "abstract"}, {"text": "Functional studies employing antagomirs have identified contributions from miR-34a and miR-132 to seizure-induced neuronal death whereas silencing miR-134 potently reduced status epilepticus, seizure-damage and the later occurrence of spontaneous seizures. Efforts to identify the in vivo target(s) of epilepsy-regulated miRNAs, is now a priority. Last, miRNA are stable, information-carrying (paracrine) signals. Profiling miRNA in biofluids may represent a novel source of disease biomarkers in epilepsy.", "begin": 1538, "document": "23485811", "end": 2044, "section": "abstract"}, {"text": "sensitivity and specificity at 79%-100% (miR-132 family) and 79%-95% (miR-134 family), and p\u30080.001. In a separate longitudinal study, the identified miRNA biomarker pairs successfully detected MCI in majority of patients at asymptomatic stage 1-5 years prior to clinical diagnosis.", "begin": 1040, "document": "23001356", "end": 1321, "section": "abstract"}, {"text": "Herpes simplex virus (HSV) causes a chronic immuno-inflammatory response in the eye that may result in corneal neovascularization during blinding immunopathological lesion stromal keratitis (SK). miR-132 is a highly conserved miRNA that is induced in endothelial cells in response to growth factors, such as vascular endothelial growth factor (VEGF).", "begin": 119, "document": "22659469", "end": 469, "section": "abstract"}, {"text": "miR-132 expression was up-regulated (10- to 20-fold) after ocular infection with HSV, an event that involved the production of both VEGF-A and IL-17.", "begin": 498, "document": "22659469", "end": 647, "section": "abstract"}, {"text": "The anti-angiogenic effect of antagomir-132 was reflected by a reduction in angiogenic Ras activity in corneal CD31-enriched cells (presumably blood vessel endothelial cells) during SK. To our knowledge, this is one of the first reports of miRNA involvement in an infectious ocular disease. Manipulating miRNA expression holds promise as a therapeutic approach to control an ocular lesion that is an important cause of human blindness.", "begin": 1091, "document": "22659469", "end": 1526, "section": "abstract"}, {"text": "Role of miR-132 in angiogenesis", "begin": 0, "document": "22659469", "end": 31, "section": "title"}, {"text": "The cyclic AMP-responsive element binding- and NMDA-regulated microRNA miR-132 was significantly down-regulated in both the schizophrenic discovery cohort and a second, independent set of schizophrenic subjects. Analysis of miR-132 target gene expression in schizophrenia gene-expression microarrays identified 26 genes up-regulated in schizophrenia subjects.", "begin": 459, "document": "22315408", "end": 818, "section": "abstract"}, {"text": "Our data suggest miR-132 dysregulation and subsequent abnormal expression of miR-132 target genes contribute to the neurodevelopmental and neuromorphological pathologies present in schizophrenia.", "begin": 1545, "document": "22315408", "end": 1740, "section": "abstract"}, {"text": "Analysis of miRNA expression profiles from sporadic progressive supranuclear palsy (PSP) patients, a major 4R-tau tauopathy, showed that miR-132 is specifically down-regulated in disease. We demonstrate that miR-132 directly targets the neuronal splicing factor polypyrimidine tract-binding protein 2 (PTBP2), which protein levels were increased in PSP patients. miR-132 overexpression or PTBP2 knockdown similarly affected endogenous 4R:3R-tau ratios in neuronal cells. Finally, we provide evidence that miR-132 is inversely correlated with PTBP2 during post-natal brain development at the time when 4R-tau becomes expressed. Taken together, these results suggest that changes in the miR-132/PTBP2 pathway could contribute to the abnormal splicing of tau exon 10 in the brain, and sheds light into the potential role played by miRNAs in a subset of tauopathies.", "begin": 768, "document": "21807765", "end": 1630, "section": "abstract"}, {"text": "Huntington's disease (HD) is a genetic neurodegenerative disease caused by abnormal CAG expansion. MicroRNAs (miRNAs) are short RNA molecules regulating gene expression, and are implicated in a variety of diseases including HD.", "begin": 0, "document": "21035445", "end": 227, "section": "abstract"}, {"text": "Nine miRNAs (miR-22, miR-29c, miR-128, miR-132, miR-138, miR-218, miR-222, miR-344, and miR-674*) were commonly down-regulated in both the 12-month-old YAC128 and 10-week-old R6/2 mice.", "begin": 1117, "document": "21035445", "end": 1302, "section": "abstract"}, {"text": "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments.", "begin": 103, "document": "20949564", "end": 236, "section": "abstract"}, {"text": "Osteosarcoma of rat and human origins showed a miRNA signature, which could discriminate good from bad responders. In particular, we identified five discriminating miRNAs (miR-92a, miR-99b, miR-132, miR-193a-5p and miR-422a) in patient tumors, which could be easily transferable to diagnosis.", "begin": 1014, "document": "20949564", "end": 1306, "section": "abstract"}, {"text": "Levels of several microRNA (miR-10a, -10b, -212, -132, -495) were significantly altered. One of them (miR-132) has been reported to be highly inducible by growth factors and to be a key regulator of neurite outgrowth. Moreover, miR-132-recognition sequences were detected in the mRNA transcripts of two differentially expressed proteins. MicroRNA may thus represent novel biomarkers for neuronal malfunction and potential therapeutic targets for human neurodegenerative diseases.", "begin": 1097, "document": "21136867", "end": 1576, "section": "abstract"}, {"text": "The data indicate that micro-RNAs encoding miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 are abundantly represented in fetal hippocampus, are differentially regulated in aged brain, and an alteration in specific micro-RNA complexity occurs in Alzheimer hippocampus. These data are consistent with the idea that altered micro-RNA-mediated processing of messenger RNA populations may contribute to atypical mRNA abundance and neural dysfunction in Alzheimer's disease brain.", "begin": 407, "document": "17314675", "end": 889, "section": "abstract"}]}, {"documents": ["23439366", "21441598", "19945378", "20109154", "19706170", "18971321", "17537822", "16545108"], "answer": ["CRISPR-Cas"], "id": "5157539ed24251bc0500008a", "snippets": [{"text": "he CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi).", "begin": 1, "document": "23439366", "end": 304, "section": "abstract"}, {"text": "RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex.", "begin": 0, "document": "19945378", "end": 60, "section": "title"}, {"text": "Compelling evidence indicates that the CRISPR-Cas system protects prokaryotes from viruses and other potential genome invaders.", "begin": 0, "document": "19945378", "end": 127, "section": "abstract"}, {"text": "RNA in defense: CRISPRs protect prokaryotes against mobile genetic elements.", "begin": 0, "document": "21441598", "end": 76, "section": "title"}, {"text": "n this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.", "begin": 588, "document": "21441598", "end": 777, "section": "abstract"}, {"text": "Bacteria have developed several defense mechanisms against bacteriophages over evolutionary time, but the concept of prokaryotic RNA interference mediated defense mechanism against phages and other invading genetic elements has emerged only recently. Clustered regularly interspaced short palindromic repeats (CRISPR) together with closely associated genes (cas genes) constitute the CASS system that is believed to provide a RNAi-like defense mechanism against bacteriophages within the host bacterium.", "begin": 0, "document": "20109154", "end": 503, "section": "abstract"}, {"text": "In many prokaryotes, noncoding RNAs that arise from the clustered regularly interspaced short palindromic repeat (CRISPR) loci are now thought to mediate defense against viruses and other molecular invaders by an RNAi-like pathway.", "begin": 0, "document": "18971321", "end": 231, "section": "abstract"}, {"text": "A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action.", "begin": 0, "document": "16545108", "end": 206, "section": "title"}]}, {"documents": ["23114438", "22796889", "22553235", "22383444", "20542902", "20534805", "20237104", "17594211", "18070960", "19386850", "17227206", "20686438", "20960935", "20649801"], "answer": [["OXA-48"], ["KPC"], ["VIM"], ["NDM"], ["IMP"], ["SME"], ["NMC"], ["GES"], ["IMI"], ["MBL"]], "id": "515870cdd24251bc0500008f", "snippets": [{"text": "The most frequent carbapenemases in Enterobacteriaceae were OXA-48, KPC and VIM-1; in P. aeruginosa it was VIM-2 and in A. baumannii OXA-23.", "begin": 513, "document": "23114438", "end": 653, "section": "abstract"}, {"text": "Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by matrix-assisted laser desorption ionization-time of flight mass spectrometry.", "begin": 0, "document": "22553235", "end": 147, "section": "title"}, {"text": "The Check-MDR CT102 DNA microarray enables detection of the most prevalent carbapenemases (NDM, VIM, KPC, OXA-48 and IMP)", "begin": 0, "document": "22383444", "end": 121, "section": "abstract"}, {"text": "OXA-48 producers were poorly detected, but all systems reliably detected isolates with KPC and most with metallo-carbapenemases.", "begin": 347, "document": "20534805", "end": 475, "section": "abstract"}, {"text": "Producers of IMP-, VIM-, and KPC-type carbapenemases with high levels of resistance to cephalosporins and to carbapenems were detected at 1x10(1) CFU/ml. The OXA-48 producers were not detected on ChromID ESBL medium unless coexpressing ESBLs, whereas carbapenemase-producing isolates with MICs of <4 microg/ml were not detected on CHROMagar KPC medium.", "begin": 347, "document": "20237104", "end": 699, "section": "abstract"}, {"text": "The most frequent carbapenemase was KPC-2 or -3 (73 strains), followed by VIM-1 (14), IMP-1 (11), SME-2 (5), and NMC-A (1). All serine carbapenemases were detected in the United States, while MbetaL-producing strains were isolated in Europe. Carbapenemase-producing Enterobacteriaceae showed high rates of resistance to most antimicrobial agents tested.", "begin": 288, "document": "18070960", "end": 641, "section": "abstract"}, {"text": "By using this methodology, isolates producing KPC, GES, Sme, IMI, and NMC-A carbapenemases were successfully distinguished from those producing other classes of beta-lactamases", "begin": 1672, "document": "19386850", "end": 1848, "section": "abstract"}, {"text": "KPC-2 and KPC-3 were the most frequently occurring carbapenemases (24 isolates, 20.2%) i", "begin": 887, "document": "17227206", "end": 975, "section": "abstract"}, {"text": "K. pneumoniae strains with known KPC (n\u2003=\u200331) or VIM (n\u2003=\u200320) carbapenemases", "begin": 167, "document": "20649801", "end": 243, "section": "abstract"}, {"text": "Carbapenemases including Klebsiella pneumoniae carbapenemases (KPC) are widespread among clinical isolates in the family Enterobacteriaceae.", "begin": 0, "document": "20960935", "end": 140, "section": "abstract"}, {"text": "Outbreak of vim-1-carbapenemase-producing Enterobacter cloacae in a pediatric intensive care unit.", "begin": 0, "document": "20686438", "end": 98, "section": "title"}, {"text": "mergence of pediatric infections caused by carbapenemases-producing Enterobacteriaceae is a critical issue as they are resistant to most \u03b2-lactam antibiotics.", "begin": 340, "document": "20686438", "end": 498, "section": "abstract"}, {"text": "SME-2-producing S. marcescens were isolated in the New York City area, Texas, and Ohio, while NMC-A was found in one E. cloacae strain from New York. In contrast, metallo-beta-lactamases were prevalent in Europe. IMP-1-producing E. cloacae (11 isolates) were detected in Turkey, while VIM-1-producing strains were found in Italy (Enterobacter spp.) and Greece (Klebsiella pneumoniae).", "begin": 1147, "document": "17227206", "end": 1531, "section": "abstract"}, {"text": "d several simple confirmatory methods that allow the recognition of bacteria producing class A carbapenemases, including KPC, Sme, IMI, NMC-A, and GES,", "begin": 402, "document": "19386850", "end": 553, "section": "abstract"}]}, {"documents": ["23436753", "23172894", "22692575", "21630460", "19416831", "22934887", "22178447", "20068102", "20005186", "19485423", "22414580"], "answer": [["CD44"], ["PARP1"], ["Mage-A4"], ["LSR"], ["RAB25"], ["S100A14"], ["MUC1"], ["Hsp90"], ["Actin"], ["14-3-3"], ["vimentin"], ["HSP70"], ["CK18"], ["moesin"], ["IDH2"], ["CRABP2"], ["SEC14L2"], ["beta-catenin"], ["MUC18"], ["Stat1"], ["CD74"]], "id": "51595fb0d24251bc0500009c", "snippets": [{"text": "We present here our results, including a large cumulative database of proteins based on the analysis of 78 TNBCs, and the identification and validation of one specific protein, Mage-A4, which was expressed in a significant fraction of TNBC and Her2-positive/ER negative lesions.", "begin": 1254, "document": "23172894", "end": 1532, "section": "abstract"}, {"text": "Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.", "begin": 0, "document": "23172894", "end": 216, "section": "title"}, {"text": "Further, we performed comparative quantitative proteomic and gene array analyses of these cells and identified potential novel markers of breast cancer cells with tumor-initiating features, such as lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14 and mucin 1 (MUC1), as well as a novel 31-gene signature capable of predicting distant metastasis in cohorts of estrogen receptor-negative human breast cancers.", "begin": 912, "document": "22692575", "end": 1334, "section": "abstract"}, {"text": "he results identify Hsp90 as a critical and multimodal target in this most difficult to treat breast cancer subtype and support the use of the Hsp90 inhibitor PU-H71 for clinical trials involving patients with TNBC.", "begin": 1503, "document": "19416831", "end": 1718, "section": "abstract"}, {"text": "We obtained differential expression patterns for several glycolytic enzymes (as for example MDH2, PGK1, TKT, Aldolase1), cytokeratins (CK7, 8, 9, 14, 17, 19), further structure proteins (vimentin, fibronectin, L-plastin), for NME1-NME2, lactoferrin, and members of the Annexin family.", "begin": 227, "document": "19485423", "end": 511, "section": "abstract"}, {"text": "he expression of calreticulin, cellular retinoic acid-binding protein II, chloride intracellular channel protein 1, EF-1-beta, galectin 1, peroxiredoxin-2, platelet-derived endothelial cell growth factor, protein disulfide isomerase and ubiquitin carboxyl-terminal hydrolase 5 were further validated using a tissue microarray containing 70 malignant breast carcinomas of various grades of atypia.", "begin": 1689, "document": "20005186", "end": 2085, "section": "abstract"}, {"text": "The first is characterized by high expression of Stat1, Mx1, and CD74.", "begin": 484, "document": "22178447", "end": 554, "section": "abstract"}, {"text": "This effect was accompanied with a marked increase in the membrane expression of beta-catenin, MUC18, plexins, integrins, and other proteins involved in cell adhesion and cancer metastasis. Taken together, our results show that Stat1/CD74 positive triple-negative tumors are more aggressive and suggest an approach for development of better diagnostics and more targeted therapies for triple negative breast cancer.", "begin": 915, "document": "22178447", "end": 1330, "section": "abstract"}, {"text": "Proteomic analysis also identified high levels of IDH2 and CRABP2 and low levels of SEC14L2 to be prognostic markers for overall breast cancer survival.", "begin": 1033, "document": "22414580", "end": 1185, "section": "abstract"}, {"text": "The expression of a selected group of high abundance and/or breast cancer-specific potential biomarkers including thromobospondin 1, galectin-3 binding protein, cathepsin D, vimentin, zinc-\u03b12-glycoprotein, CD44, and EGFR from the breast cancer cell lines and in their culture media were further validated by Western blot analysis.", "begin": 583, "document": "22934887", "end": 913, "section": "abstract"}, {"text": "his provided novel evidence for PMA regulation of the enzymes glyceraldehyde-3-phosphate dehydrogenase, nucleolar RNA helicase 2 and Heterogeneous nuclear ribonucleoprotein M.", "begin": 1179, "document": "21630460", "end": 1354, "section": "abstract"}, {"text": "Among them, we identify downregulation of components of the Ras/Raf/MAPK pathway and G(2)-M phase to contribute to its anti-proliferative effect, degradation of activated Akt and Bcl-xL to induce apoptosis, and inhibition of activated NF-kappaB, Akt, ERK2, Tyk2, and PKC to reduce TNBC invasive potential.", "begin": 1196, "document": "19416831", "end": 1501, "section": "abstract"}]}, {"documents": ["23456457", "23213374", "23115304", "22976301", "22898782", "22521416", "22261722", "21766470", "20392737", "19454482", "19321663", "19293139", "18851962", "17681131", "16240430", "14983524", "11781336", "10842375"], "answer": ["centrosome"], "id": "51596a8ad24251bc0500009e", "snippets": [{"text": "CEP family protein is the active component of centrosome", "begin": 163, "document": "23456457", "end": 219, "section": "abstract"}, {"text": "Cep135 was associated mostly with mother centrioles", "begin": 1180, "document": "23213374", "end": 1231, "section": "abstract"}, {"text": "Cep135/Bld10 is a conserved centriolar protein required for the formation of the central cartwheel, an early intermediate in centriole assembly.", "begin": 0, "document": "22976301", "end": 144, "section": "abstract"}, {"text": "Thus, in flies, Cep135/Bld10 is not essential for cartwheel assembly or for establishing the ninefold symmetry of centrioles; rather, it appears to stabilize the connection between inner and outer centriole components.", "begin": 939, "document": "22976301", "end": 1157, "section": "abstract"}, {"text": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells", "begin": 0, "document": "14983524", "end": 109, "section": "abstract"}, {"text": "135\u00a0kDa centrosomal protein (CEP135)", "begin": 634, "document": "22521416", "end": 670, "section": "abstract"}, {"text": "In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins.", "begin": 301, "document": "18851962", "end": 415, "section": "abstract"}, {"text": "Drosophila Bld10, the ortholog of Chlamydomonas reinhardtii Bld10p and human Cep135, is a ubiquitous centriolar protein that also localizes to the spermatid basal body. M", "begin": 350, "document": "19321663", "end": 520, "section": "abstract"}, {"text": "BLD10/CEP135 is a microtubule-associated protein that controls the formation of the flagellum central microtubule pair.", "begin": 0, "document": "22898782", "end": 119, "section": "title"}, {"text": "We found an evolutionarily cohesive and ancestral module, which we term UNIMOD and is defined by three components (SAS6, SAS4/CPAP and BLD10/CEP135), that correlates with the occurrence of CBBs.", "begin": 683, "document": "20392737", "end": 877, "section": "abstract"}, {"text": "pericentriolar material proteins including pericentrin and CEP135.", "begin": 717, "document": "22261722", "end": 783, "section": "abstract"}, {"text": "hereas Cep135 and CPAP formed a core structure within the proximal lumen of both parental and nascent centrioles", "begin": 690, "document": "17681131", "end": 802, "section": "abstract"}, {"text": ". Centrosome components, including \u03b3-tubulin and Cep135,", "begin": 960, "document": "21766470", "end": 1016, "section": "abstract"}, {"text": "suggesting that Cep135 is a structural component of the centrosome.", "begin": 257, "document": "10842375", "end": 324, "section": "abstract"}, {"text": "Characterization of Cep135, a novel coiled-coil centrosomal protein involved in microtubule organization in mammalian cells.", "begin": 0, "document": "11781336", "end": 124, "section": "title"}]}, {"documents": ["21670063", "21239431", "19903697", "18954857", "17164749", "16384862", "15148346", "10329215", "8301561", "3359982", "3756504", "3707599", "6327972", "20937391", "19074582", "15572044", "12010632"], "answer": [["3,5-diiodo-L-thyronine", "T2"], ["GC-24"], ["CO23"], ["DITPA", "3,5-diiodothyropropionic acid"], ["GC-1"], ["Tetrac", "3,3',5,5'-tetraiodo-thyroacetic acid"], ["KB-2115"], ["KB-141"], ["thyronamines"], ["T4-agarose"], ["CGS 23425"], ["D-T3", "3,3',5-triiodo-D-thyronine"], ["3,5-T2", "3,5-diiodo-L-thyronine"], ["DIT", "3,5-diiodo-L-tyrosine"], ["MIT", "3-monoiodo-L-tyrosine"], ["triac", "3,3',5-triiodo-thyroacetic acid"], ["3,5-Diiodo-4-hydroxyphenylpropionic acid", "DIHPA"], ["3,5-Dimethyl-3'-isopropyl-L-thyronine", "DIMIT"], ["3,5-diiodo-3'-isopropylthyroacetic acid", "IpTA2"]], "id": "515993f3d24251bc050000a0", "snippets": [{"text": "naturally occurring iodothyronine, 3,5-diiodo-L-thyronine (T2)", "begin": 397, "document": "21670063", "end": 459, "section": "abstract"}, {"text": "thyroid hormone receptor beta- and \u03b1-selective agonists GC-24 and CO23", "begin": 24, "document": "21239431", "end": 94, "section": "title"}, {"text": "two thyroid hormone agonists, the TR\u03b2-selective GC-24 and the TR\u03b1-selective CO23", "begin": 511, "document": "21239431", "end": 591, "section": "abstract"}, {"text": "Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog,", "begin": 221, "document": "19903697", "end": 303, "section": "abstract"}, {"text": "analogs DITPA and GC-1", "begin": 400, "document": "19903697", "end": 422, "section": "abstract"}, {"text": "Tetrac inhibits binding of thyroid hormone analogs to the receptor on alphavbeta3 and lacks thyromimetic activity at this site", "begin": 1184, "document": "19903697", "end": 1310, "section": "abstract"}, {"text": "thyroid hormone agonist, called GC1", "begin": 309, "document": "18954857", "end": 344, "section": "abstract"}, {"text": "Other selective thyromimetic, KB- 2115 and KB - 141", "begin": 525, "document": "18954857", "end": 576, "section": "abstract"}, {"text": "Another class of thyroid hormone analogs, the thyronamines", "begin": 599, "document": "18954857", "end": 657, "section": "abstract"}, {"text": "he thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA)", "begin": 27, "document": "16384862", "end": 90, "section": "title"}, {"text": "The thyroid hormone analogs DITPA, T(4), and T(4)-agarose,", "begin": 855, "document": "16384862", "end": 913, "section": "abstract"}, {"text": ",5-diiodothyropropionic acid (DITPA), a thyroid hormone analog", "begin": 330, "document": "16384862", "end": 392, "section": "abstract"}, {"text": "thyroid hormone analogs 3,5-diiodothyropropionic acid and CGS 23425", "begin": 71, "document": "15148346", "end": 138, "section": "title"}, {"text": "wo thyroid hormone analogs, 3,5-diidodothyropropionic acid (DITPA) and CGS 23425", "begin": 328, "document": "15148346", "end": 408, "section": "abstract"}, {"text": "several thyroid hormone analogs, including T4(3,3',5,5'-tetraiodo-L-thyronine), rT3(3,3',5'-triiodo-L-thyronine), D-T3(3,3',5-triiodo-D-thyronine), 3,5-T2(3,5-diiodo-L-thyronine), DIT (3,5-diiodo-L-tyrosine), MIT (3-monoiodo-L-tyrosine), tetrac (3,3',5,5'-tetraiodo-thyroacetic acid), triac (3, 3',5-triiodo-thyroacetic acid),", "begin": 156, "document": "10329215", "end": 482, "section": "abstract"}, {"text": ",5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA) was found to bind specifically to bacterially expressed alpha-1 and beta-1 thyroid hormone receptors", "begin": 440, "document": "8301561", "end": 588, "section": "abstract"}, {"text": "DIHPA is a novel thyromimetic compound", "begin": 1465, "document": "8301561", "end": 1503, "section": "abstract"}, {"text": "Identification of simple substituted phenols with thyromimetic activity: cardiac effects of 3,5-diiodo-4-hydroxyphenylpropionic acid", "begin": 0, "document": "8301561", "end": 132, "section": "title"}, {"text": "The relative affinity of the receptor for thyroid hormone analogs was triiodothyroacetic acid = T3 greater than T4 greater than tetraiodothyroacetic acid in oligodendrocyte and astrocyte nuclei", "begin": 1083, "document": "3359982", "end": 1276, "section": "abstract"}, {"text": "The relative binding affinity of the receptor for thyroid hormone analogs was in the order TRIAC greater than L-T3 greater than D-T3 greater than L-T4 in both cell lines", "begin": 786, "document": "3756504", "end": 955, "section": "abstract"}, {"text": "3,5-Dimethyl-3'-isopropyl-L-thyronine (DIMIT) and 3,5-diiodo-3'-isopropylthyroacetic acid (IpTA2), two thyroid hormone analogs,", "begin": 0, "document": "3707599", "end": 127, "section": "abstract"}, {"text": "synthetic thyroid analogs (3,5,3'-L-triiodothyronine, 3,5,3'-D-triiodothyronine, 3,3',5'-L- triiodothyronine , 3,5,3'-L-triiodothyroacetic acid and 3,5-L-diiodothyronine)", "begin": 82, "document": "6327972", "end": 252, "section": "abstract"}, {"text": "In the present study, we characterized the interactions of the synthetic triiodo L-thyronine analogs and thyroid hormone nuclear receptor TR\u03b2-selective agonists GC-1 and GC-24 with the wild type and V30M variant of human transthyretin (TTR).", "begin": 267, "document": "20937391", "end": 508, "section": "abstract"}, {"text": "3-Iodothyronamine (T(1)AM) is a naturally occurring thyroid hormone metabolite with distinct biological effects that are opposite those of thyroid hormone.", "begin": 0, "document": "19074582", "end": 155, "section": "abstract"}]}, {"documents": ["23079622", "22637579", "19711352", "17420258", "15925487", "19571232", "16778097"], "answer": [["inhibition of cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays"], ["decreased RhoA activation"], ["inhibition of TGF\u03b2-mediated activation of ERK and JNK"], ["phosphorylation of c-Jun"], ["transactivation of the c-Jun promoter"], ["decreased key TGFbeta responses"]], "id": "515a7ffdd24251bc050000a5", "snippets": [{"text": "Finally, our results demonstrated for the first time that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays. Overall, our findings demonstrate that km23-1 regulates RhoA and motility-associated actin modulating proteins, suggesting that km23-1 may represent a novel target for anti-metastatic therapy.", "begin": 797, "document": "23079622", "end": 1156, "section": "abstract"}, {"text": "Further, knockdown of km23-1 inhibited TGF\u03b2-mediated activation of ERK and JNK, phosphorylation of c-Jun, and transactivation of the c-Jun promoter.", "begin": 650, "document": "22637579", "end": 798, "section": "abstract"}, {"text": "knockdown (KD) of km23-1 decreased RhoA activation in Mv1Lu epithelial cells", "begin": 719, "document": "23079622", "end": 795, "section": "abstract"}, {"text": "We have previously reported that the dynein light chain (DLC) km23-1 is required for Smad2-dependent TGFbeta signaling.", "begin": 0, "document": "19711352", "end": 119, "section": "abstract"}, {"text": "Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGFbeta treatment.", "begin": 701, "document": "17420258", "end": 894, "section": "abstract"}, {"text": "Blockade of km23 using small interfering RNAs significantly decreased key TGFbeta responses, including induction of fibronectin expression and inhibition of cell growth.", "begin": 572, "document": "15925487", "end": 741, "section": "abstract"}, {"text": "On the other hand, inhibiting the endogenous DYNLRB1 with gene-specific small interfering RNA or pharmacologically with a specific inhibitor (vanadate) led to a significant (P < 0.05) decrease in folate uptake.", "begin": 1236, "document": "19571232", "end": 1446, "section": "abstract"}]}, {"documents": ["23482462", "23425695", "23422824", "22956620", "22918641", "22871838", "22300579", "21087963", "20375347", "19770725", "19714880", "18334948", "17850790", "16982797", "16923831", "15952718", "14574570", "16488965", "16865190", "11419941"], "answer": [["lacrimal gland"], ["salivary glands"], ["thyroid"], ["tear fluid"]], "id": "515b30d8d24251bc050000b0", "snippets": [{"text": "Essential for the viability of the surface epithelium of the eye and for normal vision is the thin, but protein-rich, tear film in which the small tear glycoprotein lacritin appears to play a prominent prosecretory, cytoprotective, and mitogenic role", "begin": 139, "document": "23425695", "end": 389, "section": "abstract"}, {"text": "cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland.", "begin": 0, "document": "11419941", "end": 103, "section": "title"}, {"text": "Lacritin mRNA and protein are highly expressed in human lacrimal gland, moderately in major and minor salivary glands and slightly in thyroid. No lacritin message or protein is detected elsewhere among more than 50 human tissues examined.", "begin": 479, "document": "11419941", "end": 717, "section": "abstract"}, {"text": "The lipocalin 1, lactotransferrin, lacritin, lysozyme C, lipophilin A and immunoglobulin lambda chain were identified as possible biomarker candidates with significantly higher relative levels in the tear of patients with diabetic retinopathy.", "begin": 866, "document": "22300579", "end": 1109, "section": "abstract"}, {"text": "In primates, lacritin was produced in the lacrimal gland and secreted into tear fluid.", "begin": 1483, "document": "17850790", "end": 1569, "section": "abstract"}]}, {"documents": ["22954629", "12872232", "12422360", "20641139", "12915006"], "answer": [["Proteases"], ["Keratins"], ["Bovine serum proteins"], ["Antibodies"]], "id": "515d7693298dcd4e5100000c", "snippets": [{"text": "protease autolysis or keratin contaminants.", "begin": 312, "document": "12422360", "end": 355, "section": "abstract"}, {"text": "Most of the interfering masses originate from trypsin autolysis and human keratins.", "begin": 515, "document": "12872232", "end": 598, "section": "abstract"}, {"text": "5-15% FBS. Contamination by bovine proteins is difficult to avoid because of adherence to the plastic vessel and the cultured cells.", "begin": 139, "document": "20641139", "end": 271, "section": "abstract"}, {"text": "The main disadvantage of traditional IP and co-IP is that the conditions used to elute the precipitated antigen also release the antibody thus contaminating the antigen", "begin": 221, "document": "12915006", "end": 389, "section": "abstract"}, {"text": "MaConDa: a publicly accessible mass spectrometry contaminants database.", "begin": 0, "document": "22954629", "end": 71, "section": "title"}]}, {"documents": ["23038750", "22162939", "21647425", "21777702", "19339045"], "answer": [["Use of a Multidrug Pill In Reducing cardiovascular Events' (UMPIRE) trial, European Clinical Trials database\\, as EudraCT: 2009-016278-34 and the Clinical Trials Registry\\, India as CTRI/2010/091/000250."], ["IMProving Adherence using Combination Therapy (IMPACT)', Australian New Zealand Clinical Trial Registry (ACTRN12606000067572)"], ["Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP)"], ["Phase II study of the Polycap, double-blind\\, randomised trial\\, registered with ClinicalTrials.gov\\, number NCT00443794", "ndian Polycap Study, TIPS"], ["Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term-risk (CRUCIAL trial)"], ["GEMINI trial, 14-week\\, open-label trial conducted in 1220 patients from the USA"], ["GEMINI-Australia, Asia\\, Latin America\\, Africa/Middle East (AALA) study"], ["JEWEL 1 conducted among 1138 patients from the UK and Canada"], ["JEWEL 2 conducted in 1107 patients from Europe"], ["CAPABLE54, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points\\, in the USA"], ["CUSP (The Caduet\u00ae in an Untreated Subject Population trial)"], ["TOGETHER trial"], ["A randomised controlled trial in seven countries \u2013 Australia, Brazil\\, India\\, Netherlands\\, New Zealand\\, United Kingdom and United States\\, Australian New Zealand Clinical Trials Registry (ACTRN 12607000099426)"], ["Second Indian Polycap Study, TIPS-2"]], "id": "515db020298dcd4e51000011", "snippets": [{"text": "The 'Use of a Multidrug Pill In Reducing cardiovascular Events' (UMPIRE) trial assesses whether a polypill strategy (by combining aspirin, a statin and two blood pressure lowering agents) would improve adherence to guideline-indicated therapies and would lower both blood pressure and cholesterol, in people with established cardiovascular disease. UMPIRE, running in India and three European countries (England, Ireland and the Netherlands), is an open, randomised, controlled trial designed to include 1000 participants in India and 1000 in Europe, with a followup of 12-24 months.", "begin": 404, "document": "23038750", "end": 987, "section": "abstract"}, {"text": "UMPIRE is registered with the European Clinical Trials database, as EudraCT: 2009-016278-34 and the Clinical Trials Registry, India as CTRI/2010/091/000250. The trial was part of the 'Single Pill Against Cardiovascular Events (SPACE)' collaboration, which encompasses the 'IMProving Adherence using Combination Therapy (IMPACT)' and 'Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP)' trials.", "begin": 1520, "document": "23038750", "end": 1923, "section": "abstract"}, {"text": "Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.", "begin": 0, "document": "19339045", "end": 157, "section": "title"}]}, {"documents": ["23112238", "22134010", "19193587", "16490100", "15072101", "12199723", "12022084", "11361047", "11305405", "11274308", "10030434", "9120226", "8648543", "8617181", "8603631", "7489697"], "answer": [["Skin reactions"], ["Somnolence", "drowsiness", "sedation", "lassitude"], ["Dizziness"], ["hyperactivity"], ["defiance"], ["irritability"], ["agitation"], ["aggression"], ["explosive outbursts"], ["oppositional behavior"], ["malaise"]], "id": "515db70c298dcd4e51000017", "snippets": [{"text": "he purpose of our study was to review our experience with using gabapentin to treat insomnia in children. We identified 23 children,", "begin": 156, "document": "23112238", "end": 288, "section": "abstract"}, {"text": "Adverse effects were noted in 6 children.", "begin": 839, "document": "23112238", "end": 880, "section": "abstract"}, {"text": "Five patients treated in the Children's Hospital Pain Control Service for intractable neuropathic pain were included in gabapentin treatment", "begin": 285, "document": "16490100", "end": 425, "section": "abstract"}, {"text": "We noticed a rapid improvement, in 1 week, of our patients' VAS scores (from 9 or 10 to 4 or 3) with minimal adverse effects", "begin": 614, "document": "16490100", "end": 738, "section": "abstract"}, {"text": "The charts of all children given gabapentin for seizures were reviewed.", "begin": 206, "document": "15072101", "end": 277, "section": "abstract"}, {"text": "Only 8 children (7%) reported adverse effects, and the drug was discontinued in two.", "begin": 906, "document": "15072101", "end": 990, "section": "abstract"}, {"text": "A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.", "begin": 0, "document": "12199723", "end": 97, "section": "title"}, {"text": "Two studies were conducted to determine the single-dose pharmacokinetics of gabapentin in healthy subjects age 1 month to 12 years and to guide dose selection in safety and efficacy trials in pediatric patients", "begin": 168, "document": "11361047", "end": 378, "section": "abstract"}, {"text": "Single doses of gabapentin were well tolerated by healthy pediatric subjects.", "begin": 612, "document": "11361047", "end": 689, "section": "abstract"}, {"text": "The efficacy and safety of gabapentin as add-on therapy for refractory partial seizures in 237 children, aged 3 to 12 years were evaluated over a 6-month period.", "begin": 0, "document": "11305405", "end": 161, "section": "abstract"}, {"text": "Thirteen patients (5%) withdrew during the 6-month period because of adverse events.", "begin": 655, "document": "11305405", "end": 739, "section": "abstract"}, {"text": "Twenty-six children with intellectual disability and six normal children, all suffering from refractory partial seizures, received open-label gabapentin (range = 10-50 mg kg(-1) day(-1); mean = 26.7 mg kg(-1) day(-1) as an add-on medication to their antiepileptic drug regimen", "begin": 0, "document": "10030434", "end": 276, "section": "abstract"}, {"text": "In the present patient population, patients younger than 10 years of age, all of whom had intellectual disability, were more likely to have side-effects than those older than 10 years of age. Observed adverse effects, which were generally mild, occurred in patients with baseline intellectual disability, attention deficit disorder and behavioural problems. Behavioural adverse effects warranted discontinuation of the medication in only three patients. The severity of intellectual disability (mild versus moderate or severe) did not affect the extent of the response or the occurrence of side-effects.", "begin": 768, "document": "10030434", "end": 1371, "section": "abstract"}, {"text": "However, children with intellectual disability who also are less than 10 years of age with baseline attention deficit appear to be at a higher risk of behavioural side-effects.", "begin": 1527, "document": "10030434", "end": 1703, "section": "abstract"}, {"text": "Efficacy and safety of gabapentin monotherapy were evaluated in 33 children with newly diagnosed absence epilepsy", "begin": 0, "document": "9120226", "end": 113, "section": "abstract"}, {"text": "Somnolence and dizziness were the only adverse events reported by at least two patients during gabapentin treatment. No clinically important changes in laboratory assessments or other safety parameters were observed.", "begin": 712, "document": "9120226", "end": 928, "section": "abstract"}, {"text": "Thirty-two children with refractory partial epilepsy received open-label gabapentin as an additional medication to their antiepileptic drug regimen", "begin": 0, "document": "8648543", "end": 147, "section": "abstract"}, {"text": "The major reported side effects were behavioral. These consisted of hyperactivity, irritability, and agitation that occurred in patients with baseline mental retardation with attention deficit.", "begin": 757, "document": "8648543", "end": 950, "section": "abstract"}, {"text": "We report 2 children who received GBP for intractable seizures and who developed intolerable aggressive behavior requiring dose reduction or drug discontinuation. Behavioral changes should be recognized as a possible side effect of GBP, especially in mentally retarded children.", "begin": 176, "document": "8617181", "end": 454, "section": "abstract"}, {"text": "We report 7 children who received gabapentin (GBP) as adjunctive medic ation and subsequently developed behavioral side effects. These behavioral changes consisted of intensification of baseline behaviors as well as new behavioral problems. Behaviors that parents considered most troublesome were tantrums, aggression directed toward others, hyperactivity, and defiance. All behavioral changes were reversible and were managed by dose reduction or discontinuation of GBP. All children had baseline attention deficit hyperactivity disorder and developmental delays.", "begin": 0, "document": "8603631", "end": 564, "section": "abstract"}, {"text": "We described 3 learning disabled children, 1 aged 7 and 2 aged 10 years, with intractable partial seizures who developed severe behavioral problems while receiving modest doses of GBP. The children became hyperactive and had explosive outburst consisting of aggressive and oppositional behavior. The behavioral problems were sufficiently severe to require discontinuation of GBP despite moderately improved seizure control.", "begin": 88, "document": "7489697", "end": 511, "section": "abstract"}]}, {"documents": ["23124387", "14990637", "12530495", "12454107", "9315539", "7576410", "8110005", "8512763", "1318542", "9381720"], "answer": ["50% to 80%"], "id": "515dd3d5298dcd4e5100001c", "snippets": [{"text": "The responses to IV KCl were attenuated by concomitant furosemide (p\u00a0=\u00a00.01), amphotericin B (p\u00a0<\u00a00.01), and KCl in parenteral nutrition (p\u00a0<\u00a00.01). The responses were augmented by concomitant enalapril", "begin": 1407, "document": "23124387", "end": 1609, "section": "abstract"}, {"text": "To determine whether an angiotensin-converting enzyme (ACE) inhibitor, enalapril, prevents cardiac function deterioration (defined using maximal cardiac index [MCI] on exercise testing or increase in left ventricular end-systolic wall stress [LVESWS]) in long-term survivors of pediatric cancer.", "begin": 11, "document": "14990637", "end": 306, "section": "abstract"}, {"text": "Patients with intraatrial baffle procedure for transposition of the great arteries (TGA) have diastolic dysfunction, decreased exercise capacity, stroke volume response and elevated systemic vascular resistance (SVR) during exercise.", "begin": 0, "document": "12530495", "end": 233, "section": "abstract"}, {"text": "We conclude that short-term (<1 year) use of enalapril does not improve exercise performance in patients with TGA in whom the intraatrial baffle procedure has been performed.", "begin": 1713, "document": "12530495", "end": 1887, "section": "abstract"}, {"text": "A common late effect of doxorubicin therapy for childhood cancer is reduced left-ventricular (LV) wall thickness resulting in elevated LV afterload and depressed LV function. Many children are given angiotensin-converting enzyme inhibitors, which have been studied primarily in adults. We document the long-term effects of angiotensin-converting enzyme inhibitors in doxorubicin-treated survivors of childhood cancer.", "begin": 11, "document": "12454107", "end": 428, "section": "abstract"}, {"text": "Angiotensin convertase inhibitor (Enalapril) was used in 51 children aged 4 days up to 18 years (mean 4.3 +/- 5.5, years). As many as 27 subjects were newborns (4) and infants (23). The patients suffered from circulatory insufficiency due to congestive cardiomyopathy (13 cases). 6 treated subjects suffered from circulatory insufficiency due to congenital heart malformations before cardiac surgery and 22 after it (including complex malformations operated according to Fontan method). 10 children were treated because of arterial hypertension. 4 subjects suffered form life-threatening arrhythmias coexisting with circulatory insufficiency.", "begin": 0, "document": "9381720", "end": 642, "section": "abstract"}, {"text": "4 patients (8%) died during treatment but their deaths can not be related to angiotensin convertase inhibitor therapy. In the other children (82%) the beneficial influence of angiotensin convertase inhibitor use was found (improvement in comparison with the state before convertase inhibitor introduction). In 10% of subjects enalapril did not show any significant therapeutic effect", "begin": 850, "document": "9381720", "end": 1233, "section": "abstract"}, {"text": "We conclude that the combination of ACE inhibitor and beta-blocker deserves further exploration for inclusion in any management regimen for the treatment of muscular dystrophy-associated cardiomyopathy.", "begin": 1183, "document": "7576410", "end": 1385, "section": "abstract"}, {"text": "Addition of these medications, never before attempted in the management of cardiomyopathy associated with generalized myopathic disease, complemented each other in relieving symptoms and reversing signs of congestive heart failure and DCM.", "begin": 943, "document": "7576410", "end": 1182, "section": "abstract"}, {"text": "Enalapril was clinically safe and effective for children with cardiac failure secondary to ventricular impairment, valvar regurgitation, or after cardiac surgery. Renal failure was a problem in young infants with left-to-right shunts.", "begin": 864, "document": "8110005", "end": 1098, "section": "abstract"}, {"text": "In a tertiary referral centre 63 patients underwent 67 treatment periods with enalapril. The median age was 5.4 months. All children had signs of heart failure: congestive cardiac failure with breathlessness at rest was present in 88%. Haemodynamic groups were left-to-right shunt (n = 15), impaired ventricular function (n = 14), after cardiac surgery (n = 23), valvar regurgitation (n = 12), and hypertension (n = 3). Serial clinical, radiological, and laboratory data were used to judge outcome. The mean (SD) maximal dose was 0.30 (0.21) mg/kg/day. Thirty nine (58%) patients improved, 20 (30%) showed no improvement, and eight (12%) had side effects requiring discontinuation of enalapril.", "begin": 0, "document": "8110005", "end": 694, "section": "abstract"}, {"text": "We studied the inhibition of angiotensin converting enzyme (ACE) in eight infants with congestive heart failure (CHF) poorly controlled with digoxin and diuretics, treated orally with 0.25 mg kg-1 enalapril maleate once a day", "begin": 0, "document": "8512763", "end": 225, "section": "abstract"}, {"text": "In infants with CHF, mean baseline ACE activity was significantly higher than in control infants", "begin": 584, "document": "8512763", "end": 680, "section": "abstract"}, {"text": "Converting enzyme inhibitors may benefit \"heart failure\" associated with large ventricular septal defects and normal or mildly elevated pulmonary resistance.", "begin": 1240, "document": "1318542", "end": 1397, "section": "abstract"}]}, {"documents": ["19808991", "18555882", "9549503", "9040721", "6502174", "6128697", "6889706", "22515742", "12710012", "3400500", "2904118"], "answer": ["up to > 60%"], "id": "515ddda6298dcd4e5100001f", "snippets": [{"text": "report a patient with dystonia secondary to bilateral lesions of the basal ganglia", "begin": 12, "document": "19808991", "end": 94, "section": "abstract"}, {"text": "The patient's dystonia responded to Trihexyphenidyl and to tetrabenazine, but these medications needed to be stopped because of side effects.", "begin": 494, "document": "19808991", "end": 635, "section": "abstract"}, {"text": "welve cases of status dystonicus, of various underlying aetiologies, are presented", "begin": 167, "document": "9549503", "end": 249, "section": "abstract"}, {"text": "Drug therapy with benzhexol, tetrabenazine and pimozide or haloperidol may be beneficial in some cases.", "begin": 1134, "document": "9549503", "end": 1237, "section": "abstract"}, {"text": "Over the past 15 years we have treated 526 patients with severe hyperkinetic movement disorders with tetrabenazine (TBZ)", "begin": 0, "document": "9040721", "end": 120, "section": "abstract"}, {"text": "The global response rating of 1 (marked improvement) was recorded in 89.2% of 93 patients with tardive stereotypy, 83.3% of 12 with myoclonus, 82.8% of 29 with Huntington's disease, 80.5% of 82 with tardive dystonia, 79.3% of 29 with other movement disorders, 62.9% of 108 with idiopathic dystonia", "begin": 502, "document": "9040721", "end": 799, "section": "abstract"}, {"text": "Twelve adults with severe axial dystonia, and two children with life-threatening generalised dystonia were treated with a combination of a low constant dose of tetrabenazine to which were added pimozide and benzhexol as necessary.", "begin": 462, "document": "6502174", "end": 692, "section": "abstract"}, {"text": "When benzhexol treatment alone fails in adults with severe disabling axial dystonia, or in children with life-threatening generalised dystonia, combined therapy with tetrabenazine, pimozide and benzhexol may give valuable symptomatic relief.", "begin": 1341, "document": "6502174", "end": 1582, "section": "abstract"}, {"text": "We present 42 patients with tardive dystonia. The age of onset of dystonia was 13 to 60 years.", "begin": 330, "document": "6128697", "end": 424, "section": "abstract"}, {"text": "The most frequently helpful medications were tetrabenazine (68% of patients improved) and anticholinergics (39% improved).", "begin": 682, "document": "6128697", "end": 804, "section": "abstract"}, {"text": "8-year-old boy of non-Jewish, Mexican-American descent with autosomal-dominant dystonia musculorum deformans who developed rapidly progressive and severe generalized dystonia, hyperpyrexia, myoglobinuria, and renal failure", "begin": 151, "document": "6889706", "end": 373, "section": "abstract"}, {"text": "Transient improvement was achieved with tetrabenazine and baclofen", "begin": 402, "document": "6889706", "end": 468, "section": "abstract"}]}, {"documents": ["23388391", "21965533", "21245038", "19605561", "19276069", "12590136", "11747467", "22073225", "20628353", "15769875", "15044470", "14618157", "11889047", "22817748", "12844354", "17766253", "21743004", "19955262", "11239395", "23337855", "23274303", "22442711"], "answer": [["POP2"], ["CAF1Z"], ["PARN"], ["PAN2"], ["CCR4"], ["Nocturnin"], ["ANGEL"], ["2'-PDE"]], "id": "5162c8a8298dcd4e51000047", "snippets": [{"text": "Among the deadenylase family, poly(A)-specific ribonuclease (PARN) is unique in its domain composition, which contains three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and the RRM domain", "begin": 157, "document": "23388391", "end": 377, "section": "abstract"}, {"text": "On the other hand, the interaction between CNOT7 and BTG2, a member of the antiproliferative BTG/Tob family involved in transcription and mRNA decay appears less important for proliferation of MCF7 cells, suggesting that CNOT7 does not function solely in conjunction with BTG2.", "begin": 813, "document": "19605561", "end": 1090, "section": "abstract"}, {"text": "The Tob/BTG family is a group of antiproliferative proteins containing two highly homologous regions, Box A and Box B. These proteins all associate with CCR4-associated factor 1 (Caf1), which belongs to the ribonuclease D (RNase D) family of deadenylases and is a component of the CCR4-Not deadenylase complex.", "begin": 0, "document": "19276069", "end": 310, "section": "abstract"}, {"text": "The CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA.", "begin": 0, "document": "12590136", "end": 115, "section": "abstract"}, {"text": "CCR4, an evolutionarily conserved member of the CCR4-NOT complex, is the main cytoplasmic deadenylase. It contains a C-terminal nuclease domain with homology to the endonuclease-exonuclease-phosphatase (EEP) family of enzymes.", "begin": 0, "document": "20628353", "end": 226, "section": "abstract"}, {"text": "The yeast Pop2 protein, belonging to the eukaryotic Caf1 family, is required for mRNA deadenylation in vivo.", "begin": 0, "document": "15769875", "end": 108, "section": "abstract"}, {"text": "Although CAF1 protein belongs to the DEDDh family of RNases, CCR4 appears to be the principle deadenylase of the CCR4-NOT complex.", "begin": 178, "document": "15044470", "end": 308, "section": "abstract"}, {"text": "Like CCR4, increased length of RNA substrates converted mCAF1 into a processive enzyme. In contrast to two other DEDD family members, PAN2 and PARN, mCAF1 was not activated either by PAB1 or capped RNA substrates.", "begin": 417, "document": "15044470", "end": 630, "section": "abstract"}, {"text": "The domain has the fold of the DnaQ family and represents the first structure of an RNase from the DEDD superfamily.", "begin": 346, "document": "14618157", "end": 462, "section": "abstract"}, {"text": "The evolutionarily conserved CCR4 protein, which is part of the cytoplasmic deadenylase, contains a C-terminal domain that displays homology to an Mg2+-dependent DNase/phosphatase family of proteins.", "begin": 253, "document": "11889047", "end": 452, "section": "abstract"}, {"text": "These results establish that CCR4 and most probably other members of a widely distributed CCR4-like family of proteins constitute a novel class of RNA-DNA exonucleases.", "begin": 1051, "document": "11889047", "end": 1219, "section": "abstract"}, {"text": "Deadenylases specifically catalyze the degradation of eukaryotic mRNA poly(A) tail in the 3'- to 5'-end direction with the release of 5'-AMP as the product.", "begin": 0, "document": "23388391", "end": 156, "section": "abstract"}, {"text": "Shortening and removal of the 3' poly(A) tail of mature mRNA by poly(A)-specific 3' exonucleases (deadenylases) is the initial and often rate-limiting step in mRNA degradation.", "begin": 0, "document": "23337855", "end": 176, "section": "abstract"}, {"text": "PARN, Nocturnin and Angel are three of the multiple deadenylases that have been described in eukaryotic cells.", "begin": 0, "document": "23274303", "end": 110, "section": "abstract"}, {"text": "The deadenylation process is achieved by deadenylases, which specifically catalyze the removal of the poly(A) tail at the 3'-end of eukaryotic mRNAs and release 5'-AMP as the product.", "begin": 164, "document": "22442711", "end": 347, "section": "abstract"}, {"text": "Interestingly, 2'-PDE shares both functionally and structurally characteristics with the CCR4-type exonuclease-endonuclease-phosphatase family of deadenylases.", "begin": 598, "document": "21245038", "end": 757, "section": "abstract"}, {"text": "We further show that the enzyme depends on divalent metal ions for activity and possesses specificity towards poly-A RNA similar to what has been observed for cellular deadenylases.", "begin": 701, "document": "21965533", "end": 882, "section": "abstract"}, {"text": "Interestingly, 2'-PDE shares both functionally and structurally characteristics with the CCR4-type exonuclease-endonuclease-phosphatase family of deadenylases.", "begin": 598, "document": "21245038", "end": 757, "section": "abstract"}]}, {"documents": ["16889493", "16042328", "8154510", "7296908", "578375"], "answer": [["Propyltiouracil"], ["Radioiodine"], ["beta blockers"], ["thyroidectomy"]], "id": "518cb6ab310faafe08000009", "snippets": [{"text": "6 months treatment with propranolol (160 mg/day) in eight patients with T3 (triiodothyronine) toxicosis. Serum total T3 concentrations showed a significant (p less than 0.01) and sustained fall to approximately 80% of pre-treatment values.", "begin": 69, "document": "7296908", "end": 308, "section": "abstract"}, {"text": "Both patients responded to therapy with propylthiouracil.", "begin": 490, "document": "578375", "end": 547, "section": "abstract"}]}, {"documents": ["21453886", "21317611", "21254868", "20919963", "20458240", "19420815", "18989561", "18788068", "17628557", "17667053", "18469440", "12603508", "11205659", "10981226", "9399771", "9097825", "9005529", "3069176", "6139796", "7084615", "30666"], "answer": [["Leukopenia"], ["paresthesia"], ["psoriasis"], ["alopecia"], ["hemolysis"], ["pancreatitis"], ["liver toxicity"], ["pericarditis"]], "id": "511a20f3df1ebcce7d00000c", "snippets": [{"text": "Different cutaneous side effects have been described for anti-TNF-\u03b1 therapy such as psoriasis", "begin": 173, "document": "21453886", "end": 266, "section": "abstract"}, {"text": "Anti-TNF drug-induced alopecia is a less well-known side effect of this class of drugs.", "begin": 165, "document": "21317611", "end": 252, "section": "abstract"}, {"text": "3 patients who developed scalp alopecia", "begin": 432, "document": "21317611", "end": 471, "section": "abstract"}, {"text": "Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease", "begin": 0, "document": "21254868", "end": 98, "section": "title"}, {"text": "Persistent corneal endothelial deposits associated with rifabutin therapy for Crohn's disease", "begin": 0, "document": "20458240", "end": 93, "section": "title"}, {"text": "complained of alopecia 3 days after starting 6-mercaptopurine (6-MP) and then developed severe myelosuppression", "begin": 93, "document": "19420815", "end": 204, "section": "abstract"}, {"text": "Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease", "begin": 1, "document": "18788068", "end": 100, "section": "title"}, {"text": "Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease", "begin": 0, "document": "17667053", "end": 120, "section": "title"}, {"text": "Recurrent myopericarditis in association with Crohn's disease", "begin": 0, "document": "12603508", "end": 61, "section": "title"}, {"text": "Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine", "begin": 0, "document": "11205659", "end": 90, "section": "title"}, {"text": "Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine", "begin": 1, "document": "10981226", "end": 86, "section": "title"}, {"text": "Leukopenia and thrombocytopenia are observed mostly as a side effect of therapy, particularly with use of immunosuppressive drugs", "begin": 174, "document": "9399771", "end": 303, "section": "abstract"}, {"text": "Immune thrombocytopenic purpura is rarely reported in association with inflammatory bowel disease.", "begin": 305, "document": "9399771", "end": 403, "section": "abstract"}, {"text": "Pericarditis as a side effect induced by sulfasalazine or 5-aminosalicylic acid", "begin": 149, "document": "9005529", "end": 228, "section": "abstract"}, {"text": "The commonest side-effect was hyperaesthesia, but one patient developed nephrotoxicity and one developed hepatotoxicity", "begin": 483, "document": "3069176", "end": 602, "section": "abstract"}, {"text": "The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive", "begin": 336, "document": "6139796", "end": 437, "section": "abstract"}, {"text": "The only major side effect observed was paresthesias. These occurred in 50% of the patients and developed in the patients at a mean of 6.5 mo after the onset of treatment.", "begin": 1052, "document": "7084615", "end": 1223, "section": "abstract"}, {"text": "Hemolysis is not a rare side-effect of sulfasalazine therapy", "begin": 690, "document": "30666", "end": 750, "section": "abstract"}, {"text": "17 of 40 (43%) patients with inflammatory bowel disease receiving sulfasalazine had evidence of hemolysis as detected by starch gel electrophoresis", "begin": 79, "document": "30666", "end": 226, "section": "abstract"}]}, {"documents": ["1697365", "11006094", "21741862", "20354523", "20103546", "17210241", "16829021", "16800744", "16800742", "15588589", "15015574", "14710225", "12925213", "12727843", "12725528", "12439720", "12439719", "11522960", "11478802", "21072173", "23093268", "21596022", "20574445", "20180637", "18627305", "17275179", "16800725", "16170411", "15516960", "15192120", "11258672", "11177570", "10662548"], "answer": ["15"], "id": "511a3573df1ebcce7d000018", "snippets": [{"text": "Tissue kallikreins are a group of closely related serine proteinases that are represented by multigene families in mice and rats.", "begin": 0, "document": "1697365", "end": 129, "section": "abstract"}, {"text": "Our map specifies the distance between genes to one base pair accuracy, the relative location, and the direction of transcription of all 15 genes.", "begin": 1075, "document": "11006094", "end": 1221, "section": "abstract"}, {"text": "The human tissue Kallikrein family consists of 15 genes with the majority shown to be differentially expressed in cancers and/or indicators of cancer prognosis.", "begin": 0, "document": "21741862", "end": 160, "section": "abstract"}, {"text": "The 15 members of the kallikrein-related serine peptidase (KLK) family have diverse tissue-specific expression profiles and putative proteolytic functions.", "begin": 0, "document": "20103546", "end": 155, "section": "abstract"}, {"text": "The 15 human and 24 mouse kallikreins have been implicated in pathophysiology of brain, kidney, and respiratory and reproductive systems and often are used as cancer biomarkers.", "begin": 205, "document": "17210241", "end": 382, "section": "abstract"}, {"text": "Kallikrein gene families have been identified previously in genomes of the human, the mouse, and the rat, and individual kallikrein-like genes have been found in many more species.", "begin": 0, "document": "16829021", "end": 180, "section": "abstract"}, {"text": "The human tissue kallikrein family of serine proteases (hK1-hK15 encoded by the genes KLK1-KLK15) is involved in several cancer-related processes.", "begin": 0, "document": "16800744", "end": 146, "section": "abstract"}, {"text": "The tissue kallikrein gene family consists of 15 genes tandemly arranged on human chromosome 19q13.4.", "begin": 0, "document": "16800742", "end": 101, "section": "abstract"}, {"text": "Human kallikreins are a cluster of 15 serine protease genes located in the chromosomal band 19q13.4, a non-randomly rearranged region in many solid tumors, including pancreatic cancer.", "begin": 0, "document": "15015574", "end": 184, "section": "abstract"}, {"text": "Tissue kallikrein genes (KLKs) are found on chromosome 19q13.3-4 as a gene cluster encoding 15 different serine proteases.", "begin": 102, "document": "12925213", "end": 224, "section": "abstract"}, {"text": "Project to perform in silico analyses of the expression pattern of the 15 human KLK genes in normal and cancerous ovarian tissues and cell lines.", "begin": 305, "document": "12727843", "end": 450, "section": "abstract"}, {"text": "Novel kallikrein genes were cloned recently, and it was shown that the human kallikrein family contains 15 genes tandemly aligned on chromosomal locus 19q13.3-q13.4.", "begin": 85, "document": "12725528", "end": 250, "section": "abstract"}, {"text": "The human kallikrein gene family consists of 15 serine proteases.", "begin": 0, "document": "11522960", "end": 65, "section": "abstract"}, {"text": "We have recently characterized the human kallikrein gene locus on chromosome 19q13.4, which includes 15 kallikrein genes.", "begin": 434, "document": "11478802", "end": 555, "section": "abstract"}, {"text": "The human tissue kallikrein and kallikrein-related peptidases (KLKs), encoded by the largest contiguous cluster of protease genes in the human genome, are secreted serine proteases with diverse expression patterns and physiological roles.", "begin": 293, "document": "23093268", "end": 531, "section": "abstract"}, {"text": "that forms the largest cluster of contiguous protease genes in the human genome.", "begin": 106, "document": "21596022", "end": 186, "section": "abstract"}, {"text": "Kallikrein-related peptidases (KLKs) constitute a family of 15 highly conserved serine proteases encoded by the largest uninterrupted cluster of protease-encoding genes within the human genome.", "begin": 0, "document": "20180637", "end": 193, "section": "abstract"}, {"text": "In this review, we describe the organization of the kallikrein locus and the structure of kallikrein genes and proteins.", "begin": 779, "document": "20103546", "end": 899, "section": "abstract"}, {"text": "The human tissue kallikrein gene family is the largest contiguous family of proteases in the human genome, containing 15 genes.", "begin": 190, "document": "18627305", "end": 317, "section": "abstract"}, {"text": "Human tissue kallikrein genes represent the largest contiguous group of proteases within the human genome.", "begin": 246, "document": "17275179", "end": 352, "section": "abstract"}, {"text": "Human tissue kallikreins (hKs), which are encoded by the largest contiguous cluster of protease genes in the human genome, are secreted serine proteases with diverse expression patterns and physiological roles.", "begin": 0, "document": "15516960", "end": 210, "section": "abstract"}]}, {"documents": ["17689048", "19132393", "20331964", "21060858", "21542302", "8152926", "10845458", "9680985", "10781108", "18640997", "11353082", "8389441"], "answer": [["MET"], ["CMT"], ["DRM"]], "id": "511a4d391159fa8212000003", "snippets": [{"text": "The topologies of the trees were overall congruent: four monophyletic groups corresponding to the four plant C5-MTase families were clearly distinguished. In addition, sequence analyses of the plant C5-MTase target recognition domain sequences were performed and phylogenetic trees were reconstructed showing that there is good conservation among but not within the plant C5-MTase families.", "begin": 370, "document": "17689048", "end": 760, "section": "abstract"}, {"text": "To determine the inheritance of DNA methyltransferase genes and their expression patterns we examined three major DNA methyltransferase families (MET1, CMT3 and DRM) from tobacco and the progenitor species.", "begin": 399, "document": "19132393", "end": 605, "section": "abstract"}, {"text": "The comparative investigation of transcription levels of different genes of cytosine DNA methyltransferase family MET (MET1, MET2a, MET2b, MET3) and their methylation patterns shows that there may exist some mechanisms defending the most actively transcribed gene MET1 of this family from methylation mediated silencing. In contrast to DRM2 gene we could not find any adenine methylated GATC sites in the MET1 gene.", "begin": 1060, "document": "21542302", "end": 1475, "section": "abstract"}, {"text": "Using the 1kb 3' terminal DNA fragment of the mouse methyltransferase cDNA as a probe and low stringent hybridisation conditions, a new potential methyltransferase (MTase) gene family was isolated from an Arabidopsis thaliana genomic DNA library.", "begin": 0, "document": "8152926", "end": 246, "section": "abstract"}, {"text": "The Dnmt3 family of de novo DNA methyltransferases has recently been characterized in animals. Here we describe DNA methyltransferase genes from both Arabidopsis and maize that show a high level of sequence similarity to Dnmt3, suggesting that they encode plant de novo methyltransferases. Relative to all known eukaryotic methyltransferases, these plant proteins contain a novel arrangement of the motifs required for DNA methyltransferase catalytic activity.", "begin": 292, "document": "10781108", "end": 752, "section": "abstract"}, {"text": "These results provide the first direct demonstration that DNA-METases of a higher eukaryote are encoded by a gene family.", "begin": 1296, "document": "9680985", "end": 1417, "section": "abstract"}, {"text": "Here we show that Arabidopsis DNA methyltransferase2 (AtDNMT2) is localized in nucleus and associates with histone deacetylation.", "begin": 183, "document": "20331964", "end": 312, "section": "abstract"}, {"text": "To explore possible relationships between DNA methylation level and accumulation of DNA-(cytosine-5) methyltransferase (DNMT) transcripts, the full-length coding sequences corresponding to three different DNMT families in oil palm, namely the MET, CMT, and DRM classes, have been isolated and characterized.", "begin": 344, "document": "18640997", "end": 651, "section": "abstract"}, {"text": "In Arabidopsis a SWI2/SNF2 chromatin remodeling factor-related protein DDM1 and a cytosine methyltransferase MET1 are required for maintenance of genomic cytosine methylation.", "begin": 0, "document": "11353082", "end": 175, "section": "abstract"}, {"text": "Relative to all known eukaryotic methyltransferases, these plant proteins contain a novel arrangement of the motifs required for DNA methyltransferase catalytic activity.", "begin": 582, "document": "10781108", "end": 752, "section": "abstract"}, {"text": "In the present study, the isolation and characterization of two distinct cDNAs that code for carrot DNA (cytosine-5)-methyltransferase (DNA-METase) are reported.", "begin": 0, "document": "9680985", "end": 161, "section": "abstract"}, {"text": "The Arabidopsis methylase has eight of the ten conserved sequence motifs found in prokaryote cytosine-5 methyltransferases and shows 50% homology to the murine enzyme in the methyltransferase domain.", "begin": 709, "document": "8389441", "end": 908, "section": "abstract"}, {"text": "As deduced form the DNA sequence this protein contains all conserved sequence motifs specific for the 5m cytosine MTases.", "begin": 553, "document": "8152926", "end": 674, "section": "abstract"}]}, {"documents": ["23355544", "23284292", "22904080", "22855832", "22768981", "22132139", "21435340", "18682226"], "answer": ["transcriptional initiation"], "id": "512d2fff5274a5fb07000006", "snippets": [{"text": "The histone marks appeared mainly in generic regions and were enriched around the transcription start sites (TSSs) of genes", "begin": 659, "document": "23355544", "end": 782, "section": "abstract"}, {"text": "Tri-methylated H3 lysine 4 (H3K4me3) is associated with transcriptionally active genes, but its function in the transcription process is still unclear", "begin": 0, "document": "23284292", "end": 150, "section": "abstract"}, {"text": "However, the catalytic function is critically required for transcription as H3K4me3 levels determine the efficiency of transcription elongation", "begin": 623, "document": "23284292", "end": 766, "section": "abstract"}, {"text": "Trimethylation of histone H3 Lys 4 (H3K4me3) is a mark of active and poised promoters.", "begin": 0, "document": "22855832", "end": 86, "section": "abstract"}, {"text": "Histone H3 lysine 4 trimethylation (H3K4me3) is well known to occur in the promoter region of genes for transcription activation", "begin": 0, "document": "22768981", "end": 128, "section": "abstract"}, {"text": "3'-H3K4me3 is associated with ~15% of protein-coding genes in both tissues", "begin": 348, "document": "22768981", "end": 422, "section": "abstract"}, {"text": "Furthermore, 3'-H3K4me3 modification levels correlate positively with the antisense expression levels of the associated sense genes, implying that 3'-H3K4me3 is involved in the activation of antisense transcription.", "begin": 697, "document": "22768981", "end": 912, "section": "abstract"}, {"text": "Among these are forms of histone 3 that are mono- or tri-methylated at lysine 4 (H3K4me1 or H3K4me3, respectively), which bind preferentially to promoter and enhancer elements in the mammalian genome", "begin": 654, "document": "21435340", "end": 853, "section": "abstract"}, {"text": "we find that H3K4me1 and H3K4me3 are enriched at transcriptional start sites in the genome", "begin": 1066, "document": "21435340", "end": 1156, "section": "abstract"}, {"text": "H3K4me1 and H3K4me3 generally mark cis regulatory elements", "begin": 1676, "document": "21435340", "end": 1734, "section": "abstract"}]}, {"documents": ["22270183", "20621055", "19021773"], "answer": [["Histone 3 lysine 4 mono-methylation (H3K4me1)"], ["Histone 3 lysine 4 di-methylation (H3K4me2)"]], "id": "5131bef65274a5fb07000008", "snippets": [{"text": "Using H3K4me2 as a mark for active enhancers", "begin": 202, "document": "22270183", "end": 246, "section": "abstract"}, {"text": "Hyperacetylation of histones H3 and H4, a mark of active chromatin, is established broadly across target loci by enhancers that function over long distances", "begin": 101, "document": "19021773", "end": 257, "section": "abstract"}, {"text": "The enhancer region itself was marked by mono-methylation at K4 and K9, distinguishing it from the methyl marks in the gene coding region", "begin": 881, "document": "19021773", "end": 1018, "section": "abstract"}, {"text": "H3K4 methylation to monovalent and bivalent domains", "begin": 300, "document": "20621055", "end": 351, "section": "abstract"}]}, {"documents": ["22990134", "22589170", "22378220", "21606744", "20932506", "20059439", "19921962", "18577682", "18417974", "18254450", "17364293", "14663844", "14626795", "12835583", "11717628", "11169342", "10590441", "10912967", "10550877", "10419606", "10364670", "9664617", "8633653", "8538346", "7474061", "8142051", "1415421"], "answer": [["Itramniotic bleeding"], ["CMV infection"], ["Cystic Fibrosis (CF)"], ["Fetal aneuploidy"]], "id": "5131fa145274a5fb07000009", "snippets": [{"text": "Fetal echogenic bowel at 17 weeks' gestational age as the early and only sign of a very long segment of Hirschsprung disease.", "begin": 0, "document": "18577682", "end": 125, "section": "title"}, {"text": "fetal ultrasound findings associated with intrauterine cytomegalovirus (CMV) infection", "begin": 17, "document": "18417974", "end": 103, "section": "abstract"}, {"text": "the combination of hydrops fetalis, cerebral hemorrhage, and hyperechoic bowel should raise the possibility of a CMV infection", "begin": 1109, "document": "18417974", "end": 1235, "section": "abstract"}, {"text": "strongly associated with adverse pregnancy outcome due to utero-placental insufficiency, particularly in women with elevated maternal serum alpha-fetoprotein concentration due to severe feto-maternal bleeding", "begin": 706, "document": "18254450", "end": 914, "section": "abstract"}, {"text": "Congenital cytomegalovirus infection presenting with echogenic bowel and oligohydramnios.", "begin": 0, "document": "17364293", "end": 89, "section": "title"}, {"text": "echogenic bowel does not uniformly herald an abnormal outcome. Echogenic bowel coexistent with other abnormalities (such as growth deficiency or structural malformations) may be a comarker for aneuploidy.", "begin": 922, "document": "8142051", "end": 1126, "section": "abstract"}, {"text": "Congenital cytomegalovirus infection with oligohydramnios and echogenic bowel at 14 weeks' gestation", "begin": 0, "document": "7474061", "end": 100, "section": "title"}, {"text": "Fetal echogenic bowel and a dilated loop of bowel associated with cystic fibrosis (CF) mutations delta F508 and 2183AA-->G", "begin": 0, "document": "9664617", "end": 122, "section": "title"}, {"text": "Fifteen cases (19%) were associated with maternal vaginal bleeding", "begin": 319, "document": "10364670", "end": 385, "section": "abstract"}, {"text": "Five fetuses (6.3%) had evidence of bowel obstruction or perforation not associated with cystic fibrosis (CF)", "begin": 613, "document": "10364670", "end": 722, "section": "abstract"}, {"text": "Chromosomal aberrations were found in 5 fetuses (6.3%). Intrauterine infection with cytomegalovirus, herpes simplex virus, varicella-zoster virus, or parvovirus B-19 was documented in 5 patients (6.3%).", "begin": 724, "document": "10364670", "end": 926, "section": "abstract"}, {"text": "Fetal echogenic bowel has been reported as a normal variant in the second trimester, and has also been associated with an adverse fetal outcome, including cystic fibrosis (CF)", "begin": 0, "document": "10419606", "end": 175, "section": "abstract"}]}, {"documents": ["23042552", "21731768", "21629789", "21478460", "21175683", "19704032", "19492354", "19073165", "18334644", "18282512", "18279518", "18056681", "17442748", "16533910", "19698106", "16630819", "17096848"], "answer": ["Development"], "id": "51387022bee46bd34c000002", "snippets": [{"text": "Putative HCNE peak targets are characterized by a tight association with particular promoter motifs, higher incidence of severe mutant phenotypes, and evidence of a more precise regulation of gene expression during important developmental transitions", "begin": 1058, "document": "23042552", "end": 1308, "section": "abstract"}, {"text": "Much evidence suggests that CNEs are selectively constrained and not mutational cold-spots, and there is evidence that some CNEs play a role in the regulation of development.", "begin": 507, "document": "21478460", "end": 681, "section": "abstract"}, {"text": "This result suggests that there is widespread adaptation in mammalian conserved noncoding DNA elements, some of which have been implicated in the regulation of crucially important processes, including development.", "begin": 1463, "document": "21478460", "end": 1676, "section": "abstract"}, {"text": "Some characteristics of CNEs include their high frequency in mammalian genomes, their potential regulatory role in gene expression, and their enrichment in gene deserts nearby master developmental genes", "begin": 143, "document": "21175683", "end": 345, "section": "abstract"}, {"text": "Animal genomes possess highly conserved cis-regulatory sequences that are often found near genes that regulate transcription and development.", "begin": 0, "document": "19704032", "end": 141, "section": "abstract"}, {"text": "HCNEs of both human and zebrafish function as specific developmental enhancers in zebrafish.", "begin": 585, "document": "19073165", "end": 677, "section": "abstract"}, {"text": "HCNEs from the same area often drive overlapping patterns, suggesting that multiple regulatory inputs are required to achieve robust and precise complex expression patterns exhibited by developmental genes.", "begin": 1185, "document": "19073165", "end": 1391, "section": "abstract"}, {"text": "These results suggest important roles for SINEs in the development of the mammalian neuronal network, a part of which was initiated with the exaptation of AmnSINE1 in a common mammalian ancestor.", "begin": 1401, "document": "18334644", "end": 1596, "section": "abstract"}, {"text": "Further positional analysis of these conserved noncoding elements (CNEs) in the genome demonstrates that they cluster around genes involved in developmental regulation.", "begin": 480, "document": "18282512", "end": 648, "section": "abstract"}, {"text": "The majority of tetrapod-specific UCEs are noncoding and associated with genes involved in regulation of transcription and development.", "begin": 1277, "document": "18056681", "end": 1412, "section": "abstract"}, {"text": "Fish-mammal genomic comparisons have proved powerful in identifying conserved noncoding elements likely to be cis-regulatory in nature, and the majority of those tested in vivo have been shown to act as tissue-specific enhancers associated with genes involved in transcriptional regulation of development", "begin": 0, "document": "16533910", "end": 304, "section": "abstract"}, {"text": "In 74% of cases, we were able to assign a specific set of paralogous genes with annotation relating to transcriptional regulation and/or development to each family", "begin": 792, "document": "16533910", "end": 955, "section": "abstract"}, {"text": "The most highly conserved noncoding elements (HCNEs) in mammalian genomes cluster within regions enriched for genes encoding developmentally important transcription factors (TFs). This suggests that HCNE-rich regions may contain key regulatory controls involved in development", "begin": 0, "document": "16630819", "end": 276, "section": "abstract"}, {"text": "highly conserved noncoding elements and their association with developmental regulatory genes", "begin": 37, "document": "18279518", "end": 130, "section": "title"}]}, {"documents": ["23161666", "22530047", "22272832", "21255614", "21029240", "20829083", "20623621", "19894121", "19361871", "18950873", "18773082", "18673215", "17766043", "17463082", "17343922", "16440059", "16137612", "16126908", "16106061", "15949496", "15929040", "15898103", "15492125", "15288396", "15265674", "15039233", "11829341", "11391780", "7739505", "1793022"], "answer": ["Experimental autoimmune encephalomyelitis (EAE)"], "id": "5139b31dbee46bd34c000004", "snippets": [{"text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis", "begin": 241, "document": "23161666", "end": 323, "section": "abstract"}, {"text": "Many aspects of MS can be mimicked in the animal model of myelin oligodendrocyte glycoprotein experimental autoimmune encephalomyelitis (MOG-EAE)", "begin": 282, "document": "21255614", "end": 427, "section": "abstract"}, {"text": "the chronic experimental autoimmune encephalomyelitis (EAE) mouse model of MS", "begin": 531, "document": "21029240", "end": 608, "section": "abstract"}, {"text": "The aim of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis (EAE) in the rat", "begin": 343, "document": "20829083", "end": 548, "section": "abstract"}, {"text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (MS)", "begin": 0, "document": "20623621", "end": 103, "section": "abstract"}, {"text": "Theiler's murine encephalomyelitis virus (TMEV) infection of mice is an experimental model for multiple sclerosis (MS)", "begin": 0, "document": "19894121", "end": 118, "section": "abstract"}, {"text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS)", "begin": 508, "document": "19361871", "end": 599, "section": "abstract"}, {"text": "In this study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis (EAE), similar changes occur", "begin": 448, "document": "18950873", "end": 593, "section": "abstract"}, {"text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis (MS)", "begin": 0, "document": "18673215", "end": 108, "section": "abstract"}, {"text": "we utilized the Theiler's murine encephalomyelitis virus (TMEV) model of MS", "begin": 196, "document": "17766043", "end": 271, "section": "abstract"}, {"text": "In a murine disease model, experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD)", "begin": 919, "document": "17463082", "end": 1027, "section": "abstract"}, {"text": "experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis", "begin": 45, "document": "17463082", "end": 125, "section": "title"}, {"text": "Theiler's murine encephalomyelitis virus (TMEV)", "begin": 613, "document": "17343922", "end": 660, "section": "abstract"}, {"text": "Inflammatory diseases of the CNS, such as MS and its animal model EAE", "begin": 0, "document": "16440059", "end": 69, "section": "abstract"}, {"text": "the strong impact of the classical MS model experimental autoimmune encephalomyelitis (EAE)", "begin": 152, "document": "16137612", "end": 243, "section": "abstract"}, {"text": "an animal model of multiple sclerosis (MS): disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE).", "begin": 43, "document": "1793022", "end": 191, "section": "title"}, {"text": "The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis", "begin": 0, "document": "7739505", "end": 98, "section": "title"}, {"text": "EAE is the best available model for the inflammatory processes that occur in MS, and for the disease process", "begin": 178, "document": "7739505", "end": 286, "section": "abstract"}, {"text": "The present study addressed this question using the model of experimental allergic encephalomyelitis (EAE)", "begin": 455, "document": "11391780", "end": 561, "section": "abstract"}, {"text": "The conventional animal model of MS, experimental autoimmune encephalomyelitis (EAE)", "begin": 261, "document": "15039233", "end": 345, "section": "abstract"}, {"text": "To assess neurological impairments quantitatively in an animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis (EAE)", "begin": 0, "document": "15265674", "end": 177, "section": "abstract"}, {"text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS, including central nervous system inflammation and demyelination", "begin": 155, "document": "15288396", "end": 362, "section": "abstract"}, {"text": "Both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white matter", "begin": 0, "document": "15898103", "end": 172, "section": "abstract"}, {"text": "both MS patients and the MS animal model, experimental autoimmune encephalomyelitis (EAE)", "begin": 370, "document": "15929040", "end": 459, "section": "abstract"}, {"text": "In the MS animal model experimental autoimmune encephalomyelitis (EAE)", "begin": 289, "document": "15949496", "end": 359, "section": "abstract"}, {"text": "multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis", "begin": 20, "document": "16106061", "end": 102, "section": "title"}, {"text": "inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE)", "begin": 143, "document": "16126908", "end": 256, "section": "abstract"}]}, {"documents": ["20643727", "19530187", "18000908", "17955513", "17042739", "16258006", "15964893", "14672347", "12407713", "11820058", "11746040", "11484208", "11428324", "11341328", "11197897", "10951518", "10914960", "9917362", "9600744", "9934984", "9042914", "8106171"], "answer": [["FGFR3"], ["FGFR2"], ["FGFR1"], ["MSX2"], ["NELL1"], ["RUNX2"], ["RECQL4"], ["TWIST"], ["SOX6"], ["GNAS"]], "id": "513ce3c8bee46bd34c000008", "snippets": [{"text": "GNAS, the gene for guanine nucleotide-binding protein, alpha-stimulating activity polypeptide (gene for PHP1A), identified a de novo heterozygous 3 bp in frame deletion predicting a deletion of the asparagine residue at position 377 (deltaN377", "begin": 602, "document": "19530187", "end": 845, "section": "abstract"}, {"text": "craniosynostosis genes (FGFR2, FGFR3)", "begin": 924, "document": "19530187", "end": 961, "section": "abstract"}, {"text": "Syndromic craniosynostosis due to complex chromosome 5 rearrangement and MSX2 gene triplication", "begin": 0, "document": "18000908", "end": 95, "section": "title"}, {"text": "early fusion of cranial sutures commonly observed in the dup(5q) syndrome is caused by triplication of the MSX2 gene", "begin": 782, "document": "18000908", "end": 898, "section": "abstract"}, {"text": "further evidence that extra copy of MSX2 gene leads to craniosynostosis", "begin": 52, "document": "17955513", "end": 123, "section": "title"}, {"text": "Our results support the previous finding that distal 5q-trisomy together with an extra copy of the MSX2 gene leads to abnormal closure of sutures and craniosynostosis", "begin": 737, "document": "17955513", "end": 903, "section": "abstract"}, {"text": "Craniosynostosis-associated gene nell-1 is regulated by runx2", "begin": 0, "document": "17042739", "end": 61, "section": "title"}, {"text": "The breakpoint on chromosome 11p15 disrupts the SOX6 gene, known to be involved in skeletal growth and differentiation processes", "begin": 907, "document": "16258006", "end": 1035, "section": "abstract"}, {"text": "SOX6 mutation screening of another 104 craniosynostosis patients revealed one missense mutation leading to the exchange of a highly conserved amino acid (p.D68N) in a single patient and his reportedly healthy mother", "begin": 1037, "document": "16258006", "end": 1252, "section": "abstract"}, {"text": "Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene", "begin": 0, "document": "15964893", "end": 128, "section": "title"}, {"text": "Overexpression of Nell-1, a craniosynostosis-associated gene", "begin": 0, "document": "14672347", "end": 60, "section": "title"}, {"text": "Mutations in five genes (FGFR1-, -2, -3, TWIST, and MSX2) causing craniosynostosis as the main clinical feature were described.", "begin": 139, "document": "12407713", "end": 266, "section": "abstract"}, {"text": "One of the genes involved in craniosynostosis syndromes is the fibroblast growth factor receptor 2 (FGFR2) gene, a tyrosine kinase receptor gene", "begin": 0, "document": "11820058", "end": 144, "section": "abstract"}, {"text": "Most mutations in Crouzon, Pfeiffer, and Apert syndromes are in the extracellular, third immunoglobulin-like domain and adjacent linker regions (exons IIIa and IIIc) of the fibroblast growth factor receptor 2 (FGFR2) gene", "begin": 0, "document": "11484208", "end": 221, "section": "abstract"}, {"text": "Familial craniosynostosis due to Pro250Arg mutation in the fibroblast growth factor receptor 3 gene.", "begin": 0, "document": "11428324", "end": 100, "section": "title"}, {"text": "Apert (Ap) syndrome is characterized by premature cranial suture ossification caused by fibroblast growth factor receptor 2 (FGFR-2) mutations", "begin": 0, "document": "11341328", "end": 142, "section": "abstract"}, {"text": "Recently, the substitution of proline 250 by arginine in the fibroblast growth factor receptor 3 (FGFR3) gene, has been identified in patients with craniosynostosis and defines a new syndrome on a molecular basis", "begin": 0, "document": "11197897", "end": 212, "section": "abstract"}, {"text": "Mutations in the fibroblast growth factor receptor 1, 2 and 3 (FGFR1, -2 and -3) and TWIST genes have been identified in several syndromic forms of craniosynostosis", "begin": 0, "document": "10951518", "end": 164, "section": "abstract"}, {"text": "We describe a novel heterozygous mutation of FGFR2 (943G --> T, encoding the amino acid substitution Ala315Ser) in a girl with non-syndromic unicoronal craniosynostosis.", "begin": 303, "document": "10951518", "end": 472, "section": "abstract"}, {"text": "A unique Pro250Arg mutation in fibroblast growth factor receptor 3 (FGFR3) was recently found in patients with non-syndromic craniosynostosis", "begin": 0, "document": "10914960", "end": 141, "section": "abstract"}, {"text": "a possible mechanism for MSX2-mediated craniosynostosis in humans", "begin": 123, "document": "9917362", "end": 188, "section": "title"}, {"text": "We found previously that a single amino acid substitution in the homeodomain of the human MSX2 gene is associated with the autosomal dominant disorder craniosynostosis, Boston type.", "begin": 532, "document": "9917362", "end": 713, "section": "abstract"}, {"text": "Recently, a unique Pro250Arg point mutation in fibroblast growth factor receptor 3 (FGFR3) was reported in 61 individuals with coronal craniosynostosis from 20 unrelated families", "begin": 0, "document": "9600744", "end": 178, "section": "abstract"}, {"text": "We identified a novel TWIST gene mutation in this patient, a Glu181Stop mutation predicting a premature termination of the protein carboxy-terminal to the helix 2 domain", "begin": 1240, "document": "9934984", "end": 1409, "section": "abstract"}, {"text": "A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome", "begin": 0, "document": "9042914", "end": 119, "section": "title"}, {"text": "A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis", "begin": 0, "document": "8106171", "end": 114, "section": "title"}]}, {"documents": ["21439862", "23124509", "19276629", "19273592", "19186246", "18694559", "18407555", "17429051", "15226261", "14983006", "14978161"], "answer": ["Polycystic kidney disease (PKD)"], "id": "513ce494bee46bd34c000009", "snippets": [{"text": "role of primary cilia in autosomal dominant polycystic kidney disease", "begin": 81, "document": "21439862", "end": 150, "section": "title"}, {"text": "Recent research has focused on defects in signaling mediated by the primary cilia as the causative factor in ADPKD", "begin": 310, "document": "21439862", "end": 424, "section": "abstract"}, {"text": "malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD)", "begin": 1041, "document": "19276629", "end": 1207, "section": "abstract"}, {"text": "While PKD was one of the first diseases to be linked to dysfunctional primary cilia, defects in this organelle have subsequently been associated with many other phenotypes, including cancer, obesity, diabetes as well as a number of developmental defects", "begin": 1209, "document": "19276629", "end": 1462, "section": "abstract"}, {"text": "mice display abnormalities very similar to those of patients with neonatal diabetes and hypothyroidism syndrome, including the development of diabetes and polycystic kidney disease", "begin": 147, "document": "19273592", "end": 327, "section": "abstract"}, {"text": "Although Glis3(zf/zf) mice form normal primary cilia, renal cysts contain relatively fewer cells with a primary cilium", "begin": 460, "document": "19273592", "end": 578, "section": "abstract"}, {"text": "When ciliary function is perturbed, photoreceptors may die, kidney tubules develop cysts, limb digits multiply and brains form improperly.", "begin": 470, "document": "19186246", "end": 608, "section": "abstract"}, {"text": "Here, we report that CP110 interacts with CEP290--a protein whose deficiency is implicated in human ciliary disease", "begin": 306, "document": "18694559", "end": 421, "section": "abstract"}, {"text": "The cholangiociliopathies include but are not limited to cystic and fibrotic liver diseases associated with mutations", "begin": 523, "document": "18407555", "end": 640, "section": "abstract"}, {"text": "Cysts in the kidney are among the most common inherited human pathologies, and recent research has uncovered that a defect in cilia-mediated signaling activity is a key factor that leads to cyst formation", "begin": 0, "document": "17429051", "end": 204, "section": "abstract"}, {"text": "Multiple proteins whose functions are disrupted in cystic diseases have now been localized to the cilium or at the basal body at the base of the cilium", "begin": 301, "document": "17429051", "end": 452, "section": "abstract"}, {"text": "Polaris has been shown to co-localize with primary cilia, and these structures have been implicated in the formation of renal cysts", "begin": 691, "document": "15226261", "end": 822, "section": "abstract"}, {"text": "hus, polaris and primary cilia function are required for the maturation and maintenance of proper tissue organization in the pancreas", "begin": 1112, "document": "15226261", "end": 1245, "section": "abstract"}, {"text": "In cultured renal cells, the PKHD1 gene product colocalized with polycystin-2, the gene product of autosomal dominant polycystic disease type 2, at the basal bodies of primary cilia.", "begin": 766, "document": "14983006", "end": 948, "section": "abstract"}, {"text": "Mutations of the polycystic kidney and hepatic disease 1 (PKHD1) gene", "begin": 0, "document": "14983006", "end": 69, "section": "abstract"}, {"text": "The autosomal recessive polycystic kidney disease protein is localized to primary cilia", "begin": 0, "document": "14978161", "end": 87, "section": "title"}, {"text": "It is proposed that the pathogenesis of autosomal recessive polycystic kidney disease is linked to the dysfunction of primary cilia", "begin": 1082, "document": "14978161", "end": 1213, "section": "abstract"}]}, {"documents": ["22908106", "19942153", "19789374", "18466075", "19119983", "17725434", "12796075", "1728914", "23154888", "23264396", "21748540", "21516059", "20012189", "19191742", "18996189", "16641395", "16898074", "22374714", "19108789", "15301044", "15142360", "22238404", "21633823", "21468525", "21435090", "19733399", "19226259", "17093176", "22099156", "15927726", "14751040", "18511320", "11668059", "21933675", "21595516", "17446037", "10838651", "18845642", "17931806", "17711927"], "answer": [["bile acide sequestrant"], ["ferrous sulphate"], ["sucralfate"], ["Calcium carbonate"], ["aluminium-containing antacids"], ["raloxifene"], ["proton pump inhibithors"], ["sevelamer"], ["chromium picolinate"]], "id": "513f3d1fbee46bd34c000010", "snippets": [{"text": "ommonly used drugs, such as bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, raloxifene and proton-pump inhibitors, have also been shown to interfere with the absorption of levothyroxine", "begin": 319, "document": "19942153", "end": 579, "section": "abstract"}]}, {"documents": ["19202000", "19146893", "15702403", "15533650", "9395081", "9323559"], "answer": ["alpha-galactosidase A"], "id": "51405cd123fec90375000005", "snippets": [{"text": "The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. Defective lysosomal alpha-galactosidase A (Gla) is responsible for excessive Gb3 accumulation, and one cell sensitive to the effects of Gb3 accumulation is vascular endothelium.", "begin": 0, "document": "19202000", "end": 339, "section": "abstract"}, {"text": "Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme.", "begin": 0, "document": "15702403", "end": 282, "section": "abstract"}, {"text": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500).", "begin": 0, "document": "9323559", "end": 245, "section": "abstract"}, {"text": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established.", "begin": 0, "document": "9395081", "end": 174, "section": "abstract"}]}, {"documents": ["23388203", "22891351", "22886605", "21968997", "21810481", "21673794", "21625432", "21084727", "21042593", "20141841", "19861459", "19219035", "19056893", "18606808", "18391940", "17442734", "16627239", "16374431", "15838239", "15664996", "12200433", "12054621", "10823814", "9371825", "7649406"], "answer": [["HIF1-alpha"], ["c-Myc"], ["Src"], ["STAT3"], ["SIRT6"], ["NF-\u03baB"], ["Oct1"], ["HNF4-alpha"], ["PVHL"]], "id": "514168ab23fec9037500000a", "snippets": [{"text": "myc regulates hepatic glycolysis", "begin": 35, "document": "7649406", "end": 67, "section": "title"}, {"text": "increase in c-Myc protein was able to induce liver glucose utilization and accumulation, and suggested that c-Myc transcription factor is involved in the control in vivo of liver carbohydrate metabolism", "begin": 1984, "document": "7649406", "end": 2186, "section": "abstract"}, {"text": "p53 regulates mitochondrial oxidative phosphorylation, glycolysis, glutamine metabolism, lipid metabolism, and antioxidant defense", "begin": 639, "document": "23388203", "end": 769, "section": "abstract"}, {"text": "STAT3 is a negative regulator of aerobic glycolysis.", "begin": 1520, "document": "22891351", "end": 1572, "section": "abstract"}, {"text": "HIF1 alpha-mediated switches in the energy production of tumor cells from OXPHOS to glycolysis", "begin": 608, "document": "22886605", "end": 702, "section": "abstract"}, {"text": "NF-\u03baB organizes energy metabolism networks by controlling the balance between the utilization of glycolysis and mitochondrial respiration. NF-\u03baB inhibition causes cellular reprogramming to aerobic glycolysis under basal conditions and induces necrosis on glucose starvation", "begin": 453, "document": "21968997", "end": 726, "section": "abstract"}, {"text": "Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), which is a transcription factor that enhances glycolysis in cells in response to hypoxia", "begin": 0, "document": "21810481", "end": 126, "section": "abstract"}, {"text": "SIRT6 appears to function as a corepressor of the transcription factor Hif1alpha, a critical regulator of nutrient stress responses", "begin": 450, "document": "20141841", "end": 581, "section": "abstract"}, {"text": "SIRT6-deficient cells exhibit increased Hif1alpha activity and show increased glucose uptake with upregulation of glycolysis and diminished mitochondrial respiration", "begin": 612, "document": "20141841", "end": 777, "section": "abstract"}, {"text": "c-Myc regulates genes involved in the biogenesis of ribosomes and mitochondria, and regulation of glucose and glutamine metabolism", "begin": 449, "document": "19861459", "end": 579, "section": "abstract"}, {"text": "Myc regulates gene expression either directly, such as glycolytic genes including lactate dehydrogenase A (LDHA)", "begin": 870, "document": "19861459", "end": 982, "section": "abstract"}, {"text": "loss of the widely expressed transcription factor Oct1 induces a coordinated metabolic shift: mitochondrial activity and amino acid oxidation are increased, while glucose metabolism is reduced.", "begin": 259, "document": "19219035", "end": 452, "section": "abstract"}, {"text": "PVHL is a regulator of glucose metabolism", "begin": 0, "document": "19056893", "end": 41, "section": "title"}, {"text": "Carbohydrate response element-binding protein (ChREBP) is a glucose-responsive transcription factor that plays a critical role in the glucose-mediated induction of gene products involved in hepatic glycolysis and lipogenesis", "begin": 0, "document": "18606808", "end": 224, "section": "abstract"}, {"text": "Activation of NF-kappaB, by loss of p53, caused an increase in the rate of aerobic glycolysis and upregulation of Glut3", "begin": 375, "document": "18391940", "end": 494, "section": "abstract"}, {"text": "p53 restricts activation of the IKK-NF-kappaB pathway through suppression of glycolysis", "begin": 976, "document": "18391940", "end": 1063, "section": "abstract"}, {"text": "cells express hypoxia-inducible factor (HIF)-1alpha, a transcription factor that responds to oxygen tension and regulates glycolysis", "begin": 155, "document": "17442734", "end": 287, "section": "abstract"}, {"text": "The HIF-1 dependent genic products are involved in tumoral angiogenesis, in the metabolic switch to anaerobic glycolysis and in prosurvival, proliferative and apoptotic mechanisms", "begin": 590, "document": "16627239", "end": 769, "section": "abstract"}, {"text": "he hypoxia-inducible transcription factor (HIF) regulates the expression of genes involved in angiogenesis, erythropoiesis and glycolysis", "begin": 216, "document": "16374431", "end": 353, "section": "abstract"}, {"text": "ChREBP (carbohydrate response element-binding protein) was recently identified as a candidate transcription factor in the glucose-signaling pathway", "begin": 404, "document": "15664996", "end": 551, "section": "abstract"}, {"text": "Hypoxia-inducible factor (HIF)-1 is a master transcription factor, which up-regulates glycolysis", "begin": 0, "document": "12200433", "end": 96, "section": "abstract"}, {"text": "(Src) express HIF-1alpha protein under normoxia, which results in the expression of multiple HIF-1alpha target genes.", "begin": 411, "document": "12200433", "end": 528, "section": "abstract"}, {"text": "HIF-1 alpha can then translocate to the nucleus and facilitate transcription of numerous target genes, the majority of which are involved in glycolysis and angiogenesis via heterodimerisation with the beta subunit (HIF-1 beta/ARNT)", "begin": 397, "document": "12054621", "end": 628, "section": "abstract"}, {"text": "We previously observed that the c-Myc oncogenic transcription factor regulates lactate dehydrogenase A and induces lactate overproduction. We, therefore, sought to determine whether c-Myc controls other genes regulating glucose metabolism", "begin": 155, "document": "10823814", "end": 393, "section": "abstract"}, {"text": "overexpression of the c-Myc oncoprotein deregulates glycolysis through the activation of several components of the glucose metabolic pathway", "begin": 899, "document": "10823814", "end": 1039, "section": "abstract"}, {"text": "HNF4alpha is critical for regulating glucose transport and glycolysis and in doing so is crucial for maintaining glucose homeostasis", "begin": 1837, "document": "9371825", "end": 1969, "section": "abstract"}]}, {"documents": ["23359652", "23204236", "23019013", "22590561", "22391039", "21670971", "21328342", "21035946", "20967859", "20652010", "19809428", "19549892", "19293256", "18790747", "18780829", "18289803", "17634442", "16540656", "15805273", "15623601", "12753603", "12244149", "11700073"], "answer": [["SB225002"], ["G31P"], ["SCH-527123"], ["AZ10397767"], ["SCH-479833"]], "id": "5141bcd423fec9037500000d", "snippets": [{"text": "Recent evidence indicates that CXCR2 signaling is crucial for cancer progression, and its antagonist SB225002 induces apoptosis in Wilms' tumor cells.", "begin": 0, "document": "23359652", "end": 150, "section": "abstract"}, {"text": "CXCR2 small-molecule antagonist (SB225002)", "begin": 517, "document": "23204236", "end": 559, "section": "abstract"}, {"text": "G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.", "begin": 0, "document": "23019013", "end": 121, "section": "title"}, {"text": "The CXCR2 antagonist, SCH-527123, shows antitumor activity", "begin": 0, "document": "22391039", "end": 58, "section": "title"}, {"text": "retreatment with the CXCR2 antagonist AZ10397767", "begin": 761, "document": "18790747", "end": 809, "section": "abstract"}, {"text": "The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo.", "begin": 477, "document": "22391039", "end": 690, "section": "abstract"}, {"text": "we report that targeting CXCR2 and CXCR1 activity using orally active small molecule antagonist (SCH-527123, SCH-479833) inhibits human colon cancer liver metastasis mediated by decreased neovascularization and enhanced malignant cell apoptosis.", "begin": 196, "document": "21035946", "end": 441, "section": "abstract"}, {"text": "CXCR2-specific small molecule inhibitor (AZ10397767) to investigate the recruitment and function of human neutrophils in tumors", "begin": 593, "document": "21328342", "end": 720, "section": "abstract"}]}, {"documents": ["22693219", "19234603", "18207462", "12689350", "18204916", "18834495", "22438567", "23325628", "23221174", "19635172", "22711795", "18237434", "15941473", "18487273", "19828077", "18834500", "22595237", "20617200", "18712320", "21884822"], "answer": [["GeneView"], ["PPI finder"], ["PreBIND", "Textomy"], ["BioMap"], ["eFIP", "Extracting Functional Impact of Phosphorylation"], ["Protopia"], ["STRING"]], "id": "514217a6d24251bc05000005", "snippets": [{"text": "PPI finder: a mining tool for human protein-protein interactions.", "begin": 0, "document": "19234603", "end": 65, "section": "title"}, {"text": "Extracting interactions between proteins from the literature.", "begin": 0, "document": "18207462", "end": 61, "section": "title"}, {"text": "In the meantime, there has been a great interest with scientific communities in text mining tools to find knowledge such as protein-protein interactions, which is most relevant and useful for specific analysis tasks. This paper provides a outline of the various information extraction methods in biomedical domain, especially for discovery of protein-protein interactions.", "begin": 308, "document": "18207462", "end": 680, "section": "abstract"}, {"text": "PreBIND and Textomy--mining the biomedical literature for protein-protein interactions using a support vector machine.", "begin": 0, "document": "12689350", "end": 118, "section": "title"}, {"text": "Discovering implicit protein-protein interactions in the cell cycle using bioinformatics approaches.", "begin": 0, "document": "18204916", "end": 100, "section": "title"}, {"text": "In this paper we examine if P-P interactions in regenerating tissues and cells of the anuran Xenopus laevis can be discovered from biomedical literature using computational and literature mining techniques.", "begin": 669, "document": "18204916", "end": 875, "section": "abstract"}, {"text": "P-P interactions that are implicitly appearing in literature can be effectively discovered using literature mining techniques.", "begin": 1434, "document": "18204916", "end": 1560, "section": "abstract"}, {"text": "The developed BioMap system allows discovering implicit P-P interactions from large quantity of biomedical literature data.", "begin": 1732, "document": "18204916", "end": 1855, "section": "abstract"}, {"text": "How to link ontologies and protein-protein interactions to literature: text-mining approaches and the BioCreative experience.", "begin": 0, "document": "22438567", "end": 125, "section": "title"}, {"text": "One of the most common and challenging problem in biomedical text mining is to mine protein-protein interactions (PPIs) from MEDLINE abstracts and full-text research articles because PPIs play a major role in understanding the various biological processes and the impact of proteins in diseases.", "begin": 0, "document": "23325628", "end": 295, "section": "abstract"}, {"text": "Extracting protein-protein interaction (PPI) from biomedical literature is an important task in biomedical text mining (BioTM).", "begin": 0, "document": "22595237", "end": 127, "section": "abstract"}, {"text": "Automated extraction of protein-protein interactions (PPIs) from biomedical literatures is an important topic of biomedical text mining.", "begin": 0, "document": "21884822", "end": 136, "section": "abstract"}, {"text": "Extraction of protein-protein interactions (PPIs) reported in scientific publications is one of the core topics of text mining in the life sciences.", "begin": 99, "document": "20617200", "end": 247, "section": "abstract"}, {"text": "The techniques used in text mining range from the very simple (e.g., the inference of relationships between genes from frequent proximity in documents) to the complex and computationally intensive (e.g., the analysis of sentence structures with parsers in order to extract facts about protein-protein interactions from statements in the text).", "begin": 251, "document": "18712320", "end": 594, "section": "abstract"}, {"text": "A major challenge in text mining for biomedicine is automatically extracting protein-protein interactions from the vast amount of biomedical literature.", "begin": 0, "document": "18283029", "end": 152, "section": "abstract"}, {"text": "One of the most common and challenging problem in biomedical text mining is to mine protein-protein interactions (PPIs) from MEDLINE abstracts and full-text research articles because PPIs play a major role in understanding the various biological processes and the impact of proteins in diseases.", "begin": 0, "document": "23325628", "end": 295, "section": "abstract"}, {"text": "We have developed the Extracting Functional Impact of Phosphorylation (eFIP) text mining system, which combines several natural language processing techniques to find relevant abstracts mentioning phosphorylation of a given protein together with indications of protein-protein interactions (PPIs) and potential evidences for impact of phosphorylation on the PPIs.", "begin": 539, "document": "23221174", "end": 902, "section": "abstract"}, {"text": "One of the most common and challenging problem in biomedical text mining is to mine protein-protein interactions (PPIs) from MEDLINE abstracts and full-text research articles because PPIs play a major role in understanding the various biological processes and the impact of proteins in diseases.", "begin": 0, "document": "23325628", "end": 295, "section": "abstract"}]}, {"documents": ["22416126", "22102035", "22101825", "20421735", "19423654", "18655028", "16148043"], "answer": [["PSPC1"], ["SFPQ"]], "id": "514241fcd24251bc05000006", "snippets": [{"text": "The paraspeckle component 1 (PSPC1) and non-POU-domain-containing octamer-binding protein (NONO) heterodimer is an essential structural component of paraspeckles,", "begin": 0, "document": "22102035", "end": 162, "section": "abstract"}, {"text": "PSPC1-NONO heterodimer.", "begin": 117, "document": "22101825", "end": 140, "section": "title"}, {"text": "Crystallization of a paraspeckle protein PSPC1-NONO heterodimer", "begin": 0, "document": "22102035", "end": 63, "section": "title"}, {"text": "difficult heterodimeric complex of two human proteins, paraspeckle component 1 (PSPC1) and non-POU domain-containing octamer-binding protein (NONO), that are involved in gene regulation and the structural integrity of nuclear bodies termed paraspeckles is described.", "begin": 143, "document": "22101825", "end": 409, "section": "abstract"}, {"text": "SFPQ (PSF) and NONO (p54) are nuclear proteins that interact with each other and have diverse roles in nucleic acids metabolism. The SFPQ/NONO heterodimer was previously found to enhance DNA strand break rejoining in vitro.", "begin": 272, "document": "20421735", "end": 495, "section": "abstract"}, {"text": "We identified a heterodimer, p54nrb and PSF,", "begin": 181, "document": "18655028", "end": 225, "section": "abstract"}, {"text": "P54nrb forms a heterodimer with PSP1 that localizes to paraspeckles in an RNA-dependent manner.", "begin": 0, "document": "16148043", "end": 95, "section": "title"}, {"text": "e demonstrated that the PSF heterodimer partner, p54nrb (non-POU-domain-containing, octamer binding protein), can also function as a transcription corepressor, independent of PSF.", "begin": 402, "document": "19423654", "end": 581, "section": "abstract"}, {"text": "The PSPC1/NONO heterodimer has a right-handed antiparallel coiled-coil", "begin": 1010, "document": "22416126", "end": 1080, "section": "abstract"}, {"text": "Structure of the heterodimer of human NONO and paraspeckle protein component 1", "begin": 0, "document": "22416126", "end": 78, "section": "title"}]}, {"documents": ["19421989", "18434251", "17958348", "16351738", "16225682", "15261149", "15215419", "15141026", "15070403", "12169530", "20952406", "16844989", "15647112", "15215418", "16542876", "23297037", "22987359", "22247276", "21426944", "21328706", "18467177", "18006547", "16844988", "15980452", "17557332", "22540951", "15769290", "15980447", "17597895", "17597890", "16597327", "18783592", "23555228", "18989393"], "answer": [["BETAWARE"], ["BOCTOPUS"], ["BOMP"], ["BTMX"], ["HMM-B2TMR"], ["OMPdb"], ["PRED-TMBB"], ["PROB"], ["ProfTMB"], ["PV"], ["TMB finding pipeline"], ["TMBETADISC-RBF"], ["TMBETAPRED-RBF"], ["TMBHMM"], ["TMB-Hunt", "TMB-Hunt2"], ["TMBKNN"], ["TMBpro"], ["transFold"], ["TMBETA-NET"]], "id": "51434c74d24251bc0500000c", "snippets": [{"text": "In this work, we propose a method based on radial basis networks for predicting the number of beta-strands in OMPs and identifying their membrane spanning segments.", "begin": 168, "document": "19421989", "end": 332, "section": "abstract"}, {"text": "We have developed a web server, TMBETAPRED-RBF for predicting the transmembrane beta-strands from amino acid sequence and it is available at http://rbf.bioinfo.tw/~sachen/tmrbf.html.", "begin": 624, "document": "19421989", "end": 806, "section": "abstract"}, {"text": "We have developed a prediction server, TMBETADISC-RBF, which is available at http://rbf.bioinfo.tw/~sachen/OMP.html.", "begin": 1044, "document": "18434251", "end": 1160, "section": "abstract"}, {"text": "TMB finding pipeline: novel approach for detecting beta-barrel membrane proteins in genomic sequences.", "begin": 0, "document": "17958348", "end": 102, "section": "title"}, {"text": "Interestingly, the present approach identified TMBs from all 15 families in TCDB.", "begin": 1154, "document": "17958348", "end": 1235, "section": "abstract"}, {"text": "A new decoding algorithm for hidden Markov models improves the prediction of the topology of all-beta membrane proteins.", "begin": 0, "document": "16351738", "end": 120, "section": "title"}, {"text": "A new method is presented for identification of beta-barrel membrane proteins. It is based on a hidden Markov model (HMM) with an architecture obeying these proteins' construction principles. Once the HMM is trained, log-odds score relative to a null model is used to discriminate beta-barrel membrane proteins from other proteins.", "begin": 0, "document": "15261149", "end": 331, "section": "abstract"}, {"text": "Prediction of beta-barrel membrane proteins by searching for restricted domains.", "begin": 0, "document": "16225682", "end": 80, "section": "title"}, {"text": "PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins.", "begin": 0, "document": "15215419", "end": 91, "section": "title"}, {"text": "PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins.", "begin": 0, "document": "15215419", "end": 91, "section": "title"}, {"text": "We present here a web server (PRED-TMBB, http://bioinformatics.biol.uoa.gr/PRED-TMBB) which is capable of predicting the transmembrane strands and the topology of beta-barrel outer membrane proteins of Gram-negative bacteria. The method is based on a Hidden Markov Model, trained according to the Conditional Maximum Likelihood criterion.", "begin": 346, "document": "15215419", "end": 684, "section": "abstract"}, {"text": "Predicting transmembrane beta-barrels in proteomes.", "begin": 0, "document": "15141026", "end": 51, "section": "title"}, {"text": "Here we introduced the design, statistics and results of a novel profile-based hidden Markov model for the prediction and discrimination of TMBs.", "begin": 241, "document": "15141026", "end": 386, "section": "abstract"}, {"text": "A Hidden Markov Model method, capable of predicting and discriminating beta-barrel outer membrane proteins.", "begin": 0, "document": "15070403", "end": 107, "section": "title"}, {"text": "A sequence-profile-based HMM for predicting and discriminating beta barrel membrane proteins.", "begin": 0, "document": "12169530", "end": 93, "section": "title"}, {"text": "OMPdb: a database of {beta}-barrel outer membrane proteins from Gram-negative bacteria.", "begin": 0, "document": "20952406", "end": 87, "section": "title"}, {"text": "transFold: a web server for predicting the structure and residue contacts of transmembrane beta-barrels.", "begin": 0, "document": "16844989", "end": 104, "section": "title"}, {"text": "Evaluation of methods for predicting the topology of beta-barrel outer membrane proteins and a consensus prediction method.", "begin": 0, "document": "15647112", "end": 123, "section": "title"}, {"text": "BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria.", "begin": 0, "document": "15215418", "end": 121, "section": "title"}, {"text": "This work describes the development of a program that predicts whether or not a polypeptide sequence from a Gram-negative bacterium is an integral beta-barrel outer membrane protein. The program, called the beta-barrel Outer Membrane protein Predictor (BOMP), is based on two separate components to recognize integral beta-barrel proteins.", "begin": 0, "document": "15215418", "end": 339, "section": "abstract"}, {"text": "This work describes the development of a program that predicts whether or not a polypeptide sequence from a Gram-negative bacterium is an integral beta-barrel outer membrane protein. The program, called the beta-barrel Outer Membrane protein Predictor (BOMP), is based on two separate components to recognize integral beta-barrel proteins.", "begin": 0, "document": "15215418", "end": 339, "section": "abstract"}, {"text": "On the basis of existing knowledge of beta-barrel outer-membrane proteins, several state of the art prediction methods, as well as a new in-house program (PROB) were employed for the systematic exploration of Mycobacterium tuberculosis predicted proteomes for potential beta-barrel structures.", "begin": 139, "document": "16542876", "end": 432, "section": "abstract"}, {"text": "Computational identification of beta-barrel outer-membrane proteins in Mycobacterium tuberculosis predicted proteomes as putative vaccine candidates.", "begin": 0, "document": "16542876", "end": 149, "section": "title"}, {"text": "BETAWARE: a machine-learning tool to detect and predict transmembrane beta-barrel proteins in prokaryotes.", "begin": 0, "document": "23297037", "end": 106, "section": "title"}, {"text": "Recently, we developed two top-performing methods based on machine-learning approaches to tackle both the detection of TMBBs in sets of proteins and the prediction of their topology.", "begin": 684, "document": "23297037", "end": 866, "section": "abstract"}, {"text": "Supersecondary structure prediction of transmembrane beta-barrel proteins.", "begin": 0, "document": "22987359", "end": 74, "section": "title"}, {"text": "We introduce a graph-theoretic model for predicting the supersecondary structure of transmembrane \u03b2-barrel proteins--a particular class of proteins that performs diverse important functions but it is difficult to determine their structure with experimental methods.", "begin": 0, "document": "22987359", "end": 265, "section": "abstract"}, {"text": "BOCTOPUS: improved topology prediction of transmembrane \u03b2 barrel proteins.", "begin": 0, "document": "22247276", "end": 74, "section": "title"}, {"text": "TMBHMM: a frequency profile based HMM for predicting the topology of transmembrane beta barrel proteins and the exposure status of transmembrane residues.", "begin": 0, "document": "21426944", "end": 154, "section": "title"}, {"text": "We present here TMBHMM, a computational method based on a hidden Markov model for predicting the structural topology of putative TMBs from sequence. In addition to predicting transmembrane strands, TMBHMM also predicts the exposure status (i.e., exposed to the membrane or hidden in the protein structure) of the residues in the transmembrane region, which is a novel feature of the TMBHMM method. Furthermore, TMBHMM can also predict the membrane residues that are not part of beta barrel forming strands.", "begin": 332, "document": "21426944", "end": 838, "section": "abstract"}, {"text": "We present BTMX (Beta barrel TransMembrane eXposure), a computational method to predict the exposure status (i.e. exposed to the bilayer or hidden in the protein structure) of transmembrane residues in transmembrane beta barrel proteins (TMBs). BTMX predicts the exposure status of known TM residues with an accuracy of 84.2% over 2,225 residues and provides a confidence score for all predictions.", "begin": 0, "document": "21328706", "end": 398, "section": "abstract"}, {"text": "A method for discovering transmembrane beta-barrel proteins in Gram-negative bacterial proteomes.", "begin": 0, "document": "18467177", "end": 97, "section": "title"}, {"text": "A web server based on the proposed method is available at http://yanbioinformatics.cs.usu.edu:8080/TMBKNNsubmit.", "begin": 570, "document": "18467177", "end": 682, "section": "abstract"}, {"text": "This paper presents a k-nearest neighbor (K-NN) method for discriminating TMB and non-TMB proteins.", "begin": 100, "document": "18467177", "end": 199, "section": "abstract"}, {"text": "TMBpro: secondary structure, beta-contact and tertiary structure prediction of transmembrane beta-barrel proteins.", "begin": 0, "document": "18006547", "end": 114, "section": "title"}, {"text": "PROFtmb: a web server for predicting bacterial transmembrane beta barrel proteins.", "begin": 0, "document": "16844988", "end": 82, "section": "title"}, {"text": "A consensus algorithm to screen genomes for novel families of transmembrane beta barrel proteins.", "begin": 0, "document": "17557332", "end": 97, "section": "title"}, {"text": "Here we describe a new algorithm combining composition and hidden Markov model topology based classifiers (called TMB-Hunt2), which achieves a crossvalidation accuracy of >95%, with 96.7% precision and 94.2% recall.", "begin": 554, "document": "17557332", "end": 769, "section": "abstract"}, {"text": "Tools and datasets are made available through a website called TMB-Web (http://www.bioinformatics.leeds.ac.uk/TMB-Web/TMB-Hunt2).", "begin": 1347, "document": "17557332", "end": 1476, "section": "abstract"}, {"text": "TMB-Hunt: a web server to screen sequence sets for transmembrane beta-barrel proteins.", "begin": 0, "document": "15980452", "end": 86, "section": "title"}]}, {"documents": ["7731034", "8009147", "1470196", "1318636", "1448671", "1339000", "2189179", "18506722", "17395141", "15767964", "15000529", "20979723", "10486838", "9538660", "8568672", "2833535", "19803409", "15793845", "8387255", "20514935", "18032743", "20392978", "12632823", "18644631", "9484375", "3016531", "18841652", "16100656", "9094058", "8186692", "9254841"], "answer": ["small-cell lung cancer"], "id": "5147c088d24251bc05000026", "snippets": [{"text": "The autoantibodies implicated in the Lambert-Eaton myasthenic syndrome (LES), which are known to inhibit ICa and INa in bovine adrenal chromaffin cells, also significantly inhibited INa in SCLC cells.", "begin": 1592, "document": "7731034", "end": 1792, "section": "abstract"}, {"text": "These results indicate that (i) action potentials in human SCLC cells result from the regenerative increase in voltage-gated Na+ channel conductance; (ii) fundamental characteristics of SCLC Na+ channels are the same as the classical sodium channels found in a variety of excitable cells; and (iii) in some LES patients, SCLC Na+ channels are an additional target of the pathological IgG present in the patients' sera.", "begin": 1793, "document": "7731034", "end": 2211, "section": "abstract"}, {"text": "Clinical features were those of LES and occurred insidiously in this 68-year old man: proximal weakness predominant in the lower limbs, generalized areflexia, dryness of the mouth and partial right eye palsy. Investigations disclosed a small cell lung cancer.", "begin": 110, "document": "8009147", "end": 369, "section": "abstract"}, {"text": "Voltage-gated Ca2+ channels may be important to the secretion of ectopic hormones and the etiology and pathogenesis of Lambert-Eaton syndrome, an autoimmune disorder of the motor nerve terminal in which autoantibodies directed against voltage-gated Ca2+ channels are produced.", "begin": 964, "document": "1318636", "end": 1240, "section": "abstract"}, {"text": "Lambert-Eaton syndrome is a myasthenia-like syndrome of paraneoplastic origin which is often associated with anaplastic small-cell lung cancer.", "begin": 0, "document": "1339000", "end": 143, "section": "abstract"}, {"text": "Small-cell lung cancer (SCLC) is the most common cause of LES.", "begin": 185, "document": "18506722", "end": 247, "section": "abstract"}, {"text": "We report an unusual case of LES associated with large-cell neuroendocrine carcinoma (LCNEC) of the lung.", "begin": 248, "document": "18506722", "end": 353, "section": "abstract"}, {"text": "The Lambert-Eaton syndrome is caused by antibodies against voltage-gated calcium channels and often occurs in patients with small cell lung cancer.", "begin": 406, "document": "17395141", "end": 553, "section": "abstract"}, {"text": "LEMS has a high degree of coincidence (approximately 60%) with small cell lung cancer; the remaining 40% of patients with LEMS have no detectable tumor.", "begin": 1672, "document": "15000529", "end": 1824, "section": "abstract"}, {"text": "The Lambert Eaton syndrome is a paraneoplastic manifestation of small-cell lung cancer in 50% of the cases unlike generalized myasthenia which apparently is never associated with small-cell lung cancer.", "begin": 799, "document": "10486838", "end": 1001, "section": "abstract"}, {"text": "Paraneoplastic Lambert-Eaton myasthenia syndrome is presented in two cases with small cell lung cancer.", "begin": 0, "document": "9538660", "end": 103, "section": "abstract"}, {"text": "Human small-cell lung cancer (SCLC) cells are believed to express the antigens responsible for the production of pathological antibodies in the Lambert-Eaton syndrome (LES), a Ca2+ channel disorder in which quantal transmitter release from the motor nerve terminal is impaired.", "begin": 3, "document": "8568672", "end": 280, "section": "abstract"}, {"text": "Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic autoimmune disorder caused by an IgG-mediated reduction in number of presynaptic voltage-gated calcium channels (VGCC) at the neuromuscular junction. In at least 50% of cases, the stimulus for antibody production may be VGCC on small cell lung cancer (SCLC)", "begin": 0, "document": "2833535", "end": 318, "section": "abstract"}, {"text": "Also, there was no obvious band pattern distinguishing patients with LES from those with LES and concurrent SCLC.", "begin": 691, "document": "1470196", "end": 804, "section": "abstract"}, {"text": "The cancer associated with LEMS was small-cell lung carcinoma (SCLC) in 15 cases and epidermoid lung carcinoma in 3 cases.", "begin": 157, "document": "1448671", "end": 279, "section": "abstract"}, {"text": "Etiology of this disease is uncertain but in view of its frequent association with small cell lung cancer, this specific type of neoplasm may be implicated in the initiation of autoimmune response.", "begin": 501, "document": "2189179", "end": 698, "section": "abstract"}, {"text": "Recent studies indeed support the possibility that the antigenic stimulus in the neoplastic form of LES may arise from voltage-dependent Ca2+ channels found in the lung cancer cells.", "begin": 699, "document": "2189179", "end": 881, "section": "abstract"}, {"text": "In the majority of LEMS patients, those having detectable tumor, the disease is thought to occur as a result of immune response directed initially against voltage-gated Ca2+ channels found on the lung tumor cells.", "begin": 2007, "document": "15000529", "end": 2220, "section": "abstract"}, {"text": "Radiological, bronchoscopic and histological investigations revealed small-cell lung cancer, and neurophysiological investigations confirmed a diagnosis of LEMS.", "begin": 620, "document": "20392978", "end": 781, "section": "abstract"}, {"text": "Physicians need to be aware that patients may develop PCD and LEMS associated with anti-VGCC antibody caused by small cell lung cancer, and a mass survey should be conducted and careful examinations performed.", "begin": 1787, "document": "19803409", "end": 1996, "section": "abstract"}, {"text": "Biopsy revealed small cell lung cancer (SCLC) indicating the importance of repeated chest CT in LEMS even when an existing autoimmune-like disease and negative CT may suggest an autoimmune origin.", "begin": 329, "document": "18841652", "end": 525, "section": "abstract"}, {"text": "The presence of a particular symptom associated with LEMS did not predict the presence of SCLC, but in patients with rapidly progressive LEMS the possibility of underlying lung cancer should be of particular concern.", "begin": 738, "document": "15793845", "end": 954, "section": "abstract"}, {"text": "We report a case of small-cell lung cancer (SCLC) presenting with LEMS and ventilatory failure in a 67-year-old man who initially presented with progressive limb weakness for 6 months and tachypnea with shallow breathing for 1 week.", "begin": 288, "document": "12632823", "end": 520, "section": "abstract"}, {"text": "Using this protein, we demonstrated that anti-beta-subunit antibodies are present in the sera of 23% of LEMS patients and only, in low titer, in 2% of small cell lung cancer patients without LEMS.", "begin": 442, "document": "9484375", "end": 638, "section": "abstract"}, {"text": "The gene encoding the beta 2 protein, first described as a Lambert-Eaton myasthenic syndrome (LEMS) antigen in humans, is found close to a region that undergoes chromosome rearrangements in small cell lung cancer, which occurs in association with LEMS.", "begin": 291, "document": "9254841", "end": 543, "section": "abstract"}, {"text": "We then tested sera from 72 LEMS patients' 25 with proven small cell lung cancer (SCLC) and 66 healthy or other neurological, SCLC or autoimmune disease controls in an immunoprecipitation assay using 125I-omega-CmTx-labelled (P/Q-type) VGCCs in human cerebellar extract.", "begin": 449, "document": "9094058", "end": 719, "section": "abstract"}, {"text": "In the majority of patients LEMS is associated with small cell lung cancer (SCLC).", "begin": 471, "document": "8186692", "end": 553, "section": "abstract"}, {"text": "Patients with small cell lung cancer (SCLC) in particular may develop LEMS, and SCLC is very often detected in patients affected by LEMS.", "begin": 207, "document": "8387255", "end": 344, "section": "abstract"}, {"text": "We present a 69-year-old woman who had preventive whole brain radiation after a diagnosis of paraneoplastic Lambert-Eaton syndrome related to small cell lung cancer Five months after radiation therapy, she developed radiation-induced leukoencephalopathy manifested by ataxia.", "begin": 264, "document": "20514935", "end": 539, "section": "abstract"}, {"text": "Physicians need to be aware that patients may develop PCD and LEMS associated with anti-VGCC antibody caused by small cell lung cancer, and a mass survey should be conducted and careful examinations performed.", "begin": 1787, "document": "19803409", "end": 1996, "section": "abstract"}, {"text": "Biopsy revealed small cell lung cancer (SCLC) indicating the importance of repeated chest CT in LEMS even when an existing autoimmune-like disease and negative CT may suggest an autoimmune origin.", "begin": 329, "document": "18841652", "end": 525, "section": "abstract"}, {"text": "Among the symptoms of lung cancer LEMS can be seen, but it is very rare.", "begin": 176, "document": "16100656", "end": 248, "section": "abstract"}, {"text": "The presence of a particular symptom associated with LEMS did not predict the presence of SCLC, but in patients with rapidly progressive LEMS the possibility of underlying lung cancer should be of particular concern.", "begin": 738, "document": "15793845", "end": 954, "section": "abstract"}, {"text": "We report a case of small-cell lung cancer (SCLC) presenting with LEMS and ventilatory failure in a 67-year-old man who initially presented with progressive limb weakness for 6 months and tachypnea with shallow breathing for 1 week.", "begin": 288, "document": "12632823", "end": 520, "section": "abstract"}, {"text": "Using this protein, we demonstrated that anti-beta-subunit antibodies are present in the sera of 23% of LEMS patients and only, in low titer, in 2% of small cell lung cancer patients without LEMS.", "begin": 442, "document": "9484375", "end": 638, "section": "abstract"}, {"text": "The gene encoding the beta 2 protein, first described as a Lambert-Eaton myasthenic syndrome (LEMS) antigen in humans, is found close to a region that undergoes chromosome rearrangements in small cell lung cancer, which occurs in association with LEMS.", "begin": 291, "document": "9254841", "end": 543, "section": "abstract"}, {"text": "We then tested sera from 72 LEMS patients' 25 with proven small cell lung cancer (SCLC) and 66 healthy or other neurological, SCLC or autoimmune disease controls in an immunoprecipitation assay using 125I-omega-CmTx-labelled (P/Q-type) VGCCs in human cerebellar extract.", "begin": 449, "document": "9094058", "end": 719, "section": "abstract"}, {"text": "In the majority of patients LEMS is associated with small cell lung cancer (SCLC).", "begin": 471, "document": "8186692", "end": 553, "section": "abstract"}, {"text": "Patients with small cell lung cancer (SCLC) in particular may develop LEMS, and SCLC is very often detected in patients affected by LEMS.", "begin": 207, "document": "8387255", "end": 344, "section": "abstract"}, {"text": "A patient with the Lambert-Eaton syndrome (LES) and small cell lung cancer developed respiratory failure several hours after verapamil was given.", "begin": 0, "document": "3016531", "end": 145, "section": "abstract"}]}, {"documents": ["23159405", "23032483", "22100391", "12598532", "11948422", "11566103", "11313966"], "answer": ["JNK"], "id": "5148691bd24251bc0500002d", "snippets": [{"text": "Thus, rosiglitazone's neuroprotective effect after ischemia is mediated by blocking JNK phosphorylation induced by ischemia via DUSP8 upregulation.", "begin": 1270, "document": "23032483", "end": 1417, "section": "abstract"}, {"text": "Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase.", "begin": 0, "document": "23032483", "end": 164, "section": "title"}, {"text": "These results suggest that JNK activation by H(2)O(2) plus PDTC resulted from the down-regulation of JNK phosphatases.", "begin": 1219, "document": "11313966", "end": 1337, "section": "abstract"}, {"text": "M3/6 is a dual-specificity phosphatase selective for JNK", "begin": 637, "document": "11566103", "end": 693, "section": "abstract"}, {"text": "Phosphorylation of the M3/6 dual-specificity phosphatase enhances the activation of JNK by arsenite.", "begin": 0, "document": "22100391", "end": 100, "section": "title"}, {"text": "Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK", "begin": 151, "document": "22100391", "end": 447, "section": "abstract"}, {"text": "Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase.", "begin": 432, "document": "11948422", "end": 536, "section": "abstract"}, {"text": "M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins.", "begin": 416, "document": "23159405", "end": 676, "section": "abstract"}, {"text": ". We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.", "begin": 1062, "document": "12598532", "end": 1211, "section": "abstract"}]}, {"documents": ["23283084", "21862720", "21505152", "20435186", "19840561", "19261139", "18824640"], "answer": [["patient health questionnaire-2"], ["patient health questionnaire-9"]], "id": "51486f7dd24251bc0500002e", "snippets": [{"text": "In 2008, the American Heart Association (AHA) recommended a 2-step screening method, consisting of the 2-item Patient Health Questionnaire (PHQ-2) followed by the 9-item Patient Health Questionnaire (PHQ-9), for identifying depression in cardiovascular patients.", "begin": 12, "document": "21862720", "end": 274, "section": "abstract"}, {"text": "A recent American Heart Association (AHA) Prevention Committee report recommended depression screening of all coronary heart disease patients using 2- and 9-item instruments from the Patient Health Questionnaire (PHQ-2 and PHQ-9) to identify patients who may need further assessment and treatment.", "begin": 12, "document": "20435186", "end": 309, "section": "abstract"}, {"text": "Patients were screened for depression using a protocol identical to the one endorsed by the AHA in a cardiology community clinic in Elmhurst (Queens, New York). Depression was assessed using the Patient Health Questionnaire.", "begin": 348, "document": "19840561", "end": 572, "section": "abstract"}]}, {"documents": ["23204921", "21691271", "21521028", "21354501", "21142908", "20602616", "20487194", "20070406", "19514905", "19351209", "19207023", "18680696", "18680695", "18923406", "18784465", "18673126", "18444831", "18332899", "18256392", "18192781", "17534855", "19372817", "16609367", "15247625"], "answer": ["HLA B*5701 genotyping"], "id": "51487dead24251bc05000030", "snippets": [{"text": "Pharmacogenetic studies have revealed that abacavir HSRs are highly associated with the major histocompatibility complex class I. Large studies established the effectiveness of prospective HLA-B*57:01 screening to prevent HSRs to abacavir. Accordingly to these results the abacavir label has been modified: the European Medicines Agency (EMA) and the FDA recommend/suggested that the administration of abacavir must be preceded by a specific genotyping test.", "begin": 268, "document": "23204921", "end": 726, "section": "abstract"}, {"text": "Pharmacogenomic tests offer a promising strategy to improve the safety and efficacy of drug treatment. Compelling examples, such as HLA-B*5701 testing to identify patients at risk for abacavir-associated hypersensitivity, are already changing clinical care", "begin": 0, "document": "21691271", "end": 256, "section": "abstract"}, {"text": "International HIV treatment guidelines recommend HLA-B*57:01 typing before abacavir administration, in order to reduce the incidence of abacavir hypersensitivity reactions, the major cause of early therapy discontinuation. A fast, sensitive and specific test for HLA-B*57:01 detection has been developed in the present study.", "begin": 11, "document": "21521028", "end": 336, "section": "abstract"}, {"text": "The rollout of HLA-B\u22175701 into routine clinical practice as a genetic screening test to prevent abacavir hypersensitivity provides a translational roadmap for other drugs.", "begin": 701, "document": "21354501", "end": 872, "section": "abstract"}, {"text": "he aim of the session, using real-world examples (KRAS/panitumumab and HLA-B*5701/abacavir), was to identify good scientific principles that would guide the design of studies to identify subgroups of responders during development programs (including marketed drugs), which could subsequently be used to guide treatment decisions.", "begin": 528, "document": "21142908", "end": 857, "section": "abstract"}, {"text": "HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world.", "begin": 812, "document": "20602616", "end": 965, "section": "abstract"}, {"text": "Successful results that have been achieved within the field of pharmacogenomics so far are, to name a few, HLA-B*5701 screening to avoid hypersensitivity to the antiretroviral abacavir,", "begin": 296, "document": "20487194", "end": 481, "section": "abstract"}, {"text": "Prospective pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 allele can significantly reduce the number of cases of abacavir-related hypersensitivity among HIV-infected patients treated with this drug.", "begin": 11, "document": "20070406", "end": 234, "section": "abstract"}, {"text": "development of HLA-B*5701 genetic screening as a means of preventing drug hypersensitivity reactions caused by a commonly prescribed antiretroviral drug, abacavir.", "begin": 27, "document": "19514905", "end": 190, "section": "abstract"}, {"text": "Abacavir hypersensitivity syndrome (AHS) is a potentially life-threatening illness occurring in 4-8% of those initiating the drug. Early studies identified a strong association between the MHC class I allele HLA-B*5701 and AHS. These studies suggested that HLA-B*5701 holds promise as a screening test to prevent AHS, but concern arose from HLA-B*5701-negative cases with a clinical diagnosis of AHS, and particularly from early reports of apparently low sensitivities of HLA-B*5701 for AHS in patients of non-White race. However, open screening studies suggested that HLA-B*5701 screening can largely eliminate AHS", "begin": 0, "document": "19351209", "end": 615, "section": "abstract"}, {"text": "Current HIV treatment guidelines have been revised to reflect the recommendation that HLA-B*5701 screening be incorporated into routine care for patients who may require abacavir.", "begin": 988, "document": "19351209", "end": 1167, "section": "abstract"}, {"text": "The research approach applied to AHS has led to a genetic screening test being successfully implemented globally in primary HIV clinical practice.", "begin": 1750, "document": "19351209", "end": 1896, "section": "abstract"}, {"text": "The clinical utility of prospective HLA-B*5701 screening was demonstrated in a blinded randomized clinical trial and in open-label cohorts. Screening has been incorporated into clinical practice and the ABC HSR pharmacogenetics program has been highlighted as a success by pharmacogenetics researchers.", "begin": 434, "document": "19207023", "end": 736, "section": "abstract"}, {"text": "Abacavir hypersensitivity (ABC HSR) is a treatment-limiting adverse event associated with the use of the antiretroviral medicine, abacavir.", "begin": 0, "document": "19207023", "end": 139, "section": "abstract"}, {"text": "The major histocompatibility complex allele, HLA-B*5701, was identified retrospectively and confirmed with independent sample sets.", "begin": 302, "document": "19207023", "end": 433, "section": "abstract"}, {"text": "he most significant advance for clinical practice is the correlation between the presence of the HLA-B*5701 allele and hypersensitivity reaction to abacavir. In particular, one clinical trial with a large number of patients from distinct ethnic groups found that the probability of not developing hypersensitivity reaction (immunologically confirmed) was 100% if the patient was HLA-B*5701-negative. These data suggest the need to implement this test in daily clinical practice.", "begin": 1490, "document": "18680696", "end": 1968, "section": "abstract"}, {"text": "The aim of the PREDICT-1 study was to determine the clinical utility of the pharmacogenetic test identifying HLA-B*5701 to reduce the incidence of hypersensitivity reaction to abacavir, diagnosed clinically and with immunological confirmation, as well as to reduce unwarranted withdrawal of this drug", "begin": 0, "document": "18680695", "end": 300, "section": "abstract"}, {"text": "the identification of HLA-B(*)5701 as a highly sensitive and specific predictive marker for abacavir treated patients who will develop hypersensitivity syndrome (HSS).", "begin": 1949, "document": "18923406", "end": 2116, "section": "abstract"}, {"text": "Clinical consensus panels rapidly recommended abacavir as the preferred therapy along with HLA-B(*)5701 pre-testing, immediately increasing the market share of abacavir with respect to other reverse transcriptases that are associated with there own adverse events", "begin": 2881, "document": "18923406", "end": 3144, "section": "abstract"}, {"text": "The strong association of the abacavir hypersensitivity reaction with HLA-B*5701 permits testing patients for the allele, and if present avoiding the drug and therefore preventing the reaction.", "begin": 492, "document": "18673126", "end": 685, "section": "abstract"}, {"text": "A strong statistical association between the major histocompatibility complex allele, HLA-B*5701, and clinically diagnosed ABC HSR was identified but varied between racial populations.", "begin": 351, "document": "18332899", "end": 535, "section": "abstract"}, {"text": "In a randomized, prospective study evaluating the clinical utility of HLA-B*5701 screening, avoidance of ABC in HLA-B*5701-positive patients significantly reduced clinically diagnosed ABC HSR and eliminated patch test-positive ABC HSR. Finally, a retrospective PGx study supports the generalizability of the association across races. Prospective HLA-B*5701 screening should greatly reduce the incidence of ABC HSR by identifying patients at high risk for ABC HSR before they are treated.", "begin": 650, "document": "18332899", "end": 1137, "section": "abstract"}, {"text": "the major histocompatibility complex HLA-B*5701 allele has been associated with hypersensitivity to abacavir (ABC) by several independent researchers.", "begin": 623, "document": "17534855", "end": 773, "section": "abstract"}, {"text": "Abacavir hypersensitivity reaction (ABC HSR) is a potentially life-threatening adverse reaction that affects approximately 8% of patients that initiate this antiretroviral drug. Independent groups have shown a strong predictive association between ABC HSR and HLA-B*5701, indicating that exclusion of HLA-B*5701 positive individuals from abacavir treatment would largely prevent ABC HSR.", "begin": 12, "document": "16609367", "end": 399, "section": "abstract"}, {"text": "Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians.", "begin": 11, "document": "15247625", "end": 253, "section": "abstract"}]}, {"documents": ["21164341", "19589043", "19198095", "15853578", "15372589", "14741081", "12952501", "12588639", "11147512", "11147511", "10733264", "10651109", "8784230", "1933685"], "answer": [["tolcapone"], ["entacapone"]], "id": "51487ef9d24251bc05000031", "snippets": [{"text": "Stalevo is a combination tablet comprised of levodopa, carbidopa, and the COMT inhibitor entacapone. It is available in fixed-dose combinations of levodopa/carbidopa/entacapone, 50/12.5/200, 75/18.75/200, 100/25/200, 125/31.25/200, 150/37.5/200 and 200/50/200 mg. Stalevo is currently approved for use in Parkinson's disease patients with end-of-dose wearing off.", "begin": 1251, "document": "19589043", "end": 1614, "section": "abstract"}, {"text": "Good news were marketing of ropinirole, a new non-ergot agonist, in December 2006 and entacapone, the first catechol-O-methyl transferase (COMT) inhibitor in Japan in April 2007. Having faced these new situations, Japanese Neurological Association has started revising \"the Guideline 2002 for the treatment of Parkinson's disease\".", "begin": 306, "document": "19198095", "end": 637, "section": "abstract"}, {"text": "Stalevo (Orion) combines levodopa, the dopa-decarboxylase inhibitor carbidopa and the catechol-O-methyl transferase inhibitor entacapone in a single tablet.", "begin": 620, "document": "15853578", "end": 776, "section": "abstract"}, {"text": "We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations.", "begin": 0, "document": "15372589", "end": 250, "section": "abstract"}, {"text": "The catechol-O-methyl transferase inhibitor entacapone is given in combination with levodopa/dopa decarboxylase inhibitor for Parkinson's disease (PD) patients experiencing end-of-dose wearing-off.", "begin": 0, "document": "14741081", "end": 197, "section": "abstract"}, {"text": "Entacapone (Comtess/Comtan) is Orion Pharma's original proprietary catechol-O-methyl transferase (COMT) inhibitor. Entacapone is able to slow down degradation of levodopa and improve the availability and efficacy of each levodopa dose, hence its use as a complement to levodopa/carbidopa in patients with Parkinson's disease.", "begin": 0, "document": "12952501", "end": 325, "section": "abstract"}, {"text": "Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.", "begin": 0, "document": "12588639", "end": 77, "section": "title"}, {"text": "We present a patient who suffered from sleep attacks after starting entacapone in addition to levodopa. Entacapone, a catechol-O-methyl transferase inhibitor, alters the pharmacokinetics of levodopa, leading to increase of levodopa concentration in plasma and brain.", "begin": 0, "document": "12588639", "end": 266, "section": "abstract"}, {"text": "Two COMT inhibitors, tolcapone and entacapone, have recently been made available as adjunctive agents to levodopa", "begin": 160, "document": "11147512", "end": 273, "section": "abstract"}, {"text": "Two inhibitors of catechol-O-methyl transferase (COMT), tolcapone and entacapone, have recently been introduced as adjuncts to levodopa in the treatment of Parkinson's disease patients.", "begin": 0, "document": "11147511", "end": 185, "section": "abstract"}, {"text": "Tolcapone, a peripheral and central COMT inhibitor, appears to be quite effective, producing a 47% reduction in 'off' time.", "begin": 1446, "document": "10733264", "end": 1569, "section": "abstract"}, {"text": ". Entacapone, a purely peripheral COMT inhibitor with a lower potency than tolcapone, has also proved to be effective and has not been associated with liver damage, obviating the need for testing.", "begin": 1761, "document": "10733264", "end": 1957, "section": "abstract"}, {"text": "Here we report that a treatment of the cerebral tissue with tolcapone, a central and peripheral inhibitor of COMT, does not change the membrane responses of midbrain dopamine neurons to dopamine and levodopa.", "begin": 316, "document": "10651109", "end": 524, "section": "abstract"}, {"text": "Therefore, the therapeutic action of tolcapone in Parkinson's disease, might be dependent on the reduction of COMT activity in the extracerebral tissue.", "begin": 721, "document": "10651109", "end": 873, "section": "abstract"}, {"text": "Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake.", "begin": 294, "document": "8784230", "end": 568, "section": "abstract"}, {"text": "The novel and reversible inhibitors are the catechol-O-methyl-transferase (COMT) inhibitors, Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone), and the monoamine oxidase type-B (MAO-B) inhibitor, Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide HC1).", "begin": 87, "document": "1933685", "end": 356, "section": "abstract"}]}, {"documents": ["23342320", "23208322", "22952875", "22321278", "22122181", "22023024", "21713343", "21651319", "21590310", "20854800", "20615525", "20210733", "19794411", "19752777", "19538716", "19348697", "19135231", "19069171", "18752379", "18464049", "18034618", "17496169", "16611750", "11213860"], "answer": [["CYP2C9"], ["VKORC1"], ["ORM1"], ["CYP4F2"], ["EPHX1"], ["CYP2C18"], ["CYP2C19"], ["CYP3A5"], ["protein S"], ["clotting factor V"], ["PROC"], ["GGCX"]], "id": "5148885ad24251bc05000032", "snippets": [{"text": "There are two identified genes that are responsible for the main proportion of the genetic effect: CYP2C9, which codes for the enzyme cytochrome P450 2C9 that metabolizes S-warfarin, and VKORC1, which codes for warfarin's target, vitamin K epoxide reductase.", "begin": 659, "document": "23342320", "end": 917, "section": "abstract"}, {"text": "The genes encoding for cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) are the major genetic determinants of warfarin pharmacokinetics and pharmacodynamics, respectively.", "begin": 406, "document": "22122181", "end": 622, "section": "abstract"}, {"text": "Numerous studies have demonstrated significant contributions of these genes to warfarin dose requirements. The CYP2C9 gene has also been associated with bleeding risk with warfarin. The CYP4F2 gene influences vitamin K availability and makes minor contributions to warfarin dose requirements", "begin": 623, "document": "22122181", "end": 914, "section": "abstract"}, {"text": "There are other genetic polymorphisms that may further explain the response to warfarin. The VKORC1 genotype is an important determinant of response to warfarin in Chinese, but some genetic variants found in other ethnic groups that have a large effect on warfarin response and dosing are not commonly found in Chinese", "begin": 367, "document": "22023024", "end": 685, "section": "abstract"}, {"text": "Genetic variability in the VKORC1 and CYP2C9 genes is associated with increased warfarin sensitivity", "begin": 92, "document": "20615525", "end": 192, "section": "abstract"}, {"text": "genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26.6% of dose variability.", "begin": 542, "document": "19794411", "end": 720, "section": "abstract"}, {"text": "the CYP2C9 and VKORC1 genes have been demonstrated to be determinants of warfarin response.", "begin": 332, "document": "19069171", "end": 423, "section": "abstract"}, {"text": "On the basis of these observations, the Food and Drug Administration (FDA) approved a labeling change for warfarin that includes the genetic information of VKORC1 and CYP2C9 as factors influencing interindividual variability in warfarin dosing. T", "begin": 817, "document": "19069171", "end": 1063, "section": "abstract"}, {"text": "the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, on warfarin response", "begin": 275, "document": "18752379", "end": 424, "section": "abstract"}, {"text": "The influence of CYP2C9 and VKORC1 genotypes on warfarin dose requirements has been consistently demonstrated in diverse racial and ethnic patient groups in observational studies and randomized clinical trials.", "begin": 498, "document": "18752379", "end": 708, "section": "abstract"}, {"text": "genetic factors influencing drug pharmacokinetics (CYP2C9) and pharmacodynamic response (VKORC1). In particular, the discovery of polymorphisms in the VKORC1 gene that strongly impact oral anticoagulant dose has heightened expectations that genetic testing", "begin": 445, "document": "18464049", "end": 701, "section": "abstract"}, {"text": "A strong association was found between genetic polymorphisms in six genes, including VKORC1, CYP2C9, PROC, EPHX1, GGCX, and ORM1, and interindividual variability in the anticoagulant effect of warfarin; the strongest predictors were VKORC1 and CYP2C9.", "begin": 764, "document": "17496169", "end": 1015, "section": "abstract"}, {"text": "Clinical studies showed an increased plasma level of S-warfarin, decreased clearance of S-warfarin, increased frequency of bleeding, and prolongation of hospitalization in patients with variant CYP2C9 alleles.", "begin": 571, "document": "11213860", "end": 780, "section": "abstract"}]}, {"documents": ["22312371", "20860891", "16830335", "16459992", "16377376", "12696059", "10787042", "10633134", "8768681", "8630973", "7522538", "7519874", "2562822", "2491784", "2491782", "2491780", "2491777", "20186797", "22962301", "22678692", "18331998", "23399325"], "answer": [["NF1 gene"], ["chromosome 17"]], "id": "5148e1d6d24251bc0500003a", "snippets": [{"text": "The von Recklinghausen neurofibromatosis (NF1) gene has been localized to the pericentromeric region of chromosome 17.", "begin": 0, "document": "2491777", "end": 118, "section": "abstract"}, {"text": "Nine markers from the pericentromeric region of chromosome 17 were typed in 16 British and five South African families with neurofibromatosis type 1 (NF1).", "begin": 0, "document": "2491780", "end": 155, "section": "abstract"}, {"text": "Inspection of recombinant events in families informative for several markers suggests that the NF1 gene is located between the markers EW301 (cen-p11.2) and EW206 (cen-q12) and possibly distal to pHHH202 (q11.2-q12).", "begin": 305, "document": "2491780", "end": 521, "section": "abstract"}, {"text": "The gene for von Recklinghausen neurofibromatosis type 1 (NF1) has recently been mapped to the pericentromeric region of human chromosome 17.", "begin": 0, "document": "2491782", "end": 141, "section": "abstract"}, {"text": "In addition to reporting, in accompanying papers, their individual analyses of mapping the neurofibromatosis type 1 (NF1) gene on chromosome 17, members of the International Consortium for NF1 Linkage contributed their data for our joint analysis to determine the exact sequence of flanking markers and to obtain precise estimates and confidence limits of the recombination fractions for the closest markers, in anticipation of clinical use.", "begin": 0, "document": "2491784", "end": 441, "section": "abstract"}, {"text": "To better map the location of the von Recklinghausen neurofibromatosis (NF1) gene, we have characterized a somatic cell hybrid designated 7AE-11. This microcell-mediated, chromosome-transfer construct harbors a centromeric segment and a neo-marked segment from the distal long arm of human chromosome 17.", "begin": 0, "document": "2562822", "end": 304, "section": "abstract"}, {"text": "The cosmids in the NF1 region will be an important resource for testing DNA blots of large-fragment restriction-enzyme digests from NF1 patient cell lines, to detect rearrangements in patients' DNA and to identify the 17;22 NF1 translocation breakpoint.", "begin": 1057, "document": "2562822", "end": 1310, "section": "abstract"}, {"text": "The frequent LOH surrounding the NF1 locus and lack of neurofibromin expression in these tumors suggest that NF1 gene mutations may contribute to the development of adrenal gland neoplasms in patients with NF1.", "begin": 740, "document": "7519874", "end": 950, "section": "abstract"}, {"text": "In the latter, the breakpoint in 17q occurred below the centromere and is at or in the region of the Neurofibromatosis Type 1 (NF1) gene.", "begin": 676, "document": "8630973", "end": 813, "section": "abstract"}, {"text": "Neurofibromatosis type I (NF1) is an autosomal dominant condition associated with mutations in the long arm of chromosome 17, and characterised by neurofibromas, caf\u00e9-au-lait spots and axillary freckling.", "begin": 158, "document": "10787042", "end": 362, "section": "abstract"}, {"text": "In addition, the mother's and maternal grandmother's genetic analysis showed identical mutations in the neurofibromatosis I gene on the long arm of chromosome 17, confirming the diagnosis of NF1.", "begin": 964, "document": "10787042", "end": 1159, "section": "abstract"}, {"text": "Duplicon-mediated microdeletions around the NF1 gene are frequently associated with a severe form of neurofibromatosis type I in a subgroup of patients who show an earlier onset of cutaneous neurofibromas, dysmorphic facial features, and lower IQ values.", "begin": 0, "document": "12696059", "end": 254, "section": "abstract"}, {"text": "Neurofibromatosis had been diagnosed in infancy, and genetic testing showed that the patient had a mutation in chromosome 17, consistent with neurofibromatosis type I.", "begin": 238, "document": "16377376", "end": 405, "section": "abstract"}, {"text": "Neurofibromatosis Type 1 (NF1) is one of the most common inherited diseases in humans. It is caused by a mutation in the NF1 gene on chromosome 17, and is associated with numerous central and peripheral nervous system manifestations.", "begin": 0, "document": "16459992", "end": 233, "section": "abstract"}, {"text": "In 95% of NF1 individuals, a mutation is found in the NF1 gene, and in 5% of the patients, the germline mutation consists of a microdeletion that includes the NF1 gene and several flanking genes.", "begin": 144, "document": "16830335", "end": 339, "section": "abstract"}, {"text": "Herein, we describe a unique case of anaplastic de novo astroblastoma-sarcoma, in essence a variant of gliosarcoma, occurring in a 50-year-old female with documented NF1. Genetic study (fluorescence in situ hybridization) demonstrated no chromosomal losses or gains. Testing for abnormalities of chromosomes 7, 9, 10, 12, 17, 19 and 20, including the EGFR, p16, PTEN, MDM2 and NF1 gene regions, we found the tumor to exhibit a deletion of PTEN, monosomy 17 and gains of chromosomes 19 and 20q.", "begin": 493, "document": "20860891", "end": 986, "section": "abstract"}, {"text": "Neurofibromatosis type I (NF1) is an autosomal dominant disorder affecting 1 in 3000 people. The NF1 gene is located on chromosome 17q11.2, spans 350 kb of genomic DNA, and contains 60 exons.", "begin": 0, "document": "10633134", "end": 191, "section": "abstract"}, {"text": "A patient with recurrent-remittent multiple sclerosis associated with neurofibromatosis type I is described. The case is interesting for two reasons: 1) the difficulty of evaluating MRI findings, since both entities involve similar anomalies and 2) the relation between the two entities, according to evidence from recent genetic studies showing that the myelin protein gene associated to oligodendrocytes is part of an intron of the neurofibromatosis-1 gene of chromosome 17.", "begin": 0, "document": "8768681", "end": 476, "section": "abstract"}, {"text": "Neurofibromatosis type I (NFI) is a common autosomal dominant disorder with an increased risk for developing benign and malignant tumors. The NFI gene has been cloned and maps to 17q11.2, and the gene product acts as a tumor suppressor gene.", "begin": 0, "document": "7522538", "end": 241, "section": "abstract"}, {"text": "Type 1 is caused by a genetic mutation in the NF1 gene (OMIM 613113) and symptoms can vary dramatically between individuals, even within the same family.", "begin": 124, "document": "23399325", "end": 277, "section": "abstract"}, {"text": "Direct sequencing of the NF1 gene in tumor DNA identified the presence of an inactivating NF1 somatic mutation in 41% (25/61) of analyzed sporadic tumors, associated with loss of the wild-type allele in 84% (21/25) of cases.", "begin": 847, "document": "22962301", "end": 1071, "section": "abstract"}, {"text": "A novel mutation c.4821delA was identified in NF1 gene, which predicted truncation of neurofibromin (p.Leu1607fs).", "begin": 453, "document": "22678692", "end": 567, "section": "abstract"}, {"text": "Using lymphoblastoid, fibroblast, and buccal cell samples collected from both twins and from other family members in three generations, we discovered a pathogenic nonsense mutation in exon 40 of the NF1 gene.", "begin": 675, "document": "20186797", "end": 883, "section": "abstract"}, {"text": "We also found a novel non-synonymous change in exon 16 of the NF1 gene that was transmitted from the unaffected mother to both twins and co-segregated with the pathogenic mutation in the ensuing generation.", "begin": 1063, "document": "20186797", "end": 1269, "section": "abstract"}, {"text": "The disease gene of the Chinese NF1 family was linked to NF1 locus, and a nonsense mutation, G1336X in the NF1 gene was identified.", "begin": 254, "document": "18331998", "end": 385, "section": "abstract"}, {"text": "The present study demonstrated that G1336X mutation in the NF1 gene cause Neurofibromatosis type I in the family.", "begin": 574, "document": "18331998", "end": 687, "section": "abstract"}]}, {"documents": ["21785147", "19500521", "18175099", "14620397", "11349753", "11383664", "9306053", "8905360", "8644960", "8605789", "7629986", "8306565", "1286503", "8438687", "8239101", "1354979", "1996802", "1672103", "2231833", "2113543", "2575692", "3132054", "2899985", "2893240"], "answer": ["flumazenil"], "id": "514a0a57d24251bc05000051", "snippets": [{"text": "Benzodiazepine (BZD) overdose (OD) continues to cause significant morbidity and mortality in the UK. Flumazenil is an effective antidote but there is a risk of seizures, particularly in those who have co-ingested tricyclic antidepressants.", "begin": 11, "document": "21785147", "end": 250, "section": "abstract"}, {"text": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose.", "begin": 0, "document": "19500521", "end": 152, "section": "abstract"}, {"text": "Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "begin": 2100, "document": "18175099", "end": 2227, "section": "abstract"}, {"text": "Flumazenil is indicated for reversal of sedation from benzodiazepines administered during therapeutic or diagnostic procedures and during induction or maintenance of general anesthesia, as well as for benzodiazepine overdose.", "begin": 0, "document": "14620397", "end": 225, "section": "abstract"}, {"text": "When measures are required to ensure adequate recovery of a patient's respiratory function and mental awareness, such as in patients with benzodiazepine toxicity, consideration of continuous-infusion flumazenil is warranted.", "begin": 766, "document": "14620397", "end": 990, "section": "abstract"}, {"text": "Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose.", "begin": 439, "document": "11349753", "end": 695, "section": "abstract"}, {"text": "A 54-y-old man ingested 2 g of bulk laboratory diazepam and was treated with activated charcoal, enhanced diuresis and flumazenil infusion.", "begin": 0, "document": "11383664", "end": 139, "section": "abstract"}, {"text": "Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions.", "begin": 200, "document": "9306053", "end": 390, "section": "abstract"}, {"text": "Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma.", "begin": 391, "document": "9306053", "end": 676, "section": "abstract"}, {"text": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined.", "begin": 12, "document": "8905360", "end": 277, "section": "abstract"}, {"text": "Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists.", "begin": 161, "document": "8306565", "end": 353, "section": "abstract"}, {"text": "It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy.", "begin": 613, "document": "8306565", "end": 862, "section": "abstract"}, {"text": "Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected.", "begin": 1841, "document": "8306565", "end": 2069, "section": "abstract"}, {"text": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose.", "begin": 0, "document": "1286503", "end": 131, "section": "abstract"}, {"text": "The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo.", "begin": 831, "document": "1286503", "end": 971, "section": "abstract"}, {"text": "Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded.", "begin": 1346, "document": "1286503", "end": 1539, "section": "abstract"}, {"text": "The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose.", "begin": 2286, "document": "1286503", "end": 2454, "section": "abstract"}, {"text": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose.", "begin": 0, "document": "8438687", "end": 269, "section": "abstract"}, {"text": "Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose.", "begin": 146, "document": "1354979", "end": 288, "section": "abstract"}, {"text": "In the setting of isolated benzodiazepine overdose, flumazenil is capable of completely reversing coma within one to two minutes, with this effect lasting between one and five hours.", "begin": 645, "document": "1996802", "end": 827, "section": "abstract"}, {"text": "Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration.", "begin": 319, "document": "1672103", "end": 682, "section": "abstract"}, {"text": "We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "begin": 908, "document": "1672103", "end": 1048, "section": "abstract"}, {"text": "Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection.", "begin": 1176, "document": "2231833", "end": 1307, "section": "abstract"}, {"text": "We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose.", "begin": 1383, "document": "2113543", "end": 1485, "section": "abstract"}, {"text": "Flumazenil is the first benzodiazepine antagonist which can be used in humans and is a well established for treatment of benzodiazepine overdose.", "begin": 235, "document": "2575692", "end": 380, "section": "abstract"}, {"text": "Flumazenil, a 1,4-imidazobenzodiazepine, is a highly effective, specific benzodiazepine antagonist which is indicated for use when the effect of a benzodiazepine must be attenuated or terminated at short notice.", "begin": 420, "document": "2893240", "end": 631, "section": "abstract"}, {"text": "Thus, flumazenil provides a safe and effective means of attenuating or reversing the CNS-depressant effects of benzodiazepines whenever indicated, e.g. following benzodiazepine-induced general anaesthesia, conscious sedation, or after benzodiazepine overdose, either alone or in combination with other agents.", "begin": 2200, "document": "2893240", "end": 2509, "section": "abstract"}, {"text": "In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2 mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p less than 0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p less than 0.01).", "begin": 145, "document": "2113543", "end": 665, "section": "abstract"}, {"text": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug.", "begin": 0, "document": "3132054", "end": 416, "section": "abstract"}, {"text": "Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs.", "begin": 417, "document": "3132054", "end": 615, "section": "abstract"}, {"text": "Flumazenil (Ro 15-1788) proved to be a very efficacious competitive antagonist of benzodiazepines that reliably counteracts their pharmacological actions within 1-2 min as could be demonstrated in clinical and EEG studies.", "begin": 0, "document": "2899985", "end": 222, "section": "abstract"}, {"text": "In intensive care medicine, the antagonist may be used in the treatment of benzodiazepine overdose as well as in the differential diagnosis of a coma of unknown origin.", "begin": 1243, "document": "2899985", "end": 1411, "section": "abstract"}]}, {"documents": ["23371261", "22590486", "22361999", "21934103", "21479927", "21370017", "21278441", "21221771", "21176237", "22811953", "20877447", "20564629", "20200857", "23074401", "19946260", "19536946", "19125125", "19101988", "18347556", "18942607", "18072276"], "answer": [["breast cancer"], ["colon cancer"]], "id": "514a11add24251bc05000054", "snippets": [{"text": "Prognostic and predictive markers", "begin": 243, "document": "23371261", "end": 276, "section": "abstract"}, {"text": "Oncotype DX\u00ae currently allow avoidance of an over therapy or under therapy", "begin": 366, "document": "23371261", "end": 440, "section": "abstract"}, {"text": "a high score on the Oncotype DX gene expression profile r", "begin": 432, "document": "22590486", "end": 489, "section": "abstract"}, {"text": "poor-prognosis ER-positive breast cancers in need of more aggressive therapy", "begin": 191, "document": "22590486", "end": 267, "section": "abstract"}, {"text": "luminal B class", "begin": 316, "document": "22590486", "end": 331, "section": "abstract"}, {"text": "The 21-gene recurrence score (Oncotype DX: RS) appears to augment clinico-pathologic prognostication and is predictive of adjuvant chemotherapy benefit in node-negative (N-) and node-positive (N+), endocrine-sensitive breast cancer.", "begin": 0, "document": "22361999", "end": 232, "section": "abstract"}, {"text": "Half of all breast cancers are early stage, lymph node negative, and hormone receptor positive. A 21-gene (Oncotype DX\u00ae; Genomic Health, Inc., Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit.", "begin": 12, "document": "21934103", "end": 263, "section": "abstract"}, {"text": "We hypothesized that a distinct network of immune function genes at the tumor site can predict a low risk versus high risk of distant relapse in breast cancer patients regardless of the status of ER, PR, or HER-2/neu in their tumors.", "begin": 270, "document": "21479927", "end": 503, "section": "abstract"}, {"text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes.", "begin": 1350, "document": "21479927", "end": 1694, "section": "abstract"}, {"text": "Molecular tests such as the Oncotype DX(\u00ae) breast cancer test are proving to be more effective tools for individualized patient stratification and treatment planning than traditional methods such as patient demographic variables and histopathology indicators.", "begin": 620, "document": "21370017", "end": 879, "section": "abstract"}, {"text": "Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy.", "begin": 1546, "document": "21278441", "end": 1763, "section": "abstract"}, {"text": "The oncotype DX\u00ae genomic assay has also been used to help prognosis estimation and treatment decisions.", "begin": 1222, "document": "21278441", "end": 1325, "section": "abstract"}, {"text": "The Oncotype DX Recurrence Score (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer.", "begin": 0, "document": "21221771", "end": 149, "section": "abstract"}, {"text": "the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples. This remarkable congruence suggests a biological interdependence of poor-prognosis gene signatures, breast cancer subtypes, genomic instability, and clinical outcome.", "begin": 699, "document": "19101988", "end": 1137, "section": "abstract"}, {"text": "The Oncotype DX assay is one of the molecular tests that provide predictive and prognostic information to breast cancer patients with estrogen receptor (ER)-positive and node-negative disease. This study evaluates the association of Forkhead-box protein A1 (FOXA1) and GATA-binding protein 3 (GATA3) expressions with Oncotype DX recurrences scores in 77 cases of patients with ER-positive node-negative breast carcinomas diagnosed at Indiana University.", "begin": 0, "document": "19946260", "end": 453, "section": "abstract"}, {"text": "the use of the Oncotype DX assay in estrogen receptor-positive node-negative breast cancer patients were incorporated into guidelines from both the American Society of Clinical Oncology and the National Comprehensive Cancer Network. The Oncotype DX assay is a diagnostic test which measures changes in a set of 21 genes in order to predict the likelihood of disease recurrence and also to predict which patients are most likely to respond to chemotherapy.", "begin": 30, "document": "19536946", "end": 485, "section": "abstract"}, {"text": "confirmed the clinical validity of the Oncotype DX breast cancer assay, not only as a way to predict recurrence but also as a tool for determining therapeutic benefit from adjuvant chemotherapy.", "begin": 230, "document": "18347556", "end": 424, "section": "abstract"}, {"text": "Over several decades, investigators working through National Cancer Institute-sponsored Cooperative Groups have contributed to major advances in the endocrine treatment of breast cancer.", "begin": 0, "document": "18072276", "end": 186, "section": "abstract"}, {"text": "Cooperative Group studies have contributed to the development of a molecular profiling test, Oncotype Dx, which identifies women who have an excellent prognosis with hormonal therapy alone.", "begin": 586, "document": "18072276", "end": 775, "section": "abstract"}, {"text": "In this report we compare the prognostic and predictive utility of these two tools in node-negative, ER-positive breast cancer", "begin": 359, "document": "21221771", "end": 485, "section": "abstract"}, {"text": "A retrospective chart review of 58 T1/T2, node-negative, estrogen-receptor positive breast cancer patients that underwent Oncotype DX gene assay testing between January and December 2006 was performed.", "begin": 226, "document": "18942607", "end": 427, "section": "abstract"}]}, {"documents": ["23090264", "12477530", "10649815", "10649814", "9152623", "2738821", "2803131", "2520800", "6868876", "6788711"], "answer": ["prolactinoma"], "id": "514a51c2d24251bc0500005c", "snippets": [{"text": "Prolactinoma is the most common secreting pituitary adenoma. It is typically diagnosed in women of reproductive age and is common cause of infertility.", "begin": 0, "document": "23090264", "end": 151, "section": "abstract"}, {"text": "Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis, occurring mostly in women and presenting most commonly with amenorrhea and galactorrhea. Causes of hyperprolactinemia include physiologic, pharmacologic and pathologic factors; pituitary adenoma is a common pathologic cause. Women may present with decreased libido, infertility, oligomenorrhea/amenorrhea and galactorrhea.", "begin": 199, "document": "10649815", "end": 614, "section": "abstract"}, {"text": "When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea).", "begin": 443, "document": "10649814", "end": 788, "section": "abstract"}, {"text": "Pregnancy in a woman with active acromegaly is very rare, because amenorrhea, due to hyperprolactinemia and disturbed pituitary gonadotropin secretion may cause infertility.", "begin": 0, "document": "9152623", "end": 173, "section": "abstract"}, {"text": "Of the remaining six patients who had been investigated for infertility, no demonstrable cause of infertility was found in three. Of the other three patients, one showed evidence of bilateral tubal occlusion secondary to pelvic inflammatory disease, one has had a right ectopic pregnancy followed by two abortions, and the third patient was found to have a pituitary adenoma.", "begin": 943, "document": "2738821", "end": 1318, "section": "abstract"}, {"text": "Results in 136 hyperprolactinaemic women who presented with infertility, amenorrhoea, menstrual irregularities and/or galactorrhoea are reported. There was radiographic evidence of pituitary microadenoma in 21 (15.4%) patients and 5 (3.7%) had macroadenoma.", "begin": 0, "document": "2803131", "end": 257, "section": "abstract"}, {"text": "Patients with pituitary adenoma had a significantly higher (p less than 0.001) baseline serum prolactin level (182 +/- 4.6 ng/ml) than those with no adenoma (59.2 +/- 4.2 ng/ml). All patients in the study were treated with bromocriptine (2.5-10 mg) to normalize serum prolactin or to achieve a pregnancy.", "begin": 474, "document": "2803131", "end": 778, "section": "abstract"}, {"text": "There was no significant difference in the pregnancy rate between the patients with or without pituitary adenoma.", "begin": 1349, "document": "2803131", "end": 1462, "section": "abstract"}, {"text": "Two hyperprolactinemic infertile women, one with and one without a pituitary adenoma, who were resistant to bromocriptine treatment, were treated orally with Hachimijiogan, a Chinese herbal medicine.", "begin": 0, "document": "2520800", "end": 199, "section": "abstract"}, {"text": "Infertility caused by hyperprolactinemic amenorrhea may be complicated by pituitary adenoma.", "begin": 0, "document": "6868876", "end": 92, "section": "abstract"}]}, {"documents": ["23064518", "19140748", "16939266", "8006040"], "answer": ["2.3 megadalton"], "id": "514c3fd7d24251bc05000062", "snippets": [{"text": "Here we show that the Orbitrap mass analyzer can be used to measure protein assemblies of molecular weights approaching one megadalton with sensitivity down to the detection of single ions.", "begin": 165, "document": "23064518", "end": 354, "section": "abstract"}, {"text": "Using this relationship we show that we can determine masses of both 30S subunits and intact 2.3 MDa 70S ribosomes from Thermus thermophilus.", "begin": 874, "document": "16939266", "end": 1015, "section": "abstract"}, {"text": "We confirm the existence of these subpopulations using tandem mass spectrometry of intact 30S subunits. Overall, the results show that, rather than uniform particles, gas-phase ribosomes consist of a number of discrete populations. More generally, the results establish a rigorous procedure for accurate mass measurement and spectral analysis of heterogeneous macromolecular assemblies.", "begin": 1415, "document": "16939266", "end": 1801, "section": "abstract"}]}, {"documents": ["23029374", "22967183", "22898819", "22761581", "22633409", "22563479", "22538524", "7638194", "22413869", "22323818", "22284370", "22278882", "22088914", "22072770", "22064703", "22048250", "21913078", "22704242", "21625467", "21559294", "21553025", "21532572", "21518897", "21268065", "20940144", "20864525", "20364115", "20139415", "20071334", "20035856", "22073356", "19966177", "19932585", "19789556", "19468253", "19450230", "19417133", "19282482", "19173286", "18922972", "19016755", "18536530", "18302924", "18297739", "17965600", "17929180", "17312023", "16963560", "17033890", "16807237", "17989773", "16500889", "15799776", "17576694", "20348135", "18665914", "23393137", "22934696", "21507353", "21389349", "21163962", "20820192", "20506537", "20007090", "19923434", "19825994", "19819843", "19778587"], "answer": ["DNMT1", "MET1"], "id": "51585b28d24251bc0500008d", "snippets": [{"text": "his defect does not appear in mouse models with mutations in Dnmt3a and Mthfr genes and, therefore, it is specific for the Dnmt1 gene and is suggestive of a role of DNMT1 in imprint resetting or maintenance in the male germ line.", "begin": 969, "document": "22967183", "end": 1198, "section": "abstract"}, {"text": "Specificity of Dnmt1 for methylation of hemimethylated CpG sites resides in its catalytic domain.", "begin": 0, "document": "22633409", "end": 97, "section": "title"}, {"text": "We obtained evidence that some 5-methylcytosine residues in these single-stranded DNAs can stimulate de novo methylation of adjacent sites by murine DNA 5-cytosine methyltransferase as effectively as 5-methylcytosine residues in double-stranded DNA stimulate maintenance methylation.", "begin": 827, "document": "7638194", "end": 1110, "section": "abstract"}, {"text": "We present in vitro evidence that the mammalian de novo DNA methyltransferases DNMT3A and DNMT3B, but not the maintenance enzyme DNMT1, are also redox-dependent DNA dehydroxymethylases.", "begin": 249, "document": "22898819", "end": 434, "section": "abstract"}, {"text": "We obtained evidence that some 5-methylcytosine residues in these single-stranded DNAs can stimulate de novo methylation of adjacent sites by murine DNA 5-cytosine methyltransferase as effectively as 5-methylcytosine residues in double-stranded DNA stimulate maintenance methylation.", "begin": 827, "document": "7638194", "end": 1110, "section": "abstract"}, {"text": "DNMT1, the major maintenance DNA methyltransferase in animals, helps to regulate gene expression, genome imprinting, and X-chromosome inactivation.", "begin": 0, "document": "22323818", "end": 147, "section": "abstract"}, {"text": "Correct establishment and maintenance of methylation patterns at imprinted genes has been associated with placental function and regulation of embryonic/fetal development.", "begin": 634, "document": "22088914", "end": 805, "section": "abstract"}, {"text": "Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.", "begin": 0, "document": "22072770", "end": 107, "section": "title"}, {"text": "Thus, differential expression of CTCF and DNMT1 and -3B is not critical for maintenance of restricted latency.", "begin": 1191, "document": "22072770", "end": 1301, "section": "abstract"}, {"text": "Recent studies demonstrate that UHRF1 is required for DNA methylation maintenance by targeting DNMT1 to DNA replication foci, presumably through its unique hemi-methylated DNA-binding activity and interaction with DNMT1.", "begin": 0, "document": "22064703", "end": 220, "section": "abstract"}, {"text": "It is generally accepted that DNA methyltransferases carry out specific and non-overlapping functions, Dnmt3a and Dnmt3b being responsible for the establishment of methylation around the time of implantation and Dnmt1 ensuring that methylation is faithfully copied to daughter cells via what has come to be known as \"maintenance methylation.\"", "begin": 134, "document": "22048250", "end": 476, "section": "abstract"}, {"text": "A new model is emerging that takes into account a contribution of the de novo enzymes Dnmt3a and Dnmt3b in the maintenance of the DNA methylation.", "begin": 622, "document": "22048250", "end": 768, "section": "abstract"}, {"text": "We propose here observations in support of the hypothesis that the maintenance of methylation and subsequent silencing of a handful of germ line genes requires Dnmt3b but not Dnmt1.", "begin": 1089, "document": "22048250", "end": 1270, "section": "abstract"}, {"text": "DNA methyltransferase 1 (Dnmt1) is the enzyme responsible for maintaining the methylation marks through cell division. However, the de novo methyltransferases, Dnmt3a and Dnmt3b, can also contribute to the maintenance of the methylation pattern.", "begin": 162, "document": "21913078", "end": 407, "section": "abstract"}, {"text": "These new data support the notion that de novo DNMTs also have an important role in the maintenance of DNA methylation and suggest that, in addition to acting as oncogenes, they also behave as tumor suppressors.", "begin": 569, "document": "22704242", "end": 780, "section": "abstract"}, {"text": "Structural insight into maintenance methylation by mouse DNA methyltransferase 1 (Dnmt1).", "begin": 0, "document": "21518897", "end": 89, "section": "title"}, {"text": "The DNA methyltransferase Dnmt1 is responsible for the propagation of methylation patterns to the next generation via its preferential methylation of hemimethylated CpG sites in the genome; however, how Dnmt1 maintains methylation patterns is not fully understood.", "begin": 103, "document": "21518897", "end": 367, "section": "abstract"}, {"text": "Usp7 and Uhrf1 control ubiquitination and stability of the maintenance DNA methyltransferase Dnmt1.", "begin": 0, "document": "21268065", "end": 99, "section": "title"}, {"text": "In mammals Dnmt1 is the DNA methyltransferase chiefly responsible for maintaining genomic methylation patterns through DNA replication cycles, but how its maintenance activity is controlled is still not well understood.", "begin": 0, "document": "21268065", "end": 219, "section": "abstract"}, {"text": "DMAP1 is a potent activator of DNMT1 methylation in vitro, suggesting that DMAP1 is a co-repressor that supports the maintenance and de novo action of DNMT1.", "begin": 706, "document": "20864525", "end": 863, "section": "abstract"}, {"text": "Maintenance of DNA methylation depends on DNA methyltransferase 1 (Dnmt1) and intracellular S-adenosylmethionine (SAM) levels, and is inhibited by S-adenosylhomocysteine (SAH).", "begin": 232, "document": "20035856", "end": 408, "section": "abstract"}, {"text": "We propose a new model that suggests that the maintenance of DNA methylation relies not only on the recognition of hemimethylated DNA by DNA methyltransferase 1 (DNMT1) but also on the localization of the DNMT3A and DNMT3B enzymes to specific chromatin regions that contain methylated DNA.", "begin": 252, "document": "19789556", "end": 541, "section": "abstract"}, {"text": "The maintenance methylase, DNMT1 (DNA methyltransferase 1), is a prominent enzyme in the process that is linked to DNA replication and drives the heritable nature of epigenetic modifications.", "begin": 130, "document": "19450230", "end": 321, "section": "abstract"}, {"text": "We have shown previously that these drugs selectively and rapidly induce degradation of the maintenance DNA methyltransferase (DNMT) 1 by a proteasomal pathway.", "begin": 181, "document": "19417133", "end": 341, "section": "abstract"}, {"text": "Inheritance of epigenetic information encoded by cytosine DNA methylation patterns is crucial for mammalian cell survival, in large part through the activity of the maintenance DNA methyltransferase (DNMT1).", "begin": 0, "document": "19282482", "end": 207, "section": "abstract"}, {"text": "We and others have shown that DNA methyltransferase 1 (DNMT1), the maintenance methyltransferase, contributes to the cellular response to DNA damage, yet DNMT1's exact role in this process remains unclear.", "begin": 295, "document": "20940144", "end": 500, "section": "abstract"}, {"text": "The maintenance function of Dnmt1 is regulated by its large regulatory N-terminal domain that interacts with other chromatin factors and is essential for the recognition of hemi-methylated DNA.", "begin": 301, "document": "19173286", "end": 494, "section": "abstract"}, {"text": "In the absence of a human pituitary tumor cell line, small interfering RNA-mediated knockdown of the maintenance methyltransferase DNA methyltransferase (cytosine 5)-1 (Dnmt1) was used in the murine pituitary adenoma cell line AtT-20.", "begin": 146, "document": "18922972", "end": 380, "section": "abstract"}, {"text": "We found that DNA methylation was maintained only when exogenous DNA methyltransferase 1 (DNMT1) and S-adenosyl methionine (SAM) were added to the reaction.", "begin": 806, "document": "19016755", "end": 962, "section": "abstract"}, {"text": "We examined the expression of DNMT1 and DNMT3a, representative of a maintenance and de novo methyltransferase respectively, in response to in-vitro depolarization of cortical neurons, using standard techniques such as high potassium (KCl) or the sodium channel agonist veratridine.", "begin": 357, "document": "18536530", "end": 638, "section": "abstract"}, {"text": "DNA methyltransferase-1 (DNMT1) has a higher specific activity on hemimethylated DNA than on unmethylated DNA, but this preference is too small to explain the faithful mitotic inheritance of genomic methylation patterns. New genetic studies in plants and mammals have identified a novel factor that increases the fidelity of maintenance methylation.", "begin": 0, "document": "18302924", "end": 349, "section": "abstract"}, {"text": "Dnmt1 is the main maintenance methyltransferase in the mouse and its expression is regulated by a splicing mechanism that dictates the expression of stage-specific isoforms.", "begin": 347, "document": "18297739", "end": 520, "section": "abstract"}, {"text": "Phosphorylation of serine-515 activates the Mammalian maintenance methyltransferase Dnmt1.", "begin": 0, "document": "17965600", "end": 90, "section": "title"}, {"text": "DNA methyltransferase 1 methylates hemi-methylated CG sites generated during DNA replication.", "begin": 0, "document": "17965600", "end": 93, "section": "abstract"}, {"text": "DNA methylation is catalyzed by a family of DNA methyltransferases (DNMTs) including the maintenance enzyme DNMT 1 and de novo methyltransferases DNMT 3a and DNMT 3b.", "begin": 0, "document": "17929180", "end": 166, "section": "abstract"}, {"text": "DNMT1 but not its interaction with the replication machinery is required for maintenance of DNA methylation in human cells.", "begin": 0, "document": "17312023", "end": 123, "section": "title"}, {"text": "Our data suggest that DNMT1 might be essential for maintenance of DNA methylation, proliferation, and survival of cancer cells.", "begin": 1200, "document": "16963560", "end": 1327, "section": "abstract"}, {"text": "Maintenance DNA methyltransferase (Met1) and silencing of CpG-methylated foreign DNA in Volvox carteri.", "begin": 0, "document": "17033890", "end": 103, "section": "title"}, {"text": "DNA methylation plays an important role in the gene-silencing network of higher eukaryotes. We have analyzed the 21.5-kb maintenance methyltransferase (M-MTase) gene, met1, of the multicellular green alga Volvox carteri.", "begin": 0, "document": "17033890", "end": 220, "section": "abstract"}, {"text": "DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1.", "begin": 0, "document": "16807237", "end": 152, "section": "title"}, {"text": "Methylation at the 5-position of DNA cytosine on the vertebrate genomes is accomplished by the combined catalytic actions of three DNA methyltransferases (DNMTs), the de novo enzymes DNMT3A and DNMT3B and the maintenance enzyme DNMT1.", "begin": 0, "document": "23393137", "end": 234, "section": "abstract"}, {"text": "DNA methylation, the major form of epigenetic modifications, is catalyzed by the maintenance DNA methyltransferase (DNMT) 1 and/or the de novo methyltransferases DNMT3A and DNMT3B.", "begin": 433, "document": "22934696", "end": 613, "section": "abstract"}, {"text": "The maintenance methylation of hemimethylated CpG sites by the DNA methyltransferase Dnmt1 is the molecular basis of the inheritance of DNA methylation patterns.", "begin": 0, "document": "22633409", "end": 161, "section": "abstract"}, {"text": "The allosteric site(s) on Dnmt1 can regulate processes of de novo and maintenance DNA methylation in cells.", "begin": 309, "document": "21507353", "end": 416, "section": "abstract"}, {"text": "Dnmt1 (DNA methyltransferase 1) is the principal enzyme responsible for maintenance of cytosine methylation at CpG dinucleotides in the mammalian genome.", "begin": 0, "document": "21389349", "end": 153, "section": "abstract"}, {"text": "Maintenance of genomic methylation patterns is mediated primarily by DNA methyltransferase-1 (DNMT1).", "begin": 0, "document": "21163962", "end": 101, "section": "abstract"}, {"text": "In this study, we showed that DNMT1, which encodes a methylation maintenance enzyme, is a transcriptional target of BRCA1.", "begin": 169, "document": "20820192", "end": 291, "section": "abstract"}, {"text": "DNA methyltransferases (DNMTs) are essential for maintenance of aberrant methylation in cancer cells and play important roles in the development of cancers.", "begin": 0, "document": "20506537", "end": 156, "section": "abstract"}, {"text": "DNA methyltransferase-1 (Dnmt1) is involved in the maintenance of DNA methylation patterns and is crucial for normal mammalian development.", "begin": 0, "document": "20007090", "end": 139, "section": "abstract"}, {"text": "DNMT1, which is important for maintenance of methylation, increased across development and stayed high in adult cortex.", "begin": 990, "document": "19966177", "end": 1109, "section": "abstract"}, {"text": "Our results indicate that DNMT1 plays the main role in maintenance of methylation of CXCR4 promoter, while DNMT3B may function as an accessory DNA methyltransferase to modulate CXCR4 expression in AsPC1 cells.", "begin": 1087, "document": "19932585", "end": 1296, "section": "abstract"}, {"text": "DNA methylation patterns are established and maintained by three DNA methyltransferases: DNMT1, DNMT3A, and DNMT3B.", "begin": 110, "document": "19825994", "end": 225, "section": "abstract"}, {"text": "According to their structure and functions, DNA methyltransferases (Dnmts) are divided into two major families in mammalian cells: maintenance methyltransferase (Dnmt1) and de novo methyltransferases (Dnmt3a, Dnmt3b, and Dnmt3L).", "begin": 285, "document": "19819843", "end": 514, "section": "abstract"}, {"text": "The 5-LOX DNA methylation increased with the age of the cells.", "begin": 1154, "document": "19778587", "end": 1216, "section": "abstract"}]}, {"documents": ["22398368", "7536414", "22170584", "20808780", "20139415", "19467223", "19322801", "12368098", "12206775", "11838638", "9925782", "9628353", "9207024", "9153756", "23444399", "23125037", "23085465", "23007409", "22382314", "22320963", "22280363", "22259221", "22203734", "21981419", "21842375", "21805123", "21796622", "21791605"], "answer": [["5-azacytidine", "5-aza-CR", "Vidaza\u00ae"], ["5-azadeoxycytidine", "5-aza-CdR", "Dacogen\u00ae", "5-aza-2'-deoxycytidine", "Decitabine"], ["5-azacytosine", "ZCyt"], ["5-fluorodeoxycytidine", "FdC"], ["5,6-dihydro-5-azacytosine", "DZCyt"], ["4'-thio-2'-deoxycytidine"], ["hydralazine"], ["2-(1H)-pyrimidinone riboside", "zebularine"], ["2-(1H)-pyrimidinone", "zebularine aglycon"], ["procaine"], ["procainamide"], ["RSC133"], ["Psammaplin A"]], "id": "5165932e298dcd4e51000059", "snippets": [{"text": "5-Aza-2'-deoxycytidine (5-Aza-CdR), a nucleoside analog that can inhibit DNA cytosine methylation, possesses potent antitumorigenic activities for myeloid disorders. Although 5-Aza-CdR is known to be incorporated into DNA and inhibit DNA (cytosine-5)-methyltransferases, the precise mechanisms underlying the drug's antineoplastic activity remain unclear.", "begin": 0, "document": "22398368", "end": 355, "section": "abstract"}, {"text": "The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor.", "begin": 0, "document": "7536414", "end": 139, "section": "title"}, {"text": "The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by the mechanism-based inhibitor 5-azacytosine has remained unclear, mainly because of the unavailability of a substrate in which the inhibitor, but not normal cytosine, is present at the target site.", "begin": 0, "document": "7536414", "end": 268, "section": "abstract"}, {"text": "These results suggest that, when the enzyme binds to 5-azacytosine in the presence of the cofactor, a methyl group is transferred to the N-5 position of the base, resulting in the inactivation of the enzyme.", "begin": 877, "document": "7536414", "end": 1084, "section": "abstract"}, {"text": "Rapid synthesis of new DNMT inhibitors derivatives of procainamide.", "begin": 0, "document": "22170584", "end": 67, "section": "title"}, {"text": "Six compounds resulted in potent inhibitors of the murine catalytic Dnmt3A/3L complex and of human DNMT1, at least 50 times greater than that of the parent compounds. The inhibitors showed selectivity for C5 DNA methyltransferases.", "begin": 244, "document": "22170584", "end": 475, "section": "abstract"}, {"text": "Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine.", "begin": 0, "document": "20808780", "end": 82, "section": "title"}, {"text": "DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site.", "begin": 0, "document": "19467223", "end": 157, "section": "title"}, {"text": "A number of DNA methyltransferase inhibitors are known to reactivate silenced genes; including 5-azacytidine and 2-(1H)-pyrimidinone riboside (zebularine). Zebularine is a more stable, less cytotoxic inhibitor compared to 5-azacytidine.", "begin": 110, "document": "19467223", "end": 346, "section": "abstract"}, {"text": "ODNs containing 2-(1H)-pyrimidinone at the enzymatic target site are competitive inhibitors of both prokaryotic and mammalian DNA C5 methyltransferases. We determined that the ternary complexes between the enzymes, 2-(1H)-pyrimidinone inhibitor, and the cofactor S-adenosyl methionine are maintained through the formation of a reversible covalent interaction. The differing stability and reversibility of the covalent bonds may partially account for the observed differences in cytotoxicity between zebularine and 5-azacytidine inhibitors.", "begin": 1010, "document": "19467223", "end": 1549, "section": "abstract"}, {"text": "DNA methyltransferases (DNMTs) are a family of enzymes that methylate DNA at the C5 position of cytosine residues, and their inhibition is a promising strategy for the treatment of various developmental and proliferative diseases, particularly cancers.", "begin": 0, "document": "19322801", "end": 252, "section": "abstract"}, {"text": "The inhibitory activity of hydralazine toward DNMT may be rationalized at the molecular level by similar interactions within the binding pocket (e.g., by a similar pharmacophore) as established by substrate-like deoxycytidine analogues.", "begin": 577, "document": "19322801", "end": 813, "section": "abstract"}, {"text": "Despite the different scaffolds of other non-nucleoside DNMT inhibitors such as procaine and procainamide, the current modeling work reveals that these drugs exhibit similar interactions within the DNMT1 binding site. These findings are valuable in guiding the rational design and virtual screening of novel DNMT inhibitors.", "begin": 983, "document": "19322801", "end": 1307, "section": "abstract"}, {"text": "Despite the different scaffolds of other non-nucleoside DNMT inhibitors such as procaine and procainamide, the current modeling work reveals that these drugs exhibit similar interactions within the DNMT1 binding site. These findings are valuable in guiding the rational design and virtual screening of novel DNMT inhibitors.", "begin": 983, "document": "19322801", "end": 1307, "section": "abstract"}, {"text": "Inhibition of HhaI DNA (Cytosine-C5) methyltransferase by oligodeoxyribonucleotides containing 5-aza-2'-deoxycytidine: examination of the intertwined roles of co-factor, target, transition state structure and enzyme conformation.", "begin": 0, "document": "12368098", "end": 229, "section": "title"}, {"text": "The presence of 5-azacytosine (ZCyt) residues in DNA leads to potent inhibition of DNA (cytosine-C5) methyltranferases (C5-MTases) in vivo and in vitro.", "begin": 0, "document": "12368098", "end": 152, "section": "abstract"}, {"text": "Thus, it is important to understand the critical mechanistic determinants of ZCyt's inhibitory action.", "begin": 342, "document": "12368098", "end": 444, "section": "abstract"}, {"text": "Since methyl transfer can occur only in the presence of AdoMet, these results suggest (1) that the inhibitory capacity of ZCyt in DNA is based on its ability to induce a stable, tightly closed conformation of M.HhaI that prevents DNA and co-factor release and (2) that methylation of ZCyt in DNA is not required for inhibition of M.HhaI.", "begin": 1133, "document": "12368098", "end": 1470, "section": "abstract"}, {"text": "Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases.", "begin": 0, "document": "12206775", "end": 104, "section": "title"}, {"text": "The inhibition of cytosine-[C5]-specific DNA methyltransferases (C5 MTases) by oligodeoxynucleotides containing 5-azadeoxycytidine (AzadC) and 5-fluorodeoxycytidine (FdC) provides a well-documented example of mechanism-based inhibition of enzymes central to nucleic acid metabolism.", "begin": 192, "document": "12206775", "end": 474, "section": "abstract"}, {"text": "Synthesis of oligonucleotide inhibitors of DNA (Cytosine-C5) methyltransferase containing 5-azacytosine residues at specific sites.", "begin": 0, "document": "11838638", "end": 131, "section": "title"}, {"text": "The incorporation of 5-azacytosine residues into DNA causes potent inhibition of DNA (Cytosine-C5) methyltransferases. T", "begin": 0, "document": "11838638", "end": 120, "section": "abstract"}, {"text": "Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine.", "begin": 0, "document": "9925782", "end": 130, "section": "title"}, {"text": "Substitution of DZCyt for target cytosines in C-G dinucleotides of single-stranded or double-stranded oligodeoxyribonucleotide substrates led to complete inhibition of methylation by murine DNA C5-MTase.", "begin": 856, "document": "9925782", "end": 1059, "section": "abstract"}, {"text": "Oligodeoxyribonucleotides containing DZCyt formed a tight but reversible complex with M.HhaI, and were consistently more potent as inhibitors of DNA methylation than oligodeoxyribonucleotides identical in sequence containing 5-fluorocytosine.", "begin": 1216, "document": "9925782", "end": 1458, "section": "abstract"}, {"text": "These results indicate that DZCyt can occupy the active site of M.HhaI as a transition state mimic and, because of the high degree of affinity of its interaction with the enzyme, it can act as a potent inhibitor of methylation.", "begin": 1927, "document": "9925782", "end": 2154, "section": "abstract"}, {"text": "Analysis of DNA methylation processes related to the inhibition of DNA synthesis by 5-azacytidine in Streptomyces antibioticus ETH 7451.", "begin": 0, "document": "9628353", "end": 136, "section": "title"}, {"text": "Our results suggest that some of the 5-azacytidine effects on DNA and RNA synthesis might indeed be related to the complex formation and inhibition of a cytosine-specific DNA methyltransferase.", "begin": 1022, "document": "9628353", "end": 1215, "section": "abstract"}, {"text": "DNA containing 4'-thio-2'-deoxycytidine inhibits methylation by HhaI methyltransferase.", "begin": 0, "document": "9207024", "end": 87, "section": "title"}, {"text": "The inhibitory effect of the 4'sulfur atom on enzymatic activity may be traced to perturbation of a step in the methylation reaction after DNA binding but prior to methyl transfer.", "begin": 1080, "document": "9207024", "end": 1260, "section": "abstract"}, {"text": "Treatment of Schizosaccharomyces pombe with the C5 DNA methyltransferase (C5Mtase) inhibitor 5-azacytidine (5-azaC) has previously been shown to induce G2 checkpoint-dependent cell cycle arrest.", "begin": 0, "document": "9153756", "end": 194, "section": "abstract"}, {"text": "Inhibitors of DNA methyltransferase (Dnmt) enzymes have been advocated as a means to promote and stabilize Foxp3 expression in Tregs undergoing expansion in vitro before their injection in vivo.", "begin": 185, "document": "23444399", "end": 379, "section": "abstract"}, {"text": "Booster of pluripotency: RSC133, a new synthetic derivative of indoleacrylic acid/indolepropionic acid, exhibits dual activity by inhibiting histone deacetylase and DNA methyltransferase.", "begin": 0, "document": "23125037", "end": 187, "section": "abstract"}, {"text": "DNA methyltransferase inhibitors (DNMTIs), including decitabine (DAC) and azacitidine (AZA), have recently been highlighted for the treatment of high-risk myelodysplastic syndrome (MDS); however, their action mechanisms have not been clearly defined.", "begin": 0, "document": "23085465", "end": 250, "section": "abstract"}, {"text": "Structurally, however, gemcitabine has similarities to             5-aza-2-deoxycytidine (decitabine/Dacogen\u00ae), a DNA methyltransferase inhibitor             (DNMTi).", "begin": 297, "document": "23007409", "end": 463, "section": "abstract"}, {"text": "Although 5-Aza-CdR is known to be incorporated into DNA and inhibit DNA (cytosine-5)-methyltransferases, the precise mechanisms underlying the drug's antineoplastic activity remain unclear.", "begin": 166, "document": "22398368", "end": 355, "section": "abstract"}, {"text": "Human colon cancer cell lines (HCT116, HT29, SW48, SW480) were treated with 5-aza-2'-deoxycytidine (DAC), as a DNA methyltransferase inhibitor, followed by trichostatin A (TSA), as a histone deacetylase inhibitor.", "begin": 275, "document": "22382314", "end": 488, "section": "abstract"}, {"text": "Psammaplin A (11c) is a marine metabolite previously reported to be a potent inhibitor of two classes of epigenetic enzymes: histone deacetylases and DNA methyltransferases.", "begin": 0, "document": "22280363", "end": 173, "section": "abstract"}, {"text": "Defining the parameters of zebularine-mediated tumor inhibition may advance the future development of DNA methyltransferase inhibitors as an effective cancer treatment.", "begin": 1492, "document": "22203734", "end": 1660, "section": "abstract"}, {"text": "The DNA methyltransferase inhibitor (5-aza-2-deoxycytidine) and the histone deacetylase inhibitor [trichostatin A (TSA)] both significantly up-regulated miR-146a transcriptional activation by altering the DNA-binding activity of NF-\u03baB in macrophages isolated from aged mice, which suggests that DNA methylation and histone acetylation are involved in the suppression of age-dependent miR-146a expression.", "begin": 868, "document": "21981419", "end": 1272, "section": "abstract"}, {"text": "Diverse DNA methyltransferase inhibitors are being studied as potential anticancer drugs, and there is interest in developing novel and more effective DNMTIs.", "begin": 102, "document": "21842375", "end": 260, "section": "abstract"}, {"text": "Currently, there are only a few DNMT1 inhibitors with potential application as therapeutic agents or research tools.", "begin": 120, "document": "21805123", "end": 236, "section": "abstract"}, {"text": "The effects of the deoxycytidine analogue decitabine (5-aza-2'-deoxycytidine), which depletes DNA methyl transferase 1 (DNMT1), on melanoma differentiation were examined.", "begin": 376, "document": "21796622", "end": 546, "section": "abstract"}, {"text": "Cooperative action of HDACi and DNA methylation inhibitors (DNMTi) has been reported, making combined treatment an attractive choice for cancer therapy.", "begin": 234, "document": "21791605", "end": 386, "section": "abstract"}]}, {"documents": ["21812548", "21244855", "20075332", "19893013", "17938175", "17518763", "16049055", "15491989", "15040454", "12805933", "11770083", "9043061", "8977381", "8674419", "7982978", "8035789", "8366095", "8321243", "8449897", "1532229", "1328854", "10998641", "10794526"], "answer": [["COX-2"], ["ANF"], ["estrogen receptor (ER)alpha gene"], ["calsequestrin gene", "casq2"], ["cTnT"], ["MCK"], ["alpha-cardiac actin"], ["sarco(endo)plasmic reticulum Ca2+-ATPase", "SERCA"], ["MLC-2"], ["alpha-cardiac myosin heavy chain gene"], ["phosphoglycerate mutase", "PGAM-M"], ["cardiac troponin C", "cTnC"]], "id": "517539af8ed59a060a000026", "snippets": [{"text": "Inhibition of MEF2A using siRNA attenuated HB-EGF-induced COX-2, ANF expression and cell size.", "begin": 1560, "document": "21244855", "end": 1654, "section": "abstract"}, {"text": "cardiac calsequestrin gene (casq2)", "begin": 120, "document": "17938175", "end": 154, "section": "abstract"}, {"text": "Functional studies demonstrated that site-directed mutagenesis of the proximal MEF-2 and CArG box sites significantly decreased the transcription of the gene in cardiac and skeletal muscle cells, indicating that they are important to drive cardiac and skeletal muscle-specific transcription of the casq2 gene.", "begin": 1423, "document": "17938175", "end": 1732, "section": "abstract"}, {"text": "DTEF-1 also interacts with MEF- 2 by coimmunoprecipitation and independently or cooperatively (with MEF-2) trans-activates the cTnT promoter", "begin": 885, "document": "16049055", "end": 1025, "section": "abstract"}, {"text": "An 85-bp region within the enhancer is highly conserved between human and mouse and contains a central AT-rich site, which is essential for enhancer activity. This site binds myocyte enhancer factor (MEF)2 factors, principally MEF2D and MEF2A in cardiocyte nuclear extracts. These results are discussed in the context of MEF2 activity and of the regulation of the alpha-cardiac actin locus.", "begin": 432, "document": "15491989", "end": 822, "section": "abstract"}, {"text": "The cis-acting elements, MEF-2, E boxes and A/T rich elements present in the enhancer region of the mouse MCK gene are known to regulate the expression of the gene", "begin": 261, "document": "15040454", "end": 424, "section": "abstract"}, {"text": "The sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs) belong to a family of active calcium transport enzymes encoded by the SERCA1, 2, and 3 genes. In this study, we describe the complete structure of the human SERCA2 gene and its 5 -regulatory region.", "begin": 0, "document": "12805933", "end": 253, "section": "abstract"}, {"text": "Among the DNA cis-elements present in these two regulatory regions there are potential binding sites for: GATA-4, -5, -6, Nkx-2.5/Csx, OTF-1, USF, MEF-2, SRF, PPAR/RXR, AP-2, and TREs. Upstream from position -1.5 kb, there is no significant homology among the SERCA2 genes cloned.", "begin": 972, "document": "12805933", "end": 1252, "section": "abstract"}, {"text": "The cardiac calsequestrin gene consists of 11 exons and its 5' flanking region is characterized by the presence of a TATA-like box, muscle specific promoter elements such as 7 E-boxes, 1 MEF-2, 1 MCBF and 1 Repeat (musS) motifs, as well as several muscle non-specific transcriptional elements (AP-2A, NRE1, NRE2, p53, Spel and TFI-IIA).", "begin": 554, "document": "11770083", "end": 890, "section": "abstract"}, {"text": "our laboratory identified a 28 bp HF-la/MEF-2 element in the MLC-2v promoter region, which confers cardiac ventricular chamber-specific gene expression during murine cardiogenesis,", "begin": 336, "document": "9043061", "end": 516, "section": "abstract"}, {"text": "In this study, we investigated T3R alpha 1-vs. T3R beta 1-specific interactions with the myocyte enhancer-specific factor-2 (MEF-2) on the expression of the SERCA 2 gene in transient transfection assays in embryonal heart-derived H9c2 cells.", "begin": 501, "document": "8977381", "end": 742, "section": "abstract"}, {"text": "point to T3R isoform-specific interactions with a cell type-specific transcription factor (MEF-2) in the regulation of SERCA 2 gene expression.", "begin": 1759, "document": "8977381", "end": 1902, "section": "abstract"}, {"text": "In multiple independent transgenic mouse lines, we found that both a 250 base pair myosin light chain-2 ventricular promoter fragment, as well as a dimerized 28 bp sub-element (HF-1) containing binding sites for HF1a and HF1b/MEF2 factors, directed ventricular-specific reporter expression from as early as the endogenous gene, at day 7.5-8.0 post coitum.", "begin": 519, "document": "8674419", "end": 874, "section": "abstract"}, {"text": "Myocyte-specific enhancer-binding factor (MEF-2) regulates alpha-cardiac myosin heavy chain gene expression in vitro and in vivo", "begin": 0, "document": "8366095", "end": 128, "section": "title"}, {"text": "In the MLC-2 gene, an AT-rich element (HF-1b) which contains a consensus MEF-2 site is required for cardiac tissue-specific expression.", "begin": 153, "document": "8321243", "end": 288, "section": "abstract"}, {"text": "Role of myocyte-specific enhancer-binding factor (MEF-2) in transcriptional regulation of the alpha-cardiac myosin heavy chain gene.", "begin": 0, "document": "8449897", "end": 132, "section": "title"}, {"text": "In order to analyze the transcriptional regulation of the muscle-specific subunit of the human phosphoglycerate mutase (PGAM-M) gene, chimeric genes composed of the upstream region of the PGAM-M gene", "begin": 0, "document": "1328854", "end": 199, "section": "abstract"}, {"text": "These observations define the PGAM-M enhancer as the only cardiac- and skeletal-muscle-specific enhancer characterized thus far that is mainly activated through MEF-2.", "begin": 1483, "document": "1328854", "end": 1650, "section": "abstract"}, {"text": "Transcription of each gene is independently controlled but coordinately regulated. During each embryogenesis, the beta-MHC gene is expressed as part of the cardiac myogenic program under the control of NKX-2.5, MEF-2C, and GATA-4/5/6.", "begin": 223, "document": "10998641", "end": 457, "section": "abstract"}, {"text": "We have characterized the specific DNA regulatory elements responsible for the function of the human cardiac troponin C gene (cTnC) muscle-specific enhancer in myogenic cells. We used functional transient transfection assays with deletional and site-specific mutagenesis to evaluate the role of the conserved sequence elements. Gel electrophoresis mobility shift assays (EMSA) demonstrated the ability of the functional sites to interact with nuclear proteins. We demonstrate that three distinct transcription activator binding sites commonly found in muscle-specific enhancers (a MEF-2 site, a MEF-3 site, and at least four redundant E-box sites) all contribute to full enhancer activity but a CArG box does not.", "begin": 0, "document": "10794526", "end": 713, "section": "abstract"}]}, {"documents": ["18031713", "15831522", "11731613"], "answer": [["ARB1"], ["ARB2"], ["TAK1"], ["p38"], ["TRalpha1"]], "id": "517539ca8ed59a060a000027", "snippets": [{"text": "n FM the reduced mRNA expression of ARB1 (p<0.05, -37%) and ARB2 (p<0.05, -42%) was associated with a reduction of the messenger for TRalpha1 (p<0.05, -85%) and TRalpha2 (p<0.05, -73%).", "begin": 591, "document": "18031713", "end": 776, "section": "abstract"}, {"text": "hese data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors.", "begin": 858, "document": "18031713", "end": 1052, "section": "abstract"}, {"text": "Mitigating TRalpha1 effects, both TRalpha2 and TRbeta1 attenuate TRalpha1-induced myocardial growth and gene expression by diminishing TAK1 and p38 activities, respectively.", "begin": 620, "document": "15831522", "end": 793, "section": "abstract"}, {"text": "Selective ablation of TRalpha2 resulted in an inevitable, concomitant overexpression of TRalpha1.", "begin": 422, "document": "11731613", "end": 519, "section": "abstract"}, {"text": "These data reveal that in human heart failure the reduction of beta-adrenergic receptors is associated with reduced expression of both TRalpha1 and TRalpha2 isoforms of thyroid hormone receptors.", "begin": 857, "document": "18031713", "end": 1052, "section": "abstract"}]}, {"documents": ["23282240", "22923465", "22093876", "22528351", "17431169", "16511833", "16399224", "15867427", "12213770", "12167372", "11343131", "10677855", "2165587"], "answer": [["LINE-1", "L1"], ["Alu"], ["SVA"]], "id": "517843638ed59a060a000036", "snippets": [{"text": "Half of the human genome is composed of repeated DNA, and some types are mobile within our genome (transposons and retrotransposons). Despite their abundance, only a small fraction of them are currently active in our genome (Long Interspersed Element-1 (LINE-1), Alu, and SVA elements).", "begin": 0, "document": "22528351", "end": 286, "section": "abstract"}, {"text": "Since certain types of retrotransposons, particularly members of the Alu, L1, and SVA families, are still active, their recent and ongoing propagation generates a unique and important class of human genomic diversity/polymorphism", "begin": 114, "document": "16511833", "end": 343, "section": "abstract"}, {"text": "Alu elements are the most successful SINEs (Short INterspersed Elements) in primate genomes and have reached more than 1,000,000 copies in the human genome", "begin": 0, "document": "15867427", "end": 155, "section": "abstract"}, {"text": "1 and Alu represent the most prolific human LINE and SINE families, respectively.", "begin": 120, "document": "12213770", "end": 201, "section": "abstract"}, {"text": "Only a few Alu elements are able to retropose, and the factors determining their retroposition capacity are poorly understood.", "begin": 202, "document": "12213770", "end": 328, "section": "abstract"}]}, {"documents": ["23428641", "22872506", "22232676", "21994224", "21385047", "23222129", "22688717", "22287631", "22971240", "21179022", "19835606"], "answer": ["Reads Per Kilobase per Million mapped reads (RPKM)"], "id": "5178d6be8ed59a060a000038", "snippets": [{"text": "Measures of RNA abundance are important for many areas of biology and often obtained from high-throughput RNA sequencing methods such as Illumina sequence data. These measures need to be normalized to remove technical biases inherent in the sequencing approach, most notably the length of the RNA species and the sequencing depth of a sample. These biases are corrected in the widely used reads per kilobase per million reads (RPKM) measure.", "begin": 0, "document": "22872506", "end": 441, "section": "abstract"}]}, {"documents": ["21727197", "21444689", "20624389", "20550937", "19703420", "16779818", "16702233", "16600873", "15613247", "15611332", "12653556", "11453980", "9140728", "7561689", "7504063", "20498018", "21189294", "16702234", "16682526", "20566687", "22960634", "1281815", "12093788", "11684705"], "answer": [["NDC1", "TMEM48", "NET3", "hNDC1"], ["POM121", "Nup121"], ["GP210", "Nuclear pore membrane glycoprotein 210", "Nuclear envelope pore membrane protein POM 210", "POM210", "Nup210"], ["TMEM33", "DB83"]], "id": "51bdb644047fa84d1d000001", "snippets": [{"text": "We investigated the interplay between import receptors and the transmembrane nucleoporin Pom121", "begin": 150, "document": "20624389", "end": 245, "section": "abstract"}, {"text": "the transmembrane nucleoporin POM121 is critical for the incorporation of the Nup107/160 complex into new assembly sites specifically during interphase.", "begin": 424, "document": "20550937", "end": 576, "section": "abstract"}, {"text": "The transmembrane nucleoporin NDC1", "begin": 0, "document": "19703420", "end": 34, "section": "title"}, {"text": "NDC1 is a transmembrane nucleoporin that is required for NPC assembly and nucleocytoplasmic transport.", "begin": 0, "document": "19703420", "end": 102, "section": "abstract"}, {"text": "The only protein known to localize to and be important in the assembly of both of these yeast structures is the integral membrane protein, Ndc1p. However, no homologues of Ndc1p had been characterized in metazoa. Here, we identify and analyze NDC1 homologues that are conserved throughout evolution. We show that the overall topology of these homologues is conserved. Each contains six transmembrane segments in its N-terminal half and has a large soluble C-terminal half of approximately 300 amino acids.", "begin": 298, "document": "16779818", "end": 803, "section": "abstract"}, {"text": "Although it is not known whether vertebrate NDC1 protein localizes to nuclear pores like its yeast counterpart, the human homologue contains three FG repeats in the C-terminus, a feature of many nuclear pore proteins.", "begin": 997, "document": "16779818", "end": 1214, "section": "abstract"}, {"text": "we bring together data from another study to demonstrate that the human homologue of NDC1 is the known inner nuclear membrane protein, NET3.", "begin": 1361, "document": "16779818", "end": 1501, "section": "abstract"}, {"text": "NDC1: a crucial membrane-integral nucleoporin of metazoan nuclear pore complexes", "begin": 0, "document": "16702233", "end": 80, "section": "title"}, {"text": "The conserved transmembrane nucleoporin NDC1", "begin": 0, "document": "16600873", "end": 44, "section": "title"}, {"text": "we characterize vertebrate NDC1--a transmembrane nucleoporin conserved between yeast and metazoans", "begin": 315, "document": "16600873", "end": 413, "section": "abstract"}, {"text": "gp210 is a major constituent of the nuclear pore complex (NPC) with possible structural and regulatory roles. It interacts with components of the NPC via its C-terminal domain (CTD), which follows a transmembrane domain and a massive ( approximately 200 kDa) N-terminal region that resides in the lumen of the perinuclear space.", "begin": 0, "document": "12653556", "end": 328, "section": "abstract"}, {"text": "The membrane-spanning glycoprotein gp210 is a major component of the nuclear pore complex. This nucleoporin contains a large cisternal N-terminal domain, a short C-terminal cytoplasmic tail, and a single transmembrane segment.", "begin": 0, "document": "11453980", "end": 226, "section": "abstract"}, {"text": "We propose that gp210 is organized into the pore membrane as a large array of gp210 dimers that may constitute a luminal submembranous protein skeleton.", "begin": 881, "document": "11453980", "end": 1033, "section": "abstract"}, {"text": "Patients with primary biliary cirrhosis (PBC) frequently produce autoantibodies against gp210, an integral glycoprotein of the nuclear pores. this protein consists of three main domains: a large glycosylated lumenal domain, a single hydrophobic transmembrane segment and a short cytoplasmic tail.", "begin": 0, "document": "9140728", "end": 296, "section": "abstract"}, {"text": "Patients with primary biliary cirrhosis frequently develop autoantibodies directed to gp210, a major glycoprotein of the nuclear pore complex. This protein contains a large glycosylated cisternal domain, a single transmembrane segment, and a short cytoplasmic tail.", "begin": 0, "document": "7561689", "end": 265, "section": "abstract"}, {"text": "Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210", "begin": 0, "document": "7504063", "end": 161, "section": "title"}, {"text": "Patients with primary biliary cirrhosis (PBC) frequently have autoantibodies against a 210-kD integral glycoprotein of the nuclear envelope pore membrane. This protein, termed gp210, has a 1,783-amino acid amino-terminal domain located in the perinuclear space, a 20-amino acid transmembrane segment, and a 58-amino acid cytoplasmic carboxy-terminal tail.", "begin": 0, "document": "7504063", "end": 355, "section": "abstract"}, {"text": "In this paper, we provide evidence that the transmembrane nucleoporin (Nup), POM121, but not the Nup107-160 complex, is present at new pore assembly sites at a time that coincides with inner nuclear membrane (INM) and outer nuclear membrane (ONM) fusion.", "begin": 420, "document": "21727197", "end": 674, "section": "abstract"}, {"text": "We investigated the interplay between import receptors and the transmembrane nucleoporin Pom121.", "begin": 150, "document": "20624389", "end": 246, "section": "abstract"}, {"text": "Conversely, the transmembrane nucleoporin POM121 is critical for the incorporation of the Nup107/160 complex into new assembly sites specifically during interphase.", "begin": 412, "document": "20550937", "end": 576, "section": "abstract"}, {"text": "Human NDC1 (hNDC1) likely possesses six transmembrane segments, and it is located at the nuclear pore wall.", "begin": 560, "document": "16702233", "end": 667, "section": "abstract"}, {"text": "Here, we characterize vertebrate NDC1--a transmembrane nucleoporin conserved between yeast and metazoans.", "begin": 309, "document": "16600873", "end": 414, "section": "abstract"}, {"text": "Here, we report the solution structure of the human gp210 CTD as determined by various spectroscopic techniques.", "begin": 329, "document": "12653556", "end": 441, "section": "abstract"}, {"text": "Using human gp210 isolated from HeLa cells we found the lumenal domain as the major target.", "begin": 486, "document": "9140728", "end": 577, "section": "abstract"}, {"text": "This protein, termed gp210, has a 1,783-amino acid amino-terminal domain located in the perinuclear space, a 20-amino acid transmembrane segment, and a 58-amino acid cytoplasmic carboxy-terminal tail.", "begin": 155, "document": "7504063", "end": 355, "section": "abstract"}]}, {"documents": ["23404999", "23070014", "22809326", "22426402", "22363588", "22331875", "22227450", "21966475", "21514572", "19433452", "18927485", "18644871", "18635949", "18550537", "17284523", "16585521", "15331765", "12505983", "11208145", "11082038", "10806201", "21429245", "22653298", "19117012", "15325583"], "answer": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "id": "51bdd9c2047fa84d1d000002", "snippets": [{"text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor.", "begin": 1165, "document": "23070014", "end": 1432, "section": "abstract"}, {"text": "CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a.", "begin": 671, "document": "22426402", "end": 756, "section": "abstract"}, {"text": "Lysosomes from livers of lipid-challenged mice had a marked decrease in the levels of the CMA receptor, the lysosome-associated membrane protein type 2A,", "begin": 747, "document": "22331875", "end": 900, "section": "abstract"}, {"text": "We report that Bcl-2-related early rod apoptosis was associated with the upregulation of autophagy markers including chaperone-mediated autophagy (CMA) substrate receptor LAMP-2", "begin": 994, "document": "22227450", "end": 1171, "section": "abstract"}, {"text": "we examined gene expression levels of lysosome-associated membrane 2 (LAMP-2), a CMA receptor", "begin": 617, "document": "21514572", "end": 710, "section": "abstract"}, {"text": "The lysosomal-membrane protein type 2A (LAMP-2A) acts as the receptor for the substrates of chaperone-mediated autophagy (CMA)", "begin": 110, "document": "18927485", "end": 236, "section": "abstract"}, {"text": "Chaperone-mediated autophagy (CMA) is a selective type of autophagy by which specific cytosolic proteins are sent to lysosomes for degradation. Substrate proteins bind to the lysosomal membrane through the lysosome-associated membrane protein type 2A (LAMP-2A), one of the three splice variants of the lamp2 gene, and this binding is limiting for their degradation via CMA.", "begin": 0, "document": "18644871", "end": 373, "section": "abstract"}, {"text": "Substrate proteins only bind to monomeric LAMP-2A, while the efficient translocation of substrates requires the formation of a particular high-molecular-weight LAMP-2A complex", "begin": 662, "document": "18644871", "end": 837, "section": "abstract"}, {"text": "We recently reported that UCH-L1 physically interacts with LAMP-2A, the lysosomal receptor for chaperone-mediated autophagy (CMA", "begin": 266, "document": "18635949", "end": 394, "section": "abstract"}, {"text": "In this study, we found that UCH-L1 physically interacts with LAMP-2A, the lysosomal receptor for CMA,", "begin": 460, "document": "18550537", "end": 562, "section": "abstract"}, {"text": "We have previously described an age-related decline in chaperone-mediated autophagy (CMA), a selective form of autophagy, by which particular cytosolic proteins are delivered to lysosomes after binding to the lysosome-associated membrane protein type 2A (LAMP-2A), a receptor for this pathway.", "begin": 113, "document": "17284523", "end": 406, "section": "abstract"}, {"text": "Chaperone-mediated autophagy (CMA) is a selective pathway for the degradation of cytosolic proteins in lysosomes. CMA declines with age because of a decrease in the levels of lysosome-associated membrane protein (LAMP) type 2A, a lysosomal receptor for this pathway.", "begin": 0, "document": "16585521", "end": 266, "section": "abstract"}, {"text": "Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway.", "begin": 543, "document": "15331765", "end": 853, "section": "abstract"}, {"text": "We now demonstrate that this protease activity triggers the degradation of the lysosome-associated membrane protein type 2a (lamp2a), a receptor for chaperone-mediated autophagy (CMA).", "begin": 112, "document": "12505983", "end": 296, "section": "abstract"}, {"text": "We have previously identified this receptor as the lysosome-associated membrane protein type 2a (lamp2a)", "begin": 185, "document": "11208145", "end": 289, "section": "abstract"}, {"text": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy.", "begin": 0, "document": "11082038", "end": 107, "section": "abstract"}, {"text": "These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "begin": 1007, "document": "11082038", "end": 1111, "section": "abstract"}, {"text": "A progressive age-related decrease in the levels of the lysosome-associated membrane protein type 2a that acts as a receptor for chaperone-mediated autophagy", "begin": 603, "document": "10806201", "end": 760, "section": "abstract"}, {"text": "Hsc70 and Hsp40 are members of a molecular chaperone complex required for protein transport into the lysosome during chaperone-mediated autophagy (CMA).", "begin": 584, "document": "19117012", "end": 736, "section": "abstract"}, {"text": "Once there, substrate proteins bind to the lysosome-associated membrane protein type 2 isoform A (LAMP2A), inducing assembly of this receptor protein into a higher molecular weight protein complex that is used by the substrate proteins to reach the lysosomal lumen. ", "begin": 430, "document": "22653298", "end": 696, "section": "abstract"}, {"text": "Protein substrates bind to a receptor in the lysosomal membrane, the lysosome-associated membrane protein (lamp) type 2a.", "begin": 428, "document": "15325583", "end": 549, "section": "abstract"}]}, {"documents": ["23043107", "23022382", "22948227", "22120110", "21893048", "21862879", "21620860", "20723759", "20574168", "20562859", "20418806", "19549685", "10856287", "22302004", "16303767"], "answer": [["MAP1LC3A", "microtubule-associated protein-1 light chain 3A", "LC3A"], ["MAP1LC3B", "microtubule-associated protein-1 light chain 3B", "LC3B"], ["MAP1LC3C", "microtubule-associated protein-1 light chain 3C", "LC3C"], ["GABARAP", "GABA(A) receptor-associated protein", "Gamma-aminobutyric acid receptor-associated protein", "MM46"], ["GABARAPL1", "Gamma-aminobutyric acid receptor-associated protein-like 1", "Early estrogen-regulated protein", "GABA(A) receptor-associated protein-like 1", "Glandular epithelial cell protein 1", "GEC-1"], ["GABARAPL2", "Gamma-aminobutyric acid receptor-associated protein-like 2", "GABA(A) receptor-associated protein-like 2", "Ganglioside expression factor 2", "GEF-2", "General protein transport factor p16", "Golgi-associated ATPase enhancer of 16 kDa", "GATE-16", "MAP1 light chain 3-related protein"]], "id": "51bdf045047fa84d1d000003", "snippets": [{"text": "Strikingly, in addition to ULK1 and ULK2, ATG13 and FIP200 interacted with human ATG8 proteins, all with strong preference for the GABARAP subfamily.", "begin": 482, "document": "23043107", "end": 631, "section": "abstract"}, {"text": "The expansion of the ATG8 family in higher eukaryotes suggests that specific interactions with autophagy receptors facilitate differential cargo handling. However, selective interactors of ATG8 orthologs are unknown. Here we show that the selectivity of the autophagy receptor NDP52 for LC3C is crucial for innate immunity", "begin": 215, "document": "23022382", "end": 537, "section": "abstract"}, {"text": "LC3C is required for antibacterial autophagy because in its absence the remaining ATG8 orthologs do not support efficient antibacterial autophagy.", "begin": 624, "document": "23022382", "end": 770, "section": "abstract"}, {"text": "We discovered ATG8-like proteins (MAP1LC3B, GABARAP and GABARAPL1) as novel interactors of MAPK15/ERK8,", "begin": 462, "document": "22948227", "end": 565, "section": "abstract"}, {"text": "GABARAPL1 belongs to the small family of GABARAP proteins (including GABARAP, GABARAPL1 and GABARAPL2/GATE-16), one of the two subfamilies of the yeast Atg8 orthologue.", "begin": 0, "document": "22120110", "end": 168, "section": "abstract"}, {"text": "Identification of the Atg8 family interacting motif (AIM) in Stbd1 required for interaction with GABARAPL1", "begin": 76, "document": "21893048", "end": 182, "section": "title"}, {"text": "Stbd1 has been reported to interact with a known autophagy protein, GABARAPL1, a member of the Atg8 family.", "begin": 398, "document": "21893048", "end": 505, "section": "abstract"}, {"text": "Atg8 is a yeast protein involved in the autophagic process and in particular in the elongation of autophagosomes. In mammals, several orthologs have been identified and are classed into two subfamilies: the LC3 subfamily and the GABARAP subfamily, referred to simply as the LC3 or GABARAP families. GABARAPL1 (GABARAP-like protein 1), one of the proteins belonging to the GABARAP (GABA(A) receptor-associated protein) family", "begin": 0, "document": "21862879", "end": 424, "section": "abstract"}, {"text": "The proteins that make up the GABARAP family demonstrate conservation of their amino acid sequences and protein structures. In humans, GABARAPL1 shares 86% identity with GABARAP and 61% with GABARAPL2 (GATE-16).", "begin": 565, "document": "21862879", "end": 776, "section": "abstract"}, {"text": "The selectivity is mediated by autophagy receptors, such as p62 and NBR1, which can bind to autophagic effector proteins (Atg8 in yeast, MAP1LC3 protein family in mammals) anchored in the membrane of autophagosomes.", "begin": 96, "document": "21620860", "end": 311, "section": "abstract"}, {"text": "ATG3 is the E2-like enzyme necessary for ATG8/LC3 lipidation during autophagy.", "begin": 204, "document": "20723759", "end": 282, "section": "abstract"}, {"text": "Recently, autophagy receptors, like p62/SQSTM1 and NBR1, which physically link autophagic cargo to ATG8/MAP1-LC3/GABARAP family members located on the forming autophagic membranes, have been identified.", "begin": 154, "document": "20574168", "end": 356, "section": "abstract"}, {"text": "At least eight different Atg8 orthologs belonging to two subfamilies (LC3 and GATE-16/GABARAP) occur in mammalian cells, but their individual roles and modes of action are largely unknown.", "begin": 173, "document": "20418806", "end": 361, "section": "abstract"}, {"text": "truncated DeltaN63 Atg4D displays increased activity against the Atg8 paralogue, gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAP-L1)", "begin": 589, "document": "19549685", "end": 741, "section": "abstract"}, {"text": "Structure of GATE-16, membrane transport modulator and mammalian ortholog of autophagocytosis factor Aut7p.", "begin": 0, "document": "10856287", "end": 107, "section": "title"}, {"text": "The yeast ortholog of GATE-16 is the autophagocytosis factor Aut7p. GATE-16 is also closely related to the GABA receptor-associated protein (GABARAP),", "begin": 150, "document": "10856287", "end": 300, "section": "abstract"}, {"text": "Three human Atg8 (hAtg8) homologs, LC3, GABARAP, and GATE-16, have been characterized as modifiers in reactions mediated by hAtg7 (an E1-like enzyme) and hAtg3 (an E2-like enzyme) as in yeast Atg8 lipidation, but their final targets have not been identified.", "begin": 126, "document": "16303767", "end": 384, "section": "abstract"}]}, {"documents": ["12775843", "22943432", "18174224", "15843685"], "answer": ["25"], "id": "517170c48ed59a060a00000d", "snippets": [{"text": "The human selenoproteome consists of 25 selenoproteins.", "begin": 448, "document": "12775843", "end": 503, "section": "abstract"}]}]